ANNUAL REPORT

FY 2023 — Annual report

FY 2023PDF · 533 pages3.2 MB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
☒ 	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2023
OR
☐ 	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from 	to
Commission file number: 001-16751
ELEVANCE HEALTH, INC.
(Exact name of registrant as specified in its charter)
Indiana 	35-2145715
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer Identification Number)
220 Virginia Avenue
Indianapolis, Indiana 46204
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (833) 401-1577
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading symbol(s) 	Name of each exchange on which registered
Common Stock, Par Value $0.01 	ELV 	New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: NONE
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No ¨
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer 	☒ 	Accelerated filer 	☐
Non-accelerated filer 	☐ 	Smaller reporting company 	☐
Emerging growth company 	☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. x
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the
correction of an error to previously issued financial statements. ¨
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the
registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b) ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant (assuming solely for the purposes of this calculation that all
directors and executive officers of the registrant are “affiliates”) as of June 30, 2023 was approximately $104,634,460,663.
As of February 1, 2024, 232,668,735 shares of the registrant’s common stock were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Part III of this Annual Report on Form 10-K incorporates by reference information from the registrant’s Definitive Proxy Statement for the Annual Meeting of Shareholders to be
held May 15, 2024.
1

-- 1 of 533 --

Elevance Health, Inc.
Annual Report on Form 10-K
For the Year Ended December 31, 2023
Table of Contents
PART I
ITEM 1. 	BUSINESS 	3
ITEM 1A. 	RISK FACTORS 	23
ITEM 1B. 	UNRESOLVED STAFF COMMENTS 	38
ITEM 1C. 	CYBERSECURITY 	38
ITEM 2. 	PROPERTIES 	39
ITEM 3. 	LEGAL PROCEEDINGS 	39
ITEM 4. 	MINE SAFETY DISCLOSURES 	39
PART II
ITEM 5. 	MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES
OF EQUITY SECURITIES 	40
ITEM 6. 	[RESERVED] 	42
ITEM 7. 	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 	42
ITEM 7A. 	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 	64
ITEM 8. 	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 	66
ITEM 9. 	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 	132
ITEM 9A. 	CONTROLS AND PROCEDURES 	132
ITEM 9B. 	OTHER INFORMATION 	135
ITEM 9C. 	DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 	135
PART III
ITEM 10. 	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 	135
ITEM 11. 	EXECUTIVE COMPENSATION 	135
ITEM 12. 	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER
MATTERS 	135
ITEM 13. 	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 	136
ITEM 14. 	PRINCIPAL ACCOUNTANT FEES AND SERVICES 	136
PART IV
ITEM 15. 	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 	137
ITEM 16. 	FORM 10-K SUMMARY 	141
SIGNATURES 	148
-1-

-- 2 of 533 --

References in this Annual Report on Form 10-K to the terms “we,” “our,” “us,” “Elevance Health” or the “Company” refer to Elevance Health, Inc., an
Indiana corporation, and, unless the context otherwise requires, its direct and indirect subsidiaries. References to the term “states” include the District of
Columbia and Puerto Rico, unless the context otherwise requires.
FORWARD-LOOKING STATEMENTS
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,”
“may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These
statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and
expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and
uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or
implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of
the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities
and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law,
we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include,
but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact
of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19, and other catastrophes; the impact of new or changes in
existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified
products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or breaches or our failure to
comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; information technology disruptions;
changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our
ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid
programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers
for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative
change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with
providers on cost-effective and competitive terms; failure to effectively maintain and modernize our information systems; risks associated with providing
healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party
with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint ventures and strategic
alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible
restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common
stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our
substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost
of financing; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular;
events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated
with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business
combinations.
-2-

-- 3 of 533 --

PART I
ITEM 1. BUSINESS.
General
Elevance Health and its subsidiaries, referred to throughout this document as “we,” “us,” “our,” the “Company” or “Elevance Health,” is a leading health
company bringing together the concepts of elevate and advance, in order to exemplify and follow our bold purpose of improving the health of humanity. We serve
people across their entire health journey to better address their full range of needs with an integrated whole-health approach. Through our broad view, we aim to
meaningfully improve the health of the people and communities we serve. We strive to deliver on our mission by maximizing the power of partnerships, innovating
to fuel growth and health equity, and maintaining a high-performance culture. Our strategy is to be a lifetime trusted health partner through the following four core
focus areas:
• Whole Health – Partner to address physical, behavioral and social needs to improve health, affordability, quality, equity, and access for individuals and
communities.
• Exceptional Experiences – Put the consumers we serve at the center of all that we do, personalizing engagement to meet consumers where they are and
optimize health outcomes across individuals and populations.
• Care Provider Enablement – Be the easiest payer to work with by supporting care provider partners with data, insights, and tools they need to deliver
exceptional care for our consumers.
• Digital Platform – Use digital technologies such as AI to transform the way we operate our business and interact with consumers by driving improvements
in efficiency and experiences and converting data into actionable insights.
With an unyielding commitment to meeting the needs of our diverse customers, we are guided by the following values:
• Community – We put people first
• Diversity – We value our differences
• Integrity – We build trust
• Agility – We embrace change
• Leadership – We lead by example
We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 47 million medical members through our
affiliated health plans as of December 31, 2023. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group,
Medicaid and Medicare markets. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss
insurance, provider network access, medical management, care management, wellness programs, actuarial services and other administrative services. We provide
services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits
(“FEHB”) Program. We provide an array of specialty services both to customers of our subsidiary health plans and also to unaffiliated health plans, including
pharmacy services, dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our
members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana,
Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and
upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do
business as Anthem Blue Cross and Anthem Blue Cross and Blue Shield. We also conduct business through arrangements with other BCBS licensees, as well as
other strategic partners. In addition, we serve members in numerous states as Amerigroup, Freedom Health, HealthSun, MMM, Optimum Healthcare, Simply
Healthcare and/or Wellpoint. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.
Through various subsidiaries, we also offer pharmacy services through our CarelonRx business, and other healthcare related services as Carelon Insights, Carelon
Health, Carelon Behavioral Health and CareMore.
-3-

-- 4 of 533 --

As we announced in 2022, we are organizing our brand portfolio into the following core go-to-market brands:
• Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed
plans;
• Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and
• Carelon — this brand brings together our healthcare related services and capabilities, including our CarelonRx and Carelon Services businesses, under a
single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. Given this
evolution, we reviewed and modified how we manage our business, monitor our performance and allocate resources, and made changes to our reportable segments
beginning in the first quarter of 2023. We now report our results of operations in the following four reportable segments: Health Benefits (aggregates our previously
reported Commercial & Specialty Business and Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and
Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to
our other reportable segments). During the fourth quarter of 2023, we moved our Carelon Global Solutions international businesses from the Corporate & Other
reportable segment to the Carelon Services reportable segment. All prior period reportable segment information has been reclassified for comparability to conform
to the current presentation.
For additional discussion, see “Reportable Segments” below in this “Business” section and Note 1, “Organization,” and Note 20, “Segment Information,” of
the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
We believe healthcare is local and that we have the strong local presence required to understand and meet local customer needs with regard to any product
customers are enrolled in with us. Further, we believe we are well-positioned to deliver what customers want: innovative, choice-based and affordable products;
distinctive service; simplified transactions; and better access to information for quality care. Our local presence, combined with our national expertise, has created
opportunities for collaborative programs that reward physicians and hospitals for clinical quality and excellence. We feel that our commitment to health
improvement and care management provides added value to customers and healthcare professionals. Ultimately, we believe that practical and sustainable
improvements in healthcare must focus on improving healthcare quality while managing costs for total affordability. We have implemented initiatives driving
payment innovation and partnered with providers to lower cost and improve the quality of healthcare for our members, and we continue to develop new and
innovative ways to effectively manage risk and engage our members. Further, we continue to expand our financial arrangements with providers to implement
payment models that advance value-based care. We believe focusing on quality of care rather than volume of care is the foundation for improving patient outcomes.
Our value-based payment model supports patient-centered care by improving collaboration between providers and health partners and delivering to our patients the
right care, at the right time, in the right place. In addition, we are focused on achieving efficiencies from our national scale while optimizing service performance
for our customers. Finally, we expect to continue to rationalize our portfolio of businesses and products and align our investments to optimize our core businesses,
invest in high-growth opportunities, and accelerate capabilities and services.
Impact on Our Results of Operations
Our results of operations depend in large part on our ability to accurately predict and effectively manage healthcare costs through effective contracting with
providers of care to our members, product pricing, medical management and health and wellness programs, including service coordination and case management
for addressing complex and specialized healthcare needs, innovative product design and our ability to maintain or achieve improvement in our Centers for
Medicare and Medicaid Services (“CMS”) Star ratings. CMS Star ratings affect Medicare Advantage plan reimbursements as well as our eligibility to earn quality-
based bonus payments for those plans. See “Regulation” below in this “Business” section for additional information on our CMS Star ratings. For additional
information on our networks and provider relations, product pricing and healthcare cost management programs, see “Pricing and Underwriting of Our Products,”
“Networks and Provider Relations,” “Medical Management Programs,” “Care Management and Wellness Products and Programs” and “Healthcare Quality
Initiatives” below in this “Business” section.
-4-

-- 5 of 533 --

Advances in medical technology, including new specialty drugs, the aging population and other demographic characteristics continue to contribute to rising
healthcare costs. Our managed care plans and products are designed to encourage providers and members to participate in quality, cost-effective health benefit
programs by using the full range of our innovative medical management services, health-outcomes based initiatives and health quality-based financial incentives.
We believe our market position and high business retention rates will enable us to realize the long-term benefits of investing in preventive and early detection
programs. Our ability to provide cost-effective health benefits products and services is enhanced through a disciplined approach to internal cost containment,
prudent management of our risk exposure and successful integration of acquired businesses. In addition, our ability to manage operating expenses continues to be a
driver of our overall profitability.
Our future results of operations will be impacted by certain external forces and resulting changes in our business model and strategy. Changes to our business
environment will continue as elected officials at the national and state levels enact, and both elected officials and candidates for election propose, modifications to
existing laws and regulations, including changes to taxes and fees. For additional discussion, see “Regulation” below in this “Business” section and Part I, Item 1A
“Risk Factors” included in this Annual Report on Form 10-K.
Our results of operations are also impacted by levels and mix of membership, which can change as a result of the quality and pricing of our health benefits
products and services, an aging population, economic conditions, changes in unemployment, the continued and future impact of large-scale emergencies like the
COVID-19 pandemic, acquisitions, entry into new markets and expansions in or exits from existing markets. These membership trends could be negatively
impacted by various factors that could have a material adverse effect on our future results of operations such as general economic downturns that result in business
failures, failure to obtain new customers or retain existing customers, premium increases, benefit changes, membership impacts caused by Medicaid
redeterminations, changes in how our members access healthcare services, or our exit from a specific market. See Part I, Item 1A “Risk Factors” and Part II, Item 7
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in this Annual Report on Form 10-K.
We continue to enhance interactions with customers, providers, brokers, agents, employees and other stakeholders through digital technology and
improvements to internal operations. Our approach includes not only the sales and distribution of health benefits products through digital technology, but also
implementing advanced capabilities that improve services benefiting customers, agents, brokers and providers while optimizing administrative costs. These
enhancements can also help improve the quality, coordination and safety of healthcare through increased communications between patients and their physicians.
Through our participation in various federal government programs, we generated approximately 29% of our total consolidated revenues from agencies of the
U.S. government for the year ended December 31, 2023 and 28% for the years ended December 31, 2022 and 2021, respectively. The majority of these revenues
are contained in our Health Benefits segment as described below. An immaterial amount of our total consolidated revenues is derived from activities outside of the
U.S. and Puerto Rico.
Reportable Segments
In 2022, we managed and presented our operations through the following four reportable segments: Commercial & Specialty Business, Government Business,
CarelonRx and Other. In the first quarter of 2023, we reorganized our reportable segments as described below. Previously reported information in this Annual
Report on Form 10-K has been reclassified to conform to the new presentation and reflect changes that occurred in 2023.
Our Health Benefits segment offers a comprehensive suite of health plans and services to our Individual, Employer Group risk-based, Employer Group fee-
based, BlueCard , Medicare, Medicaid and FEHB program members. Our Health Benefits segment also includes our National Government Services business. The
Health Benefits segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and
provides a variety of specialty and other insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance benefits.
Our CarelonRx segment includes our pharmacy business. CarelonRx markets and offers pharmacy services, including pharmacy benefit management (“PBM”)
services, to our affiliated health plan customers, as well as to external customers outside of the health plans we own. CarelonRx offers a comprehensive pharmacy
services portfolio, which includes all core
®
-5-

-- 6 of 533 --

pharmacy services, such as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a
prescription drug database and member services.
Our Carelon Services segment integrates physical, behavioral, social and pharmacy services to deliver whole health affordably by creating value through the
offering of market-competitive services powered by analytics. Carelon Services offers a broad array of healthcare related services and capabilities to internal and
external customers including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services and subrogation
services, as well as health and wellness programs. At the end of 2023, Carelon Services integrated Carelon Global Solutions into the Carelon family of offerings.
The companies under Carelon Global Solutions have been providing services related to data management, information technology, and business operations since
2019 and were previously included within our Corporate & Other segment.
Our Corporate & Other segment includes our businesses that do not individually meet the quantitative threshold for an operating segment, as well as corporate
expenses not allocated to our other reportable segments.
For additional information, see Note 20, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual
Report on Form 10-K.
Membership
Our medical membership includes the following customer types: Individual, Employer Group risk-based, Employer Group fee-based, BlueCard , Medicare,
Medicaid and FEHB. In addition, we also serve customers who purchase one or more of our other products or services that are often ancillary to our health
business.
Our products are generally developed and marketed with an emphasis on the differing needs of our customers. In particular, our product development and
marketing efforts take into account the differing characteristics between the various customers served by us, as well as the unique needs of educational and public
entities, labor groups, the FEHB program, national employers and state-run programs servicing low-income, high-risk and underserved markets. Overall, we seek
to establish pricing and product designs to provide value for our customers while achieving an appropriate level of profitability for each of our customer categories
balanced with the competitive objective to grow market share. We believe that one of the keys to our success has been our focus on these distinct customer types,
which better enables us to develop benefit plans and services that meet our customers’ unique needs. Further, CarelonRx was built to simplify pharmacy care and
focus on the whole person, and we expect it will make it easier for our customers to achieve better health outcomes at a lower total cost of care while improving
consumer experience.
We market our Individual, Medicare and certain Employer Group products with a smaller employee base through direct marketing activities and an extensive
network of independent agents, brokers and retail partnerships. Products for commercial customers with a larger employee base are generally sold through
independent brokers or consultants retained by the customer who work with industry specialists from our in-house sales force. In the Individual markets, we offer
on-exchange products through state- or federally-facilitated marketplaces (the “Public Exchange”) in compliance with the Patient Protection and Affordable Care
Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively, the “ACA”) and off-exchange products. Federal subsidies are
available for certain members, subject to income and family size, who purchase Public Exchange products.
We made the decision to expand our participation in the Individual state- or federally-facilitated marketplaces for 2024. We also expect growth in our Public
Exchange membership as Medicaid members who are no longer eligible for Medicaid coverage continue to exit the Medicaid program and seek coverage
elsewhere. For 2024, we are offering Individual Public Exchange products in 141 of the 143 rating regions in which we operate, in comparison to 138 of the 143
rating regions in 2023. See “Regulation” below in this “Business” section for additional discussion about the Public Exchange marketplace.
Being a licensee of the BCBS association of companies, of which there were 34 independent primary licensees including us as of December 31, 2023, provides
significant market value, especially when competing for very large multi-state employer groups. For example, each BCBS member company is able to utilize other
BCBS licensees’ substantial provider networks and discounts when any BCBS member works or travels outside of the state in which their policy is written. This
program is referred to as BlueCard . BlueCard host members are generally members who reside in or travel to a state in which an Elevance Health subsidiary is
the Blue Cross and/or Blue Shield licensee and who are covered under an employer-
®
® 	®
-6-

-- 7 of 533 --

sponsored health plan serviced by a non-Elevance Health controlled BCBS licensee, which is the “home” plan. We perform certain administrative functions for
BlueCard host members, including claims pricing and administration, for which we receive service fees from the BlueCard members’ home plan. Other
administrative functions, including maintenance of enrollment information and customer services, are performed by the home plan. See “BCBSA Licenses” below
in this “Business” section for additional information on our BCBSA licenses. We refer to members in our service areas licensed by the BCBSA as our BCBS-
branded, or Anthem BCBS, business. Non-BCBS-branded business refers to members in our non-BCBS-branded, or Wellpoint plans, which include Amerigroup,
Freedom Health, HealthSun, MMM, Optimum Healthcare and Simply Healthcare plans.
For additional information describing each of our customer types and changes in medical membership over the last three years, see “Management’s Discussion
and Analysis of Financial Condition and Results of Operations - Membership” included in Part II, Item 7 of this Annual Report on Form 10-K.
Product and Service Descriptions
Various forms of managed care products have been developed to contain the cost of healthcare by negotiating contracts with hospitals, physicians and other
providers to deliver high-quality healthcare to members at favorable rates. These products usually feature medical management and other quality and cost
optimization measures such as pre-admission review and approval for certain non-emergency services, pre-authorization of outpatient surgical procedures, network
credentialing to determine that network physicians and hospitals have the required certifications and expertise, and various levels of care management programs to
help members better understand and navigate the healthcare system. In addition, providers may have incentives to achieve certain quality measures, may share
medical cost risk or may have other incentives to deliver quality medical services in a cost-effective manner. Also, certain plans offer members incentives for
healthy behaviors, such as smoking cessation and weight management. Members are charged periodic, prepaid premiums and generally pay copayments,
coinsurance and/or deductibles when they receive services.
Health Benefits
• Commercial Risk-Based Products. We offer employer groups a diversified mix of managed care risk-based products including: Preferred Provider Organization
(“PPO”), Health Maintenance Organization (“HMO”), Consumer-Driven Health Plans (“CDHP”), Traditional Indemnity and Point-of-Service (“POS”) plans.
PPO plans generally provide members the freedom to choose any healthcare provider, but require the member to pay a greater portion of the provider’s fee in
the event the member chooses not to use a provider participating in the PPO’s network. HMOs include comprehensive managed care benefits generally
through a participating network of physicians, hospitals and other providers. CDHPs generally combine a high-deductible PPO plan with an employer-funded
and/or employee-funded personal care account, which may result in tax benefits to the employee and allow some or all of the dollars remaining in the personal
care account at year-end to be rolled over to the next year for future healthcare needs. Traditional indemnity plans offer the member an option to select any
healthcare provider for covered services, with coverage subject to deductibles and coinsurance and with member cost-sharing usually limited by out-of-pocket
maximums. POS products blend the characteristics of HMO, PPO and indemnity plans. In general, POS plans allow members to choose to seek care from a
provider within the plan’s network or outside the network, subject to, among other things, certain deductibles and coinsurance.
We also offer Individual risk-based products on and off the Public Exchange, covering essential health benefits (as defined in the ACA) along with many other
requirements and cost-sharing features.
• Commercial Fee-Based Products. We provide a broad array of managed care services to fee-based groups, including claims processing, provider network
access, medical management, care management and wellness programs, actuarial services and other administrative services. Fee-based health plans are also
able to use our provider networks and to realize savings through our negotiated provider arrangements, while allowing employers the ability to design certain
health benefit plans in accordance with their own requirements and objectives. We also charge a premium to underwrite stop loss insurance for employers that
maintain fee-based plans but want to limit their retained risk.
In addition, we perform certain administrative functions for BlueCard host members, discussed under “Membership” above, including claims pricing and
administration, for which we receive service fees from the BlueCard members’
® 	®
®
®
-7-

-- 8 of 533 --

home plans. Other administrative functions, including maintenance of enrollment information and customer service, are performed by the home plan.
• Specialty Products. We offer an array of products and services to both risk-based and fee-based customers in conjunction with our health plans as well as to
unaffiliated healthcare plans that are not Elevance Health subsidiaries.
◦ Stop Loss Insurance. Our stop loss insurance arrangements are built around our clients’ needs while assuming 100% of the risk. We offer specific and
aggregate plans that will provide options to meet our clients’ coverage terms, budget and risk tolerance; active claims management to help avoid errors and
missing claims; as well as cost containment to assist our clients with claims and cost control.
◦ Dental. Our dental plans include networks in certain states in which we operate and are offered on both a risk-based and fee-based basis. Our members
also have access to additional dental providers through our participation in the National Dental GRID, a national dental network developed by and for
BCBS plans that offers in-network discounts across the country.
◦ Vision. Our vision plans include networks within the states in which we operate and are offered on both a risk-based and fee-based basis.
◦ Life. We offer an array of competitive individual and group term life insurance benefit products. The life insurance products include term life and
accidental death and dismemberment.
◦ Disability. We offer short-term and long-term disability and leave of absence products.
◦ Supplemental Health. We offer supplemental health products, including accident, critical illness and hospital indemnity, which provide coverage for
specific conditions or circumstances.
• Medicare Plans. We offer a wide variety of plans, products and options to individuals age 65 and older such as Medicare Advantage, including Special Needs
Plans (“SNPs”), dual-eligible programs through Medicare-Medicaid Plans (“MMPs”), Medicare Supplement plans and Medicare Part D Prescription Drug
Plans (“Medicare Part D”).
Medicare Advantage plans provide Medicare beneficiaries with a managed care alternative to traditional Medicare and often include a Medicare Part D benefit.
In addition, our Medicare Advantage SNPs provide tailored benefits to special needs individuals who are institutionalized or have severe or disabling chronic
conditions and to dual-eligible customers, who are low-income seniors and persons under age 65 with disabilities. Medicare Advantage SNPs are coordinated
care plans specifically designed to provide targeted care, covering all the healthcare services considered medically necessary for members and often providing
professional care coordination services, with personal guidance and programs that help members maintain their health. Medicare Advantage membership also
includes Medicare Advantage members in our Group Retiree Solutions business who are retired members of commercial accounts or groups who are not
affiliated with our commercial accounts that have selected a Medicare Advantage product through us. MMP is focused on serving members who are dually
eligible for Medicaid and Medicare. Medicare Supplement plans typically pay the difference between healthcare costs incurred by a beneficiary and amounts
paid by the traditional Medicare Fee-For-Service program. Medicare Part D offers a prescription drug plan to Medicare and MMP beneficiaries.
• Medicaid Plans and Other State-Sponsored Programs. Our Medicaid business includes our managed care alternatives through public-funded healthcare
programs, including Medicaid; Medicaid expansion programs; Temporary Assistance for Needy Families (“TANF”); programs for seniors and people with
disabilities (“SPD”); Children’s Health Insurance Programs (“CHIP”); and specialty programs such as those focused on long-term services and support
(“LTSS”), HIV/AIDS, children living in foster care, behavioral health and/or substance abuse disorders, and intellectual disabilities and/or developmental
disabilities. The Medicaid program makes federal matching funds available to all states for the delivery of healthcare benefits for low income and/or high
medical risk individuals. These programs are managed by the individual states based on broad federal guidelines. Our Medicaid plans also cover certain dual-
eligible customers, as previously described above, who also receive Medicare benefits. In 2023, we provided Medicaid and other state sponsored services, such
as administrative services, in Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Indiana, Iowa, Kentucky, Louisiana, Maryland,
Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, North Carolina, Ohio, Puerto Rico, South Carolina, Tennessee, Texas, Virginia, Washington,
West Virginia and Wisconsin.
-8-

-- 9 of 533 --

• Federal Employees Health Benefits Program. FEHB members consist of United States government employees and their dependents within our geographic
markets through our participation in the national contract between the BCBSA and the U.S. Office of Personnel Management.
• Medicare Administrative Operations. Through our NGS subsidiary, we serve as a fiscal intermediary, carrier and Medicare administrative contractor for the
federal government by providing administrative services for the Medicare program, Parts A and B, which generally provides coverage for persons who are 65
or older and for persons who are under 65 and disabled or with end-stage renal disease. Part A of the Medicare program provides coverage for services
provided by hospitals, skilled nursing facilities and other healthcare facilities. Part B of the Medicare program provides coverage for services provided by
physicians, physical and occupational therapists and other professional providers, as well as certain durable medical equipment and medical supplies.
CarelonRx
Our subsidiary CarelonRx markets and offers pharmacy services to our affiliated health plan customers throughout the country in our Health Benefits segment,
as well as to customers outside of the health plans we own. Our comprehensive pharmacy services portfolio includes all core pharmacy services, such as home
delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database and
member services.
CarelonRx delegates certain core pharmacy services to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation (“CVS”), pursuant to
an agreement that is set to terminate on December 31, 2025 (the “CVS Agreement”).
Carelon Services
Business units in Carelon Services offer a broad array of healthcare related services and capabilities to internal and external customers, including utilization
management, behavioral health, integrated care delivery, palliative care, payment integrity services and subrogation services, health and wellness programs,
information technology services and global business process support. Key services offered include:
• Advanced Analytics and Services. We leverage data, analytics, and insights to help improve outcomes and lower the cost of care, by ensuring that our
members receive safe, appropriate, high-quality, cost-effective care and that our providers are reimbursed accurately and timely.
• Behavioral Health. We provide comprehensive behavioral health management services through clinical and network administration. In a limited capacity, we
also provide high-quality, evidence-based behavioral healthcare and counseling services through licensed clinicians in convenient and accessible locations.
• Care Delivery. We provide highly integrated, personalized care to patients with chronic and complex conditions, whether in their home, care centers, mobile
units, skilled nursing facilities, hospitals, or virtually. Additionally, we provide non-hospice, community-based palliative care to deliver an extra layer of
personalized support and whole-person care.
Competition
The managed care industry is highly competitive, both nationally and in our local markets. Competition continues to be intense due to aggressive marketing,
pricing, bid activity for government-sponsored programs, business consolidations, new strategic alliances, new competitors in the market, a proliferation of new
products, technological advancements, the impact of legislative reform, increased quality awareness and price sensitivity among customers and changing market
practices, such as increased usage of telehealth.
We believe that participants in the managed care industry compete for customers based on quality of service, price, access to provider networks, access to care
management and wellness programs (including health information), innovation, effective use of digital technology, breadth and flexibility of products and benefits,
expertise and reputation (including National Committee on Quality Assurance (“NCQA”) accreditation status as well as CMS Star ratings), brand recognition
-9-

-- 10 of 533 --

and financial stability. Our ability to attract and retain customers is substantially tied to our ability to distinguish ourselves from our competitors in these areas.
We believe our exclusive right to market products under the most recognized brand in the industry, BCBS, in our most significant markets provides us with
greater brand recognition over competitive product offerings. Typically, we are the largest participant in each of our BCBS branded markets, and thus are closely-
watched by other health benefits companies.
Product pricing remains competitive and we strive to price our health benefit products and design our Medicare and Medicaid bids consistent with anticipated
underlying medical trends. We believe our pricing and bid strategy, based on predictive modeling, proprietary research and data-driven processes, has positioned us
to benefit from the potential growth opportunities available through entry into new markets, expansions in existing markets and as a result of any future changes to
the current regulatory scheme. We believe that our pricing and bid strategy, brand name and network quality will provide a strong foundation for membership
growth opportunities in the future.
Our provider networks give us a highly competitive unit cost position and provide distinctive service levels which allow us to offer a broad range of affordable
health benefit products to our customers. To build our provider networks, we compete with other health benefits plans for the best contracts with hospitals,
physicians and other providers. We believe that physicians and other providers primarily consider customer volume, reimbursement rates, timeliness of
reimbursement and administrative service capabilities along with the reduction of non-value added administrative tasks when deciding whether to contract with a
health benefits plan.
At the sales and distribution level, we compete for qualified agents and brokers to recommend and distribute our products. Strong competition exists among
insurance companies and health benefits plans for agents and brokers with demonstrated ability to secure new business and maintain existing accounts. We believe
that the quality and price of our products, support services, reputation and prior relationships, along with a reasonable commission structure, are the factors agents
and brokers consider in choosing whether to market our products. We believe that we have good relationships with our agents and brokers, and that our products,
support services and commission structure compare favorably to those of our competitors in all of our markets.
In addition, the pharmacy industry is highly competitive, and CarelonRx is subject to competition from national, regional and local pharmacy service
providers, insurers, health plans, large retail pharmacy chains, large retail stores, supermarkets, mail order pharmacies, web pharmacies and specialty pharmacies.
Strong competition within the pharmacy industry has generated greater demand for lower product and service pricing, increased revenue sharing and enhanced
product and service offerings.
Pricing and Underwriting of Our Products
We price our products based on our assessment of current healthcare claim costs and emerging healthcare cost trends, combined with charges for
administrative expenses, risk and profit. We continually review our product designs and pricing guidelines on a national and regional basis so that our products
remain competitive and consistent with our profitability goals and strategies.
Our revenue on Medicare policies is based on annual bids submitted to CMS. We base the commercial and Medicaid premiums we charge and our Medicare
bids on our estimates of future medical costs over the fixed contract period. In applying our pricing to each employer group and customer, we aim to maintain
consistent, competitive and disciplined underwriting standards. We employ our proprietary accumulated actuarial and financial data to determine underwriting and
pricing parameters for both our risk-based and fee-based businesses.
In most circumstances, our pricing and underwriting decisions follow a prospective rating process in which a fixed premium is determined at the beginning of
the contract period. For our risk-based business, any deviation, favorable or unfavorable, from the medical costs assumed in determining the premium is our
responsibility. Some of our larger groups employ retrospective rating reviews, where positive experience is partially refunded to the group, and negative experience
is charged against a rate stabilization fund established from the group’s favorable experience or charged against future favorable experience. In addition, our ACA
and government risk-based contracts may include minimum medical loss ratio, risk adjustment, or risk corridor arrangements, which also stabilize premiums based
upon claims experience.
-10-

-- 11 of 533 --

Our pharmacy services pricing through CarelonRx is presented to market via discounts off the average wholesale price for drugs dispensed through the retail,
mail and specialty channels as well as through rebate projections. We utilize group-specific script data, formulary, network and clinical care program selection
combined with administrative expense, risk and profit guidance to set market competitive pricing discounts and rebate projections. Pharmacy services pricing
guidelines guide the underwriting process and undergo an annual external review process to ensure market competitiveness.
Networks and Provider Relations
Our relationships with physicians, hospitals and professionals that render healthcare services to our members are guided by local, regional and national
standards for network development, reimbursement and contract methodologies. While following industry standards, we are simultaneously seeking to lead
transformation efforts within our healthcare system, moving from a fragmented model premised on episodic intervention to one based on proactive, coordinated
care built around the needs of the patient. A key element of this transformation involves a transition from traditional fee-for-service payment models to models
where providers are paid based on the value, both in quality and affordability, of the care they deliver.
We establish “market-based” hospital reimbursement payments that we believe are fair, but aggressive, and among the most competitive in the market. We
also seek to ensure that physicians in our network are paid in a timely manner at appropriate rates. In many instances, we deploy multi-year contracting strategies,
including case rates or fixed rates, to limit our exposure to medical cost inflation and to increase cost predictability. We maintain both broad and narrow provider
networks to ensure member choice, based on both price and access needs, while implementing programs designed to improve the quality of care our members
receive. Increasingly, we are supplementing our broad-based networks with smaller or more cost-effective networks that are designed to be attractive to a more
price-sensitive customer segment, such as Public Exchange customers.
Our reimbursement strategies vary across markets and depend on the degree of consolidation and integration of physician groups and hospitals. Under a fee-
for-service reimbursement methodology for physicians, fee schedules are developed at the state level based on an assessment of several factors and conditions,
including the CMS resource-based relative value system (“RBRVS”), medical practice cost inflation and physician supply. We utilize CMS RBRVS fee schedules
as a reference point for fee schedule development and analysis. The RBRVS structure was developed, maintained, and updated by CMS and is used by the
Medicare program and other major health plans. In addition, we have implemented and continue to expand physician incentive contracting, or “pay-for-
performance,” which ties physician payment levels to performance on clinical measures.
While we generally do not delegate full financial responsibility to our physician providers in the form of capitation-based reimbursement, we maintain
capitation-based arrangements in certain markets where we determine that market dynamics result in it being a useful method to lower costs and reduce
underwriting risk. Our provider engagement and contracting strategies have evolved to include value-based contracting arrangements that meet providers where
they are in the movement from traditional fee-for-service to value-based care. These programs are designed to support commercial, Medicare and Medicaid
programs and the unique characteristics of these populations. Our value-based contracting programs are designed to reward our contracted providers for improving
the overall quality of care they deliver by adhering to evidence-based medicine. In addition, these value-based contracts also share with the providers total cost of
care savings that are achieved by adhering to evidence-based medicine over time. For providers who contract in one of our value-based programs, we work with
them to share gaps in care information and other important data to assist them in managing the care of their patients. Often providers will also grant us access to
data to support the efficient administration of program components. This data can allow us to more efficiently capture information regarding the risk of our
membership and the overall adherence to evidence-based medicine, as well as information to more efficiently perform utilization management administration.
Our hospital contracts provide for a variety of reimbursement arrangements depending on local market dynamics and current hospital utilization efficiency.
Most hospitals are reimbursed a fixed amount per day or reimbursed a per-case amount, per admission, for inpatient covered services. A small percentage of
hospitals, primarily rural, sole community hospitals, are reimbursed on a discount from approved charge basis for covered services. Our “per-case” reimbursement
methods utilize many of the same attributes contained in Medicare’s Diagnosis Related Groups methodology. Hospital outpatient services are reimbursed by fixed
case rates, fee schedules or percent of approved charges. Our hospital contracts recognize unique hospital attributes, such as academic medical centers or
community hospitals, and the volume of care
-11-

-- 12 of 533 --

performed for our members. To improve predictability of expected costs, we frequently use a multi-year contracting approach with providers. In addition, the
majority of our hospital contracts include a pay-for-performance component where reimbursement levels are linked to improved clinical performance, patient
safety and medical error reduction.
Seasonality
We experience seasonality in our Health Benefits segment. While our premium revenues are not seasonal, our benefit costs typically increase during the year
as our risk-based members pay their contractual portion of claims responsibility under annual deductibles and reach their out-of-pocket maximum limits.
Medical Management Programs
We have a broad array of medical management activities that facilitate improvements in the quality of care provided to our members and promote cost-
effective medical care. These medical management activities and programs are administered and directed by physicians and nurses with the goal of ensuring that
the care delivered to our members is supported by appropriate medical and scientific evidence, is received on a timely basis and occurs in the most appropriate
setting. The medical management programs available to our members may vary depending on the particular plan or product in which they participate.
Care coordination is one of the strategies we utilize and is based on nationally recognized criteria developed by third-party medical specialists to help
coordinate inpatient as well as outpatient care and monitor appropriate utilization of such services. Our case management focuses on identifying membership that
will require a high level of intervention and providing assistance to manage their healthcare needs. Precertification is utilized to assess appropriateness of certain
hospitalizations and other medical services prior to the services being rendered. Our medical policy committee determines our national policies and guidelines for
the application of medical technologies, procedures and services and reviews these policies and guidelines at least once a year or as new published clinical evidence
becomes available. We are actively engaged with our hospital and physician networks to enable them to improve medical and surgical care and achieve better
outcomes for our members. We also work with outside experts through a process of external review to provide our members scientifically and clinically evidence-
based medical care. Our web-based tools allow our members to obtain or compare cost estimates for care, including out-of-pocket costs.
We remain committed to assisting our members in making informed and value-based healthcare decisions, providing for easier navigation of healthcare
services and delivering a better healthcare experience.
Care Management and Wellness Products and Programs
We continue to expand our suite of integrated care management programs and tools. Availability of these programs and tools to our members may depend on
the particular plan or product in which they participate. Our care management tools and programs are designed to increase quality and reduce medical costs for our
members and help them make better decisions about their well-being as they navigate the healthcare system. Our digital engagement platform, Sydney Health, is
designed to give our members access to personalized health and wellness resources; medical, pharmacy, dental, vision, life and disability benefits details; as well as
virtual care services, all in one place. Our care management, infertility services and maternity management programs serve as adjuncts to physician care. Through
these programs, medical professionals help to educate participants regarding their care and condition. Our 24/7 NurseLine offers access to qualified, registered
nurses to allow our members to make informed decisions about the appropriate level of care and avoid unnecessary worry. Our CareMore subsidiary specializes in
whole-person care for members with complex and chronic conditions to improve clinical outcomes and patient well-being. Our Aspire Health subsidiary engages
with members near end of life and/or requiring palliative care to manage serious illnesses and improve quality of life during a difficult time. Beginning in 2024,
Aspire Health and CareMore have rebranded and now operate under the new name, Carelon Health. With our integrated information systems and sophisticated data
analytics, we help our members improve their compliance with evidence-based care guidelines, provide personal care notes that alert members to potential gaps in
care, enable more prudent healthcare choices and assist in the realization of member out-of-pocket cost savings. Our employee assistance programs provide 24/7
telephonic support for personal and crisis events and provide resources such as counseling and referral assistance with childcare, health and wellness, financial
issues, legal issues, adoption and daily living. We have a comprehensive behavioral health case management program supporting a wide range of members who are
impacted by their behavioral health conditions, including specialty areas such as eating disorders, anxiety, depression and substance abuse. The program assists
members and their
-12-

-- 13 of 533 --

families with obtaining appropriate behavioral health treatment, offering community resources, providing education and telephonic support, and promoting
provider collaboration.
Healthcare Quality Initiatives
Increasingly, the healthcare industry is able to define quality healthcare based on effective, safe, equitable and affordable care in preventive health, outcomes of
care and optimal care management for chronic disease. A key to our success has been our ability to develop partnerships by working with our network physicians,
hospitals, and social resources providers to improve the quality outcomes of the healthcare and social impact services provided to our members, their families, and
the community-at-large. Our ability to promote quality medical care, address health-related social risks, and advance health equity has been recognized by NCQA,
the largest and most respected national accreditation program for managed care health plans.
Several quality healthcare measures, including the Healthcare Effectiveness Data and Information Set (“HEDIS ”), have been incorporated into NCQA’s
accreditation processes. HEDIS measures range from preventive services, such as screening mammography and pediatric immunization, to elements of care,
including decreasing the complications of diabetes, improving treatment for patients with heart disease, integration of behavioral health, and racial and ethnic
stratification measurement to help close healthcare disparities.
Through our Carelon Medical Benefits Management, Inc. subsidiary, formerly known as AIM Specialty Health, we promote appropriate, safe and affordable
member care in areas including imaging, sleep disorders, cardiac testing, oncology drugs and musculoskeletal procedures. These expanded specialty benefit
management solutions leverage clinical expertise and technology to engage provider communities and members in the more effective and efficient use of outpatient
services and to promote the most appropriate use of clinical services to improve the quality of care.
Through our Carelon Post Acute Solutions, Inc. subsidiary, formerly known as myNEXUS, Inc., we perform management review for home health and post-
acute institutional services provided to Medicare members, with the goal of ensuring they receive appropriate, high-quality care and supporting their transition back
into the home. Effective management of these services can help reduce preventable hospital admissions and readmissions, thereby improving healthcare outcomes
for patients. Additionally, Carelon Post Acute Solutions, Inc. has developed programs to address healthcare quality by identifying and closing care gaps. A social
determinants of health program screens our members for social needs and connects members to appropriate community resources to encourage better care
outcomes. Both medical benefits management and post acute solutions programs are examples of how we facilitate improvements in the quality of care provided to
our members and promote cost-effective medical care.
The physical aspects of health have been traditionally the focus and the priority for healthcare. However, unique life circumstances and experiences impact
every individual and their health. We seek to understand our members' health-related social needs to create a healthcare system that synchronizes care delivery for
physical, behavioral, social and pharmacy needs. We are advancing our efforts through consistent screening of our members for their social needs by using
industry-standard tools such as the Protocol for Responding to & Assessing Patients’ Assets, Risks & Experiences, co-creating social action plans with our
members, connecting members to related social support services, and evaluating the entire process for continuous quality improvement. We are committed to
ensuring that all people, regardless of age, race or ethnicity, sexual orientation, gender identity, disability, and geographic or financial access can receive
individualized care. Harnessing data gives a more complete picture of each individual and their health needs and can help make healthcare more personalized and
equitable. Strengthening communities has a positive effect on health; therefore, we value and nurture our local ties, which are a key component of our whole-health
approach and drive us to work closely with community organizations that create support networks. Using our data, we also identify the resources needed to support
local residents, including the people who we serve, to ensure those resources can better meet local needs.
BCBSA Licenses
We are a party to license agreements with the BCBSA that entitle us to the exclusive, and in certain areas, non-exclusive, use of the Blue Cross and Blue Shield
names and marks in assigned geographic territories. BCBSA is a national association of independent Blue Cross and Blue Shield companies, the primary function
of which is to promote and preserve the integrity of the BCBS names and marks, as well as provide certain coordination among the member companies. Each
BCBSA licensee is an independent legal organization and is not responsible for obligations of other BCBSA member organizations. Although
®
®
-13-

-- 14 of 533 --

previously we did not have a right to sell products and services using the BCBS names and marks outside of the states in which we are licensed to sell BCBS
products, under the terms of the subscriber settlement agreement and release (“Subscriber Settlement Agreement”) among the class of plaintiffs, BCBSA and Blue
Cross and/or Blue Shield licensees, including us (the “Blue plans”) and some large national employers with self-funded plans (specifically identified in the
Subscriber Settlement Agreement), have a right to request a second Blue plan bid in addition to a bid from the local Blue plan. The Subscriber Settlement
Agreement received final approval in August 2022.
We are required to pay an annual license fee to the BCBSA based on enrollment and also to comply with various requirements and restrictions regarding our
operations and our use of the BCBS names and marks. These requirements and restrictions include, among other things: minimum capital and liquidity
requirements; enrollment and customer service performance requirements; participation in programs that provide portability of membership between plans;
disclosures to the BCBSA relating to enrollment and financial conditions; disclosures as to the structure of the BCBS system in contracts with third parties and in
public statements; plan governance requirements; cybersecurity requirements; a requirement that at least 80% (or, in the case of Blue Cross of California,
substantially all) of a licensee’s annual combined local net revenue, as defined by the BCBSA, attributable to healthcare plans and related services within its service
areas must be sold, marketed, administered or underwritten under the BCBS names and marks; a requirement that neither a plan nor any of its licensed affiliates
may permit an entity other than a plan or a licensed affiliate to obtain control of the plan or the licensed affiliate or to acquire a substantial portion of its assets
related to licensable services; governance requirements such as a requirement that we divide our Board of Directors into three classes serving staggered three-year
terms; a requirement that we guarantee certain contractual and financial obligations of our licensed affiliates; and a requirement that we indemnify the BCBSA
against any claims asserted against it resulting from the contractual and financial obligations of any subsidiary that serves as a fiscal intermediary providing
administrative services for Medicare Parts A and B. In addition, a change of control or violation of the BCBSA ownership limitations on our capital stock,
impending financial insolvency or the appointment of a trustee or receiver or the commencement of any action against us seeking our dissolution could cause a
termination of our license agreements.
We believe that we and our licensed affiliates are currently in compliance with these standards. The standards under the license agreements may be modified in
certain instances by the BCBSA. See Part I, Item 1A, “Risk Factors” in this Annual Report on Form 10-K for additional details on the impact if we were not to
comply with these license agreements and Note 14, “Commitments and Contingencies – Litigation and Regulatory Proceedings – Blue Cross Blue Shield Antitrust
Litigation,” of the Notes to our Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K for additional information on the
Subscriber Settlement Agreement.
Regulation
General
Our operations are subject to comprehensive and detailed state, federal and international regulation throughout the jurisdictions in which we do business. These
laws and regulations, which can vary significantly from jurisdiction to jurisdiction, restrict how we conduct our businesses and result in additional burdens and
costs to us. Further, federal and state laws and regulations are subject to amendments and changing interpretations in each jurisdiction. The application of these
complex legal and regulatory requirements to the detailed operation of our businesses creates areas of uncertainty. In addition, there are numerous proposed
healthcare laws and regulations at the federal and state levels, including single payer, Medicare for All and public option proposals, some of which could materially
adversely affect our businesses if they were to be enacted.
Supervisory agencies, including federal and state regulators, departments of health and insurance and secretaries of state, have broad authority to:
• grant, suspend and revoke licenses to transact business;
• regulate our products and services in great detail;
• regulate, limit, or suspend our ability to market products, including participation in Medicare and the Public Exchanges;
• determine through a procurement process our ability to participate in certain programs, including state Medicaid programs;
-14-

-- 15 of 533 --

• retroactively adjust premium rates;
• monitor our solvency and reserve adequacy;
• audit, and recover audit discrepancies, including risk adjustment data validation (“RADV”) audits;
• scrutinize our investment activities on the basis of quality, diversification and other quantitative criteria; and
• impose monetary and criminal sanctions for non-compliance with regulatory requirements.
To carry out these tasks, these government entities periodically examine our operations and accounts.
The health benefits business, pharmacy services, and related healthcare products and services businesses also may be adversely impacted by court and
regulatory decisions that expand or invalidate the interpretations of existing statutes and regulations. It is uncertain whether we could recoup, through higher
premiums or other measures, the increased costs of mandated benefits or other increased costs caused by potential legislation, regulation or court rulings. See Part
I, Item 1A “Risk Factors” in this Annual Report on Form 10-K.
The Consolidation Appropriations Act of 2023
Under the Consolidated Appropriations Act of 2023, Congress decoupled Medicaid eligibility redetermination from the Public Health Emergency initially
declared in January 2020 relating to COVID-19 (the “PHE”). As a result, states were permitted to begin removing ineligible beneficiaries from their Medicaid
programs starting April 1, 2023, and the majority of our Medicaid markets began doing so as of June 30, 2023. This process is anticipated to take up to 14 months
to complete, although most states are expected to complete the redetermination process by June 30, 2024. As redeterminations have resumed, we have experienced
a decline in our Medicaid membership. We have seen, and we expect to continue to see, growth in our commercial plans, including through the Public Exchanges,
and Medicare as members who are no longer eligible for Medicaid coverage in our 14 commercial states seek coverage elsewhere. On May 11, 2023, the PHE
ended in accordance with the Biden Administration’s January 30, 2023 announcement.
The Inflation Reduction Act of 2022
The Inflation Reduction Act of 2022 (the “Inflation Reduction Act”), which was signed into law in August 2022, contains a variety of provisions that impact
our business, including an extension of the American Rescue Plan Act of 2021's enhanced Premium Tax Credits (“PTC”) through 2025; imposing a new corporate
alternative minimum tax; providing a one percent excise tax on repurchases of stock made after December 31, 2022; allowing CMS to negotiate prices on a limited
set of prescription drugs in Medicare Parts B and D beginning in 2026; instituting caps on insulin cost sharing in Medicare Parts B and D; redesigning of the
Medicare Part D benefit; adding a requirement that drug manufacturers pay rebates if prices increase beyond inflation; and delaying the implementation of the
Trump Administration Medicare drug rebate rule to 2032. The extension of the enhanced PTC has allowed for growth in Individual Public Exchange enrollment as
Medicaid eligibility redeterminations have resumed, supporting continuity of coverage for more people.
The Consolidated Appropriations Act of 2021
The Consolidated Appropriations Act of 2021 (the “2021 Appropriations Act”) has impacted us since its passage and in the future may have a material effect
upon our business, including procedures and coverage requirements related to surprise medical bills and new mandates for continuity of care for certain patients,
price comparison tools, disclosure of broker compensation, mental health parity reporting, and reporting on pharmacy benefits and drug costs. The requirements of
the 2021 Appropriations Act applicable to us have varying effective dates, some of which were effective in December 2021 and during 2022, and others that were
extended into 2023 since the enactment of the 2021 Appropriations Act.
State Regulation of Insurance Companies and HMOs
Our insurance and HMO subsidiaries must obtain a certificate of authority and maintain that license in the jurisdictions in which they conduct business. The
National Association of Insurance Commissioners (“NAIC”) has adopted model regulations that, where adopted by states, require expanded governance practices,
risk and solvency assessment reporting and the filing of periodic financial and operating reports. Most states have adopted these or similar measures to expand the
scope of regulations relating to corporate governance and internal control activities of HMOs and insurance companies. Health insurers and HMOs are subject to
state examination and periodic license renewal.
-15-

-- 16 of 533 --

In addition, we are regulated as an insurance holding company and are subject to the insurance holding company acts of the states in which our insurance
company and HMO subsidiaries are domiciled. These acts contain certain reporting requirements, as well as restrictions on transactions between an insurer or
HMO and its affiliates, and may restrict the ability of our regulated subsidiaries to pay dividends to our holding companies. These holding company laws and
regulations generally require registration with applicable state departments of insurance and the filing of reports describing capital structure, ownership, financial
condition, certain intercompany transactions, enterprise risks, corporate governance and general business operations. State insurance holding company laws and
regulations require notice or prior regulatory approval of transactions including acquisitions, material intercompany transfers of assets, guarantees and other
transactions between the regulated companies and their affiliates, including parent holding companies. Applicable state insurance holding company acts also restrict
the ability of any person to obtain control of an insurance company or HMO without prior regulatory approval. “Control” is generally defined as the direct or
indirect power to direct or cause the direction of the management and policies of a person and is presumed to exist if a person directly or indirectly owns or controls
10% or more of the voting securities of another person. Dispositions of control generally are also regulated under the state insurance holding company acts.
The states of domicile of our regulated subsidiaries have statutory risk-based capital (“RBC”) requirements for health and other insurance companies and
HMOs based on the Risk-Based Capital (RBC) For Health Organizations Model Act. These RBC requirements are intended to assess the capital adequacy of life
and health insurers and HMOs, taking into account the risk characteristics of a company’s investments and products. In general, under these laws, an insurance
company or HMO must submit a report of its RBC level to the insurance department or insurance commissioner of its state of domicile for each calendar year. The
law requires increasing degrees of regulatory oversight and intervention as a company’s RBC declines. As of December 31, 2023, the RBC levels of our insurance
and HMO subsidiaries exceeded all applicable mandatory RBC requirements. For more information on RBC capital and additional liquidity and capital
requirements for a licensee of the BCBSA, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital
Resources – Capital Resources,” included in Part II, Item 7 of this Annual Report on Form 10-K.
Ongoing Requirements and Changes Stemming from the ACA
Since its enactment in 2010, the ACA has introduced new risks, regulatory challenges and uncertainties, has impacted our business model and strategy and has
required changes in the way our products are designed, underwritten, priced, distributed and administered. We expect the ACA will continue to significantly impact
our business and results of operations, including pricing, minimum medical loss ratios (“MLRs”) and the geographies in which our products are available. We also
expect further and ongoing regulatory guidance on a number of issues related to Medicare, including evolving methodology for ratings and quality bonus
payments. CMS also frequently proposes changes to its program that audits data submitted under the risk adjustment programs in ways that could increase financial
recoveries from plans. We will continue to evaluate the impact of the ACA as any further developments occur.
Certain significant provisions of the ACA include, among others:
• The creation of Public Exchanges for individuals and small group customers.
• The establishment of minimum MLR thresholds by line of business for the commercial market (which may be subject to more restrictive MLR thresholds
under state regulations, such as those in New York). Medicare Advantage or Medicare Part D prescription drug plans that do not meet the mandated
threshold will have to pay a minimum MLR rebate, will be subject to restricted enrollment if MLR is below the threshold for three consecutive years and
are subject to contract termination if the plan’s MLR is below the threshold for five consecutive years. In addition, state Medicaid programs are required to
set managed care capitation rates such that a minimum MLR is projected to be achieved; however, states are not required to collect remittances if the
minimum MLR is not achieved.
Approximately 52.3% and 18.0% of our premium revenue and medical membership, respectively, were subject to the minimum MLR regulations as of
and for the year ended December 31, 2023. Approximately 52.3% and 17.5% of our premium revenue and medical membership, respectively, were subject
to the minimum MLR regulations as of and for the year ended December 31, 2022.
• The creation of an incentive payment program for Medicare Advantage plans. CMS developed the Medicare Advantage Star ratings system, which awards
between 1.0 and 5.0 Stars to Medicare Advantage plans based on
-16-

-- 17 of 533 --

performance in several categories, including quality of care and customer service. The Star ratings are used by CMS to award quality-based bonus
payments to plans that receive a rating of 4.0 or higher. The methodology and measures included in the Star ratings system can be modified by CMS
annually. CMS released our 2024 Star ratings in October 2023, which will be used to determine our Medicare Advantage plans’ Star quality bonus
payments beginning in 2025. Based on our membership at September 1, 2023, 34% of our Medicare Advantage members were in plans with 2024 Star
ratings of at least 4.0 Stars, compared to 64% of our Medicare Advantage members being in plans with 2023 Star ratings of at least 4.0 Stars based on our
membership at September 1, 2022. This change in our 2024 Star ratings is expected to impact our Star quality bonus payments and plan level rebates
beginning in 2025. We expect a reduction to our 2025 operating revenue of approximately $500 million, net of offsets from contracting provisions.
Further, we expect to partially mitigate the financial impact to our 2025 operating gain and net income through various strategies such as contract
diversification, operating expense efficiencies, capital deployment alternatives and network enhancements.
• The implementation of a Medicare Advantage payment formula, which prevents reimbursement rates from increasing as much as otherwise would be
expected.
We continue to evaluate our experience in the Public Exchange markets. Based on the viability of the Public Exchanges and availability of federal subsidies,
we have made a decision to expand our participation in the Individual state, or federally-facilitated, marketplaces for 2024. We also expect continued growth in our
Public Exchange membership as Medicaid members who are no longer eligible for Medicaid coverage continue to exit the Medicaid program and seek coverage
elsewhere. For 2024, we are offering Individual Public Exchange products in 141 of the 143 rating regions in which we operate, in comparison to 138 of the 143
rating regions in 2023. Any variation from our expectations regarding acuity, enrollment levels, adverse selection, or other assumptions utilized in setting premium
rates could have a material adverse effect on our results of operations, financial position, and cash flows, and may require further adjustments to our rates and
participation going forward. Changes to our business environment are likely to continue as elected officials at the federal and state levels continue to enact, and
both elected officials and candidates for election continue to propose, significant modifications to existing laws and regulations, including changes to taxes and
fees.
Pharmacy Services and Drug Benefit Regulation
Pharmacy services, including PBMs, are regulated at both the federal and state levels and must comply with federal and state statutes and regulations
governing a PBM's business, including, but not limited to pharmacy network restrictions and configurations, formulary management, affiliate pharmacy
reimbursement, anti-steering to affiliated pharmacies, pharmacy effective rates, guarantees and reconciliations, reimbursement pricing type mandates, purchase
discount and/or rebate arrangements with drug manufacturers, advertising and licensing. For example, in recent years the state and federal governments have
banned certain PBM business practices, including “gag clauses,” which prohibit pharmacists from informing patients when a lower cost drug was available as a
substitute, and “clawbacks,” which occurred when PBMs sought to recoup the difference between the reimbursed cost of the drug and the patient’s copay when the
drug itself was less expensive than the copay paid by the patient. Regulation in the states varies dramatically and ranges from licensure of PBMs as third-party
administrators, licensure specifically as a PBM, and licensure accompanied by additional disclosures and limitations of business practices to varying degrees.
PBMs are also subject to continued changes in public policy, legislation, laws, and regulations relating to drug benefits and pharmacy services, which include,
but are not limited to (1) regulation of rebates from drug manufacturers that would require rebate dollars to be applied at the point-of-sale, (2) federal policy
changes to set the prices for a subset of drugs covered under the Medicare program, (3) reforms to the Medicare drug benefit, such as beneficiary cost-sharing
changes that aim to lower consumer costs, (4) attempts at both the federal and state levels to prohibit the use of spread pricing contracts in both the commercial and
Medicaid markets, (5) prior authorizations of drugs, (6) transparency and public disclosure of costs and profits, (7) prohibiting exclusive specialty and mail
pharmacy networks, (8) limiting accreditation and credentialing requirements, and (9) consumer choice/any willing provider requirements. These changes in public
policy, legislation, laws, and regulations have the potential to have broad impacts on our pharmacy benefit management services and could materially adversely
affect our business.
Our pharmacy services business include home delivery and specialty pharmacies, as well as clinic-based pharmacies, which must be licensed as pharmacies in
the states in which they are located. Certain pharmacies must also register with the U.S. Drug Enforcement Agency (“DEA”) and individual state-controlled
substance authorities to dispense controlled
-17-

-- 18 of 533 --

substances. In addition to adhering to the laws and regulations in the states where our pharmacies are located, we may also be required to comply with certain laws
and regulations in certain states into which one of our pharmacies delivers prescription drugs, including those requiring us to register with Boards of Pharmacy as a
non-resident pharmacy. These non-resident states generally expect our pharmacies to follow the laws of the state in which the pharmacies are located, but some
non-resident states also require us to comply with certain of their pharmacy regulations as well. Additionally, pharmacies that participate in Medicare or Medicaid
pharmacy networks are required to comply with applicable Medicare and Medicaid provider rules and regulations.
Privacy, Confidentiality and Data Standards Regulation
The federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and the administrative simplification provisions of HIPAA impose a
number of requirements on covered entities (including insurers, HMOs, group health plans, providers and clearinghouses) and their business associates relating to
the use, disclosure and safeguarding of protected health information. These requirements include uniform standards of common electronic healthcare transactions;
privacy and security regulations; and unique identifier rules for employers, health plans and providers.
Also, the Health Information Technology for Economic and Clinical Health (“HITECH”) Act provisions of the American Recovery and Reinvestment Act of
2009 and corresponding implementing regulations have imposed additional requirements on the use and disclosure of protected health information such as
additional data breach notification and reporting requirements, contracting requirements for HIPAA business associate agreements, strengthened enforcement
mechanisms and increased penalties for HIPAA violations. Federal consumer protection laws may also apply in some instances to privacy and security practices
related to personally identifiable information.
The federal Gramm-Leach-Bliley Act generally places restrictions on the disclosure of non-public information to non-affiliated third parties, and requires
financial institutions, including insurers, to provide customers with notice regarding how their non-public personal information is used, including an opportunity to
“opt out” of certain disclosures. State departments of insurance and certain federal agencies adopted implementing regulations as required by federal law.
The Cybersecurity Information Sharing Act of 2015 encourages organizations to share cyber threat indicators with the federal government and, among other
things, directed HHS to develop a set of voluntary cybersecurity best practices for organizations in the healthcare industry, which were issued in 2018.
New cybersecurity disclosure rules adopted by the Securities and Exchange Commission (SEC) became effective in December 2023. Public companies that
experience a cybersecurity incident that is determined by the company to be material are now required to file a Current Report on Form 8-K describing the material
aspects of the nature, scope and timing of the incident, and the material impact or reasonably likely material impact on the company, including its financial
condition and results of operations, within four business days after the company determines that the incident is material.
In addition, Public Exchanges are required to adhere to privacy and security standards with respect to personally identifiable information and to impose privacy
and security standards that are at least as protective as those the Public Exchange has implemented for itself on insurers offering plans through the Public
Exchanges and their designated downstream entities, including pharmacy services providers and other business associates. These standards may differ from, and be
more stringent than, HIPAA.
Furthermore, states have begun enacting more comprehensive privacy laws and regulations addressing consumer rights to data protection or transparency that
may affect our privacy and security practices, such as state laws like the California Privacy Rights Act of 2020 that govern the use, disclosure and protection of
member data and impose additional breach notification requirements. The NAIC is drafting a new privacy model act, which could expand consumer privacy rights.
State consumer protection laws may also apply to privacy and security practices related to personally identifiable information, including information related to
consumers and care providers. Complying with conflicting cybersecurity regulations and varying enforcement philosophies, which may differ from state to state,
requires significant resources and may materially and adversely affect our ability to standardize our products and services across state lines.
-18-

-- 19 of 533 --

Federal regulations have been finalized in the following areas that will continue to materially impact our operations:
• Federal regulations on data interoperability that require claims data to be made available to third parties unaffiliated with us that may not be HIPAA
regulated; and
• Federal regulations requiring hospitals and health insurers to publish negotiated prices for services, including the health plan price transparency
regulations issued in October 2020 by the U.S. Departments of Health and Human Services, Labor and Treasury (the “Health Plan Transparency Rule”).
Beginning in July 2022, the Health Plan Transparency Rule required us to disclose, on a monthly basis, detailed pricing information regarding negotiated rates
for all covered items and services between the plan or issuer and in-network providers and historical payments to, and billed charges from, out-of-network
providers. Additionally, beginning in 2023, we were required to make available to members personalized out-of-pocket cost information and the underlying
negotiated rates for 500 covered healthcare items and services, including prescription drugs. Effective January 1, 2024, this requirement has expanded to include all
items and services.
Employee Retirement Income Security Act of 1974
The provision of services to certain employee welfare benefit plans is subject to the Employee Retirement Income Security Act of 1974, as amended
(“ERISA”), a complex set of laws and regulations subject to interpretation and enforcement by the Internal Revenue Service and the Department of Labor. ERISA
regulates certain aspects of the relationships between us, the employers that maintain employee welfare benefit plans subject to ERISA and participants in such
plans. Some of our administrative services and other activities may also be subject to regulation under ERISA. In addition, certain states require licensure or
registration of companies providing third-party claims administration services for benefit plans. We provide a variety of products and services to employee welfare
benefit plans that are covered by ERISA. Plans subject to ERISA can also be subject to state laws, and the question of whether and to what extent ERISA preempts
a state law has been, and will continue to be, interpreted by many courts.
Guaranty Fund Assessments
Under insolvency or guaranty association laws in most states, insurance companies and HMOs can be assessed for amounts paid by guaranty funds for
policyholder losses incurred when an insurance company or HMO becomes insolvent. Most state insolvency or guaranty association laws currently provide for
assessments based upon the amount of premiums received on insurance underwritten within such state (with a minimum amount payable even if no premium is
received). Under many of these guaranty association laws, assessments are made retrospectively. Some states permit insurers or HMOs to recover assessments paid
through full or partial premium tax offsets or through future policyholder surcharges. The amount and timing of any future assessments cannot be predicted with
certainty; however, future assessments are likely to occur.
International Regulation
We have various international subsidiaries, which provide administrative and other services, that are subject to different, and sometimes more stringent, legal
and regulatory requirements that vary widely by jurisdiction. In addition, our non-U.S. operations are subject to U.S. laws regulating the conduct and activities of
U.S.-based businesses operating abroad, including but not limited to, the Foreign Corrupt Practices Act and corresponding foreign laws governing anti-bribery,
anti-corruption, anti-money laundering, data protection and privacy, employment, and other regulatory oversight initiatives.
Human Capital
The foundation of our strategy starts with our culture, and our associates are critical to fulfilling our purpose of improving the health of humanity. As of
December 31, 2023, our employee population, including all full-time, part-time and temporary workers, consisted of approximately 104,900 individuals, 78,100 in
the United States and 26,800 internationally. We believe we have built a high-performance culture that enhances our ability to deliver on our commitments and
guides us to address the challenges of today. We believe that our culture allows us to attract and retain talented and experienced individuals to support the
communities we serve.
Each year we conduct an internal associate engagement survey that provides our associates with an opportunity to share their opinions and experiences with
respect to their roles, their teams and the Company, and we also offer online feedback tools. Our management team reviews, monitors and analyzes associate
feedback and acts on responses to identify
-19-

-- 20 of 533 --

opportunities to adjust our policies and benefits to improve our associates’ experiences. More than 90% of our associates participated in the survey conducted in
2023.
Because dedication to human capital management is a core component of our corporate governance, the Compensation and Talent Committee of our Board of
Directors regularly reviews and discusses management's approach to talent acquisition and retention, and also monitors our programs and practices related to
workforce diversity and inclusion.
Inclusion & Diversity
The diversity of our associates is central to achieving key strategies and improving performance. We strive to attract, develop, maintain and support a diverse
and inclusive workforce comprised of a vast array of backgrounds, life experiences and cultures, which we believe enables a deeper connection with our members,
allowing us to better serve our members and communities, and drives greater business results. In order to build diverse and inclusive teams, our CEO and executive
management set expectations for inclusive leadership and hold leaders accountable for achieving results.
As of December 31, 2023, our U.S. associate population was approximately 77% female and 50% racially and ethnically diverse, while 65% of our managers
in the U.S. were female and 38% were racially or ethnically diverse.
Fair Pay
We are committed to a fair pay workplace. We were in the first cohort of companies certified by the Fair Pay Workplace (“FPW”), an independent certification
that takes a holistic approach to pay equity, partnering to design an annual pay equity action plan that includes a perpetual review of all positions, new hires and
promotions to effect meaningful and measurable change. This independent certification is based on a set of publicly available rules and standards and the endorsed
methodology of a group of leading experts from forward-thinking corporations, academia, human resources, data science and the legal field. After partnering with
and overseeing our review process, FPW has validated our analysis of our associate population, which found that pay for females in the U.S. is within 1% of their
male counterparts and pay for people of color in the U.S. is equal to their white counterparts, after taking into account neutral job-related factors.
Talent Development
Growing and developing our talent internally is key to our succession plans and our ability to lead at our best every day. To inspire a high-performance culture
and promote talent excellence, we offer individual, career and leadership development opportunities, encouraging associates to continually learn and grow. We
offer various instructor-led and virtual instructor-led programs and maintain a vast curriculum of relevant, on-demand learning and development resources. In 2023,
we invested a significant amount in human capital development, averaging approximately 28 hours of training and development per associate. Over 19% of our
U.S. workforce participated in our nine business resource groups, which provide associates meaningful opportunities to connect, collaborate and grow.
Health & Wellbeing
We have the privilege of touching the lives of millions of people each day, starting with the health of our own associates. To improve the health and wellbeing
of our associates, we offer a comprehensive compensation package, including competitive salaries, a 401(k) plan and medical, dental, vision and disability
coverage. In addition, we offer our associates wellness and behavioral health programs and tools to help them get and stay healthy and more easily manage their
work and personal lives. In 2023, we formalized our workforce practices and instituted a mixed hybrid, remote and in-office workplace strategy. We also foster
associate engagement through a variety of activities based in our key office locations.
-20-

-- 21 of 533 --

Information About Our Executive Officers
The following sets forth certain information regarding our executive officers and Chief Accounting Officer as of February 1, 2024.
Name 	Age 	Position
Gail K. Boudreaux 	63 	President and Chief Executive Officer
Mark B. Kaye 	44 	Executive Vice President and Chief Financial Officer
Peter D. Haytaian 	54 	Executive Vice President and President, Carelon and CarelonRx
Charles M. Kendrick, Jr. 	58 	Executive Vice President and President, Commercial & Specialty Health Benefits
Ratnakar V. Lavu 	53 	Executive Vice President and Chief Digital Information Officer
Felicia F. Norwood 	64 	Executive Vice President and President, Government Health Benefits
Blair W. Todt 	56 	Executive Vice President and Chief Legal and Administrative Officer
Ronald W. Penczek 	59 	Chief Accounting Officer and Controller
Ms. Boudreaux has served as our President and Chief Executive Officer and a Director of the Company since November 2017. Prior to joining us, she served
as Chief Executive Officer of GKB Global Health, LLC (healthcare consulting firm) from 2015 to November 2017. Prior thereto, Ms. Boudreaux was Executive
Vice President of UnitedHealth Group Incorporated (diversified healthcare company) from 2008 to 2015, including roles as Chief Executive Officer of
UnitedHealthCare (managed healthcare company), a subsidiary of UnitedHealth Group Incorporated from 2011 to 2014 and President of the Commercial Business
of UnitedHealthCare from 2008 to 2011. Before joining United HealthCare, she worked at Health Care Service Corporation (“HCSC”) (health insurance company)
as Executive Vice President of External Operations from 2005 to 2008 and President of Blue Cross and Blue Shield of Illinois from 2002 to 2005. Before joining
HCSC, Ms. Boudreaux held various positions at Aetna, Inc. (“Aetna”) (managed healthcare company), including Senior Vice President, Group Insurance.
Mr. Kaye has served as our Executive Vice President and Chief Financial Officer since November 2023. Prior to joining us, he served as the Executive Vice
President and Chief Financial Officer of Moody’s Corporation (“Moody’s”) from April 2021 to September 2023, with responsibility for all global finance activities
across the company and as Senior Vice President-Chief Financial Officer from August 2018 to April 2021. Prior to Moody’s, he served as Senior Vice President and
Head of Financial Planning and Analysis at Massachusetts Mutual Life Insurance Company (“MassMutual”) from February 2016 until July 2018, and Chief
Financial Officer of MassMutual U.S. since July 2015. Prior to that, Mr. Kaye served as Chief Financial Officer and Senior Vice President, Retirement Solutions, at
Voya Financial (formerly ING U.S.) from 2011 to 2015, and Mr. Kaye previously held various senior financial and risk reporting positions at ING U.S. and ING
Group. Prior to that, Mr. Kaye worked in the investment banking division of Credit Suisse First Boston.
Mr. Haytaian has served as our Executive Vice President and President of Carelon (formerly known as our Diversified Business Group) and CarelonRx
(formerly known as IngenioRx) since October 2021. Prior to his current role, Mr. Haytaian served as Executive Vice President and President of our Commercial &
Specialty Business Division beginning in April 2018. From June 2014 until April 2018, Mr. Haytaian served as our Executive Vice President and President of the
Government Business Division. Mr. Haytaian joined the Company in 2012 with our acquisition of Amerigroup Corporation (“Amerigroup”) and served as
President of our Medicaid business from 2013 until 2014. From 2005 to 2013, Mr. Haytaian held several leadership positions with Amerigroup, including serving
as Chief Executive Officer of the North Region for Amerigroup’s Medicaid business from 2012 until 2013. Mr. Haytaian has extensive experience leading
Medicare and Medicaid programs with Amerigroup and, prior thereto, with Oxford Health Plans, Inc.
Mr. Kendrick has served as our Executive Vice President and President of our Commercial & Specialty Health Benefits since October 2021. From January
2021 until October 2021, Mr. Kendrick served as President of our Commercial Business West Markets (California, Colorado, Indiana, Kentucky, Missouri, Nevada,
Ohio and Wisconsin). Mr. Kendrick joined us in 1995, and has held numerous leadership roles across the organization, including serving as President, Anthem
National Accounts/Central Markets from 2015 until January 2021 and President of National Accounts and General Manager for Anthem Blue Cross and Blue
Shield of Georgia from 2010 until 2015.
-21-

-- 22 of 533 --

Mr. Lavu joined Elevance Health as our Executive Vice President and Chief Digital Information Officer on February 5, 2024. Prior to joining us, he served as
Global Chief Digital Information Officer of Nike, Inc. (“Nike”) from July 2019 to February 2023. Prior to Nike, he served as Chief Technology Officer/CIO of
Kohl’s Corporation (“Kohls”) from March 2016 to June 2019, and he previously held other positions with Kohls beginning in 2011, including Executive Vice
President, Digital Technology, and Senior Vice President of Digital Innovation. Prior to that, Mr. Lavu served as Chief Technology Officer at Redbox Automated
Retail, LLC from October 2009 to October 2011.
Ms. Norwood has served as our Executive Vice President and President of our Government Health Benefits since June 2018. Prior to joining us, she was
Director of The Department of Healthcare and Family Services for the State of Illinois from 2015 to June 2018. Prior to that appointment, Ms. Norwood held a
variety of leadership roles at Aetna, with her most recent role as President of the Mid-America Region for Aetna from 2010 until 2013.
Mr. Todt has served as our Executive Vice President and Chief Legal Officer since November 2020 and as our Chief Administration Officer since April 2023.
Mr. Todt also served as our interim head of human resources and global security and safety team from January 2022 until March 2023. Prior to joining us, Mr. Todt
served as Senior Vice President, Legal, Compliance & Business Performance and Chief Legal Officer of HCSC from 2016 to July 2020. Prior to joining HCSC,
Mr. Todt held a variety of leadership roles at WellCare Health Plans, Inc. (health insurance company), with his most recent role as Senior Vice President, Chief
Legal and Administrative Officer and Secretary from 2010 until 2016.
Mr. Penczek has served as our Controller since November 2015 and as our Chief Accounting Officer since December 2015. He served as our Vice President
and Controller from 2013 to 2015. Prior to that appointment, Mr. Penczek served as Vice President and Assistant Controller from 2008 to 2013 and in various other
roles in our finance department from 2006 until 2008. Before joining us in 2005, Mr. Penczek was a Staff Vice President with CNA Insurance from 2000 to 2005
and had various positions with PricewaterhouseCoopers LLP from 1992 to 2000, including as a Manager.
Available Information
We are a large accelerated filer (as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) and are required, pursuant
to Item 101 of Regulation S-K, to provide certain information regarding our website and the availability of certain documents filed with or furnished to the U.S.
Securities and Exchange Commission (“SEC”). The SEC maintains a website that contains reports, proxy and information statements and other information
regarding issuers at www.sec.gov. Our website is www.elevancehealth.com. We have included our website address throughout this Annual Report on Form 10-K as
a textual reference only. The information contained on, or accessible through, our website is not incorporated into this Annual Report on Form 10-K or any of our
other SEC filings. We make available through our website, free of charge, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on
Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we
electronically file such material with or furnish it to the SEC. We also include on our website our Corporate Governance Guidelines, our Code of Conduct and the
charter of each standing committee of our Board of Directors. In addition, we intend to disclose on our website any amendments to, or waivers from, our Code of
Conduct that are required to be publicly disclosed pursuant to rules of the SEC and the New York Stock Exchange. Elevance Health, Inc. is an Indiana corporation
incorporated on July 17, 2001.
-22-

-- 23 of 533 --

ITEM 1A. RISK FACTORS.
In evaluating our business, the risks described below, as well as the other information contained in this Annual Report on Form 10-K, should be carefully
considered. Any one or more of such risks could materially and adversely affect our business, financial condition, results of operations and stock price and could
cause our actual results of operations and financial condition to vary materially from past or anticipated future results of operations and financial condition.
Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect us.
BUSINESS RISKS
If we fail to appropriately predict, price for and manage healthcare costs, the profitability of our products and services could decline, which could materially
adversely affect our business, cash flows, financial condition and results of operations.
Our profitability depends on accurately predicting and pricing healthcare costs and our ability to manage future healthcare costs through medical management,
product design, negotiation of favorable provider contracts and underwriting criteria. Total healthcare costs are affected by the type, number and cost of individual
services rendered. Numerous factors affecting healthcare costs may adversely affect our ability to predict and manage healthcare costs, and may impact our
business, cash flows, financial condition and results of operations. These factors include, among others, changes in healthcare practices, demographic
characteristics including the aging population, short and long-term risks associated with our members' lifestyle decisions, medical cost inflation, increased labor
costs, evolution of new technologies, drugs and treatments, increased cost of individual services, increased number and cost of prescription drugs, clusters of high
cost cases, increased use of services, including resulting from pandemics, large-scale medical emergencies, increasing natural disasters in connection with climate
change and other public health crises, new mandated benefits and treatment guidelines and changes to other regulations impacting our business.
Slight differences between predicted and actual medical costs or utilization rates as a percentage of premium revenues can result in significant changes in our
results of operations. Generally, our premiums on Commercial policies and Medicaid contracts are fixed for a 12-month period and are determined based on data
from several months prior to the commencement of the premium period. Our revenue from Medicare policies is based on bids submitted to CMS six months prior
to the start of the contract year. CMS has explicit gain and loss margin requirements within the bids, as well as contract-specific federal MLR annual requirements.
Accordingly, the costs we incur in excess of our benefit cost projections cannot be recovered in the contract year through higher premiums. Existing Medicaid
contract rates are often established by the applicable state, and our actual costs may exceed those rates. Many factors, including those discussed above, may cause
actual costs to exceed those estimated and reflected in our Commercial premiums and Medicare and Medicaid bids.
Although federal and state premium and risk adjustment mechanisms could help offset health benefit costs above our projections if the assumptions we use to
set our premium rates are significantly different than actual results, our results of operations and financial condition could still be adversely affected. The reserves
that we establish for health insurance policy benefits and other contractual rights and benefits are based on assumptions concerning a number of factors, including
trends in healthcare costs, expenses, general economic conditions and other factors. To the extent the actual claims experience is unfavorable compared to our
underlying assumptions, our incurred losses would increase, and future earnings could be adversely affected.
In addition to the challenge of managing healthcare costs, we face pressure to contain premium rates. Our customers may renegotiate their contracts to seek to
contain their costs or may move to a competitor to obtain more favorable premiums. Further, federal and state regulatory agencies may restrict or prevent entirely
our ability to implement changes in premium rates. A limitation on our ability to increase or maintain our premium or reimbursement levels or a significant loss of
membership resulting from our need to increase or maintain premium or reimbursement levels could adversely affect our business, cash flows, financial condition
and results of operations.
We expanded our participation in the Public Exchange markets for 2023 and as a result, offered Individual Public Exchange products in most of the rating
regions in which we operate. We further expanded in a limited number of additional counties in 2024. Any variation from our expectations regarding acuity,
enrollment levels, adverse selection, or other assumptions utilized in setting premium rates could have a material adverse effect on our results of operations,
financial position, and cash flows, and may require further adjustments to our rates and participation in Public Exchanges going forward.
-23-

-- 24 of 533 --

A significant reduction in the enrollment in our health benefits programs, pharmacy services or diversified products and services, particularly in states where
we have large regional concentrations, could have an adverse effect on our business, cash flows, financial condition and results of operations.
A significant reduction in the number of enrollees in our health benefits programs, pharmacy services, or diversified products and services could adversely
affect our business, cash flows, financial condition and results of operations. Factors that have contributed, and may continue to contribute to, a reduction in
enrollment include: reductions in workforce by existing customers, a reduction in Medicaid membership due to the end of the temporary suspension of eligibility
redetermination for Medicaid recipients in response to the COVID-19 pandemic, a general economic upturn that results in fewer individuals being eligible for
Medicaid programs, a general economic downturn that results in business failures and high unemployment rates, employers no longer offering certain healthcare
coverage as an employee benefit or electing to offer coverage on a voluntary, employee-funded basis, participation on Public Exchanges, federal and state
regulatory changes, failure to obtain new customers or retain existing customers, premium increases and benefit changes, our exit from a specific market, negative
publicity and news coverage, and failure to attain or maintain nationally recognized accreditations.
The states in which we operate with the largest concentrations of revenues include California, Virginia, New York, Ohio, Indiana, Florida, Texas and Georgia.
Due to this concentration of business in these states, we are exposed to potential losses resulting from the risk of state-specific or regional economic downturns
impacting these states. If any such negative economic conditions do not improve, we may experience a reduction in existing and new business, which could have a
material adverse effect on our business, cash flows, financial condition and results of operations.
A cyber-attack or other privacy or data security incident could result in an unauthorized disclosure of sensitive or confidential information, cause a loss of
data, disrupt our operations, give rise to remediation or other expenses, expose us to liability under federal, state and international laws, and subject us to
litigation and investigations, which could have an adverse effect on our business, cash flows, financial condition and results of operations.
As part of our normal operations, we collect, store, process, retain and analyze certain sensitive and confidential information, including personal information
subject to privacy, security and data breach notification requirements. Some of the data we process, store and transmit is outside of the U.S. due to the structure of
our information technology systems and our internal business operations. We are subject to a variety of continuously evolving federal, state and international laws
and rules regarding collection, dissemination, receipt, maintenance, protection, use, transmission, disclosure, privacy, confidentiality, security, availability, integrity,
creation, processing and disposal of sensitive or confidential information that, depending on the specific business and intended data use, include without limitation,
HIPAA's privacy and security rules, HIPAA's HITECH rule, the Gramm-Leach-Bliley Act, the General Data Protection Regulation and numerous state laws
governing personal information, including the California Consumer Privacy Act, as amended by the California Privacy Rights Act. We have programs in place to
detect, contain and respond to data, privacy and security incidents and provide employee awareness training regarding phishing, malware, and other risks to protect
against privacy and cybersecurity incidents. Our facilities and systems, and those of our third-party service providers, including our business associates, are
regularly the target of, and may be vulnerable to, cyber-attacks, security breaches, acts of vandalism, computer viruses, misplaced or lost data, programming and/or
human errors, negligent or wrongful conduct by associates or others with permitted access to our systems and information, or other threats.
We cannot ensure that we or our third-party service providers will be able to identify, prevent or contain the effects of cyber-attacks or other cybersecurity risks
that bypass our or their security measures or disrupt our or their information technology systems or business. Hardware, software or applications we develop or
procure from third parties may contain defects in design, manufacturer defects or other problems that could unexpectedly compromise information security. In
addition, because the techniques used to obtain unauthorized access, disable, disrupt or degrade service or sabotage systems change frequently, are becoming
increasingly sophisticated, and may not immediately produce signs of intrusion, we may be unable to anticipate these techniques, timely discover or counter them
or implement adequate preventative measures. Viruses, worms, malicious software programs or other unauthorized methods of acquiring data may be used to attack
our systems or otherwise exploit any security vulnerabilities which may cause system disruptions or shutdowns, or may cause personal, proprietary or confidential
information to be disclosed, misappropriated or compromised. We have business continuation and resiliency plans which are maintained, updated and tested
regularly in an effort to ensure successful containment and remediation of potential disruptions or cyber events. Cybersecurity and the continued development and
enhancement of our
-24-

-- 25 of 533 --

controls, processes and practices designed to protect our systems, computers, software, data and networks from attack, damage and unauthorized access remain a
priority for us.
We have been, and may in the future be, subject to litigation and governmental investigations related to cyber-attacks, privacy incidents and security breaches.
Any such future litigation or governmental investigation could divert the attention of management from the operation of our business, result in reputational damage
and have a material adverse impact on our business, cash flows, financial condition, and results of operations. Moreover, our programs to detect, contain, and
respond to data security incidents as well as contingency plans and insurance coverage for potential liabilities of this nature may not be sufficient to cover all claims
and liabilities.
Noncompliance with any privacy, security or data protection laws and regulations, or any security breach, cyber-attack or cyber-security breach, and any
incident involving the misappropriation, theft, loss or other unauthorized disclosure or use of, or access to, sensitive or confidential information, whether by us or
by one of our third-party service providers or their vendors, could require us to expend significant resources to continue to modify or enhance our protective
measures and to remediate any damage. In addition, this could negatively affect our operations, cause system disruptions, damage our reputation, cause
membership losses and contract breaches, and could also result in regulatory enforcement actions, material fines and penalties, litigation or other actions that could
have a material adverse effect on our business, cash flows, financial condition and results of operations.
If we fail to responsibly use and protect data, or if such data is found to be inaccurate or unreliable, our business and customers could suffer adverse
consequences.
We use de-identified and aggregated data to create analytic models designed to predict, and potentially improve, outcomes and patient care. The collection,
maintenance, protection, use, transmission, disclosure and disposal of sensitive personal information is regulated at the federal, state, international and industry
levels and requirements are also imposed on us and vendors through contracts with clients. We are also subject to various other consumer protection laws that
regulate our communications with customers. Certain of our businesses are also subject to the Payment Card Industry Data Security Standard, which is designed to
protect credit card account data as mandated by payment card industry entities. In addition, more jurisdictions are regulating the collection, use and transfer of data
across borders. These laws, rules, regulations and contractual requirements are subject to change, and the regulatory environment surrounding data protection and
privacy is generally becoming more onerous. Compliance with existing or new privacy, security or data protection laws, regulations and requirements may result in
increased enforcement, costs, and may constrain or require us to alter our business model or operations.
Further, if the data we rely upon to run our businesses is found to be inaccurate or unreliable or if we fail to maintain or protect our information systems and
data integrity effectively, we could experience failures in our technology products; lose existing customers; have difficulty attracting new customers; experience
problems in determining medical cost estimates and establishing appropriate pricing; have difficulty preventing, detecting and controlling fraud; have disputes with
customers, physicians and other healthcare professionals; become subject to regulatory sanctions, penalties, investigations or audits; incur increases in operating
expenses; or suffer other adverse consequences.
There are various risks associated with participating in Medicare and Medicaid programs, including dependence upon government funding and the timing of
payments, compliance with government contracts and increased regulatory oversight.
We contract with various federal and state agencies, including CMS, to provide managed health benefits services, such as Medicare Advantage, Medicare Part
D, Medicare Supplement, Medicaid, TANF, SPD, LTSS, CHIP, Medicaid expansion programs and various specialty programs, products and services. We also
provide various administrative services for other entities offering medical and/or prescription drug plans to their Medicaid or Medicare eligible members, and we
offer employer group waiver plans which provide medical and/or prescription drug coverage to retirees. We also participate in programs in several states for the
care of dual-eligible members. Regulatory reform initiatives or changes in existing laws or regulations applicable to these programs, or their interpretations, are
difficult to predict and could have a material adverse effect on our business, cash flows, financial condition and results of operations.
Revenues from the Medicare and Medicaid programs are dependent, in whole or in part, upon annual funding from the federal government and/or applicable
state governments, and base premium rates paid by each state or federal agency differ depending upon a combination of factors such as defined upper payment
limits, a member’s health status, age, gender, county
-25-

-- 26 of 533 --

or region, benefit mix, member eligibility category and risk scores. Future rates may be affected by continued government efforts to contain costs and federal and
state budgetary constraints. Certain state contracts are subject to cancellation in the event of the unavailability of state funds. Additionally, ongoing CMS changes to
the calculation of risk in the Medicare Advantage program may impact our federal funding. The federal government or any state in which we operate could
decrease rates paid to us, pay us less than the amount necessary to keep pace with our cost trends, cancel our contracts retroactively or seek an adjustment to
previously negotiated rates. In addition, various states’ Medicare-Medicaid dual-eligible plans are still subject to uncertainty surrounding payment rates and other
requirements, which could affect where we seek to participate in these programs. An unexpected reduction in payments, inadequate government funding or
significantly delayed payments for these programs may adversely affect our business, cash flows, financial condition and results of operations.
Other potential risks associated with Medicare Advantage and Medicare Part D plans include increased medical or pharmaceutical costs, data corrections
identified as a result of ongoing auditing and monitoring activities, potential uncollectability of receivables resulting from processing and/or verifying enrollment,
inadequacy of underwriting assumptions, inability to receive and process correct information (including inability due to systems issues by the federal government,
the applicable state government or us), uncollectability of premiums from members and limited enrollment periods. Actual results may be materially different than
our assumptions and estimates and could have a material adverse effect on our business, financial condition and results of operations.
Our contracts with CMS and state governmental agencies contain certain provisions regarding data submission, risk adjustment, provider network and
directory maintenance, quality measures, claims payment, timely and accurate processing of appeals and grievances, oversight of service providers, encounter data,
continuity of care, call center performance and other requirements specific to federal and state program regulations. We have been subject in the past, and may
again be in the future, to administrative actions, fines, penalties, liquidated damages or retrospective adjustments in payments made to our health plans as a result of
a failure to comply with these requirements, which has impacted, and in the future could impact our profitability. We have experienced retroactive rate adjustments
by certain state Medicaid agencies in the past, and such rate adjustments may occur in the future. Further, our state Medicaid contracts have not always been
renewed, we have not always been awarded new contracts as a result of the competitive procurement process, and in some cases, we have lost members under
existing contracts as a result of a post-award challenge by unsuccessful bidders, each of which could take place again in the future and have a material adverse
effect on our business, cash flows, financial condition and results of operations.
The Star Rating System utilized by CMS to evaluate Medicare Advantage Plans may have a significant effect on our revenue, as higher-rated plans tend to
experience increased enrollment, plans with a Star Rating of 4.0 or higher are eligible for quality-based bonus payments and plans with a Star Rating of 5.0 can
market to and enroll members year-round. CMS continues to change its rating system to make achieving and maintaining a 4.0 or higher Star Rating more difficult.
CMS released our 2024 Star Ratings in October 2023, which will be used to determine our Medicare Advantage plans' quality bonus payments in 2025. Based on
our membership at September 1, 2023, 34% of our Medicare Advantage members were in plans with 2024 Star Ratings of at least 4.0 Stars, compared to 64% of
our Medicare Advantage members being in plans with 2023 Star Ratings of at least 4.0 Stars based on our membership at September 1, 2022. This change in our
2024 Star ratings is expected to negatively impact our Medicare quality bonus payments, plan level rebates and operating revenue beginning in 2025 and our
enrollment may be negatively impacted as consumers seek higher rated plans. Further, if we do not improve our Star Ratings, or if quality-based bonus payments
are reduced or eliminated, we will experience further negative impact on our revenues and the benefits that our plans can offer, which could materially and
adversely affect the marketability of our plans, our membership levels, results of operations, financial condition and cash flows. Similarly, if we fail to meet or
exceed any performance standards imposed by state Medicaid programs in which we participate, we may not receive performance-based bonus payments or may
incur penalties.
In addition, our failure to comply with federal and state healthcare laws and regulations applicable to our participation in Medicaid and Medicare programs,
including those directed at preventing fraud, abuse and discrimination, could result in investigations, litigation, fines, restrictions on, or exclusions from, program
participation, or the imposition of corporate integrity agreements or other agreements with a federal or state governmental agency, any of which could adversely
impact our business, cash flows, financial condition and results of operations.
We are periodically subject to government audits, including CMS RADV audits of our Medicare Advantage Plans to validate diagnostic data, patient claims
and financial reporting, and audits of our Medicare Part D plans by the Medicare Part D Recovery Audit Contractor (“RAC”), as well as state Medicaid RAC
programs. In addition, we routinely perform ordinary
-26-

-- 27 of 533 --

course reviews of, among other things, our Medicare Advantage data submitted to CMS. These governmental audits, or changes in how these audits are conducted,
including changes that may result from the final RADV Audit rule that was issued in 2023, and internal reviews, could result in reports or disclosures for prior,
current or future filing years to federal or state regulatory agencies, submission of data corrections, and/or significant adjustments in payments made to our health
plans and future Medicare Advantage bids, which could adversely affect our financial condition and results of operations. Additionally, state regulators are
increasingly conducting audits to assess the quality of services we provide to our Medicare members. If we fail to report and correct errors discovered through our
own auditing procedures, during a RADV or RAC audit or during state regulatory audits, or otherwise fail to comply with applicable laws and regulations, we
could be subject to fines, civil penalties or other sanctions, which could have a material adverse effect on our ability to participate in these programs, and on our
financial condition, cash flows and results of operations.
Our Medicare and Medicaid contracts are also subject to various MLR rules, including minimum MLR thresholds, rebate requirements and audits, which could
adversely affect our membership and revenues if any of our state Medicare or Medicaid plans do not meet an applicable minimum MLR threshold. If a Medicare
Advantage, MMP or Medicare Part D contract pays minimum MLR rebates for three consecutive years, it will become ineligible to enroll new members. If a
Medicare Advantage or Medicare Part D contract pays such rebates for five consecutive years, it will be terminated by CMS.
A change in our healthcare product mix may impact our profitability.
Our healthcare products that involve greater potential risk generally tend to be more profitable than administrative services products and those healthcare
products where the employer groups assume the underwriting risks. Individuals and small employer groups are more likely to purchase our higher-risk healthcare
products because such purchasers are generally unable or unwilling to bear greater liability for healthcare expenditures. Typically, government-sponsored programs
also involve our higher-risk healthcare products. A shift of enrollees from more profitable products to less profitable products could have a material adverse effect
on our cash flows, financial condition and results of operations.
If we fail to develop and maintain satisfactory relationships with hospitals, physicians, pharmacy service providers and other healthcare providers, our
business, cash flows, financial condition and results of operations may be adversely affected.
Our profitability is dependent in part upon our ability to contract on favorable terms with hospitals, physicians, pharmacy services providers and supply chain
partners and other healthcare providers. These partners may elect not to contract with us, and the failure to secure or maintain cost-effective contracts on
competitive terms may result in a loss of membership or higher medical costs, which could adversely affect our business. In addition, consolidation among
healthcare providers, Accountable Care Organizations practice management companies, and other organizational structures that physicians, hospitals and other care
providers choose, as well as the ability of larger employers to contract directly with providers, has changed and may continue to change the way that these
providers interact with us and may alter the competitive landscape overall. Such organizations or groups of physicians may compete directly with us or be owned
by one of our competitors, which may impact our relationship with these providers or affect the way that we price our products and estimate our costs. Such
competition may require us to incur costs to change our operations, which could adversely affect our business, cash flows, financial condition, and results of
operations. In addition, price transparency initiatives, such as the Health Plan Transparency Rule, may impact our ability to obtain or maintain favorable contract
terms. For example, beginning in 2021, hospitals were required to publish online payer-specific negotiated charges for each item or service the hospital provides.
Our inability to contract with providers, or if providers attempt to use their market position to negotiate more favorable contracts or place us at a competitive
disadvantage, or the inability of providers to provide adequate care, could adversely affect our business. In addition, we do not have contracts with all providers
that render services to our members and, as a result, may not have a pre-established agreement about the amount of compensation those out-of-network providers
will accept for the services they render. State and federal laws, such as the No Surprises Act, define the compensation that must be paid to out-of-network providers
in certain scenarios, and related litigation has lessened the weight of the Qualifying Payment Amount during independent dispute resolution processes, which may
result in an increase in rates we must pay to out-of-network providers. Both our lack of contracts with certain providers and the development of new federal and
state laws could result in significant litigation or arbitration proceedings, to the extent a provider attempts to obtain payment from our members for the difference
between the amount we have paid and the amount they have charged, or other increases in rates paid to out-of-network providers.
-27-

-- 28 of 533 --

We are dependent on the success of our relationships with third parties for various services and functions.
We contract with various third parties to perform certain functions and services and provide us with certain information technology systems. Certain of these
third parties provide us with significant portions of our business infrastructure and operating requirements. For example, a single vendor can provide to us a wide
range of technology infrastructure services, such as end user (help desk and field support), data center, mainframe, payment card handling, storage and database
services and multi-cloud management services, and we are subject to the risks of any operational failure, termination or other restraints in such an arrangement. We
could become overly dependent on key vendors, which could cause us to lose core competencies. A termination of our agreements with, or disruption in the
performance of, one or more of these service providers could result in service disruptions or unavailability, reduced service quality and effectiveness, increased or
duplicative costs or an inability to meet our obligations to our customers. In addition, we may also have to seek alternative service providers, which may be
unavailable or only available on less favorable contract terms. Any of these outcomes could adversely affect our business, reputation, cash flows, financial
condition and operating results.
Our pharmacy services business would be adversely affected if we are unable to contract on favorable terms with third-party vendors, including
pharmaceutical manufacturers. We delegate certain PBM services, including, but not limited to, claims adjudication, pharmacy network administration, rebate
administration, advanced home delivery back-end dispensing, and customer service, to CVS pursuant to the CVS Agreement. If CVS fails to provide PBM services
as contractually required, we may not be able to meet the full demands of our customers, which could have a material adverse effect on our business, reputation and
results of operations. Additionally, we may not maintain favorable terms and conditions, including financial terms, to compete in the market. For additional
information on the CVS Agreement, see “Business — Product and Service Descriptions,” in Part I, Item 1 of this Annual Report on Form 10-K.
The failure to effectively maintain and upgrade our information systems, or the availability and integrity of our data, could adversely affect our business.
Our business depends significantly on effective information systems, and we have many different information systems for our various businesses, including
those that we have acquired as a result of our merger and acquisition activities. Our information systems require an ongoing investment, commitment of significant
resources to maintain and enhance existing systems, and development of new systems to keep pace with continuing changes in information processing technology,
emerging cyber-security risks, changing customer preferences, evolving industry and regulatory standards and legal requirements, including as a result of the ACA,
the Health Plan Transparency Rule, the 2021 Appropriations Act and federal data interoperability regulations. In addition, we may obtain significant portions of our
systems-related or other services from independent third parties (and their vendors), which may make our operations vulnerable if such third parties fail to perform
and oversee adequately. Further, unauthorized third parties present additional risk, including by propagating misinformation related to products, business and the
health industry.
Failure to adequately implement, consolidate, integrate, streamline, maintain and upgrade effective and efficient information systems with sufficiently
advanced technological capabilities could result in investigations, audits, fines and penalties, competitive and cost disadvantages to us compared to our
competitors, could divert management’s time, and could have a material adverse effect on our business, financial condition and results of operations. Failure or
disruption of our performance of, or our ability to perform, key business functions, including as a result of the unavailability or cyber-attack of our information
technology systems or those of third parties (including cloud service providers), could decrease response times, lower levels of service satisfaction and harm our
reputation. Our systems interface with and depend on third-party systems and we could experience service denials if demand for such service exceeds capacity, or
these systems fail or experience interruption. Despite our adoption and continued enhancement of business continuity and disaster recovery strategies, there is no
guarantee that such efforts will be effective, which could interrupt the functionality of our information technology systems or those of third parties. Our failure to
implement adequate business continuity and disaster recovery strategies could significantly reduce our ability to provide products and services to our customers and
clients, which could have a material adverse effect on our business and results of operations.
In addition, connectivity amongst technologies is becoming increasingly important, with recent trends bringing greater consumer engagement in healthcare;
therefore, the pace at which our customers will need enhanced technologies with sophisticated applications for mobile interfaces will quicken. If the information
systems we rely upon to run our business were found to be inaccurate or unreliable or if we fail to adequately maintain, upgrade, enhance, expand and protect our
information systems, security controls and data integrity effectively, we could experience problems in determining medical
-28-

-- 29 of 533 --

cost estimates and establishing appropriate pricing and reserves, have disputes with customers and providers, lengthen the pace of integration activities or otherwise
delay the launch of acquired products, face regulatory problems, including sanctions and penalties, incur increases in operating expenses or suffer other adverse
consequences, including a decrease in membership. Further, as connectivity of technologies advances, artificial intelligence and business processes supported by
large language models that are used by businesses and consumers may not operate as expected or may lead to unintentional bias, discrimination and/or data
exposure.
We are subject to risks associated with pandemics, like the COVID-19 pandemic, as well as other extreme events, large-scale medical emergencies and public
health crises, which could have a material adverse effect on our business, results of operations, and financial condition and financial performance.
A pandemic or other large-scale medical emergency or public health crisis, such as the COVID-19 pandemic, referred to collectively as “public health crises,”
may cause illness, death, quarantines, business and school shutdowns, reductions in business activity, travel and financial transactions, unemployment, inflation,
labor shortages, supply chain interruptions and overall economic and financial market instability. The following are some risks that we could experience as a result
of future public health crises, all of which could have a material adverse effect on our business, cash flows, financial condition and results of operations:
• Increased healthcare costs due to higher utilization rates of medical facilities and services and behavioral health services, increased labor costs resulting
from labor shortages and increases in medical expenses and associated hospital and pharmaceutical costs, including testing, treatment and the
administration of vaccines and other therapeutics and costs due to care deferred during the public health crisis, which may lead to additional care resulting
from missed treatments.
• Increased estimation uncertainty for our claims liability, as well as decreased predictability of Medicare and Medicaid rates due to changes in utilization of
medical facilities and services, medical expenses and other costs.
• A reduction in enrollment in our health benefits, pharmacy services, or other healthcare services and products or a change in membership mix to less
profitable lines of business by existing customers due to reductions in workforce and other impacts of an economic downturn.
• Cash flow volatility or shortfalls caused by delayed, delinquent or non-collectable payments.
If any future public health crisis occurs and continues for a prolonged period, these risks could be exacerbated, and cause further impact to our business and
operations. Additionally, other extreme events such as natural disasters, war, terrorism, increased crime, and civil unrest could create public health crises or
otherwise have a material adverse effect on our business, cash flows, financial condition and results of operations. In the event of a public health crises, we may
need to make temporary policy changes, such as waiving various medical requirements, assisting with replacement medications, transferring prescriptions and
expanding our help line. Natural disasters, such as wildfires, hurricanes and snow and ice storms, have impacted and may in the future impact our customers,
associates, facilities and third-party vendors located in the affected area. Furthermore, climate change could result in certain types of natural disasters occurring
more frequently or with more intense effects, which could have a long-term impact on general economic conditions and the health benefits and pharmacy services
industries in particular.
LEGAL, REGULATORY AND PUBLIC POLICY RISKS
We are subject to significant government regulation, and changes or proposed changes in the regulation of our business by federal and state regulators may
adversely affect our business, cash flows, financial condition and results of operations and the market price of our securities.
We are subject to significant state and federal regulation associated with many aspects of our business, including, but not limited to, licensing, premiums,
marketing activities, provider contracting, access and payment standards, and corporate governance and financial reporting matters, as described in greater detail in
Part I, Item 1, “Business—Regulation” in this Annual Report on Form 10-K. Further, the integration into our business of entities that we acquire, or the expansion
of our business into new businesses or jurisdictions, may affect the way in which existing laws and rules apply to us.
Changes to existing laws, rules and regulations or judicial interpretation, application or enforcement thereof, or development of new laws, rules, regulatory
interpretations or judgments could force us to change how we conduct our business, affect the products and services we offer (and where we offer them), restrict
revenue and enrollment growth,
-29-

-- 30 of 533 --

increase our costs, including operating, healthcare technology and administrative costs, restrict our ability to obtain new product approvals and implement changes
in premium rates, and require enhancements to our compliance infrastructure and internal controls environment, which could adversely impact our business and
results of operations. In addition, legislative and/or regulatory policies or proposals that seek to manage the healthcare industry or otherwise impact our business
may cause the market price of our securities to decrease, even if such policies or proposals never become effective. In particular, further regulations and
modifications to the ACA and laws and regulations stemming from the ACA could impact the market for our products, funding for ACA programs, the regulations
applicable to us and the fees and taxes payable by us and otherwise affect our business and future operations, some of which may adversely affect our financial
condition and results of operations.
We are required to obtain and maintain insurance, licenses and other regulatory approvals to market certain of our products and services, to increase prices for
certain regulated products and services and to consummate some of our acquisitions and dispositions. Delays in obtaining or failure to obtain or maintain these
approvals, as well as future regulatory action by state or federal authorities, could have a material adverse effect on the profitability or marketability of our health
benefits, pharmacy services, healthcare and other products and services or on our business, financial condition, and results of operations. In addition, changes in
government regulations or policies that apply to government-sponsored programs such as Medicare and Medicaid including, among other things, reimbursement
levels, quality-based bonus payment determinations, eligibility and redetermination requirements, benefit coverage requirements and additional governmental
participation, could also adversely affect our business, cash flows, financial condition, and results of operations. The annual redetermination process for Medicaid
recipients was temporarily suspended in response to the COVID-19 pandemic; however, pursuant to the 2023 Appropriations Act, states began removing ineligible
beneficiaries from their Medicaid programs starting April 1, 2023. Where states allow certain programs to expire or have not opted for Medicaid expansion under
the ACA or to expand managed care programs, we have experienced reduced Medicaid enrollment and reduced growth opportunities. If future modifications to
laws and regulations significantly reduce Medicaid enrollment, our Medicaid business will be negatively impacted.
We have experienced past assessments under state or federal insolvency or guaranty association laws applicable to insurance companies, HMOs and other
payers, and may experience assessments in the future if, for example, premiums established by other companies for their health insurance products, including
certain long-term care products, are inadequate to cover their costs. Any such assessment could expose us to the risk of paying a portion of an impaired or insolvent
insurance company’s claims through state guaranty associations. We are not currently able to estimate our potential financial obligations, losses or the availability
of offsets associated with potential guaranty association assessments; however, any significant increase in guaranty association assessments could have a material
adverse effect on our business, cash flows, financial condition, and results of operations.
We expect state legislatures will continue to focus on healthcare delivery and financing issues, including actions to reduce or limit increases to premium
payments, provider billing protections, greater access to care and broader reforms of state health insurance markets. State ballot initiatives could also be put to
voters that could materially impair our operating environment. If enacted into law, these state proposals and actions could have a material adverse impact on our
business, cash flows, operations or financial condition. Additionally, state legislative actions and litigation could impact ERISA pre-emption. Further, in the past,
Congress has considered, and may consider in the future, various forms of managed care reform legislation which, if adopted, could fundamentally alter the
treatment of coverage decisions under ERISA, including limiting ERISA’s preemptive effect on state laws, and other laws and could increase our costs, expose us
to expanded liability, permit greater state regulation on our operations, or require us to revise the ways in which we conduct business.
We are subject to various risks associated with our international operations.
As we expand and operate our business outside of the U.S., we are presented with different challenges, including challenges in adapting to new markets,
languages, business, labor and cultural practices, regulatory environments and local civil unrest or political controversy. Adapting to these challenges could require
us to devote significant senior management attention and other resources. If we are unable to successfully manage our international operations, our business, cash
flows, financial condition and results of operations could be adversely affected. In the future, we may acquire or operate new businesses outside of the U.S.,
increasing our exposure to these risks.
Certain of our subsidiaries operate internationally and are subject to regulation in the jurisdictions in which they are organized or conduct business related to,
among other things, local and cross border taxation, intellectual property,
-30-

-- 31 of 533 --

investment, management control, labor, anti-fraud, anti-corruption and privacy and data protection, which vary by jurisdiction. In addition, we are subject to U.S.
laws that regulate the conduct and activities of U.S.-based businesses operating abroad, such as the Foreign Corrupt Practices Act. Violations of these laws and
regulations could result in fines, criminal sanctions against us, our officers or associates, restrictions or outright prohibitions on the conduct of our business and
significant reputational harm and could adversely affect our ability to market our products and services, which may have a material adverse effect on our business,
financial condition and results of operations.
We face risks related to litigation.
We are, and may in the future be, a party to a variety of legal actions that may affect our business, such as administrative charges before government agencies,
employment and employment discrimination-related suits, employee benefit claims, breach of contract actions, tort claims and intellectual property-related
litigation. In addition, because of the nature of our business, we are subject to a variety of legal actions relating to our business operations, including the design,
administration and offering of our products and services. These could include claims relating to the denial or limitation of health benefits; federal and state false
claims act laws; dispensing of drugs associated with our pharmacy services business; professional liability claims arising out of the delivery of healthcare and
related services to the public; development or application of medical policies and coverage and clinical guidelines; medical malpractice actions; allegations of anti-
competitive and unfair business activities; provider disputes over reimbursement and contracts; provider tiering programs; narrow networks; termination of
provider contracts; the recovery of overpayments from providers; fee-based business; disputes over co-payment calculations; reimbursement of out-of-network
claims; the failure to disclose certain business practices; the failure to comply with various state or federal laws, including but not limited to, ERISA and the Mental
Health Parity Act; and customer audits and contract performance, including government contracts. These actions or proceedings could result in substantial costs to
us, require management to spend substantial time focused on litigation, result in negative media attention, and may adversely affect our business, reputation,
financial condition, results of operations and cash flows.
We are also involved in, or may in the future be party to, pending or threatened litigation incidental to the business we transact or arising out of our operations,
including, but not limited to, breaches of security and violations of privacy requirements, shareholder actions, compliance with federal and state laws and
regulations (including qui tam or “whistleblower” actions), or sales and acquisitions of businesses or assets. From time to time, we are involved as a party in
various governmental investigations, audits, reviews and administrative proceedings, including challenges relating to the award of government contracts. These
investigations, audits and reviews include routine and special investigations by state insurance departments, various federal regulators including CMS and the HHS
Office of Inspector General, state attorneys general, the Department of Justice, and various offices of the U.S. Attorney General. Following an investigation, we
may be subject to civil or criminal fines, penalties, and other sanctions if we are determined to be in violation of applicable laws or regulations. Liabilities that may
result from these actions could have a material adverse effect on our cash flows, results of operations and financial condition.
Recent court decisions and legislative activity may increase our exposure for any of these types of claims. In some cases, substantial non-economic (including
injunctive relief), treble or punitive damages may be sought. Our international footprint also subjects us to additional potential disputes or differing interpretations
related to contractual rights, tax positions, and regulatory oversight. Some liabilities and damages may not be covered by the insurance we carry, insurers may
dispute coverage, or the amount of insurance may not be enough to cover the damages awarded. In addition, insurance coverage for all or certain forms of liability
may become unavailable or prohibitively expensive in the future. Any adverse judgment against us resulting in such damage awards could result in negative
publicity and have an adverse effect on our cash flows, results of operations and financial condition.
There are various risks associated with providing health benefits and other healthcare diversified products and services.
We continue to evolve our business to offer products and services beyond traditional health insurance, including digital health technology, pharmacy services,
behavioral and clinical care services, which subjects us to litigation and regulatory risks that are different from our traditional product and services offerings and
may materially affect our exposure to other risks.
The direct provision of healthcare services by certain of our subsidiaries involves risks of additional litigation brought against us or our associates for alleged
malpractice or professional liability claims arising out of the delivery of healthcare and related services. In addition, liability may arise from maintaining healthcare
premises that serve the public. Behavioral
-31-

-- 32 of 533 --

health services may also raise the risk profile of our business given the critical and sensitive nature of the services provided. In addition, we are, to a certain extent,
self-insured with regard to litigation risks, including claims of medical malpractice against our affiliated physicians and us, and it is possible that the level of actual
losses will significantly exceed the liabilities recorded for our estimates of the probable costs resulting from self-insured matters. The defense of any actions may
result in significant expenses, and if we fail to maintain adequate insurance coverage for these liabilities, or if such insurance is not available, the resulting costs
could adversely affect our business, cash flows, financial condition and results of operations. As we become more involved in direct care delivery and the provision
of other services, such as crisis management services, there will be an increased possibility of litigation.
Additionally, many states in which certain of our subsidiaries operate limit the practice of medicine to licensed individuals or professional organizations
comprised of licensed individuals. Business corporations generally may not exercise control over the medical decisions of physicians, and we are not licensed to
practice medicine. Rules and regulations relating to the practice of medicine, fee-splitting between physicians and referral sources, and similar issues vary from
state to state, and any enforcement actions by governmental officials alleging non-compliance with these rules and regulations could adversely affect our business,
cash flows, financial condition and results of operations. Further, in certain states we are required to use professional corporations that are not affiliates, which
exposes us to risk in the event the physician owners of those professional corporations take actions that are in breach of the contractual obligations that exist
between us.
We rely on agreements with customers, confidentiality agreements with associates and third parties, and our trademarks, trade secrets, copyrights and patents
to protect our proprietary rights. These legal protections and precautions may not prevent misappropriation of our proprietary information. Litigation and
misappropriation of our proprietary information could hinder our ability to market and sell products and services, which could materially and adversely affect our
results of operations, financial position and cash flows. Further, certain of our businesses use, develop or sell software products that may contain unexpected design
defects or may encounter unexpected complications during integration or when used with other technologies utilized by the customer. A failure of these products to
operate as intended and in a seamless fashion with other products could also materially and adversely affect our results of operations, financial position and cash
flows.
Our pharmacy services business and pharmacy related operations are subject to risks and uncertainties that are in addition to those we face in our core
healthcare business.
We provide pharmacy services and are responsible to regulators and our customers for the delivery of those pharmacy services that we contract to provide. Our
pharmacy services business is subject to the risks inherent in the dispensing, packaging, fulfillment and distribution of pharmaceuticals and other healthcare
products, including exposure to liabilities and reputational harm related to purported dispensing and other operational errors by us or our pharmacy services
suppliers. Any failure by us or one of our pharmacy services suppliers to adhere to the laws and regulations applicable to the dispensing of pharmaceuticals could
subject our pharmacy services business to civil and criminal penalties.
Our pharmacy services business is subject to federal and state laws and regulations that govern its relationships with pharmaceutical manufacturers, physicians,
pharmacies and customers, including without limitation, federal and state anti-kickback laws, beneficiary inducement laws, consumer protection laws, ERISA,
HIPAA and laws related to the operation of mail-service pharmacies, as well as an increasing number of licensure, registration and other laws and accreditation
standards that impact the business practices of a pharmacy services business. In addition, the pharmacy services business, which conducts business through home
delivery and specialty pharmacies, is subject to federal and state laws and regulations, including those of state boards of pharmacy, individual state-controlled
substance authorities, the U.S. Drug Enforcement Agency and the U.S. Food and Drug Administration. Growth of our home delivery and specialty pharmacy
business subjects us to an increase in licensure requirements, and regulatory and operational risks as our pharmacy services business becomes more vertically
integrated. Also, we and our third-party vendors may be subject to certain registration requirements and state and federal laws related to the practice of pharmacy.
Noncompliance with applicable laws and regulations by us or our third-party vendors could have material adverse effects on our business, results of operations,
financial condition, liquidity and reputation.
Federal and state legislatures and regulators also regularly consider new laws and regulations and changes to existing regulations and policies for the industry
that could materially affect current industry practices and our business, including the regulation implemented by HHS in November 2020 related to drug
manufacturer rebates, spread pricing contract arrangements, the pricing of pharmaceuticals, the 2021 Appropriations Act and potential new regulations regarding
rebates, fees from pharmaceutical companies, the development and use of formularies and other utilization management tools, the use
-32-

-- 33 of 533 --

of average wholesale prices or other pricing benchmarks, pricing for specialty pharmaceuticals, limited access to networks and pharmacy network reimbursement
methodologies and reporting requirements. Recent case law, such as the 2020 U.S. Supreme Court reinstatement of an Arkansas law regulating PBMs, as well as
industry publications like the 2021 NAIC white paper on the topic, may increase and impact greater state regulation of PBMs. Further, various government
agencies have conducted and continue to conduct investigations and studies into certain pharmacy services practices, which have resulted and may in the future
result in PBMs agreeing to civil penalties, including the payment of money and entry into corporate integrity agreements, or could materially and adversely impact
the pharmacy services business model.
We are a party to license agreements with the BCBSA that entitle us to the exclusive and, in certain areas, non-exclusive use of the BCBS names and marks in
our geographic territories. The termination of these license agreements or changes in the terms and conditions of these license agreements could adversely
affect our business, cash flows, financial condition and results of operations.
Our license agreements with the BCBSA contain certain requirements and restrictions regarding our operations and our use of the BCBS names and marks, and
failure to comply with those requirements could result in a termination of the license agreements. The license agreements may be modified by the BCBSA, which
could have a material adverse effect on our future expansion plans or results of operations. Further, BCBS licensees have certain requirements to perform
administrative services for members of other BCBS licensees. As of December 31, 2023, we provided health benefit and other healthcare services to approximately
35 million Blue Cross and/or Blue Shield enrollees. If we or another BCBS licensee are not in compliance with all legal requirements or are unable to perform
administrative services as required, this could have an adverse effect on our members and our ability to maintain our licenses, which could have a material adverse
effect on our business, cash flows, financial condition and results of operations.
Upon the occurrence of an event causing termination of the license agreements, we would no longer have the right to use the BCBS names and marks or to sell
BCBS health insurance products and services in one or more of our service areas. Furthermore, the BCBSA would be free to issue a license to use the BCBS names
and marks in these service areas to another entity. Our existing BCBS members would be provided with instructions for obtaining alternative products and services
licensed by the BCBSA. We believe that the BCBS names and marks are valuable identifiers of our products and services in the marketplace.
Upon termination of either license agreement, the BCBSA would have the right to impose a “Re-establishment Fee” upon us, which would be used in part to
fund the establishment of a replacement Blue Cross and/or Blue Shield licensee in the vacated service area. The fee is set at $98.33 per licensed enrollee. If the Re-
establishment Fee was applied to our total Blue Cross and/or Blue Shield enrollees of approximately 35 million as of December 31, 2023, we would be assessed
approximately $3 billion by the BCBSA. As a result, termination of the license agreements would have a material adverse effect on our business, cash flows,
financial condition and results of operations. For more information on the BCBSA license agreements, including requirements, restrictions and termination events
set forth in these license agreements, see Part I, Item 1, “Business — BCBSA Licenses” of this Annual Report on Form 10-K.
Indiana law, other applicable laws, our articles of incorporation and bylaws, and provisions of our BCBSA license agreements may prevent or discourage
takeovers and business combinations that our shareholders might consider to be in their best interest.
Indiana law, other applicable laws and regulations and provisions in our articles of incorporation and bylaws may delay, defer, prevent or render more difficult
a takeover attempt that our shareholders might consider to be in their best interests. For instance, they may prevent our shareholders from receiving the benefit from
any premium to the market price of our common stock offered by a bidder in a takeover context or adversely affect the price that some investors are willing to pay
for our stock.
The insurance holding company system acts and certain health statutes of the states in which our insurance company or HMO subsidiaries are regulated restrict
the ability of any person to obtain control of an insurance company or HMO without prior regulatory approval. Further, the Indiana Business Corporation Law
contains business combination provisions that, in general, prohibit for five years any business combination with a beneficial owner of 10% or more of our common
stock unless the holder’s acquisition of the stock was approved in advance by our Board of Directors.
Our articles of incorporation and bylaws contain provisions that could have anti-takeover effects and may delay, defer or prevent a takeover attempt that our
shareholders might consider to be in their best interests. Our articles of incorporation
-33-

-- 34 of 533 --

provide that no person may beneficially own shares of voting capital stock beyond specified ownership limits, except with the prior approval of a majority of the
“continuing directors.” The ownership limits, which may not be exceeded without the prior approval of the BCBSA, are the following: (1) for any institutional
investor (as defined in our articles of incorporation), one share less than 10% of our outstanding voting securities; (2) for any non-institutional investor (as defined
in our articles of incorporation), one share less than 5% of our outstanding voting securities; and (3) for any person, one share less than the number of shares of our
common stock or other equity securities (or a combination thereof) representing a 20% ownership interest in us.
In addition, our articles of incorporation and bylaws: divide our Board of Directors into three classes serving staggered three-year terms (which is required by
our license agreements with the BCBSA); permit our Board of Directors to determine the terms of and issue one or more series of preferred stock without further
action by shareholders; restrict the maximum number of directors and the ability to increase that number; limit the ability of shareholders to remove directors;
impose restrictions on shareholders’ ability to fill vacancies on our Board of Directors; impose advance notice requirements for shareholder proposals and
nominations of directors to be considered at meetings of shareholders; prohibit shareholders from amending certain provisions of our bylaws; and impose
restrictions on who may call a special meeting of shareholders.
STRATEGIC RISKS
We face competition in many of our markets, and if we fail to adequately adapt to changes in our industry and develop and implement strategic growth
opportunities, our ability to compete and grow may be adversely affected.
As a health company offering health benefits, pharmacy services and other diversified products and services, we operate in a highly competitive industry that is
subject to significant changes from and competition due to legislative reform, business consolidations, new strategic alliances, new market entrants, aggressive
marketing practices, technological advancements and changing market practices such as increasing usage of telehealth. We also must respond to pricing and other
actions taken by existing competitors and potentially disruptive new entrants in the Public Exchanges and in our other lines of business. These factors have
produced and will continue to produce significant pressures on our profitability and membership. Furthermore, decisions to buy our products and services are
increasingly made or influenced by consumers, through means such as direct purchasing (for example, Medicare Advantage plans) and insurance exchanges that
allow individual choice, or by large employers that may increasingly be able to contract directly with providers. To compete effectively under these unique market
pressures in the consumer-driven marketplace, we are required to develop and deliver innovative and potentially disruptive products and services to satisfy
evolving market demands.
In addition, the pharmacy services industry is highly competitive, and our pharmacy services business unit is subject to competition from national, regional and
local pharmacy services providers, other insurers, health plans, large retail pharmacy chains, large retail stores, supermarkets, mail order and web pharmacies,
discount cards and specialty pharmacies. Strong competition within the pharmacy services business has generated greater demand for lower product and service
pricing and enhanced product and service offerings. Our inability to maintain positive trends, contract on favorable terms with CVS, wholesalers or pharmaceutical
manufacturers for, among other things, rebates, discounts, administrative fees and inventory purchase prices, or a failure to identify and implement new ways to
mitigate pricing pressures, could negatively impact our ability to attract or retain customers, negatively impact our margins and have a material adverse effect on
our business and results of operations. In addition, legislative reforms such as the regulation issued by HHS related to rebates and the 2021 Appropriations Act,
which requires reporting of plan spending, the cost of plan pharmacy benefits, enrollee premiums and any manufacturer rebates received by the plan or issuer, may
adversely affect our competitive position, cash flows, financial condition and results of operations.
In order to achieve our long-term financial targets, we need to not only grow our profitable medical membership, but also continue to profitably grow and
diversify our sources of revenue and earnings, including through the increased sale of our pharmacy services, both integrated and external, other healthcare services
and products, and specialty products, such as dental, vision and other supplemental products, expand our products and services and establish new cost of care
solutions. If we are unable to execute our strategy with respect to the growth of our healthcare, pharmacy services, and other diversified products and services
businesses, or if we are unable to acquire or develop and successfully manage new opportunities that further our strategic objectives and differentiate our products
and services from our competitors, our ability to profitably grow our business could be adversely affected.
-34-

-- 35 of 533 --

We are currently dependent on the non-exclusive services of independent agents and brokers in the marketing of our healthcare products, particularly with
respect to individuals, seniors and certain group customers. We face intense competition for the services and allegiance of these independent agents and brokers,
who may also market the products of our competitors. Our relationship with our brokers and independent agents could be adversely impacted by changes in our
business practices to address legislative changes, including potential reductions in commissions and consulting fees paid to agents and brokers. We cannot ensure
that we will be able to compete successfully against current and future competitors for these services or that competitive pressures faced by us will not materially
and adversely affect our business, cash flows, financial condition and results of operations.
For additional information, see “Business — Competition” in Part I, Item 1 of this Annual Report on Form 10-K.
We have built a significant portion of our current business through mergers and acquisitions, joint ventures, strategic alliances and investments, and although
we expect to pursue such opportunities in the future, we are subject to risks resulting from such business combinations.
The following are some of the risks associated with mergers, acquisitions, divestitures, joint ventures and strategic alliances and investments, referred to
collectively as business combinations, that could have a material adverse effect on our business, cash flows, financial condition and results of operations:
• some business combinations may not achieve anticipated revenues, earnings or cash flow, business opportunities, synergies, growth prospects or other
anticipated benefits;
• we may assume liabilities that were not disclosed to us, or which were underestimated, and which could lead to legal challenges, investigations and
enforcement actions, and we may not be able to adequately recover from sellers or insurance carriers for such assumed liabilities;
• we may experience difficulties in integrating business combinations, including into our internal control environment and culture, be unable to integrate
business combinations successfully or as quickly as expected and be unable to realize anticipated economic, operational and other benefits in a timely
manner or at all;
• business combinations and proposed business combinations that are not completed could disrupt our ongoing business, lead to the incurrence of significant
fees, distract management, result in the loss of key associates, divert resources, result in tax costs or inefficiencies and make it difficult to maintain our
current business standards, controls, information technology systems, policies and procedures;
• IT system vulnerabilities may be more acute for IT systems associated with recently acquired businesses, and we may be unable to address such
vulnerabilities, inadequacies, or failures immediately after acquiring a business, which could undermine integration activities, delay launch of acquired
products, and increase infrastructure risk;
• we may finance future business combinations by issuing common stock for some or all of the purchase price, which could dilute the ownership interests of
our shareholders;
• we may compete with other firms, some of which may have greater financial and other resources, to acquire attractive companies;
• we may experience disputes with or competition from our partners or former partners in our strategic alliances, investments and joint ventures, which could
result in litigation or a loss of business;
• we may not be able to obtain the required regulatory approval for an acquisition in a timely manner, if at all, and government actions such as actions by the
FTC or DOJ, may affect our ability to complete our business combinations; and
• future business combinations may make it difficult to comply with the requirements of the BCBSA and lead to a risk that our BCBSA license agreements
may be terminated.
We face intense competition to attract and retain associates. Further, managing key executive succession and retention is critical to our success.
Our success depends on our ability to attract, develop and retain qualified associates, including those with diverse backgrounds, experience and skill sets, to
operate and expand our business. We face intense competition for experienced and highly skilled associates, and we may be unable to attract and retain such
associates or competition among potential associates may result in increasing salaries. Adverse changes to our corporate culture could harm our business operations
and our ability to retain key associates and executives. An inability to retain existing associates or attract additional associates could have a material adverse effect
on our business, cash flows, financial condition and results of operations.
-35-

-- 36 of 533 --

In addition, if we are unable to attract, retain and effectively manage the succession plans for key associates and executives, including our President and Chief
Executive Officer, our business, results of operations and future performance could be adversely affected. We may have difficulty in replacing key executives
because of the limited number of qualified individuals with the breadth of skills and experience required to operate and successfully expand our business. The
succession plans we have in place for members of our senior management and employment arrangements with certain key executives do not guarantee that the
services of our senior executives will continue to be available to us or that we will be able to attract, transition and retain suitable successors.
Restrictions on our ability to obtain funds from our regulated subsidiaries could limit our ability to repurchase shares, pay dividends and meet our obligations
and materially adversely affect our business, cash flows, financial condition and results of operations.
As a holding company, we are dependent on dividends and administrative expense reimbursements from our subsidiaries. Among other restrictions, state
insurance and HMO laws restrict the ability of most of our regulated subsidiaries to pay dividends. In some states, we have made special undertakings that may
further limit the ability of our regulated subsidiaries to pay dividends. Our ability to repurchase shares, pay dividends to our shareholders and meet our obligations,
including paying operating expenses and debt service on our outstanding and future indebtedness, will depend upon the receipt of dividends from our subsidiaries.
An inability of our subsidiaries to pay dividends in the future in an amount sufficient for us to meet our financial obligations may materially adversely affect our
business, cash flows, financial condition and results of operations.
In addition, most of our regulated subsidiaries are subject to minimum capital requirements and periodic financial reporting that require them to report their
results of risk-based capital calculations to the departments of insurance and the NAIC. Failure to maintain these minimum standards could subject our regulated
subsidiaries to corrective action, including state supervision or liquidation. We are also a party to license agreements with the BCBSA which contain additional
minimum capital and liquidity requirements. Changes to existing minimum capital requirements could further restrict the ability of our regulated subsidiaries to pay
dividends and adversely affect our business.
Our regulated subsidiaries are subject to state laws and regulations that require diversification of their investment portfolios and limit the amount of
investments in certain investment categories. Failure to comply with these laws and regulations might cause investments exceeding regulatory limitations to be
treated as non-admitted assets for purposes of measuring statutory surplus and risk-based capital, and in some instances, require the sale of those investments.
We have substantial indebtedness outstanding and may incur additional indebtedness in the future, which could adversely affect our ability to pursue desirable
business opportunities and to react to changes in the economy or our industry.
Our debt service obligations require us to use a portion of our cash flow to pay interest and principal on debt instead of for other corporate purposes, including
funding future expansion. We are exposed to interest rate risk to the extent of our variable rate indebtedness. Increases in interest rates have increased our cost of
borrowing, and volatility in U.S. and global financial markets could impact our access to, or further increase the cost of, financing. If our cash flow and capital
resources are insufficient to service our debt obligations, we may be forced to seek extraordinary dividends from our subsidiaries, sell assets, seek additional equity
or debt capital or restructure our debt. However, these measures might be unsuccessful or inadequate to meet scheduled debt service obligations or may not be
available on commercially reasonable terms.
We may also incur future debt obligations that might subject us to restrictive covenants that could affect our financial and operational flexibility. Our breach or
failure to comply with any of these covenants could result in a default under our credit facilities or other indebtedness. If we default under our credit agreement, the
lenders could cease to make further extensions of credit or cause all of our outstanding debt obligations under our credit agreement to become immediately due and
payable, together with accrued and unpaid interest. If the indebtedness under our notes or our credit agreement or our other indebtedness is accelerated, we may be
unable to repay or finance the amounts due, on commercially reasonable terms, or at all.
A downgrade in our credit ratings could have an adverse effect on our business, cash flows, financial condition and results of operations.
Claims-paying ability, financial strength and debt ratings by nationally recognized statistical rating organizations are important factors in establishing the
competitive position of insurance and health benefits companies. We believe our strong
-36-

-- 37 of 533 --

credit ratings are an important factor in marketing our products to customers. In addition, if our credit ratings are downgraded or placed under review, our business,
cash flows, financial condition and results of operations could be adversely impacted by limitations on future borrowings and a potential increase in our borrowing
costs. Each of the ratings organizations reviews our ratings periodically, and there can be no assurance that our current ratings will be maintained in the future.
The value of our intangible assets may become impaired.
As of December 31, 2023, we had $36 billion of goodwill and other intangible assets, representing 33% of our total consolidated assets. In accordance with
applicable accounting standards, we periodically evaluate our goodwill and other intangible assets for potential impairment, using assumptions and judgments
regarding the estimated fair value of our reporting units. Estimated fair values might be significantly different if other reasonable assumptions and estimates were to
be used. If estimated fair values are less than the carrying values of goodwill and other intangible assets with indefinite lives in future impairment tests, or if
significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future
income.
The value we place on intangible assets may be adversely impacted if existing or future business combinations fail to perform in a manner consistent with our
assumptions. In addition, from time to time we divest businesses, and any such divestiture could result in significant asset impairment and disposition charges,
including those related to goodwill and other intangible assets. Further, the estimated value of our reporting units may be impacted because of business decisions
we make associated with any future changes to laws and regulations, which could unfavorably affect the carrying value of certain goodwill and other intangible
assets and result in impairment charges in future periods. Any future evaluations requiring an impairment of our goodwill and other intangible assets could
materially affect our results of operations and shareholders’ equity which could, in turn, negatively impact our debt ratings or potentially impact our compliance
with existing debt covenants.
The value of our investments is influenced by varying economic and market conditions, and a decrease in value may result in a loss charged to income.
We maintain a significant investment portfolio of cash equivalents and short-term and long-term investments in a variety of securities, which are subject to
general credit, liquidity, market and interest rate risks. As a result, we may experience a reduction in value or loss of our investments, which may have a negative
adverse effect on our results of operations, liquidity and financial condition. Changes in the economic environment, including periods of increased volatility in the
securities markets, recent changes in interest rates and currency exchange rates, can increase the difficulty of assessing investment impairment and increase the risk
of potential impairment of these assets. There is continuing risk that declines in the fair value of our investments may occur and material impairments may be
charged to income in future periods, resulting in recognized losses.
GENERAL RISKS
We also face other risks that could adversely affect our business, financial condition or results of operations, which include:
• adverse securities and credit market conditions, which could impact our ability to meet liquidity needs;
• any requirement to restate financial results in the event of inappropriate application of accounting principles;
• changes in tax laws and regulations or uncertainty in the interpretation of tax laws and regulations that could impact the future value of our deferred tax
assets and deferred tax liabilities, or result in significant one-time charges in the current or future taxable years;
• a significant failure of our internal control over financial reporting;
• negative publicity, including as a result of governmental investigations, adverse media coverage and political debate surrounding industry regulation;
• provider fraud that is not prevented or detected and impacts our medical costs or those of self-insured customers; and
• failure of our corporate governance policies or procedures.
-37-

-- 38 of 533 --

ITEM 1B. UNRESOLVED STAFF COMMENTS.
None.
ITEM 1C. CYBERSECURITY
We operate in a highly-regulated industry. Federal, state and international laws and contractual commitments guide our collection, use and disclosure of
confidential information such as protected health information, personal financial information and personally identifiable information. Our success depends on
maintaining a high level of trust among our stakeholders, including our consumers, clients, business partners, providers, regulators and associates. Failure to
effectively secure, maintain and upgrade our information systems, or the availability and integrity of our data, could adversely affect our business, including our
business strategy, cash flows, financial condition and results of operations.
Cybersecurity Risk Assessment
We work to identify and manage cybersecurity risks through established processes and accountability. We also conduct periodic reviews and updates to uphold
our security standards. Our management has implemented ongoing and annual risk assessment processes to identify and manage risks that could affect our ability to
safeguard sensitive data or provide reliable transaction processing. These risks include, but are not limited to:
• Regulatory compliance
• Third-party management, including risks from business partners and software providers
• Mergers and acquisitions
• System availability and disruption of business operations
• Data security
• Vulnerability and configuration management
• Fraud and extortion
• Reputational risk
As of December 31, 2023, no known cybersecurity threats have materially affected, or are reasonably likely to materially affect, the Company, including our
business strategy, cash flows, financial condition or results of operations. See Part I, Item 1A. "Risk Factors” for more information on the Company’s
cybersecurity-related risks.
Governance and Management of Cybersecurity Risk
Our Board of Directors (“Board”) oversees and guides our business and oversees our exposure to major risks. The Board receives periodic reports from
management on various risks, and delegates to its Audit Committee certain oversight responsibilities. The Board monitors cybersecurity risks and receives a report
at least quarterly from our Chief Information Security Officer (the “CISO”) regarding our Information Security Program. In addition, certain cybersecurity
incidents are escalated to the Board in accordance with our escalation criteria as described below. Periodically, the Board also receives third party assessments of
our information security. The Audit Committee receives regular updates on both information security and data privacy matters, and oversees data privacy, integrity,
incident and breach risks.
We have a cross-organizational steering committee, the Information Security Steering Committee (“ISSC”), that supports direction and governance of our
enterprise-wide Information Security Program. The ISSC is chaired by the CISO and is comprised of accountable senior business leaders including the Chief
Compliance Officer (“CCO”), Chief Risk Officer (“CRO”), legal counsel, and human resources, procurement and business segment leaders.
In addition to the ISSC, we have defined risk functions to cover overall enterprise risks and information technology and cybersecurity risks, including:
• IT Risk Management program led by the CISO
• Compliance led by the CCO
• Internal Audit led by Chief Audit Executive (“CAE”)
• Enterprise Risk Management programs led by the CRO
• Third-Party Risk Management, comprised of business and information security leaders
• IT Due Diligence, comprised of business, technology and information security leaders
• Corporate Insurance Program, including cybersecurity insurance, led by the Treasurer
-38-

-- 39 of 533 --

To evaluate cybersecurity and privacy incidents and enable the Company to comply with public disclosure requirements, we have defined escalation criteria in
support of our incident response processes. We have a Cyber Incident Response Taskforce, comprised of our Chief Privacy Officer, our CISO, and applicable legal
counsel and business and corporate services leaders, which is responsible for reviewing such incidents and reporting relevant incidents to a subcommittee of our
disclosure committee in order to assess the materiality of an incident as well as reporting to the senior leadership team, the chief legal officer, the CEO and
ultimately the Board based on the facts and circumstances of an incident.
Cybersecurity Expertise
Our Information Security Program has been established with the mission of minimizing risk to our member, client and associate data and it is managed by our
CISO. Our current CISO has over 30 years of experience in information security and technology and has held a wide variety of technical and strategic leadership
positions. He holds advanced certifications including Certified Information Systems Security Professional and Certified Secure Software Lifecycle Professional.
Our associates, including those responsible for cybersecurity, are evaluated for competence, including the knowledge and skills necessary to accomplish tasks
that define associates’ roles and responsibilities and undergo regular training regarding privacy, security, ethics and compliance. Our job summaries contain specific
educational and knowledge requirements necessary for cybersecurity jobs. In addition, a criminal background check is completed for all new associates and
performance reviews are conducted annually to measure performance results and achievements and to assess the job competency of our associates.
We use our Information Security teams, as well as trusted third-party auditors, recognized cybersecurity consultants and certified assessors, to assess
cybersecurity risks, related controls, and alignment to relevant regulatory and legal requirements. A third party evaluates our Information Security Program and
control environment at least annually. Assessments are performed against industry best practices and widely recognized security frameworks.
ITEM 2. PROPERTIES.
We lease our principal executive offices located at 220 Virginia Avenue, Indianapolis, Indiana. In addition to this location, we have operating facilities located
in each state where we operate as licensees of the BCBSA and in other states or countries where we operate under our other brands. A majority of these locations
are also leased properties. Our facilities support our various business segments. We operate in a hybrid workforce environment and believe that our properties are
adequate and suitable for our business as presently conducted; however, we are continuing to evaluate our real estate strategy in response to the changing needs of
our workforce and business.
ITEM 3. LEGAL PROCEEDINGS.
For information regarding our legal proceedings, see Note 14, “Commitments and Contingencies – Litigation and Regulatory Proceedings,” of the Notes to
Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K, which information is incorporated herein by reference.
ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.
-39-

-- 40 of 533 --

PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY
SECURITIES.
Market Information
Our common stock, par value $0.01 per share, is listed on the NYSE under the symbol “ELV.”
Holders
As of February 1, 2024, there were 48,679 shareholders of record of our common stock.
Securities Authorized for Issuance under Equity Compensation Plans
The information required by this Item concerning securities authorized for issuance under our equity compensation plans is set forth in Part III, Item 12,
“Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” in this Annual Report on Form 10-K.
Issuer Purchases of Equity Securities
The following table presents information related to our repurchases of common stock for the periods indicated (in millions, except share and per share data):
Period
Total Number
of Shares
Purchased
Average
Price Paid
per Share
Total Number
of Shares
Purchased as
Part of
Publicly
Announced
Programs
Approximate
Dollar Value
of Shares that
May Yet Be
Purchased
Under the
Programs
October 1, 2023 to October 31, 2023 	216,670 $ 	452.69 	215,962 $ 	5,031
November 1, 2023 to November 30, 2023 	866,646 	461.05 	866,041 	4,632
December 1, 2023 to December 31, 2023 	914,923 	473.05 	912,664 	4,200
1,998,239 	1,994,667
1 Total number of shares purchased includes 3,572 shares delivered to or withheld by us in connection with employee payroll tax withholding upon exercise or vesting of
stock awards. Stock grants to employees and directors and stock issued for stock option plans and stock purchase plans in the consolidated statements of shareholders’
equity are shown net of these shares purchased.
2 Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of Directors, which the Board evaluates
periodically. During the year ended December 31, 2023, we repurchased 5,773,932 shares at an aggregate cost of $2,676 under the program, including the cost of
options to purchase shares. The Board of Directors has authorized our common stock repurchase program since 2003. On January 24, 2023, our Audit Committee,
pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to our common stock repurchase program. No duration has been placed on
our common stock repurchase program, and we reserve the right to discontinue the program at any time.
1 	2
-40-

-- 41 of 533 --

Performance Graph
The following Performance Graph and related information compares the cumulative total return to shareholders of our common stock for the period from
December 31, 2018 through December 31, 2023, with the cumulative total return over such period of (i) the Standard & Poor’s 500 Stock Index (the “S&P 500
Index”) and (ii) the Standard and Poor’s 500 Health Care Index (the “S&P 500 Health Care Index”). The graph assumes an investment of $100 on December 31,
2018 in each of our common stock and these indices (and the reinvestment of all dividends).
The comparisons shown in the graph below are based on historical data, and we caution that the stock price performance shown in the graph below is not
indicative of, and is not intended to forecast, the potential future performance of our common stock. Information used in the graph was obtained from S&P Global
Market Intelligence, a source believed to be reliable, but we are not responsible for any errors or omissions in such information. The following graph and related
information shall not be deemed “soliciting materials” or to be “filed” with the SEC, nor shall such information be incorporated by reference into any future filing
under the Exchange Act, except to the extent that we specifically incorporate it by reference into such filing.
December 31,
2018 	2019 	2020 	2021 	2022 	2023
Elevance Health, Inc. 	$ 100 $ 116 $ 125 $ 183 $ 205 $ 191
S&P 500 Index 	100 	131 	156 	200 	164 	207
S&P 500 Health Care Index 	100 	121 	137 	173 	170 	173
Based upon an initial investment of $100 on December 31, 2018 with dividends reinvested.
-41-

-- 42 of 533 --

ITEM 6. [RESERVED]
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
References to the terms “we,” “our,” “us,” “Elevance Health” or the “Company” used throughout this Management’s Discussion and Analysis of Financial
Condition and Results of Operations (“MD&A”) refer to Elevance Health, Inc., an Indiana corporation, and, unless the context otherwise requires, its direct and
indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context otherwise requires.
This MD&A should be read in conjunction with our audited consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.
This MD&A generally discusses 2023 and 2022 items and year-over-year comparisons between 2023 and 2022. A detailed discussion of 2021 items and year-
over-year comparisons between 2022 and 2021 that are not included in this Annual Report on Form 10-K can be found in “Management’s Discussion and Analysis
of Financial Condition and Results of Operations” in Part II, Item 7 included in Exhibit 99.1 to our Quarterly Report on Form 10-Q for the three months ended
September 30, 2023.
Overview
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in
terms of medical membership, serving approximately 47 million medical members through our affiliated health plans as of December 31, 2023. We are an
independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the
Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine,
Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York),
Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue
Cross and Anthem Blue Cross and Blue Shield. We also conduct business through arrangements with other BCBS licensees, as well as other strategic partners. In
addition, we serve members in numerous states as Amerigroup, Freedom Health, HealthSun, MMM, Optimum Healthcare, Simply Healthcare and/or Wellpoint. We
are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries. Through various subsidiaries, we
also offer pharmacy services through our CarelonRx business, and other healthcare related services as Carelon Insights, Carelon Health, Carelon Behavioral Health
and CareMore.
As we announced in 2022, we are organizing our brand portfolio into the following core go-to-market brands:
• Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed
plans;
• Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and
• Carelon — this brand brings together our healthcare related services and capabilities, including our CarelonRx and Carelon Services businesses, under a
single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. Given this
evolution, we reviewed and modified how we manage our business, monitor our performance and allocate resources, and made changes to our reportable segments
beginning in the first quarter of 2023. We now report our results of operations in the following four reportable segments: Health Benefits (aggregates our previously
reported Commercial & Specialty Business and Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and
Corporate & Other (our businesses that do not individually meet the quantitative
-42-

-- 43 of 533 --

thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments). During the fourth quarter of 2023, we moved
our Carelon Global Solutions international businesses from the Corporate & Other reportable segment to the Carelon Services reportable segment. All prior period
reportable segment information has been reclassified for comparability to conform to the current presentation.
Our results of operations discussed throughout this MD&A are determined in accordance with generally accepted accounting principles (“GAAP”). We also
calculate operating gain and operating margin to further aid investors in understanding and analyzing our core operating results. Operating gain is calculated as
total operating revenue less benefit expense, cost of products sold and operating expense. Operating margin is calculated as operating gain divided by operating
revenue. Our definition of operating gain and operating margin may not be comparable to similarly titled measures reported by other companies. We use these
measures as a basis for evaluating segment performance, allocating resources, forecasting future operating periods and setting incentive compensation targets. This
information is not intended to be considered in isolation or as a substitute for income before income tax expense, net income or fully-diluted shareholders’ earnings
per share (“EPS”) prepared in accordance with GAAP. For additional details on operating gain, see our “Reportable Segments Results of Operations” discussion
included in this MD&A. For a reconciliation of reportable segment operating revenue to the amounts of total revenue included in the consolidated statements of
income and a reconciliation of reportable segment operating gain to income before income tax expense, see Note 20, “Segment Information,” of the Notes to
Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
Our operating revenue consists of premiums, product revenue, and service fees. Premium revenue is generated from risk-based contracts where we indemnify
our policyholders against costs for covered health and life insurance benefits. Product revenue represents services performed by CarelonRx for unaffiliated
pharmacy customers and includes ingredient costs (net of any rebates or discounts), including co-payments made by or on behalf of the customer, and service fees.
Unaffiliated pharmacy customers include our fee-based employer groups that contract with CarelonRx for pharmacy services and external customers outside of the
health plans we own. Service fees are generated from our fee-based customers for the processing of transactions or network discount savings realized, revenues
from our Medicare processing business and revenues from other health-related businesses, including care management programs and miscellaneous other income.
Our benefit expense primarily includes costs of care for health services consumed by our risk-based members, such as outpatient care, inpatient hospital care,
professional services (primarily physician care) and pharmacy benefit costs. All four components are affected both by unit costs and utilization rates. Unit costs
include the cost of outpatient medical procedures per visit, inpatient hospital care per admission, physician fees per office visit and prescription drug prices.
Utilization rates represent the volume of consumption of health services and typically vary with the age and health status of our members and their social and
lifestyle choices, along with clinical protocols and medical practice patterns in each of our markets. A portion of benefit expense recognized in each reporting
period consists of actuarial estimates of claims incurred but not yet paid by us. Any changes in these estimates are recorded in the period the need for such an
adjustment arises. While we offer a diversified mix of managed care products and services through our managed care plans, our aggregate cost of care can fluctuate
based on a change in the overall mix of these products and services. Our managed care plans include: Preferred Provider Organizations; Health Maintenance
Organizations; Point-of-Service plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited
benefit products.
We classify certain quality improvement costs as benefit expense. Quality improvement activities are those designed to improve member health outcomes,
prevent hospital readmissions and improve patient safety. They also include expenses for wellness and health promotion provided to our members. These quality
improvement costs may be comprised of expenses incurred for: (i) medical management, including care coordination and case management; (ii) health and
wellness, including disease management services for such conditions as diabetes, high-risk pregnancies, congestive heart failure and asthma management and
wellness initiatives like weight-loss programs and smoking cessation treatments; and (iii) clinical health policy, such as identification and use of best clinical
practices to avoid harm, identifying clinical errors and safety concerns, and identifying potential adverse drug interactions.
Our cost of products sold represents the cost of pharmaceuticals dispensed by CarelonRx for our unaffiliated pharmacy customers (net of rebates or discounts),
including any co-payments made by or on behalf of the customer, per-claim administrative fees for prescription fulfillment and certain direct costs related to sales
and administration of customer contracts.
-43-

-- 44 of 533 --

Our operating expenses consist of fixed and variable costs. Examples of fixed costs are depreciation, amortization and certain facilities expenses. Certain
variable costs, such as premium taxes, vary directly with premium volume. Commission expense generally varies with premium or membership volume. Other
variable costs, such as salaries and benefits, do not vary directly with changes in premium but are more aligned with changes in membership or services provided to
our customers. The acquisition or loss of a significant block of business would likely impact staffing levels and thus, associated compensation expense. Other
variable costs include professional and consulting expenses and advertising. Other factors can impact our administrative cost structure, including systems
efficiencies, inflation and changes in productivity.
Our results of operations depend in large part on our ability to accurately predict and effectively manage healthcare costs through effective contracting with
providers of care to our members, product pricing, medical management and health and wellness programs, innovative product design and our ability to maintain or
achieve improvement in our Centers for Medicare and Medicaid Services Star ratings. Several economic factors related to healthcare costs, such as regulatory
mandates of coverage as well as direct-to-consumer advertising by providers and pharmaceutical companies, have a direct impact on the volume of care consumed
by our members. The potential effect of escalating healthcare costs, any changes in our ability to negotiate competitive rates with our providers and any regulatory
or market-driven restrictions on our ability to obtain adequate premium rates to offset overall inflation in healthcare costs, including increases in unit costs and
utilization resulting from the aging of the population and other demographics, the impact of epidemics and pandemics, as well as advances in medical technology
and pharmaceuticals, may impose further risks to our ability to profitably underwrite our business and may have a material adverse impact on our results of
operations.
We intend to expand through a combination of organic growth, strategic acquisitions and efficient use of capital in both existing and new markets. Our growth
strategy is designed to enable us to take advantage of additional economies of scale, as well as provide us access to new and evolving technologies and products. In
addition, we believe geographic and product diversity reduces our exposure to local or regional regulatory, economic and competitive pressures and provides us
with increased opportunities for growth. We market and offer pharmacy services through CarelonRx and other subsidiaries, and we expect CarelonRx to continue to
improve our ability to integrate pharmacy benefits within our medical and specialty platform. We have continued growing our government-sponsored business
through organic growth and acquisitions. In all other markets, we intend to maintain our position by delivering excellent service, offering competitively priced
products, providing access to high-quality provider networks and effectively capitalizing on the brand strength of the Blue Cross and Blue Shield names and marks.
For additional information about our business and reportable segments, see Part I, Item 1 “Business” and Note 20, “Segment Information” of the Notes to
Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
Business Trends
In 2023, we made the decision to expand our participation in the Individual state- or federally-facilitated marketplaces (the “Public Exchange”) for 2024. For
2024, we are offering Individual Public Exchange products in 141 of the 143 rating regions in which we operate, in comparison to 138 of the 143 rating regions in
2023. Changes to our business environment are likely to continue as elected officials at the national and state levels continue to enact, and both elected officials and
candidates for election continue to propose, significant modifications to existing laws and regulations, including changes to taxes and fees. In addition, the
continuing growth in our government-sponsored business exposes us to increased regulatory oversight.
CarelonRx markets and offers pharmacy services to our affiliated health plan customers throughout the country, as well as to customers outside of the health
plans we own. Our comprehensive pharmacy services portfolio includes all core pharmacy services, such as home delivery and specialty pharmacies, claims
adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database and member services. CarelonRx delegates certain
core pharmacy services to CVS, pursuant to the CVS Agreement that is set to terminate on December 31, 2025. CarelonRx also operates a specialty pharmacy and
beginning in 2024, will assume responsibility for pharmacy mail order front-end intake and member services.
Pricing Trends: We strive to price our health benefit products consistent with anticipated underlying medical cost trends. We frequently make adjustments to
respond to legislative and regulatory changes as well as pricing and other actions
-44-

-- 45 of 533 --

taken by existing competitors and new market entrants. Revenues from the Medicare and Medicaid programs are dependent, in whole or in part, upon annual
funding from the federal government and/or applicable state governments. Product pricing remains competitive.
Medical Cost Trends: Our medical cost trends are primarily driven by increases in the utilization of services across all provider types and the unit cost
increases of these services. We work to mitigate these trends through various medical management programs such as care and condition management, program
integrity and specialty pharmacy management and utilization management, as well as benefit design changes. There are many drivers of medical cost trends that
can cause variance from our estimates, such as changes in the level and mix of services utilized, regulatory changes, aging of the population, health status and other
demographic characteristics of our members, epidemics, pandemics, advances in medical technology, new high-cost prescription drugs, provider contracting
inflation, labor costs and healthcare provider or member fraud.
For additional discussion regarding business trends, see Part I, Item 1 “Business” of this Annual Report on Form 10-K.
Regulatory Trends and Uncertainties
Under the Consolidated Appropriations Act of 2023, Congress decoupled Medicaid eligibility redeterminations from the Public Health Emergency initially
declared in January 2020 relating to COVID-19 (the “PHE”). As a result, states were permitted to begin removing ineligible beneficiaries from their Medicaid
programs starting April 1, 2023, and the majority of our Medicaid markets began doing so as of June 30, 2023. This process is anticipated to take up to 14 months
to complete, although most states are expected to complete the redetermination process by June 30, 2024. As redeterminations have resumed, we have experienced
a decline in our Medicaid membership. Over time, we expect growth in our commercial plans, including through the Public Exchanges, as members who are no
longer eligible for Medicaid coverage in our 14 commercial states seek coverage elsewhere. On May 11, 2023, the PHE ended in accordance with the Biden
Administration’s January 30, 2023 announcement.
The Inflation Reduction Act of 2022, which was signed into law in August 2022, contains a variety of provisions that impact our business including an
extension of the American Rescue Plan Act of 2021's enhanced Premium Tax Credits (“PTC”) through 2025; imposing a new corporate alternative minimum tax;
providing a one percent excise tax on repurchases of stock made after December 31, 2022; allowing the Centers for Medicare and Medicaid Services (“CMS”) to
negotiate prices on a limited set of prescription drugs in Medicare Parts B and D beginning in 2026; instituting caps on insulin cost sharing in Medicare Parts B and
D; redesigning of the Medicare Part D benefit; adding a requirement that drug manufacturers pay rebates if prices increase beyond inflation; and delaying the
implementation of the Trump Administration Medicare drug rebate rule to 2032. The extension of the enhanced PTC has allowed for growth in Individual Public
Exchange enrollment as Medicaid eligibility redeterminations have resumed, supporting continuity of coverage for more people.
The Consolidated Appropriations Act of 2021 (the “2021 Appropriations Act”) has impacted and in the future may have a material effect upon our business,
including procedures and coverage requirements related to surprise medical bills and new mandates for continuity of care for certain patients, price comparison
tools, disclosure of broker compensation, mental health parity reporting and reporting on pharmacy benefits and drug costs. The requirements of the 2021
Appropriations Act applicable to us had varying effective dates, some of which were effective in December 2021 and during 2022, and others which were extended
into 2023 since the enactment of the 2021 Appropriations Act.
The health plan price transparency regulations issued by the U.S. Departments of Health and Human Services, Labor and Treasury required us in 2022 to begin
disclosing detailed pricing information regarding negotiated rates for all covered items and services between the plan or issuer and in-network providers and
historical payments to, and billed charges from, out-of-network providers. Additionally, beginning in 2023, we were required to make available to members
personalized out-of-pocket cost information and the underlying negotiated rates for 500 covered healthcare items and services, including prescription drugs.
Effective January 1, 2024, this requirement has expanded to include all items and services.
The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively, the “ACA”),
continues to impact our business and results of operations, including pricing, minimum medical loss ratios and the geographies in which our products are available.
We also expect further and ongoing regulatory guidance on a number of issues related to Medicare, including evolving methodology for ratings and quality bonus
payments. CMS also frequently proposes changes to its program that audits data submitted under the risk adjustment programs in ways that could increase financial
recoveries from plans.
-45-

-- 46 of 533 --

For additional discussion regarding regulatory trends and uncertainties, and risk factors that could cause actual results to differ materially from those contained
in forward-looking statements made in this Annual Report on Form 10-K, see Part I, Item 1 “Business — Regulation” and Part I, Item 1A “Risk Factors.”
Other Significant Items
Business and Operational Matters
During the third quarter of 2023, based on a strategic review of our operations, assets and investments, management implemented the “2023-2024 Business
Efficiency Program” to refine the focus of our investments, and optimize our physical footprint. The 2023-2024 Business Efficiency Program includes the write-off
of certain information technology assets and contract exit costs, a reduction in staff including the relocation of certain job functions, and the impairment of assets
associated with the closure or partial closure of data centers and offices. The 2023-2024 Business Efficiency Program is expected to be substantially complete by
the end of the third quarter of 2024. For additional information, see Note 4, “Business Optimization Initiatives,” and Note 18, “Leases,” of the Notes to
Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
Pursuant to CMS’s Medicare Advantage Star ratings system, CMS annually awards between 1.0 and 5.0 Stars to Medicare Advantage plans based on
performance in several categories. Plans must have a Star rating of 4.0 or higher to qualify for bonus payments. CMS released our 2024 Star ratings in October
2023, which will be used to determine our Medicare Advantage plans’ Star quality bonus payments beginning in 2025. Based on our membership at September 1,
2023, 34% of our Medicare Advantage members were in plans with 2024 Star ratings of at least 4.0 Stars, compared to 64% of our Medicare Advantage members
being in plans with 2023 Star ratings of at least 4.0 Stars based on our membership at September 1, 2022. This change in our 2024 Star ratings is expected to
impact our Star quality bonus payments and plan level rebates beginning in 2025. We expect a reduction to our 2025 operating revenue of approximately $500, net
of offsets from contracting provisions due to this change in Star ratings. Further, we expect to partially mitigate the financial impact to our 2025 operating gain and
net income through various strategies such as contract diversification, operating expense efficiencies, capital deployment alternatives and network enhancements.
On January 4, 2024, we announced our entrance into an agreement to acquire Paragon Healthcare, Inc., a company providing infusion services and injectable
therapies through its omnichannel model of ambulatory infusion centers, home infusion pharmacies, and other specialty pharmacy services. This acquisition aligns
with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we
serve. The acquisition is expected to close in the first half of 2024 and is subject to standard closing conditions and customary approvals.
On December 31, 2023, we entered into an agreement to acquire Centers Plan for Healthy Living LLC and Centers for Specialty Care Group IPA, LLC
(“Centers”). Centers is a managed long-term care plan that serves New York state Medicaid and dually-eligible Medicaid/Medicare members, enabling adults with
long-term care needs and disabilities to live safely and independently in their own home. The acquisition is expected to close in the third quarter of 2024 and is
subject to standard closing conditions and customary approvals.
On March 28, 2023, we announced our entrance into an agreement to sell our life and disability businesses to StanCorp Financial Group, Inc. (“The Standard”),
a provider of financial protection products and services for employers and individuals. Upon closing, we and The Standard will enter into a product distribution
partnership. The divestiture is expected to close in the first half of 2024 and is subject to standard closing conditions and customary approvals.
On February 15, 2023, we completed our acquisition of BioPlus Parent, LLC and subsidiaries (“BioPlus”) from CarepathRx Aggregator, LLC. Prior to the
acquisition, BioPlus was one of the largest independent specialty pharmacy organizations in the United States. BioPlus, which operates as part of CarelonRx, seeks
to connect payors and providers of specialty pharmaceuticals to meet the medication therapy needs of patients with complex medical conditions. This acquisition
aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that aim to improve the lives of the
people we serve.
On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service & Indemnity Company, d/b/a Blue Cross and Blue
Shield of Louisiana, or BCBSLA, an independent licensee of the BCBSA that provides
-46-

-- 47 of 533 --

healthcare plans to the Individual, Employer Group, Medicaid and Medicare markets, primarily in the State of Louisiana. This acquisition aligns with our vision to
be an innovative, valuable, and inclusive healthcare partner as we bring our innovative whole-health solutions to BCBSLA’s members. The acquisition is subject to
closing conditions and approvals.
For additional information, see Note 3, “Business Acquisitions and Divestitures,” of the Notes to Consolidated Financial Statements included in Part II, Item 8
of this Annual Report on Form 10-K.
Litigation Matters
In the consolidated multi-district proceeding in the United States District Court for the Northern District of Alabama (the “Court”) captioned In re Blue Cross
Blue Shield Antitrust Litigation (“BCBSA Litigation”), the BCBSA and Blue Cross and/or Blue Shield licensees, including us (the “Blue plans”) previously
approved a settlement agreement and release with the plaintiffs representing a putative nationwide class of health plan subscribers (the “Subscriber Settlement
Agreement”), which agreement required the Court’s approval to become effective. Generally, the lawsuits in the BCBSA Litigation challenge elements of the
licensing agreements between the BCBSA and the independently owned and operated Blue plans. The cases were brought by two putative nationwide classes of
plaintiffs, health plan subscribers and providers. The Subscriber Settlement Agreement applies only to the subscriber class. The defendants continue to contest the
consolidated cases brought by the provider plaintiffs.
In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval Order”). In compliance with the
Subscriber Settlement Agreement, the Company paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by the
Company of $596, which amount was accrued in 2020. Four notices of appeal of the Final Approval Order were filed prior to the September 2022 appeal deadline.
Those appeals were heard by a panel of the United States Court of Appeals for the Eleventh Circuit (the “Eleventh Circuit”) in September 2023. In October 2023,
the Eleventh Circuit affirmed the Final Approval Order. Petitions for rehearing filed by certain appellants in November 2023 and December 2023 remain pending.
In the event all appellate rights are exhausted in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations
under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement
Agreement. For additional information regarding the BCBSA Litigation, see Note 14, “Commitments and Contingencies – Litigation and Regulatory Proceedings –
Blue Cross Blue Shield Antitrust Litigation,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
Selected Operating Performance
During the year ended December 31, 2023, total medical membership decreased by 0.6 million, or 1.2%. The decrease in medical membership was driven
primarily by attrition in Medicaid due to the resumption of eligibility redeterminations and declines in our Employer Group risk-based business, partially offset by
growth in BlueCard, Individual Public Exchange health plans and Medicare Advantage membership.
Operating revenue for the year ended December 31, 2023 was $170,209, an increase of $14,549, or 9.3%, from the year ended December 31, 2022. The
increase in operating revenue was primarily driven by higher premium revenues in our Health Benefits business resulting from premium rate increases to more
accurately reflect the cost of care. The increase was further attributable to growth in our CarelonRx pharmacy product revenue driven by growth in external
pharmacy members and the acquisition of BioPlus in the first quarter of 2023.
Net income for the year ended December 31, 2023 was $5,991, an increase of $103, or 1.7%, from the year ended December 31, 2022. The increase in net
income was primarily due to higher premium revenues in our Health Benefits business resulting from premium rate increases to more accurately reflect the cost of
care. The increase was further attributable to growth in our CarelonRx pharmacy product revenue driven by growth in external pharmacy members and the
acquisition of BioPlus in the first quarter of 2023. These increases were partially offset by the business optimization charges recorded in the third quarter of 2023.
Our fully-diluted shareholders’ earnings per share (“EPS”) for the year ended December 31, 2023 was $25.22, an increase of $0.94, or 3.9%, from the year
ended December 31, 2022. Our diluted shares for the year ended December 31, 2023 were 237.4, a decrease of 5.4, or 2.2%, compared to the year ended
December 31, 2022. The increase in EPS resulted from fewer diluted shares outstanding, as well as increased shareholders’ net income.
-47-

-- 48 of 533 --

Operating cash flow for the year ended December 31, 2023 was $8,061, or approximately 1.3 times net income. Operating cash flow for the year ended
December 31, 2022 was $8,399, or approximately 1.4 times net income. The decrease in operating cash flow was primarily due to the timing of working capital
changes, partially offset by higher net income in 2023, when excluding the non-cash impact of the business optimization charges recorded in the third quarter of
2023, as well as the non-recurrence of the Subscriber Settlement Agreement payment made in September 2022.
Membership
Our medical membership includes the following customer types: Individual, Employer Group risk-based, Employer Group fee-based, BlueCard , Medicare,
Medicaid and our Federal Employees Health Benefits (“FEHB”) Program. We refer to members in our service areas licensed by the BCBSA as our BCBS-branded,
or Anthem BCBS, business. Non-BCBS-branded business refers to members in our non-BCBS-branded, or Wellpoint plans, which include Amerigroup, Freedom
Health, HealthSun, MMM, Optimum Healthcare and Simply Healthcare plans. In addition to the above medical membership, we also serve customers who
purchase one or more of our other products or services that are often ancillary to our health business.
• Individual consists of individual customers under age 65 and their covered dependents. Individual policies are generally sold through independent agents
and brokers, retail partnerships, our in-house sales force or via the Public Exchanges. Individual business is sold on a risk-based basis. We offer on-
exchange products through Public Exchanges and off-exchange products. Federal premium subsidies are available only for certain Public Exchange
Individual products. Unsubsidized Individual customers are generally more sensitive to product pricing and, to a lesser extent, the configuration of the
network and the efficiency of administration. Customer turnover is generally higher with Individual as compared to Employer Group risk-based.
Individual business accounted for 2.2%, 1.7% and 1.7% of our medical members at December 31, 2023, 2022 and 2021, respectively.
• Employer Group risk-based consists of employer customers who purchase products on a full-risk basis, which are products for which we charge a
premium and indemnify our policyholders against costs for health benefits. Employer Group risk-based accounts include Local Group customers and
National Accounts. Local Group consists of those employer customers with less than 5% of eligible employees located outside of the headquarter state, as
well as customers with more than 5% of eligible employees located outside of the headquarter state with up to 5,000 eligible employees. In addition, Local
Group includes Student Health members. National Accounts generally consist of multi-state employer groups primarily headquartered in an Elevance
Health service area with at least 5% of the eligible employees located outside of the headquarter state and with more than 5,000 eligible employees. Some
exceptions are allowed based on broker and consultant relationships. Employer Group risk-based accounts are generally sold through brokers or
consultants who work with industry specialists from our in-house sales force and are offered both on and off the Public Exchanges. Employer Group risk-
based accounted for 8.0%, 8.4% and 8.8% of our medical members at December 31, 2023, 2022 and 2021, respectively.
• Employer Group fee-based customers represent employer groups, Local Group, and National Accounts, who purchase fee-based products and elect to
retain most or all of the financial risk associated with their employees’ healthcare costs. Some fee-based customers choose to purchase stop loss coverage
to limit their retained risk. Employer Group fee-based accounts are generally sold through independent brokers or consultants retained by the customer
working with our in-house sales force. Employer Group fee-based accounted for 43.1%, 42.4% and 42.7% of our medical members at December 31, 2023,
2022 and 2021, respectively.
• BlueCard host customers represent enrollees of Blue Cross and/or Blue Shield plans not owned by Elevance Health who receive healthcare services in
our BCBSA licensed markets. BlueCard membership consists of estimated host members using the national BlueCard program. Host members are
generally members who reside in or travel to a state in which an Elevance Health subsidiary is the Blue Cross and/or Blue Shield licensee and who are
covered under an employer-sponsored health plan issued by a non-Elevance Health controlled BCBSA licensee (the “home plan”). We perform certain
functions, including claims pricing and administration, for BlueCard members, for which we receive service fees from the BlueCard members’ home
plans. Other administrative functions, including maintenance of enrollment information and customer service, are performed by the home plan. Host
members are computed using, among other things, the average number of BlueCard claims received per month. BlueCard host membership accounted
for 14.6%, 13.6% and 13.6% of our medical members at December 31, 2023, 2022 and 2021, respectively.
®
®
® 	®
® 	®
® 	®
-48-

-- 49 of 533 --

• Medicare customers are Medicare-eligible individual members age 65 and over who have enrolled in Medicare Advantage, including Special Needs Plans
(“SNPs”), also known as Medicare Advantage SNPs; dual-eligible programs through Medicare-Medicaid Plans (“MMPs”); Medicare Supplement plans;
and Medicare Part D Prescription Drug Plans (“Medicare Part D”). Medicare Advantage plans provide Medicare beneficiaries with a managed care
alternative to traditional Medicare and often include a Medicare Part D benefit. In addition, our Medicare Advantage SNPs provide tailored benefits to
special needs individuals who are institutionalized or have severe or disabling chronic conditions and to dual-eligible customers, who are low-income
seniors and persons under age 65 with disabilities. Medicare Advantage SNPs are coordinated care plans specifically designed to provide targeted care,
covering all the healthcare services considered medically necessary for members and often providing professional care coordination services, with
personal guidance and programs that help members maintain their health. Medicare Advantage membership also includes Medicare Advantage members
in our Group Retiree Solutions business who are retired members of commercial accounts or retired members of groups who are not affiliated with our
commercial accounts who have selected a Medicare Advantage product through us. Medicare Supplement plans typically pay the difference between
healthcare costs incurred by a beneficiary and amounts paid by Medicare. Medicare Part D offers a prescription drug plan to Medicare and MMP
beneficiaries. MMP, which was established as a result of the passage of the ACA, is focused on serving members who are dually eligible for Medicaid and
Medicare. Medicare Supplement and Medicare Advantage products are marketed in the same manner, primarily through independent agents and brokers.
Medicare program business accounted for 6.3%, 6.2% and 6.2% of our medical members at December 31, 2023, 2022 and 2021, respectively.
• Medicaid membership represents eligible members who receive health benefits through publicly funded healthcare programs, including Medicaid, ACA-
related Medicaid expansion programs, Temporary Assistance for Needy Families, programs for seniors and people with disabilities, Children’s Health
Insurance Programs, and specialty programs such as those focused on long-term services and support, HIV/AIDS, foster care, behavioral health and/or
substance abuse disorders, and intellectual disabilities or developmental disabilities, among others. Total Medicaid program business accounted for 22.4%,
24.3% and 23.4% of our medical members at December 31, 2023, 2022 and 2021, respectively.
• FEHB members consist of United States government employees and their dependents who receive health benefits within our geographic markets through
our participation in the national contract between the BCBSA and the U.S. Office of Personnel Management. FEHB business accounted for 3.5%, 3.4%
and 3.6% of our medical members at December 31, 2023, 2022 and 2021, respectively.
-49-

-- 50 of 533 --

The following table presents our medical membership by customer type as of December 31, 2023, 2022 and 2021. Also included below is other membership
by product and other metrics. The membership data and other metrics presented are unaudited and in certain instances include estimates of the number of members
represented by each contract at the end of the period. The CarelonRx Quarterly Adjusted Scripts metric represents adjusted script volume based on the number of
days a prescription covers. On an adjusted basis, one 90-day script counts the same as three 30-day scripts. The Carelon Services Consumers Served metric
represents the number of consumers receiving one or more healthcare related services from Carelon Services who are members of our affiliated health plans as well
as those who are members of non-affiliated health plans.
2023 vs. 2022 	2022 vs. 2021
2023 	2022 	2021 	Change 	% Change 	Change 	% Change
Medical Membership (in thousands)
Individual 	1,025 	789 	759 	236 	29.9 % 	30 	4.0 %
Employer Group Risk-Based 	3,756 	3,988 	4,006 	(232) 	(5.8) % 	(18) 	(0.4)%
Commercial Risk-Based 	4,781 	4,777 	4,765 	4 	0.1 % 	12 	0.3 %
BlueCard 	6,838 	6,462 	6,178 	376 	5.8 % 	284 	4.6 %
Employer Group Fee-Based 	20,227 	20,174 	19,395 	53 	0.3 % 	779 	4.0 %
Commercial Fee-Based 	27,065 	26,636 	25,573 	429 	1.6 % 	1,063 	4.2 %
Medicare Advantage 	2,047 	1,977 	1,859 	70 	3.5 % 	118 	6.3 %
Medicare Supplement 	923 	947 	952 	(24) 	(2.5) % 	(5) 	(0.5)%
Total Medicare 	2,970 	2,924 	2,811 	46 	1.6 % 	113 	4.0 %
Medicaid 	10,503 	11,571 	10,600 	(1,068) 	(9.2) % 	971 	9.2 %
Federal Employees Health Benefits 	1,642 	1,623 	1,625 	19 	1.2 % 	(2) 	(0.1)%
Total Medical Membership 	46,961 	47,531 	45,374 	(570) 	(1.2) % 	2,157 	4.8 %
Other Membership (in thousands)
Life and Disability Members 	4,629 	4,834 	4,782 	(205) 	(4.2) % 	52 	1.1 %
Dental Members 	6,820 	6,692 	6,674 	128 	1.9 % 	18 	0.3 %
Dental Administration Members 	1,729 	1,586 	1,491 	143 	9.0 % 	95 	6.4 %
Vision Members 	9,944 	9,813 	8,031 	131 	1.3 % 	1,782 	22.2 %
Medicare Part D Standalone Members 	260 	271 	438 	(11) 	(4.1) % 	(167) 	(38.1)%
Other Metrics (in millions)
CarelonRx Quarterly Adjusted Scripts 	78.0 	82.0 	(4.0) 	(4.9)%
Carelon Services Consumers Served 	103.3 	105.0 	(1.7) 	(1.6)%
December 31, 2023 Compared to December 31, 2022
Medical Membership
Total medical membership declined during the twelve months ended December 31, 2023. This was driven primarily by attrition in Medicaid due to the
resumption of eligibility redeterminations and declines in our Employer Group risk-based business, partially offset by growth in BlueCard, Individual Public
Exchange health plans and Medicare Advantage membership.
Other Membership
Our other membership can be impacted by changes in our medical membership, as our medical members often purchase our other products that are ancillary to
our health business. Life and disability membership decreased primarily due to lapses associated with our Employer Group risk-based accounts. Dental
membership increased primarily due to favorable sales in our FEHB, Individual and National businesses, partially offset by lapses in our Employer Group risked-
based accounts. Dental administration membership increased primarily due to favorable in-group change with other BCBSA plans associated
®
-50-

-- 51 of 533 --

with the FEHB program. Vision membership increased due to sales exceeding lapses in our Individual and Medicare Advantage businesses.
Consolidated Results of Operations
Our consolidated summarized results of operations and other information for the years ended December 31, 2023, 2022 and 2021 are as
follows:
Change
Years Ended December 31 	2023 vs. 2022 	2022 vs. 2021
2023 	2022 	2021 	$ 	% 	$ 	%
Total operating revenue 	$ 	170,209 	$ 	155,660 	$ 	136,943 	$ 	14,549 	9.3 % $ 	18,717 	13.7 %
Net investment income 	1,825 	1,485 	1,378 	340 	22.9 % 	107 	7.8 %
Net (losses) gains on financial instruments 	(694) 	(550) 	318 	(144) 	26.2 % 	(868) 	(273.0)%
Total revenues 	171,340 	156,595 	138,639 	14,745 	9.4 % 	17,956 	13.0 %
Benefit expense 	124,330 	116,642 	102,571 	7,688 	6.6 % 	14,071 	13.7 %
Cost of products sold 	17,293 	13,035 	10,895 	4,258 	32.7 % 	2,140 	19.6 %
Operating expense 	20,087 	17,700 	15,918 	2,387 	13.5 % 	1,782 	11.2 %
Other expense 	1,915 	1,618 	1,260 	297 	18.4 % 	358 	28.4 %
Total expenses 	163,625 	148,995 	130,644 	14,630 	9.8 % 	18,351 	14.0 %
Income before income tax expense 	7,715 	7,600 	7,995 	115 	1.5 % 	(395) 	(4.9)%
Income tax expense 	1,724 	1,712 	1,846 	12 	0.7 % 	(134) 	(7.3)%
Net income 	5,991 	5,888 	6,149 	103 	1.7 % 	(261) 	(4.2)%
Net (gain) loss attributable to noncontrolling
interests 	(4) 	6 	9 	(10) 	NM 	(3) 	NM
Shareholders’ net income 	$ 	5,987 	$ 	5,894 	$ 	6,158 	$ 	93 	1.6 % $ 	(264) 	(4.3)%
Average diluted shares outstanding 	237.4 	242.8 	246.8 	(5.4) 	(2.2)% 	(4.0) 	(1.6)%
Diluted shareholders’ earnings per share 	$ 	25.22 	$ 	24.28 	$ 	24.95 	$ 	0.94 	3.9 % $ 	(0.67) 	(2.7)%
Effective tax rate 	22.3 % 	22.5 % 	23.1 % 	(20) bp 	(60) bp
Benefit expense ratio 	87.0 % 	87.6 % 	87.4 % 	(60) bp 	20 bp
Operating expense ratio 	11.8 % 	11.4 % 	11.6 % 	40 bp 	(20) bp
Income before income tax expense as a percentage
of total revenues 	4.5 % 	4.9 % 	5.8 % 	(40) bp 	(90) bp
Shareholders’ net income as a percentage of total
revenues 	3.5 % 	3.8 % 	4.4 % 	(30) bp 	(60) bp
Certain of the following definitions are also applicable to all other results of operations tables in this discussion:
NM Not meaningful.
1 Includes interest expense, amortization of other intangible assets and loss on extinguishment of debt.
2 Benefit expense ratio represents benefit expense as a percentage of premium revenue. Premiums for the years ended December 31, 2023, 2022 and 2021 were $142,854,
$133,229 and $117,373, respectively. Premiums are included in total operating revenue presented above.
3 bp = basis point; one hundred basis points = 1%.
4 Operating expense ratio represents operating expense as a percentage of total operating revenue.
Year Ended December 31, 2023 Compared to the Year Ended December 31, 2022
Total operating revenue increased primarily as a result of higher premium revenues in our Health Benefits business resulting from premium rate increases to
more accurately reflect the cost of care. The increase was further attributable to growth in our CarelonRx pharmacy product revenue driven by growth in external
pharmacy members and the acquisition of BioPlus in the first quarter of 2023.
Net investment income increased primarily due to higher income from fixed maturity securities, partially offset by reduced income from alternative
investments and lower dividends on equity securities.
1
3 	3
2 	3 	3
4 	3 	3
3 	3
3 	3
-51-

-- 52 of 533 --

Net losses on financial instruments increased due to increased losses on other invested assets, partially offset by higher gains on marketable equity securities.
Benefit expense increased primarily due to medical cost trends.
Our benefit expense ratio decreased slightly, primarily driven by premium rate increases in our Health Benefit segment to more accurately reflect the cost of
care.
Cost of products sold reflects the cost of pharmaceuticals dispensed by CarelonRx for our unaffiliated pharmacy customers. Cost of products sold increased as
the corresponding pharmacy product revenues increased.
Operating expense increased primarily due to the business optimization charges recorded in the third quarter of 2023, including internally developed software
impairment and severance costs, as well as expenses incurred for anticipated future growth.
Our operating expense ratio increased primarily due to the business optimization charges recorded in 2023, partially offset by the favorable impact of operating
revenue growth.
Other expense increased primarily due to increased interest expense and increased amortization of other intangible assets. Interest expense increased as we
issued additional debt at higher interest rates. The amortization of intangible assets increased due to recent acquisitions as well as the rebranding of our products.
The amortization period of certain intangible assets was shortened to align with anticipated dates the new branding will take place.
Our effective income tax rate decreased from 22.5% to 22.3%, primarily due to the impact of geographic changes in our mix of earnings in 2023.
Our shareholders’ net income as a percentage of total revenues decreased in 2023 as compared to 2022 as a result of all the factors discussed above.
-52-

-- 53 of 533 --

Reportable Segments Results of Operations
The following table presents a summary of our reportable segment financial information for the years ended December 31, 2023, 2022 and 2021:
Years Ended December 31
Change
2023 vs. 2022 	2022 vs. 2021
2023 	2022 	2021 	$ 	% 	$ 	%
Operating Revenue 	Restated 	Restated
Health Benefits 	$ 	148,571 	$ 	138,484 	$ 	121,728 $ 	10,087 	7.3 % $ 	16,756 	13.8 %
CarelonRx 	33,835 	28,526 	25,431 	5,309 	18.6 % 	3,095 	12.2 %
Carelon Services 	14,147 	12,860 	10,130 	1,287 	10.0 % 	2,730 	26.9 %
Corporate & Other 	479 	399 	95 	80 	20.1 % 	304 	320.0 %
Eliminations 	(26,823) 	(24,609) 	(20,441) 	(2,214) 	9.0 % 	(4,168) 	20.4 %
Total operating revenue 	$ 	170,209 	$ 	155,660 	$ 	136,943 $ 	14,549 	9.3 % $ 	18,717 	13.7 %
Operating Gain (Loss)
Health Benefits 	$ 	6,888 	$ 	6,022 	$ 	5,850 $ 	866 	14.4 % $ 	172 	2.9 %
CarelonRx 	1,975 	1,868 	1,684 	107 	5.7 % 	184 	10.9 %
Carelon Services 	680 	535 	187 	145 	27.1 % 	348 	186.1 %
Corporate & Other 	(1,044) 	(142) 	(162) 	(902) 	635.2 % 	20 	(12.3)%
Operating Margin
Health Benefits 	4.6 % 	4.3 % 	4.8 % 	30 bp 	(50) bp
CarelonRx 	5.8 % 	6.5 % 	6.6 % 	(70) bp 	(10) bp
Carelon Services 	4.8 % 	4.2 % 	1.8 % 	60 bp 	240 bp
1 Includes expenses of $36 for business optimization initiatives in 2022 and $153 for business optimization initiatives in 2021.
2 Includes expenses of $1 for business optimization initiatives in 2021.
3 Includes expenses of $5 for business optimization initiatives in 2022 and $33 for business optimization initiatives in 2021.
4 Includes expense of $753 for business optimization initiatives in 2023 and (credit) of $(2) for business optimization initiatives in 2022.
5 bp = basis point; one hundred basis points = 1%.
The following table summarizes Health Benefits operating revenues by Commercial, Medicare, Medicaid and FEHB lines of business for the years ended
December 31, 2023, 2022 and 2021:
Years Ended December 31
Change
2023 vs. 2022 	2022 vs. 2021
2023 	2022 	2021 	$ 	% 	$ 	%
Health Benefits Operating Revenue
Commercial 	$ 	43,266 $ 	41,674 $ 	38,809 $ 	1,592 	3.8 % $ 	2,865 	7.4 %
Medicare 	35,067 	31,604 	26,611 	3,463 	11.0 % 	4,993 	18.8 %
Medicaid 	56,601 	52,886 	44,106 	3,715 	7.0 % 	8,780 	19.9 %
FEHB 	13,637 	12,320 	12,202 	1,317 	10.7 % 	118 	1.0 %
Total Health Benefits operating revenues 	$ 	148,571 $ 	138,484 $ 	121,728 $ 	10,087 	7.3 % $ 	16,756 	13.8 %
Year Ended December 31, 2023 Compared to the Year Ended December 31, 2022
Health Benefits
Operating revenue and operating gain increased primarily as a result of higher premium revenues due to premium rate increases to more accurately reflect the
cost of care.
1
2
3
4
5 	5
5 	5
5 	5
-53-

-- 54 of 533 --

CarelonRx
Operating revenue increased primarily as a result of higher prescription volumes associated with growth in external pharmacy members served and the
acquisition of BioPlus in the first quarter of 2023.
The increase in operating gain was primarily a result of higher prescription volumes associated with growth in external pharmacy members served and the
acquisition of BioPlus in the first quarter of 2023, partially offset by lower service fees and expenses incurred for anticipated future growth.
Carelon Services
Operating revenue increased primarily due to the continued expansion of our post-acute care services performed for our Medicare business and behavioral
health services performed for our Medicaid business.
The increase in operating gain was primarily driven by the continued expansion of our post-acute care services and improved performance in our medical
management business, partially offset by medical cost trends.
Corporate & Other
The increase in operating loss was primarily due to the business optimization charges recorded in the third quarter of 2023, as well as an increase in
unallocated corporate expenses.
Critical Accounting Policies and Estimates
We prepare our consolidated financial statements in conformity with GAAP. Application of GAAP requires management to make estimates and assumptions
that affect the amounts reported in our consolidated financial statements and accompanying notes and within this MD&A. We consider our most important
accounting policies that require significant estimates and management judgment to be those policies with respect to liabilities for medical claims payable, goodwill
and other intangible assets and investments, which are discussed below. Our other significant accounting policies are summarized in Note 2, “Basis of Presentation
and Significant Accounting Policies,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
We continually evaluate the accounting policies and estimates used to prepare the consolidated financial statements. In general, our estimates are based on
historical experience, evaluation of current trends, information from third-party professionals and various other assumptions that we believe to be reasonable under
the known facts and circumstances. Estimates can require a significant amount of judgment, and a different set of assumptions could result in material changes to
our reported results.
Medical Claims Payable
The most subjective accounting estimate in our consolidated financial statements is our liability for medical claims payable. At December 31, 2023, this
liability was $16,111 and represented 23.2% of our total consolidated liabilities. We record this liability and the corresponding benefit expense for incurred but not
paid claims, including the estimated costs of processing such claims. Incurred but not paid claims include (1) an estimate for claims that are incurred but not
reported, as well as claims reported to us but not yet processed through our systems, which approximated 93.9%, or $15,123, of our total medical claims liability as
of December 31, 2023; and (2) claims reported to us and processed through our systems but not yet paid, which approximated 6.1%, or $988, of the total medical
claims payable as of December 31, 2023. The level of claims payable processed through our systems but not yet paid may fluctuate from one period-end to the
next, from approximately 1% to 6% of our total medical claims liability, due to timing of when claim payments are made.
Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in the aggregate, employing
actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Our reserving practice for claim liabilities is to
consistently recognize the appropriate amount of reserve within a level of confidence required by Actuarial Standards of Practice. We determine the amount of the
liability for incurred but not paid claims by following a detailed actuarial process that uses both historical claim payment patterns as well as emerging medical cost
trends to project our best estimate of claim liabilities. Under this process, historical paid claims data is formatted into “claim triangles,” which compare claim
incurred dates to the dates of claim payments. This information
-54-

-- 55 of 533 --

is analyzed to create “completion factors” that represent the average percentage of total incurred claims that have been paid through a given date after being
incurred. Completion factors are applied to claims paid through the period-end date to estimate the ultimate claim expense incurred for the period. Actuarial
estimates of incurred but not paid claim liabilities are then determined by subtracting the actual paid claims from the estimate of the ultimate incurred claims.
For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims incurred in those months is generally low.
This makes the completion factor methodology less reliable for such months. Therefore, incurred claims for recent months are not projected from historical
completion and payment patterns; rather, they are projected by estimating the claims expense for those months based on recent claims expense levels and
healthcare trend levels (“trend factors”).
Our reserve methodology, which relies upon historical information, must be adjusted to account for known or suspected operational and environmental
changes. Adjustments are carried out by our actuaries, drawing on expert knowledge and taking into account their estimate of emerging impacts to benefit costs and
payment speed. Factors such as changes in levels of utilization, unit costs, business mix, benefit plan designs, provider reimbursements, processing system
modifications, claim inventory levels, claim processing and submission patterns, and operational changes resulting from business combinations are considered
when developing our reserve estimates. We also compare prior period liabilities to revised claim liabilities based on subsequent claim development. In these
comparisons, methods and assumptions remain constant as reserves are recalculated; rather, the availability of additional paid claims information drives changes in
the re-estimate of the unpaid claim liability. To the extent appropriate, changes in such development are recorded as a change to current period benefit expense.
On a regular basis, we review cost trends and utilization assumptions set upon initial establishment of claim liabilities. We utilize subsequent paid claims
activity to monitor and continuously adjust the claims liability and benefit expense. If actual results are determined to be materially different than assumptions
regarding cost trends and utilization, future periods of our income statement and overall financial position could be impacted. Adjustments made to prior year
estimates may result in either an additional benefit expense or a reduction of benefit expense in the period the adjustment is made. The variability of healthcare
costs necessitates that claim liabilities be adjusted each period and are sometimes significant compared to the net income recorded in that period. An actuary’s
judgment that a portion of the prior period liability is no longer needed or that an additional liability should have been accrued triggers the immediate recognition
of prior period development. Once sufficient information is available to ascertain that the re-estimate of the liability is reasonable, the determination is made.
While numerous factors contribute to our medical claims payable liability estimation, the two assumptions having the most significant impact on our incurred
but not paid claims liability as of December 31, 2023, were the completion and trend factors. These vital assumptions can be affected by variables such as
utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory
levels, claim processing and submission patterns, and operational changes resulting from business combinations.
There is variation in the reasonable choice of completion factors by duration for durations of three months through twelve months where the completion factors
have the most significant impact. As previously discussed, completion factors tend to be less reliable for the most recent months and therefore are not specifically
utilized for months one and two. In our analysis for the claim liabilities at December 31, 2023, the variability in months three to five was estimated to be between
40 and 90 basis points, while months six through twelve have much lower estimated variability ranging from 0 to 30 basis points.
The difference in completion factor assumptions results in variability of 2%, or approximately $289, in the December 31, 2023 incurred but not paid claims
liability, depending on the completion factors chosen. It is important to note that the completion factor methodology inherently assumes that historical completion
rates will be reflective of the current period. However, it is possible that the actual completion rates for the current period will develop differently from historical
patterns and therefore could fall outside the possible variations described herein.
The other major assumption used in the establishment of the December 31, 2023 incurred but not paid claim liability was the trend factors. In our analysis for
the period ended December 31, 2023, there was a 330 basis point differential in the high and low trend factors. This range of trend factors would imply variability
of 3%, or approximately $545, in the incurred but
-55-

-- 56 of 533 --

not paid claims liability, depending upon the trend factors used. Because historical trend factors are often not representative of current claim trends, the trend
experience for the most recent six to nine months, plus knowledge of recent events likely affecting current trends, have been taken into consideration in establishing
the incurred but not paid claims liability at December 31, 2023.
See Note 12, “Medical Claims Payable,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K, for
a reconciliation of the beginning and ending balance for medical claims payable for the years ended December 31, 2023, 2022 and 2021. Components of the total
incurred claims for each year include amounts accrued for current year estimated claims expense as well as adjustments to prior year estimated accruals. In Note
12, “Medical Claims Payable,” the line labeled “Net incurred medical claims: Prior years redundancies” accounts for those adjustments made to prior year
estimates. The impact of any reduction of “Net incurred medical claims: Prior years redundancies” may be offset as we establish the estimate of “Net incurred
medical claims: Current year”, or as we establish liabilities for premium refunds based upon the minimum medical loss ratio (“MLR”), the relative health risk of
members, and other contractual or regulatory requirements. Our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability
for our claims. When we recognize a release of the redundancy, we disclose the amount that is not in the ordinary course of business, if material.
The ratio of current year medical claims paid as a percent of current year net medical claims incurred was 88.0% for 2023, 87.3% for 2022 and 87.8% for
2021. This ratio serves as an indicator of claims processing speed whereby 2023 claims were processed at a similar speed to 2022 and 2021.
We calculate the percentage of prior year redundancies in the current year as a percent of prior year net incurred claims payable less prior year redundancies in
the current year in order to demonstrate the development of the prior year reserves. For the year ended December 31, 2023, this metric was 11.4%, largely driven
by favorable trend factor development at the end of 2022 as well as favorable completion factor development from 2022. For the year ended December 31, 2022,
this metric was 7.0% and was largely driven by favorable trend factor development at the end of 2021. For the year ended December 31, 2021, this metric was
18.1%, reflecting the estimation uncertainty due to COVID-19 at the end of 2020, and was largely driven by favorable trend factor development at the end of 2020
as well as favorable completion factor development from 2020.
We calculate the percentage of prior year redundancies in the current year as a percent of prior year net incurred medical claims to indicate the percentage of
redundancy included in the preceding year calculation of current year net incurred medical claims. We believe this calculation supports the reasonableness of our
prior year estimate of incurred medical claims. For the year ended December 31, 2023, this metric was 1.4%, which was calculated using the redundancy of $1,571.
This metric was 0.9% for 2022 and 2.0% for 2021. The 2021 metric was impacted by the estimation uncertainty due to COVID-19.
The following table shows the variance between total net incurred medical claims as reported in Note 12, “Medical Claims Payable,” of the Notes to
Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K, for each of 2022 and 2021 and the incurred claims for such
years had it been determined retrospectively (computed as the difference between “net incurred medical claims – current year” for the year shown and “net incurred
medical claims – prior years redundancies” for the immediately following year):
Years Ended December 31
2022 	2021
Total net incurred medical claims, as reported 	$ 	112,545 	$ 	98,737
Retrospective basis, as described above 	111,843 	99,571
Variance 	$ 	702 	$ 	(834)
Variance to total net incurred medical claims, as reported 	0.6 % 	(0.8)%
Given that our business is primarily short tailed (which means that medical claims are generally paid within twelve months of the member receiving service
from the provider), the variance to total net incurred medical claims, as reported above, is used to assess the reasonableness of our estimate of ultimate incurred
medical claims for a given calendar year with
-56-

-- 57 of 533 --

the benefit of one year of experience. We expect that substantially all of the development of the 2023 estimate of medical claims payable will be known during
2024.
The 2022 variance to total net incurred medical claims, as reported of 0.6% was more than the 2021 percentage of (0.8)%. This was primarily driven by the
fact that the change in prior year redundancy reported for 2022 as compared to 2021 increased, whereas the change in the prior year redundancy reported for 2021
as compared to 2020 decreased.
Goodwill and Other Intangible Assets
Our consolidated goodwill and other intangible assets at December 31, 2023 were $35,590, and represented 32.7% of our total consolidated assets and 90.5%
of our consolidated shareholders’ equity at December 31, 2023.
We follow FASB guidance for business combinations and goodwill and other intangible assets, which specifies the types of acquired intangible assets that are
required to be recognized and reported separately from goodwill. Under the guidance, goodwill and other intangible assets (with indefinite lives) are not amortized
but are tested for impairment at least annually. Furthermore, goodwill and other intangible assets are allocated to reporting units for purposes of the annual
impairment test. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, which include
goodwill and other intangible assets. In addition, certain other intangible assets with indefinite lives, such as trademarks, are also tested separately.
We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth quarter of each year. These
tests involve the use of estimates related to the fair value of goodwill at the reporting unit level and other intangible assets with indefinite lives, and require a
significant degree of management judgment and the use of subjective assumptions. Certain interim impairment tests are also performed when potential impairment
indicators exist or changes in our business or other triggering events occur. We have the option of first performing a qualitative assessment for each reporting unit
to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, which is an indication that our goodwill may be
impaired. These qualitative impairment tests include assessing events and factors that could affect the fair value of the indefinite-lived intangible assets. Our
procedures include assessing our financial performance, macroeconomic conditions, industry and market considerations, various asset specific factors and entity
specific events. If we determine that a reporting unit’s goodwill may be impaired after utilizing these qualitative impairment analysis procedures, we are required to
perform a quantitative impairment test.
Our quantitative impairment test utilizes the projected income and market valuation approaches for goodwill and the projected income approach for our
indefinite lived intangible assets. Use of the projected income and market valuation approaches for our goodwill impairment test reflects our view that both
valuation methodologies provide a reasonable estimate of fair value. The projected income approach is developed using assumptions about future revenue,
expenses and net income derived from our internal planning process. These estimated future cash flows are then discounted. Our assumed discount rate is based on
our industry’s weighted-average cost of capital. Market valuations are based on observed multiples of certain measures including revenue; earnings before interest,
taxes, depreciation and amortization; and book value of invested capital (debt and equity) and include market comparisons to publicly traded companies in our
industry.
We did not incur any impairment losses as a result of our 2023 annual impairment tests, as it was determined that it is more likely than not that the estimated
fair values of our reporting units were substantially in excess of the carrying values as of December 31, 2023. Additionally, we do not believe that the estimated fair
values of our reporting units are at risk of becoming impaired in the next twelve months.
If estimated fair values are less than the carrying values of goodwill and other intangibles with indefinite lives in future annual impairment tests, or if
significant impairment indicators are noted relative to other intangible assets subject to amortization, we may be required to record impairment losses against future
income.
For additional information, see Note 3, “Business Acquisitions and Divestitures,” and Note 10, “Goodwill and Other Intangible Assets,” of the Notes to
Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
-57-

-- 58 of 533 --

Investments
Current and long-term marketable investment securities were $30,719 at December 31, 2023 and represented 28.2% of our total consolidated assets at
December 31, 2023. We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed
maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual
maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
Our impairment review is subjective and requires a high degree of judgment. We conduct this review on a quarterly basis, using both qualitative and
quantitative factors. Such factors considered include the extent to which a security’s market value has been less than its cost, the reasons for the decline in value
(i.e., credit event compared to liquidity, general credit spread widening, currency exchange rate or interest rate factors), financial condition and near term prospects
of the issuer, including the credit ratings and changes in the credit ratings of the issuer, recommendations of investment advisors, and forecasts of economic, market
or industry trends.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will
have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an
impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we
will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as
an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component
of the impairment is recognized in accumulated other comprehensive (loss) income. Furthermore, unrealized losses entirely caused by non-credit-related factors
related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive
(loss) income.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost
basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate
implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions
regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and
changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and
estimates regarding timing and amount of recoveries associated with a default.
We have a committee of accounting and investment associates and management that is responsible for managing the impairment review process. We believe
that we have adequately reviewed our investment securities for impairment and that our investment securities are carried at fair value. We have established an
allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. Given the inherent uncertainty of changes in market
conditions and the significant judgments involved, there is continuing risk that declines in fair value may occur and additional impairment losses on investments
may be recorded in future periods.
In addition to marketable investment securities, we held additional long-term investments of $6,107, or 5.6% of total consolidated assets, at December 31,
2023. These long-term investments consisted primarily of certain other equity investments, the cash surrender value of corporate-owned life insurance policies and
mortgage loans. Due to their less liquid nature, these investments are classified as long-term.
Through our investing activities, we are exposed to financial market risks, including those resulting from changes in interest rates and changes in equity market
valuations. We manage market risks through our investment policy, which establishes credit quality limits and limits on investments in individual issuers.
Ineffective management of these risks could have an impact on our future results of operations and financial condition. Our investment portfolio includes fixed
maturity securities with a fair value of $30,490 at December 31, 2023. The weighted-average credit rating of these securities was “A” as of December 31, 2023.
Included in this balance are investments in fixed maturity securities of states, municipalities and political subdivisions and asset-backed assets of $993 and $0,
respectively, that are guaranteed by third parties. With the
-58-

-- 59 of 533 --

exception of 17 securities with a fair value of $9, these securities are all investment-grade and carry a weighted-average credit rating of “AA” as of December 31,
2023. The securities are guaranteed by a number of different guarantors, and we do not have any material exposure to any single guarantor, neither indirectly
through the guarantees, nor directly through investment in the guarantor. Further, due to the high underlying credit rating of the issuers, the weighted-average credit
rating of the fixed maturity securities without a guarantee, for which such information is available, was “A” as of December 31, 2023.
Fair values of fixed maturity and equity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party
pricing services, which generally use Level I or Level II inputs for the determination of fair value in accordance with FASB guidance for fair value measurements
and disclosures. We have controls in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition, we periodically
review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable.
We obtain quoted market prices for each security from the pricing services, which are derived through recently reported trades for identical or similar
securities, making adjustments through the reporting date based upon available market observable information. For securities not actively traded, the pricing
services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the
markets for similar securities. Inputs that are often used in these valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit
spreads, default rates and prepayment speeds. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing
services to determine whether the prices are reasonable estimates of fair value. Our analysis includes procedures such as a review of month-to-month price
fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the
years ended December 31, 2023 and 2022.
In certain circumstances, it may not be possible to derive pricing model inputs from observable market activity, and therefore, such inputs are estimated
internally. Such securities are designated Level III in accordance with FASB guidance. Securities designated Level III at December 31, 2023 totaled $665 and
represented approximately 1.9% of our total assets measured at fair value on a recurring basis. Our Level III securities primarily consisted of certain corporate
securities and equity securities for which observable inputs were not always available and the fair values of these securities were estimated using inputs including,
but not limited to, prepayment speeds, credit spreads, default rates and benchmark yields.
For additional information, see Part II, Item 7A, “Quantitative and Qualitative Disclosures about Market Risk” of this Annual Report on Form 10-K and Note
2, “Basis of Presentation and Significant Accounting Policies,” Note 5, “Investments,” and Note 7, “Fair Value,” of the Notes to Consolidated Financial Statements
included in Part II, Item 8 of this Annual Report on Form 10-K.
New Accounting Pronouncements
For information regarding new accounting pronouncements that were issued or became effective during the year ended December 31, 2023 that had, or are
expected to have, a material impact on our financial position, results of operations or financial statement disclosures, see the “Recently Adopted Accounting
Guidance” and “Recent Accounting Guidance Not Yet Adopted” sections of Note 2, “Basis of Presentation and Significant Accounting Policies,” of the Notes to
Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
Liquidity and Capital Resources
Introduction
Our cash receipts result primarily from premiums, product revenue, service fees, investment income, proceeds from the sale or maturity of our investment
securities, proceeds from borrowings, and proceeds from the issuance of common stock under our employee stock plans. Cash disbursements result mainly from
claims payments, operating expenses, taxes, purchases of investment securities, interest expense, payments on borrowings, acquisitions, capital expenditures,
repurchases of our debt securities and common stock and the payment of cash dividends. Cash outflows fluctuate with the amount and timing of settlement of these
transactions. Any future decline in our profitability would likely have an unfavorable impact on our liquidity.
-59-

-- 60 of 533 --

We manage our cash, investments and capital structure so we are able to meet the short-term and long-term obligations of our business while maintaining
financial flexibility and liquidity. We forecast, analyze and monitor our cash flows to enable investment and financing within the overall constraints of our financial
strategy.
A substantial portion of the assets held by our regulated subsidiaries are in the form of cash and cash equivalents and investments. After considering expected
cash flows from operating activities, we generally invest cash that exceeds our near term obligations in longer term marketable fixed maturity securities to improve
our overall investment income returns. Our investment strategy is to make investments consistent with insurance statutes and other regulatory requirements, while
preserving our asset base. Our investments are generally available-for-sale to meet liquidity and other needs. Our subsidiaries pay out excess capital annually in the
form of dividends to their respective parent companies for general corporate use, as permitted by applicable regulations.
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, debt
ratings, contractual restrictions, regulatory requirements and market conditions. The securities and credit markets have in the past experienced higher than normal
volatility. Interest rates on fixed debt income securities have increased since the beginning of 2022, which may increase our borrowing costs if we elect to issue
debt. During recent years, the federal government and various governmental agencies have taken a number of steps to strengthen the regulation of the financial
services market. In addition, governments around the world have developed their own plans to provide stability and security in the credit markets and to ensure
adequate capital in certain financial institutions.
A summary of our major sources and uses of cash and cash equivalents for the years ended December 31, 2023, 2022 and 2021 is as follows:
Years Ended December 31 	$ Change
2023 	2022 	2021 	2023 vs. 2022 	2022 vs. 2021
Sources of Cash:
Net cash provided by operating activities 	$ 	8,061 $ 	8,399 $ 	8,364 $ 	(338) $ 	35
Issuances of short- and long-term debt, net of repayments 	626 	862 	2,719 	(236) 	(1,857)
Issuances of common stock under employee stock plans 	152 	182 	203 	(30) 	(21)
Other sources of cash, net 	— 	762 	— 	(762) 	762
Total sources of cash 	8,839 	10,205 	11,286 	(1,366) 	(1,081)
Uses of Cash:
Purchases of investments, net of proceeds from sales, maturities, calls and
redemptions 	(2,700) 	(2,338) 	(4,056) 	(362) 	1,718
Repurchase and retirement of common stock 	(2,676) 	(2,316) 	(1,900) 	(360) 	(416)
Purchases of subsidiaries, net of cash acquired 	(1,552) 	(649) 	(3,476) 	(903) 	2,827
Purchases of property and equipment 	(1,296) 	(1,152) 	(1,087) 	(144) 	(65)
Cash dividends 	(1,395) 	(1,229) 	(1,104) 	(166) 	(125)
Other uses of cash, net 	(80) 	— 	(514) 	(80) 	514
Total uses of cash 	(9,699) 	(7,684) 	(12,137) 	(2,015) 	4,453
Effect of foreign exchange rates on cash and cash equivalents 	(1) 	(14) 	(10) 	13 	(4)
Net (decrease) increase in cash and cash equivalents 	$ 	(861) $ 	2,507 $ 	(861) $ 	(3,368) $ 	3,368
Liquidity—Year Ended December 31, 2023 Compared to Year Ended December 31, 2022
The decline in cash provided by operating activities was primarily due to the timing of working capital changes, partially offset by higher net income in 2023,
when excluding the non-cash impact of the business optimization charges recorded in the third quarter of 2023, as well as the non-recurrence of the Subscriber
Settlement Agreement payment made in September 2022.
Other significant changes in sources and uses of cash year-over-year included a) lower sources of cash from other sources of cash, net, issuances of short- and
long-term debt, net of repayments and issuances of common stock under
-60-

-- 61 of 533 --

employee stock plans and b) increased uses of cash from purchases of subsidiaries, net of cash acquired, purchases of investments, net of proceeds from sales,
maturities, calls and redemptions, the repurchase and retirement of common stock, cash dividends, the purchase of property and equipment and other uses of cash,
net.
Financial Condition
We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and investments in fixed maturity and equity
securities of $37,245 at December 31, 2023. Since December 31, 2022, total cash, cash equivalents and investments in fixed maturity and equity securities
increased by $2,201, primarily due to cash generated from operations. This increase was partially offset by cash used for common stock repurchases, acquisitions,
purchases of property and equipment and cash dividends paid to shareholders.
Many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends and other distributions that may be
paid to their respective parent companies. Certain accounting practices prescribed by insurance regulatory authorities, or statutory accounting practices, differ from
GAAP. Changes that occur in statutory accounting practices, if any, or other regulatory requirements, could impact our subsidiaries’ future dividend capacity. In
addition, we have agreed to certain undertakings to regulatory authorities, including the requirement to maintain certain capital levels in certain of our subsidiaries.
At December 31, 2023, we held $1,564 of cash, cash equivalents and investments at the parent company, which are available for general corporate use,
including investment in our businesses, acquisitions, potential future common stock repurchases and dividends to shareholders, repurchases of debt securities and
debt and interest payments.
Periodically, we access capital markets and issue debt (“Notes”) for long-term borrowing purposes, for example, to refinance debt, to finance acquisitions or
for share repurchases. Certain of these Notes may have a call feature that allows us to redeem the Notes at any time at our option and/or a put feature that allows a
Note holder to redeem the Notes upon the occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. For more
information on our debt, including redemptions and issuances, see Note 13, “Debt,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of
this Annual Report on Form 10-K.
We calculate our consolidated debt-to-capital ratio, a non-GAAP measure, from the amounts presented on our audited consolidated balance sheets included in
Part II, Item 8 of this Annual Report on Form 10-K. Our debt-to-capital ratio is calculated as total debt divided by total debt plus total shareholders’ equity. Total
debt is the sum of short-term borrowings, current portion of long-term debt and long-term debt, less current portion. We believe our debt-to-capital ratio assists
investors and rating agencies in measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants include a maximum debt-to-
capital ratio that we cannot and did not exceed. Our debt-to-capital ratio may not be comparable to similarly titled measures reported by other companies. Our
consolidated debt-to-capital ratio was 38.9% and 39.9% as of December 31, 2023 and 2022, respectively.
Our senior debt is rated “A” by S&P Global Ratings, “BBB+” by Fitch Ratings, Inc., “Baa2” by Moody’s Investor Service, Inc. and “bbb+” by AM Best
Company, Inc. We intend to maintain our senior debt investment grade ratings. If our credit ratings are downgraded, our business, liquidity, financial condition and
results of operations could be adversely impacted by limitations on future borrowings and a potential increase in our borrowing costs.
Capital Resources
We have a shelf registration statement on file with the U.S. Securities and Exchange Commission to register an unlimited amount of any combination of debt
or equity securities in one or more offerings. Specific information regarding terms and securities being offered will be provided at the time of an offering. Proceeds
from future offerings are expected to be used for general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of
credit to our subsidiaries and the financing of possible acquisitions or business expansions.
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. The 5-Year Facility provides credit of
up to $4,000 and matures in April 2027. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants
requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-
Year
-61-

-- 62 of 533 --

Facility. As of December 31, 2023, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 39.1%. We do not believe the restrictions
contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of December 31, 2023, we were in compliance with all of our
debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility at December 31, 2023.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. Should commercial
paper issuance become unavailable, we have the ability to use a combination of cash on hand and/or our 5-Year Facility, which provides for credit in the amount of
$4,000, to redeem any outstanding commercial paper upon maturity. At December 31, 2023, we had $0 outstanding under our commercial paper program.
Beginning in 2023, we have reclassified our commercial paper balances from long-term debt to short-term debt as our intent is to not replace short-term
commercial paper outstanding at expiration with additional short-term commercial paper for an uninterrupted period extending for more than one year.
While there is no assurance in the current economic environment, we believe the lenders participating in our 5-Year Facility, if market conditions allow, would
be willing to provide financing in accordance with their legal obligations.
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home
Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively the “FHLBs”). As a member, we have the ability to obtain short-term cash
advances, subject to certain minimum collateral requirements. At December 31, 2023, we had $225 of outstanding short-term borrowings from the FHLBs.
As discussed in “Financial Condition” above, many of our subsidiaries are subject to various government regulations that restrict the timing and amount of
dividends and other distributions that may be paid. Based upon these requirements, we currently estimate that approximately $4,400 of dividends will be paid to us
by our subsidiaries during 2024. During 2023, we received $4,909 of dividends from our subsidiaries.
In addition to regulations regarding the timing and amount of dividends, our regulated subsidiaries’ states of domicile have statutory risk-based capital
(“RBC”) requirements for health and other insurance companies and health maintenance organizations largely based on the National Association of Insurance
Commissioners (“NAIC”) Risk-Based Capital (RBC) for Health Organizations Model Act (the “RBC Model Act”). These RBC requirements are intended to
measure capital adequacy, taking into account the risk characteristics of an insurer’s investments and products. The NAIC sets forth the formula for calculating the
RBC requirements, which are designed to take into account asset risks, insurance risks, interest rate risks and other relevant risks with respect to an individual
insurance company’s business. In general, under the RBC Model Act, an insurance company must submit a report of its RBC level to the state insurance
department or insurance commissioner, as appropriate, at the end of each calendar year. Our regulated subsidiaries’ respective RBC levels as of December 31, 2023
were in excess of all applicable mandatory RBC requirements. In addition to exceeding these RBC requirements, we are in compliance with the liquidity and
capital requirements for a licensee of the BCBSA and with the tangible net worth requirements applicable to certain of our California subsidiaries. For additional
information, see Note 22, “Statutory Information,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-
K.
Future Sources and Uses of Liquidity
Short-Term Liquidity Requirements
As previously described, our cash disbursements result mainly from claims payments, administrative expenses, taxes, purchases of investment securities,
interest expense, payments on borrowings, acquisitions, capital expenditures, repurchases of our debt securities and common stock and the payment of cash
dividends. We believe cash on hand, operating cash receipts, investments and amounts available under our commercial paper program, our 5-Year Facility and
borrowings available from the FHLBs will be adequate to fund our expected cash disbursements over the next twelve months.
-62-

-- 63 of 533 --

Long-Term Liquidity Requirements
As of December 31, 2023, our long-term cash disbursements required under various contractual obligations and commitments were:
• Debt and interest expense: Future debt and estimated interest payments were $40,491, with $2,661 due within the next twelve months. For additional
information, see Note 13 “Debt,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-K.
• Operating leases: We lease office space and certain computer equipment, for which the future estimated payments were $956, with $195 due within the next
twelve months. For additional information, see Note 18, “Leases,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual
Report on Form 10-K.
• Other liabilities: These liabilities primarily consist of future policy reserves, projected other postretirement benefits, deferred compensation, supplemental
executive retirement plan liabilities and certain other miscellaneous long-term obligations. Amounts due within twelve months were $31, with $1,210 due in
future periods. Estimated future payments for funded pension benefits have been excluded from these numbers, as we had no funding requirements under the
Employee Retirement Income Security Act of 1974, as amended, at December 31, 2023, as a result of the value of the assets in the plans. In addition, gross
liabilities for uncertain tax positions and interest for which we cannot reasonably estimate the timing of the resolutions with the respective taxing authorities
have not been included. For further information, see Note 8, “Income Taxes,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of
this Annual Report on Form 10-K.
• Purchase obligations: These obligations include estimated payments for future services under contractual arrangements from third-party service vendors.
Amounts due within the next twelve months for these purchase obligations were $2,188, while longer term payments were $1,580. For further information, see
Note 14, “Commitments and Contingencies,” of the Notes to Consolidated Financial Statements included in Part II, Item 8 of this Annual Report on Form 10-
K.
• Investment commitments: These include unfunded capital commitments for alternative investments and low-income housing tax credits. Estimated amounts
due were $1,321, including $298 due within the next twelve months.
In addition to the contractual obligations and commitments discussed above, we have a variety of other contractual agreements related to acquiring materials
and services used in our operations. However, we do not believe these other agreements contain material noncancelable commitments.
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The
declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial
condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
On January 23, 2024, our Audit Committee declared a quarterly cash dividend to shareholders of $1.63 per share on the outstanding shares of our common
stock. This quarterly dividend is payable on March 22, 2024 to the shareholders of record as of March 8, 2024.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. As of December 31, 2023, we had Board authorization of
$4,200 to repurchase our common stock. No duration has been placed on our common stock repurchase program, and we reserve the right to discontinue the
program at any time. We intend to utilize this authorization over a multi-year period, subject to market and industry conditions.
We believe that funds from future operating cash flows, cash and investments and funds available under our credit facilities and/or from public or private
financing sources will be sufficient for future operations and commitments, and for capital acquisitions and other strategic transactions.
We do not have any off-balance sheet derivative instruments, guarantee transactions, agreements or other contractual arrangements or any indemnification
agreements that will require funding in future periods. We have not transferred assets to an unconsolidated entity that serves as credit, liquidity or market risk
support to such entity. We do not hold any variable interest in an unconsolidated entity where such entity provides us with financing, liquidity, market risk or credit
risk support.
-63-

-- 64 of 533 --

See Note 2 “Subsidiary Transactions,” of the Notes to Condensed Financial Statements (Parent Company Only) included in Part IV, Item 15 of this Annual Report
on Form 10-K for additional detail on the Elevance Health, Inc. parent guarantees of certain subsidiaries.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
(In Millions, Except As Otherwise Stated Herein)
As a result of our investing and borrowing activities, we are exposed to financial market risks, including those resulting from changes in interest rates and
changes in market valuations. Potential impacts discussed below are based upon sensitivity analyses performed on our financial position as of December 31, 2023.
Actual results could vary from these estimates. Our primary objectives with our investment portfolio are to provide safety and preservation of capital, sufficient
liquidity to meet cash flow requirements, the integration of investment strategy with the business operations and an attainment of a competitive after-tax total
return.
Investments
Our investment portfolio is exposed to three primary sources of risk: credit quality risk, interest rate risk and market valuation risk.
The primary risks associated with our fixed maturity securities, which are classified as available-for-sale, are credit quality risk and interest rate risk. Credit
quality risk is defined as the risk of a credit event, such as a ratings downgrade or default, to an individual fixed maturity security and the potential loss attributable
to that event. Credit quality risk is managed through our investment policy, which establishes credit quality limitations on the overall portfolio as well as
diversification and percentage limits on securities of individual issuers. The result is a well-diversified portfolio of fixed maturity securities, with an average credit
rating of approximately “A.” Interest rate risk is defined as the potential for economic losses on fixed maturity securities due to a change in market interest rates.
Our fixed maturity portfolio is invested primarily in U.S. government securities, corporate bonds, asset-backed bonds, mortgage-related securities and municipal
bonds, all of which have exposure to changes in the level of market interest rates. Interest rate risk is managed by maintaining asset duration within a band based
upon our liabilities, operating performance and liquidity needs. Additionally, we have the capability of holding any security to maturity, which would allow us to
realize full par value.
Investments in fixed maturity securities include corporate securities, which account for 48% of our total fixed maturity securities at December 31, 2023 and are
subject to credit/default risk. In a declining economic environment, corporate yields will usually increase, prompted by concern over the ability of corporations to
make interest payments, thus causing a decrease in the price of corporate securities, and the decline in value of the corporate fixed maturity portfolio. We manage
this risk through fundamental credit analysis, diversification of issuers and industries and an average credit rating of our corporate fixed maturity portfolio of
approximately “BBB.”
Market risk for fixed maturity securities is addressed by actively managing the duration, allocation and diversification of our investment portfolio. We have
evaluated the impact on the fixed maturity portfolio’s fair value considering an immediate 100 basis point change in interest rates. A 100 basis point increase in
interest rates would result in an approximate $1,414 decrease in fair value, whereas a 100 basis point decrease in interest rates would result in an approximate
$1,497 increase in fair value. While we classify our fixed maturity securities as “available-for-sale” for accounting purposes, we believe our cash flows and the
duration of our portfolio should allow us to hold securities to maturity, thereby avoiding the recognition of losses should interest rates rise significantly.
Our equity portfolio is comprised of large capitalization and small capitalization domestic equities, foreign equities, exchange-traded funds and index mutual
funds. Our equity portfolio is subject to the volatility inherent in the stock market, driven by concerns over economic conditions, earnings and sales growth,
inflation, and consumer confidence. These systemic risks cannot be managed through diversification alone. However, more routine risks, such as stock/industry
specific risks, are managed by investing in a diversified equity portfolio.
Our other invested assets, reported within our long-term investments, are primarily subject to private market exposures, including private equity and private
credit investments. These investments are also indirectly subject to market valuation risk, as public market valuations will form a basis for valuations for these
investments. Given their illiquid nature, we focus on
-64-

-- 65 of 533 --

appropriate sizing of these investments relative to our liquidity needs and risk tolerance. Our risk tolerance is formed by the level of illiquidity and short-term price
movements from market valuation risk we are willing to accept relative to the higher long-term expected returns over the life of these investments.
As of December 31, 2023, 1% of our marketable investments were equity securities. An immediate 10% decrease in each equity investment’s value, arising
from market movement, would result in a fair value decrease of $23. Alternatively, an immediate 10% increase in each equity investment’s value, attributable to the
same factor, would result in a fair value increase of $23.
For additional information regarding our investments, see Note 5, “Investments,” of the Notes to Consolidated Financial Statements included in Part II, Item 8
and “Critical Accounting Policies and Estimates - Investments” within Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results
of Operations” included in this Annual Report on Form 10-K.
Long-Term Debt
Our total long-term debt at December 31, 2023 consisted of senior unsecured notes and subordinated surplus notes issued by one of our insurance subsidiaries.
At December 31, 2023, the carrying value and estimated fair value of our long-term debt was $24,895 and $23,569, respectively. This debt is subject to interest rate
risk, as these instruments have fixed interest rates and the fair value is affected by changes in market interest rates. Should interest rates increase or decrease in the
future, the estimated fair value of our fixed rate debt would decrease or increase accordingly.
For additional information regarding our long-term debt, see Note 7, “Fair Value,” and Note 13, “Debt,” of the Notes to Consolidated Financial Statements
included in Part II, Item 8 of this Annual Report on Form 10-K.
Derivatives
We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates. We attempt to mitigate our
exposure to interest rate risk through the use of derivative financial instruments. These strategies include the use of interest rate swaps and forward contracts, which
are used to lock-in interest rates or to hedge (on an economic basis) interest rate risks associated with variable rate debt. We have used these types of instruments as
designated hedges against specific liabilities.
Changes in interest rates will affect the estimated fair value of these derivatives. As of December 31, 2023, we recorded a net liability of $37, the estimated fair
value of the swaps at that date. We have evaluated the impact on the interest rate swaps’ fair value considering an immediate 100 basis point change in interest
rates. A 100 basis point increase in interest rates would result in an approximate $59 decrease in fair value, whereas a 100 basis point decrease in interest rates
would result in an approximate $59 increase in fair value.
For additional information regarding our derivatives, see Note 6, “Derivative Financial Instruments,” of the Notes to Consolidated Financial Statements
included in Part II, Item 8 of this Annual Report on Form 10-K.
-65-

-- 66 of 533 --

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
Elevance Health, Inc.
CONSOLIDATED FINANCIAL STATEMENTS
Years ended December 31, 2023, 2022 and 2021
Contents
Reports of Independent Registered Public Accounting Firm (PCAOB ID:42) 	67
Audited Consolidated Financial Statements:
Consolidated Balance Sheets 	69
Consolidated Statements of Income 	70
Consolidated Statements of Comprehensive Income 	71
Consolidated Statements of Cash Flows 	72
Consolidated Statements of Shareholders’ Equity 	73
Notes to Consolidated Financial Statements 	74
-66-

-- 67 of 533 --

Report of Independent Registered
Public Accounting Firm
To the Shareholders and the Board of Directors of Elevance Health, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Elevance Health, Inc. (the Company) as of December 31, 2023 and 2022, the related
consolidated statements of income, comprehensive income, cash flows and shareholders’ equity for each of the three years in the period ended December 31, 2023,
and the related notes and financial statement schedule listed in the Index at Item 15(c) (collectively referred to as the “consolidated financial statements”). In our
opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the
results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted
accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal
control over financial reporting as of December 31, 2023, based on criteria established in Internal Control—Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 21, 2024 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements
based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to
assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such
procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe
that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be
communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially
challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial
statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the
account or disclosures to which it relates.
-67-

-- 68 of 533 --

Valuation of Incurred but Not Paid Claims
Description of the Matter 	Medical claims payable was $16,111 million at December 31, 2023, a significant portion of which related to the Company’s
estimate for claims that are incurred but not paid. As discussed in Note 2 to the consolidated financial statements, the
Company’s liability for incurred but not paid claims is determined using actuarial methods that include a number of factors
and assumptions, including completion factors, which represent the average percentage of total incurred claims that have been
paid through a given date after being incurred based on historical paid claims data, and trend factors, which represent an
estimate of claims expense based on recent claims expense levels and healthcare cost levels. There is significant uncertainty
inherent in determining management’s best estimate of completion and trend factors, which are used to calculate actuarial
estimates of incurred but not paid claims.
Auditing management’s estimate of incurred but not paid claims was complex and required the involvement of our actuarial
specialists due to the highly judgmental nature of the completion and trend factor assumptions used in the valuation process.
The significant judgment was primarily due to the sensitivity of management’s best estimate of completion and trend factor
assumptions, which have a significant impact on the valuation of incurred but not paid claims.
How We Addressed the
Matter in Our Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s
actuarial process for estimating the liability for incurred but not paid claims. These audit procedures included among others,
testing management review controls over completion and trend factor assumptions and the review and approval processes that
management has in place for estimating the liability for incurred but not paid claims.
To test the Company’s liability for incurred but not paid claims, our audit procedures included, among others, testing the
completeness and accuracy of the underlying claims and membership data recorded in the source claims processing and
disbursement systems to the data used by management in developing completion and trend factor assumptions and agreeing a
sample of incurred and paid claims to source documentation. With the support of actuarial specialists, we analyzed the
Company’s completion and trend factor assumptions based on historical claim experience and emerging cost trends and
independently calculated a range of reasonable reserve estimates for comparison to management’s best estimate of the
liability for incurred but not paid claims. Additionally, we performed a review of the prior period liabilities for incurred but
not paid claims to subsequent claims development.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 1944.
Indianapolis, Indiana
February 21, 2024
-68-

-- 69 of 533 --

Elevance Health, Inc.
Consolidated Balance Sheets
December 31,
2023 December 31,
2022
(In millions, except share data)
Assets
Current assets:
Cash and cash equivalents 	$ 	6,526 $ 	7,387
Fixed maturity securities (amortized cost of $30,446 and $28,226; allowance for credit losses of $4 and $9) 	29,614 	25,952
Equity securities 	229 	953
Premium receivables 	7,902 	7,083
Self-funded receivables 	4,558 	4,663
Other receivables 	5,405 	4,298
Other current assets 	5,795 	5,281
Total current assets 	60,029 	55,617
Long-term investments:
Fixed maturity securities (amortized cost of $890 and $789; allowance for credit losses of $0 and $0) 	876 	752
Other invested assets 	6,107 	5,685
Property and equipment, net 	4,359 	4,316
Goodwill 	25,317 	24,383
Other intangible assets 	10,273 	10,315
Other noncurrent assets 	1,967 	1,687
Total assets 	$ 	108,928 $ 	102,755
Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable 	$ 	16,111 $ 	15,596
Other policyholder liabilities 	5,600 	5,933
Unearned income 	1,402 	1,112
Accounts payable and accrued expenses 	6,910 	5,607
Short-term borrowings 	225 	265
Current portion of long-term debt 	1,649 	1,500
Other current liabilities 	9,894 	9,683
Total current liabilities 	41,791 	39,696
Long-term debt, less current portion 	23,246 	22,349
Reserves for future policy benefits 	778 	803
Deferred tax liabilities, net 	1,970 	2,015
Other noncurrent liabilities 	1,738 	1,562
Total liabilities 	69,523 	66,425
Commitments and Contingencies—Note 14
Shareholders’ equity
Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none 	— 	—
Common stock, par value 0.01, shares authorized - 900,000,000; shares issued and outstanding - 233,071,088 and 237,958,067 	2 	2
Additional paid-in capital 	8,868 	9,084
Retained earnings 	31,749 	29,647
Accumulated other comprehensive loss 	(1,313) 	(2,490)
Total shareholders’ equity 	39,306 	36,243
Noncontrolling interests 	99 	87
Total equity 	39,405 	36,330
Total liabilities and equity 	$ 	108,928 $ 	102,755
See accompanying notes.
-69-

-- 70 of 533 --

Elevance Health, Inc.
Consolidated Statements of Income
Years Ended December 31
(In millions, except per share data) 	2023 	2022 	2021
Revenues
Premiums 	$ 	142,854 $ 	133,229 $ 	117,373
Product revenue 	19,452 	14,978 	12,657
Service fees 	7,903 	7,453 	6,913
Total operating revenue 	170,209 	155,660 	136,943
Net investment income 	1,825 	1,485 	1,378
Net (losses) gains on financial instruments 	(694) 	(550) 	318
Total revenues 	171,340 	156,595 	138,639
Expenses
Benefit expense 	124,330 	116,642 	102,571
Cost of products sold 	17,293 	13,035 	10,895
Operating expense 	20,087 	17,700 	15,918
Interest expense 	1,030 	851 	798
Amortization of other intangible assets 	885 	767 	441
Loss on extinguishment of debt 	— 	— 	21
Total expenses 	163,625 	148,995 	130,644
Income before income tax expense 	7,715 	7,600 	7,995
Income tax expense 	1,724 	1,712 	1,846
Net income 	5,991 	5,888 	6,149
Net (gain) loss attributable to noncontrolling interests 	(4) 	6 	9
Shareholders’ net income 	$ 	5,987 $ 	5,894 $ 	6,158
Shareholders’ earnings per share
Basic 	$ 	25.38 $ 	24.56 $ 	25.26
Diluted 	$ 	25.22 $ 	24.28 $ 	24.95
Dividends per share 	$ 	5.92 $ 	5.12 $ 	4.52
See accompanying notes.
-70-

-- 71 of 533 --

Elevance Health, Inc.
Consolidated Statements of Comprehensive Income
Years Ended December 31
(In millions) 	2023 	2022 	2021
Net income 	$ 	5,991 $ 	5,888 $ 	6,149
Other comprehensive income (loss), net of tax:
Change in net unrealized gains/losses on investments 	1,117 	(2,260) 	(457)
Change in non-credit component of impairment losses on investments 	— 	(3) 	2
Change in net unrealized gains/losses on cash flow hedges 	18 	10 	11
Change in net periodic pension and postretirement costs 	40 	(70) 	123
Change in future policy benefits 	(3) 	32 	(7)
Foreign currency translation adjustments 	(1) 	(13) 	(9)
Other comprehensive income (loss) 	1,171 	(2,304) 	(337)
Net (gain) loss attributable to noncontrolling interests 	(4) 	6 	9
Other comprehensive loss attributable to noncontrolling interests 	6 	11 	2
Total shareholders’ comprehensive income 	$ 	7,164 $ 	3,601 $ 	5,823
See accompanying notes.
-71-

-- 72 of 533 --

Elevance Health, Inc.
Consolidated Statements of Cash Flows
Years Ended December 31
(In millions) 	2023 	2022 	2021
Operating activities
Net income 	$ 	5,991 $ 	5,888 $ 	6,149
Adjustments to reconcile net income to net cash provided by operating activities:
Net losses (gains) on financial instruments 	694 	550 	(318)
Equity in net earnings (losses) of other invested assets 	33 	(293) 	(562)
Depreciation and amortization 	1,745 	1,675 	1,302
Deferred income taxes 	(602) 	(115) 	342
Impairment of property and equipment 	446 	7 	73
Share-based compensation 	289 	264 	255
Changes in operating assets and liabilities:
Receivables, net 	(1,762) 	(2,510) 	(2,138)
Other invested assets 	(79) 	11 	(70)
Other assets 	(675) 	133 	41
Policy liabilities 	147 	2,411 	2,523
Unearned income 	290 	(42) 	(113)
Accounts payable and other liabilities 	1,640 	824 	719
Income taxes 	(103) 	(338) 	140
Other, net 	7 	(66) 	21
Net cash provided by operating activities 	8,061 	8,399 	8,364
Investing activities
Purchases of investments 	(16,236) 	(24,946) 	(18,669)
Proceeds from sale of investments 	10,596 	11,988 	10,269
Maturities, calls and redemptions from investments 	2,940 	10,620 	4,344
Changes in securities lending collateral 	78 	(301) 	(956)
Purchases of subsidiaries, net of cash acquired 	(1,552) 	(649) 	(3,476)
Purchases of property and equipment 	(1,296) 	(1,152) 	(1,087)
Other, net 	(102) 	(120) 	(63)
Net cash used in investing activities 	(5,572) 	(4,560) 	(9,638)
Financing activities
Proceeds from long-term borrowings 	2,574 	3,071 	3,462
Repayments of long-term borrowings 	(1,909) 	(1,899) 	(1,068)
Proceeds from short-term borrowings 	225 	1,365 	1,375
Repayments of short-term borrowings 	(265) 	(1,675) 	(1,050)
Changes in securities lending payable 	(77) 	302 	956
Changes in bank overdrafts 	114 	933 	(376)
Repurchase and retirement of common stock 	(2,676) 	(2,316) 	(1,900)
Cash dividends 	(1,395) 	(1,229) 	(1,104)
Proceeds from issuance of common stock under employee stock plans 	152 	182 	203
Taxes paid through withholding of common stock under employee stock plans 	(99) 	(93) 	(102)
Other, net 	7 	41 	27
Net cash (used in) provided by financing activities 	(3,349) 	(1,318) 	423
Effect of foreign exchange rates on cash and cash equivalents 	(1) 	(14) 	(10)
Change in cash and cash equivalents 	(861) 	2,507 	(861)
Cash and cash equivalents at beginning of year 	7,387 	4,880 	5,741
Cash and cash equivalents at end of year 	$ 	6,526 $ 	7,387 $ 	4,880
See accompanying notes.
-72-

-- 73 of 533 --

Elevance Health, Inc.
Consolidated Statements of Shareholders’ Equity
Total Shareholders’ Equity
Common Stock Additional
Paid-in
Capital
Accumulated
Other
Comprehensive
(Loss) Income
Noncontrolling
Interests
Total
Equity	(In millions)
Number
of Shares
Par
Value
Retained
Earnings
January 1, 2021 	245.4 $ 	3 $ 	9,244 $ 	23,802 $ 	138 $ 	— $ 	33,187
Net income 	— 	— 	— 	6,158 	— 	(9) 	6,149
Other comprehensive loss 	— 	— 	— 	(335) 	(2) 	(337)
Accumulated noncontrolling interest 	— 	— 	— 	— 	— 	79 	79
Repurchase and retirement of common stock 	(5.1) 	(1) 	(192) 	(1,707) 	— 	— 	(1,900)
Dividends and dividend equivalents 	— 	— 	— 	(1,111) 	— 	— 	(1,111)
Issuance of common stock under employee
stock plans, net of related tax benefits 	1.5 	— 	355 	— 	— 	— 	355
Convertible debenture repurchases and
conversions 	— 	— 	(259) 	— 	— 	— 	(259)
December 31, 2021 	241.8 	2 	9,148 	27,142 	(197) 	68 	36,163
Adoption of Accounting Standards Update
2020-06 (Note 2) 	— 	— 	— 	(23) 	— 	— 	(23)
January 1, 2022 	241.8 	2 	9,148 	27,119 	(197) 	68 	36,140
Net income 	— 	— 	— 	5,894 	— 	(6) 	5,888
Other comprehensive loss 	— 	— 	— 	— 	(2,293) 	(11) 	(2,304)
Noncontrolling interests adjustment 	— 	— 	— 	— 	— 	36 	36
Repurchase and retirement of common stock 	(4.8) 	— 	(184) 	(2,132) 	— 	— 	(2,316)
Dividends and dividend equivalents 	— 	— 	— 	(1,234) 	— 	— 	(1,234)
Issuance of common stock under employee
stock plans, net of related tax benefits 	1.0 	— 	352 	— 	— 	— 	352
Convertible debenture repurchases and
conversions 	— 	(232) 	— 	— 	— 	(232)
December 31, 2022 	238.0 	2 	9,084 	29,647 	(2,490) 	87 	36,330
Net income 	— 	— 	— 	5,987 	— 	4 	5,991
Other comprehensive income (loss) 	— 	— 	— 	— 	1,177 	(6) 	1,171
Noncontrolling interests adjustment 	— 	— 	— 	— 	— 	14 	14
Repurchase and retirement of common stock 	(5.8) 	— 	(217) 	(2,481) 	— 	— 	(2,698)
Dividends and dividend equivalents 	— 	— 	— 	(1,404) 	— 	— 	(1,404)
Issuance of common stock under employee
stock plans, net of related tax benefits 	0.9 	— 	342 	— 	— 	— 	342
Convertible debenture repurchases and
conversions 	— 	— 	(341) 	— 	— 	— 	(341)
December 31, 2023 	233.1 $ 	2 $ 	8,868 $ 	31,749 $ 	(1,313) $ 	99 $ 	39,405
See accompanying notes.
-73-

-- 74 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements
December 31, 2023
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
1. Organization
References to the terms “we,” “our,” “us” or “Elevance Health” used throughout these Notes to Consolidated Financial Statements refer to Elevance Health,
Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of
Columbia and Puerto Rico, unless the context otherwise requires.
Elevance Health is a health company with the purpose of improving the health of humanity. We are one of the largest health insurers in the United States in
terms of medical membership, serving approximately 47 million medical members through our affiliated health plans as of December 31, 2023. We offer a broad
spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets. In addition, we provide a broad array
of managed care services to fee-based customers, including claims processing, stop loss insurance, provider network access, medical management, care
management, wellness programs, actuarial services and other administrative services. We provide services to the federal government in connection with our Federal
Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both
to customers of our subsidiary health plans and also to unaffiliated health plans, including pharmacy services, dental, vision, life, disability and supplemental health
insurance benefits, as well as integrated health services.
We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our
members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana,
Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and
upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do
business as Anthem Blue Cross and Anthem Blue Cross and Blue Shield. We also conduct business through arrangements with other BCBS licensees as well as
other strategic partners. In addition, we serve members in numerous states as Amerigroup, Freedom Health, HealthSun, MMM, Optimum Healthcare, Simply
Healthcare and/or Wellpoint. We are licensed to conduct insurance operations in all 50 states, the District of Columbia and Puerto Rico through our subsidiaries.
As we announced in 2022, we are organizing our brand portfolio into the following core go-to-market brands:
• Anthem Blue Cross/Anthem Blue Cross and Blue Shield — represents our existing Anthem-branded and affiliated Blue Cross and/or Blue Shield licensed
plans;
• Wellpoint — we are uniting select non-BCBSA licensed Medicare, Medicaid and commercial plans under the Wellpoint name; and
• Carelon — this brand brings together our healthcare related services and capabilities, including our CarelonRx and Carelon Services businesses, under a
single brand name.
Our branding strategy reflects the evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. Given this
evolution, we reviewed and modified how we manage our business, monitor our performance and allocate resources, and made changes to our reportable segments
beginning in the first quarter of 2023. We now report our results of operations in the following four reportable segments: Health Benefits (aggregates our previously
reported Commercial & Specialty Business and Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and
Corporate & Other (our businesses that do not individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to
our other reportable segments). During the fourth quarter of 2023, we moved our Carelon Global Solutions international businesses from the Corporate & Other
reportable segment to the Carelon Services reportable segment. All prior period reportable segment information has been
-74-

-- 75 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
reclassified for comparability to conform to the current presentation. For additional discussion, see Note 20, “Segment Information.”
2. Basis of Presentation and Significant Accounting Policies
Basis of Presentation: The accompanying consolidated financial statements include the accounts of Elevance Health and its subsidiaries and have been
prepared in conformity with U.S. generally accepted accounting principles (“GAAP”). All significant intercompany accounts and transactions have been eliminated
in consolidation.
The accompanying consolidated financial statements and the notes to the consolidated financial statements have been recast and are presented as they would
have appeared had we changed our reportable segments, discussed in Note 20, “Segment Information,” and adopted the long-duration contracts accounting
standard, discussed in this Note 2 below, prior to January 1, 2023.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and
liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the period. We translate the revenues and expenses of those subsidiaries to
USD using the average exchange rates in effect during the period. The net effect of these translation adjustments is included in “Foreign currency translation
adjustments” in our consolidated statements of comprehensive income.
Reclassifications: Certain prior year amounts have been reclassified to conform to the current year presentation.
Use of Estimates: The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the
amounts reported in our consolidated financial statements and accompanying notes. Our most significant estimate relates to estimates and judgments for medical
claims payable. Actual results could differ from those estimates.
Cash and Cash Equivalents: Cash and cash equivalents includes available cash and all highly liquid investments with maturities of three months or less when
purchased. We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash
and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled $294 and $258 at December 31, 2023 and 2022, respectively, and
are included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed
maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual
maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.
If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will
have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an
impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we
will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as
an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component
of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to
fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost
basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate
implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions
regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and
changes in value. For all other securities, cash flow estimates are driven by assumptions regarding
-75-

-- 76 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the
estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and
anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since
the purchase date of the securities. Such adjustments are reported within net investment income.
The changes in fair value of our marketable equity securities are recognized in our results of operations within net gains and losses on financial instruments.
Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption “Other invested assets” in our consolidated
balance sheets.
Mortgage loans on real estate are classified as held for investment and are reported at their amortized cost basis net of loss allowance under the caption “Other
invested assets” in our consolidated balance sheets. Amortized cost is the amount at which the loan is originated, adjusted for accrued interest, amortization of
premium, discount and net deferred fees or costs, collection of cash and write-offs.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash
surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial
decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The
equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment realized gains and losses are recorded on the trade date. Realized gains
and losses are determined on the basis of the cost or amortized cost of the specific securities sold.
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in
exchange for cash and securities collateral. Under Financial Accounting Standards Board (“FASB”) guidance related to accounting for transfers and servicing of
financial assets and extinguishments of liabilities, we recognize the collateral as an asset, which is reported in other current assets on our consolidated balance
sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported in other current liabilities. The securities
on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are
included in accumulated other comprehensive income as a separate component of shareholders’ equity. The market value of loaned securities and that of the
collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of
the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to
market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which
provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to
higher quality and shorter duration instruments.
Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends,
future forecasts and our judgment regarding the ability to collect specific accounts.
Premium receivables include the uncollected amounts from insured groups, individuals and government programs. Premium receivables are reported net of an
allowance for doubtful accounts of $212 and $152 at December 31, 2023 and 2022, respectively.
Self-funded receivables include administrative fees, claims and other amounts due from fee-based customers. Self-funded receivables are reported net of an
allowance for doubtful accounts of $87 and $68 at December 31, 2023 and 2022, respectively.
-76-

-- 77 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades,
accrued investment income and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of $941 and $744
at December 31, 2023 and 2022, respectively.
Income Taxes: We file a consolidated U.S. federal income tax return. Deferred income tax assets and liabilities are recognized for temporary differences
between the financial statement and tax return basis of assets and liabilities based on enacted tax rates and laws and are reported net on our consolidated balance
sheets. The deferred tax benefits of the deferred tax assets are recognized to the extent realization of such benefits is more likely than not. Deferred income tax
expense or benefit generally represents the net change in deferred income tax assets and liabilities during the year, excluding the impact from amounts initially
recorded for business combinations, if any, and amounts recorded to accumulated other comprehensive income. Current income tax expense represents the tax
consequences of revenues and expenses currently taxable or deductible on various income tax returns for the year reported.
The Internal Revenue Code subjects a U.S. shareholder to tax on Global Intangible Low-Taxed Income (“GILTI”) earned by certain foreign subsidiaries. We
have elected to account for GILTI tax in the year the tax is incurred.
The Inflation Reduction Act of 2022 includes a provision that imposes a new corporate alternative minimum tax (the “Corporate AMT”) that became effective
for us beginning January 1, 2023. We have elected to account for the effects of the Corporate AMT on deferred tax assets and carryforwards and tax credits in the
period they arise. We have also elected to disregard Corporate AMT when evaluating the need for a valuation allowance for non-Corporate AMT deferred tax
assets. We do not believe the Corporate AMT will have a material impact on our consolidated financial position, results of operations, cash flows or related
disclosures. Additionally, the Inflation Reduction Act of 2022 imposes an excise tax on the fair market value of net stock repurchases made after December 31,
2022. These are included as a charge to retained earnings as a component of the repurchase and retirement of common stock.
We account for income tax contingencies in accordance with FASB guidance that contains a model to address uncertainty in tax positions and clarifies the
accounting for income taxes by prescribing a minimum recognition threshold, which all income tax positions must achieve before being recognized in the financial
statements.
Property and Equipment: Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is computed principally by the straight-
line method over estimated useful lives ranging from fifteen to thirty years for buildings and improvements, three to five years for computer equipment and
software, and seven years for furniture and other equipment. Leasehold improvements are depreciated over the term of the related lease. Certain costs related to the
development or purchase of internal-use software are capitalized and amortized over estimated useful lives ranging from three to ten years.
Goodwill and Other Intangible Assets: FASB guidance requires business combinations to be accounted for using the acquisition method of accounting, and it
also specifies the types of acquired intangible assets that are required to be recognized and reported separately from goodwill. Goodwill represents the excess of the
cost of acquisition over the fair value of net assets acquired. Other intangible assets represent the values assigned to customer relationships, provider and hospital
networks, Blue Cross and Blue Shield and other trademarks, licenses and other agreements, such as non-compete agreements. Goodwill and other intangible assets
are allocated to reportable segments based on the relative fair value of the components of the businesses acquired.
Goodwill and other intangible assets with indefinite lives are not amortized but are tested for impairment at least annually. Goodwill and other intangible assets
are allocated to reporting units for purposes of the annual goodwill impairment test. Other intangible assets with indefinite lives, such as trademarks, are tested for
impairment separately. We complete our annual impairment tests of existing goodwill and other intangible assets with indefinite lives during the fourth quarter of
each year. Our impairment tests require us to make assumptions and judgments regarding the estimated fair value of our reporting units, including goodwill and
other intangible assets with indefinite lives. Certain interim impairment tests are also performed when potential impairment indicators exist or changes in our
business or other triggering events occur.
FASB guidance allows for qualitative assessments of whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount for
purposes of a goodwill impairment analysis and whether it is more likely than not that an indefinite-lived intangible asset is impaired for purposes of an indefinite-
lived intangible asset impairment analysis. Estimated fair values developed based on our assumptions and judgments might be different if other reasonable
assumptions
-77-

-- 78 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
and estimates were to be used. Qualitative analysis involves assessing situations and developments that could affect key drivers used to evaluate whether the fair
value of our goodwill and indefinite-lived intangible assets are impaired. Our procedures include assessing our financial performance, macroeconomic conditions,
industry and market considerations, various asset specific factors, and entity specific events.
Quantitative analysis must be performed if qualitative analyses are not conclusive. Entities also have the option to bypass the assessment of qualitative factors
and proceed directly to performing quantitative analyses. Fair value for purposes of a quantitative goodwill impairment test is calculated using a blend of the
projected income and market valuation approaches. The projected income approach is developed using assumptions about future revenue, expenses and net income
derived from our internal planning process. Our assumed discount rate is based on our industry’s weighted-average cost of capital and reflects volatility associated
with the cost of equity capital. Market valuations include market comparisons to publicly traded companies in our industry and are based on observed multiples of
certain measures including revenue; earnings before interest, taxes, depreciation and amortization (“EBITDA”); and book value of invested capital.
A goodwill impairment loss is recognized to the extent that the carrying amount exceeds the asset’s fair value. This determination consists of a one-step test
comparing the fair value of a reporting unit, including goodwill, to its carrying amount. If the carrying amount of a reporting unit exceeds its fair value, an
impairment loss is recognized. This goodwill impairment loss is equal to the excess of the reporting unit’s carrying amount over its fair value.
Fair value for purposes of a quantitative impairment test for indefinite-lived intangible assets is estimated using a projected income approach. We recognize an
impairment loss when the estimated fair value of indefinite-lived intangible assets is less than the carrying value. If significant impairment indicators are noted
relative to other intangible assets subject to amortization, we may be required to record impairment losses against future income.
Derivative Financial Instruments: We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward
contracts, put and call options, collars, swaptions, embedded derivatives and warrants. Derivatives embedded within non-derivative instruments, such as options
embedded in convertible fixed maturity securities, are bifurcated from the host instrument when the embedded derivative is not clearly and closely related to the
host instrument. Our use of derivatives is limited by statutes and regulations promulgated by the various regulatory bodies to which we are subject, and by our own
derivative policy. Our derivative use is generally limited to hedging purposes, on an economic basis, and we generally do not use derivative instruments for
speculative purposes.
We have exposure to economic losses due to interest rate risk arising from changes in the level or volatility of interest rates. We attempt to mitigate our
exposure to interest rate risk through active portfolio management, including rebalancing our existing portfolios of assets and liabilities, as well as changing the
characteristics of investments to be purchased or sold in the future. In addition, derivative financial instruments are used to modify the interest rate exposure of
certain liabilities or forecasted transactions. These strategies include the use of interest rate swaps and forward contracts, which are used to lock-in interest rates or
to hedge, on an economic basis, interest rate risks associated with variable rate debt. We have used these types of instruments as designated hedges against specific
liabilities.
All investments in derivatives are recorded as assets or liabilities at fair value. If certain correlation, hedge effectiveness and risk reduction criteria are met, a
derivative may be specifically designated as a hedge of exposure to changes in fair value or cash flow. The accounting for changes in the fair value of a derivative
depends on the intended use of the derivative and the nature of any hedge designation thereon. Amounts excluded from the assessment of hedge effectiveness, if
any, are reported in results of operations immediately. If the derivative is not designated as a hedge, the gain or loss resulting from the change in the fair value of
the derivative is recognized in results of operations in the period of change. Cash flows associated with the settlement of non-designated derivatives are shown on a
net basis in investing activity in our consolidated statements of cash flow.
From time to time, we may also purchase derivatives to hedge, on an economic basis, our exposure to foreign currency exchange fluctuations associated with
the operations of certain of our subsidiaries. We generally use futures or forward contracts for these transactions. We generally do not designate these contracts as
hedges and, accordingly, the changes in fair value of these derivatives are recognized in results of operations immediately.
Credit exposure associated with non-performance by the counterparties to derivative instruments is generally limited to the uncollateralized fair value of the
asset related to instruments recognized in the consolidated balance sheets. We attempt to
-78-

-- 79 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
mitigate the risk of non-performance by selecting counterparties with high credit ratings and monitoring their creditworthiness and by diversifying derivatives
among multiple counterparties. At December 31, 2023, we believe there were no material concentrations of credit risk with any individual counterparty.
We generally enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. Certain of
our derivative agreements also contain credit support provisions that require us or the counterparty to post collateral if there are declines in the derivative fair value
or our credit rating. The derivative assets and derivative liabilities are reported at their fair values net of collateral and netting by the counterparty.
Retirement Benefits: We recognize the funded status of pension and other postretirement benefit plans on the consolidated balance sheets based on fiscal-year-
end measurements of plan assets and benefit obligations. Prepaid pension benefits represent prepaid costs related to defined benefit pension plans and are reported
with other noncurrent assets. Postretirement benefits represent outstanding obligations for retiree medical, life, vision and dental benefits. Liabilities for pension
and other postretirement benefits are reported with noncurrent assets, current liabilities and noncurrent liabilities based on the amount by which the actuarial
present value of benefits payable in the next twelve months included in the benefit obligation exceeds the fair value of plan assets.
We determine the expected return on plan assets using the calculated value of plan assets, which recognizes changes in the fair value of plan assets in a
systematic manner over three years. We apply a corridor approach to amortize unrecognized actuarial gains or losses. Under this approach, only accumulated net
actuarial gains or losses in excess of 10% of the greater of the projected benefit obligation or the fair value of plan assets are amortized over the average remaining
service or lifetime of the workforce as a component of net periodic benefit cost.
The discount rate reflects the current rate at which the pension liabilities could be effectively settled at the end of the year based on our most recent
measurement date. We use the annual spot rate approach for setting our discount rate. Under the spot rate approach, individual spot rates from a full yield curve of
published rates are used to discount each plan’s cash flows to determine the plan’s obligations.
The assumed healthcare cost trend rates used to measure the expected cost of other postretirement benefits are based on an initial assumed healthcare cost trend
rate declining to an ultimate healthcare cost trend rate over a select number of years.
Medical Claims Payable: Liabilities for medical claims payable include estimated provisions for incurred but not paid claims on an undiscounted basis, as
well as estimated provisions for expenses related to the processing of claims. Incurred but not paid claims include (1) an estimate for claims that are incurred but
not reported, as well as claims reported to us but not yet processed through our systems; and (2) claims reported to us and processed through our systems but not
yet paid.
Liabilities for both claims incurred but not reported and reported but not yet processed through our systems are determined in the aggregate, employing
actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. Our reserving practice for claim liabilities is to
consistently recognize the appropriate amount of reserve within a level of confidence required by Actuarial Standards of Practice. We determine the amount of the
liability for incurred but not paid claims by following a detailed actuarial process that uses both historical claim payment patterns as well as emerging medical cost
trends to project our best estimate of claim liabilities. Under this process, historical paid claims data is formatted into “claim triangles,” which compare claim
incurred dates to the dates of claim payments. This information is analyzed to create “completion factors” that represent the average percentage of total incurred
claims that have been paid through a given date after being incurred. Completion factors are applied to claims paid through the period-end date to estimate the
ultimate claim expense incurred for the period. Actuarial estimates of incurred but not paid claim liabilities are then determined by subtracting the actual paid
claims from the estimate of the ultimate incurred claims.
For the most recent incurred months (typically the most recent two months), the percentage of claims paid for claims incurred in those months is generally low.
This makes the completion factor methodology less reliable for such months. Therefore, incurred claims for recent months are not projected from historical
completion and payment patterns; rather, they are projected by estimating the claims expense for those months based on recent claims expense levels and
healthcare trend levels (“trend factors”).
On a regular basis, we review cost trends and utilization assumptions set upon initial establishment of claim liabilities. We utilize subsequent paid claims
activity to monitor and continuously adjust the claims liability and benefit expense. If
-79-

-- 80 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
actual results are determined to be materially different than assumptions regarding cost trends and utilization, future periods of our income statement and overall
financial position could be impacted.
Premium deficiencies are recognized when it is probable that expected claims and administrative expenses will exceed future premiums on existing medical
insurance contracts without consideration of investment income. Determination of premium deficiencies for longer duration life and disability contracts includes
consideration of investment income. For purposes of evaluating premium deficiencies, contracts are deemed to be either short or long duration and are grouped in a
manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. Once established, reserves for premium deficiencies
are released commensurate with actual claims experience over the remaining life of the contract. No reserves for premium deficiencies were established at
December 31, 2023 or 2022.
Benefit expense includes incurred medical claims as well as quality improvement expenses for our risk-based members. Quality improvement activities are
those designed to improve member health outcomes, prevent hospital readmissions and improve patient safety. They also include expenses for wellness and health
promotion provided to our members.
Other Policyholder Liabilities: Other policyholder liabilities include rate stabilization reserves associated with retrospectively rated insurance contracts and
certain case-specific reserves. Other policyholder liabilities also include liabilities for premium refunds based upon the minimum medical loss ratio (“MLR”), the
relative health risk of members, and other contractual or regulatory requirements. Rate stabilization reserves represent accumulated premiums that exceed what
customers owe us based on actual claim experience. The timing of payment of these retrospectively rated refunds is based on the contractual terms with our
customers and can vary from period to period based on the specific contractual requirements.
We are required to meet certain minimum MLR thresholds prescribed by the Patient Protection and Affordable Care Act and the Health Care and Education
Reconciliation Act of 2010, as amended (collectively the “ACA”). If we do not meet or exceed the minimum MLR thresholds specified by the ACA, we are
required to pay rebates to certain customers. Minimum MLR rebates are calculated by subsidiary, state and applicable line of business in accordance with
regulations issued by the Department of Health and Human Services (“HHS”). Such calculations are made using estimated calendar year medical loss expense and
premiums, as defined by HHS.
We follow HHS guidelines for determining the types of expenses that may be included in our minimum MLR rebate calculations, which differ from benefit
expense and premiums as reported in our consolidated financial statements prepared in conformity with GAAP. Certain amounts reported as expense in our
consolidated GAAP financial statements may be reported as a reduction of premiums in accordance with HHS regulations. In addition, profit amounts included in
our payments to third-party administrative service providers are recorded as benefit expense in our consolidated GAAP financial statements, while HHS does not
allow for the inclusion of these expenses within the medical loss expense for purposes of calculating minimum MLR.
Reserves for Future Policy Benefits: Reserves for future policy benefits include liabilities for life and long-term disability insurance policy benefits based
upon interest, mortality and morbidity assumptions from published actuarial tables, modified based upon our experience. Future policy benefits also include
liabilities for insurance policies for which some of the premiums received in earlier years are intended to pay anticipated benefits to be incurred in future years.
Future policy benefits are continually monitored and reviewed, and when reserves are adjusted, differences are reflected in benefit expense.
We believe that our liabilities for future policy benefits, along with future premiums received, are adequate to satisfy our ultimate benefit liability; however,
these estimates are inherently subject to a number of variable circumstances. Consequently, the actual results could differ materially from the amounts recorded in
our consolidated financial statements.
Revenue Recognition: Premiums for risk-based contracts are recognized as revenue over the period insurance coverage is provided, and, if applicable, net of
amounts recognized for MLR rebates, risk adjustment, reinsurance and risk corridor under contractual premium stabilization arrangements, the ACA or other
regulatory requirements. Premiums may also include performance incentives and penalties, which are recognized based on contractual terms. We estimate amounts
receivable and payable under these contractual terms, and to the extent that such estimated amounts vary from the final amounts paid, the adjustments are included
in earnings in the period of final settlement. Premium payments from contracted government agencies are based on eligibility lists produced by the government
agencies. Premiums related to the unexpired contractual coverage periods are reflected in the accompanying consolidated balance sheets as unearned income.
Premiums include revenue adjustments for retrospectively rated contracts where revenue is based on the estimated loss experience of the
-80-

-- 81 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
contract. Premium rates for certain lines of business are subject to approval by the Department of Insurance of each respective state. Additionally, delays in annual
premium rate changes from contracted government agencies require that we defer the recognition of any increases to the period in which the premium rates become
final. The value of the impact can be significant in the period in which it is recognized depending on the magnitude of the premium rate increase, the membership
to which it applies and the length of the delay between the effective date of the rate increase and the final contract date. Premium rate decreases are recognized in
the period the change in premium rate becomes effective and the change in the rate is known, which may be prior to the period when the contract amendment
affecting the rate is finalized.
Service fees include revenue from certain group contracts that provide for the group to be at risk for all, or with supplemental insurance arrangements, a
portion, of their claims experience. We charge these fee-based groups an administrative fee, which is based on the number of members in a group and the group’s
claim experience. In addition, service fees include amounts received for the administration of Medicare, certain other government programs, and administrative
services arrangements of our Carelon subsidiaries. Generally, each fee-based arrangement includes services which constitute a single suite of services provided and
for which consideration is based upon an agreed-upon rate, regardless of the amount of services provided in a given period. As with premiums, each fee-based
arrangement may include terms with retroactive rate or membership adjustments, performance incentives and penalties, each of which is a form of variable
consideration within the transaction price. As such, each fee-based arrangement contains a single performance obligation that constitutes a series, and revenue is
recognized over time as the services are performed. All benefit payments under these programs are excluded from benefit expense.
The determination of whether services are distinct performance obligations that should be accounted for separately or combined as one unit of accounting may
require significant judgment. The estimation of variable consideration to be recognized requires significant judgment in the determination of the level of
achievement of performance incentives, service level achievements subject to performance penalties, and the completion level of tasks subject to implementation
fees.
Product revenue includes revenue for services performed by CarelonRx for unaffiliated pharmacy customers as well as any co-payments and subsidies made
by or on behalf of affiliated customers. Unaffiliated pharmacy customers include our fee-based groups that have contracted with CarelonRx for pharmacy services
and third-party health plans. Product revenues and costs of goods sold for our affiliated health plans are eliminated in consolidation, excluding co-payments and
subsidies made by or on behalf of affiliated customers. Product revenue for pharmacy services is recognized using the gross method at the negotiated contract price
when CarelonRx has concluded that it is the principal and it controls the services before prescription drugs are transferred to the customer. CarelonRx determined it
is the principal due to its contractual rights to design and develop a listing of prescription drugs offered to the customer (formulary management); its control over
establishing the pharmacy network available to the customer to have its prescription fulfilled (network management); and its discretion over establishing the pricing
for prescription drugs. Overall, control over these activities indicate CarelonRx is primarily responsible for fulfilling the promise to provide pharmacy services.
Product revenue includes ingredient costs (net of any rebates or discounts), including any co-payments and subsidies made by or on behalf of the customer, and
administrative fees. CarelonRx recognizes revenue when control of the prescription drugs is transferred to customers, in an amount it expects to be entitled to in
exchange for the products or services provided.
For our non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheets
at December 31, 2023 and 2022. Revenue recognized in 2023 and 2022 from performance obligations related to prior years, such as due to changes in transaction
price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to
unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.
Cost of Products Sold: CarelonRx’s cost of products sold includes the cost of prescription drugs dispensed to unaffiliated pharmacy customers (net of rebates
or discounts). Cost of products sold includes per-claim administrative fees for prescription fulfillment by its vendor and certain CarelonRx direct costs related to
sales and administration of customer contracts.
Share-Based Compensation: Our current compensation philosophy provides for share-based compensation, including stock options, restricted stock awards
and an employee stock purchase plan. Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at
the date of the grant. Restricted stock awards are
-81-

-- 82 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
issued at the fair value of the stock on the grant date. The employee stock purchase plan allows for a purchase price per share which is 90% of the fair value of a
share of common stock on the lower of the first or last trading day of the plan quarter. The employee stock purchase plan discount is recognized as compensation
expense based on GAAP guidance. All other share-based payments to employees are recognized as compensation expense in our consolidated statements of income
based on their fair values. Additionally, excess tax benefits, which result from actual tax benefits realized when awards vest or options are exercised exceeding
deferred tax benefits previously recognized based on grant date fair value, are recognized as tax benefits in the consolidated statements of income.
Advertising and Marketing Costs: We use print, broadcast and other advertising to promote our products and to develop our corporate image. We market our
products through direct marketing activities and an extensive network of independent agents, brokers and retail partnerships for Individual and Medicare
customers, and for certain Employer Group risk-based customers with a smaller employee base. Products for Employer Group risk-based customers with a larger
employee base are generally sold through independent brokers or consultants retained by the customer who work with industry specialists from our in-house sales
force. In the Individual and Group markets, we offer products through state or federally facilitated marketplaces, or Public Exchanges, and off-exchange
products. The cost of advertising and marketing for product promotion is expensed as incurred, while advertising and marketing costs associated with our corporate
image are expensed when first aired. Total advertising and marketing expense was $599, $511 and $588 for the years ended December 31, 2023, 2022 and 2021,
respectively.
Leases: We lease office space and certain computer and related equipment under noncancelable operating leases. We determine whether an arrangement is or
contains a lease at its inception. We recognize lease liabilities based on the present value of the minimum lease payments not yet paid by using the lease term, any
amounts probable of being owed under any residual value guarantees and the discount rate determined at lease commencement. As our leases do not generally
provide an implicit rate, we use our incremental secured borrowing rate commensurate with the underlying lease terms to determine the present value of our lease
payments. Our lease liabilities may include amounts for options to extend or terminate a lease when it is reasonably certain that we will exercise that option. We
recognize operating right-of-use (“ROU”) assets at an amount equal to the lease liability adjusted for prepaid or accrued rent, the remaining balance of any lease
incentives and unamortized initial direct costs.
The operating lease liabilities are reported in other current liabilities and other noncurrent liabilities and the related ROU assets are reported in other noncurrent
assets on our consolidated balance sheets. Lease expense for our operating leases is calculated on a straight-line basis over the lease term and is reported in
operating expense on our consolidated statements of income. For our office space leases, we account for the lease and non-lease components (such as common area
maintenance) as a single lease component. We also do not recognize a lease liability or ROU asset for our office space leases whose lease terms, at commencement,
are twelve months or less and that do not include a purchase option or option to extend that we are reasonably certain to exercise.
We assess our ROU assets for impairment when there are indicators of impairment and compare the carrying amount of the ROU asset to its estimated
undiscounted future cash flows. If the estimated undiscounted future cash flows are less than the carrying amount of the ROU asset, an impairment calculation is
performed. An impairment loss is recorded for the difference of the ROU asset’s carrying value that exceeds its estimated discounted cash flows. During the years
ended December 31, 2023, 2022 and 2021, we recorded $23, $34 and $136, respectively, for impairment and abandonment of ROU assets. See Note 18, “Leases,”
for additional information about the ROU asset impairment and abandonment charges.
Shareholders’ Earnings per Share: Earnings per share amounts, on a basic and diluted basis, have been calculated based upon the weighted-average common
shares outstanding for the period.
Basic shareholders’ earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted-average
number of common shares outstanding for the period. Diluted shareholders’ earnings per share may include the dilutive effect of stock options, restricted stock and
convertible debentures, using the treasury stock method. The treasury stock method assumes exercise of stock options and vesting of restricted stock, with the
assumed proceeds used to purchase common stock at the average market price for the period. The difference between the number of shares assumed issued and the
number of shares assumed purchased represents the dilutive shares.
-82-

-- 83 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
Recently Adopted Accounting Guidance: In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services—Insurance
(Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 changed the effective date and early application of
Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts,
which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year to our interim and annual reporting periods
beginning after December 15, 2022. This standard requires us to review cash flow assumptions for our long-duration insurance contracts at least annually and
recognize the effect of changes in future cash flow assumptions in net income. This standard also requires us to update discount rate assumptions quarterly and
recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount our reserves for future policy benefits will be based
on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of our liabilities. In addition, this standard
changes the amortization method for deferred acquisition costs. We adopted these amendments on January 1, 2023, using the modified retrospective transition
method for changes to the liability for future policy benefits and deferred acquisition costs as of the transition date, January 1, 2021. While the adoption did not
have an overall material impact, our prior period financial statements presented in this Annual Report on Form 10-K have been restated to reflect the impacts of our
adoption as required by the new standard. Adjustments of $(131) and $54, respectively, were made to shareholders’ net income for the years ended December 31,
2022 and 2021, which include adjustments to benefit expense of $155 and $(74), respectively. In addition, the following balance sheet adjustments were made at
years ended December 31, 2022 and 2021: $(17) and $(4), respectively, to total assets; $47 and $(39), respectively, to total liabilities; $13 and $(19), respectively, to
accumulated other comprehensive loss; and $(64) and $35, respectively to shareholders’ equity and total equity.
In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and
Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
(“ASU 2020-06”). The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities,
simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted
shareholders’ earnings per share calculation and expand disclosure requirements. The amendments became effective for our annual and interim reporting periods
beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase
to our reported debt outstanding of $31, a decrease to our deferred tax liabilities of $8, and a corresponding cumulative-effect reduction to our opening retained
earnings of $23, by eliminating the bifurcation of the embedded conversion option. These amounts were not material to our overall consolidated financial position.
The adoption of ASU 2020-06 did not have an impact on our results of operations or our consolidated cash flows. Use of the if-converted method did not have an
impact on our overall shareholders’ earnings per share calculation.
Recent Accounting Guidance Not Yet Adopted: In November 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic
280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). The amendments in ASU 2023-07 are intended to improve reportable segment
disclosure requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 is effective for our fiscal year beginning after
December 15, 2023, and interim periods within our fiscal year beginning after December 15, 2024. The amendments are to be applied retrospectively to all prior
periods presented in the financial statements, and upon transition, the significant segment expense categories and amounts disclosed in the prior periods should be
based on the significant segment expense categories identified and disclosed in the period of adoption. We are currently evaluating the effects the adoption of ASU
2023-07 will have on our consolidated financial statements and related disclosures.
In August 2023, the FASB issued Accounting Standards Update No. 2023-05, Business Combinations—Joint Venture Formations (Subtopic 805-60):
Recognition and Initial Measurement (“ASU 2023-05”). ASU 2023-05 clarifies existing guidance to reduce diversity in practice and is requiring a joint venture to
recognize and initially measure its assets and liabilities using a new basis of accounting, at fair value, upon formation. These amendments are effective
prospectively for all joint venture formations with a formation date on or after January 1, 2025. We do not believe the adoption of ASU 2023-05 will have a
material impact on our consolidated financial statements and disclosures.
There were no other new accounting pronouncements that were issued or became effective during the year ended December 31, 2023 that had, or are expected
to have, a material impact on our financial position, results of operations, cash flows or financial statement disclosures.
-83-

-- 84 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
3. Business Acquisitions and Divestitures
Completed Acquisitions
During the year ended December 31, 2023, we completed business combinations for total cash consideration of approximately $1,655. These acquisitions
included BioPlus Parent, LLC and subsidiaries (“BioPlus”) which were acquired in February 2023. Prior to the acquisition, BioPlus was one of the largest
independent specialty pharmacy organizations in the United States. BioPlus seeks to connect payors and providers of specialty pharmaceuticals to meet the
medication therapy needs of patients with complex medical conditions. The purchase prices for all business combinations were preliminarily allocated to the
tangible and intangible net assets acquired based on management's initial estimates of their fair values, of which $820 was allocated to finite-lived intangible assets
and $918 to goodwill. Of these amounts, $1,718 was allocated to our CarelonRx reportable segment and $20 to our Carelon Services reportable segment. The
majority of goodwill is not deductible for income tax purposes. As of December 31, 2023, the initial accounting for the acquisition had not been finalized. Any
subsequent adjustments made to the assets acquired or liabilities assumed during the measurement period will be recorded as an adjustment to goodwill. The
proforma effects of this acquisition for prior periods were not material to our consolidated results of operations.
During the year ended December 31, 2022, we completed business combinations for total cash consideration of approximately $751. These acquisitions
included Integra MLTC, Inc. (“Integra”), acquired in May 2022, a managed long-term care plan serving New York state Medicaid members, enabling adults with
long-term care needs and disabilities to live safely and independently in their own homes. The purchase prices for all business combinations were allocated to the
tangible and intangible net assets acquired based on management’s final estimates of their fair values, of which $89 was allocated to finite-lived intangible assets,
$250 to indefinite-lived intangible assets, and $161 to goodwill including measurement period adjustments of $16 during the year ended December 31, 2023. The
intangible assets and goodwill acquired were assigned to our Health Benefits reportable segment. The majority of goodwill is deductible for income tax purposes.
The proforma effects of these acquisitions for prior periods were not material to our consolidated results of operations.
Acquired tangible assets (liabilities) at the acquisition date were:
2023 	2022
Cash, cash equivalents and short-term investments 	$ 	6 $ 	170
Accounts receivable and other current assets 	241 	240
Property, equipment and other long-term assets 	18 	109
Medical claims and other policyholder liabilities payable 	— 	(185)
Accounts payable and other current liabilities 	(159) 	(20)
Other long-term liabilities 	(2) 	(15)
Deferred tax liabilities 	(187) 	(48)
Total net tangible assets (liabilities) 	$ 	(83) $ 	251
The preliminary purchase price allocations for the various business combinations are subject to adjustment as valuation analyses, primarily related to
intangible assets and contingent and tax liabilities, are finalized.
-84-

-- 85 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
Acquisition date fair values and weighted-average useful lives assigned to intangible assets include:
2023 	2022
Fair Value
Weighted Average
Useful Life 	Fair Value
Weighted Average
Useful Life
Customer-related 	$ 	796 	25 years $ 	85 	10 years
Provider and hospital relationships 	— 	— 	2 	15 years
Other 	24 	5 years 	2 	0.5 years
State Medicaid licenses 	— 	— 	250 	Indefinite
Total intangible assets 	$ 	820 	$ 	339
The results of operations and financial condition of acquired entities have been included in our consolidated results and the results of the corresponding
operating segment as of the date of acquisition. Through December 31, 2023, the impact of the acquired entities on revenue and net earnings was not material.
Unaudited pro forma revenues for the years ended December 31, 2023 and 2022 as if the acquisitions had occurred on January 1, 2022 were immaterial for both
periods.
Pending Divestiture
On March 28, 2023, we announced our entrance into an agreement to sell our life and disability businesses to StanCorp Financial Group, Inc. (“The
Standard”), a provider of financial protection products and services for employers and individuals. Upon closing, we and The Standard will enter into a product
distribution partnership. The divestiture is expected to close in the first half of 2024 and is subject to standard closing conditions and customary approvals. The
related net assets held for sale and results of operations for the life and disability businesses to be divested as of and for the year ended December 31, 2023 were not
material.
Pending Acquisitions
On January 4, 2024, we announced our entrance into an agreement to acquire Paragon Healthcare, Inc., a company providing infusion services and injectable
therapies through its omnichannel model of ambulatory infusion centers, home infusion pharmacies, and other specialty pharmacy services. This acquisition aligns
with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we
serve. The acquisition is expected to close in the first half of 2024 and is subject to standard closing conditions and customary approvals.
On December 31, 2023, we entered into an agreement to acquire Centers Plan for Healthy Living LLC and Centers for Specialty Care Group IPA, LLC
(“Centers”). Centers is a managed long-term care plan that serves New York state Medicaid and dually-eligible Medicaid/Medicare members, enabling adults with
long-term care needs and disabilities to live safely and independently in their own home. This acquisition aligns with Elevance Health’s strategic plan to grow the
Health Benefits segment and leverage industry-leading expertise while serving Medicaid and dually eligible populations. The acquisition is expected to close in the
third quarter of 2024 and is subject to standard closing conditions and customary approvals.
On January 23, 2023, we announced our entrance into an agreement to acquire Louisiana Health Service & Indemnity Company, d/b/a Blue Cross and Blue
Shield of Louisiana, an independent licensee of the BCBSA that provides healthcare plans to the Individual, Employer Group, Medicaid and Medicare markets,
primarily in the State of Louisiana. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care
management programs that improve the lives of the people we serve. The acquisition is subject to closing conditions and approvals.
4. Business Optimization Initiatives
2023-2024 Business Efficiency Program
In the third quarter of 2023, we implemented the “2023-2024 Business Efficiency Program” as a result of a strategic review of our operations, assets and
investments. The purpose of this program is to enhance operating efficiency, refine the
-85-

-- 86 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
focus of our investments and optimize our physical footprint. This efficiency program includes the write-off of certain information technology assets and contract
exit costs, a reduction in staff including the relocation of certain job functions, and the impairment of assets associated with the closure or partial closure of data
centers and offices. We anticipate substantial completion of the 2023-2024 Business Efficiency Program by the end of the third quarter of 2024. Cash outlays
associated with this program, primarily for personnel-related costs, are expected to be paid through 2024.
In 2023, we incurred $752 of expense, which included $468 of pre-tax charges for information technology assets and contract write-offs related to projects that
have been de-prioritized and stopped, $230 of pre-tax personnel-related charges for the reduction and/or relocation of workforce, which includes severance and
related costs primarily determined under our existing severance plans, and $54 of pre-tax charges from asset impairments related to the closure or partial closure of
data centers and offices, including operating lease-related ROU assets and other property and equipment. These charges were recognized in operating expense in
the Corporate & Other segment; see Note 20, “Segment Information.”
2020 Business Optimization Program
During 2020, our management introduced initiatives across the enterprise to optimize our business operations, including recognition of liabilities for future
payments for employee termination costs in connection with the repositioning and reskilling of our workforce.
During 2021, we identified reductions of office space and recorded a charge of $202 in operating expense related to this optimization program. This charge
included $136 for impairment and abandonment of operating-lease related ROU assets and $66 for impairment and abandonment of property and equipment. The
charges recognized in the Health Benefits, CarelonRx, Carelon Services and Corporate & Other segments in 2021, were $168, $1, $33 and $0, respectively.
During 2022, while evaluating our real estate strategy as it relates to the changing needs of a more hybrid remote workforce, we identified additional
reductions of office space and recorded a net charge of $39 in operating expense related to this optimization program. This charge included $34 for impairment and
abandonment of operating-lease related ROU assets and $7 for impairment and abandonment of property and equipment. In addition, we released $2 of employee
termination costs. The net charges (benefits) recognized in the Health Benefits, CarelonRx, Carelon Services and Corporate & Other segments in 2022, were $36,
$0, $5 and $(2), respectively.
During 2023, we released $33 of employee termination costs related to this optimization program, as reflected in the table below, which was recognized in the
Health Benefits segment.
Liabilities for Employee Termination Costs
A summary of the activity for the year ended December 31, 2023 and the ending balance at that date, related to the liability for employee termination costs, is
as follows:
Health Benefits 	CarelonRx 	Carelon Services
Corporate &
Other 	Total
2023-2024 Business Efficiency Program
Liabilities for employee termination costs at January 1, 2023 	$ 	— $ 	— $ 	— $ 	— $ 	—
Charges 	— 	— 	— 	230 	230
Payments 	— 	— 	— 	(39) 	(39)
Total liabilities for employee termination costs ending balance at
December 31, 2023 	$ 	— $ 	— $ 	— $ 	191 $ 	191
-86-

-- 87 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
Health Benefits 	CarelonRx 	Carelon Services
Corporate &
Other 	Total
2020 Business Optimization Initiatives
Liabilities for employee termination costs at January 1, 2023 	$ 	80 $ 	1 $ 	— $ 	— $ 	81
Payments 	(39) 	(1) 	— 	— 	(40)
Releases 	(33) 	— 	— 	— 	(33)
Total liabilities for employee termination costs ending balance at
December 31, 2023 	$ 	8 $ 	— $ 	— $ 	— $ 	8
5. Investments
A summary of current and long-term fixed maturity securities, available-for-sale, at December 31, 2023 and 2022 is as follows:
Cost or
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Allowance For
Credit Losses
Estimated
Fair Value
December 31, 2023
Fixed maturity securities:
United States Government securities 	$ 	1,873 $ 	25 $ 	(54) $ 	— $ 	1,844
Government sponsored securities 	112 	1 	(3) 	— 	110
Foreign government securities 	5 	1 	(2) 	— 	4
States, municipalities and political subdivisions, tax-exempt 	3,985 	69 	(152) 	— 	3,902
Corporate securities 	14,838 	322 	(580) 	(2) 	14,578
Residential mortgage-backed securities 	4,071 	40 	(279) 	— 	3,832
Commercial mortgage-backed securities 	2,174 	13 	(138) 	(2) 	2,047
Other asset-backed securities 	4,278 	25 	(130) 	— 	4,173
Total fixed maturity securities 	$ 	31,336 $ 	496 $ 	(1,338) $ 	(4) $ 	30,490
December 31, 2022
Fixed maturity securities:
United States Government securities 	$ 	1,502 $ 	2 $ 	(103) $ 	— $ 	1,401
Government sponsored securities 	82 	1 	(5) 	— 	78
Foreign government securities 	321 	1 	(46) 	(2) 	274
States, municipalities and political subdivisions, tax-exempt 	4,389 	19 	(265) 	— 	4,143
Corporate securities 	13,721 	31 	(1,218) 	(5) 	12,529
Residential mortgage-backed securities 	2,978 	9 	(324) 	— 	2,663
Commercial mortgage-backed securities 	2,055 	1 	(176) 	(2) 	1,878
Other asset-backed securities 	3,967 	12 	(241) 	— 	3,738
Total fixed maturity securities 	$ 	29,015 $ 	76 $ 	(2,378) $ 	(9) $ 	26,704
Other asset-backed securities primarily consist of collateralized loan obligations and other debt securities.
-87-

-- 88 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
For fixed maturity securities in an unrealized loss position at December 31, 2023 and 2022, the following table summarizes the aggregate fair values and gross
unrealized losses by length of time those securities have continuously been in an unrealized loss position.
Less than 12 Months 	12 Months or Greater
Number of
Securities
Estimated
Fair Value
Gross
Unrealized
Loss
Number of
Securities
Estimated
Fair Value
Gross
Unrealized
Loss
(Securities are whole amounts)
December 31, 2023
Fixed maturity securities:
United States Government securities 	35 $ 	552 $ 	(9) 	44 $ 	370 $ 	(45)
Government sponsored securities 	0 	— 	— 	40 	52 	(3)
Foreign government securities 	0 	— 	— 	2 	4 	(2)
States, municipalities and political subdivisions, tax-
exempt 	203 	354 	(2) 	1,034 	1,811 	(150)
Corporate securities 	389 	608 	(15) 	2,624 	6,871 	(565)
Residential mortgage-backed securities 	183 	438 	(5) 	1,620 	2,075 	(274)
Commercial mortgage-backed securities 	112 	353 	(6) 	534 	1,317 	(132)
Other asset-backed securities 	110 	394 	(18) 	761 	2,342 	(112)
Total fixed maturity securities 	1,032 $ 	2,699 $ 	(55) 	6,659 $ 	14,842 $ 	(1,283)
December 31, 2022
Fixed maturity securities:
United States Government securities 	61 $ 	701 $ 	(40) 	38 $ 	442 $ 	(63)
Government sponsored securities 	39 	73 	(4) 	6 	5 	(1)
Foreign government securities 	150 	100 	(10) 	198 	142 	(36)
States, municipalities and political subdivisions, tax-
exempt 	1,398 	2,615 	(147) 	396 	652 	(118)
Corporate securities 	3,551 	7,826 	(549) 	2,204 	3,521 	(669)
Residential mortgage-backed securities 	1,341 	1,435 	(121) 	496 	982 	(203)
Commercial mortgage-backed securities 	457 	1,082 	(76) 	324 	719 	(100)
Other asset-backed securities 	784 	2,203 	(124) 	398 	1,074 	(117)
Total fixed maturity securities 	7,781 $ 	16,035 $ 	(1,071) 	4,060 $ 	7,537 $ 	(1,307)
Unrealized losses on our securities shown in the table above have not been recognized into income because, as of December 31, 2023, we do not intend to sell
these investments and it is likely that we will not be required to sell these investments prior to their anticipated recovery. The declines in fair values are largely due
to increasing interest rates driven by the higher rate of inflation and other market conditions.
Allowances for credit losses have been recorded in the amounts of $4 and $9 at December 31, 2023 and 2022, respectively, for declines in fair value due to
unfavorable changes in the credit quality characteristics that impact our assessment of collectability of principal and interest.
-88-

-- 89 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
The amortized cost and fair value of fixed maturity securities at December 31, 2023, by contractual maturity, are shown below. Expected maturities may differ
from contractual maturities because the issuers of the securities may have the right to prepay obligations.
Amortized
Cost
Estimated
Fair Value
Due in one year or less 	$ 	473 $ 	470
Due after one year through five years 	7,350 	7,193
Due after five years through ten years 	10,495 	10,325
Due after ten years 	6,773 	6,624
Mortgage-backed securities 	6,245 	5,878
Total fixed maturity securities 	$ 	31,336 $ 	30,490
Equity Securities
A summary of current equity securities at December 31, 2023 and 2022 is as follows:
December 31, 2023 	December 31, 2022
Equity Securities:
Exchange traded funds 	$ 	106 $ 	822
Common equity securities 	45 	43
Private equity securities 	78 	88
Total 	$ 	229 $ 	953
Investment Income
The major categories of net investment income for the years ended December 31, 2023, 2022 and 2021 are as follows:
2023 	2022 	2021
Fixed maturity securities 	$ 	1,387 $ 	971 $ 	755
Equity securities 	18 	48 	43
Cash equivalents 	305 	77 	5
Other invested assets 	157 	432 	616
Investment income 	1,867 	1,528 	1,419
Investment expenses 	(42) 	(43) 	(41)
Net investment income 	$ 	1,825 $ 	1,485 $ 	1,378
-89-

-- 90 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
Investment (Losses) Gains
Net investment (losses) gains for the years ended December 31, 2023, 2022 and 2021 are as follows:
2023 	2022 	2021
Net gains (losses):
Fixed maturity securities:
Gross realized gains from sales 	$ 	47 $ 	52 $ 	170
Gross realized losses from sales 	(488) 	(469) 	(44)
Impairment (losses) recoveries recognized in income 	(15) 	(31) 	1
Net realized gains on fixed maturity securities 	(456) 	(448) 	127
Equity securities:
Unrealized (losses) gains recognized on equity securities still held 	(1) 	(78) 	2
Net realized (losses) gains recognized on equity securities sold 	6 	(102) 	(73)
Net (losses) gains on equity securities 	5 	(180) 	(71)
Other investments:
Gross gains 	103 	96 	293
Gross losses 	(63) 	(64) 	(22)
Impairment losses recognized in income 	(291) 	(34) 	(16)
Net (losses) gains on other investments 	(251) 	(2) 	255
Net (losses) gains on investments 	$ 	(702) $ 	(630) $ 	311
A primary objective in the management of our fixed maturity and equity portfolios is to maximize total return relative to underlying liabilities and respective
liquidity needs. In achieving this goal, assets may be sold to take advantage of market conditions or other investment opportunities as well as tax considerations.
Sales will generally produce realized gains and losses. In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not
limited to: (i) changes in the investment environment; (ii) expectations that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an
industry; (iv) changes in credit quality; or (v) changes in expected cash flow.
Total proceeds from sales, maturities, calls or redemptions of fixed maturity securities was $12,289, $22,048 and $10,565 for the years ended December 31,
2023, 2022 and 2021, respectively.
A significant judgment in the valuation of investments is the determination of when a credit loss has occurred. We follow a consistent and systematic process
for recognizing impairments on securities that sustain credit declines in value. We have established a committee responsible for the impairment review process. The
decision to impair a security incorporates both quantitative criteria and qualitative information. The impairment review process considers a number of factors
including, but not limited to: (i) the extent to which the fair value is less than book value, (ii) the financial condition and near term prospects of the issuer, (iii) our
intent and ability to retain impaired investments for a period of time sufficient to allow for any anticipated recovery in fair value, (iv) our intent to sell or the
likelihood that we will need to sell a fixed maturity security before recovery of its amortized cost basis, (v) whether the debtor is current on interest and principal
payments, (vi) the reasons for the decline in value (i.e., credit event compared to liquidity, general credit spread widening, currency exchange rate or interest rate
factors) and (vii) general market conditions and industry or sector specific factors. When a decision has been made to sell an impaired security or it is more likely
than not that the impaired security will be required to be disposed of prior to recovery of its cost basis, the security is written down to fair value at the reporting
date. For all other impaired securities, if the impairment is deemed to be credit related, an allowance is created.
Investment securities are exposed to various risks, such as interest rate, market and credit. Due to the level of risk associated with certain investment securities
and the level of uncertainty related to changes in the value of investment securities, it is possible that changes in these risk factors in the near term could have a
material adverse impact on our results of operations or shareholders’ equity.
-90-

-- 91 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
At December 31, 2023 and 2022, there were no individual investments that exceeded 10% of shareholders’ equity.
At December 31, 2023 and 2022, there were eleven and eight respectively, fixed maturity investments that did not produce income during the years then ended.
As of December 31, 2023 and 2022, we had committed approximately $1,321 and $1,504, respectively, to future capital calls from various third-party
investments in exchange for an ownership interest in the related entities.
As of December 31, 2023 and 2022, we had committed approximately $497 and $185, respectively, to future investments in rated notes.
At December 31, 2023 and 2022, securities with carrying values of approximately $876 and $752, respectively, were deposited by our insurance subsidiaries
under requirements of regulatory authorities.
Accrued Investment Income
Accrued investment income totaled $301 and $245 at December 31, 2023 and 2022, respectively. We recognize accrued investment income under the caption
“Other receivables” on our consolidated balance sheets.
Securities Lending Programs
The fair value of the cash and securities received as collateral for securities loaned at December 31, 2023 and 2022 was $2,380 and $2,457, respectively. The
collateral received was 102% of the market value of the loaned securities at each of December 31, 2023 and 2022.
We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we recognize a corresponding liability
for the obligation to return the collateral to the borrower under the caption “Other current liabilities.” The securities on loan are reported in the applicable
investment category on our consolidated balance sheets.
At December 31, 2023 and 2022, the remaining contractual maturities of our securities lending transactions included overnight and continuous transactions of
cash for $2,255 and $2,221, respectively, United States Government securities for $99 and $224, respectively, and residential mortgage-backed securities for $26
and $12, respectively.
-91-

-- 92 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
6. Derivative Financial Instruments
We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, collars,
swaptions, embedded derivatives and warrants. We also enter into master netting agreements which reduce credit risk by permitting net settlement of transactions.
At December 31, 2023 and 2022, we had received collateral of $35 and $57, respectively, related to our derivative financial instruments.
A summary of the aggregate contractual or notional amounts and estimated fair values related to derivative financial instruments at December 31, 2023 and
2022 is as follows:
Contractual/
Notional
Amount 	Balance Sheet Location
Estimated Fair Value
Asset 	(Liability)
December 31, 2023
Hedging instruments
Interest rate swaps - fixed to floating 	$ 	1,475 	Other assets/other liabilities 	$ 	15 $ 	(52)
Non-hedging instruments
Derivatives embedded in convertible securities 	15 	Fixed maturity securities 	1 	—
Interest rate swaps 	5
Equity securities/other assets/other
liabilities 	— 	—
Options 	161 	Other assets/other liabilities 	— 	(85)
Collars 	19 	Equity securities 	14 	(3)
Futures/Forwards 	151 Equity securities/other assets/other
liabilities 	7 	—
Subtotal non-hedging 	351 	Subtotal non-hedging 	22 	(88)
Total derivatives 	$ 	1,826 	Total derivatives 	37 	(140)
Amounts netted 	(15) 	15
Net derivatives 	$ 	22 $ 	(125)
December 31, 2022
Hedging instruments
Interest rate swaps - fixed to floating 	$ 	1,125 	Other assets/other liabilities 	$ 	3 $ 	(60)
Non-hedging instruments
Derivatives embedded in convertible securities 	18 	Fixed maturity securities 	4 	—
Interest rate swaps 	5 Equity securities/other assets/other
liabilities 	— 	—
Options 	— 	Other assets/other liabilities 	1 	—
Collars 	19 	Equity securities 	23 	(9)
Futures/Forwards 	358 Equity securities/other assets/other
liabilities 	2 	(2)
Subtotal non-hedging 	400 	Subtotal non-hedging 	30 	(11)
Total derivatives 	$ 	1,525 	Total derivatives 	33 	(71)
Amounts netted 	(12) 	12
Net derivatives 	$ 	21 $ 	(59)
-92-

-- 93 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
Fair Value Hedges
We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating
rates. The floating rates payable on all of our fair value hedges are benchmarked to the Secured Overnight Financing Rate. A summary of our outstanding fair value
hedges at December 31, 2023 and 2022 is as follows:
Type of Fair Value Hedges
Year
Entered
Into
Outstanding Notional Amount Interest Rate
Received 	Expiration Date	2023 	2022
Interest rate swap 	2023 	$ 	300 $ 	— 	5.500 % 	April 15, 2032
Interest rate swap 	2023 	150 	— 	2.550 	September 15, 2030
Interest rate swap 	2023 	500 	— 	4.900 	February 8, 2026
Interest rate swap 	2023 	125 	— 	4.101 	September 1, 2027
Interest rate swap 	2023 	100 	— 	2.250 	November 15, 2029
Interest rate swap 	2022 	150 	150 	5.500 	April 15, 2032
Interest rate swap 	2022 	75 	75 	4.101 	September 1, 2027
Interest rate swap 	2022 	75 	75 	2.250 	November 15, 2029
Interest rate swap 	2021 	— 	150 	2.550 	September 15, 2030
Interest rate swap 	2021 	— 	100 	2.250 	November 15, 2029
Interest rate swap 	2020 	— 	75 	4.101 	September 1, 2027
Interest rate swap 	2018 	— 	50 	4.101 	September 1, 2027
Interest rate swap 	2018 	— 	450 	3.300 	January 15, 2023
Total notional amount outstanding 	$ 	1,475 $ 	1,125
The following amounts were recorded on our consolidated balance sheets related to cumulative basis adjustments for fair value hedges at December 31, 2023
and 2022:
Balance Sheet Classification in Which Hedged Item is
Included
Carrying Amount of Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment Included
in the Carrying Amount of the Hedged Liability
2023 	2022 	2023 	2022
Long-term debt 	$ 	23,246 $ 	22,349 $ 	(37) $ 	(57)
Cash Flow Hedges
We have entered into a series of forward starting pay fixed interest rate swaps with the objective of eliminating the variability of cash flows in the interest
payments on future financings that were anticipated at the time of entering into the swaps. During 2023 and 2022, swaps in the notional amount of $550 and $700,
respectively, were terminated.
The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was $211 and $229 at
December 31, 2023 and 2022, respectively. As of December 31, 2023, the total amount of amortization over the next twelve months for all cash flow hedges is
estimated to increase interest expense by approximately $13. No amounts were excluded from effectiveness testing.
-93-

-- 94 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
Non-Hedging Derivatives
A summary of the effect of non-hedging derivatives on our consolidated statements of income for the years ended December 31, 2023, 2022 and 2021 is as
follows:
Type of Non-hedging Derivatives
Income Statement Location of
Gain (Loss) Recognized
Derivative
(Loss) Gain
Recognized
Year ended December 31, 2023
Derivatives embedded in convertible securities 	Net (losses) gains on financial instruments 	$ 	(2)
Options (including swaptions) 	Net (losses) gains on financial instruments 	3
Collars 	Net (losses) gains on financial instruments 	(3)
Futures 	Net (losses) gains on financial instruments 	10
Total 	$ 	8
Year ended December 31, 2022
Derivatives embedded in convertible securities 	Net (losses) gains on financial instruments 	$ 	(3)
Interest rate swaps 	Net (losses) gains on financial instruments 	(4)
Options (including swaptions) 	Net (losses) gains on financial instruments 	13
Collars 	Net (losses) gains on financial instruments 	10
Futures 	Net (losses) gains on financial instruments 	64
Total 	$ 	80
Year ended December 31, 2021
Interest rate swaps 	Net (losses) gains on financial instruments 	$ 	(4)
Options 	Net (losses) gains on financial instruments 	4
Futures 	Net (losses) gains on financial instruments 	7
Total 	$ 	7
In January 2023, we made an equity investment that resulted in our minority interest ownership of Project Freedom Holdings, LLC, which is the ultimate
parent of LIBERTY Dental Plan Corporation (“Liberty Dental”). Liberty Dental engages in dental insurance and dental health care administration. As part of the
Liberty Dental transaction, we entered into a shareholders’ agreement with the majority owners that provides for certain rights and obligations of each party,
including certain put and call options. These options could result in our purchase of the units held by the majority owners in 2026 and 2027. We have calculated the
fair value of the net put option, which is a Level III measurement (see Note 7, “Fair Value”), using a Monte Carlo simulation, which relies on assumptions,
including cash flow projections, risk-free rates, volatility and details specific to the put and call options. Significant changes in assumptions could result in
significantly lower or higher fair value measurements. The net put option’s fair value liability of $85, measured at the date of acquisition, is included in “Other
noncurrent liabilities.” We have elected to not mark the net put option to market, and the fair value of the net put option will remain on the balance sheet until it's
exercised or expires.
-94-

-- 95 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
7. Fair Value
Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used
to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:
Level Input: 	Input Definition:
Level I 	Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II 	Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the
measurement date.
Level III 	Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the
measurement date.
The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value
in the consolidated balance sheets:
Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less and are purchased daily at par
value with specified yield rates. Due to the short-term nature of the funds, we designate all cash equivalents as Level I.
Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available.
These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to
facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political
subdivisions, mortgage-backed securities, United States Government securities, foreign government securities, and certain other asset-backed securities. For
securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs
that are currently observable in the markets for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to
determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values
obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads,
default rates and prepayment speeds. We also have certain fixed maturity securities, primarily collateralized loan obligation securities, rated note securities and
corporate debt securities, that are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes, net asset value of
underlying loans or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and
prepayment speeds that are not observable in the markets.
Equity securities: Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities,
quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are
available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated
based on each security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity
securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital,
long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.
Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained
primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements
and disclosures.
Derivatives: Fair values are generally based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We
independently verify prices provided by the counterparties using valuation models that incorporate market observable inputs for similar derivative transactions.
These derivatives are designated as Level II securities. Fair values of certain derivatives where market observable inputs are not available are estimated using
-95-

-- 96 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
assumptions such as cash flow projections, risk-free rates, volatility and details specific to the derivative contract. These derivatives are designated as Level III
securities.
In addition, the following methods and assumptions were used to determine the fair value of each class of pension benefit plan assets and other benefit plan
assets not defined above (see Note 11, “Retirement Benefits,” for fair values of benefit plan assets):
Mutual funds: Fair values are based on quoted market prices, which represent the net asset value (“NAV”) of shares held.
Partnership investments: Fair values are estimated based on the plan’s ownership share of the partnerships’ net assets, as reported in their periodic capital
statements, and are valued using NAV as a practical expedient. The partnerships primarily consist of a real estate investment fund which acquires investments in
real estate entities, and an energy fund which invests in public and private oil and gas companies principally through privately issued securities.
Collective investment trusts (“CITs”): Fair values are based on the NAV of the units held by the plan at year end and are valued using NAV as a practical
expedient. The CITs are passive index funds that seek investment results that generally correspond to the performance of the Bloomberg U.S. Intermediate Treasury
Index.
Commingled fund: Fair value is based on NAV per fund share and is valued using NAV as a practical expedient. The fund primarily invests in publicly traded
equity securities of issuers within the fund’s benchmark. The objective of the fund is to produce returns in excess of the relevant benchmark over rolling five-year
periods.
Insurance company contracts: Fair value is based on the fair value of the underlying investments of the account as determined by the insurance company.
Investment in DOL 103-12 trust: Fair value is based on the plan’s proportionate share of the fair value of investments held by the trust, qualified as a
Department of Labor Regulation 2520.103-12 entity (“DOL 103-12 trust”) as reported in the audited financial statements of the trust, where the trustee applies fair
value measurements to the underlying investments of the trust.
Life insurance contracts: Fair value is based on the cash surrender value of the policies as reported by the insurance carriers.
-96-

-- 97 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at December 31, 2023 and 2022 is as
follows:
Level I 	Level II 	Level III 	Total
December 31, 2023
Assets:
Cash equivalents 	$ 	2,210 $ 	— $ 	— $ 	2,210
Fixed maturity securities, available-for-sale:
United States Government securities 	— 	1,844 	— 	1,844
Government sponsored securities 	— 	110 	— 	110
Foreign government securities 	— 	4 	— 	4
States, municipalities and political subdivisions, tax-exempt 	— 	3,902 	— 	3,902
Corporate securities 	— 	14,532 	46 	14,578
Residential mortgage-backed securities 	— 	3,830 	2 	3,832
Commercial mortgage-backed securities 	— 	2,047 	— 	2,047
Other asset-backed securities 	— 	3,634 	539 	4,173
Total fixed maturity securities, available-for-sale 	— 	29,903 	587 	30,490
Equity securities:
Exchange traded funds 	106 	— 	— 	106
Common equity securities 	12 	33 	— 	45
Private equity securities 	— 	— 	78 	78
Total equity securities 	118 	33 	78 	229
Other invested assets - common equity securities 	111 	— 	— 	111
Securities lending collateral 	— 	2,382 	— 	2,382
Derivatives - other assets 	— 	10 	— 	10
Total assets 	$ 	2,439 $ 	32,328 $ 	665 $ 	35,432
Liabilities:
Derivatives - other liabilities 	$ 	— $ 	(40) $ 	— $ 	(40)
Total liabilities 	$ 	— $ 	(40) $ 	— $ 	(40)
December 31, 2022
Assets:
Cash equivalents 	$ 	3,567 $ 	— $ 	— $ 	3,567
Fixed maturity securities, available-for-sale:
United States Government securities 	— 	1,401 	— 	1,401
Government sponsored securities 	— 	78 	— 	78
Foreign government securities 	— 	274 	— 	274
States, municipalities and political subdivisions, tax-exempt 	— 	4,143 	— 	4,143
Corporate securities 	— 	12,392 	137 	12,529
Residential mortgage-backed securities 	— 	2,663 	— 	2,663
Commercial mortgage-backed securities 	— 	1,878 	— 	1,878
Other asset-backed securities 	— 	3,382 	356 	3,738
Total fixed maturity securities, available-for-sale 	— 	26,211 	493 	26,704
Equity securities:
Exchange traded funds 	822 	— 	— 	822
Common equity securities 	2 	41 	— 	43
Private equity securities 	— 	— 	88 	88
Total equity securities 	824 	41 	88 	953
Other invested assets - common equity securities 	103 	— 	— 	103
Securities lending collateral 	— 	2,457 	— 	2,457
Derivatives - other assets 	— 	3 	— 	3
Total assets 	$ 	4,494 $ 	28,712 $ 	581 $ 	33,787
Liabilities:
Derivatives - other liabilities 	$ 	— $ 	(60) $ 	— $ 	(60)
Total liabilities 	$ 	— $ 	(60) $ 	— $ 	(60)
-97-

-- 98 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the years ended
December 31, 2023, 2022 and 2021 is as follows:
Corporate
Securities
Residential
Mortgage-
backed
Securities
Other Asset-
Backed Securities
Equity
Securities 	Total
Year ended December 31, 2023
Beginning balance at January 1, 2023 	$ 	137 $ 	— $ 	356 $ 	88 $ 	581
Total gains (losses):
Recognized in net income 	(10) 	— 	— 	(4) 	(14)
Recognized in accumulated other comprehensive income 	6 	— 	3 	— 	9
Purchases 	38 	— 	191 	15 	244
Sales 	(88) 	— 	(17) 	(21) 	(126)
Settlements 	(21) 	— 	— 	— 	(21)
Transfers into Level III 	6 	2 	6 	— 	14
Transfers out of Level III 	(22) 	— 	— 	— 	(22)
Ending balance at December 31, 2023 	$ 	46 $ 	2 $ 	539 $ 	78 $ 	665
Change in unrealized gains or losses included in net income related to assets
still held at December 31, 2023 	$ 	— $ 	— $ 	— $ 	(6) $ 	(6)
Year ended December 31, 2022
Beginning balance at January 1, 2022 	$ 	336 $ 	5 $ 	19 $ 	89 $ 	449
Total gains (losses):
Recognized in net income 	— 	— 	(1) 	— 	(1)
Recognized in accumulated other comprehensive income 	(1) 	— 	(16) 	— 	(17)
Purchases 	56 	— 	370 	17 	443
Sales 	(210) 	— 	(14) 	(18) 	(242)
Settlements 	(41) 	— 	— 	— 	(41)
Transfers into Level III 	9 	— 	— 	— 	9
Transfers out of Level III 	(12) 	(5) 	(2) 	— 	(19)
Ending balance at December 31, 2022 	$ 	137 $ 	— $ 	356 $ 	88 $ 	581
Change in unrealized gains or losses included in net income related to assets
still held at December 31, 2022 	$ 	— $ 	— $ 	— $ 	— $ 	—
Year ended December 31, 2021
Beginning balance at January 1, 2021 	$ 	325 $ 	2 $ 	5 $ 	60 $ 	392
Total gains (losses):
Recognized in net income 	2 	— 	— 	17 	19
Recognized in accumulated other comprehensive income 	3 	— 	— 	— 	3
Purchases 	179 	4 	17 	16 	216
Sales 	(18) 	— 	— 	(4) 	(22)
Settlements 	(157) 	— 	— 	— 	(157)
Transfers into Level III 	3 	— 	— 	— 	3
Transfers out of Level III 	(1) 	(1) 	(3) 	— 	(5)
Ending balance at December 31, 2021 	$ 	336 $ 	5 $ 	19 $ 	89 $ 	449
Change in unrealized gains or losses included in net income related to assets
still held at December 31, 2021 	$ 	— $ 	— $ 	— $ 	18 $ 	18
There were no individually material transfers into or out of Level III during the years ended December 31, 2023, 2022 or 2021.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but
are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions and Divestitures,” we completed our acquisition
of BioPlus in 2023 and our acquisition of Integra
-98-

-- 99 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
in 2022. The net assets acquired in these acquisitions and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs.
The majority of assets acquired and liabilities assumed were recorded at their carrying values as of the respective date of acquisition, as their carrying values
approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our acquisitions of BioPlus and
Integra were estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could
be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Also in 2023,
we entered into a shareholders’ agreement which included certain put and call options associated with our minority interest ownership of Liberty Dental. The
resulting net put option liability was recorded at its fair value measured at the date of acquisition using Level III inputs with an election not to mark the derivative
to market, which is further discussed and disclosed in Note 6, “Derivatives”. Other than the assets acquired and liabilities assumed in our acquisitions of BioPlus
and Integra and the net put option on Liberty Dental described above, there were no material assets or liabilities measured at fair value on a nonrecurring basis
during the years ended December 31, 2023 or 2022.
Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in
active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are
estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our
assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value
involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower
determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows.
Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each
security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the
reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices
received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury
personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes
procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted
market prices obtained from the pricing services during the years ended December 31, 2023, 2022 or 2021.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair
values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in the consolidated balance
sheets.
Non-financial instruments such as property and equipment, other current assets, deferred income taxes, intangible assets and certain financial instruments, such
as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic
value.
The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income,
accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the short-term nature of these items. These assets and
liabilities are not listed in the table below.
The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value on the
consolidated balance sheets:
Other invested assets: Other invested assets primarily include our investments in limited partnerships, joint ventures and other non-controlled corporations and
mortgage loans, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-
controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost
net of loss allowance. The fair value of mortgage loans is measured using discounted cash flows benchmarked against the 10-year U.S. Treasury yield plus a market
rate spread. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which
approximates fair value.
-99-

-- 100 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or if no quoted market
prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt—commercial paper: The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest
rates at market value.
Long-term debt—senior unsecured notes and surplus notes: The fair values of our notes are based on quoted market prices in active markets for the same or
similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and
remaining maturities.
Long-term debt—convertible debentures: The fair value of our convertible debentures was based on the quoted market price in the active private market in
which the convertible debentures traded.
A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at
December 31, 2023 and 2022 is as follows:
Carrying
Value
Estimated Fair Value
Level I 	Level II 	Level III 	Total
December 31, 2023
Assets:
Other invested assets 	$ 	5,996 $ 	— $ 	— $ 	5,972 $ 	5,972
Liabilities:
Debt:
Short-term borrowings 	225 	— 	225 	— 	225
Notes 	24,895 	— 	23,569 	— 	23,569
December 31, 2022
Assets:
Other invested assets 	$ 	5,582 $ 	— $ 	— $ 	5,558 $ 	5,558
Liabilities:
Debt:
Short-term borrowings 	265 	— 	265 	— 	265
Notes 	23,786 	— 	21,861 	— 	21,861
Convertible debentures 	63 	— 	463 	— 	463
-100-

-- 101 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
8. Income Taxes
The components of deferred income taxes at December 31, 2023 and 2022 are as follows:
2023 	2022
Deferred income tax assets:
Accrued expenses 	$ 	553 $ 	379
Bad debt reserves 	415 	301
Insurance reserves 	178 	166
Lease liabilities 	172 	200
Retirement liabilities 	132 	173
Deferred compensation 	44 	34
Federal and state carryforwards 	455 	328
Investment basis 	31 	340
Other 	166 	131
Subtotal 	2,146 	2,052
Less: valuation allowance 	(271) 	(187)
Total deferred income tax assets 	1,875 	1,865
U.S. federal and state intangible assets 	2,070 	2,059
Foreign (including Puerto Rico) intangible assets 	330 	380
Capitalized software 	485 	601
Depreciation and amortization 	54 	62
Retirement assets 	319 	317
Lease right-of-use assets 	110 	123
Prepaid expenses 	249 	201
Total deferred income tax liabilities 	3,617 	3,743
Net deferred income tax liabilities 	$ 	1,742 $ 	1,878
We recognized $228 and $137 of deferred tax asset under the caption “Other noncurrent assets” at December 31, 2023 and 2022, respectively. We recognized
$1,970 and $2,015 of deferred tax liability under the caption “Deferred tax liabilities, net” at December 31, 2023 and 2022.
As of December 31, 2023, we have established U.S. deferred taxes for undistributed earnings from certain non-U.S. subsidiaries, which are included in the
Investment basis component above, consistent with prior years.
Significant components of the provision for income taxes for the years ended December 31, 2023, 2022 and 2021 consist of the following:
2023 	2022 	2021
Current tax expense:
Federal 	$ 	1,899 $ 	1,455 $ 	1,468
Foreign (including Puerto Rico) 	95 	98 	47
State and local 	420 	244 	165
Total current tax expense 	2,414 	1,797 	1,680
Deferred tax expense (benefit) 	(690) 	(85) 	166
Total income tax expense 	$ 	1,724 $ 	1,712 $ 	1,846
-101-

-- 102 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
State and local current tax expense is reported gross of federal benefit in the preceding table, and includes amounts related to audit settlements, uncertain tax
positions, state tax credits and true up of prior years’ tax. Such items are included on a net of federal tax basis in multiple lines in the following rate reconciliation
table.
A reconciliation of income tax expense recorded in the consolidated statements of income and amounts computed at the statutory federal income tax rate for
the years ended December 31, 2023, 2022 and 2021 is as follows:
2023 	2022 	2021
Amount 	Percent 	Amount 	Percent 	Amount 	Percent
Amount at statutory rate 	$ 	1,620 	21.0 % $ 	1,596 	21.0 % $ 	1,679 	21.0 %
State and local income taxes net of federal tax expense/benefit 	124 	1.6 	190 	2.5 	201 	2.5
Tax exempt interest and dividends received deduction 	(15) 	(0.2) 	(19) 	(0.3) 	(22) 	(0.3)
Change in valuation allowance 	84 	1.1 	51 	0.7 	81 	1.0
Other, net 	(89) 	(1.2) 	(106) 	(1.4) 	(93) 	(1.1)
Total income tax expense 	$ 	1,724 	22.3 % $ 	1,712 	22.5 % $ 	1,846 	23.1 %
During the year ended December 31, 2023, we recognized income tax expense of $1,724, or $7.26 per diluted share. The decrease in effective income tax rate
for 2023 compared to 2022 was primarily due to the impact of geographic changes in the mix of 2023 earnings.
During the year ended December 31, 2022, we recognized income tax expense of $1,712, or $7.05 per diluted share. The decrease in effective income tax rate
for 2022 compared to 2021 was primarily due to the impact of geographic changes in the mix of 2022 earnings.
During the year ended December 31, 2021, we recognized income tax expense of $1,846, or $7.48 per diluted share.
The change in the carrying amount of gross unrecognized tax benefits from uncertain tax positions for the years ended December 31, 2023 and 2022 is as
follows:
2023 	2022
Balance at January 1 	$ 	349 $ 	271
Additions based on:
Tax positions related to current year 	19 	22
Tax positions related to prior years 	119 	57
Reductions based on:
Tax positions related to prior years 	(19) 	(1)
Balance at December 31 	$ 	468 $ 	349
The table above excludes interest, net of related tax benefits, which is treated as income tax expense (benefit) under our accounting policy. The interest is
included in the amounts described in the following paragraph.
The amount of unrecognized tax benefits that would impact our effective tax rate in future periods, if recognized, was $450 and $328 at December 31, 2023
and 2022, respectively. Also included in the table above, at December 31, 2023, is $2 that would be recognized as an adjustment to additional paid-in capital, which
would not affect our effective tax rate.
For the years ended December 31, 2023, 2022 and 2021 we recognized net interest expense of $24, $13 and $9, respectively. We had accrued approximately
$79 and $55 for the payment of interest at December 31, 2023 and 2022, respectively.
As of December 31, 2023, as further described below, certain tax years remain open to examination by the Internal Revenue Service (“IRS”) and various state,
local and foreign authorities. As a result of these examinations and discussions
-102-

-- 103 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
with taxing agencies, we have recorded amounts for uncertain tax positions. It is anticipated that the amount of unrecognized tax benefits will change in the next
twelve months due to possible settlements of audits and changes in temporary items. However, the ultimate resolution of these items is dependent on the
completion of negotiations with various taxing authorities. While it is difficult to determine when other tax settlements will actually occur, it is reasonably possible
that one could occur in the next twelve months and our unrecognized tax benefits could be reduced within a range of approximately $111 to $217.
We are a member of the IRS Compliance Assurance Process (“CAP”). The objective of CAP is to reduce taxpayer burden and uncertainty while assuring the
IRS of the accuracy of tax returns prior to filing, thereby reducing or eliminating the need for post-filing examinations.
As of December 31, 2023, the IRS examination of our 2023 and 2022 tax years continues to be in process.
In certain states, we pay premium taxes in lieu of state income taxes. Premium taxes are reported in operating expense.
At December 31, 2023, we had federal net operating loss carryforwards of $192, of which $69 will expire beginning 2032 through 2043 and $123 have an
indefinite carryforward period. State and foreign net operating loss carryforwards expire beginning 2024 through 2042, with some having an indefinite
carryforward period.
Income taxes receivable totaled $543 and $440 at December 31, 2023 and 2022, respectively. We recognize the income tax receivable as an asset under the
caption “Other current assets” in our consolidated balance sheets.
During 2023, 2022 and 2021, federal income taxes paid totaled $1,936, $1,594 and $1,299, respectively.
9. Property and Equipment
A summary of property and equipment at December 31, 2023 and 2022 is as follows:
2023 	2022
Computer software, purchased and internally developed 	$ 	6,195 $ 	5,604
Computer equipment, furniture and other equipment 	955 	828
Leasehold improvements 	715 	648
Building and improvements 	37 	38
Land and improvements 	1 	1
Property and equipment, gross 	7,903 	7,119
Accumulated depreciation and amortization 	(3,544) 	(2,803)
Property and equipment, net 	$ 	4,359 $ 	4,316
Depreciation expense for 2023, 2022 and 2021 was $107, $123 and $136, respectively. Amortization expense on computer software and leasehold
improvements for 2023, 2022 and 2021 was $765, $661 and $532, respectively, which includes amortization expense on computer software, both purchased and
internally developed, for 2023, 2022 and 2021 of $685, $599 and $485, respectively. Capitalized costs related to the internal development of software of $5,870 and
$5,354 at December 31, 2023 and 2022, respectively, are reported with computer software.
Impairment of property and equipment for the years ended December 31, 2023, 2022 and 2021 was $446, $7, and $73, respectively, which is included in
operating expense and primarily related to our activities disclosed in Note 4, “Business Optimization Initiatives.”
-103-

-- 104 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
10. Goodwill and Other Intangible Assets
A summary of the change in the carrying amount of goodwill for our segments (see Note 20, “Segment Information”) for 2023 and 2022 is as follows:
Health Benefits 	CarelonRx 	Carelon Services 	Total
Balance as of January 1, 2022 	$ 	21,942 $ 	59 $ 	2,227 $ 	24,228
Acquisitions and adjustments 	146 	— 	9 	155
Balance as of December 31, 2022 	22,088 	59 	2,236 	24,383
Acquisitions and adjustments 	16 	898 	20 	934
Balance as of December 31, 2023 	$ 	22,104 $ 	957 $ 	2,256 $ 	25,317
Accumulated impairment as of December 31, 2023 	$ 	— $ 	— $ 	— $ 	—
As required by FASB guidance, we completed annual impairment tests of existing goodwill and other intangible assets with indefinite lives during 2023, 2022
and 2021. We perform these annual impairment tests during the fourth quarter. FASB guidance also requires interim impairment testing to be performed when
potential impairment indicators exist. These tests involve the use of estimates related to the fair value of goodwill and intangible assets with indefinite lives and
require a significant degree of management judgment and the use of subjective assumptions. Qualitative testing procedures include assessing our financial
performance, macroeconomic conditions, industry and market considerations, various asset specific factors and entity specific events. For quantitative testing, the
fair values are estimated using the projected income and market valuation approaches, incorporating Level III internal estimates for inputs, including, but not
limited to, revenue projections, income projections, cash flows and discount rates. We did not incur any impairment losses in 2023, 2022 or 2021, as the estimated
fair values of our reporting units were substantially in excess of their carrying values.
The components of other intangible assets as of December 31, 2023 and 2022 are as follows:
2023 	2022
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Gross
Carrying
Amount
Accumulated
Amortization
Net
Carrying
Amount
Intangible assets with finite lives:
Customer relationships 	$ 	6,263 $ 	(3,817) $ 	2,446 $ 	5,791 $ 	(3,693) $ 	2,098
Provider and hospital relationships 	326 	(164) 	162 	326 	(146) 	180
Other 	242 	(44) 	198 	1,010 	(440) 	570
Total 	6,831 	(4,025) 	2,806 	7,127 	(4,279) 	2,848
Intangible assets with indefinite lives:
Blue Cross and Blue Shield and other trademarks 	5,991 	— 	5,991 	5,991 	— 	5,991
State Medicaid licenses 	1,476 	— 	1,476 	1,476 	— 	1,476
Total 	7,467 	— 	7,467 	7,467 	— 	7,467
Other intangible assets 	$ 	14,298 $ 	(4,025) $ 	10,273 $ 	14,594 $ 	(4,279) $ 	10,315
In 2023, additions to the gross carrying amount of customer relationships relate to the acquisition of BioPlus. The decrease in the gross and net carrying
amount of intangible assets with finite lives—other primarily related to the accelerated amortization of certain trade names in connection with the new branding
strategy, which was substantially completed in 2023.
Intangible assets, along with the related accumulated amortization, are removed from the table above at the end of the fiscal year in which they become fully
amortized.
As of December 31, 2023, the estimated amortization expense for each of the five succeeding years is as follows: 2024, $438; 2025, $374; 2026, $318; 2027,
$277; and 2028, $236.
-104-

-- 105 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
11. Retirement Benefits
We sponsor various non-contributory employee defined benefit plans through certain subsidiaries.
The Elevance Health Cash Balance Plan A and the Elevance Health Cash Balance Plan B are cash balance pension plans covering certain eligible employees of
the affiliated companies that participate in these plans. Effective January 1, 2006, benefits were curtailed, with the result that most participants stopped accruing
benefits but continue to earn interest on benefits accrued prior to the curtailment. Certain participants subject to collective bargaining and certain other participants
who met grandfathering rules continued to accrue benefits. Participants who did not receive credits and/or benefit accruals were included in the Elevance Health
Cash Balance Plan A, while employees who were still receiving credits and/or benefits participated in the Elevance Health Cash Balance Plan B. Effective January
1, 2019, benefits under the Elevance Health Cash Balance Plan B were curtailed. All grandfathered participants no longer have pay credits added to their accounts
but continue to earn interest on existing account balances. Participants continue to earn years of pension service for vesting purposes. Several pension plans
acquired through various corporate mergers and acquisitions were merged into these plans in prior years.
The Employees’ Retirement Plan of Blue Cross of California (the “BCC Plan”) is a defined benefit pension plan that covers eligible employees of Blue Cross
of California who are covered by a collective bargaining agreement. Effective January 1, 2007, benefits were curtailed under the BCC Plan with the result that no
Blue Cross of California employees hired or rehired after December 31, 2006 are eligible to participate in the BCC Plan.
All of the plans’ assets consist primarily of equity securities, fixed maturity securities, investment funds and cash. The funding policies for all plans are to
contribute amounts at least sufficient to meet the minimum funding requirements set forth in the Employee Retirement Income Security Act of 1974, as amended
(“ERISA”), as further amended by the Pension Protection Act of 2006, and in accordance with income tax regulations, plus such additional amounts as are
necessary to provide assets sufficient to meet the benefits to be paid to plan participants.
The following tables disclose consolidated “pension benefits,” which include the defined benefit pension plans described above, and consolidated “other
benefits,” which include postretirement health and welfare benefits including medical, vision and dental benefits offered to certain employees. Calculations were
computed using assumptions at the December 31 measurement dates.
The reconciliation of the benefit obligation is as follows:
Pension Benefits 	Other Benefits
2023 	2022 	2023 	2022
Benefit obligation at beginning of year 	$ 	1,415 $ 	1,859 $ 	277 $ 	343
Interest cost 	68 	52 	14 	7
Plan participant contributions 	— 	— 	16 	17
Actuarial (gain) loss 	40 	(362) 	(12) 	(54)
Settlements 	(27) 	(74) 	— 	—
Benefits paid 	(103) 	(60) 	(40) 	(36)
Benefit obligation at end of year 	$ 	1,393 $ 	1,415 $ 	255 $ 	277
-105-

-- 106 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
The changes in the fair value of plan assets are as follows:
Pension Benefits 	Other Benefits
2023 	2022 	2023 	2022
Fair value of plan assets at beginning of year 	$ 	1,734 $ 	2,216 $ 	299 $ 	371
Actual return on plan assets 	199 	(352) 	42 	(61)
Employer contributions 	4 	4 	— 	—
Plan participant contributions 	— 	— 	16 	17
Settlements 	(27) 	(74) 	— 	—
Benefits paid 	(103) 	(60) 	(44) 	(28)
Fair value of plan assets at end of year 	$ 	1,807 $ 	1,734 $ 	313 $ 	299
The net amount included in the consolidated balance sheets is as follows:
Pension Benefits 	Other Benefits
2023 	2022 	2023 	2022
Noncurrent assets 	$ 	459 $ 	363 $ 	58 $ 	22
Current liabilities 	(7) 	(6) 	— 	—
Noncurrent liabilities 	(38) 	(38) 	— 	—
Net amount at December 31 	$ 	414 $ 	319 $ 	58 $ 	22
The net amounts included in accumulated other comprehensive income (loss) that have not been recognized as components of net periodic benefit costs are as
follows:
Pension Benefits 	Other Benefits
2023 	2022 	2023 	2022
Net actuarial (loss) gain 	$ 	(625) $ 	(672) $ 	38 $ 	5
Prior service credit 	— 	— 	2 	3
Net amount before tax at December 31 	$ 	(625) $ 	(672) $ 	40 $ 	8
The accumulated benefit obligation for the defined benefit pension plans was $1,391 and $1,413 at December 31, 2023 and 2022, respectively.
As of December 31, 2023, certain pension plans had accumulated benefit obligations in excess of plan assets. Such plans had accumulated benefit obligation
and fair value of plan assets of $44 and $0, respectively. In addition, certain plans had projected benefit obligations in excess of plan assets. Such plans had
projected benefit obligation and fair value of plan assets of $44 and $0, respectively.
The weighted-average assumptions used in calculating the benefit obligations for all plans are as follows:
Pension Benefits 	Other Benefits
2023 	2022 	2023 	2022
Discount rate 	4.91 % 	5.18 % 	4.83 % 	5.12 %
Rate of compensation increase 	3.00 % 	3.00 % 	3.00 % 	3.00 %
Expected rate of return on plan assets 	6.47 % 	6.58 % 	6.64 % 	6.57 %
Interest crediting rate 	4.50 % 	4.25 % 	4.50 % 	3.89 %
-106-

-- 107 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
The components of net periodic benefit credit included in the consolidated statements of income are as follows:
2023 	2022 	2021
Pension Benefits
Interest cost 	$ 	68 $ 	52 $ 	34
Expected return on assets 	(127) 	(101) 	(134)
Recognized actuarial loss 	9 	16 	25
Settlement loss 	7 	28 	26
Net periodic benefit credit 	$ 	(43) $ 	(5) $ 	(49)
Other Benefits
Service cost 	$ 	— $ 	— $ 	1
Interest cost 	14 	7 	5
Expected return on assets 	(21) 	(26) 	(26)
Amortization of prior service credit 	(2) 	(4) 	(4)
Net periodic benefit credit 	$ 	(9) $ 	(23) $ 	(24)
During the years ended December 31, 2023, 2022 and 2021, we incurred total settlement losses of $7, $28 and $26, respectively, as lump-sum payments
exceeded the service cost and interest cost components of net periodic benefit cost for certain of our plans.
The weighted-average assumptions used in calculating the net periodic benefit cost for all plans are as follows:
2023 	2022 	2021
Pension Benefits
Discount rate 	5.18 % 	2.70 % 	2.24 %
Rate of compensation increase 	3.00 % 	3.00 % 	3.00 %
Expected rate of return on plan assets 	6.58 % 	5.02 % 	6.72 %
Interest crediting rate 	4.25 % 	3.82 % 	3.82 %
Other Benefits
Discount rate 	5.12 % 	2.49 % 	1.99 %
Rate of compensation increase 	3.00 % 	3.00 % 	3.00 %
Expected rate of return on plan assets 	6.57 % 	6.43 % 	6.60 %
Interest crediting rate 	3.89 % 	1.56 % 	0.87 %
The assumed healthcare cost trend rates used to measure the expected cost of pre-Medicare (those who are not currently eligible for Medicare benefits) other
benefits at our December 31, 2023 measurement date was 8.00% for 2024, with a gradual decline to 4.50% by the year 2035. The assumed healthcare cost trend
rates used to measure the expected cost of post-Medicare (those who are currently eligible for Medicare benefits) other benefits at our December 31, 2023
measurement date was 6.50% for 2024, with a gradual decline to 4.50% by the year 2035. These estimated trend rates are subject to change in the future.
Plan assets include a diversified mix of equity securities, investment grade fixed maturity securities and other types of investments across a range of sectors
and levels of capitalization to maximize long-term return for a prudent level of risk. The weighted-average target allocation for pension benefit plan assets is 34%
equity securities, 61% fixed maturity securities, and 5% to all other types of investments. Equity securities primarily include a mix of domestic securities, foreign
securities and mutual funds invested in equities. Fixed maturity securities primarily include corporate bonds, treasury securities and asset-backed investments
issued by corporations and the U.S. government. Other types of investments include insurance contracts designed specifically for employee benefit plans, an
investment in a DOL 103-12 trust and certain alternative investments.
-107-

-- 108 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
As of December 31, 2023, there were no significant concentrations of investments in the pension benefit assets or other benefit assets. No plan assets were
invested in Elevance Health common stock.
Pension benefit assets and other benefit assets recorded at fair value are categorized based upon the level of judgment associated with the inputs used to
measure their fair value. In accordance with FASB guidance, certain alternative investments that are measured at fair value using the NAV per share (or its
equivalent) as a practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented are intended to permit reconciliation of the
fair value hierarchy to the total plan assets.
The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December 31, 2023, excluding cash, investment
income receivable and amounts due to/from brokers, resulting in a net asset of $43, and excluding estimated claims settlements to be paid from other benefit assets
of $(23), are as follows (see Note 7, “Fair Value,” for additional information regarding the definition of level inputs):
Level I 	Level II 	Level III 	Total
December 31, 2023
Pension Benefit Assets:
Cash equivalents 	$ 	2 $ 	— $ 	— $ 	2
Equity securities:
U.S. securities 	390 	— 	— 	390
Foreign securities 	94 	— 	— 	94
Mutual funds 	42 	— 	— 	42
Fixed maturity securities:
Government securities 	— 	70 	— 	70
Corporate securities 	— 	522 	— 	522
Asset-backed securities 	— 	2 	— 	2
Other types of investments:
Insurance company contracts 	— 	— 	143 	143
Total pension benefit assets at fair value 	$ 	528 $ 	594 $ 	143 	1,265
Alternative investments 	500
Total pension benefit assets 	$ 	1,765
Other Benefit Assets:
Equity securities:
U.S. securities 	$ 	7 $ 	— $ 	— $ 	7
Foreign securities 	2 	— 	— 	2
Mutual funds 	17 	— 	— 	17
Other types of investments:
Life insurance contracts 	— 	— 	289 	289
Investment in DOL 103-12 trust 	— 	9 	— 	9
Total other benefit assets at fair value 	$ 	26 $ 	9 $ 	289 	324
Alternative investments 	11
Total other benefit assets 	$ 	335
-108-

-- 109 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
The fair values of our pension benefit assets and other benefit assets by asset category and level inputs at December 31, 2022, excluding cash, investment
income receivable and amounts due to/from brokers, resulting in a net asset of $36, and excluding estimated claims settlements to be paid from other benefit assets
of $(17), are as follows:
Level I 	Level II 	Level III 	Total
December 31, 2022
Pension Benefit Assets:
Equity securities:
U.S. securities 	$ 	489 $ 	— $ 	— $ 	489
Foreign securities 	145 	— 	— 	145
Mutual funds 	39 	— 	— 	39
Fixed maturity securities:
Government securities 	— 	247 	— 	247
Corporate securities 	— 	275 	— 	275
Asset-backed securities 	— 	185 	— 	185
Other types of investments:
Insurance company contracts 	— 	— 	154 	154
Total pension benefit assets at fair value 	$ 	673 $ 	707 $ 	154 	1,534
Alternative investments 	164
Total pension benefit assets 	$ 	1,698
Other Benefit Assets:
Equity securities:
U.S. securities 	$ 	7 $ 	— $ 	— $ 	7
Foreign securities 	1 	— 	— 	1
Mutual funds 	17 	— 	— 	17
Fixed maturity securities:
Government securities 	— 	3 	— 	3
Corporate securities 	— 	3 	— 	3
Asset-backed securities 	— 	3 	— 	3
Other types of investments:
Life insurance contracts 	— 	— 	270 	270
Investment in DOL 103-12 trust 	— 	10 	— 	10
Total other benefit assets at fair value 	$ 	25 $ 	19 $ 	270 	314
Alternative investments 	2
Total other benefit assets 	$ 	316
In order to conform with current year presentation, the table above includes a reclassification of the commingled fund from Level II into alternative
investments measured using NAV as a practical expedient. This reclassification did not have any impact on total plan assets.
-109-

-- 110 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
The following table provides additional information on the alternative investments that are measured using NAV as a practical expedient:
Fair Value as of December 31 Unfunded Commitments
as of December 31, 2023 Redemption Frequency (if
applicable) 	Redemption Notice Period
2023 	2022
Collective investment trusts:
Pension benefit assets 	$ 	346 $ 	—
Other benefit assets 	9 	—
Total CITs 	355 	— $ 	— 	Daily 	2 days
Commingled fund:
Pension benefit assets 	84 	93
Other benefit assets 	2 	2
Total commingled fund 	86 	95 	— 	1st & 15th of the month 	7 business days
Partnership investments 	70 	71 	1 	Not Applicable 	Not Applicable
Total alternative investments 	$ 	511 $ 	166 $ 	1
A reconciliation of the beginning and ending balances of plan assets measured at fair value using Level III inputs for the years ended December 31, 2023, 2022
and 2021 is as follows:
Insurance
Company
Contracts
Life
Insurance
Contracts 	Total
Year ended December 31, 2023
Beginning balance at January 1, 2023 	$ 	154 $ 	270 $ 	424
Actual return on plan assets relating to assets still held at the reporting date 	3 	37 	40
Purchases 	6 	— 	6
Sales 	(20) 	(18) 	(38)
Ending balance at December 31, 2023 	$ 	143 $ 	289 $ 	432
Year ended December 31, 2022
Beginning balance at January 1, 2022 	$ 	179 $ 	338 $ 	517
Actual return on plan assets relating to assets still held at the reporting date 	(22) 	(53) 	(75)
Purchases 	9 	— 	9
Sales 	(12) 	(15) 	(27)
Ending balance at December 31, 2022 	$ 	154 $ 	270 $ 	424
Year ended December 31, 2021
Beginning balance at January 1, 2021 	$ 	189 $ 	323 $ 	512
Actual return on plan assets relating to assets still held at the reporting date 	(6) 	26 	20
Purchases 	5 	— 	5
Sales 	(9) 	(11) 	(20)
Ending balance at December 31, 2021 	$ 	179 $ 	338 $ 	517
There were no other transfers into or out of Level III during the years ended December 31, 2023, 2022 or 2021.
Our current funding strategy is to fund an amount at least equal to the minimum required funding as determined under ERISA with consideration of maximum
tax deductible amounts. We may elect to make discretionary contributions up to the
-110-

-- 111 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
maximum amount deductible for income tax purposes. For the years ended December 31, 2023, 2022 and 2021, no material contributions were necessary to meet
ERISA required funding levels. However, during each of the years ended December 31, 2023, 2022 and 2021, we made tax deductible discretionary contributions
to the pension benefit plans of $4, $4, and $7, respectively. Employer contributions to other benefit plans represent discretionary contributions and do not include
payments to retirees for current benefits.
Our estimated future payments for pension benefits and other benefits, which reflect expected future service, as appropriate, are as follows:
Pension
Benefits Other
Benefits
2024 	$ 	125 $ 	29
2025 	120 	28
2026 	119 	27
2027 	115 	25
2028 	113 	24
2029 - 2033 	492 	99
In addition to the defined benefit plans, we maintain the Elevance Health 401(k) Plan, which is a qualified defined contribution plan covering substantially all
employees. Voluntary employee contributions are matched by us subject to certain limitations. Contributions made by us totaled $316, $275 and $241 during 2023,
2022 and 2021, respectively.
12. Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable for the years ended December 31, 2023, 2022 and 2021 is as follows:
2023 	2022 	2021
Gross medical claims payable, beginning of year 	$ 	15,348 $ 	13,282 $ 	11,135
Ceded medical claims payable, beginning of year 	(6) 	(21) 	(46)
Net medical claims payable, beginning of year 	15,342 	13,261 	11,089
Business combinations and purchase adjustments 	— 	133 	420
Net incurred medical claims:
Current year 	121,798 	113,414 	100,440
Prior years redundancies 	(1,571) 	(869) 	(1,703)
Total net incurred medical claims 	120,227 	112,545 	98,737
Net payments attributable to:
Current year medical claims 	107,146 	98,997 	88,156
Prior years medical claims 	12,565 	11,600 	8,829
Total net payments 	119,711 	110,597 	96,985
Net medical claims payable, end of year 	15,858 	15,342 	13,261
Ceded medical claims payable, end of year 	7 	6 	21
Gross medical claims payable, end of year 	$ 	15,865 $ 	15,348 $ 	13,282
Amounts incurred related to prior years vary from previously estimated liabilities as the claims are ultimately settled. Liabilities at any period-end are
continually reviewed and re-estimated as information regarding actual claims payments, or runout, becomes known. This information is compared to the
originally established year end liability. Negative amounts reported for incurred medical claims related to prior years result from claims being settled for amounts
less than originally estimated. The prior year redundancy of $1,571 shown above for the year ended December 31, 2023 represents an estimate based on paid claim
activity from January 1, 2023 to December 31, 2023. Medical claim liabilities are usually described as
-111-

-- 112 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
having a “short tail,” which means that they are generally paid within twelve months of the member receiving service from the provider. Accordingly, the majority
of the $1,571 redundancy relates to claims incurred in calendar year 2022.
The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the
years ended December 31, 2023, 2022 and 2021, which are the completion and trend factors. These vital assumptions can be affected by variables such as
utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory
levels, claim processing and submission patterns, and operational changes resulting from business combinations. We had increased estimation uncertainty on our
incurred but not reported liability at December 31, 2022, 2021 and 2020. Slowdowns in claims submission patterns and increases in utilization levels for COVID-
19 testing and treatment are the primary factors that led to the increased estimation uncertainty.
Favorable Developments
by Changes in Key Assumptions
2023 	2022 	2021
Assumed trend factors 	$ 	(895) $ 	(859) $ 	(1,429)
Assumed completion factors 	(676) 	(10) 	(274)
Total 	$ 	(1,571) $ 	(869) $ 	(1,703)
The favorable development recognized in 2023 resulted primarily from trend factors in late 2022 developing more favorably than originally expected.
Favorable development in the completion factors in late 2022 also contributed to the favorable development in 2023.
The favorable development recognized in 2022 resulted primarily from trend factors in late 2021 developing more favorably than originally expected as well
as a smaller contribution from completion factor development.
The favorable development recognized in 2021 resulted primarily from trend factors in late 2020 developing more favorably than originally expected as well
as a smaller but significant contribution from completion factor development.
The reconciliation of net incurred medical claims to benefit expense included in the consolidated statements of income is as follows:
Years Ended December 31
2023 	2022 	2021
Total net incurred medical claims 	$ 	120,227 $ 	112,545 $ 	98,737
Quality improvement and other claims expense 	4,103 	4,097 	3,834
Benefit expense 	$ 	124,330 $ 	116,642 $ 	102,571
Incurred claims development, net of reinsurance, for the years ended December 31, 2023, 2022 and 2021 is as follows:
Cumulative Incurred Claims and Allocated Claim Adjustment
Expenses, Net of Reinsurance
2021 	2022 	2023
Claim Years 	(Unaudited) 	(Unaudited)
2021 & Prior 	$ 	110,247 $ 	109,378 $ 	109,542
2022 	113,546 	111,812
2023 	121,798
Total 	$ 	343,152
-112-

-- 113 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
Paid claims development, net of reinsurance, for the years ended December 31, 2023, 2022 and 2021 is as follows:
Cumulative Paid Claims and Allocated Claim Adjustment
Expenses, Net of Reinsurance
2021 	2022 	2023
Claim Years 	(Unaudited) 	(Unaudited)
2021 & Prior 	$ 	96,986 $ 	108,586 $ 	109,179
2022 	98,997 	110,969
2023 	107,146
Total 	$ 	327,294
At December 31, 2023, the total of incurred but not reported liabilities plus expected development on reported claims was $363, $843 and $14,652 for the
claim years 2021 and prior, 2022 and 2023, respectively.
At December 31, 2023, the cumulative number of reported claims was 480, 462 and 430 for the claim years 2021 and prior, 2022 and 2023, respectively.
The information about incurred claims development, paid claims development and cumulative number of reported claims for the years ended December 31,
2021 and 2022 is unaudited and presented as supplementary information.
The cumulative number of reported claims for each claim year has been developed using historical data captured by our claim payment systems. The provided
claim amounts are not a precise tool for understanding utilization of medical services. They could be impacted by a variety of factors, including changes in provider
billing practices, provider reimbursement arrangements, mix of services, benefit design or processing systems. The cumulative number of reported claims has been
provided to comply with FASB accounting standards and is not used by management in its claims analysis. Our cumulative number of reported claims may not be
comparable to similar measures reported by other health benefits companies.
The reconciliation of incurred and paid claims development information for the three years ended December 31, 2023, reflected in the tables above, to the
consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of December 31, 2023, is as follows:
Total
Cumulative incurred claims and allocated claim adjustment expenses, net of reinsurance 	$ 	343,152
Less: Cumulative paid claims and allocated claim adjustment expenses, net of reinsurance 	327,294
Net medical claims payable, end of year 	15,858
Ceded medical claims payable, end of year 	7
Insurance lines other than short duration 	246
Gross medical claims payable, end of year 	$ 	16,111
13. Debt
Short-term Borrowings
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home
Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the “FHLBs”). As a member we have the ability to obtain short-term cash
advances, subject to certain minimum collateral requirements. At December 31, 2023 and 2022, $225 and $265, respectively, were outstanding under our short-
term FHLB borrowings. Outstanding short-term FHLB borrowings at December 31, 2023 had fixed interest rates of 5.460%.
-113-

-- 114 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
Long-term Debt
The carrying value of our long-term debt at December 31, 2023 and 2022 consists of the following:
2023 	2022
Senior unsecured notes:
3.300%, due 2023 	$ 	— $ 	1,000
0.450%, due 2023 	— 	500
3.350%, due 2024 	850 	849
3.500%, due 2024 	799 	798
2.375%, due 2025 	1,251 	1,252
5.350%, due 2025 	399 	398
1.500%, due 2026 	747 	746
4.900%, due 2026 	496 	—
3.650%, due 2027 	1,595 	1,592
4.101%, due 2028 	1,236 	1,234
2.875%, due 2029 	821 	820
2.250%, due 2030 	1,075 	1,071
2.550%, due 2031 	972 	968
4.100%, due 2032 	595 	595
5.500%, due 2032 	658 	644
4.750%, due 2033 	992 	—
5.950%, due 2034 	335 	334
5.850%, due 2036 	397 	396
6.375%, due 2037 	364 	364
5.800%, due 2040 	114 	114
4.625%, due 2042 	860 	859
4.650%, due 2043 	975 	974
4.650%, due 2044 	768 	767
5.100%, due 2044 	548 	548
4.375%, due 2047 	1,388 	1,388
4.550%, due 2048 	840 	840
3.700%, due 2049 	813 	812
3.125%, due 2050 	988 	988
3.600%, due 2051 	1,233 	1,233
4.550%, due 2052 	689 	689
6.100%, due 2052 	742 	741
5.125%, due 2053 	1,083 	—
4.850%, due 2054 	247 	247
Surplus note:
9.000%, due 2027 	25 	25
Senior convertible debentures:
2.750%, due 2042 	— 	63
Total long-term debt 	24,895 	23,849
Current portion of long-term debt 	(1,649) 	(1,500)
Long-term debt, less current portion 	$ 	23,246 $ 	22,349
114

-- 115 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
All debt is a direct obligation of Elevance Health, Inc., except for the surplus note and the FHLB borrowings.
We generally issue senior unsecured notes (“Notes”) for long-term borrowing purposes. Certain of these Notes may have a call feature that allows us to redeem
the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the occurrence of both a change in control event and a
downgrade of the Notes below an investment grade rating.
On February 8, 2023, we issued $500 aggregate principal amount of 4.900% Notes due 2026 (the “2026 Notes”), $1,000 aggregate principal amount of
4.750% Notes due 2033 (the “2033 Notes”), and $1,100 aggregate principal amount of 5.125% Notes due 2053 (the “2053 Notes”) under our shelf registration
statement. Interest on the 2026 Notes is payable semi-annually in arrears on February 8 and August 8 of each year, commencing August 8, 2023. Interest on the
2033 Notes and 2053 Notes is payable semi-annually in arrears on February 15 and August 15 of each year, commencing August 15, 2023. We used the net
proceeds for working capital and general corporate purposes, including, but not limited to, the funding of acquisitions, repayment of short-term and long-term debt
and the repurchase of our common stock pursuant to our share repurchase program.
On January 17, 2023, we repaid, at maturity, the $1,000 outstanding balance of our 3.300% senior unsecured notes. On March 15, 2023, we repaid, at maturity,
the $500 outstanding balance of our 0.450% senior unsecured notes.
On December 1, 2022, we repaid, at maturity, the $750 outstanding balance of our 2.950% senior unsecured notes.
On November 4, 2022, we issued $400 aggregate principal amount of 5.350% Notes due 2025, $650 aggregate principal amount of 5.500% Notes due 2032
and $750 aggregate principal amount of 6.100% Notes due 2052 under our shelf registration statement. Interest on these notes is payable semi-annually in arrears
on April 15 and October 15 of each year, commencing April 15, 2023. We used the net proceeds for working capital and general corporate purposes, such as the
funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.
On May 16, 2022, we repaid, at maturity, the $850 outstanding balance of our 3.125% senior unsecured notes.
On April 29, 2022, we issued $600 aggregate principal amount of 4.100% Notes due 2032 and $700 aggregate principal amount of 4.550% Notes due 2052
under our shelf registration statement. Interest on these notes is payable semi-annually in arrears on May 15 and November 15 of each year, commencing
November 15, 2022. We used the net proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and
long-term debt and the repurchase of our common stock pursuant to our share repurchase program.
On May 15, 2021, we redeemed the $700 outstanding principal balance of our 3.700% Notes due August 15, 2021 at a redemption price equal to 100% of the
aggregate principal amount of the notes being redeemed, plus accrued and unpaid interest.
On March 17, 2021, we issued $500 aggregate principal amount of 0.450% Notes due 2023, $750 aggregate principal amount of 1.500% Notes due 2026,
$1,000 aggregate principal amount of 2.550% Notes due 2031 and $1,250 aggregate principal amount of 3.600% Notes due 2051 under our shelf registration
statement. Interest on these notes is payable semiannually in arrears on March 15 and September 15 of each year, commencing September 15, 2021. We used the
net proceeds for working capital and general corporate purposes, such as the funding of acquisitions, repayment of short-term and long-term debt and the
repurchase of our common stock pursuant to our share repurchase program.
Additionally, during the year ended December 31, 2021, we repurchased $52 of outstanding principal amount of certain other senior unsecured notes, plus
applicable premium for early redemption plus accrued and unpaid interest, for cash totaling $67. We recognized a loss on extinguishment of debt of $15 for the
repurchase of these notes.
The surplus note is an unsecured obligation of Anthem Insurance Companies, Inc. (“Anthem Insurance”), a wholly owned subsidiary, and is subordinate in
right of payment to all of Anthem Insurance’s existing and future indebtedness. Any payment of interest or principal on the surplus note may be made only with the
prior approval of the Indiana Department of Insurance (“IDOI”) and only out of capital and surplus funds of Anthem Insurance that the IDOI determines to be
available for the payment under Indiana insurance laws.
115

-- 116 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. The 5-Year Facility provides credit of
up to $4,000 and matures in April 2027. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants
requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-
Year Facility. As of December 31, 2023, our debt-to-capital ratio, as defined and calculated under the 5-Year Facility, was 38.9%. We do not believe the restrictions
contained in our 5-Year Facility covenants materially affect our financial or operating flexibility. As of December 31, 2023, we were in compliance with all of our
debt covenants under the 5-Year Facility. There were no amounts outstanding under the 5-Year Facility at any time during the years ended December 31, 2023 or
2022.
We have an authorized commercial paper program of up to $4,000, the proceeds of which may be used for general corporate purposes. At December 31, 2023
and 2022, we had $0 outstanding under our commercial paper program. Beginning in 2023, we have reclassified our commercial paper balances from long-term
debt to short-term debt as our intent is to not replace short-term commercial paper outstanding at expiration with additional short-term commercial paper for an
uninterrupted period extending for more than one year.
Convertible Debentures
On March 15, 2023, we redeemed all of our outstanding senior unsecured convertible debentures due 2042 (the “Debentures”), pursuant to the indenture dated
as of October 9, 2012 (the “Indenture”) between us and The Bank of New York Mellon Trust Company, N.A., as trustee. The Debentures were redeemed at a
redemption price equal to 100% of the principal amount of the Debentures plus accrued and unpaid interest to, but excluding, the date of redemption for cash
totaling $5. During the three months ended March 31, 2023, $59 of aggregate principal amount of the Debentures was surrendered for conversion by certain
holders in accordance with the terms and conditions of the Indenture. We elected to settle the excess of the principal amount of the conversions with cash for total
payments during the three months ended March 31, 2023 of $404.
During the year ended December 31, 2022, $41 aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance
with the terms and provisions of the Indenture. We elected to settle the excess of the principal amount of the conversion with cash for total payments of $299.
During the year ended December 31, 2021, $54 aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with
the terms and provisions of the Indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments of $302. We
recognized a loss on the extinguishment of debt related to the Debentures of $6, based on the fair values of the debt on the conversion settlement dates.
Prior to 2022, we accounted for these Debentures in accordance with the FASB cash conversion guidance for debt with conversion and other options at the
time of issue. As a result, the value of the embedded conversion option, net of deferred taxes and equity issuance costs, was bifurcated from its debt host and
recorded as a component of additional paid-in capital in our consolidated balance sheets. We adopted ASU 2020-06 on January 1, 2022 using the modified
retrospective transition method, eliminating the bifurcation of the embedded conversion option. For additional information, see Note 2, “Basis of Presentation and
Significant Accounting Policies.”
During the years ended December 31, 2023, 2022 and 2021, we recognized $0, $2 and $4, respectively, of interest expense related to the Debentures, of which
$0, $2 and $3, respectively, represented interest expense recognized at the stated interest rate of 2.750% and $0, $0 and $1, respectively, represented interest
expense resulting from amortization of the debt discount.
Interest paid on our total outstanding debt during 2023, 2022 and 2021 was $1,032, $878, and $822, respectively.
We were in compliance with all applicable covenants under all of our outstanding debt agreements at December 31, 2023 and 2022.
Future maturities of all long-term debt outstanding at December 31, 2023 are as follows: 2024, $1,649; 2025, $1,650; 2026, $1,243; 2027, $1,595; 2028,
$1,236 and thereafter, $17,522.
116

-- 117 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
14. Commitments and Contingencies
Litigation and Regulatory Proceedings
We are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases
have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can
reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether
any loss is probable or reasonably possible. In addition, even where loss is possible or probable or an exposure to loss exists in excess of the liability already
accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible or probable loss or range
of losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal
issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and
scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in
many cases, the plaintiffs have not specified damages in their complaint or in court filings.
With respect to the cases described below, we contest liability and/or the amount of damages in each matter, and we believe we have meritorious defenses. We
do not believe the outcome of any known pending or threatened legal actions or proceedings will, in the aggregate, have a material impact on our financial position.
However, unanticipated outcomes do sometimes occur, which could result in liabilities in excess of our accruals and could have a material adverse effect on our
consolidated financial position or results of operations.
In addition to the lawsuits described below, we are also involved in other pending and threatened litigation of the character incidental to our business and are
from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings (“government actions”). These
government actions include routine and special inquiries by and disclosures to state insurance departments, state attorneys general, U.S. Regulatory Agencies, the
U.S. Attorney General and subcommittees of the U.S. Congress. Such government actions could result in the imposition of civil or criminal fines, penalties, other
sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these government actions,
or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.
Blue Cross Blue Shield Antitrust Litigation
We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the “Blue plans”)
across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned In re Blue Cross Blue Shield Antitrust
Litigation that is pending in the U.S. District Court for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue
plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of
each plan, restrictions on acquisitions, rules governing the BlueCard and National Accounts programs and other arrangements in violation of the Sherman
Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and
providers.
In April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, determining that the defendants’ aggregation of
geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard program and other alleged Section 1
Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard
to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of
material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.
The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the “Subscriber Settlement Agreement”), which
agreement required the Court’s approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement
payment and contains certain terms imposing non-monetary obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements
(which rule
®
®
117

-- 118 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to
request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan.
In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class
were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by
the opt-out deadline.
In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the “Final Approval Order”). The Court amended its Final
Approval Order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In compliance with
the Subscriber Settlement Agreement, we paid $506 into an escrow account in September 2022, for an aggregate and full settlement payment by us of $596, which
was accrued in 2020.
Four notices of appeal of the Final Approval Order were filed prior to the September 2022 appeal deadline. Those appeals were heard by a panel of the United
States Court of Appeals for the Eleventh Circuit in September 2023. In October 2023, the Eleventh Circuit affirmed the Court’s Final Approval Order approving the
subscriber settlement. Petitions for rehearing filed by certain appellants in November 2023 and December 2023 remain pending. In the event that all appellate
rights are exhausted in a manner that affirms the Court’s Final Approval Order, the defendants’ payment and non-monetary obligations under the Subscriber
Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement.
In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants
opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determined the standard of review
applicable to the providers’ claims. In response to that order, the parties filed renewed standard of review motions in May 2021. In June 2021, the parties filed
summary judgment motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain defendants’ motion for
partial summary judgment against the provider plaintiffs who had previously released claims against such defendants, and (ii) granting the provider plaintiffs’
motion for partial summary judgment, determining that Ohio v. American Express Co. does not affect the standard of review in this case. In August 2022, the Court
issued orders (i) granting in part the defendants’ motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the
“national best efforts” rule, the rule of reason applies to the provider plaintiffs’ market allocation conspiracy claims, and (ii) denying the provider plaintiffs’ motion
for partial summary judgment on the standard of review, reaffirming its prior holding that the provider groups’ boycott claims are subject to the rule of reason. In
December 2023, the Court denied defendants’ motion for summary judgment on providers’ damage claims as time-barred and speculative and provider plaintiffs’
motion for partial summary judgment on the defendants’ single entity defense due to the existence of genuine issues of material fact. Providers plaintiffs’ motion
for class certification, filed in October 2020, remains pending. We intend to continue to vigorously defend the provider litigation, which we believe is without
merit; however, its ultimate outcome cannot be presently determined.
A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are: Alaska Air Group,
Inc., et al. v. Anthem, Inc., et al., No. 2:21-cv-01209-AMM (N.D. Ala.) (“Alaska Air”); JetBlue Airways Corp., et al. v. Anthem, Inc., et al., No. 2:22-cv-00558-
GMB (N.D. Ala.) (“Jet Blue”); Metropolitan Transportation Authority v. Blue Cross and Blue Shield of Alabama et al., No. 2:22-cv-00265-RDP (N.D. Ala.)
(dismissed without prejudice in June 2023); Bed Bath & Beyond Inc. v. Anthem, Inc., No. 2:22-cv-01256-SGC (N.D. Ala.); Hoover, et al. v. Blue Cross Blue Shield
Association, et al., No. 2:22-cv-00261-RDP (N.D. Ala.); and VHS Liquidating Trust v. Blue Cross of California, et al., No. RG21106600 (Cal. Super.) (“VHS”). In
February 2023, the Court denied the defendants’ motion to dismiss based on a statute of limitations defense in Alaska Air and Jet Blue. In September 2023, the
California court presiding over the VHS case, upheld its prior order granting in part defendants’ motion to strike based on the statute of limitations. We intend to
continue to vigorously defend these follow-on cases, which we believe are without merit; however, their ultimate outcome cannot be presently determined.
118

-- 119 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
Express Scripts, Inc. PBM Litigation
In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for PBM services, captioned Anthem, Inc. v. Express
Scripts, Inc., in the U.S. District Court for the Southern District of New York (the “District Court”). The lawsuit sought to recover over $14,800 in damages for
pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the “ESI Agreement”), over $158 in damages related
to operational breaches, as well as various declarations under the ESI Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good
faith and to agree in writing to new pricing terms (the “Pricing Claim”); (ii) was required to provide competitive benchmark pricing to us through the term of the
ESI Agreement; (iii) has breached the ESI Agreement; and (iv) is required under the ESI Agreement to provide post-termination services, at competitive benchmark
pricing, for one year following any termination.
Express Scripts disputed our contractual claims and it sought declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI
Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under
the ESI Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claimed that we have been
unjustly enriched by its payment of $4,675 at the time we entered into the ESI Agreement. In March 2017, the District Court granted our motion to dismiss Express
Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such ruling, Express
Scripts’ only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which we
opposed. In March 2022, the District Court granted in part and denied in part Express Scripts’ motion for summary judgment. The District Court dismissed our
declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary
judgment decision, the only remaining claims as of the filing of this Annual Report on Form 10-K were (i) our operational breach claim based on Express Scripts’
prior authorization processes and (ii) Express Scripts’ counterclaim for breach of the market check provision of the ESI Agreement. Express Scripts filed a second
motion for summary judgment in June 2022, challenging our remaining operational breach claims, which the District Court denied in March 2023. In November
2023, the District Court issued a final judgment ending the lawsuit in the District Court after the parties settled and stipulated to dismiss the only remaining claim
that had not been disposed of by the court order or stipulation. In December 2023, we filed a notice of appeal with the United States Court of Appeal for the Second
Circuit (the “Second Circuit”), regarding the Pricing Claim. The Second Circuit has ordered the parties to mediate the Pricing Claim in February 2024. The ultimate
outcome of this appeal cannot be presently determined.
Medicare Risk Adjustment Litigation
In March 2020, the U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Elevance Health, Inc. in the U.S. District Court for the Southern District of
New York (the “New York District Court”) in a case captioned United States v. Anthem, Inc. The DOJ’s suit alleges, among other things, that we falsely certified
the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C
and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-
adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the
False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September
2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in
the amended complaint, all of which the New York District Court denied in October 2022. In November 2022, we filed an answer. In March 2023, discovery
commenced, and an initial case management conference was held in April 2023. The Court entered a scheduling order requiring fact discovery to be completed by
June 2024 and expert discovery to be completed by February 2025. We intend to continue to vigorously defend this suit, which we believe is without merit;
however, the ultimate outcome cannot be presently determined.
Investigations of CareMore and HealthSun
With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data submitted to CMS (unrelated to our
retrospective chart review program) at CareMore Health Plans, Inc. (“CareMore”), one of our California subsidiaries, and HealthSun Health Plans, Inc.
(“HealthSun”), one of our Florida subsidiaries. Our CareMore investigation has resulted in the termination of CareMore’s relationship with one contracted provider
in California. Our
119

-- 120 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
HealthSun investigation has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued after the
acquisition. We have voluntarily self-disclosed the existence of both of our investigations to CMS and the Criminal and Civil Divisions of the DOJ. We cooperated
with the investigations of the Criminal and Civil Divisions of the DOJ related to these risk adjustment practices, and have submitted corrected data to CMS related
to these investigations. In an action filed in the Delaware Court of Chancery, we also asserted indemnity claims for escrowed funds under the HealthSun purchase
agreement for, among other things, breach of healthcare and financial representation provisions, based on the conduct discovered during our investigation. The
litigation related to our indemnity claims has been resolved. In October 2023, the DOJ declined to prosecute HealthSun. HealthSun agreed to repay, and has now
repaid, CMS approximately $53.
Other Contingencies
From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the
ordinary course of business. We, like Health Maintenance Organizations (“HMOs”) and health insurers generally, exclude certain healthcare and other services
from coverage under our HMO, Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees
arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage
award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty
of obtaining reasonable reimbursement of coverage claims.
Contractual Obligations and Commitments
In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through
June 2025. The agreement superseded certain prior agreements for such services and includes provisions for additional services not provided under those
agreements. Our remaining commitment under this agreement at December 31, 2023 is approximately $481. We will have the ability to terminate the agreement
upon the occurrence of certain events, subject to early termination fees.
We formed CarelonRx, to market and offer pharmacy services to our affiliated health plan customers, as well as to external customers outside of the health
plans we own, starting in the second quarter of 2019. The comprehensive pharmacy services portfolio includes all core pharmacy services, such as home delivery
and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database and member
services. CarelonRx delegates certain core pharmacy services to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to an
agreement, that is set to terminate on December 31, 2025.
Vulnerability from Concentrations
Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, investment securities, premium
receivables and instruments held through hedging activities. All investment securities are managed by professional investment managers within policies authorized
by our Board of Directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. Concentrations
of credit risk with respect to premium receivables are limited due to the large number of employer groups that constitute our customer base in the states in which
we conduct business. As of December 31, 2023, there were no significant concentrations of financial instruments in a single investee, industry or geographic
location.
15. Capital Stock
Stock Incentive Plans
Our Board of Directors has adopted the 2017 Elevance Health Incentive Compensation Plan (the “2017 Incentive Plan”) which has been approved by our
shareholders. The term of the 2017 Incentive Plan is such that no awards may be granted on or after May 18, 2027. The 2017 Incentive Plan gives authority to the
Compensation Committee of the Board of Directors to make incentive awards to our non-employee directors, employees and consultants, consisting of stock
options, stock, restricted stock, restricted stock units, cash-based awards, stock appreciation rights, performance shares and performance
120

-- 121 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
units. The 2017 Incentive Plan limits the number of available shares for issuance to 37.5 shares, subject to adjustment as set forth in the 2017 Incentive Plan.
Stock options are granted for a fixed number of shares with an exercise price at least equal to the fair value of the shares at the grant date. Stock options vest
over three years in equal annual installments and generally have a term of ten years from the grant date.
Certain option grants contain provisions whereby the employee continues to vest in the award subsequent to termination due to retirement. Our attribution
method for newly granted awards considers all vesting and other provisions, including retirement eligibility, in determining the requisite service period over which
the fair value of the awards will be recognized.
Awards of restricted stock or restricted stock units are issued at the fair value of the stock on the grant date and may also include one or more performance
measures that must be met for the award to vest. For restricted stock or restricted stock units without performance measures, the restrictions lapse in three equal
annual installments. Restricted stock or restricted stock units with performance measures vest in three year installments. Performance units issued in 2023 will vest
in 2026, based on certain revenue and earnings targets over the three year period of 2023 to 2025. Performance units issued in 2022 will vest in 2025, based on
certain revenue and earnings targets over the three year period of 2022 to 2024. Performance units issued in 2021 will vest in 2024, based on certain revenue and
earnings targets over the three year period of 2021 to 2023.
For the years ended December 31, 2023, 2022 and 2021, we recognized share-based compensation expense of $289, $264 and $255, respectively, as well as
related tax benefits of $73, $66 and $65, respectively.
A summary of stock option activity for the year ended December 31, 2023 is as follows:
Number of
Shares
Weighted-Average
Option Price
per Share
Weighted-Average
Remaining
Contractual Life
(Years)
Aggregate
Intrinsic
Value
Outstanding at January 1, 2023 	2.8 $ 	293.28
Granted 	0.6 	468.48
Exercised 	(0.3) 	261.93
Forfeited or expired 	(0.1) 	403.22
Outstanding at December 31, 2023 	3.0 	327.14 	5.96 $ 	431
Exercisable at December 31, 2023 	1.9 	267.05 	4.82 $ 	393
The intrinsic value of options exercised during the years ended December 31, 2023, 2022 and 2021 amounted to $69, $120 and $121, respectively. We
recognized tax benefits of $18, $31 and $32 during the years ended December 31, 2023, 2022 and 2021, respectively, from option exercises and disqualifying
dispositions. During the years ended December 31, 2023, 2022 and 2021, we received cash of $87, $120 and $148, respectively, from exercises of stock options.
The total fair value of restricted stock awards that vested during the years ended December 31, 2023, 2022 and 2021 was $285, $261 and $287, respectively.
A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the year ended December 31, 2023 is
as follows:
Restricted
Stock Shares
and Units
Weighted-Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 2023 	1.2 $ 	357.21
Granted 	0.6 	467.79
Vested 	(0.6) 	302.76
Forfeited 	(0.1) 	419.21
Nonvested at December 31, 2023 	1.1 	423.94
121

-- 122 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
During the year ended December 31, 2023, we granted approximately 0.2 restricted stock units that are contingent upon us achieving certain revenue and
earnings targets over the three year period of 2023 to 2025. These grants have been included in the activity shown above, but will be subject to adjustment at the
end of 2025, based on results in the three year period.
As of December 31, 2023, the total remaining unrecognized compensation expense related to nonvested stock options and restricted stock, including restricted
stock units and performance units, amounted to $39 and $200, respectively, which will be amortized over the weighted-average remaining requisite service periods
of 10 months and 12 months, respectively.
As of December 31, 2023, there were approximately 11.8 shares of common stock available for future grants under the 2017 Incentive Plan.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. Expected volatility assumptions used in the binomial lattice
model are based on an analysis of implied volatility of publicly traded options on our stock and historical volatility of our stock price. The risk-free interest rate is
derived from the U.S. Treasury strip rates at the time of the grant. The expected term of the options was derived from the outputs of the binomial lattice model,
which incorporates post-vesting forfeiture assumptions based on an analysis of historical data. The dividend yield was based on our estimate of future dividend
yields. Similar groups of employees that have dissimilar exercise behavior are considered separately for valuation purposes. We utilize the multiple-grant approach
for recognizing compensation expense associated with each separately vesting portion of the share-based award.
The following weighted-average assumptions were used to estimate the fair values of options granted during the years ended December 31, 2023, 2022 and
2021:
2023 	2022 	2021
Risk-free interest rate 	3.95 % 	1.97 % 	1.44 %
Volatility factor 	29.00 % 	29.00 % 	30.00 %
Dividend yield (annual) 	1.30 % 	1.10 % 	1.50 %
Weighted-average expected life (years) 	4.40 	5.10 	5.50
The following weighted-average fair values per share were determined for the years ending December 31, 2023, 2022 and 2021:
2023 	2022 	2021
Options granted during the year 	$ 	126.90 $ 	116.92 $ 	79.91
Restricted stock awards granted during the year 	467.79 	453.70 	317.70
The binomial lattice option-pricing model requires the input of subjective assumptions including the expected stock price volatility. Because our stock option
grants have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the
fair value estimate, in our opinion, existing models do not necessarily provide a reliable single measure of the fair value of our stock option grants.
Employee Stock Purchase Plan
We have registered 14.0 shares of common stock for the Employee Stock Purchase Plan (the “Stock Purchase Plan”), which is intended to provide a means to
encourage and assist employees in acquiring a stock ownership interest in Elevance Health. Pursuant to the terms of the Stock Purchase Plan, an eligible employee
is permitted to purchase no more than $25,000 (actual dollars) worth of stock in any calendar year, based on the fair value of the stock at the end of each plan
quarter. Employees become participants by electing payroll deductions from 1% to 15% of gross compensation. Once purchased, the stock is accumulated in the
employee’s investment account. The Stock Purchase Plan allows participants to purchase shares of our common stock at a discounted price per share of 90% of the
fair value of a share of common stock on the lower of the first or last trading day of the plan quarter purchase period. The Stock Purchase Plan discount was
recognized as compensation expense for the year ended December 31, 2023, based on GAAP guidance. During the years ended
122

-- 123 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
December 31, 2023, 2022 and 2021, we issued 0.1, 0.1 and 0.1 shares, respectively, under the Stock Purchase Plan, and we received cash of $65, $62 and $55,
respectively, for such shares. As of December 31, 2023, 4.2 shares were available for issuance under the Stock Purchase Plan.
Use of Capital and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The
declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial
condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
A summary of the cash dividend activity for the years ended December 31, 2023 and 2022 is as follows:
Declaration Date 	Record Date 	Payment Date
Cash Dividend
per Share 	Total
Year ended December 31, 2023
January 24, 2023 	March 10, 2023 	March 24, 2023 	$ 	1.48 	$ 	351
April 18, 2023 	June 9, 2023 	June 23, 2023 	1.48 	350
July 18, 2023 	September 8, 2023 	September 22, 2023 	1.48 	348
October 17, 2023 	December 6, 2023 	December 21, 2023 	1.48 	346
Year ended December 31, 2022
January 25, 2022 	March 10, 2022 	March 25, 2022 	$ 	1.28 	$ 	309
April 19, 2022 	June 10, 2022 	June 24, 2022 	1.28 	309
July 19, 2022 	September 9, 2022 	September 23, 2022 	1.28 	306
October 18, 2022 	December 5, 2022 	December 21, 2022 	1.28 	305
On January 23, 2024, our Audit Committee declared a quarterly cash dividend to shareholders of $1.63 per share on the outstanding shares of our common
stock. This quarterly dividend is payable on March 22, 2024 to the shareholders of record as of March 8, 2024.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 24, 2023, our Audit Committee, pursuant to
authorization granted by the Board of Directors, authorized a $5,000 increase to our common stock repurchase program. No duration has been placed on our
common stock repurchase program, and we reserve the right to discontinue the program at any time. We intend to utilize this authorization over a multi-year period,
subject to market and industry conditions. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume,
pricing and timing. The repurchases are affected from time to time in the open market, through negotiated transactions, including accelerated share repurchase
agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is
discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The
excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.
A summary of common stock repurchases for the years ended December 31, 2023 and 2022 is as follows:
Years Ended December 31
2023 	2022
Shares repurchased 	5.8 	4.8
Average price per share 	$ 	463.53 $ 	478.99
Aggregate cost 	$ 	2,676 $ 	2,316
Authorization remaining at end of year 	$ 	4,200 $ 	1,876
123

-- 124 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
We expect to utilize the remaining authorized amount over a multi-year period, subject to market and industry conditions.
For additional information regarding the use of capital for debt security repurchases, see Note 13, “Debt.”
124

-- 125 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
16. Accumulated Other Comprehensive (Loss) Income
A reconciliation of the components of accumulated other comprehensive (loss) income at December 31, 2023, 2022, and 2021 is as follows:
2023 	2022 	2021
Net unrealized investment gains:
Beginning of year balance 	$ 	(1,755) $ 	494 $ 	949
Other comprehensive income (loss) before reclassifications, net of tax (expense) benefit of $(218), $926, and $121,
respectively 	760 	(2,614) 	(357)
Amounts reclassified from accumulated other comprehensive income, net of tax benefit (expense) of $(113), $(94),
and $27, respectively 	357 	354 	(100)
Other comprehensive (loss) income 	1,117 	(2,260) 	(457)
Other comprehensive loss attributable to noncontrolling interests, net of tax benefit (expense) of $1, $(3), and $1,
respectively 	6 	11 	2
End of year balance 	(632) 	(1,755) 	494
Non-credit components of impairments on investments:
Beginning of year balance 	(3) 	— 	(2)
Other comprehensive income, net of tax benefit (expense) of $0, $0,and $(1), respectively 	— 	(3) 	2
End of year balance 	(3) 	(3) 	—
Net cash flow hedges:
Beginning of year balance 	(229) 	(239) 	(250)
Other comprehensive income, net of tax benefit (expense) of $6, $(6), and $(3), respectively 	18 	10 	11
End of year balance 	(211) 	(229) 	(239)
Pension and other postretirement benefits:
Beginning of year balance 	(499) 	(429) 	(552)
Other comprehensive income (loss), net of tax expense of $(39), $(23), and $(36), respectively 	40 	(70) 	123
End of year balance 	(459) 	(499) 	(429)
Future policy benefits:
Beginning of year balance 	13 	(19) 	—
Adoption of ASU 2018-12 	— 	— 	(12)
Other comprehensive (loss) income, net of tax benefit (expense) of $1, $(10), and $2, respectively 	(3) 	32 	(7)
End of year balance 	10 	13 	(19)
Foreign currency translation adjustments:
Beginning of year balance 	(17) 	(4) 	5
Other comprehensive loss, net of tax benefit of $1, $6, and $2 	(1) 	(13) 	(9)
End of year balance 	(18) 	(17) 	(4)
Total:
Total beginning of year accumulated other comprehensive (loss) income 	(2,490) 	(197) 	150
Adoption of ASU 2018-12 	— 	— 	(12)
Total other comprehensive income (loss), net of tax (expense) benefit of $(362), $799, and $112, respectively 	1,171 	(2,304) 	(337)
Total other comprehensive loss attributable to noncontrolling interests, net of tax benefit (expense) of $1, $(3), and
$1, respectively 	6 	11 	2
Total end of year accumulated other comprehensive loss 	$ 	(1,313) $ 	(2,490) $ 	(197)
125

-- 126 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
17. Reinsurance
We reinsure certain risks with other companies and assume risk from other companies. We remain primarily liable to policyholders under ceded insurance
contracts and are contingently liable for amounts recoverable from reinsurers in the event that such reinsurers do not meet their contractual obligations.
A summary of direct, assumed and ceded premiums earned for the years ended December 31, 2023, 2022 and 2021 is as follows:
2023 	2022 	2021
Direct 	$ 	136,927 $ 	127,788 	$ 	112,265
Assumed 	5,988 	5,505 	5,182
Ceded 	(61) 	(64) 	(74)
Net premiums 	$ 	142,854 $ 	133,229 	$ 	117,373
Percentage—assumed to net premiums 	4.2 % 	4.1 % 	4.4 %
The table above includes certain reclassifications between direct and assumed premiums for 2022 and 2021. These reclassifications did not impact any
amounts presented in the consolidated financial statements. The difference between written premiums and earned premiums is immaterial in each of the years
presented above.
A summary of net premiums earned by segment (see Note 20, “Segment Information”) for the years ended December 31, 2023, 2022 and 2021 is as follows:
2023 	2022 	2021
Reportable segments:
Health Benefits 	$ 	141,515 $ 	131,964 $ 	115,725
Carelon Services 	1,679 	1,499 	1,786
Eliminations 	(340) 	(234) 	(138)
Net premiums 	$ 	142,854 $ 	133,229 $ 	117,373
The effect of reinsurance on benefit expense for the years ended December 31, 2023, 2022 and 2021 is as follows:
2023 	2022 	2021
Direct 	$ 	119,409 $ 	112,061 $ 	98,211
Assumed 	4,984 	4,633 	4,441
Ceded 	(63) 	(52) 	(81)
Net benefit expense 	$ 	124,330 $ 	116,642 $ 	102,571
The table above includes certain reclassifications between direct and assumed benefit expense for 2022 and 2021. These reclassifications did not impact any
amounts presented in the consolidated financial statements.
126

-- 127 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
18. Leases
We lease office space and certain computer and related equipment using noncancelable operating leases. Our leases have remaining lease terms of 1 year to 12
years.
The information related to our leases is as follows:
Balance Sheet Location 	December 31, 2023 	December 31, 2022
Operating Leases
ROU assets 	Other noncurrent assets 	$ 	584 $ 	604
Lease liabilities, current 	Other current liabilities 	164 	181
Lease liabilities, noncurrent 	Other noncurrent liabilities 	685 	751
Years Ended December 31
2023 	2022 	2021
Lease Expense
Operating lease expense 	$ 	155 $ 	143 $ 	261
Short-term and variable lease expense 	43 	35 	45
Sublease income 	(5) 	(3) 	(4)
Total lease expense 	$ 	193 $ 	175 $ 	302
Our activities as disclosed in Note 4, “Business Optimization Initiatives,” include reducing our office space footprint. As a result, we performed an interim
impairment test during the years ended December 31, 2023, 2022 and 2021, and recorded impairment charges of $23, $34 and $136, respectively, for impairment
and abandonment of ROU assets which are included in the operating lease expense shown above.
Years Ended December 31
2023 	2022
Other information
Operating cash paid for amounts included in the measurement of lease liabilities, operating leases 	$ 	206 $ 	204
ROU assets obtained in exchange for new lease liabilities, operating leases 	$ 	59 $ 	113
Weighted average remaining lease term in years, operating leases 	6 	7
Weighted average discount rate, operating leases 	3.66 % 	2.98 %
At December 31, 2023, future lease payments for noncancelable operating leases with initial or remaining terms of one year or more are as follows:
2024 	$ 	195
2025 	167
2026 	133
2027 	105
2028 	89
Thereafter 	267
Total future minimum payments 	956
Less imputed interest 	(107)
Total lease liabilities 	$ 	849
127

-- 128 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
19. Shareholders’ Earnings per Share
The denominator for basic and diluted shareholders’ earnings per share at December 31, 2023, 2022 and 2021 is as follows:
2023 	2022 	2021
Denominator for basic shareholders’ earnings per share—weighted-average shares 	235.9 	240.0 	243.8
Effect of dilutive securities—employee stock options, non-vested restricted stock awards and convertible
debentures 	1.5 	2.8 	3.0
Denominator for diluted shareholders’ earnings per share 	237.4 	242.8 	246.8
During the years ended December 31, 2023, 2022 and 2021, weighted-average shares related to certain stock options of 0.8, 0.4 and 0.2, respectively, were
excluded from the denominator for diluted shareholders’ earnings per share because the stock options were anti-dilutive.
During the years ended December 31, 2023, 2022 and 2021, we issued approximately 0.2, 0.2 and 0.3 restricted stock units, respectively, of which vesting was
contingent upon us meeting certain earnings targets. Contingent restricted stock units are excluded from the denominator for diluted shareholders’ earnings per
share and are included only if and when the contingency is met. The 2023 contingent restricted stock units are being measured over the three year period of 2023
through 2025, the 2022 contingent restricted stock units are being measured over the three year period of 2022 through 2024 and the 2021 contingent restricted
stock units are being measured over the three year period of 2021 through 2023. Contingent restricted stock units generally vest in March of the year following
each measurement period.
20. Segment Information
As discussed in Note 1, “Organization,” we are reorganizing our brand portfolio into three core go-to-market brands. Our branding strategy reflects the
evolution of our business from a traditional health insurance company to a lifetime, trusted health partner. Given this evolution, we reviewed and modified how we
manage our business, monitor our performance and allocate resources, and made changes to our reportable segments beginning in the first quarter of 2023. We now
report our results of operations in the following four reportable segments: Health Benefits (aggregates our previously reported Commercial & Specialty Business
and Government Business segments), CarelonRx, Carelon Services (previously included in our Other segment) and Corporate & Other (our businesses that do not
individually meet the quantitative thresholds for an operating segment, as well as corporate expenses not allocated to our other reportable segments). During the
fourth quarter of 2023, we moved our Carelon Global Solutions international businesses from the Corporate & Other reportable segment to the Carelon Services
reportable segment. All prior period reportable segment information has been reclassified for comparability to conform to the current presentation.
Our Health Benefits segment offers a comprehensive suite of health plans and services to our Individual, Employer Group risk-based, Employer Group fee-
based, BlueCard®, Medicare, Medicaid and FEHB program members. Our Health Benefits segment also includes our National Government Services business. The
Health Benefits segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers; and
provides a variety of specialty and other insurance products and services such as stop loss, dental, vision, life, disability and supplemental health insurance benefits.
Our CarelonRx segment includes our pharmacy services business. CarelonRx markets and offers pharmacy services to our affiliated health plan customers, as
well as to external customers outside of the health plans we own. CarelonRx offers a comprehensive pharmacy services portfolio, which includes all core pharmacy
services, such as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription
drug database and member services.
Our Carelon Services segment integrates physical, behavioral, social and pharmacy services to deliver whole health affordably through creating value by
offering market-competitive services, powered by analytics. Carelon Services offers a broad array of healthcare related services and capabilities to internal and
external customers including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services and subrogation
services,
128

-- 129 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
as well as health and wellness programs. At the end of 2023, Carelon Services integrated Carelon Global Solutions into the Carelon family of offerings. The
companies under Carelon Global Solutions have been providing services related to data management, information technology, and business operations since 2019
and were previously included within our Corporate & Other segment.
Our Corporate and Other segment includes our businesses that do not individually meet the quantitative threshold for an operating segment, as well as
corporate expenses not allocated to our other reportable segments.
We define operating revenues to include premiums, product revenue and service fees. Operating revenues are derived from premiums and fees received,
primarily from the sale and administration of health benefits and pharmacy products and services. Operating gain is calculated as total operating revenue less
benefit expense, cost of products sold and operating expense.
Affiliated revenues represent revenues or costs for services provided to our subsidiaries by CarelonRx and Carelon Services, in addition to certain
administrative and other services provided by our international businesses, which are recorded at cost or management’s estimate of fair market value. These
affiliated revenues are eliminated in consolidation. For segment reporting, we present all capitation risk arrangements on a gross basis; therefore, eliminations also
include adjustments for capitated risk arrangements that are recognized on a net basis under GAAP.
Through our participation in various federal government programs, we generated approximately 29% of our total consolidated revenues from agencies of the
U.S. government for the year ended December 31, 2023, and 28% for each of the years ended December 31, 2022 and 2021. The majority of these revenues are
contained in our Health Benefits segment. An immaterial amount of our total consolidated revenues is derived from activities outside of the U.S. and Puerto Rico.
The accounting policies of the segments are consistent with those described in the summary of significant accounting policies in Note 2, “Basis of Presentation
and Significant Accounting Policies,” except that all capitation risk arrangements are reported on a gross basis with an adjustment included in eliminations for
capitated risk arrangements that are presented on a net basis under GAAP. We evaluate performance of the reportable segments based on operating gain or loss as
defined above. We evaluate net investment income, net gains (losses) on financial instruments, interest expense, amortization expense, gain or loss on
extinguishment of debt, income taxes and assets and liabilities on a consolidated basis, as these items are managed in a corporate shared service environment and
are not the responsibility of segment operating management.
129

-- 130 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
Financial data by reportable segment for the years ended December 31, 2023, 2022 and 2021 is as follows:
Carelon
Health
Benefits 	CarelonRx
Carelon
Services 	Total
Corporate
& Other 	Eliminations 	Total
Year Ended December 31, 2023
Premiums 	$ 	141,515 $ 	— $ 	1,679 $ 	1,679 $ 	— $ 	(340) $ 	142,854
Product revenue 	— 	19,452 	— 	19,452 	— 	— 	19,452
Service fees 	7,056 	6 	813 	819 	28 	— 	7,903
Operating revenue - unaffiliated 	148,571 	19,458 	2,492 	21,950 	28 	(340) 	170,209
Operating revenue - affiliated 	— 	14,377 	11,655 	26,032 	451 	(26,483) 	—
Operating revenue - total 	$ 	148,571 $ 	33,835 $ 	14,147 $ 	47,982 $ 	479 $ 	(26,823) $ 	170,209
Operating gain (loss) 	$ 	6,888 $ 	1,975 $ 	680 $ 	2,655 $ 	(1,044) $ 	— $ 	8,499
Depreciation and amortization of
property and equipment 	$ 	— $ 	— $ 	— $ 	— $ 	872 $ 	— $ 	872
Year Ended December 31, 2022 (Restated)
Premiums 	$ 	131,964 $ 	— $ 	1,499 $ 	1,499 $ 	— $ 	(234) $ 	133,229
Product revenue 	— 	14,978 	— 	14,978 	— 	— 	14,978
Service fees 	6,520 	— 	889 	889 	44 	— 	7,453
Operating revenue - unaffiliated 	138,484 	14,978 	2,388 	17,366 	44 	(234) 	155,660
Operating revenue - affiliated 	— 	13,548 	10,472 	24,020 	355 	(24,375) 	—
Operating revenue - total 	$ 	138,484 $ 	28,526 $ 	12,860 $ 	41,386 $ 	399 $ 	(24,609) $ 	155,660
Operating gain (loss) 	$ 	6,022 $ 	1,868 $ 	535 $ 	2,403 $ 	(142) $ 	— $ 	8,283
Depreciation and amortization of
property and equipment 	$ 	— $ 	— $ 	— $ 	— $ 	784 $ 	— $ 	784
Year Ended December 31, 2021 (Restated)
Premiums 	$ 	115,725 $ 	— $ 	1,786 $ 	1,786 $ 	— $ 	(138) $ 	117,373
Product revenue 	— 	12,657 	— 	12,657 	— 	— 	12,657
Service fees 	6,003 	— 	844 	844 	66 	— 	6,913
Operating revenue - unaffiliated 	121,728 	12,657 	2,630 	15,287 	66 	(138) 	136,943
Operating revenue - affiliated 	— 	12,774 	7,500 	20,274 	29 	(20,303) 	—
Operating revenue - total 	$ 	121,728 $ 	25,431 $ 	10,130 $ 	35,561 $ 	95 $ 	(20,441) $ 	136,943
Operating gain (loss) 	$ 	5,850 $ 	1,684 $ 	187 $ 	1,871 $ 	(162) $ 	— $ 	7,559
Depreciation and amortization of
property and equipment 	$ 	— $ 	— $ 	— $ 	— $ 	668 $ 	— $ 	668
130

-- 131 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
Asset, liability and equity details by reportable segment have not been disclosed, as we do not internally report such information.
A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the years
ended December 31, 2023, 2022 and 2021 is as follows:
2023 	2022 	2021
Reportable segments’ operating revenues 	$ 	170,209 $ 	155,660 $ 	136,943
Net investment income 	1,825 	1,485 	1,378
Net (losses) gains on financial instruments 	(694) 	(550) 	318
Total revenues 	$ 	171,340 $ 	156,595 $ 	138,639
A reconciliation of reportable segments’ operating gain to income before income tax expense included in our consolidated statements of income for the years
ended December 31, 2023, 2022 and 2021 is as follows:
2023 	2022 	2021
Income before income tax expense 	$ 	7,715 $ 	7,600 $ 	7,995
Net investment income 	(1,825) 	(1,485) 	(1,378)
Net losses (gains) on financial instruments 	694 	550 	(318)
Interest expense 	1,030 	851 	798
Amortization of other intangible assets 	885 	767 	441
Loss on extinguishment of debt 	— 	— 	21
Reportable segments’ operating gain 	$ 	8,499 $ 	8,283 $ 	7,559
21. Related Party Transactions
We have an equity investment in APC Passe, LLC, which offers Medicaid products in Arkansas. During the years ended December 31, 2023, 2022 and 2021,
in the normal course of business, we assumed premiums of $481, $501 and $462, respectively, from APC Passe, LLC, which is included in our total assumed
premiums (see Note 17, “Reinsurance”).
In January 2023, we made an equity investment that resulted in our minority interest ownership of Liberty Dental. During the year ended December 31, 2023,
in the normal course of business, Liberty Dental recognized $426 in revenue for administrative services provided to our members, primarily for those members in
our Medicare Advantage plans.
22. Statutory Information
The majority of our insurance and HMO subsidiaries report their accounts in conformity with accounting practices prescribed or permitted by state insurance
regulatory authorities, commonly referred to as statutory accounting, which vary in certain respects from GAAP. However, certain of our insurance and HMO
subsidiaries, including Blue Cross of California, Blue Cross of California Partnership Plan, Inc., Golden West Health Plan, Inc., Beacon Health Options of
California, Inc. and CareMore Health Plan are regulated by the California Department of Managed Health Care (“DMHC”) and report their accounts in conformity
with GAAP (these entities are collectively referred to as the “DMHC regulated entities”). Typical differences of GAAP reporting as compared to statutory reporting
are the recognition of all assets including those that are non-admitted for statutory purposes and recognition of all deferred tax assets without regard to statutory
limits. The National Association of Insurance Commissioners (“NAIC”) developed a codified version of the statutory accounting principles, designed to foster
more consistency among the states for accounting guidelines and reporting. Prescribed statutory accounting practices are set forth in a variety of publications of the
NAIC as well as state laws, regulations and general administrative rules.
Our statutory basis insurance and HMO subsidiaries are subject to risk-based capital (“RBC”) requirements. RBC is a method developed by the NAIC to
determine the minimum amount of statutory capital appropriate for an insurance company or HMO to support its overall business operations in consideration of its
size and risk profile. The formula for determining the amount of RBC specifies various factors, weighted based on the perceived degree of risk, which are applied
to certain
131

-- 132 of 533 --

Elevance Health, Inc.
Notes to Consolidated Financial Statements (continued)
financial balances and financial activity. Below minimum RBC requirements are classified within certain levels, each of which requires specified corrective action.
Additionally, the DMHC regulated entities are subject to capital and solvency requirements as prescribed by the DMHC. As of December 31, 2023 and 2022, all of
our regulated subsidiaries exceeded the minimum applicable mandatory RBC requirements and/or capital and solvency requirements of their applicable
governmental regulator.
The statutory RBC necessary to satisfy regulatory requirements of our statutory basis insurance and HMO subsidiaries was approximately $7,800 and $7,900
as of December 31, 2023 and 2022, respectively. The tangible net equity required for the DMHC regulated entities was approximately $950 and $710 as of
December 31, 2023 and 2022, respectively. Statutory basis capital and surplus of our insurance and HMO subsidiaries and capital and surplus of our other regulated
subsidiaries, excluding the DMHC regulated entities, was $19,808 and $19,048 at December 31, 2023 and 2022, respectively. GAAP equity of the DMHC
regulated entities was $3,975 and $3,795 at December 31, 2023 and 2022, respectively.
Our ability to pay dividends and credit obligations is significantly dependent on receipt of dividends from our subsidiaries. The payment of dividends to us by
our insurance and HMO subsidiaries without prior approval of the insurance departments of each subsidiary’s domiciliary jurisdiction is limited by formula.
Dividends in excess of these amounts are subject to prior approval by the respective state insurance departments or the DMHC. During 2023, our insurance and
HMO subsidiaries paid aggregate cash dividends of $4,909 to the parent company, including cash dividends which required prior approval from regulatory
authorities. We currently estimate that approximately $4,400 of dividends will be paid to the parent company in 2024.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.
There have been no changes in or disagreements with our independent registered public accounting firm on accounting or financial disclosures.
ITEM 9A. CONTROLS AND PROCEDURES.
Evaluation of Disclosure Controls and Procedures
We carried out an evaluation as of December 31, 2023, under the supervision and with the participation of our management, including our Chief Executive
Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the
Exchange Act. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are
effective in timely alerting them to material information relating to us (including our consolidated subsidiaries) required to be disclosed in our reports under the
Exchange Act. In addition, based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures
were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and
communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required
disclosures.
Management’s Report on Internal Control over Financial Reporting
Management, under the supervision and with the participation of the principal executive officer and principal financial officer, of Elevance Health, Inc. (the
“Company”) is responsible for establishing and maintaining effective internal control over financial reporting (“Internal Control”), as such term is defined in the
Exchange Act. The Company’s Internal Control is designed to provide reasonable assurance regarding the reliability of the Company’s financial reporting and the
preparation of financial statements for external reporting purposes in accordance with GAAP. The Company’s Internal Control includes those policies and
procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the
Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and
that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a
material effect on the financial statements.
132

-- 133 of 533 --

Because of inherent limitations in any Internal Control, no matter how well designed, misstatements due to error or fraud may occur and not be detected.
Accordingly, even effective Internal Control can provide only reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with GAAP.
Management, under the supervision and with the participation of the principal executive officer and principal financial officer, assessed the effectiveness of the
Company’s Internal Control as of December 31, 2023. Management’s assessment was based on criteria established in Internal Control—Integrated Framework
(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
The Company completed its acquisition of BioPlus Parent, LLC and subsidiaries in February 2023. As permitted by the U.S. Securities and Exchange
Commission, management's assessment as of December 31, 2023 did not include the Internal Control of BioPlus Parent, LLC and subsidiaries, which are included
in the Company's consolidated financial statements as of December 31, 2023. Such operations of BioPlus Parent, LLC and subsidiaries constituted 2% and 4% of
the Company's total assets and net assets, respectively, as of December 31, 2023, and 1% and 0% of the Company's total revenues and net income, respectively, for
the year then ended.
Based on management’s assessment, which excluded assessment of Internal Control of BioPlus Parent, LLC and subsidiaries, management has concluded that
the Company’s Internal Control was effective as of December 31, 2023 to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external reporting purposes in accordance with GAAP.
Ernst & Young LLP, the Company’s independent registered public accounting firm, has audited the consolidated financial statements of the Company for the
year ended December 31, 2023, and has also issued an audit report dated February 21, 2024, on the effectiveness of the Company’s Internal Control as of
December 31, 2023, which is included in this Annual Report on Form 10-K.
/S/ GAIL K. BOUDREAUX 	/S/ MARK B. KAYE
President and Chief Executive Officer 	Executive Vice President and Chief Financial Officer
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting that occurred during the three months ended December 31, 2023 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
133

-- 134 of 533 --

Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Directors of Elevance Health, Inc.
Opinion on Internal Control over Financial Reporting
We have audited Elevance Health, Inc.’s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control—
Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion,
Elevance Health, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on the
COSO criteria.
As indicated in the accompanying Management’s Report on Internal Control over Financial Reporting, management’s assessment of and conclusion on the
effectiveness of internal control over financial reporting did not include the internal controls of BioPlus Parent, LLC and subsidiaries, which is included in the 2023
consolidated financial statements of the Company and constituted 2% and 4% of total and net assets, respectively, as of December 31, 2023 and 1% and 0% of
revenues and net income, respectively, for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an
evaluation of the internal control over financial reporting of BioPlus Parent, LLC and subsidiaries.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance
sheets of Elevance Health, Inc. as of December 31, 2023 and 2022, the related consolidated statements of income, comprehensive income, cash flows and
shareholders’ equity for each of the three years in the period ended December 31, 2023, and the related notes and financial statement schedule listed in the Index at
Item 15(c) and our report dated February 21, 2024 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal
control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express
an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the
Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating
the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the
circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial
reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions
and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with
authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with
the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
Indianapolis, Indiana
February 21, 2024
134

-- 135 of 533 --

ITEM 9B. OTHER INFORMATION.
Rule 10b5-1 Trading Plans
Peter D. Haytaian, an executive officer of the Company, adopted a stock trading plan on December 4, 2023, pursuant to which he may sell up to 21,095 shares
of the Company’s common stock prior to December 2, 2024. This trading plan was entered into during an open insider trading window and is intended to satisfy the
affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, and the Company’s policies regarding transactions in our securities.
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.
None.
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.
The information required by this Item concerning our Executive Officers is included in Part I, Item 1, “Business - Information about our Executive Officers.”
The information required by this Item concerning our Directors and nominees for Director, information about our Audit Committee members and financial
expert(s), disclosure of any delinquent filers under Section 16(a) of the Exchange Act and our Code of Conduct is incorporated herein by reference from our
definitive Proxy Statement for our 2024 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the
end of our last fiscal year.
ITEM 11. EXECUTIVE COMPENSATION.
The information required by this Item concerning remuneration of our Executive Officers and Directors, material transactions involving such Executive
Officers and Directors and Compensation Committee interlocks, as well as the Compensation and Talent Committee Report and the CEO pay ratio are incorporated
herein by reference from our definitive Proxy Statement for our 2024 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation
14A within 120 days after the end of our last fiscal year.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.
Securities Authorized for Issuance under Equity Compensation Plans
Securities authorized for issuance under our equity compensation plans as of December 31, 2023 are as follows:
Plan
Category
Number of securities to be
issued upon exercise of
outstanding options, warrants and
rights
(a)
Weighted-average
exercise price of
outstanding options, warrants and
rights
(b)
Number of securities
remaining available for
future issuance under equity
compensation plans (excluding
securities reflected in column (a))
(c)
Equity compensation plans approved by shareholders as of December 31,
2023 	4,739,034 	$327.13 	15,977,193
1 We have no equity compensation plans pursuant to which awards may be granted in the future that have not been approved by shareholders.
2 Includes shares that may be issued under the Elevance Health Incentive Compensation Plan and the 2017 Elevance Health Incentive Compensation Plan pursuant to the
following outstanding awards: 2,984,903 stock options, 527,664 unvested restricted stock units, and 1,226,466 performance stock units (assuming that the outstanding
performance stock units are earned at the maximum award level).
3 Represents the weighted average exercise price of outstanding stock options. Does not take into consideration outstanding restricted stock units or performance stock units,
which, once vested, may be converted into shares of our common stock on a one-for-one basis upon distribution at no additional cost.
1
2 	3 	4
135

-- 136 of 533 --

4 Excludes securities reflected in the first column, “Number of securities to be issued upon exercise of outstanding options, warrants and rights”. Includes 11,812,885 shares of
common stock available for issuance as stock options, restricted stock awards, performance stock awards, performance awards and stock appreciation rights under the 2017
Elevance Health Incentive Compensation Plan at December 31, 2023. Includes 4,164,308 shares of common stock available for issuance under the Stock Purchase Plan at
December 31, 2023.
The information required by this Item concerning the stock ownership of management and five percent beneficial owners is incorporated herein by reference
from our definitive Proxy Statement for our 2024 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days
after the end of our last fiscal year.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.
The information required by this Item concerning certain relationships and related person transactions and Director independence is incorporated herein by
reference from our definitive Proxy Statement for our 2024 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within
120 days after the end of our last fiscal year.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.
The information required by this Item concerning principal accountant fees and services is incorporated herein by reference from our definitive Proxy
Statement for our 2024 Annual Meeting of Shareholders, which will be filed with the SEC pursuant to Regulation 14A within 120 days after the end of our last
fiscal year.
136

-- 137 of 533 --

PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.
(a) 1. Financial Statements:
The following consolidated financial statements of the Company are set forth in Part II, Item 8:
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of December 31, 2023 and 2022
Consolidated Statements of Income for the years ended December 31, 2023, 2022, and 2021
Consolidated Statements of Comprehensive Income for the years ended December 31, 2023, 2022, and 2021
Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021
Consolidated Statements of Shareholders’ Equity for the years ended December 31, 2023, 2022 and 2021
Notes to Consolidated Financial Statements
2. Financial Statement Schedule:
The following financial statement schedule of the Company is included in Item 15(c):
Schedule II—Condensed Financial Information of Registrant (Parent Company Only).
All other schedules for which provision is made in the applicable accounting regulations of the SEC are not required under the related instructions, are
inapplicable, or the required information is included in the consolidated financial statements, and therefore, have been omitted.
3. Exhibits required to be filed as part of this report:
Exhibit
Number 	Exhibit
3.1 Amended and Restated Articles of Incorporation of the Company, as amended and restated effective June 27, 2022, incorporated by reference to
Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 28, 2022.
3.2 Bylaws of the Company, as amended effective October 4, 2023, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on
Form 8-K filed on October 5, 2023.
4.1 Indenture, dated as of December 9, 2004, between the Company and The Bank of New York Trust Company, N.A., as trustee, including the Form
of the Company’s 5.950% Notes due 2034, incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on
December 15, 2004.
4.2 Indenture, dated as of January 10, 2006, between the Company and The Bank of New York Mellon Trust Company, N.A. (formerly known as The
Bank of New York Trust Company, N.A.), as trustee, incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K
filed on January 11, 2006.
(a) 	Form of 5.85% Notes due 2036, incorporated by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed on January
11, 2006.
(b) 	Form of 6.375% Notes due 2037, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on June 8,
2007.
(c) 	Form of 5.800% Notes due 2040, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on
August 12, 2010.
(d) 	Form of 4.625% Notes due 2042, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on May 7,
2012.
(e) 	Form of 4.650% Notes due 2043, incorporated by reference to Exhibit 4.5 to the Company’s Current Report on Form 8-K filed on
September 10, 2012.
137

-- 138 of 533 --

Exhibit
Number 	Exhibit
(f) 	Form of 5.100% Notes due 2044, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on July 31,
2013.
(g) 	Form of 3.500% Notes due 2024, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on August
12, 2014.
(h) 	Form of 4.650% Notes due 2044, incorporated by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed on August
12, 2014.
(i) 	Form of 4.850% Notes due 2054, incorporated by reference to Exhibit 4.5 to the Company’s Current Report on Form 8-K filed on August
12, 2014.
4.3 Subordinated Indenture, dated as of May 12, 2015, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee,
incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on May 12, 2015.
4.4 Indenture dated as of November 21, 2017 between the Company and The Bank of New York Mellon Trust Company, N.A. as trustee,
incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on November 21, 2017.
(a) 	Form of 3.350% Notes due 2024, incorporated by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed on
November 21, 2017.
(b) 	Form of 3.650% Notes due 2027, incorporated by reference to Exhibit 4.5 to the Company’s Current Report on Form 8-K filed on
November 21, 2017.
(c) 	Form of 4.375% Notes due 2047, incorporated by reference to Exhibit 4.6 to the Company’s Current Report on Form 8-K filed on
November 21, 2017.
(d) 	Form of 4.101% Notes due 2028, incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on March
2, 2018.
(e) 	Form of 4.550% Notes due 2048, incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on March
2, 2018.
(f) 	Form of 2.375% Notes due 2025, incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on
September 9, 2019.
(g) 	Form of 2.875% Notes due 2029, incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on
September 9, 2019.
(h) 	Form of 3.700% Notes due 2049, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on
September 9, 2019.
(i) 	Form of 2.250% Notes due 2030, incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on May 5,
2020.
(j) 	Form of 3.125% Notes due 2050, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on May 5,
2020.
(k) 	Form of 1.500% Notes due 2026, incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on March
17, 2021.
(l) 	Form of 2.550% Notes due 2031, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on March
17, 2021.
(m) Form of 3.600% Notes due 2051, incorporated by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed on March
17, 2021.
(n) 	Form of 4.100% Notes due 2032, incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on April 29,
2022.
(o) 	Form of 4.550% Notes due 2052, incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on April 29,
2022.
138

-- 139 of 533 --

Exhibit
Number 	Exhibit
(p) 	Form of 5.350% Notes due 2025, incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on
November 4, 2022.
(q) 	Form of 5.500% Notes due 2032, incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on
November 4, 2022.
(r) 	Form of 6.100% Notes due 2052, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on
November 4, 2022.
(s) 	Form of 4.900% Notes due 2026, incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on
February 8, 2023.
(t) 	Form of 4.750% Notes due 2033, incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on
February 8, 2023.
(u) 	Form of 5.125% Notes due 2053, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on
February 8, 2023.
4.5 	Upon the request of the Securities and Exchange Commission, the Company will furnish copies of any other instruments defining the rights of
holders of long-term debt of the Company or its subsidiaries.
4.6 	Description of the Company’s Securities Registered Pursuant to Section 12 of the Exchange Act, incorporated by reference to Exhibit 4.7 to the
Company's Annual Report on Form 10-K for the year ended December 31, 2022.
10.1 * Elevance Health Incentive Compensation Plan, as amended and restated effective June 28, 2022, incorporated by reference to Exhibit 10.1 to the
Company's Annual Report on Form 10-K for the year ended December 31, 2022.
(a) 	Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2016 and 2017, incorporated by reference to
Exhibit 10.2(s) to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016.
10.2 * 2017 Elevance Health Incentive Compensation Plan, as amended and restated effective June 28, 2022, incorporated by reference to Exhibit 10.2
to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.
(a) 	Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2018, incorporated by reference to Exhibit 10.2(d)
to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.
(b) 	Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement commencing July 2018, incorporated by reference to
Exhibit 10.2(h) to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.
(c) 	Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2019, incorporated by reference to Exhibit 10.2(l)
to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019.
(d) 	Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2020, incorporated by reference to Exhibit 10.2(l)
to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.
(e) 	Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2020, incorporated by reference to Exhibit 10.2(m) to
the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.
(f) 	Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2020, incorporated by reference to Exhibit 10.2(n) to
the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.
(g) 	Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2021, incorporated by reference to Exhibit
10.2(m) to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021.
139

-- 140 of 533 --

Exhibit
Number 	Exhibit
(h) 	Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2021, incorporated by reference to Exhibit 10.2(n) to
the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021.
(i) 	Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2021, incorporated by reference to Exhibit 10.2(o) to
the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021.
(j) 	Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2022, as amended and restated effective June 28,
2022, incorporated by reference to Exhibit 10.2(l) to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.
(k) 	Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2022, as amended and restated effective June 28, 2022,
incorporated by reference to Exhibit 10.2(m) to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.
(l) 	Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2022, as amended and restated effective June 28,
2022, incorporated by reference to Exhibit 10.2(n) to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.
(m) Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for 2023, incorporated by reference to Exhibit 10.2(o)
to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.
(n) 	Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2023, incorporated by reference to Exhibit 10.2(p) to
the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.
(o) 	Form of Incentive Compensation Plan Performance Stock Unit Award Agreement for 2023, incorporated by reference to Exhibit 10.2(q) to
the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023.
10.3 * Elevance Health Comprehensive Nonqualified Deferred Compensation Plan, as amended and restated effective January 1, 2024.
10.4 * Elevance Health Executive Agreement Plan, as amended and restated effective June 28, 2022, incorporated by reference to Exhibit 10.4 to the
Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.
10.5 * Elevance Health Executive Salary Continuation Plan, as amended and restated effective June 28, 2022, incorporated by reference to Exhibit 10.5
to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.
10.6 * Elevance Health Directed Executive Compensation Plan, as amended and restated effective June 28, 2022, incorporated by reference to Exhibit
10.6 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.
10.7 * Elevance Health Board of Directors Compensation Program, as amended and restated effective May 10, 2023, incorporated by reference to
Exhibit 10.7 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023.
10.8 * Elevance Health Board of Directors’ Deferred Compensation Plan, as amended and restated effective June 28, 2022, incorporated by reference to
Exhibit 10.8 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.
10.9 * (a) 	Form of Employment Agreement between the Company and each of the following: John E. Gallina, Peter D. Haytaian, and Gloria
McCarthy, incorporated by reference to Exhibit A to Exhibit 10.41 to the Company’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2007.
(b) 	Form of Employment Agreement between the Company and Gail Boudreaux, incorporated by reference to Exhibit A to Exhibit 10.1 to the
Company’s Current Report on Form 8-K filed on November 6, 2017.
(c) 	Form of Employment Agreement between the Company and each of the following: Charles Morgan Kendrick, Felicia F. Norwood, and
Blair W. Todt incorporated by reference to Exhibit 10.9(d) to the Company’s Quarterly Report on Form 10-Q for the quarter ended June
30, 2018.
140

-- 141 of 533 --

Exhibit
Number 	Exhibit
(d) 	Form of Employment Agreement between the Company and Mark Kaye, incorporated by reference to Exhibit 10.9(d) to the Company's
Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.
10.10 * Offer Letter, by and between the Company and Gail Boudreaux, dated as of November 5, 2017, incorporated by reference to Exhibit 10.1 to the
Company’s Current Report on Form 8-K filed on November 6, 2017.
10.11 * Offer Letter, by and between the Company and Mark Kaye, dated as of August 2, 2023, incorporated by reference to Exhibit 10.1 to the
Company’s Current Report on Form 8-K filed on August 8, 2023.
10.12 	Blue Cross License Agreement by and between Blue Cross Blue Shield Association and the Company, including revisions, if any, adopted by the
Member Plans through November 16, 2023.
10.13 	Blue Shield License Agreement by and between Blue Cross Blue Shield Association and the Company, including revisions, if any, adopted by the
Member Plans through November 16, 2023.
21 	Subsidiaries of the Company.
23 	Consent of Independent Registered Public Accounting Firm.
31.1 	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
32.2 	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
97 	Elevance Health, Inc. Incentive Compensation Recoupment Policy, amended and restated effective as of October 3, 2023.
101.INS 	XBRL Instant Document - the instant document does not appear in the Interactive Data File because its XBRL tags are embedded within the
Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document.
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF 	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE 	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 	Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.
* 	Indicates management contracts or compensatory plans or arrangements.
(b) Exhibits
The response to this portion of Item 15 is set forth in paragraph (a) 3 above.
(c) Financial Statement Schedule
Schedule II—Condensed Financial Information of Registrant (Parent Company Only).
ITEM 16. FORM 10-K SUMMARY.
None.
141

-- 142 of 533 --

Schedule II—Condensed Financial Information of Registrant
Elevance Health, Inc. (Parent Company Only)
Balance Sheets
(In millions, except share data) December 31,
2023 December 31,
2022
Assets
Current assets:
Cash and cash equivalents 	$ 	1,483 $ 	942
Fixed maturity securities (amortized cost of $0 and $175; allowance for credit losses of $0 and $0) 	— 	163
Equity securities 	80 	104
Other receivables 	58 	55
Other current assets 	959 	721
Total current assets 	2,580 	1,985
Other invested assets 	822 	783
Property and equipment, net 	178 	187
Deferred tax assets, net 	199 	313
Investments in subsidiaries 	63,426 	58,978
Other noncurrent assets 	217 	240
Total assets 	$ 	67,422 $ 	62,486
Liabilities and shareholders’ equity
Liabilities
Current liabilities:
Accounts payable and accrued expenses 	$ 	1,709 $ 	894
Net due to subsidiaries 	734 	789
Current portion of long-term debt 	1,649 	1,500
Other current liabilities 	413 	361
Total current liabilities 	4,505 	3,544
Long-term debt, less current portion 	23,221 	22,324
Other noncurrent liabilities 	390 	375
Total liabilities 	28,116 	26,243
Commitments and contingencies—Note 5
Shareholders’ equity
Preferred stock, without par value, shares authorized - 100,000,000; shares issued and outstanding - none 	— 	—
Common stock, par value $0.01, shares authorized - 900,000,000; shares issued and outstanding - 233,071,088 and 237,958,067 	2 	2
Additional paid-in capital 	8,868 	9,084
Retained earnings 	31,749 	29,647
Accumulated other comprehensive loss 	(1,313) 	(2,490)
Total shareholders’ equity 	39,306 	36,243
Total liabilities and shareholders’ equity 	$ 	67,422 $ 	62,486
See accompanying notes.
142

-- 143 of 533 --

Elevance Health, Inc. (Parent Company Only)
Statements of Income
Years ended December 31
(In millions) 	2023 	2022 	2021
Revenues
Net investment income 	$ 	25 $ 	4 $ 	6
Net (losses) gains on financial instruments 	(100) 	2 	6
Service fees 	8 	7 	24
Total revenues 	(67) 	13 	36
Expenses
Operating expense 	352 	188 	119
Interest expense 	1,017 	845 	794
Loss on extinguishment of debt 	— 	— 	21
Total expenses 	1,369 	1,033 	934
Loss before income tax credits and equity in net income of subsidiaries 	(1,436) 	(1,020) 	(898)
Income tax credits 	(214) 	(461) 	(244)
Equity in net income of subsidiaries 	7,209 	6,453 	6,812
Shareholders’ net income 	$ 	5,987 $ 	5,894 $ 	6,158
See accompanying notes.
143

-- 144 of 533 --

Elevance Health, Inc. (Parent Company Only)
Statements of Comprehensive Income
Years ended December 31
(in millions) 	2023 	2022 	2021
Shareholders’ net income 	$ 	5,987 $ 	5,894 $ 	6,158
Other comprehensive income (loss), net of tax:
Change in net unrealized gains/losses on investments 	1,123 	(2,249) 	(455)
Change in non-credit component of impairment losses on investments 	— 	(3) 	2
Change in net unrealized gains/losses on cash flow hedges 	18 	10 	11
Change in net periodic pension and postretirement costs 	40 	(70) 	123
Change in future policy benefits 	(3) 	32 	(7)
Foreign currency translation adjustments 	(1) 	(13) 	(9)
Other comprehensive income (loss) 	1,177 	(2,293) 	(335)
Total shareholders’ comprehensive income 	$ 	7,164 $ 	3,601 $ 	5,823
See accompanying notes.
144

-- 145 of 533 --

Elevance Health, Inc. (Parent Company Only)
Statements of Cash Flows
Years ended December 31
(In millions) 	2023 	2022 	2021
Net cash provided by operating activities 	$ 	4,113 $ 	1,447 $ 	2,038
Investing activities
Purchases of investments 	(95) 	(367) 	(2,059)
Proceeds from sales, maturities, calls and redemptions of investments 	212 	618 	2,449
Repayment (issuance) of note to subsidiary 	— 	1,500 	(1,500)
Capitalization of subsidiaries 	(363) 	(411) 	(807)
Changes in securities lending collateral 	42 	36 	173
Purchases of property and equipment, net of sales 	(55) 	(47) 	(77)
Net cash provided by (used in) investing activities 	(259) 	1,329 	(1,821)
Financing activities
Net (repayments of) proceeds from short-term borrowings 	— 	(300) 	50
Proceeds from long-term borrowings 	2,574 	3,071 	3,462
Repayments of long-term borrowings 	(1,909) 	(1,899) 	(1,068)
Changes in securities lending payable 	(42) 	(36) 	(173)
Repurchase and retirement of common stock 	(2,676) 	(2,316) 	(1,900)
Cash dividends 	(1,466) 	(1,290) 	(1,158)
Proceeds from issuance of common stock under employee stock plans 	152 	182 	203
Taxes paid through withholding of common stock under employee stock plans 	(99) 	(93) 	(102)
Other, net 	153 	217 	399
Net cash used in financing activities 	(3,313) 	(2,464) 	(287)
Change in cash and cash equivalents 	541 	312 	(70)
Cash and cash equivalents at beginning of year 	942 	630 	700
Cash and cash equivalents at end of year 	$ 	1,483 $ 	942 $ 	630
See accompanying notes.
145

-- 146 of 533 --

Elevance Health, Inc.
(Parent Company Only)
Notes to Condensed Financial Statements
December 31, 2023
(In Millions, Except Per Share Data)
1. Basis of Presentation and Significant Accounting Policies
In the parent company only financial statements of Elevance Health, Inc. (“Elevance Health”), Elevance Health’s investment in subsidiaries is stated at cost
plus equity in undistributed earnings of the subsidiaries. Elevance Health’s share of net income of its unconsolidated subsidiaries is included in income using the
equity method of accounting.
Certain amounts presented in the parent company only financial statements are eliminated in the consolidated financial statements of Elevance Health.
Elevance Health’s parent company only financial statements should be read in conjunction with Elevance Health’s audited consolidated financial statements
and the accompanying notes included in Part II, Item 8 of this Annual Report on Form 10-K.
2. Subsidiary Transactions
Dividends from Subsidiaries
Elevance Health received cash dividends from subsidiaries of $4,909, $3,097 and $3,134 during 2023, 2022 and 2021, respectively.
Dividends to Subsidiaries
Certain subsidiaries of Elevance Health own shares of Elevance Health common stock. Elevance Health paid cash dividends to subsidiaries related to these
shares of common stock in the amount of $71, $61 and $54 during 2023, 2022 and 2021, respectively.
Investments in Subsidiaries
Capital contributions to subsidiaries were $363, $411 and $3,271 during 2023, 2022 and 2021, respectively.
Amounts Due From and To Subsidiaries
At December 31, 2023 and 2022, Elevance Health reported amounts due (to) from subsidiaries of $(734) and $(789), respectively. The amounts due (to) and
from subsidiaries primarily include amounts for allocated operating expenses or daily cash management activities. These items are routinely settled, and as such,
are classified as current liabilities or assets.
In June 2021 Elevance Health entered into a short-term loan agreement with a subsidiary for the amount of $1,500, which is also included in amounts due from
subsidiaries at December 31, 2021. This loan was repaid in February 2022.
Guarantees on Behalf of Subsidiaries
Elevance Health guarantees contractual or financial obligations or solvency requirements for certain of its subsidiaries. These guarantees approximated $435 at
December 31, 2023. There were no payments made on these guarantees in 2023.
3. Derivative Financial Instruments
The information regarding derivative financial instruments contained in Note 6, “Derivative Financial Instruments,” of the Notes to Consolidated Financial
Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.
146

-- 147 of 533 --

4. Long-Term Debt
The information regarding long-term debt contained in Note 13, “Debt,” of the Notes to Consolidated Financial Statements of Elevance Health and its
subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.
5. Commitments and Contingencies
The information regarding commitments and contingencies contained in Note 14, “Commitments and Contingencies,” of the Notes to Consolidated Financial
Statements of Elevance Health and its subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.
6. Capital Stock
The information regarding capital stock contained in Note 15, “Capital Stock,” of the Notes to Consolidated Financial Statements of Elevance Health and its
subsidiaries, included in Part II, Item 8 of this Annual Report on Form 10-K, is incorporated herein by reference.
147

-- 148 of 533 --

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
ELEVANCE HEALTH, INC.
By: 	/s/ GAIL K. BOUDREAUX
Gail K. Boudreaux
President and Chief Executive Officer
Dated: February 21, 2024
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and
in the capacities and on the dates indicated.
Signature 	Title 	Date
/s/ GAIL K. BOUDREAUX President and Chief Executive Officer, Director
(Principal Executive Officer) February 21, 2024
Gail K. Boudreaux
/s/ MARK B. KAYE Executive Vice President and Chief Financial Officer (Principal Financial
Officer) February 21, 2024
Mark B. Kaye
/s/ RONALD W. PENCZEK 	Chief Accounting Officer and Controller (Principal Accounting Officer) 	February 21, 2024
Ronald W. Penczek
/s/ ELIZABETH E. TALLETT 	Chair of the Board 	February 21, 2024
Elizabeth E. Tallett
/s/ R. KERRY CLARK 	Director 	February 21, 2024
R. Kerry Clark
/s/ SUSAN D. DEVORE 	Director 	February 21, 2024
Susan D. DeVore
/s/ ROBERT L. DIXON, JR. 	Director 	February 21, 2024
Robert L. Dixon, Jr.
/s/ LEWIS HAY III 	Director 	February 21, 2024
Lewis Hay III
/s/ BAHIJA JALLAL 	Director 	February 21, 2024
Bahija Jallal
/s/ ANTONIO F. NERI 	Director 	February 21, 2024
Antonio F. Neri
/s/ RAMIRO G. PERU 	Director 	February 21, 2024
Ramiro G. Peru
/s/ RYAN M. SCHNEIDER 	Director 	February 21, 2024
Ryan M. Schneider
/s/ DEANNA D. STRABLE 	Director 	February 21, 2024
Deanna D. Strable
148

-- 149 of 533 --

Exhibit 10.3
ELEVANCE HEALTH
COMPREHENSIVE NON-QUALIFIED DEFERRED
COMPENSATION PLAN
(AS AMENDED AND RESTATED EFFECTIVE
JANUARY 1, 2024)

-- 150 of 533 --

Exhibit 10.3
TABLE OF CONTENTS
Page
ARTICLE I HISTORY AND PURPOSE 	1
1.01 	History 	1
1.02 	Purpose 	2
ARTICLE II DEFINITIONS 	2
2.01 	“Account” 	2
2.02 	“Administrator” 	3
2.03 	“Affiliate” 	3
2.04 	“Anthem LTIP” 	3
2.05 	“Anthem Plan” 	3
2.06 	“Anthem SERP” 	3
2.07 	“Anthem SERP Participant” 	3
2.08 	“Beneficiary” 	3
2.09 	“Bonus” 	3
2.10 	“Bonus Deferral” 	3
2.11 	“Code” 	3
2.12 	“Committee” 	3
2.13 	“Company” 	4
2.14 	“Company Contribution” 	4
2.15 	“Compensation” 	4
2.16 	“Compensation Deferral” 	4
2.17 	“Election Form” 	4
2.18 	“Eligible Employee” 	4
2.19 	“In-Service Payout” 	4
2.20 	“Key Employee” 	4
2.21 	“Make-Up Contribution” 	4
2.22 	“Matching Contribution” 	5
2.23 	“Merged Plan” 	5
2.24 	“Participant” 	5
2.25 	“Pension Benefit” 	5
2.26 	“Pension Plan” 	5
2.27 	“Plan” 	5
2.28 	“Plan Year” 	5
2.29 	“Predecessor Plan” 	5
2.30 	“Predecessor Plan Account” 	5
2.31 	“Predecessor Plan Participant” 	5
2.32 	“Regulations” 	5
2.33 	“Savings Plan” 	5
2.34 	“Separation from Service” 	5
2.35 	“Trigon Plan” 	6
2.36 	“Trigon SERP” 	6
2.37 	“UGS Pension Plan” 	6
2.38 	“WellPoint Plan” 	6
i Elevance Health NQDCP 2023

-- 151 of 533 --

Exhibit 10.3
Page
2.39 	“WellPoint SERP Participant” 	6
2.40 	“2005 Anthem SERP” 	6
2.41 	“2005 WellPoint Plan” 	6
2.42 	“2005 Anthem Plan” 	6
2.43 	“2005 Trigon Plan” 	6
2.44 	“2005 Trigon SERP” 	6
ARTICLE III ELIGIBILITY AND PARTICIPATION 	6
3.01 	Eligibility 	6
3.02 	Participation 	7
3.03 	Enrollment Requirements 	7
3.04 	Cessation of Participation 	7
ARTICLE IV DEFERRALS AND CONTRIBUTIONS 	8
4.01 	Compensation 	8
4.02 	Bonus 	9
4.03 	Matching Contributions 	9
4.04 	Non-Elective Contributions 	10
ARTICLE V SUPPLEMENTAL PENSION PLAN CONTRIBUTIONS 	11
5.01 	Eligibility for Supplemental Pension Contribution 	11
5.02 	In General 	11
5.03 	Former DeCare Dental Pension Plan Participants 	12
5.04 	QSERP 	13
ARTICLE VI EARNINGS 	13
6.01 	Investment Funds 	13
6.02 	Conversion of Investments from Predecessor Plans and Merged Plans 	13
ARTICLE VII VESTING 	13
7.01 	Elective Deferrals under the Plan 	13
7.02 	Supplemental Pension Plan Contributions 	14
7.03 	Predecessor or Merged Plans 	14
7.04 	Company and/or Make-Up Contributions 	14
7.05 	Matching Contributions 	14
ARTICLE VIII DISTRIBUTIONS 	14
8.01 	Annual Election 	14
8.02 	Time for Distribution 	14
8.03 	In-Service Payout 	14
8.04 	Separation from Service 	15
8.05 	Subsequent Changes in Elections 	16
8.06 	Death 	16
8.07 	Hardship Withdrawal 	16
8.08 	Valuation 	17
8.09 	Tax Withholding 	17
ii
Elevance Health NQDCP 2023

-- 152 of 533 --

Exhibit 10.3
Page
8.10 	Payment of Small Accounts 	17
8.11 	Right of Offset 	17
8.12 	Bona Fide Dispute 	18
8.13 	Income Inclusion Under Code Section 409A 	18
8.14 	Effect of Rehire 	18
ARTICLE IX EFFECT ON PREDECESSOR AND MERGED PLANS 	18
9.01 	Coordination With Predecessor Plans 	18
9.02 	Predecessor Plan Accounts 	18
9.03 	Merged Plans 	19
ARTICLE X CLAIMS PROCEDURES 	19
10.01 	Presentation of Claim 	19
10.02 	Decision on Initial Claim 	19
10.03 	Right to Review 	20
10.04 	Decision on Review 	20
10.05 	Form of Notice and Decision 	21
10.06 	Legal Action 	21
ARTICLE XI ADMINISTRATION 	21
11.01 	Plan Administration 	21
11.02 	Powers, Duties and Procedures 	21
11.03 	Agents 	22
11.04 	Binding Effect of Decisions 	22
11.05 	Information 	22
11.06 	Coordination with Other Benefits 	22
ARTICLE XII MISCELLANEOUS 	22
12.01 	Limitation of Rights 	22
12.02 	Additional Restrictions 	22
12.03 	Indemnification 	23
12.04 	Assignment 	23
12.05 	Inability to Locate Recipient 	23
12.06 	Amendment and Termination 	23
12.07 	Applicable Law 	23
12.08 	No Funding 	23
12.09 	Trust 	24
iii
Elevance Health NQDCP 2023

-- 153 of 533 --

Exhibit 10.3
ELEVANCE HEALTH
COMPREHENSIVE NON-QUALIFIED DEFERRED
COMPENSATION PLAN
(AS AMENDED AND RESTATED EFFECTIVE
JANUARY 1, 2024)
ARTICLE I
HISTORY AND PURPOSE
1.01 	History. Elevance Health, Inc. (f/k/a Anthem, Inc. and WellPoint, Inc.) (the “Company”) established the WellPoint, Inc. 2005
Comprehensive Executive Non-Qualified Retirement Plan, originally effective January 1, 2005 (“WellPoint Plan”), as a new plan for certain types
of deferred compensation subject to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), which governs nonqualified
deferred compensation arrangements. The Company amended and restated the WellPoint Plan effective January 1, 2006, and renamed it the
WellPoint, Inc. Comprehensive Non-Qualified Deferred Compensation Plan (the “Plan”). The Company amended and restated the Plan effective as
of November 1, 2006, then restated it again effective as of January 1, 2009, for compliance with the final regulations issued under Code Section
409A. The Company subsequently amended and restated the Plan, most recently via a restatement effective June 28, 2022, and First Amendment
thereto adopted in December 2022, effective January 1, 2023. The Company hereby amends and restates the Plan effective January 1, 2024, to
incorporate the 2022 amendment noted above, reflect minor changes to the process for making deferral elections under the Plan, amend the
definition of Administrator, and make other clarifying changes.
(a) Merged Plans. In addition, effective January 1, 2005, the Company, one of its predecessors or entities related to the Company
or a predecessor also established the following nonqualified deferred compensation plans applicable to amounts subject to Code Section
409A.
(i) the 2005 Anthem Supplemental Executive Retirement Plan;
(ii) the 2005 Anthem Deferred Compensation Plan (the “Anthem Plan”);
(iii) the 2005 Trigon Insurance Company 401(k) Restoration Plan; and (iv) the 2005 Supplemental Retirement Plan for
Certain Employees of Trigon Insurance Company.
Each of the foregoing plans were separately maintained for the 2005 calendar year and cover deferred compensation that related
solely to the 2005 calendar year. The Company subsequently ceased accruals and merged each of the plans into the Anthem Plan effective
as of December 31, 2005, and are referred to herein as the Merged Plans (either alone or collectively).
1 Elevance Health NQDCP 2023

-- 154 of 533 --

Exhibit 10.3
(b) Predecessor Plans. The Company or one of its predecessors separately maintained the following nonqualified deferred
compensation plans, which cover amounts earned and vested as of December 31, 2004 (including vested bonuses earned in 2004 and paid
in 2005):
(i) each pre-2005 Anthem Long-Term Incentive Plan;
(ii) the WellPoint Health Networks Inc. Comprehensive Executive Non-Qualified Retirement Plan;
(iii) the Anthem Supplemental Executive Retirement Plan;
(iv) the Anthem Deferred Compensation Plan;
(v) the Trigon Insurance Company 401(k) Restoration Plan; and
(vi) the Supplemental Retirement Plan for Certain Employees of Trigon Insurance Company.
Each of the foregoing plans is referred to as a “Predecessor Plan(s).” Benefits ceased to accrue under the Predecessor Plans effective
December 31, 2004, and, as such, are grandfathered for purposes of Code Section 409A. Solely for administrative purposes, Predecessor
Plan Account balances, determined as of December 31, 2005, became accounted for under the 2005 WellPoint Plan effective as of January
1, 2006. In all other respects, each Predecessor Plan Account remains subject exclusively to the terms of the Predecessor Plan to which it
relates.
1.02 Purpose. Except as otherwise provided herein, the Plan applies only to Participants to whose Account contributions are credited under
Article IV and Article V. The purpose of the Plan is for certain management and highly compensated employees to (1) restore certain benefits that
cannot be provided under the tax-qualified plans maintained by the Company and its affiliates and (2) provide additional opportunities to defer one
or more items of their compensation.
The Plan is intended to comply with Code Section 409A and shall be interpreted, administered, and operated as necessary to comply with
the requirements of Code Section 409A and applicable Treasury Regulations. Notwithstanding any Plan provision to the contrary, the Committee
and/or the Administrator may, in their sole discretion, prescribe rules to facilitate compliance with Code Section 409A, which may include
requirements for and/or limitations on an Eligible Employee’s elections under this Plan and/or the Savings Plan. The Plan is further intended to be a
plan that is unfunded and maintained by the Company primarily for the purpose of providing deferred compensation for a select group of
management or highly compensated employees within the meaning of the Employee Retirement Income Security Act of 1974 (“ERISA”).
2
Elevance Health NQDCP 2023

-- 155 of 533 --

Exhibit 10.3
ARTICLE II
DEFINITIONS
In this Plan, the following terms have the meanings indicated below:
2.01 “Account” means the account maintained under the Plan for each Participant which is credited with amounts under Article IV and
Article V of the Plan and adjusted periodically for investment performance under Article VI of the Plan and distributions or withdrawals in
accordance with Article VIII. The Account of each Participant who is also a Predecessor Plan Participant shall also include the Predecessor Plan
Account maintained on behalf of that Predecessor Plan Participant, as adjusted periodically for investment performance under Article VI of the Plan
and distributions or withdrawals in accordance with the terms of the Predecessor Plan to which it relates. Each Participant’s Account shall be
divided into a series of Plan Year subaccounts, one for each Plan Year for which the Participant defers any Compensation under the Plan. To the
extent it considers necessary or appropriate, the Administrator may further divide each such Plan Year subaccount into a series of separate
subaccounts so that each category of deferred Compensation may be credited to its own separate subcategories within that particular Plan Year
subaccount.
2.02 “Administrator” means the Company’s Vice President, Total Rewards.
2.03 “Affiliate” means an entity other than the Company whose employees participate in the tax-qualified retirement plans of ATH Holding
Company, LLC or whose employees are authorized to participate in the Plan by the Committee.
2.04 “Anthem LTIP” means each pre-2005 Anthem Long-Term Incentive Plan.
2.05 “Anthem Plan” means the Anthem Deferred Compensation Plan.
2.06 “Anthem SERP” means the Anthem Supplemental Executive Retirement Plan.
2.07 “Anthem SERP Participant” means an individual who is eligible on or after January 1, 2006, to earn a benefit under the 2005 Anthem
SERP.
2.08 “Beneficiary” means the person or persons, trust or estate designated in writing, to receive a Participant’s vested Account if the
Participant dies before distribution of the entire vested balance credited to that Account. A Participant may designate one or more primary
Beneficiaries and one or more secondary Beneficiaries. A Participant’s Beneficiary designation must be made in writing pursuant to such
procedures as the Administrator may establish and delivered to the Administrator before the Participant’s death. The Participant may revoke or
change this designation at any time before his or her death by following such procedures as the Administrator will establish. If the Administrator
has not received a Participant’s Beneficiary designation before the Participant’s death or if the Participant does not otherwise have an effective
Beneficiary designation on file when he or she dies, the vested balance of such Participant’s Account will be distributed to his or her estate.
2.09 “Bonus” means an amount awarded to an Eligible Employee under an annual incentive plan maintained by the Company as
determined by the Administrator.
3
Elevance Health NQDCP 2023

-- 156 of 533 --

Exhibit 10.3
2.10 “Bonus Deferral” means an election by a Participant to defer the receipt of a Bonus in accordance with the requirements of Article IV.
2.11 “Code” means the Internal Revenue Code of 1986, as amended from time to time.
2.12 “Committee” means the Compensation and Talent Committee of the Company’s Board of Directors or a subcommittee of two or more
members thereof. The Committee’s powers, duties, responsibilities, and discretionary authority are set forth in Article XI.
2.13 “Company” means Elevance Health, Inc., an Indiana corporation.
2.14 “Company Contribution” means, for any one Plan Year, the amount determined in accordance with Section 4.04.
2.15 “Compensation” means the respective definitions of compensation as set forth in the Savings Plan for elective deferrals and matching
contributions, as constituted from time to time and as the context requires. In either case, the respective definition of compensation as set forth in
the Savings Plan is determined without regard to the application of the limitation under Code Section 401(a)(17). Effective for Compensation
Deferrals relating to compensation earned in Plan Years beginning on and after January 1, 2020, Compensation means base salary and commissions
paid in the year to which the Compensation Deferrals relate, consistent with Code Section 409A and the regulations promulgated thereunder.
2.16 “Compensation Deferral” means an election by a Participant to defer the receipt of the portion of his or her Compensation in
accordance with the requirements of Article IV.
2.17 “Election Form” means the forms or processes established from time to time by the Administrator that a Participant completes and
returns to the Administrator to make a deferral election, make or change a payment election, and/or make or change an investment election. To the
extent authorized by the Administrator, an Election Form may be electronic or set forth in some other media or format.
2.18 “Eligible Employee” means each employee of the Company or an Affiliate who is eligible to participate in the Plan pursuant to Section
3.01, provided that “Eligible Employee” shall not include any employee who is a bona fide resident of Puerto Rico as described in the Code or is
performing services in Puerto Rico.
2.19 “In-Service Payout” means a complete distribution of a Participant’s vested Plan Year subaccount (including the related Matching
Contribution) as of a specified date elected by a Participant.
2.20 “Key Employee” means for the period January 1 through December 31 each individual identified by the Administrator as of the
immediately preceding September 30
4
Elevance Health NQDCP 2023

-- 157 of 533 --

Exhibit 10.3
as a “key employee,” as defined under Code Section 416(i), disregarding Code Section 416(i)(5).
2.21 “Make-Up Contribution” means the contribution described under Section 4.04.
2.22 “Matching Contribution” means a matching contribution pursuant to Section 4.03.
2.23 “Merged Plan” means the 2005 Anthem SERP, the 2005 Anthem Plan, the 2005 Trigon Plan or the 2005 Trigon SERP.
2.24 “Participant” means a current or former Eligible Employee for whom an Account (including one or more Plan Year subaccounts) is
maintained. A Participant shall also include a Predecessor Plan Participant for the limited purposes set forth in the Plan.
2.25 “Pension Benefit” means the benefit payable to an individual under the Pension Plan or the UGS Pension Plan, as the context requires.
2.26 “Pension Plan” means the qualified pension plan maintained by ATH Holding Company, LLC or its predecessors under which a
Participant is actively accruing a benefit, which may include the Elevance Health Cash Balance Pension Plan B, as amended from time to time or
renamed, and/or such other qualified pension plan maintained by ATH Holding Company, LLC.
2.27 “Plan” means this Elevance Health Comprehensive Non-Qualified Deferred Compensation Plan, as amended from time to time.
2.28 “Plan Year” means the calendar year.
2.29 “Predecessor Plan” means any of the WellPoint Plan, the Anthem SERP, the Anthem Plan, the various Anthem LTIPs, the Trigon Plan,
or the Trigon SERP, each of which cover grandfathered benefits not subject to Code Section 409A.
2.30 “Predecessor Plan Account” means a hypothetical or bookkeeping account reflecting a grandfathered benefit under a Predecessor Plan,
the amount of which was transferred to the Plan on December 31, 2005. Such account is credited with additional earnings pursuant to Article VI.
2.31 “Predecessor Plan Participant” means an individual who was eligible to participate in one or more of the Predecessor Plans and who,
as of December 31, 2005 (the date Predecessor Plan Accounts were transferred to the Plan), has a Predecessor Plan Account.
2.32 “Regulations” mean Treasury Regulations issued under the Code.
2.33 “Savings Plan” means the Elevance Health 401(k) Plan, as amended from time to time, or renamed.
5 Elevance Health NQDCP 2023

-- 158 of 533 --

Exhibit 10.3
2.34 “Separation from Service” means termination of the Participant’s employment relationship (within the meaning of Code Section 409A
and Regulations issued thereunder) with the Company and its affiliates and any other service relationship defined in such applicable Regulations,
other than by reason of death. For purposes of the foregoing, whether an entity is affiliated with the Company shall be determined pursuant to the
controlled group rules of Code Section 414, as modified by Code Section 409A. However, the Participant’s employment relationship with the
employer shall be treated as continuing intact while the individual is on a military leave, sick leave, or other bona fide leave of absence if the period
of such leave does not exceed six months (or longer, if required by statute or contract). If the period of the leave exceeds six months and the
Participant’s right to reemployment is not provided either by statute or contract, the employment relationship is deemed to terminate on the first
date immediately following such six-month period for purposes of Code Section 409A only.
2.35 “Trigon Plan” means the Trigon Insurance Company 401(k) Restoration Plan.
2.36 “Trigon SERP” means the Supplemental Retirement Plan for Certain Employees of Trigon Insurance Company.
2.37 “UGS Pension Plan” means the UGS Pension Plan, as amended from time to time, and any predecessor qualified pension plan
maintained by National Government Services, Inc.
2.38 “WellPoint Plan” means the WellPoint Health Networks Inc. Comprehensive Executive Non-Qualified Retirement Plan.
2.39 “WellPoint SERP Participant” means an individual who is eligible on or after January 1, 2006, to earn a benefit under Section 4.01 of
the 2005 WellPoint Plan.
2.40 “2005 Anthem SERP” means the 2005 Anthem Supplemental Executive Retirement Plan.
2.41 “2005 WellPoint Plan” means the WellPoint, Inc. 2005 Comprehensive Executive Non-Qualified Retirement Plan, as in effect on
December 31, 2005.
2.42 “2005 Anthem Plan” means the 2005 Anthem Deferred Compensation Plan.
2.43 “2005 Trigon Plan” means the 2005 Trigon Insurance Company 401(k) Restoration Plan.
2.44 “2005 Trigon SERP” means the 2005 Supplemental Retirement Plan for Certain Employees of Trigon Insurance Company.
ARTICLE III
ELIGIBILITY AND PARTICIPATION
3.01 Eligibility. An employee of the Company or an Affiliate shall be an Eligible Employee for a Plan Year only if he or she is invited by
the Administrator to participate in
6
Elevance Health NQDCP 2023

-- 159 of 533 --

Exhibit 10.3
the Plan for such Plan Year, and only if his or her Compensation equaled or exceeded the Code Section 401(a)(17) compensation limit in effect at
the time he or she initially became eligible to participate. The Administrator may determine an individual is an Eligible Employee for the
immediately following Plan Year pursuant to any rules and requirements adopted by the Administrator for such purpose. Such rules and
requirements do not need to be consistent from Plan Year to Plan Year or among individuals. An individual who is determined to be an Eligible
Employee shall be permitted to make a Compensation Deferral and Bonus Deferral election effective for the Plan Year that begins immediately
following the Administrator’s determination of the individual as an Eligible Employee in accordance with the rules set forth in Article IV. Except as
otherwise provided in this Section, an individual who is determined to be an Eligible Employee shall not be permitted to make a Compensation
Deferral with respect to Compensation earned, or a Bonus Deferral with respect to the Bonus to be paid, in the Plan Year in which he or she is first
determined to be an Eligible Employee. Such an individual may make a Bonus Deferral for the Bonus earned in such Plan Year pursuant to the rules
set forth in Article IV provided the individual becomes an Eligible Employee before or during the enrollment period established for such Plan Year.
In addition to and notwithstanding the foregoing or any provision to the contrary in Sections 4.01 and 4.02, an Eligible Employee who (a) is
hired on or after January 2, 2019; (b) has never been a Participant in the Plan; and (c) is not eligible for and does not participate in any other plan
that would be aggregated with this Plan under Code Section 409A and the regulations promulgated thereunder may make a Compensation Deferral
election by filing an Election Form with the Administrator within thirty (30) days after such individual initially becomes an Eligible Employee, but
such election will apply only to Compensation for services to be performed subsequent to the election. Any such election shall be irrevocable on the
thirtieth (30th) day after such individual initially becomes an Eligible Employee.
Notwithstanding any Plan provision to the contrary, the Committee or the Administrator may, in their sole discretion, place further
requirements and/or limitations on an Eligible Employee’s participation in any portion of the Plan.
3.02 Participation. To begin participation in the Plan, an Eligible Employee shall properly complete and timely submit an Election Form to
the Administrator in accordance with the Administrator’s rules. An Eligible Employee shall become a Participant on the first day on which a
deferral of an elected amount or contribution is first credited to his or her Account. The Administrator may establish from time to time such other
enrollment requirements as it determines in its sole discretion are necessary.
3.03 Enrollment Requirements. Election Forms shall be completed and filed with the Administrator by the time periods set forth in Article
IV for the particular type of compensation to be deferred or during such other enrollment period as the Administrator determines in accordance with
such Article. Subject to Section 8.05, a Participant may change or revoke a deferral or distribution election any time before such election becomes
irrevocable, which shall occur as of the applicable deadline specified in Article IV unless the Administrator establishes an earlier deadline. Unless
the Administrator determines otherwise, a new Election Form shall be required for each Plan Year in which an Eligible
7 Elevance Health NQDCP 2023

-- 160 of 533 --

Exhibit 10.3
Employee wants to defer his or her Compensation or Bonus. A Participant’s Election Form shall specify the form of payment, from among the
forms of payment specified in Article VIII. Unless otherwise specified herein or determined by the Administrator, the election made by the
Participant for each Plan Year shall apply to all amounts credited to the Participant’s Plan Year subaccount for such Plan Year.
3.04 Cessation of Participation.
(a) Loss of Eligibility. An individual who qualifies as an Eligible Employee for a particular Plan Year will continue to be an
Eligible Employee until such time as the Administrator determines otherwise, including that the Eligible Employee no longer satisfies the Plan’s
eligibility requirements or is not a member of a select group of management or highly compensated employees. Any determination of ineligibility
shall be effective for an immediately following Plan Year. Any individual who ceases to be an Eligible Employee shall continue to be a Participant
with respect to amounts credited to his or her Account until such amounts are completely distributed to him or her in accordance with the Plan.
(b) Committee Discretion. Notwithstanding any Plan provision to the contrary, the Committee shall have the sole discretionary authority to
exclude a Participant from making further deferrals under the Plan with such exclusion becoming effective as of the first day of the next succeeding
Plan Year. Such Participant shall remain a Participant in the Plan until his Account balance is paid in full.
(c) 	Hardship Withdrawals. Elective or deemed deferrals made by a Participant who receives a hardship withdrawal shall be canceled
pursuant to Section 8.07. The Participant shall remain a Participant in the Plan until his Account balance is paid in full.
(d) Separation from Service or Death. Notwithstanding anything in the Plan to the contrary, upon a Participant’s Separation from Service
or death, if earlier, any outstanding distribution election shall be given effect to the extent any amounts covered by such election are paid after such
event.
ARTICLE IV
DEFERRALS AND CONTRIBUTIONS
4.01 Compensation.
(a) 	Elections. Subject to Article III (including the last paragraph of Section 3.01), an Eligible Employee may make a Compensation
Deferral by filing an Election Form with the Administrator before the beginning of the Plan Year in which the Compensation is earned. All deferrals
shall be made on a pre-tax basis. The Administrator may prescribe such rules and requirements regarding Compensation Deferral elections as it
deems appropriate.
(b) Amount. For each Plan Year, an Eligible Employee may elect to make a Compensation Deferral for each payroll period in a percentage
(not to exceed 80%) of his or her Compensation. Deferrals to the Plan shall begin only after the Eligible Employee has made the maximum elective
deferral contributions permitted under the Savings Plan for the
8
Elevance Health NQDCP 2023

-- 161 of 533 --

Exhibit 10.3
Plan Year under Code Section 402(g) (the “402(g) limit”). Effective for Compensation earned on or after January 1, 2023, the 402(g) limit for a Plan
Year includes the applicable limit under Code Section 402(g)(1)(C) if the Eligible Employee is eligible to make catch-up contributions (as defined
therein) during such Plan Year.
(c) 	No Changes. Subject to Section 3.03 and the second to last paragraph of Section 3.01, a Compensation Deferral election shall be
irrevocable as of the first day of the Plan Year to which the Election Form relates, or the deadline established by the Administrator, if earlier.
(d) 	Crediting. Compensation Deferrals made by a Participant will be credited to his or her applicable Plan Year subaccount as soon as
practical after the date that the Compensation amount to which those Compensation Deferrals relate would have otherwise been paid.
4.02 Bonus.
(a) Elections. The Administrator may prescribe such rules and requirements regarding Bonus Deferral elections.
(i) 	Generally. Subject to Article III (including the last paragraph of Section 3.01), an Eligible Employee may make a Bonus
Deferral by filing an Election Form with the Administrator before the beginning of the Plan Year in which the Bonus is
earned. All deferrals shall be made on a pre-tax basis.
(ii) 	Performance-Based Compensation. Notwithstanding anything in the Plan to the contrary, to the extent the Committee
determines that a Bonus constitutes “performance-based compensation” (within the meaning of Code Section 409A and
Regulations issued thereunder), the Committee may permit an Eligible Employee to file an Election Form with the
Administrator on or before a date that occurs no later than six months before the end of the performance period provided
that (A) the Eligible Employee performs services continuously from the later of the beginning of the performance period or
the date the criteria are established through the date the Election Form is submitted and (B) the compensation is not readily
ascertainable (within the meaning of Code Section 409A and Regulations issued thereunder) as of the date the Election
Form is filed. If a Bonus Deferral election is made pursuant to this paragraph after the beginning of the Plan Year in which
the Bonus is earned, such election shall be void if the Bonus becomes payable as a result of the Eligible Employee’s death
before the satisfaction of the performance criteria.
(b) 	Amount. For each Plan Year, an Eligible Employee may elect to make a Bonus Deferral in a percentage (not to exceed 80%) with
respect to his or her Bonus. However, effective for Bonus amounts earned during or after the 2022 Plan Year (i.e.,
9
Elevance Health NQDCP 2023

-- 162 of 533 --

Exhibit 10.3
payable in during or after the 2023 Plan Year), deferral to the Plan shall occur only if, at the time the Bonus is payable, the Eligible Employee has
made the maximum elective deferral contributions permitted under the Savings Plan for the Plan Year under the 402(g) limit (as defined above),
including the applicable limit under Code Section 402(g)(1)(C) if the Eligible Employee is eligible to make catch-up contributions (as defined
therein) during such Plan Year.
(c) 	No Changes. Subject to Section 3.03 and the second to last paragraph of Section 3.01, such Bonus Deferral election shall be
irrevocable as of the first day of the Plan Year to which the Election Form relates or the deadline established by the Administrator, if earlier.
(d) Crediting. Bonus Deferrals made by the Participant will be credited to his or her applicable Plan Year subaccount as soon as practical
after the date that the Bonus amount to which those Bonus Deferrals relate would have otherwise been paid.
4.03 Matching Contributions.
(a) Eligibility. Participants shall be entitled to a Matching Contribution under the Plan only to the extent he or she has satisfied the
eligibility requirements for an employer matching contribution under the Savings Plan.
(b) Amount. The amount of the Matching Contribution to which a Participant is entitled will be a percentage of Compensation that he or
she elects to defer under the Plan applied to the matching contribution formula then in effect under the Savings Plan less the amount of
matching contribution made, if any, under the Savings Plan.
(c) Crediting. The Matching Contributions to which the Participant is entitled will be credited to his or her applicable Plan Year
subaccount at such time and in such manner as determined by the Administrator and as applied uniformly to all Participants.
4.04 Non-Elective Contributions.
(a) Eligibility. For each Plan Year, the Company or an Affiliate, in its sole discretion, may, but is not required to, credit any amount it
desires as a Company Contribution and/or Make-Up Contribution to the Plan Year subaccount of one or more Participants, on such terms as
it determines, which need not be the same for each Participant.
(b) Company Contribution.
(i) Form of Payment. A Participant who receives a Company Contribution may make a separate election as to the form of payment
for such Amount. Any Election Form pursuant to which a Participant selects a form of payment must be filed with the Administrator
either:
(A) During a period of at least 30 days, or as otherwise specified
10
Elevance Health NQDCP 2023

-- 163 of 533 --

Exhibit 10.3
by the Administrator in its discretion, that occurs before the beginning of the Plan Year in which the Company
Contribution is earned or begins to be earned, as the case may be, or
(B) Within 30 days after the Company Contribution is awarded, provided the Company Contribution is subject to a
vesting schedule of at least 12 months from the date the completed Election Form is filed with the Administrator
(taking into account any automatic vesting provisions that may be provided upon certain terminations from
employment that may occur before such 12 month period).
If no such Election Form is filed, then the form of payment shall be a lump sum at Separation from Service.
(ii) No Changes. Subject to Section 3.03, a Participant’s Election Form shall be irrevocable as of the first day of the Plan
Year to which the Election Form relates.
(iii) 	Amount. The Company Contribution credited to a Participant shall be determined by the Committee or the
Administrator, in their discretion. Such contribution may be smaller or larger than the amount credited to any other
Participant, and the amount credited to any Participant for a Plan Year may be zero, even though one or more other
Participants receive a Company Contribution for that Plan Year. Crediting of a Company Contribution for one Plan
Year does not guarantee a Company Contribution for subsequent Plan Years.
(c) Make-Up Contribution.
(i) Form of Payment. If a Participant is credited with a Make-Up Contribution, such contribution shall be paid in a lump
sum at the earlier of the Participant’s Separation from Service or death.
(ii) 	Amount. The Make-Up Contribution credited to a Participant shall be determined by the Committee or the
Administrator, in their discretion.
(d) Crediting. Company and Make-Up Contributions will be credited to a Participant’s applicable Plan Year subaccount as soon as
practical after the date that the Company or Affiliate determines such contributions shall be made.
11
Elevance Health NQDCP 2023

-- 164 of 533 --

Exhibit 10.3
ARTICLE V
SUPPLEMENTAL PENSION PLAN CONTRIBUTIONS
5.01 Eligibility for Supplemental Pension Contribution. A Participant whose benefit under the Pension Plan or UGS Pension Plan, as the
case may be, is limited as a result of Code Section 401(a)(17) or Code Section 415, shall be credited with a Supplemental Pension Contribution as
described in this Article. Supplemental Pension Contributions made to this Plan ceased as of January 1, 2019, and no Supplemental Pension
Contributions shall be made to this Plan for Plan Years on and after January 1, 2019.
5.02 In General. Except as otherwise provided in this Article, the Supplemental Pension Contribution shall be equal to the difference
between the amount which was actually credited to his account under the Pension Plan or the UGS Pension Plan, as the case may be, and the amount
which would have been credited to his account had the amount not been limited as a result of Code Section 401(a)(17) or Code Section 415. The
Supplemental Pension Contribution to which the Participant is entitled will be credited to his applicable Plan Year subaccount as of the date that the
Pension Benefit to which such Supplemental Pension Contribution relates would otherwise have been credited under the Pension Plan.
5.03 Former DeCare Dental Pension Plan Participants. An individual who was a named participant in the DeCare Dental Deferred
Compensation Plan and/or the DeCare Dental Restoration Plan as of such plans’ termination on or about April 9, 2009, became a Participant under
this Article as of April 9, 2009. Such Participant shall be eligible for a Supplemental Pension Contribution if he previously participated in the
DeCare Dental Pension Plan, met the Rule of 65 (as defined under the Pension Plan) as of December 31, 2009, and became a Participant in the
Pension Plan on January 1, 2010. In such circumstance, the Supplemental Pension Contribution will be equal to the “Supplemental Part A Benefit,”
the “Supplemental A* Benefit,” if any, plus the “Supplemental Part B Benefit,” if any, each as further described below.
(a) The Supplemental Part A Benefit will be equal to:
(i) 	the Part A Benefit (as determined under and set forth in the Pension Plan) that would have been payable to the
Participant without regard to Code Section 401(a)(17) or Code Section 415, as of December 31, 2014 (or such
earlier Separation from Service) less the Part A Benefit actually payable to the Participant under the Pension Plan
and determined in an annuity, less
(ii) 	an annuity equivalent of any lump sum amount received by the Participant from (i) the DeCare Dental Deferred
Compensation Plan and the DeCare Dental Restoration Plan upon the respective plans’ termination, and (ii) if
applicable, the non-qualified plans sponsored by BCBSM, Inc. (d/b/a Blue Cross Blue Shield of Minnesota) that
provided benefits in excess of the benefits provided under such entity’s qualified plans.
The Part A Benefit formula uses a Participant’s actual “Salary” (as defined in Exhibit S of the Pension Plan), to
determine the Part A Benefit.
12 Elevance Health NQDCP 2023

-- 165 of 533 --

Exhibit 10.3
In the event a Participant has an individual agreement that provides for certain assumptions to apply in the determination of
Salary, the terms of the agreement shall be given effect.
The Supplemental Part A Benefit will be credited to a Plan Year subaccount as soon as administratively feasible
after December 31, 2014, or Separation from Service, as the case may be.
(b) If the Participant continues to be eligible to participate in the Pension Plan after December 31, 2014, the Supplemental Part A*
Benefit will be equal to the Benefit Transition Adjustment (as determined and defined under the Pension Plan) without regard to Code
Section 401(a)(17) less the actual Benefit Transition Adjustment payable to the Participant under the Pension Plan. Such Benefit Transition
Adjustment will be determined each Plan Year. The Supplemental Part A* Benefit to which the Participant is entitled will be credited to his
applicable Plan Year subaccount as of the date that the Benefit Transition Adjustment to which such Supplemental Part A* Benefit relates
would otherwise have been credited under the Pension Plan.
(c) If the Participant continues to be eligible to participate in the Pension Plan after December 31, 2014, the Supplemental Part B
Benefit will be determined under, and credited pursuant to, Section 5.02 of this Article.
5.04 QSERP. Notwithstanding anything in this Article to the contrary and subject to Section 12.06, the Company reserves the discretion to
credit some or all of a Participant’s Supplemental Pension Contributions including earnings on such amounts, on a prospective or retroactive basis,
to the Pension Plan or the UGS Pension Plan, as the case may be. Any such credit shall only be made if it is consistent with applicable rules
governing the Pension Plan and/or the UGS Pension Plan and Code Section 409A and Regulations issued thereunder.
ARTICLE VI
EARNINGS
6.01 Investment Funds. Amounts credited to a Participant’s Account under the Plan shall be credited with earnings, at periodic intervals
determined by the Administrator, at a rate equal to the actual rate of return for such period on the investment fund or funds, index or indices, or
vehicle or vehicles selected by that Participant. The investment options shall be comparable to those offered under the Savings Plan, from time to
time, except for the option to invest in Company common stock or the brokerage option (or other self-managed account option that may be offered
under the Savings Plan). The Committee may offer other investment options in its discretion. The rate of return on such investment vehicles shall be
tracked solely for the purpose of determining the phantom investment gain, earnings and losses to be credited to the Participant’s Account during the
deferral period. Neither the Company nor any of its affiliates shall be obligated to make any actual investment.
6.02 Conversion of Investments from Predecessor Plans and Merged Plans. Before January 1, 2006, amounts representing Predecessor Plan
Account balances and account balances from Merged Plans were credited with earnings based on investment options available under the Predecessor
Plan or Merged Plan to which they related. Effective as of January 1, 2006, those
13 Elevance Health NQDCP 2023

-- 166 of 533 --

Exhibit 10.3
Predecessor Plan Accounts (or accounts from Merged Plans) shall be credited with earnings in accordance with Section 6.01. Before January 1,
2006, the Committee shall prescribe rules (that may vary among classes of Participants) that provide each Predecessor Plan Participant (and
Participant with a Merged Plan account balance) an opportunity to select the investment fund or funds or index or indices to be used as the basis for
crediting his or her Predecessor Plan Account (or Merged Plan account) with earnings as of January 1, 2006. To the extent the Committee has not
received investment direction from a Participant before December 15, 2005 with respect to his or her Predecessor Plan Account or Merged Plan
account, such Predecessor Plan Account or Merged Plan account shall be credited with earnings based upon a default investment option under the
Savings Plan designated as such by the Committee or in accordance with such other rules as may be adopted by the Committee and applied on a
consistent, uniform basis.
ARTICLE VII
VESTING
7.01 	Elective Deferrals under the Plan. As of October 1, 2019, each Participant is 100% vested in that portion of his or her Account
attributable to any Salary Deferrals (made before January 1, 2014), Compensation Deferrals and Bonus Deferrals, made on or after January 1, 2006.
With respect to Compensation Deferrals and Bonus Deferrals made on and after October 1, 2019, each Participant will be 100% vested in that
portion of his or her Account attributable to these Deferrals.
7.02 Supplemental Pension Plan Contributions. All Supplemental Pension Plan Contributions as determined in accordance with Article V of
the Plan shall be 100% vested.
7.03 Predecessor or Merged Plans. As of October 1, 2019, any Participant whose Account is attributable to deferrals made and accruals
earned before January 1, 2006, under a Predecessor Plan or Merged Plan are vested in such deferrals and accruals.
7.04 Company and/or Make-Up Contributions. Vesting of any Company Contributions and Make-Up Contributions shall be determined by
the Company or Affiliate, in its sole discretion, and need not be the same for all Participants.
7.05 Matching Contributions. Notwithstanding anything in the Plan to the contrary, effective for periods after January 1, 2019, any
Participant whose date of hire is on or after January 2, 2019 shall not be vested in any Matching Contribution until such Participant has completed a
two year Period of Service (as defined in the Savings Plan), at which time such Participant shall be 100% vested in Matching Contributions.
ARTICLE VIII
DISTRIBUTIONS
8.01 Annual Election. Participants must indicate on an Election Form which of the distribution options described below will govern payment
of the Plan Year subaccount to which deferred amounts are credited before the beginning of the Plan Year in which the compensation is earned, or
such earlier or later time as may be specified by the Administrator pursuant to Article III or Article IV. Unless otherwise specified in the Plan or
permitted by the Administrator, such distribution election applies to all amounts credited to the Plan Year subaccount, including, but not limited to,
Matching Contributions and Supplemental Pension Contributions.
14
Elevance Health NQDCP 2023

-- 167 of 533 --

Exhibit 10.3
8.02 Time for Distribution. Except as otherwise provided in Section 8.07, distribution of a Participant’s Account shall be made on the
earliest to occur of:
(a) The date elected by a Participant under Section 8.03 with respect to an In-Service Payout;
(b) The date set forth in Section 8.04 with respect to the Participant’s Separation from Service; or
(c) The date set forth in Section 8.06 with respect to the Participant’s death.
8.03 	In-Service Payout. A Participant may irrevocably select, on his or her Election Form, a specified date to receive a lump sum In-
Service Payout of all vested amounts credited to a Plan Year subaccount. Payment shall be made as soon as administratively feasible following the
specified date and before the later of (i) December 31 of the calendar year containing the specified date, or (ii) the 15th day of the third month
following the specified date. If any amounts are unvested at the time of the elected In-Service Payout date, but later become vested, such remaining
amounts shall be paid at the earlier of the Participant’s Separation from Service or Death. Notwithstanding anything in this Section to the contrary, in
the event of the Participant’s Separation from Service or death before the specified payment date, payment shall instead be made in a lump sum upon
such Separation from Service or death, as the case may be.
8.04 Separation from Service. Upon a Participant’s Separation from Service for any reason other than death, a Participant’s vested Plan Year
subaccount shall be paid or begin to be paid as soon as administratively feasible following Separation from Service and before the later of (i)
December 31 of the calendar year in which the Participant’s Separation from Service occurs, or the 15 day of the third month following the
Participant’s Separation from Service. Notwithstanding the foregoing, distributions made to a Key Employee upon such separation shall be paid or
begin to be paid no earlier than the first day following the six month anniversary of the Participant’s Separation from Service unless the Participant
dies before or during such six-month period, in which case, such six-month delay shall not apply and payment shall be made pursuant to Section
8.06. Subsequent installment payments shall be made thereafter on or about the anniversary of the first installment payment.
Payment shall be made to the Participant in such form as determined below in subsection (a), (b), or (c).
(a) Lump Sum. A Participant’s Plan Year subaccount balance shall be paid in a lump sum if:
(i) timely elected by the Participant pursuant to the Plan; or
(ii) no valid payment election is in effect when distribution is to be made.
(b) Annual Installments.
(i) Effective for amounts credited to subaccounts for Plan Years beginning on and after January 1, 2020, a Participant may
elect to
th
15
Elevance Health NQDCP 2023

-- 168 of 533 --

Exhibit 10.3
receive payment of his or her Plan Year subaccount balances in annual installments with a minimum installment
period of two years and a maximum installment period of 15 years, provided that each installment shall be
calculated by dividing the existing account balance by the number of years remaining in the elected installment
period.
(ii) Effective for amounts credited to subaccounts for Plan Years beginning before January 1, 2020, a Participant may elect
to receive payment of his or her Plan Year subaccount balance in either:
(A) five annual installments; or
(B) ten annual installments.
(c) Exceptions. Notwithstanding the foregoing provisions, the following shall apply:
(i) If a Participant’s Account balance constituting contributions (other than Company and Make-Up Contributions) for all
Plan Years at Separation from Service or death, whichever is earlier, is equal to or less than the limit then in effect
under Code Section 402(g)(1)(B), such balance shall be paid in a lump sum in lieu of any election to receive
installments.
(ii) A Participant who is entitled to receive a Supplemental Part A Benefit, as provided under Article V, shall receive such
benefit in a lump sum. Payment of the Supplemental Part A* Benefit, if any, and Supplemental Part B Benefit, if
any, shall be made as otherwise specified in the Plan.
8.05 Subsequent Changes in Elections.
(a) Participants who previously elected to receive an In-Service Payout pursuant to Section 8.03 shall be permitted to change his
or her election to delay the time for payment until the fifth anniversary of the date the lump sum distribution would otherwise have been
made. However, no such change of election under this Section shall have any force or effect or become effective until the expiration of the
12-month period measured from the filing date of such election. In addition, each such change of election with respect to an original election
to receive an In-Service Payout shall be valid only if such election is made at least 12 months before the date of the scheduled distribution.
In no event, however, may any change to the time for payment in effect for the Plan Year subaccount result in any acceleration of the
distribution of that subaccount. Notwithstanding anything in this Section to the contrary, in the event of the Participant’s Separation from
Service or death after a subsequent election is made but before the end of the five-year delay described above, payment shall instead be
made in a lump sum upon such Separation from Service or death, as the case may be.
16
Elevance Health NQDCP 2023

-- 169 of 533 --

Exhibit 10.3
(b) Notwithstanding any provision in the Plan to the contrary, on or before December 31, 2008, Participants may make changes to
distribution elections previously filed with respect to amounts deferred under the Plan that relate to Plan Years 2005 through 2008 consistent
with transition relief provided by the Department of the Treasury in Notice 2006-79, Notice 2007-86 and proposed regulations promulgated
under Code Section 409A.
8.06 Death. If a Participant dies with a vested balance credited to one or more of his or her Plan Year subaccounts, whether or not the
Participant was receiving payouts from those subaccounts at the time of his or her death, then the Participant’s Beneficiary will receive the vested
balance of each of those Plan Year subaccounts in a lump sum. If a Participant has any unvested Matching Contributions or Supplemental Pension
Contributions credited to the Participant’s Account as of death, such amounts will become fully vested, nonforfeitable and distributed pursuant to
this Section.
8.07 Hardship Withdrawal. This Section shall only apply to amounts credited to a Participant’s Account that are subject to Code Section
409A. Any hardship withdrawal right with respect to grandfathered amounts (within the meaning of Code Section 409A) shall be subject to rules, if
any, of the Predecessor Plans. If a Participant (A) incurs a severe financial hardship as a result of (i) an illness or accident involving the Participant,
his or her spouse, Beneficiary or any dependent (as determined pursuant to Code Section 152(a)), (ii) a casualty loss involving the Participant’s
property or (iii) other similar extraordinary and unforeseeable event beyond the Participant’s control and (B) does not have any other resources
available, whether through reimbursement or compensation (by insurance or otherwise) or liquidation of existing assets (to the extent such
liquidation would not itself result in financial hardship), to satisfy such financial emergency, then the Participant may apply to the Administrator for
an immediate distribution from the vested portion of his or her Account (but not the Predecessor Plan Account) in an amount necessary to satisfy
such financial hardship and the tax liability attributable to such distribution. The Administrator shall have complete discretion to accept or reject the
request and shall in no event authorize a distribution in an amount in excess of that reasonably required to meet such financial hardship and the tax
liability attributable to that distribution.
Any hardship withdrawal shall be made only to the extent permitted in accordance with Regulation Section 1.409A-3(i)(3). As a condition
of the Administrator’s acceptance of a request for a hardship withdrawal under this Section, the Participant’s election to make Compensation
Deferrals and/or Bonus Deferrals shall be terminated for the remainder of the Plan Year in which the hardship withdrawal is taken. In addition, such
Participant shall be suspended from making Compensation Deferrals and Bonus Deferrals for the Plan Year immediately after the Plan Year in which
the hardship withdrawal is taken. Such Participant, if then an Eligible Employee, may make a deferral election that relates to the second Plan Year
following the Plan Year in which the hardship withdrawal was made in accordance with Article III and Article IV.
8.08 Valuation. The amount to be distributed from any Plan Year subaccount pursuant to this Article VIII shall be determined on the basis of
the vested balance credited to that subaccount as of the most recent practicable date (as determined by the Administrator or its delegate) preceding
the date of the actual distribution.
8.09 Tax Withholding. Income taxes and other taxes payable with respect to an Account shall be deducted from amounts payable under the
Plan. All federal, state, or local taxes that the
17
Elevance Health NQDCP 2023

-- 170 of 533 --

Exhibit 10.3
Administrator determines are required to be withheld from any payments made pursuant to this Article VIII shall be withheld.
8.10 Payment of Small Accounts. The Administrator may, in its sole discretion which shall be evidenced in writing no later than the date of
payment, elect to pay the value of the Participant’s Account in a single lump sum if the balance of such Account is not greater than the applicable
dollar amount under Code Section 402(g)(1)(B), provided the payment represents the complete liquidation of the Participant’s interest in the Plan
and all other account balance plans as determined pursuant to Regulation Section 1.409A-1(c)(2).
8.11 Right of Offset. The Company or an Affiliate shall have the right to offset any amounts payable to a Participant under the Plan to
reimburse the Company or an Affiliate for liabilities or obligations of the Participant to the Company or Affiliate if the following conditions are met:
(a) the liabilities or obligations of the Participant to the Company or Affiliate were incurred in the ordinary course of the service
relationship between the Participant and the Company or Affiliate;
(b) the entire amount to be offset does not exceed $5,000 in any taxable year of the Participant; and
(c) the offset is made at the same time and in the same amount as the liabilities or obligations otherwise would have been due and
collected from the Participant.
8.12 Bona Fide Dispute. The Committee or the Administrator shall have the discretion to accelerate the time or schedule of payment under
the Plan pursuant to Regulation Section 1.409A-3(j)(4)(xiv) where such payment occurs as part of an arm’s length settlement of a bona fide dispute
between the Company or an Affiliate and a Participant as to the Participant’s right to the deferred amount.
8.13 Income Inclusion Under Code Section 409A. The Committee or the Administrator shall have the discretion to accelerate the time or
schedule of payment under the Plan if the Plan fails to meet the requirements of Code Section 409A and Regulations issued thereunder, provided that
any such payment does not exceed the amount required to be included in income as a result of such failure.
8.14 Effect of Rehire. In the event a Participant experiences a Separation from Service, begins receiving payment of his or her Account and
is subsequently rehired by the Company or an Affiliate, distributions shall continue as regularly scheduled.
ARTICLE IX
EFFECT ON PREDECESSOR AND MERGED PLANS
9.01 Coordination With Predecessor Plans. Solely for ease of administration, the Predecessor Plans may be attached as exhibits to the Plan
and are incorporated by reference herein. Except as otherwise specifically provided in the Plan, eligibility for and entitlement to benefits under the
Predecessor Plans are governed solely by the terms of those Predecessor Plans. Effective January 1, 2005 (or such earlier date as may be provided in
a Predecessor Plan), Participants ceased
18 Elevance Health NQDCP 2023

-- 171 of 533 --

Exhibit 10.3
to accrue further benefits under the Predecessor Plans; however, Predecessor Plan benefits continue to accrue earnings per the Predecessor Plan
terms before January 1, 2006, and pursuant to the Plan effective as of January 1, 2006.
9.02 Predecessor Plan Accounts. Although benefits accrued under Predecessor Plans are grandfathered for purposes of Code Section 409A to
the extent such amounts were earned and vested as of December 31, 2004, for administrative purposes, the December 31, 2005 Predecessor Plan
Account balance of any Predecessor Plan Participant became accounted for under the Plan as of January 1, 2006 and shall be subject to Article VI. In
all other respects, each Predecessor Plan Account shall remain subject exclusively to the terms of the Predecessor Plan to which it relates, including
without limitation the existing distribution election (commencement date and form of distribution) applicable to the Predecessor Participant’s
Predecessor Plan Account. Any change in that distribution election must be made in compliance with the applicable provisions of the applicable
Predecessor Plan.
9.03 Merged Plans. The 2005 Anthem Plan, the 2005 Anthem SERP, the 2005 Trigon Plan and the 2005 Trigon SERP were merged into the
Plan effective as of December 31, 2005. All benefits accrued under such merged plans are subject to Code Section 409A. In conjunction with the
merger, on and after January 1, 2006, benefits ceased to accrue under the 2005 Anthem Plan, the 2005 Anthem SERP, the 2005 Trigon Plan, and the
2005 Trigon SERP except as otherwise provided in the Plan. The rights and obligations of participants in the Merged Plans before their effective
dates of merger shall be governed solely by the terms of the Merged Plans; provided, however, that to the extent minimally necessary to comply with
the requirements of Section 409A of the Code, the requirements and restrictions of Sections 5.01(a)-(c) and 8.01(a)-(d) of the 2005 WellPoint Plan
shall apply, effective as of January 1, 2005, to the portion of the Participant’s Account attributable to the 2005 Anthem Plan. Distributions of
amounts attributable to Merged Plan benefits are made pursuant to a Participant’s election in effect under the applicable Merged Plan. If no such
election is on file, amounts shall be distributed in a single lump sum payment.
ARTICLE X
CLAIMS PROCEDURES
10.01 Presentation of Claim. No application is required for the commencement of benefits under the Plan. However, if a Participant or
Beneficiary (“Claimant”) believes that he or she is entitled to a greater benefit under the Plan, the Claimant may submit a signed, written application
to the Committee for such a greater benefit. If such a claim relates to the contents of a notice received by the Claimant, the claim must be made
within 90 days after such notice was received by the Claimant. All other claims shall be made within 180 days of the date on which the event that
caused the claim to arise occurred. The claim shall state with particularity the determination desired by the Claimant. A claim shall be considered to
have been made when a written communication made by the Claimant or the Claimant’s representative is received by the Committee or its
authorized delegate. References to the Committee in this Article includes references to the Administrator and, if applicable, the Administrator’s
delegate. The Administrator may further delegate, orally or in writing, authority to decide certain claims under this Article.
10.02 Decision on Initial Claim. The Committee shall consider a Claimant’s claim and provide written notice to the Claimant of any denial
within a reasonable time, but no later than 90 days after receipt of the claim. If an extension of time beyond the initial 90-day period for
19 Elevance Health NQDCP 2023

-- 172 of 533 --

Exhibit 10.3
processing is required, written notice of the extension shall be provided to the Claimant before the initial 90-day period expires indicating the special
circumstances requiring an extension of time and the date by which the Committee expects to render a final decision. In no event shall the period, as
extended, exceed 180 days. If the Committee denies, in whole or in part, the claim, the notice shall set forth in a manner calculated to be understood
by the Claimant:
(a) The specific reasons for the denial of the claim, or any part thereof;
(b) Specific references to pertinent Plan provisions upon which such denial was based;
(c) A description of any additional material or information necessary for the Claimant to perfect the claim, and an explanation of
why such material or information is necessary; and
(d) An explanation of the claim review procedure, which explanation shall also include a statement of the Claimant’s right to bring
a civil action under ERISA Section 502(a) following a denial of the claim upon review.
10.03 Right to Review. A Claimant is entitled to appeal any claim that has been denied in whole or in part. To do so, the Claimant must
submit a signed, written request for review with the Committee within 60 days after receiving a notice from the Committee that a claim has been
denied, in whole or in part. Absent receipt by the Committee of a written request for review within such 60-day period, the claim shall be deemed to
be conclusively denied. The Claimant (or the Claimant’s duly authorized representative) may:
(a) Review and/or receive copies of, upon request and free of charge, all documents, records, and other information relevant to the
Claimant’s claim; and/or
(b) Submit written comments, documents, records, or other information relating to her claim, which the Committee shall take into
account in considering the claim on review, without regard to whether such information was submitted or considered in the initial review of
the claim.
If a Claimant requests to review and/or receive copies of relevant information pursuant to subsection (a) above before filing a written request
for review, the 60-day period for submitting the written request for review will be tolled during the period beginning on the date the Claimant makes
such request and ending on the date the Claimant reviews or receives such relevant information.
10.04 Decision on Review. The Committee shall render its decision on review promptly, and not later than 60 days after it receives a written
request for review of the denial, unless other special circumstances require additional time. In such case, the Committee will notify the Claimant,
before the expiration of the initial 60-day period and in writing, of the need for additional time, the reason the additional time is necessary, and the
date (no later than 60 days after expiration of the initial 60-day period) by which the Committee expects to render its decision on review.
Notwithstanding the foregoing, if the Committee determines that an extension of the initial 60-day period is required due to the Claimant’s failure to
submit information necessary for the Committee to decide the claim, the time period by which the Committee must make its determination on
review shall be tolled from the
20
Elevance Health NQDCP 2023

-- 173 of 533 --

Exhibit 10.3
date on which the notification of the extension is sent to the Claimant until the date on which the Claimant responds to the request for additional
information. The decision on review shall be written in a manner calculated to be understood by the Claimant, and shall contain:
(a) Specific reasons for the decision;
(b) Specific references to the pertinent Plan provisions upon which the decision was based;
(c) A statement that the Claimant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all
documents, records, or other information relevant (within the meaning of Department of Labor Regulation Section 2560.5031(m)(8)) to the
Claimant’s claim;
(d) A statement of the Claimant’s right to bring a civil action under ERISA Section 502(a) following a wholly or partially denied
claim for benefits; and
(e) Such other matters as the Committee deems relevant.
10.05 Form of Notice and Decision. Any notice or decision by the Committee under this Article may be furnished electronically in
accordance with Department of Labor Regulation Section 2520.104b-(1)(c)(i), (iii) and (iv).
10.06 Legal Action. Any final decision by the Committee shall be binding on all parties. A Claimant’s compliance with the foregoing
provisions of this Article is a mandatory prerequisite to a Claimant’s right to commence any legal action with respect to any claim for benefits under
the Plan. Any such legal action must be initiated no later than 180 days after the Committee renders its final decision. If a final determination of the
Committee is challenged in court, such determination shall not be subject to de novo review and shall not be overturned unless proven to be arbitrary
and capricious based on the evidence considered by the Committee at the time of such determination.
ARTICLE XI
ADMINISTRATION
11.01 Plan Administration. The Committee has overall responsibility for the Plan, but the Administrator shall have responsibility for the day-
to-day administration of the Plan, as specified herein and as otherwise delegated by the Committee. The Administrator and members of the
Committee may be Participants under this Plan. Any individual serving on the Committee who is a Participant shall not vote or act on any matter
relating solely to himself or herself. The Administrator or any other individual charged with administrative authority may not act on any matter
involving such individual’s own participation in the Plan. Notwithstanding the foregoing, the Committee shall have the exclusive authority to resolve
any matter that relates solely to an executive officer’s participation in, or benefits under, the Plan.
11.02 Powers, Duties and Procedures. The Committee and the Administrator shall have full and complete discretionary authority to (i) make,
amend, interpret and enforce all appropriate rules and regulations for the administration of the Plan, including any rules relating to trading
restrictions as it determines necessary, and (ii) decide or resolve any and all questions including interpretations
21
Elevance Health NQDCP 2023

-- 174 of 533 --

Exhibit 10.3
of the Plan, as may arise in connection with the claims procedures set forth in Article X or otherwise with regard to the Plan. The Committee and the
Administrator shall have complete control and authority to determine the rights and benefits of all claims, demands and actions arising out of the
provisions of the Plan of any Participant or Beneficiary or other person having or claiming to have any interest under the Plan. When making a
determination or calculation, the Committee and the Administrator may rely on information furnished by a Participant or the Company, an Affiliate
or other related entity. Benefits under the Plan shall be paid only if the Committee or Administrator decides in its sole discretion that the Participant
or Beneficiary is entitled to them. The Committee and Administrator may delegate such powers and duties as they determine for the efficient
administration of the Plan.
11.03 Agents. In the administration of this Plan, the Committee or the Administrator may, from time to time, employ agents and delegate to
them such administrative duties as it sees fit (including acting through a duly appointed representative) and may from time to time consult with
counsel who may be counsel to the Company, an Affiliate or other related entity.
11.04 Binding Effect of Decisions. Notwithstanding any other provision of the Plan to the contrary, the Committee, the Administrator or
their delegates shall have complete discretion to interpret the Plan and to decide all matters under the Plan. Any such interpretation shall be final,
conclusive, and binding on all Participants, Beneficiaries and any person claiming under or through any Participant, in the absence of clear and
convincing evidence that the Committee or its delegate acted arbitrarily and capriciously.
11.05 Information. To enable the Committee and the Administrator to perform their functions, the Company, an Affiliate or other related
entity shall supply full and timely information to the Committee or the Administrator, as the case may be, on all matters relating to the compensation
of its Participants, the dates of the death or Separation from Service and such other pertinent information as the Committee or Administrator may
reasonably require.
11.06 Coordination with Other Benefits. The benefits provided to a Participant and the Beneficiary under the Plan are in addition to any
other benefits available to such Participant under any other plan or program for employees of the Company, an Affiliate or other related entity. The
Plan shall supplement and shall not supersede, modify, or amend any other such plan or program except as may otherwise be expressly provided.
ARTICLE XII
MISCELLANEOUS
12.01 Limitation of Rights. Participation in the Plan does not give any individual the right to be retained in the service of the Company, any
Affiliate or other related entity, or to interfere with the right of the Company, any Affiliate or other related entity to discipline or discharge the
individual at any time, with or without cause, or to modify the Salary, Compensation or Bonus of such individual at any time.
12.02 Additional Restrictions. If the Administrator determines that additional restrictions or limitations must be placed on the investment
vehicles utilized for measuring the return on the amounts credited to Participant Accounts, the right of Participants to make investment elections
with respect to their Accounts, their ability to make or change distribution elections, their ability to
22
Elevance Health NQDCP 2023

-- 175 of 533 --

Exhibit 10.3
defer distributions or to change the commencement date for the distribution of their benefits or the method of such distribution or their rights or
status as creditors under the Plan in order to avoid current income taxation of amounts deferred under the Plan, the Administrator may, in its sole
discretion, amend the Plan to impose such restrictions or limitations, cease deferrals under the Plan and/or defer distribution dates under the Plan.
12.03 Indemnification. The Company will indemnify and hold harmless the Directors, the members of the Committee, the Administrator,
any delegate of the Committee or the Administrator, and employees of the Company and its Affiliates, from and against any and all liabilities,
claims, costs and expenses, including attorneys’ fees, arising out of an alleged breach in the performance of their fiduciary duties under the Plan,
other than such liabilities, claims, costs and expenses as may result from the gross negligence or willful misconduct of such persons. The Company
shall have the right, but not the obligation, to conduct the defense of such persons in any proceeding to which this Section applies.
12.04 Assignment. To the fullest extent permitted by law, benefits under the Plan and rights thereto are not subject in any manner to
anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment, or garnishment by creditors of a Participant or a Beneficiary.
12.05 Inability to Locate Recipient. If a benefit under the Plan remains unpaid for two (2) years from the date it becomes payable, solely by
reason of the inability of the Administrator to locate the Participant or Beneficiary entitled to the payment, the benefit shall be treated as forfeited.
Any amount forfeited in this manner shall be restored without interest upon presentation of an authenticated written claim by the person entitled to
the benefit.
12.06 Amendment and Termination.
(a) The Committee may, at any time, amend or terminate the Plan. Any amendment must be made in writing; no oral amendment
will be effective. Except to the limited extent authorized pursuant to Section 12.02, no amendment may, without the consent of an affected
Participant (or, if the Participant is deceased, the Participant’s Beneficiary), adversely affect the Participant’s or the Beneficiary’s rights and
obligations under the Plan with respect to amounts already credited to a Participant’s Account, and all amounts deferred under the Plan
before the date of any such amendment or termination of the Plan shall continue to become due and payable in accordance with the
distribution provisions of Article VIII as in effect immediately before such amendment or termination.
(b) 	Notwithstanding subsection (a), if the Company exercises its discretion under Article V and determines an amendment is
necessary to the Plan, participant consent shall only be required if the amendment impacts Supplemental Contributions and earnings credited
through December 31, 2008.
(c) Upon termination of the Plan, the Committee reserves the discretion to accelerate distribution of the Accounts of Participants in
accordance with regulations promulgated by the Department of Treasury under Code Section 409A.
23 Elevance Health NQDCP 2023

-- 176 of 533 --

Exhibit 10.3
12.07 Applicable Law. To the extent not governed by Federal law, the laws of the State of Indiana shall govern the Plan. If any provision of
the Plan is held to be invalid or unenforceable, the remaining provisions of the Plan will continue to be fully effective.
12.08 No Funding. The obligation to pay the vested balance of each Participant’s Account shall at all times be an unfunded and unsecured
obligation of the Company or its Affiliates, as the case may be, and Participants and Beneficiaries shall have the status of general unsecured creditors
of the Company or applicable Affiliate. Except to the extent provided below in Section 12.09, Plan benefits will be paid from the general assets of
the Company, and nothing in the Plan will be construed to give any Participant or any other person rights to any specific assets of the Company or its
Affiliates. In all events, it is the intention of the Company and its Affiliates and all Participants that the Plan be treated as unfunded for tax purposes
and for purposes of Title I of ERISA.
12.09 Trust. The benefits under the Plan will be paid from the assets of a grantor trust (the “Trust”) established by the Company to assist it
and its Affiliates in meeting their obligations hereunder and, to the extent that such assets are not sufficient, by the Company or the applicable
Affiliate out of their general assets. The Trust shall conform to the terms of the Internal Revenue Service Model Trust in Internal Revenue Service
Procedure 92-64 (or any successor procedure).
* * *
IN WITNESS WHEREOF, the undersigned authorized delegate has executed this Amendment on this ____ day of December, 2023.
By: /s/ Michael J. Berry
Michael J. Berry
Vice President, Total Rewards
Elevance Health, Inc.
24
Elevance Health NQDCP 2023

-- 177 of 533 --

Exhibit 10.12
BLUE CROSS LICENSE AGREEMENT
(Includes revisions, if any, adopted by Member Plans through their November 16, 2023 meeting)
This agreement by and between Blue Cross and Blue Shield Association ("BCBSA") and The Blue Cross Plan,
known as_________________________(the "Plan").
Preamble
WHEREAS, the Plan and/or its predecessor(s) in interest (collectively the "Plan") had the right to use the BLUE
CROSS and BLUE CROSS Design service marks (collectively the "Licensed Marks") for health care plans in its service
area, which was essentially local in nature;
WHEREAS, the Plan was desirous of assuring nationwide protection of the Licensed Marks, maintaining uniform
quality controls among Plans (unless otherwise defined in this Agreement, Plans shall mean Member Plans as that term is
defined in BCBSA’s Bylaws) (“Member Plans”), facilitating the provision of cost effective health care services to the public and
otherwise benefiting the public;
WHEREAS, to better attain such ends, the Plan and the predecessor of BCBSA in 1972 simultaneously executed the
BCA License Agreement (s) and the Ownership Agreement; and
WHEREAS, BCBSA and the Plan desire to supercede said Agreement(s) and to revise certain provisions of the
Ownership Agreement to reflect their current practices and to assure the continued integrity of the Licensed Marks and of the
BLUE CROSS system;
NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
Amended as of June 15, 2023

-- 178 of 533 --

Agreement
1. 	BCBSA hereby grants to the Plan, upon the terms and conditions of this License Agreement (“Agreement” or
“Primary License Agreement”), the right to use BLUE CROSS in its trade and/or corporate name (the "Licensed
Name"), and the right to use the Licensed Marks, in the sale, marketing and administration of health care plans and
related services in the Service Area set forth and defined in paragraph 5 below. As used herein, health care plans
and related services shall include acting as a nonprofit health care plan, a for-profit health care plan, or mutual
health insurer operating on a not-for-profit or for- profit basis, under state law; financing access to health care
services; when working with a bank that holds the relevant license to use the Licensed Name and Marks, offering: (i)
tax- favored savings accounts for medical expenses and means for accessing such accounts, such as debit cards or
checks, that are provided solely to support access to such tax- favored savings accounts, all pursuant to such
license, or (ii) prepaid rewards cards that are provided for completion of a wellness program, all pursuant to such
license; providing health care management and administration; administering, but not underwriting, non- health
portions of Workers’ Compensation Insurance; delivering health care services, except hospital services (as defined
in the Guidelines to Membership Standards Applicable to Regular Members); and performing the Eligibility and
Enrollment functions of HR administration for all benefit plans offered by a group account to its members, including
benefit plans not provided by the Plan, provided that the Plan has contracted to provide Health Coverage under the
Licensed Marks to the account (as the terms “Health Coverage,” “Eligibility” and “Enrollment” are defined in Exhibit
4, Paragraph 2.t.).
2. 	The Plan may use the Licensed Marks and Name in connection with the offering of: i) health care plans and related
services in the Service Area through Controlled Affiliates, provided that each such Controlled Affiliate is separately
licensed to use the Licensed Marks and Name under the terms and conditions contained in the agreement attached
as Exhibit 1 hereto (the "Controlled Affiliate License Agreement"); and ii) insurance coverages offered by life insurers
under the applicable law in the Service Area, other than those which the Plan may offer in its own name, provided
through Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed to use the Licensed
Marks and Name under the terms and conditions contained in the agreement attached as Exhibit 1A hereto (the
"Controlled Affiliate License Agreement Applicable to Life Insurance Companies") or the Agreement attached as
Exhibit 1A1 hereto (the “Controlled Affiliate Trademark License Agreement for Life and Disability Insurance
Products”) and further provided that the offering of such services does not and will not dilute or tarnish the unique
value of the Licensed Marks and Name; and iii) administration and underwriting of
Workers’ Compensation Insurance Controlled Affiliates, provided that each such Controlled Affiliate is separately
licensed to use the Licensed Marks and Name under the terms and conditions contained in the Agreement attached
as Exhibit 1 hereto (the “Controlled Affiliate License”); and iv) regional Medicare Advantage PPO products in
cooperation with one or more other Plans through jointly-held Controlled Affiliates, provided that each such
Controlled Affiliate is separately licensed to use the Licensed Marks and Name under the terms and conditions
contained in the Agreement attached as Exhibit 1B hereto (the “Controlled Affiliate License Agreement Applicable to
Regional Medicare Advantage PPO Products”); and v) regional Medicare Part D Prescription Drug Plan products in
cooperation with one or more other Plans through jointly-held Controlled Affiliates, provided that each such
Controlled Affiliate is separately licensed to use the Licensed Marks and Name under the terms and conditions
contained in the Agreement attached as Exhibit 1C hereto (the “Controlled Affiliate License Agreement Applicable to
Regional Medicare Part D Prescription Drug Plan Products”). A “Controlled Affiliate” is defined as an entity that
meets the requirements of bona fide control stated herein and has executed a Controlled Affiliate License
Agreement. Unless otherwise approved in writing by BCBSA, bona fide control shall have the meaning set forth in
Paragraphs 2a and 2b. If the entity meets the standards of Paragraph 2a.B but not Paragraph 2a.A, the entity, its
owners, and persons with authority to select or appoint members or board members, other than a Plan or Plans,
have received written approval of BCBSA.
Amended as of June 15, 2023

-- 179 of 533 --

2a. With respect to the Controlled Affiliate Licenses authorized in clauses i) through iii) of Paragraph 2, bona fide
control shall mean that the Plan (the “Sponsoring Plan”) must have:
A. The legal authority, directly or indirectly through wholly-owned subsidiaries: (a) to select members of the
Controlled Affiliate's governing body having more than 50% voting control thereof; (b) to exercise control over
the policy and operations of the Controlled Affiliate; (c) to prevent any change in the articles of incorporation,
bylaws or other establishing or governing documents of the Controlled Affiliate with which the Sponsoring
Plan does not concur. In addition, the Sponsoring Plan directly or indirectly through wholly-owned subsidiaries
shall own more than 50% of any for- profit Controlled Affiliate, provided that in instances where the
Sponsoring Plan formed a publicly traded Controlled Affiliate Licensee and such publicly traded Controlled
Affiliate Licensee owns and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or
indirectly shall own and control more than 50% of any Controlled Affiliate that is indirectly owned and
controlled by the publicly traded Controlled Affiliate Licensee; or
B. The legal authority directly or indirectly through wholly-owned subsidiaries: (a) to select members of the
Controlled Affiliate's governing body having not less than 50% voting control thereof; (b) to prevent any change
in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate
with which the Sponsoring Plan does not concur; (c) to exercise control over the policy and operations of the
Controlled Affiliate at least equal to that exercised by persons or entities (jointly or individually) other than the
Sponsoring Plan. Notwithstanding anything to the contrary in through (c) hereof, the Controlled Affiliate’s
establishing or governing documents must also require written approval by the Sponsoring Plan before the
Controlled Affiliate can:
1. Change its legal and/or trade name;
2. Change the geographic area in which it operates;
3. Change any of the types of businesses in which it engages;
4. Create, or become liable for by way of guarantee, any indebtedness, other than indebtedness arising in
the ordinary course of business;
5. Sell any assets, except for sales in the ordinary course of business or sales of equipment no longer
useful or being replaced;
6. Make any loans or advances except in the ordinary course of business;
7. Enter into any arrangement or agreement with any party directly or indirectly affiliated with any of the
owners of the Controlled Affiliate or persons or entities with the authority to select or appoint members or
board members of the Controlled Affiliate, other than the Sponsoring Plan or other Plans (excluding
owners of stock holdings of under 5% in a publicly traded Controlled Affiliate);
8. Conduct any business other than under the Licensed Marks and Name;
9. Take any action that the Sponsoring Plan or BCBSA reasonably believes will adversely affect the
Licensed Marks or Names.
Amended as of June 15, 2023
-2-

-- 180 of 533 --

In addition, the Sponsoring Plan directly or indirectly through wholly owned subsidiaries shall own at least 50%
of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan formed a publicly
traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate Licensee owns and controls
other Controlled Affiliate Licensees, the Sponsoring Plan directly or indirectly shall own and control at least
50% of any Controlled Affiliate that is indirectly owned and controlled by the publicly traded Controlled Affiliate
Licensee; or
C. With respect to a Controlled Affiliate that is 100% controlled by Member Plans including the Sponsoring Plan
and which offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and/or Special Need
Plans products and services, the legal authority by the Sponsoring Plan together with such other Member
Plans (a) to select all members of the Controlled Affiliate’s governing body; (b) to prevent any change in the
articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate; (c) to
exercise control over the policy and operations of the Controlled Affiliate. In addition, the Sponsoring Plan and
such other Member Plans shall own 100% of any for-profit Controlled Affiliate, with the Sponsoring Plan and
such other Member Plans each having an ownership interest. Such 100% control and ownership by Member
Plans shall be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA.
Further, the Sponsoring Plan and such other Member Plans shall execute the “Addendum to Controlled Affiliate
License” attached as Exhibit B-1 to Exhibit 1 attached hereto; or
Amended as of June 20, 2019
-2a-

-- 181 of 533 --

D. With respect to a Controlled Affiliate that is 100% controlled by another Member Plan which on a Blue-branded
basis within the Plan’s Service Area, offers solely a Basic Medicare Part D Prescription Drug product, the legal
authority by the other Member Plan: (a) to select all members of the Controlled Affiliate’s governing body; (b) to
prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the
Controlled Affiliate; (c) to exercise control over the policy and operations of the Controlled Affiliate. In addition,
the Member Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control and ownership by the
Member Plan shall be direct or, if indirect, solely through affiliates that are licensed to use marks owned by
BCBSA. Further, the Sponsoring Plan and Participating Plan as defined on the Controlled Affiliate License
Agreement shall execute the “Addendum to Controlled Affiliate License” attached as Exhibit B-2 to Exhibit 1
attached hereto
E. With respect to a Controlled Affiliate that operates as a clinic, the legal authority by the Sponsoring Plan to
exercise control over the policy and operations of the Controlled Affiliate as defined in Exhibit 1, Standard
1(E) and the Guidelines to Administer Standard 1(E). In addition, if the clinic is for- profit, the Sponsoring
Plan shall own at least 50% of the Controlled Affiliate and prevent any change in the articles of incorporation,
bylaws or other establishing documents of the Controlled Affiliate with which the Sponsoring Plan does not
concur.
F. With respect to any Plan affiliation(s) entered into after June 15, 2023, the Plan has entered into a contractual
agreement that meets the criteria set forth in Exhibit 1, Standard 1(F) and the Guidelines to Administer
Standard 1(F) and Protocol for Determining Automatic Transfer of Primary License Agreement Pursuant to
Contractual Control.
2b. With respect to the Controlled Affiliate License Agreements authorized in clauses iv) and v) of Paragraph 2, bona fide
control shall mean that the Controlled Affiliate is organized and operated in such a manner that it meets the following
requirements:
A. 	The Controlled Affiliate is owned or controlled by two or more Plans authorized to use the Licensed Marks
pursuant to this License Agreement with BCBSA (for purposes of this subparagraph A. through subparagraph
C., the “Controlling Plans”); and
Amended as of June 15, 2023
-2b-

-- 182 of 533 --

B. 	Each Controlling Plan is authorized pursuant to this Agreement to use the Licensed Marks in a geographic
area in the Region (as that term is defined in such Controlled Affiliate License Agreements) and every
geographic area in the Region is so licensed to at least one of the Controlling Plans; and
C. The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries (a)
to select members of the Controlled Affiliate’s governing body having not less than 100% voting control
thereof; (b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing
documents of the Controlled Affiliate with which the Controlling Plans do not concur; and (c) to exercise
control over the policy and operations of the Controlled Affiliate. Notwithstanding anything to the contrary in
(a) through (c) of this subparagraph E., the Controlled Affiliate’s establishing or governing documents must
also require written approval by each of the Controlling Plans before the Controlled Affiliate can:
1. Change its legal and/or trade names;
2. Change the geographic area in which it operates (except such approval shall not be required with respect
to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one
of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA
sponsored by such Controlling Plan);
3. Change any of the type(s) of businesses in which it engages (except such approval shall not be required
with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the
Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement
with BCBSA sponsored by such Controlling Plan);
4. Take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the
Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly owned subsidiaries shall own 100% of
any for-profit Controlled Affiliate.
Amended as of June 19, 2014
(The next page is page 3)
-2c-

-- 183 of 533 --

3. 	With respect to an affiliate that is not licensed to use the Licensed Marks and Name, the Plan may, in
communications that contain the Licensed Marks or Name, indicate its corporate relationship to the affiliate and
permit such affiliate to indicate its corporate relationship to the Plan, solely in the circumstances, style and manner
specified in the BlueCross BlueShield Brand Book consistent with the avoidance of confusion or mistake or the
dilution or tarnishment of the Licensed Marks and Name. No rights are hereby created in any unlicensed affiliate to
use the Licensed Marks or Name.
4. 	The Plan recognizes the importance of a comprehensive national network of independent BCBSA licensees which
are committed to strengthening the Licensed Marks and Name. The Plan further recognizes that its actions within
its Service Area may affect the value of the Licensed Marks and Name nationwide. The Plan agrees (a) to maintain
in good standing its membership in BCBSA; (b) promptly to pay its dues to BCBSA, said dues to represent the
royalties for this License Agreement; (c) materially to comply with all applicable laws; (d) to comply with the
Membership Standards Applicable to Regular Members of BCBSA, a current copy of which is attached as Exhibit 2
hereto; and (e) reasonably to permit BCBSA, upon a written, good faith request and during reasonable business
hours, to inspect the Plan's books and records necessary to ascertain compliance herewith. As to other Plans and
third parties, BCBSA shall maintain the confidentiality of all documents and information furnished by the Plan
pursuant hereto, or pursuant to the Membership Standards, and clearly designated by the Plan as containing
proprietary information of the Plan.
5. 	The rights hereby granted are exclusive to the Plan within the geographical area(s) served by the Plan on June 30,
1972, and/or as to which the Plan has been granted a subsequent license, which is hereby defined as the "Service
Area," except that BCBSA reserves the right to use the Licensed Marks in said Service Area, and except to the
extent that said Service Area may overlap areas served by one or more other licensed Blue Cross Plans as of said
date or subsequent license, as to which overlapping areas the rights hereby granted are nonexclusive as to such
other Plan or Plans only.
Amended as of June 15, 2023
-3-

-- 184 of 533 --

6. 	Except as expressly provided by BCBSA with respect to National Accounts, Government Programs and certain other
necessary and collateral uses, the current rules and regulations governing which are attached as Exhibit 3 and
Exhibit 4 hereto, and are contained in other documents referenced herein, or as expressly provided herein, the Plan
may not use the Licensed Marks and Name outside the Service Area or in connection with other goods and
services, nor may the Plan use the Licensed Marks or Name in a manner which is intended to transfer in the Service
Area the goodwill associated therewith to another mark or name. Nothing herein shall be construed to prevent the
Plan from engaging in lawful activity anywhere under other marks and names not confusingly similar to the Licensed
Marks and Name, provided that engaging in such activity does and will not dilute or tarnish the unique value of the
Licensed Marks and Name. In addition to any and all remedies available hereunder, BCBSA may impose monetary
fines on the Plan for the Plan’s use of the Licensed Marks and Names outside the Service Area, and provided that
the procedure used in imposing a fine is consistent with procedures specifically prescribed by BCBSA from time to
time in regulations of general application. In the case of regional Medicare Advantage PPO and regional Medicare
Part D Prescription Drug Plan products offered by consenting and participating Plans in a region that includes the
Service Areas, or portions thereof, of more than one Plan, such fine may be imposed jointly on the consenting and
participating Plans for use of the Licensed Marks and Name in any geographic area of the region in which a Plan
having exclusive rights to the Licensed Marks and Name does not consent to and participate in such offering,
provided that the basis for imposition of such fine is consistent with rules specifically prescribed by BCBSA from time
to time in regulations of general application.
7. 	The Plan agrees that it will display the Licensed Marks and Name only in such form, style and manner as shall be
specifically prescribed by BCBSA from time-to-time in regulations of general application in order to prevent
impairment of the distinctiveness of the Licensed Marks and Name and the goodwill pertaining thereto. The Plan
shall cause to appear on all materials on or in connection with which the Licensed Marks or Name are used such
legends, markings and notices as BCBSA may reasonably request in order to give appropriate notice of service
mark or other proprietary rights therein or pertaining thereto.
8. 	BCBSA agrees that: (a) it will not grant any other license effective during the term of this License Agreement for the
use of the Licensed Marks or Name which is inconsistent with the rights granted to the Plan hereunder; and (b) it will
not itself use the Licensed Marks in derogation of the rights of the Plan or in a manner to deprive the Plan of the full
benefits of this License Agreement, provided that BCBSA shall have the right to use the Licensed Marks in
conjunction with any national offering under the Federal Employees Health Benefits Program in the manner set forth
in Exhibit 4, Paragraph 4 (including subparagraphs) to this License Agreement. The Plan agrees that it will not
attack the title of BCBSA in and to the Licensed Marks or Name or attack the validity of the Licensed Marks or of this
License Agreement. The Plan further agrees that all use by it of the Licensed Marks and Name or any similar mark
or name shall inure to the benefit of BCBSA, and the Plan shall cooperate with BCBSA in effectuating the
assignment to BCBSA of any service mark or trademark registrations of the Licensed Marks or any similar mark or
name held by the Plan or a Controlled Affiliate of the Plan, all or any portion of which registration consists of the
Licensed Marks.
Amended as of November 16, 2006
-3a-

-- 185 of 533 --

9.(a). Should the Plan fail to comply with the provisions of paragraphs 2-4, 6, 7 and/or 12, and not cure such failure
within thirty (30) days of receiving written notice thereof (or commence curing such failure within such thirty day
period and continue diligent efforts to complete the curing of such failure if such curing cannot reasonably be
completed within such thirty day period), BCBSA shall have the right to issue a notice that the Plan is in a state
of noncompliance. Except as to the termination of a Plan's License Agreement or the merger of two or more
Plans, disputes as to noncompliance, and all other disputes between or among BCBSA, the Plan, other Plans
and/or Controlled Affiliates, shall be submitted promptly to mediation and mandatory dispute resolution
pursuant to the rules and regulations of BCBSA, a current copy of which is attached as Exhibit 5 hereto, and
shall be timely presented and resolved. The mandatory dispute resolution panel shall have authority to issue
orders for specific performance and assess monetary penalties. If a state of noncompliance as aforesaid is
undisputed by the Plan or is found to exist by a mandatory dispute resolution panel and is uncured as provided
above, BCBSA shall have the right to seek judicial enforcement of the License Agreement. Except, however, as
provided in paragraphs 9(d)(iii), 15(a)(i)-(viii), and 15(a)(x) below, no Plan's license to use the Licensed Marks
and Name may be finally terminated for any reason without the affirmative vote of three-fourths of the Plans
and three-fourths of the total then current weighted vote of all the Plans.
(b). Notwithstanding any other provision of this License Agreement, a Plan's license to use the Licensed Marks
and Name may be forthwith terminated by the affirmative vote of three-fourths of the Plans and three-fourths of
the total then current weighted vote of all the Plans at a special meeting expressly called by BCBSA for the
purpose on ten (10) days written notice to the Plan advising of the specific matters at issue and granting the
Plan an opportunity to be heard and to present its response to Member Plans for: (i) failure to comply with any
minimum capital or liquidity requirement under the Membership Standard on Financial Responsibility; or (ii)
impending financial insolvency; or (iii) the pendency of any action instituted against the Plan seeking its
dissolution or liquidation or its assets or seeking appointment of a trustee, interim trustee, receiver or other
custodian for any of its property or business or seeking the declaration or establishment of a trust for any of its
property of business, unless this License Agreement has been earlier terminated under paragraph 15(a); or (iv)
such other reason as is determined in good faith immediately and irreparably to threaten the integrity and
reputation of BCBSA, the Plans and/or the Licensed Marks.
Amended as of March 16, 2006
-4-

-- 186 of 533 --

(c). To the extent not otherwise provided therein, neither: (i) the Membership Standards Applicable to Regular
Members of BCBSA; nor (ii) the rules and regulations governing Government Programs and certain other uses;
nor (iii) the rules and regulations governing mediation and mandatory dispute resolution, may be amended
unless and until each such amendment is first adopted by the affirmative vote of three-fourths of the Plans and
of three-fourths of the total then current weighted vote of all the Plans. The rules and regulations governing
National Accounts and other national programs required by the Membership Standards Applicable to Regular
Members of BCBSA (Exhibit 2) are contained, in addition to those set forth in Exhibit 3, in the following
documents, as amended from time to time: (1) the Inter-Plan Programs Policies and Provisions; (2) Inter- Plan
Medicare Advantage Program Policies and Provisions. The voting requirements specified in rules and
regulations governing such national programs may not be amended unless and until each such amendment is
first adopted by the affirmative vote of three- fourths of the Plans and of three-fourths of the total then current
weighted vote of all the Plans.
Amended as of November 21, 2014
-4a-

-- 187 of 533 --

(d). The Plan may operate as a for-profit company on the following conditions:
(i) The Plan shall discharge all responsibilities which it has to the Association and to other Plans by virtue of
this Agreement and the Plan's membership in BCBSA.
(ii) The Plan shall not use the licensed Marks and Name, or any derivative thereof, as part of its legal name or
any symbol used to identify the Plan in any securities market. The Plan shall use the licensed Marks and
Name as part of its trade name within its service area for the sale, marketing and administration of health
care and related services in the service area.
(iii) Plan's license to use the Licensed Marks and Name shall automatically terminate effective: (a) thirty days
after the Plan knows, or there is an SEC filing indicating that, any Institutional Investor, has become the
Beneficial Owner of securities representing 10% or more of the voting power of the Plan (“Excess
Institutional Voter”), unless such Excess Institutional Voter shall cease to be an Excess Institutional Voter
prior to such automatic termination becoming effective; (b) thirty days after the Plan knows, or there is an
SEC filing indicating that, any Noninstitutional Investor has become the Beneficial Owner of securities
representing 5% or more of the voting power of the Plan (“Excess Noninstitutional Voter”) unless such
Excess Noninstitutional Voter shall cease to be an Excess Noninstitutional Voter prior to such automatic
termination becoming effective; (c) thirty days after the Plan knows, or there is an SEC filing indicating
that, any Person has become the Beneficial Owner of 20% or more of the Plan’s then outstanding
common stock or other equity securities which (either by themselves or in combination) represent an
ownership interest of 20% or more pursuant to determinations made under paragraph 9(d)(iv) below
(“Excess Owner”), unless such Excess Owner shall cease to be an Excess Owner prior to such automatic
termination becoming effective; (d) ten business days after individuals who at the time the Plan went
public constituted the Board of Directors of the Plan (together with any new directors whose election to the
Board was approved by a vote of 2/3 of the directors then still in office who were directors at the time the
Plan went public or whose election or nomination was previously so approved) (the "Continuing
Directors") cease for any reason to constitute a majority of the Board of Directors; or (e) ten business days
after the Plan consolidates with or merges with or into any person or conveys, assigns, transfers or sells
all or substantially all of its assets to any person other than a merger in which the Plan is the surviving
entity and immediately after which merger, no person is an Excess Institutional Voter, an Excess
Noninstitutional Voter or an Excess Owner: provided that, if requested by the affected Plan in a writing
received by BCBSA prior to such automatic termination
Amended as of September 17, 1997
-5-

-- 188 of 533 --

becoming effective, the provisions of this paragraph 9(d)(iii) may be waived, in whole or in part, upon the
affirmative vote of a majority of the disinterested Plans and a majority of the total then current weighted
vote of the disinterested Plans. Any waiver so granted may be conditioned upon such additional
requirements (including but not limited to imposing new and independent grounds for termination of this
License) as shall be approved by the affirmative vote of a majority of the disinterested Plans and a
majority of the total then current weighted vote of the disinterested Plans. If a timely waiver request is
received, no automatic termination shall become effective until the later of: (1) the conclusion of the
applicable time period specified in paragraphs 9(d)(iii)(a)-
(d) above, or (2) the conclusion of the first Member Plan meeting after receipt of such a waiver request.
In the event that the Plan's license to use the Licensed Marks and Name is terminated pursuant to this
Paragraph 9(d)(iii), the license may be reinstated in BCBSA’s sole discretion if, within 30 days of the
date of such termination, the Plan demonstrates that the Person referred to in clause (a), (b) or (c) of the
preceding paragraph is no longer an Excess Institutional Voter, an Excess Noninstitutional Voter or an
Excess Owner.
(iv) The Plan shall not issue any class or series of security other than (i) shares of common stock having
identical terms or options or derivatives of such common stock, (ii) non-voting, non-convertible debt
securities or (iii) such other securities as the Plan may approve, provided that BCBSA receives notice at
least thirty days prior to the issuance of such securities, including a description of the terms for such
securities, and BCBSA shall have the authority to determine how such other securities will be counted in
determining whether any Person is an Excess Institutional Voter, Excess Noninstitutional Voter or an
Excess Owner.
(v) For purposes of paragraph 9(d)(iii), the following definitions shall apply:
(a) "Affiliate" and "Associate" shall have the respective meanings ascribed to such terms in
Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of
1934, as amended and in effect on November 17, 1993 (the "Exchange Act").
(b) A Person shall be deemed the "Beneficial Owner" of and shall be deemed to
"beneficially own" any securities:
(i) which such Person or any of such Person's Affiliates or Associates
beneficially owns, directly or indirectly;
Amended as of September 17, 1997
-5a-

-- 189 of 533 --

(ii) which such Person or any of such Person's Affiliates or Associates has (A) the right to acquire
(whether such right is exercisable immediately or only after the passage of time) pursuant to
any agreement, arrangement or understanding, or upon the exercise of conversion rights,
exchange rights, warrants or options, or otherwise; or (B) the right to vote pursuant to any
agreement, arrangement or understanding; provided, however, that a Person shall not be
deemed the Beneficial Owner of, or to beneficially own, any security if the agreement,
arrangement or understanding to vote such security (1) arises solely from a revocable proxy or
consent given to such Person in response to a public proxy or consent solicitation made
pursuant to, and in accordance with, the applicable rules and regulations promulgated under
the Exchange Act and (2) is not also then reportable on Schedule 13D under the Exchange
Act (or any comparable or successor report); or
(iii) which are beneficially owned, directly or indirectly, by any other Person (or any Affiliate or
Associate thereof) with which such Person (or any of such Person's Affiliates or Associates)
has any agreement, arrangement or understanding (other than customary agreements with
and between underwriters and selling group members with respect to a bona fide public
offering of securities) relating to the acquisition, holding, voting (except to the extent
contemplated by the proviso to (b)(ii)(B) above) or disposing of any securities of the Plan.
Notwithstanding anything in this definition of Beneficial Ownership to the contrary, the phrase
"then outstanding," when used with reference to a Person's Beneficial Ownership of securities
of the Plan, shall mean the number of such securities then issued and outstanding together
with the number of such securities not then actually issued and outstanding which such
Person would be deemed to own beneficially hereunder.
(c) A Person shall be deemed an “Institutional Investor” if (but only if) such Person (i) is an
entity or group identified in the SEC’s Rule 13d-1(b)(1)(ii) as constituted on June 1, 1997,
and (ii) every filing
made by such Person with the SEC under Regulation 13D-G (or any successor Regulation)
with respect to such Person’s Beneficial Ownership of Plan securities shall have contained a
certification identical to the one required by item 10 of SEC Schedule 13G as constituted on
June 1, 1997.
(d) “Noninstitutional Investor” means any Person who is not an Institutional Investor.
(e) "Person" shall mean any individual, firm, partnership, corporation, trust, association, joint
venture or other entity, and shall include any successor (by merger or otherwise) of such
entity.
Amended as of September 17, 1997
-5b-
(The next page is page 6)

-- 190 of 533 --

10. 	This License Agreement shall remain in effect: (a) until terminated as provided herein; or (b) until this and all such other
License Agreements are terminated by the affirmative vote of three-fourths of the Plans and three-fourths of the total then
current weighted vote of all the Plans; or (c) until termination of aforesaid Ownership Agreement; or (d) until terminated
by the Plan upon eighteen (18) months written notice to BCBSA or upon a shorter notice period approved by BCBSA in
writing at its sole discretion.
11. 	Except as otherwise provided in paragraph 15 below or by the affirmative vote of three- fourths of the Plans and
three-fourths of the total then current weighted vote of all the Plans, or unless this and all such other License
Agreements are simultaneously terminated by force of law, the termination of this License Agreement for any
reason whatsoever shall cause the reversion to BCBSA of all rights in and to the Licensed Marks and Name, and
the Plan agrees that it will promptly discontinue all use of the Licensed Marks and Name, will not use them
thereafter, and will promptly, upon written notice from BCBSA, change its corporate name so as to eliminate the
Licensed Name therefrom.
12. 	The license hereby granted to Plan to use the Licensed Marks and Name is and shall be personal to the Plan so
licensed and shall not be assignable by any act of the Plan, directly or indirectly, without the written consent of
BCBSA. Said license shall not be assignable by operation of law, nor shall Plan mortgage or part with possession
or control of this license or any right hereunder, and the Plan shall have no right to grant any sublicense to use the
Licensed Marks and Name.
13. 	BCBSA shall maintain appropriate service mark registrations of the Licensed Marks and BCBSA shall take such
lawful steps and proceedings as may be necessary or proper to prevent use of the Licensed Marks by any person
who is not authorized to use the same. Any actions or proceedings undertaken by BCBSA under the provisions of
this paragraph shall be at BCBSA's sole cost and expense. BCBSA shall have the sole right to determine whether
or not any legal action shall be taken on account of unauthorized use of the Licensed Marks, such right not to be
unreasonably exercised. The Plan shall report any unlawful usage of the Licensed Marks to BCBSA in writing and
agrees, free of charge, to cooperate fully with BCBSA's program of enforcing and protecting the service mark
rights, trade name rights and other rights in the Licensed Marks.
14. 	The Plan hereby agrees to save, defend, indemnify and hold BCBSA and any other Plan(s) harmless from and
against all claims, damages, liabilities and costs of every kind, nature and description which may arise as a result
of the activities of the Plan or of any hospital, medical group, clinic or other provider of health services that is
owned or controlled directly or indirectly by Plan. BCBSA hereby agrees to save, defend, indemnify and hold the
Plan and any other Plan(s) harmless from and against all claims, damages, liabilities And costs of every kind,
nature and description which may arise exclusively and directly as a result of the activities of BCBSA.
Amended as of June 21, 2012
-6-

-- 191 of 533 --

15. (a). This Agreement shall automatically terminate upon the occurrence of any of the following events: (i) a voluntary
petition shall be filed by the Plan or by BCBSA seeking bankruptcy, reorganization, arrangement with creditors
or other relief under the bankruptcy laws of the United States or any other law governing insolvency or debtor
relief, or (ii) an involuntary petition or proceeding shall be filed against the Plan or BCBSA seeking bankruptcy,
reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or
any other law governing insolvency or debtor relief and such petition or proceeding is consented to or
acquiesced in by the Plan or BCBSA or is not dismissed within sixty (60) days of the date upon which the
petition or other document commencing the proceeding is served upon the Plan or BCBSA respectively, or (iii)
an order for relief is entered against the Plan or BCBSA in any case under the bankruptcy laws of the United
States, or the Plan or BCBSA is adjudged bankrupt or insolvent (as that term is defined in the Uniform
Commercial Code as enacted in the state of Illinois) by any court of competent jurisdiction, or (iv) the Plan or
BCBSA makes a general assignment of its assets for the benefit of creditors, or (v) any government or any
government official, office, agency, branch, or unit assumes control of the Plan or delinquency proceedings
(voluntary or involuntary) are instituted, or (vi) an action is brought by the Plan or BCBSA seeking its
dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or other
custodian for any of its property or business, or (vii) an action is instituted by any governmental entity or officer
against the Plan or BCBSA seeking its dissolution or liquidation of its assets or seeking appointment of a
trustee, interim trustee, receiver or other custodian for any of its property or business and such action is
consented to or acquiesced in by the Plan or BCBSA or is not dismissed within one hundred thirty (130) days
of the date upon which the pleading or other document commencing the action is served upon the Plan or
BCBSA respectively, provided that if the action is stayed or its prosecution is enjoined, the one hundred thirty
(130) day period is tolled for the duration of the stay or injunction, and provided further, that the Association’s
Board of Directors may toll or extend the 130 day period at any time prior to its expiration, or (viii) a trustee,
interim trustee, receiver or other custodian for any of the Plan's or BCBSA's property or business is appointed,
or the Plan or BCBSA is ordered dissolved or liquidated, or (ix) the Plan shall fail to pay its dues and shall not
cure such failure within thirty (30) days of receiving written notice thereof, or (x) if, due to regulatory action, the
Plan together with any applicable Controlled Affiliate becomes unable to do business using the Names and
Marks in any State or portion thereof included in its Service Area, provided that: (i) automatic termination shall
not occur prior to the exhaustion by any such Plan of its rights to appeal or challenge such regulatory action;
and (ii) in the event the Plan is licensed to do business using the Names and Marks in multiple States or
portions of States, the termination of its License Agreement shall be solely limited to the State(s) or portions
thereof in which the regulatory action applies. By not appealing or challenging such regulatory action within
the time prescribed by law or regulation, and in any event no later than 120 days after such action is taken, a
Plan shall be deemed to have exhausted its rights to appeal or challenge, and automatic termination shall
proceed.
-7-

-- 192 of 533 --

Notwithstanding any other provision of this Agreement, a declaration or a request for declaration of the
existence of a trust over any of the Plan’s or BCBSA’s property or business shall not in itself be deemed to
constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of
subparagraphs 15(a)(vii) and (viii) of this Agreement.
Amended as of March 26, 2015
-7a-

-- 193 of 533 --

(b). BCBSA, or the Plans (as provided and in addition to the rights conferred in Paragraph 10(b) above), may
terminate this Agreement immediately upon written notice upon the occurrence of either of the following
events: (a) the Plan or BCBSA becomes insolvent (as that term is defined in the Uniform Commercial Code
enacted in the state of Illinois), or (b) any final judgment against the Plan or BCBSA remains unsatisfied or
unbonded of record for a period of sixty (60) days or longer.
(c). 	If this License Agreement is terminated as to BCBSA for any reason stated in subparagraphs 15(a) and (b)
above, the ownership of the Licensed Marks shall revert to each of the Plans as provided in the Ownership
Agreement.
(d). Upon termination of this License Agreement or any Controlled Affiliate License Agreement of a Larger
Controlled Affiliate, as defined in Exhibit 1 to this License Agreement, the following conditions shall apply,
except that, in the event of a partial termination of this Agreement pursuant to Paragraph 15 (a)(x)(ii) of this
Agreement, the notices, national account listing, payment and audit right listed below shall be applicable
solely with respect to the geographic area for which the Plan’s license to use the Licensed Names and Marks
is terminated:
(i) The terminated entity shall send a notice through the U.S. mails, with first class postage affixed, to all
individual and group customers, providers, brokers and agents of products or services sold, marketed,
underwritten or administered by the terminated entity or its Controlled Affiliates under the Licensed Marks
and Name. The form and content of the notice shall be specified by BCBSA and shall, at a minimum,
notify the recipient of the termination of the license, the consequences thereof, and instructions for
obtaining alternate products or services licensed by BCBSA, subject to any conflicting state law and
state regulatory requirements. This notice shall be mailed within 15 days after termination or, if
termination is pursuant to paragraph 10(d) of this Agreement, within 15 days after the written notice to
BCBSA described in paragraph 10(d).
(ii) The terminated entity shall deliver to BCBSA within five days of a request by BCBSA a listing of national
accounts in which the terminated entity is involved (in a Control, Participating or Servicing capacity),
identifying the national account and the terminated entity's role therein. For those accounts where the
terminated entity is the Control Plan, the Plan must also indicate the Participating and Servicing Plans in
the national account syndicate.
Amended as of June 16, 2005
-8-

-- 194 of 533 --

(iii) Unless the cause of termination is an event stated in paragraph 15(a) or (b) above respecting BCBSA,
the Plan and its Licensed Controlled Affiliates shall be jointly liable for payment to BCBSA of an amount
equal to the Re- Establishment Fee (described below) multiplied by the number of Licensed Enrollees of
the terminated entity and its Licensed Controlled Affiliates; provided that if any other Plan is permitted by
BCBSA to use marks or names licensed by BCBSA in the Service Area established by this Agreement,
the Re- Establishment Fee shall be multiplied by a fraction, the numerator of which is the number of
Licensed Enrollees of the terminated entity and its Licensed Controlled Affiliates and the denominator of
which is the total number of Licensed Enrollees in the Service Area. The Re-Establishment Fee shall be
indexed to a base fee of $80. The Re-Establishment Fee through December 31, 2005 shall be $80. The
Re-Establishment Fee for calendar years after December 31, 2005 shall be adjusted on January 1 of
each calendar year up to and including January 1, 2010 and shall be the base fee multiplied by 100%
plus the cumulative percentage increase or decrease in the Plans’ gross administrative expense
(standard BCBSA definition) per Licensed Enrollee since December 31, 2004. The adjustment shall end
on January 1, 2011, at which time the Re-Establishment Fee shall be fixed at the then-current amount
and no longer automatically adjusted. For example, if the Plans’ gross administrative expense per
Licensed Enrollee was $278.60, $285.00 and $290.00 for calendar year end 2004, 2005 and 2006,
respectively, the January 1, 2007 Re-Establishment Fee would be $83.27 (100% of the base fee plus
$1.84 for calendar year 2005 and $1.43 for calendar year 2006). Licensed Enrollee means each and
every person and covered dependent who is enrolled as an individual or member of a group receiving
products or services sold, marketed or administered under marks or names licensed by BCBSA as
determined at the earlier of (a) the end of the last fiscal year of the terminated entity which ended prior to
termination or (b) the fiscal year which ended before any transactions causing the termination began.
Notwithstanding the foregoing, the amount payable pursuant to this subparagraph (d)(iii) shall be due
only to the extent that, in
Amended as of June 16, 2005
-8a-

-- 195 of 533 --

BCBSA's opinion, it does not cause the net worth of the Plan to fall below 100% of the Health Risk-
Based Capital formula or its equivalent under any successor formula, as set forth in the applicable
financial responsibility standards established by BCBSA (provided such equivalent is approved for
purposes of this sub paragraph by the affirmative vote of three-fourths of the Plans and three-fourths of
the total then current weighted vote of all the Plans), measured as of the date of termination and
adjusted for the value of any transactions not made in the ordinary course of business. This payment
shall not be due in connection with transactions exclusively by or among Plan or their affiliates, including
reorganizations, combinations or mergers, where the BCBSA Board of Directors determines that the
license termination does not result in a material diminution in the number of Licensed Enrollees or
theextent of their coverage. At least 50% of the Re Establishment Fee shall be awarded to the Plan (or
Plans) that receive the new license(s) for the service area(s) at issue; provided, however, that such
award shall not become due or payable until all disputes, if any, regarding the amount of and BCBSA’s
right to such Re-Establishment Fee have been finally resolved; and provided further that the award shall
be based on the final amount actually received by BCBSA. The Board of Directors shall adopt a
resolution which it may amend from time to time that shall govern BCBSA’s use of its portion of the
award. In the event that the terminated entity’s license is reinstated by BCBSA or is deemed to have
remained in effect without interruption by a court of competent jurisdiction, BCBSA shall reimburse the
Plan (and/or its Licensed Controlled Affiliates, as the case may be) for payments made under this
subparagraph only to the extent that such payments exceed the amounts due to BCBSA pursuant to
subparagraph 15(d)(vi) and any costs associated with reestablishing the Service Area, including any
payments made by BCBSA to a Plan or Plans (or their Licensed Controlled Affiliates) for purposes of
replacing the terminated entity.
(iv) The terminated entity shall comply with all financial settlement procedures set forth in BCBSA’s
License Termination Contingency Plan, as amended from time to time and shall work diligently and in
good faith with BCBSA, any Alternative Control Licensee or Replacement Licensee and any existing or
potential
Amended as of June 16, 2005
-8b-

-- 196 of 533 --

new account for Blue-branded products and services to minimize the disruption of termination, and
honor, to the fullest extent possible, the desire of accounts to continue to receive or obtain Blue-branded
products and services through a new Licensee (“Transition”). Such diligence and good faith on the part of
the terminated entity shall include, but not be limited to: (a) working cooperatively with BCBSA to protect
the Names and Marks from potential harm; (b) cooperating with BCBSA’s use of the Names and Marks in
the terminated entity’s former service area during the termination and Transition; (c) transmitting, upon
the request of an existing Blue account or of BCBSA with consent and on behalf of an existing Blue
account, all member and account- data relating to the Federal Employee Program to BCBSA, and all
member and account data relating to other programs to an Alternative Control Licensee or Replacement
Licensee; (d) working with BCBSA and the Alternative Control or Replacement Licensee with respect to
potential new Blue accounts headquartered in the terminated entity’s former service area; (e) continuing
to service Blue accounts during the Transition; (f) continuing to comply with National Programs, Federal
Employee Program and NASCO policies and procedures and all voluntary BCBSA programs, policies
and performance standards, such as Away From Home Care, including being responsible for payment of
all penalties for non-compliance duly levied in conformity with the License Agreements, Membership
Standards, or the Federal Employee Program agreements, that may arise during the Transition; (g)
maintaining and providing access to its provider networks, as defined by Federal Employee Program
agreements and National Account Program Policies and Provisions, and Inter-Plan Programs Policies
and Provisions, and making those networks and discounts available to members and providers who
participate in National Programs and the Federal Employee Program during the Transition; (h)
maintaining its technical connections and processing capabilities during the Transition; and (i) working
diligently to conclude all financial settlements and account reconciliations as negotiated in the termination
transition agreement.
Amended as of November 16, 2006
-8c-

-- 197 of 533 --

(v) Notwithstanding any other provision in this Agreement, BCBSA shall have the right, with the approval of
its Board of Directors, to assess additional fines against the terminated entity during the Transition in the
event it fails to maintain and provide access to provider networks as defined by Federal Employee
Program agreements, National Account Program Policies and Provisions, and Inter-Plan Programs
Policies and Provisions, and/or pass on applicable discounts. Such fines shall be in addition to any other
assessments, fees or liquidated damages payable herein, or under existing policies and programs and
shall be imposed to make whole BCBSA and/or the Plans. Terminated entity shall pay any such fines to
BCBSA no later than 30 days after they are approved by the Board of Directors.
(vi) BCBSA shall have the right to examine and audit and/or hire at terminated entity’s expense a third-
party auditor to examine and audit the books and records of the terminated entity and its Licensed
Controlled Affiliates to verify compliance with the terms and requirements this paragraph 15(d).
(vii) Subsequent to termination of this Agreement, the terminated entity and its affiliates, agents, and
employees shall have an ongoing and continuing obligation to protect all BCBSA and Blue Licensee data
that was acquired or accessed during the period this Agreement was in force, including but not limited to
all confidential processes, pricing, provider, discount and other strategic and competitively sensitive
information (“Blue Information”) from disclosure, and shall not, either alone or with another entity,
disclose such Blue Information or use it in any manner to compete without the express written
permission of BCBSA.
(viii) As to a breach of 15 (d) (i), (ii), (iii), (iv), (vi), or (vii) the parties agree that the obligations are
immediately enforceable in a court of competent jurisdiction. As to a breach of 15 (d) (i), (ii), (iv), (vi), or
(vii) by the Plan, the parties agree there is no adequate remedy at law and BCBSA is entitled to obtain
specific performance.
Amended as of November 16, 2006
-8d-

-- 198 of 533 --

(ix) In the event that the terminated entity’s license is reinstated by BCBSA or is deemed to have remained
in effect without interruption by a court of competent jurisdiction, the Plan and its Licensed Controlled
Affiliates shall be jointly liable for reimbursing BCBSA the reasonable costs incurred by BCBSA in
connection with the termination and the reinstatement or court action, and any associated legal
proceedings, including but not limited to: outside legal fees, consulting fees, public relations fees,
advertising costs, and costs incurred to develop, lease or establish an interim provider network. Any
amount due to BCBSA under this subparagraph may be waived in whole or in part by the BCBSA Board
of Directors in its sole discretion.
(e). BCBSA shall be entitled to enjoin the Plan or any related party in a court of competent jurisdiction from entry
into any transaction which would result in a termination of this License Agreement unless the License
Agreement has been terminated pursuant to paragraph 10 (d) of this Agreement upon the required six (6)
month written notice.
(f). BCBSA acknowledges that it is not the owner of assets of the Plan.
Amended as of June 16, 2006
-8e-

-- 199 of 533 --

16. This Agreement supersedes any and all other agreements between the parties with respect to the subject matter
herein, and contains all of the covenants and agreements of the parties as to the licensing of the Licensed Marks
and Name. This Agreement may be amended only by the affirmative vote of three-fourths of the Plans and three-
fourths of the total then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate
Secretary.
17. If any provision or any part of any provision of this Agreement is judicially declared unlawful, each and every other
provision, or any part of any provision, shall continue in full force and effect notwithstanding such judicial
declaration.
18. No waiver by BCBSA or the Plan of any breach or default in performance on the part of BCBSA or the Plan or
any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any
subsequent breach or default in performance of said terms, covenants or conditions.
19a. All notices provided for hereunder shall be in writing and shall be sent in duplicate by regular mail to BCBSA or the
Plan at the address currently published for each by BCBSA and shall be marked respectively to the attention of the
President and, if any, the General Counsel, of BCBSA or the Plan.
19b. Except as provided in paragraphs 9(b), 9(d)(iii), 15(a), and 15(b) above, this Agreement may be terminated for a
breach only upon at least 30 days’ written notice to the Plan advising of the specific matters at issue and granting the
Plan an opportunity to be heard and to present its response to the Member Plans.
19c. For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the Blue
Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes
equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes
(if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all
questions requiring an affirmative three-fourths weighted vote of the Plans, voting shall occur pursuant to BCBSA’s
Bylaws.
Amended as of June 15, 2023
(The next page is page 9)
-8f-

-- 200 of 533 --

20. Nothing herein contained shall be construed to constitute the parties hereto as partners or joint venturers, or either
as the agent of the other, and Plan shall have no right to bind or obligate BCBSA in any way, nor shall it represent
that it has any right to do so. BCBSA shall have no liability to third parties with respect to any aspect of the
business, activities, operations, products, or services of the Plan.
21. This Agreement shall be governed, construed and interpreted in accordance with the laws of the State of Illinois.
IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed, effective
as of the date of last signature written below.
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By___________________________________________
Title__________________________________________
Date_________________________________________
PLAN:
By___________________________________________
Title__________________________________________
Date__________________________________________
-9-

-- 201 of 533 --

EXHIBIT 1
BLUE CROSS
CONTROLLED AFFILIATE LICENSE AGREEMENT
(Includes revisions adopted by Member Plans through their November 16, 2023 meeting)
This Agreement by and among Blue Cross and Blue Shield Association ("BCBSA") and_______(“Controlled Affiliate"), a
Controlled Affiliate of the Blue Cross Plan, known as_______("Plan" or “Sponsoring Plan”), which is also a Party signatory
hereto.
WHEREAS, BCBSA is the owner of the BLUE CROSS and BLUE CROSS Design service marks;
WHEREAS, Plan and Controlled Affiliate desire that the latter be entitled to use the BLUE CROSS and BLUE
CROSS Design service marks (collectively the "Licensed Marks") as service marks and be entitled to use the term BLUE
CROSS in a trade name ("Licensed Name");
NOW THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby
agree as follows:
1. GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled Affiliate the right to use
the Licensed Marks and Name in connection with, and only in connection with: (i) health care plans and related
services, as defined in BCBSA's License Agreement with Plan, and administering the non-health portion of workers’
compensation insurance, and (ii) underwriting the indemnity portion of workers’ compensation insurance, provided
that Controlled Affiliate’s total premium revenue comprises less than 15 percent of the Sponsoring Plan’s net
subscription revenue.
This grant of rights is non-exclusive and is limited to the Service Area served by the Plan Subject to paragraph
3A(3) of this Agreement, Controlled Affiliate may use the Licensed Marks and Name in its legal name on the
following conditions: (i) the legal name must be approved in advance, in writing, by BCBSA; (ii) Controlled Affiliate
shall not do business outside the Service Area under any name or mark; and (iii) Controlled Affiliate shall not use
the Licensed Marks and Name, or any derivative thereof, as part of any name or symbol used to identify itself in
any securities market, unless such Controlled Affiliate is a not-for-profit company which may use the Licensed
Marks and Name, or an approved derivative therefor, to identify itself in debt securities markets. Controlled Affiliate
may use the Licensed Marks and Name in its Trade Name only with the prior, written, consent of BCBSA.
Amended as of March 26, 2015
1

-- 202 of 533 --

2. QUALITY CONTROL
A. 	Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services
and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they
may be amended by BCBSA from time-to-time.
B. 	Controlled Affiliate agrees to comply with all applicable federal, state and local laws.
C. Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by
Plan or by BCBSA) a report or reports to Plan
and BCBSA demonstrating Controlled Affiliate's compliance with the requirements of this
Agreement including but not limited to the quality control provisions of this paragraph and the
attached Exhibit A.
D. Controlled Affiliate agrees that Plan and/or BCBSA may, from time-to- time, upon reasonable
notice, review and inspect the manner and method of ControlledAffiliate's rendering of service
and use of the Licensed Marks and Name.
E. 	As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a
manner, that the Sponsoring Plan has:
(1) The legal authority directly or indirectly through wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having not less than 50% voting
control thereof; and
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing
documents of the Controlled Affiliate with which the Sponsoring Plan does not concur; and
(c) to exercise control over the policy and operations of the Controlled Affiliate at least equal to that
exercised by persons or entities (jointly or individually) other than the Sponsoring Plan; and
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s establishing or
governing documents must also require written approval by the Sponsoring Plan before the Controlled
Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates;
(iii) change any of the type(s) of businesses in which it engages;
Amended as of September 19, 2014
2

-- 203 of 533 --

(iv) create, or become liable for by way of guarantee, any indebtedness, other than
indebtedness arising in the ordinary course of business;
(v) sell any assets, except for sales in the ordinary course of business or sales of equipment no
longer useful or being replaced;
(vi) make any loans or advances except in the ordinary course of business;
(vii) enter into any arrangement or agreement with any party directly or indirectly affiliated with any of
the owners or persons or entities with the authority to select or appoint members or board members
of the Controlled Affiliate, other than the Sponsoring Plan or other Plans (excluding owners of stock
holdings of under 5% in a publicly traded Controlled Affiliate);
(viii) conduct any business other than under the Licensed Marks and Name;
(ix) take any action that the Sponsoring Plan or BCBSA reasonably believes will adversely
affect the Licensed Marks and Name.
In addition, the Sponsoring Plan directly or indirectly through wholly owned subsidiaries shall own at
least 50% of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan
formed a publicly traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate
Licensee owns and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or
indirectly shall own and control at least 50% of any Controlled Affiliate that is indirectly owned and
controlled by the publicly traded Controlled Affiliate Licensee.
Or
(2) The legal authority directly or indirectly through wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having more than 50%
voting control thereof and;
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or
governing documents of the Controlled Affiliate with which the Sponsoring Plan does
not concur; and
(c) to exercise control over the policy and operations of the Controlled Affiliate.
Amended as of March 26, 2015
3

-- 204 of 533 --

In addition, the Sponsoring Plan directly or indirectly through wholly-owned subsidiaries shall own more
than 50% of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan
formed a publicly traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate
Licensee owns and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or
indirectly shall own and control more than 50% of any Controlled Affiliate that is indirectly owned and
controlled by the publicly traded Controlled Affiliate Licensee.
Or
(3) With respect to a Controlled Affiliate that is 100% controlled by Plans including the Sponsoring Plan and
which offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and/or Special Need
Plans products and services, the Sponsoring Plan has the legal authority together with such other Plans:
(a) to select all members of the Controlled Affiliate’s governing body; and
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing
documents of the Controlled Affiliate; and
(c) to exercise control over the policy and operations of the Controlled Affiliate.
In addition, the Sponsoring Plan and such other Plans shall own 100% of any for-profit Controlled
Affiliate with the Sponsoring Plan and such other Plans each having an ownership interest. Such control
and ownership by Plans must be direct or, if indirect, solely through affiliates that are licensed to use
marks owned by BCBSA. Further, the Sponsoring Plan and such other Plans shall execute a separate
Addendum to Controlled Affiliate License Agreement attached hereto as Exhibit B-1 for each product
noted in Paragraph 2E(3) that is licensed to use the Marks.
Or
(4) With respect to a Controlled Affiliate that is 100% controlled by a Sponsoring Plan which
on a Blue-branded basis, only offers a Basic Medicare Part D Prescription Drug Plan
product, the Sponsoring Plan has the legal authority:
(a) to select all members of the Controlled Affiliate’s governing body; and
(b) to prevent any change in the articles of incorporation, bylaws or other
establishing or governing documents of the Controlled Affiliate; and
(c) to exercise control over the policy and operations of the Controlled Affiliate.
Amended June 20, 2019
4

-- 205 of 533 --

In addition, the Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control
and ownership by Sponsoring Plan must be direct or, if indirect, solely through affiliates that are licensed
to use marks owned by BCBSA. Further, the Participating Plan as defined in Exhibit B-2 and the
Sponsoring Plan shall execute the Addendum to Controlled Affiliate License Agreement attached hereto
as Exhibit B-2.
Or
(5) With respect to a Controlled Affiliate that operates as a clinic, absent an alternative method of control
approved in writing by BCBSA, the Sponsoring Plan shall have bona fide operational control over the
Controlled Affiliate as specified in Exhibit A, Standard 1(E) and the Guidelines to Administer Standard
1(E). In addition, if the clinic is for-profit, the Sponsoring Plan shall own at least 50% of the Controlled
Affiliate and prevent any change in the articles of incorporation, bylaws or other establishing documents
of the Controlled Affiliate with which the Sponsoring Plan does not concur.
Or
(6) With respect to any Plan affiliation(s) entered into after June 15, 2023, the Controlled Affiliate has
entered into a contractual agreement with the Sponsoring Plan that meets the criteria set forth in Exhibit
A, Standard 1(F) and the Guidelines to Administer Standard 1(F) and Protocol for Determining Automatic
Transfer of Primary License Agreement Pursuant to Contractual Control.
Amended as of June 15, 2023
5

-- 206 of 533 --

3. FOR-PROFIT, PUBLICLY TRADED LICENSEES
A. The Controlled Affiliate may operate as a for-profit publicly traded company on the following
conditions:
(1) The Controlled Affiliate shall discharge all responsibilities which it has to the Association and to other
Plans by virtue of this Agreement.
(2) The Controlled Affiliate shall provide 90 days advance written notice to BCBSA prior to the initial filing
with the SEC.
(3) The Controlled Affiliate shall not use the Licensed Marks and Name, or any derivative thereof, as part of
its legal name or any symbol used to identify the Controlled Affiliate in any securities market. The
Controlled Affiliate shall use the Licensed Marks and Name as part of its trade name within its service
area for the sale, marketing and administration of health care and related services in the service area.
(4) The Controlled Affiliate’s license to use the Licensed Marks and Name shall automatically terminate
effective: (a) thirty days after the Controlled Affiliate knows, or there is an SEC filing indicating that, any
Institutional Investor, has become the Beneficial Owner of securities representing 10% or more of the
voting power of the Controlled Affiliate (“Excess Institutional Voter”), unless such Excess Institutional
Voter shall cease to be an Excess Institutional Voter prior to such automatic termination becoming
effective; (b) thirty days after the Controlled Affiliate knows, or there is an SEC filing indicating that, any
Noninstitutional Investor, other than a Plan or Plans or Controlled Affiliate Licensee or Licensees has
become the Beneficial Owner of securities representing 5% or more of the voting power of the Controlled
Affiliate (“Excess Noninstitutional Voter”) unless such Excess Noninstitutional Voter shall cease to be an
Excess Noninstitutional Voter prior to such automatic termination becoming effective; (c) thirty days after
the Controlled Affiliate knows, or there is an SEC filing indicating that, any Person has become the
Beneficial Owner, other than a
Amended as of June 20, 2019
6

-- 207 of 533 --

Plan or Plans or Controlled Affiliate Licensee or Licensees, of 20% or more of the Controlled Affiliate’s
then outstanding common stock or other equity securities which (either by themselves or in combination)
represent an ownership interest of 20% or more pursuant to determinations made under paragraph
3A(4) below (“Excess Owner”), unless such Excess Owner shall cease to be an Excess Owner prior to
such automatic termination becoming effective; (d) ten business days after individuals who at the time
the Controlled Affiliate went public constituted the Board of Directors of the Controlled Affiliate (together
with any new directors whose election to the Board was approved by a vote of 2/3 of the directors then
still in office who were directors at the time the Controlled Affiliate went public or whose election or
nomination was previously so approved) (the “Continuing Directors”) cease for any reason to constitute
a majority of the Board of Directors; or (e) ten business days after the Controlled Affiliate consolidates
with or merges with or into any person or conveys, assigns, transfers or sells all or substantially all of its
assets to any person other than amerger in which the Sponsoring Plan is the surviving entity and
immediately after which merger, no person is an Excess Institutional Voter, an Excess Noninstitutional
Voter or an Excess Owner: provided that, if requested by the affected Controlled Affiliate in a writing
received by BCBSA prior to such automatic termination becoming effective, the provisions of this
paragraph 3A(4) may be waived, in whole or in part, upon the affirmative vote of a majority of the
disinterested Plans and majority of the total then current weighted vote of the disinterested Plans. Any
waiver so granted may be conditioned upon such additional requirements (including but not limited to
imposing new and independent grounds for termination of this License) as shall be approved by the
affirmative vote of a majority of the disinterested Plans and a majority of the total then current weighted
vote of the disinterested Plans. If a timely waiver request is received, no automatic termination shall
become effective until the later of: (1) the conclusion of the applicable time period specified in
paragraphs 3A(4) (a)-(d) above, or (2) the conclusion of the first Member Plan meeting after receipt of
such a waiver request.
In the event that the Controlled Affiliate’s license, or any other license, to use the Licensed Marks and
Name is terminated pursuant to Paragraph 3A(4), the license may be reinstated in BCBSA’s sole
discretion if, within 30 days of the date of such termination, the Controlled Affiliate demonstrates that the
Person referred to in clause (a), (b), or (c) of the preceding paragraph is no longer an Excess
Institutional Voter, an Excess Noninstitutional Voter or an Excess Owner.
(5) The Controlled Affiliate shall not issue any class or series of security other than (i) shares of common stock
having identical terms or options or derivatives of such common stock, (ii) non-voting, non-convertible debt
securities or (iii) such other securities as the Controlled Affiliate may approve, provided that BCBSA receives
notice at least thirty days prior to the issuance of such securities, including a description of the terms for such
securities, and BCBSA shall have the authority to determine how such other securities will be counted in
determining whether any Person is an Excess Institutional Voter, Excess Noninstitutional Voter or an Excess
Owner.
(6) For purposes of paragraph 3A(4) above, the following definitions shall apply:
(i) “Affiliate” and “Associate” shall have the respective meanings ascribed to such terms in Rule 12b-2
of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended and
in effect on November 17, 1993 (the “Exchange Act”). -7-

-- 208 of 533 --

(ii) A Person shall be deemed the “Beneficial Owner” of and shall be deemed to “beneficially own” any
securities:
(1) which such Person or any of such Person’s Affiliates or Associates beneficially owns,
directly or indirectly;
i. which such Person or any of such Person’s Affiliates or Associates has the right to acquire
(whether such right is exercisable immediately or only after the passage of time) pursuant to
any agreement, arrangement or understanding, or upon the exercise of conversion rights,
exchange rights, warrants or options, or otherwise; or (B) the right to vote pursuant to any
agreement, arrangement or understanding; provided, however, that a Person shall not be
deemed the Beneficial Owner of, or to beneficially own, any security if the agreement,
arrangement or understanding to vote such security (1) arises solely from a revocable proxy or
consent given to such Person in response to a public proxy or consent solicitation made
pursuant to, and in accordance with, the applicable rules and regulations promulgated under
the Exchange Act and (2) is not also then reportable on Schedule 13D under the Exchange
Act (or any comparable or successor report); or
(3) which are beneficially owned, directly or indirectly, by any other Person (or any Affiliate or
Associate thereof) with which such Person (or any of such Person’s Affiliates or Associates)
has any agreement, arrangement or understanding (other than customary agreements with
and between underwriters and selling group members with respect to a bona fide public
offering of securities) relating to the acquisition, holding, voting (except to the extent
contemplated by the proviso to (ii)2(B) above) or disposing of any securities of the
Controlled Affiliate.
Notwithstanding anything in this definition of Beneficial Ownership to the contrary, the phrase
“then outstanding,” when used with reference to a Person’s Beneficial Ownership of securities
of the Controlled Affiliate, shall mean the number of such securities then issued and
outstanding together with the number of such securities not then actually issued and
outstanding which such Person would be deemed to own beneficially hereunder.
Amended as of March 26, 2015
-8-

-- 209 of 533 --

(iii) A Person shall be deemed an “Institutional Investor” if (but only if) such Person (i) is an entity or
group identified in the SEC’s Rule 13d-1(b)(1)(ii) as constituted on June 1, 1997, and (ii) every filing
made by such Person with the SEC under Regulation 13D-G (or any successor Regulation) with
respect to such Person’s Beneficial Ownership of Plan securities shall have contained a
certification identical to the one required by item 10 of SEC Schedule 13G as constituted on June 1,
1997.
(iv) “Noninstitutional Investor” means any Person who is not an Institutional Investor.
(v) “Person” shall mean any individual, firm, partnership, corporation, trust, association, joint venture
or other entity, and shall include any successor (by merger or otherwise) of such entity.
4. SERVICE MARK USE
A. Controlled Affiliate recognizes the importance of a comprehensive national network
of independent BCBSA licensees which are committed to strengthening the Licensed Marks and Name. The
Controlled Affiliate further recognizes that its actions within its Service Area may affect the value of the Licensed
Marks and Name nationwide.
B. Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and Name, including
but not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks and
Name and shall comply with such rules (generally applicable to Controlled Affiliates licensed to use the
Licensed Marks and Name) relative to service mark use, as are issued from time-to-time by BCBSA.
Controlled Affiliate recognizes and agrees that all use of the Licensed Marks and Name by Controlled Affiliate
shall inure to the benefit of BCBSA.
C. Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in a manner that transfers
or is intended to transfer in the Service Area the goodwill associated therewith to another mark or name, nor
may Controlled Affiliate engage in activity that may dilute or tarnish the unique value of the Licensed Marks and
Name.
D. If Controlled Affiliate meets the standards of 2E(1) but not 2E(2) above and any of Controlled Affiliate's
advertising or promotional material is reasonably determined by BCBSA and/or the Plan to be in contravention
of rules and regulations governing the use of the Licensed Marks and Name, Controlled Affiliate shall for
ninety (90) days thereafter obtain prior approval from BCBSA of advertising and promotional efforts using the
Licensed Marks and Name, approval or disapproval thereof to be forthcoming within five (5) business days of
receipt of same by BCBSA or its designee. In all advertising and promotional efforts, Controlled Affiliate shall
observe the Service Area limitations applicable to Plan.
Amended as of March 26, 2015
-9-

-- 210 of 533 --

E. Notwithstanding any other provision in the Plan’s License Agreement with BCBSA or in this Agreement,
Controlled Affiliate shall use its best efforts to promote and build the value of the Licensed Marks and Name.
5. SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell, encumber or mortgage, by
operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the sole option of
Plan or BCBSA. This Agreement and all rights and duties hereunder are personal to Controlled Affiliate.
6. INFRINGEMENT
Controlled Affiliate shall promptly notify Plan and Plan shall promptly notify BCBSA of any suspected acts of
infringement, unfair competition or passing off that may occur in relation to the Licensed Marks and Name.
Controlled Affiliate shall not be entitled to require Plan or BCBSA to take any actions or institute any proceedings to
prevent infringement, unfair competition or passing off by third parties. Controlled Affiliate agrees to render to Plan
and BCBSA, without charge, all reasonable assistance in connection with any matter pertaining to the protection of
the Licensed Marks and Name by BCBSA.
7. LIABILITY INDEMNIFICATION
Controlled Affiliate and Plan hereby agree to save, defend, indemnify and hold BCBSA harmless from and against all
claims, damages, liabilities and costs of every kind, nature and description (except those arising solely as a result of
BCBSA's negligence) that may arise as a result of or related to: (i) Controlled Affiliate's rendering of services under
the Licensed Marks and Name; or (ii) the activities of any hospital, medical group, clinic or other provider of health
services that is owned or controlled directly or indirectly by Plan or Controlled Affiliate.
8. LICENSE TERM
A. Except as otherwise provided herein, the license granted by this Agreement shall remain in effect for a period
of one (1) year and shall be automatically extended for additional one (1) year periods unless terminated
pursuant to the provisions herein.
B. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any
further action by any party or entity in the event that: (i) the Plan ceases to be authorized to use the Licensed
Marks and Name; or (ii) pursuant to Paragraph 15(a)(x) of the Blue Cross License Agreement the Plan
ceases to be authorized to use the Licensed Names and Marks in the geographic area served by the
Controlled Affiliate provided, however, that if the Controlled Affiliate is serving more than one State or portions
thereof, the termination of this Agreement shall be
Amended as of March 26, 2015
-10-

-- 211 of 533 --

limited to the State(s) or portions thereof in which the Plan’s license to use the Licensed Marks and Names is
terminated. By not appealing or challenging such regulatory action within the time prescribed by law or
regulation, and in any event no later than 120 days after such action is taken, a Plan shall be deemed to have
exhausted its rights to appeal or challenge, and automatic termination shall proceed.
C. Notwithstanding any other provision of this Agreement, this license to use the Licensed Marks and Name may
be forthwith terminated by the Plan or the affirmative vote of the majority of the Board of Directors of BCBSA
present and voting at a special meeting expressly called by BCBSA for the purpose on ten (10) days written
notice to the Plan advising of the specific matters at issue and granting the Plan an opportunity to be heard
and to present its response to the Board for: (1) failure to comply with any applicable minimum capital or
liquidity requirement under the quality control standards of this Agreement; or (2) failure to comply with the
"Organization and Governance" quality control standard of this Agreement; or (3) impending financial
insolvency; or (4) for a Smaller Controlled Affiliate (as defined in Exhibit A), failure to comply with any of the
applicable requirements of Standards 2, 3, 4, 5 or 7 of attached Exhibit A; or (5) the pendency of any action
instituted against the Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking
appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business or
seeking the declaration or establishment of a trust for any of its property or business, unless this Controlled
Affiliate License Agreement has been earlier terminated under paragraph 8(E); or (6) failure by a Controlled
Affiliate that meets the standards of 2E(1) but not 2E(2) above to obtain BCBSA's written consent to a change
in the identity of any owner, in the extent of ownership, or in the identity of any person or entity with the
authority to select or appoint members or board members, provided that as to publicly traded Controlled
Affiliates this provision shall apply only if the change affects a person or entity that owns at least 5% of the
Controlled Affiliate's stock before or after the change; or (7) such other reason as is determined in good faith
immediately and irreparably to threaten the integrity and reputation of BCBSA, the Plans, any other licensee
including Controlled Affiliate and/or the Licensed Marks and Name.
D. Except as otherwise provided in Paragraphs 8(B), 8(C) or 8(E) herein, should Controlled Affiliate fail to comply
with the provisions of this Agreement and not cure such failure within thirty (30) days of receiving written notice
thereof (or commence a cure within such thirty day period and continue diligent efforts to complete the cure if
such curing cannot reasonably be completed within such thirty day period) BCBSA or the Plan shall have the
right to issue a notice that the Controlled Affiliate is in a state of noncompliance. If a state of noncompliance as
aforesaid is undisputed by the Controlled Affiliate or is found to exist by a mandatory dispute resolution panel
and is uncured as provided above, BCBSA shall have the right to seek judicial enforcement of the Agreement
or to issue a notice of termination thereof. Notwithstanding any other provisions of this Agreement, any
disputes as to the termination of this License pursuant to Paragraphs 8(B), 8(C) or 8(E) of this Agreement shall
not be subject to mediation and mandatory dispute resolution. All other disputes between BCBSA, the Plan
and/or Controlled Affiliate shall be submitted promptly to mediation and mandatory dispute resolution. The
mandatory dispute resolution panel shall have authority to issue orders for
Amended as of March 26, 2015
-11-

-- 212 of 533 --

specific performance and assess monetary penalties. Except, however, as provided in Paragraphs
8(B) and 8(E) of this Agreement, this license to use the Licensed Marks and Name may not be
finally terminated for any reason without the affirmative vote of a majority of the present and voting
members of the Board of Directors of BCBSA.
E. This Agreement and all of Controlled Affiliate’s rights hereunder shall immediately terminate without any
further action by any party or entity in the event that:
(1) Controlled Affiliate shall no longer comply with item 2(E) above;
(2) 	Appropriate dues, royalties and other payments for Controlled Affiliate pursuant to paragraph 10 hereof,
which are the royalties for this License Agreement, are more than sixty (60) days in arrears to BCBSA; or
(3) Any of the following events occur: (i) a voluntary petition shall be filed by Controlled Affiliate seeking
bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the
United States or any other law governing insolvencyor debtor relief, or (ii) an involuntary petition or
proceeding shall be filed against Controlled Affiliate seeking bankruptcy, reorganization, arrangement
with creditors or other relief under the bankruptcy laws of the United States or any other law governing
insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by Controlled
Affiliate or is not dismissed within sixty (60) days of the date upon which the petition or other document
commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order for relief is entered
against Controlled Affiliate in any case under the bankruptcy laws of the United States, or Controlled
Affiliate is adjudged bankrupt or insolvent as those terms are defined in the Uniform Commercial Code as
enacted in the State of Illinois by any court of competent jurisdiction, or (iv) Controlled Affiliate makes a
general assignment of its assets for the benefit of creditors, or (v) any government or any government
official, office, agency, branch, or unit assumes control of Controlled Affiliate or delinquency proceedings
(voluntary or involuntary) are instituted, or (vi) an action is brought by Controlled Affiliate seeking its
dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or
other custodian for any of its property or business, or (vii) an action is instituted by any governmental
entity or officer against Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the
appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business
and such action is consented to or acquiesced in by Controlled Affiliate or is not dismissed within one
hundred thirty (130) days of the date upon which the pleading or other document commencing the action
is served upon the Controlled Affiliate, provided that if the action is stayed or its prosecution is enjoined,
the one hundred thirty (130) day period is tolled for the duration of the stay or injunction, and provided
further, that the Association’s Board of Directors may toll or extend the 130 day period at any time prior to
its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any of Controlled Affiliate's
property or business is appointed or the Controlled Affiliate is ordered dissolved or liquidated.
Notwithstanding any other provision of this Agreement, a declaration or a request for declaration of the
existence of a trust over any of the Controlled Affiliate’s property or business shall not in itself be deemed
to
Amended as of March 26, 2015
-12-

-- 213 of 533 --

constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of
subparagraphs 8(E)(3)(vii) and (viii) of this Agreement.
(4) The for-profit, publicly traded Controlled Affiliate is terminated pursuant to Paragraph 3A(4) of this
Agreement. In which case, the licenses of any Controlled Affiliates directly or indirectly owned by the
terminated for-profit, publicly traded Controlled Affiliate also shall immediately terminate as provided for
in paragraph 3A(4) of this Agreement.
F. Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately
discontinue all use of the Licensed Marks and Name, including any use in its trade name.
G. Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its customers that it is no
longer a licensee of BCBSA and, if directed by the Association’s Board of Directors, shall provide instruction on
how the customer can contact BCBSA or a designated licensee to obtain further information on securing
coverage. The notification required by this paragraph shall be in writing and in a form approved by BCBSA.
The BCBSA shall have the right to audit the terminated entity's books and records to verify compliance with
this paragraph.
H. In the event this Agreement terminates pursuant to 8(B) hereof, or in the event the Controlled Affiliate is a
Larger Controlled Affiliate (as defined in Exhibit A), upon termination of this Agreement, the provisions of
Paragraph 8.G. shall not apply and the following provisions shall apply, except that, in the event of a partial
termination of this Agreement pursuant to Paragraph 8(B)(ii) of this Agreement, the notices, national account
listing, payment, and audit right listed below shall be applicable solely with respect to the geographic area for
which the Plan’s license to use the Licensed Names and Marks is terminated.
(1) The Controlled Affiliate shall send a notice through the U.S. mails, with first class postage affixed, to all
individual and group customers, providers, brokers and agents of products or services sold, marketed,
underwritten or administered by the Controlled Affiliate under the Licensed Marks and Name. The form
and content of the notice shall be specified by BCBSA and shall, at a minimum, notify the recipient of the
termination of the license, the consequences thereof, and instructions for obtaining alternate products or
services licensed by BCBSA, subject to any conflicting state law and state regulatory requirements. This
notice shall be mailed within 15 days after termination.
(2) The Controlled Affiliate shall deliver to BCBSA within five days of a request by BCBSA a listing of national
accounts in which the Controlled Affiliate is involved (in a control, participating or servicing capacity),
identifying the national account and the Controlled Affiliate’s role therein.
Amended as of March 26, 2015
-13-

-- 214 of 533 --

(3) Unless the cause of termination is an event respecting BCBSA stated in paragraph 15(a) or (b) of the
Plan’s license agreement with BCBSA to use the Licensed Marks and Name, the Controlled Affiliate, the
Plan, and any other Licensed Controlled Affiliates of the Plan shall be jointly liable for payment to BCBSA
of an amount equal to the Re-Establishment Fee (described below) multiplied by the number of Licensed
Enrollees of the Controlled Affiliate; provided that if any other Plan is permitted by BCBSA to use marks
or names licensed by BCBSA in the Service Area established by this Agreement, the Re- Establishment
Fee shall be multiplied by a fraction, the numerator of which is the number of Licensed Enrollees of the
Controlled Affiliate, the Plan, and any other Licensed Controlled Affiliates and the denominator of which is
the total number of Licensed Enrollees in the Service Area.
The Re-Establishment Fee shall be indexed to a base fee of $80. The Re- Establishment Fee through
December 31, 2005 shall be $80. The Re- establishment Fee for calendar years after December 31,
2005 shall be adjusted on January 1 of each calendar year up to and including January 1, 2010 and shall
be the base fee multiplied by 100% plus the cumulative percentage increase or decrease in the Plans’
gross administrative expense (standard BCBSA definition) per Licensed Enrollee since December 31,
2004. The adjustment shall end on January 1, 2011, at which time the Re- Establishment Fee shall be
fixed at the then- current amount and no longer automatically adjusted. For example, if the Plans’ gross
administrative expense per Licensed Enrollee was $278.60, $285.00 and $290.00 for calendar year end
2004, 2005 and 2006, respectively, the January 1, 2007 Re-Establishment Fee would be $83.27 (100%
of base fee plus $1.84 for calendar year 2005 and $1.43 for calendar year 2006). Licensed Enrollee
means each and every person and covered dependent who is enrolled as an individual or member of a
group receiving products or services sold, marketed or administered under marks or names licensed by
BCBSA as determined at the earlier of (i) the end of the last fiscal year of the terminated entity which
ended prior to termination or (ii) the fiscal year which ended before any transactions causing the
termination began. Notwithstanding the foregoing, the amount payable pursuant to this subparagraph H.
(3) shall be due only to the extent that, in BCBSA’s opinion, it does not cause the net worth of the
Controlled Affiliate, the Plan or any other Licensed Controlled Affiliates of the Plan to fall below 100% of
the Health Risk-Based Capital formula, or its equivalent under any successor formula, as set forth in the
applicable financial responsibility standards established by BCBSA (provided such equivalent is
approved for purposes of this sub paragraph by the affirmative vote of three-fourths of the Plans and
three-fourths of the total then current weighted vote of all the Plans); measured as of the date of
termination, and adjusted for the value of any transactions not made in the ordinary course of business.
This payment shall not be due in connection with transactions exclusively by or among Plans or their
affiliates, including reorganizations, combinations or mergers, where the BCBSA Board of Directors
determines that the license termination does not result in a material diminution in the number of Licensed
Enrollees or the extent of their coverage. At least 50% of the Re- Establishment Fee shall be awarded to
the Plan (or Plans) that receive the new license(s) for the service area(s) at issue; provided, however,
that such award shall not become due or payable until all disputes, if any, regarding the amount of and
BCBSA’s right to such Re- Establishment Fee have been finally resolved; and provided further that the
award shall be
Amended as of March 26, 2015
-14-

-- 215 of 533 --

based on the final amount actually received by BCBSA. The Board of Directors shall adopt a resolution
which it may amend from time to time that shall govern BCBSA’s use of its portion of the award. In the
event that the Controlled Affiliate’s license is reinstated by BCBSA or is deemed to have remained in
effect without interruption by a court of competent jurisdiction, BCBSA shall reimburse the Controlled
Affiliate (and/or the Plan or its other Licensed Controlled Affiliates, as the case may be) for payments
made under this subparagraph 8.H.(3) only to the extent that such payments exceed the amounts due to
BCBSA pursuant to paragraph 8.M. and any costs associated with reestablishing the Service Area,
including payments made by BCBSA to a Plan or Plans (or their Licensed Controlled Affiliates) for
purposes of replacing the Controlled Affiliate.
(4) BCBSA shall have the right to examine and audit and/or hire at terminated entity’s expense a third party auditor
to examine and audit the books and records of the Controlled Affiliate, the Plan, and any other Licensed
Controlled Affiliates of the Plan to verify compliance with this paragraph 8.H.
(5) Subsequent to termination of this Agreement, the terminated entity and its affiliates, agents, and employees
shall have an ongoing and continuing obligation to protect all BCBSA and Blue Licensee data that was acquired
or accessed during the period this Agreement was in force, including but not limited to all confidential
processes, pricing, provider, discount and other strategic and competitively sensitive information (“Blue
Information”) from disclosure, and shall not, either alone or with another entity, disclose such Blue Information
or use it in any manner to compete without the express written permission of BCBSA.
(6) As to a breach of 8.H.(1), (2), (3), (4) or (5) the parties agree that the obligations are immediately enforceable in
a court of competent jurisdiction. As to a breach of 8.H.(1), (2) or (4) by the Controlled Affiliate, the parties agree
there is no adequate remedy at law and BCBSA is entitled to obtain specific performance.
I. 	This Agreement shall remain in effect until terminated by the Controlled Affiliate or the Plan upon not less than
eighteen (18) months written notice to the Association or upon a shorter notice period approved by BCBSA in
writing at its sole discretion, or until terminated as otherwise provided herein. The Plan’s right to terminate
without cause upon such notice is unfettered and may be exercised in the Plan’s sole discretion.
J. 	In the event the Controlled Affiliate is a Smaller Controlled Affiliate (as defined in Exhibit A), the Controlled
Affiliate agrees to be jointly liable for the amount described in H.3. and M. hereof upon termination of the
BCBSA license agreement of any Larger Controlled Affiliate of the Plan.
K. 	BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of competent
jurisdiction from entry into any transaction which would result in a termination of this Agreement unless the
Plan’s license from BCBSA to use the Licensed Marks and Names has been terminated pursuant to 10(d) of
the Plan’s license agreement upon the required 18 months written notice.
Amended as of March 26, 2015
-15-

-- 216 of 533 --

L. 	BCBSA acknowledges that it is not the owner of assets of the Controlled Affiliate.
M. In the event that the Plan has more than 50 percent voting control of the Controlled Affiliate under Paragraph
2(E)(2) above and is a Larger Controlled Affiliate (as defined in Exhibit A), then the vote called for in
Paragraphs 8(C) and 8(D) above shall require the affirmative vote of three-fourths of the Plans and three-
fourths of the total then current weighted vote of all the Plans.
N. In the event this Agreement terminates and is subsequently reinstated by BCBSA or is deemed to have
remained in effect without interruption by a court of competent jurisdiction, the Controlled Affiliate, the Plan,
and any other Licensed Controlled Affiliates of the Plan shall be jointly liable for reimbursing BCBSA the
reasonable costs incurred by BCBSA in connection with the termination and the reinstatement or court action,
and any associated legal proceedings, including but not limited to: outside legal fees, consulting fees, public
relations fees, advertising costs, and costs incurred to develop, lease or establish an interim provider network.
Any amount due to BCBSA under this subparagraph may be waived in whole or in part by the BCBSA Board of
Directors in its sole discretion.
9. DISPUTE RESOLUTION
The parties agree that any disputes between them or between or among either of them and one or more Plans or
Controlled Affiliates of Plans that use in any manner the Blue Cross and Blue Cross Marks and Name are subject
to the Mediation and Mandatory Dispute Resolution process attached to and made a part of Plan's License from
BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-to-time, which documents are
incorporated herein by reference as though fully set forth herein.
10. LICENSE FEE
Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth in
Exhibit C.
11. JOINT VENTURE
Nothing contained in the Agreement shall be construed as creating a joint venture, partnership, agency or
employment relationship between Plan and Controlled Affiliate or between either and BCBSA.
12. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall
be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its
President and, if any, its General Counsel.
Amended as of March 26, 2015
-16-

-- 217 of 533 --

13. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This
Agreement may only be amended by the affirmative vote of three-fourths of the Plans and three-fourths of the
total then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.
14. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such findings shall in no way
affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for
any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of
this Agreement.
15. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or any other licensee
of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or
default in performance of said terms, covenants or conditions.
15A. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the
Blue Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes
equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes
(if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all
questions requiring an affirmative three-fourths weighted vote of the Plans, voting shall occur pursuant to BCBSA’s
Bylaws.
Amended as of March 26, 2015
-16-

-- 218 of 533 --

THIS PAGE IS INTENTIONALLY BLANK.

-- 219 of 533 --

16. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of
the State of Illinois.
17. HEADINGS
The headings inserted in this agreement are for convenience only and shall have no bearing on the
interpretation hereof.
IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed and effective
as of the date of last signature written below.
Controlled Affiliate:
By:______________________________________________
Date:____________________________________________
Plan:
By:_______________________________________________
Date:_____________________________________________
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:_______________________________________________
Date:_____________________________________________
Amended as of March 26, 2015
-18-

-- 220 of 533 --

EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
November 2023
PREAMBLE
For purposes of definition:
• 	A "smaller Controlled Affiliate:" (1) comprises less than fifteen percent (15%) of Sponsoring Plan's and its licensed
Controlled Affiliates' total member enrollment (as reported on the BCBSA Quarterly Enrollment Report, excluding rider
and freestanding coverage, and treating an entity seeking licensure as licensed);* or (2) underwrites the indemnity
portion of workers’ compensation insurance and has total premium revenue less than 15 percent of the Sponsoring
Plan’s net subscription revenue.
• 	A "larger Controlled Affiliate" comprises fifteen percent (15%) or more of Sponsoring Plan's and its licensed Controlled
Affiliates' total member enrollment (as reported on the BCBSA Quarterly Enrollment Report, excluding rider and
freestanding coverage, and treating an entity seeking licensure as licensed.)*
Changes in Controlled Affiliate status:
If any Controlled Affiliate's status changes regarding: its Plan ownership level, its risk acceptance or direct delivery of
medical care, the Controlled Affiliate shall notify BCBSA within thirty (30) days of such occurrence in writing and come into
compliance with the applicable standards within six (6) months.
If a smaller Controlled Affiliate’s health and workers’ compensation administration business reaches or surpasses fifteen
percent (15%) of the total member enrollment of the Sponsoring Plan and licensed Controlled Affiliates, the Controlled
Affiliate shall:
Amended as of September 19, 2014
-19-

-- 221 of 533 --

EXHIBIT A (continued)
1. Within thirty (30) days, notify BCBSA of this fact in writing, including evidence that the Controlled Affiliate
meets the minimum liquidity and capital (BCBSA “Health Risk-Based Capital (HRBC)” as defined by the
NAIC and state- established minimum reserve) requirements of the larger Controlled Affiliate Financial
Responsibility standard; and
2. Within six (6) months after reaching or surpassing the fifteen percent (15%) threshold, demonstrate
compliance with all license requirements for a larger Controlled Affiliate.
If a Controlled Affiliate that underwrites the indemnity portion of workers’ compensation insurance receives a
change in rating or proposed change in rating, the Controlled Affiliate shall notify BCBSA within 30 days of
notification by the external rating agency.
*For purposes of this calculation, The numerator equals:
Applicant Controlled Affiliate's member enrollment, as defined in BCBSA's Quarterly Enrollment Report
(excluding rider and freestanding coverage).
The denominator equals:
Numerator PLUS Sponsoring Plan and all other licensed Controlled Affiliates' member enrollment, as
reported in BCBSA's Quarterly Enrollment Report (excluding rider and freestanding coverage).
Amended as of September 19, 2014
-20-

-- 222 of 533 --

EXHIBIT A (continued)
STANDARDS FOR LICENSED CONTROLLED AFFILIATES
Each licensed controlled affiliate shall be subject to certain standards as determined below:
1. What percent of the licensed controlled affiliate is controlled by the Sponsoring Plan and other Plans?
More than 50% by
Sponsoring Plan
ò
Standard 1A, 4
Or
Contractual Control
ò
Standard 1F, 4
50% by Sponsoring
Plan
ò
Standard 1B, 4
100% Plan control but less
than 50% Sponsoring Plan
Control and it offers solely
Medicaid, Medicare
Advantage PPO, Medicare
Advantage HMO and/or
Special Need Plans
products and services
ò
100% Sponsoring Plan
control and on a Blue-
branded basis, it only offers
a Basic Medicare Part D
Prescription Drug Plan
product
ò
Standard 1D, 4
At least 50% by
Sponsoring Plan or
operational Control by
Sponsoring Plan and it
solely operates as a Clinic
as defined in Standard 1E.
ò
Standard 1E, 4
IN ADDITION,
2. Is risk being assumed?
Yes 	No
ò 	ø 	÷ 	ò
Controlled Affiliate
underwrites any
indemnity portion of
workers’
compensation
insurance
Controlled Affiliate
comprises < 15% of
total member
enrollment of
Sponsoring Plan and its
licensed affiliates, and
does not underwrite the
indemnity portion of
workers’ compensation
insurance
Controlled Affiliate
comprises > 15% of total
member enrollment of
Sponsoring Plan and its
licensed affiliates, and
does not underwrite the
indemnity portion of
workers’ compensation
insurance
Controlled Affiliate comprises
< 15% of total member
enrollment of Sponsoring
Plan and its licensed affiliates
Controlled Affiliate comprises > 15% of total
member enrollment of Sponsoring Plan and
its licensed affiliates
ò 	ò 	ò 	ò 	ò
Standards 7A- 7E, 11 Standard 2
(Guidelines 1.1,1.2)
and Standard 11
Standard 6H
Standard 2
(Guidelines 1.1,1.3)
and Standard 11
Standard 6H

-- 223 of 533 --

IN ADDITION,
3. Is medical care being directly provided as a staff model HMO?
Yes 	No
ò 	ò
Standard 3A 	Standard 3B
Amended June 15, 2023
-21-

-- 224 of 533 --

EXHIBIT A (continued)
STANDARDS FOR LICENSED CONTROLLED AFFILIATES
Each licensed controlled affiliate shall be subject to certain standards as determined below:
IN ADDITION,
4. Is the licensed controlled affiliate operating as a Clinic as defined in Standard 1(E)?
Yes
ò
Standard 3C and Standard 2, 1.4 (if organized as a health plan that also operates as a Clinic)
5. If the controlled affiliate has health or workers’ compensation administration business, does such business comprise 15% or more of the total
member enrollment of Plan and its licensed Controlled Affiliates?
Yes 	No
ò 	÷ 	÷ 	ø
Standards 6A- 6J 	Controlled Affiliate is
not a former
primary licensee and is not
subject to Standard 1(C)
Controlled Affiliate is
a former primary
licensee
Controlled Affiliate is not a former
primary licensee and is subject to
Standard 1(C)
ò 	ò 	ò
Standards 5,8,9B,10,11 	Standards 5,8,9A,10,11
Standards 5,8,9B,11
Amended June 20, 2019
-22

-- 225 of 533 --

EXHIBIT A (continued)
Standard 1 - Organization and Governance
1A.) The Standard for more than 50% Plan control is:
A Controlled Affiliate shall be organized and operated in such a manner that a Plan authorized to use the Licensed Marks
in the Service Area of the Controlled Affiliate pursuant to the separate Primary License Agreement with BCBSA , has the
legal authority, directly or indirectly through wholly-owned subsidiaries: 1) to select members of the Controlled Affiliate’s
governing body having more than 50% voting control thereof; and 2) to prevent any change in the articles of incorporation,
bylaws or other establishing or governing documents of the Controlled Affiliate with which the Sponsoring Plan does not
concur; and 3) to exercise control over the policy and operations of the Controlled Affiliate. In addition, the Sponsoring Plan
directly or indirectly through wholly-owned subsidiaries shall own more than 50% of any for-profit Controlled Affiliate.
1B.) The Standard for 50% Plan control is:
A Controlled Affiliate shall be organized and operated in such a manner that a Plan authorized to use the Licensed
Marks in the Service Area of the Controlled Affiliate pursuant to the separate Primary License Agreement with
BCBSA has the legal authority, directly or indirectly through wholly-owned subsidiaries:
1) 	to select members of the Controlled Affiliate’s governing body having not less than 50% voting control
thereof; and
2) 	to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of
the Controlled Affiliate with which the Sponsoring Plan does not concur; and
3) to exercise control over the policy and operations of the Controlled Affiliate at least equal to that exercised by
persons or entities (jointly or individually) other than the Sponsoring Plan.
Amended as on September 19, 2014
-23-

-- 226 of 533 --

EXHIBIT A (continued)
Notwithstanding anything to the contrary in 1) through 3) hereof, the Controlled Affiliate’s establishing or governing
documents must also require written approval by Sponsoring Plan before the Controlled Affiliate can:
• 	change the geographic area in which it operates
• 	change its legal and/or trade names
• 	change any of the types of businesses in which it engages
• 	create, or become liable for by way of guarantee, any indebtedness, other than indebtedness arising in the
ordinary course of business
• 	sell any assets, except for sales in the ordinary course of business or sales of equipment no longer useful or
being replaced
• 	make any loans or advances except in the ordinary course of business
• 	enter into any arrangement or agreement with any party directly or indirectly affiliated with any of the owners
or persons or entities with the authority to select or appoint members or board members of the Controlled
Affiliate, other than the Sponsoring Plan or other Plans (excluding owners of stock holdings of under 5% in a
publicly traded Controlled Affiliate)
• 	conduct any business other than under the Licensed Marks and Name
• 	take any action that the Sponsoring Plan or BCBSA reasonably believes will adversely affect the Licensed
Marks and Name.
In addition, the Sponsoring Plan directly or indirectly through wholly-owned subsidiaries shall own at least 50% of
any for-profit Controlled Affiliate.
1C.) The Standard for a Controlled Affiliate that offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage
HMO and/or Special Need Plans products and service and has 100% Plan control but less than 50% Sponsoring
Plan Control is:
A Controlled Affiliate shall be organized and operated in such a manner that (i) it offers solely Medicaid, Medicare
Advantage PPO, Medicare Advantage HMO and/or Special Need Plans products and services; and (ii) a Plan
authorized to use the Licensed Marks in the Service Area of the Controlled Affiliate pursuant to the separate Primary
License Agreement with BCBSA has the legal authority together with Other Plans:
Amended as on September 27, 2018
-24-

-- 227 of 533 --

EXHIBIT A (continued)
1) to select all members of the Controlled Affiliate’s governing body; and
2) to prevent any change in the articles of incorporation, bylaws, or other establishing or governing documents of
the Controlled Affiliate; and
3) to exercise control over the policy and operations of the Controlled Affiliate.
In addition, the Sponsoring Plan and such other Plans shall own 100% of any for- profit Controlled Affiliate, with
the Sponsoring Plan and such other Plans each having an ownership interest. Such 100% control and
ownership by Plans shall be direct or, if
indirect, solely through affiliates that are licensed to use marks owned by BCBSA. Further, the Sponsoring Plan and
such other Plans shall execute the Addendum to Controlled Affiliate License.
1D.) The Standard for a Controlled Affiliate that on a Blue-branded basis only offers a Basic Medicare Part D Prescription
Drug Plan product and has 100% Plan control is:
A Controlled Affiliate shall be organized and operated in such a manner that
(i) on a Blue-branded basis, it only offers a Basic Medicare Part D Prescription Drug Plan product; and
(ii) the Sponsoring Plan has the legal authority:
1) to select all members of the Controlled Affiliate's governing body; and
2) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of
the Controlled Affiliate; and
3) to exercise control over the policy and operations of the Controlled Affiliate.
In addition, the Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control and
ownership by Sponsoring Plan must be direct or, if indirect, solely through affiliates that are licensed to use
marks owned by BCBSA.
Further, the Sponsoring Plan and Participating Plan shall execute the Addendum to Controlled Affiliate License.
1E.) The Standard for a Controlled Affiliate that operates as a Clinic and the Sponsoring Plan has control of the Clinic is:
A Controlled Affiliate shall be organized in such a manner that it operates as a Clinic and the Sponsoring Plan
exercises operation control over the Controlled Affiliate.
In addition, if the Clinic is for-profit, the Sponsoring Plan shall own at least 50% of the Controlled Affiliate and prevent
any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled
Affiliate.
25-

-- 228 of 533 --

EXHIBIT A (continued)
1F.) The Standard for possessing contractual control over a Controlled Affiliate is:
With respect to any Plan affiliations entered into after June 15, 2023, a Primary Licensee has entered into a
contractual agreement where:
(i) It has outsourced 50% or more of the expenditures for overall management and strategic direction to
another Primary Licensee, or
(ii) A regulatory agency has determined that a change of control or a corporate affiliation has occurred, or
(iii) Officers of a Primary Licensee perform roles for another Primary Licensee.
(This excludes Controlled Affiliates pursuant to paragraphs 2(a)(C) and 2(a)(D) of the Primary License Agreement).
The Primary License Agreement will automatically transfer, and the Plan will automatically become a Controlled
Affiliate of the other Primary Licensee unless otherwise approved in writing by BCBSA.
Amended June 15, 2023
-26-

-- 229 of 533 --

EXHIBIT A (continued)
Standard 2 – Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its
contractual obligations to its customers. If a risk- assuming Controlled Affiliate ceases operations for any reason, Blue
Cross and/or Blue Cross Plan coverage will be offered to all Controlled Affiliate subscribers without exclusions, limitations
or conditions based on health status. If a nonrisk-assuming Controlled Affiliate ceases operations for any reason,
Sponsoring Plan will provide for services to its customers. The requirements of the preceding two sentences shall apply
to all lines of business unless a line of business is specially exempted from the requirement(s) by the BCBSA Board of
Directors.
Standard 3 – State Licensure/Certification
3A.) The Standard for a Controlled Affiliate that employs, owns or contracts on a substantially exclusive basis for medical
services is:
A Controlled Affiliate shall maintain unimpaired licensure or certification for its medical care providers to operate
under applicable state laws.
3B.) The Standard for a Controlled Affiliate that does not employ, own or contract on a substantially exclusive basis for
medical services is:
A Controlled Affiliate shall maintain unimpaired licensure or certification to operate under applicable state laws.
3C.) The Standard for a Controlled Affiliate that operates as a Clinic as defined in Standard 1(E) is:
A Controlled Affiliate shall maintain appropriate and unimpaired licensure and certifications.
Standard 4 – Certain Disclosures
A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public
statements of 1) the structure of the Blue Cross and Blue Shield System; and 2) the independent nature of every
licensee; and 3) the Controlled Affiliate's financial condition.
Amended as on June 20, 2019
-27-

-- 230 of 533 --

EXHIBIT A (continued)
Standard 5 – Reports and Records for Certain Smaller Controlled Affiliates
For a smaller Controlled Affiliate that does not underwrite the indemnity portion of workers’ compensation insurance, the
Standard is:
A Controlled Affiliate and/or its Sponsoring licensed Plan shall furnish, on a timely and accurate basis, reports and records
relating to these Standards and the License Agreements between BCBSA and Controlled Affiliate.
Standard 6 – Other Standards for Larger Controlled Affiliates Standards 6(A) – (I) that follow
apply to larger Controlled Affiliates. Standard 6(A): Board of Directors
A Controlled Affiliate Governing Board shall act in the interest of its Corporation in providing cost-effective health care
services to its customers. A Controlled Affiliate shall maintain a governing Board, which shall control the Controlled
Affiliate, composed of a majority of persons other than providers of health care services, who shall be known as public
members. A public
member shall not be an employee of or have a financial interest in a health care provider, nor be a member of a
profession which provides health care services.
Standard 6(B): Responsiveness to Customers
A Controlled Affiliate shall be operated in a manner responsive to customer needs and requirements.
Standard 6(C): Participation in National Programs
A Controlled Affiliate shall effectively and efficiently participate in each national program as from time to time may be
adopted by the Member Plans for the purposes of providing portability of membership between the licensees and ease of
claims processing for customers receiving benefits outside of the Controlled Affiliate's Service Area.
Amended as on September 19, 2014
-28-

-- 231 of 533 --

EXHIBIT A (continued)
Standard 6(C): Participation in National Programs (continued)
Such programs are applicable to licensees, and include:
1. BlueCard Program;
2. Inter-Plan Teleprocessing System (ITS);
3. National Account Programs
4. Business Associate Agreement for Blue Cross and Blue Shield Licensees, effective April
14, 2003; and
5. Inter-Plan Medicare Advantage Program.
Standard 6(D):Financial Performance Requirements
In addition to requirements under the national programs listed in Standard 6C: Participation in National Programs, a
Controlled Affiliate shall take such action as required to ensure its financial performance in programs and contracts of an
inter-licensee nature or where BCBSA is a party.
Standard 6(E): Cooperation with Plan Performance Response Process
A Controlled Affiliate shall cooperate with BCBSA's Board of Directors and its Organization and Governance Committee in the
administration of the Plan Performance Response Process and in addressing Controlled Affiliate performance problems
identified thereunder.
Standard 6(F): Independent Financial Rating
A Controlled Affiliate shall obtain a rating of its financial strength from an independent rating agency approved by BCBSA's
Board of Directors for such purpose.
Standard 6(G): Local Best Efforts
Notwithstanding any other provision in the Plan’s License Agreement with BCBSA or in this License Agreement, during
each year, a Controlled Affiliate shall use its best efforts to promote and build the value of the Blue Cross Mark.
Standard 6(H): Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its
contractual obligations to its customers.
Amended as on April 27, 2021
-29-

-- 232 of 533 --

EXHIBIT A (continued)
Standard 6(I): Reports and Records
A Controlled Affiliate shall furnish to BCBSA on a timely and accurate basis reports and records relating to
compliance with these Standards and the License Agreements between BCBSA and Controlled Affiliate. Such
reports and records are the following:
A) BCBSA Controlled Affiliate Licensure Information Request; and
B) Triennial trade name and service mark usage material, including disclosure material; and
C) Changes in the ownership and governance of the Controlled Affiliate, including changes in its charter,
articles of incorporation, or bylaws, changes in a Controlled Affiliate's Board composition, or changes in
the identity of the Controlled Affiliate's Principal Officers, and changes in risk acceptance, contract
growth, or direct delivery of medical care; and
D) Semi-annual “Health Risk-Based Capital (HRBC) Report” as defined by the NAIC, Annual Certified
Audit Report, Insurance Department Examination Report, Annual Statement filed with State
Insurance Department (with all attachments), and
Amended as on November 17, 2021
-30-

-- 233 of 533 --

EXHIBIT A (continued)
Standard 6(J): Control by Unlicensed Entities Prohibited
No Controlled Affiliate shall cause or permit an entity other than a Plan or a Licensed Controlled Affiliate thereof to obtain
control of the Controlled Affiliate or to acquire a substantial portion of its assets related to licensable services.
Standard 7 - Other Standards for Risk-Assuming Workers’ Compensation Controlled
Affiliates
Standards 7(A) - (E) that follow apply to Controlled Affiliates that underwrite the indemnity portion of workers’
compensation insurance.
Standard 7 (A): Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its
contractual obligations to its customers.
Standard 7(B): Reports and Records
A Controlled Affiliate shall furnish, on a timely and accurate basis, reports and records relating to compliance with these
Standards and the License Agreements between BCBSA and the Controlled Affiliate. Such reports and records are the
following:
A. BCBSA Controlled Affiliate Licensure Information Request; and
B. Triennial trade name and service mark usage materials, including disclosure materials; and
C. Annual Certified Audit Report, Annual Statement as filed with the State Insurance Department (with all
attachments), Annual NAIC’s Risk-Based Capital Worksheets for Property and Casualty Insurers; and
D. Quarterly Estimated Risk-Based Capital for Property and Casualty Insurers, Insurance Department Examination
Report; and
Amended as of November 17, 2011
-31-

-- 234 of 533 --

EXHIBIT A (continued)
E. Notification of all changes and proposed changes to independent ratings within 30 days of
receipt and submission of a copy of all rating reports; and
F. Changes in the ownership and governance of the Controlled Affiliate including changes in its
charter, articles of incorporation, or bylaws, changes in a Controlled Affiliate’s Board
composition, Plan control, state license status, operating area, the Controlled Affiliate’s
Principal Officers or direct delivery of medical care.
Standard 7(C): Loss Prevention
A Controlled Affiliate shall apply loss prevention protocol to both new and existing business. Standard 7(D): Claims
Administration
A Controlled Affiliate shall maintain an effective claims administration process that includes all the necessary functions to
assure prompt and proper resolution of medical and indemnity claims.
Standard 7(E): Disability and Provider Management
A Controlled Affiliate shall arrange for the provision of appropriate and necessary medical and rehabilitative services to facilitate
early intervention by medical professionals and timely and appropriate return to work.
Amended as of November 16, 2000
-32-

-- 235 of 533 --

EXHIBIT A (continued)
Standard 8 - Cooperation with Controlled Affiliate License Performance Response Process
Protocol
A Controlled Affiliate and its Sponsoring Plan shall cooperate with BCBSA’s Board of Directors and its Organization and
Governance Committee in the administration of the Controlled Affiliate License Performance Response Process Protocol
(ALPRPP) and in addressing Controlled Affiliate compliance problems identified thereunder.
Standard 9(A) - Participation in National Programs by Smaller Controlled Affiliates that were former Primary
Licensees
A smaller controlled affiliate that formerly was a Primary Licensee shall effectively and efficiently participate in certain
national programs from time to time as may be adopted by Member Plans for the purposes of providing ease of claims
processing for customers receiving benefits outside of the Controlled Affiliate’s service area and be subject to certain
relevant financial and reporting requirements.
A. National program requirements include:
• 	BlueCard Program;
• 	Inter-Plan Teleprocessing System (ITS);
• 	National Account Programs.
B. Financial Requirements include:
• 	Standard 6(D): Financial Performance Requirements and Standard 6(H): Financial Responsibility; or
• 	A financial guarantee covering the Controlled Affiliate’s Inter-Plan Programs obligations in a form, and from a
guarantor, acceptable to BCBSA.
Amended as of November 21, 2014
-33-

-- 236 of 533 --

EXHIBIT A (continued)
Standard 9(A) - Participation in National Programs by Smaller Controlled Affiliates that were former Primary
Licensees
C. Reporting requirements include:
• The Semi-annual Health Risk-Based Capital (HRBC) Report.
Amended as of June 13, 2002
-34-

-- 237 of 533 --

EXHIBIT A (continued)
Standard 9(B) - Participation in National Programs by Smaller Controlled Affiliates
A smaller controlled affiliate shall participate in national programs in accordance with BlueCard and other relevant Policies
and Provisions shall effectively and efficiently participate in national programs from time to time as may be adopted by
Member Plans for the purposes of providing ease of claims processing for customers receiving benefits outside of the
controlled affiliate’s service area and be subject to certain relevant financial and reporting requirements.
A. National program requirements include:
• 	BlueCard Program;
• 	Inter-Plan Teleprocessing System (ITS);
• 	National Account Programs.
B. Financial Requirements include:
• 	Standard 6(D): Financial Performance Requirements and Standard 6(H): Financial Responsibility; or
• 	A financial guarantee covering the Controlled Affiliate’s Inter-Plan Programs obligations in a form, and from a
guarantor, acceptable to BCBSA.
Amended as of June 20, 2013
-35-

-- 238 of 533 --

EXHIBIT A (continued)
Standard 10 - Participation in Inter-Plan Medicare Advantage Program
A smaller controlled affiliate for which this standard applies pursuant to the Preamble section of Exhibit A of the Controlled
Affiliate License Agreement shall effectively and efficiently participate in certain national programs from time to time as
may be adopted by Member Plans for the purposes of providing ease of claims processing for customers receiving
benefits outside of the controlled affiliate’s service area.
National program requirements include:
A. Inter-Plan Medicare Advantage Program.
Standard 11: Participation in Master Business Associate Agreement by Smaller Controlled Affiliate
Licensees
Effective April 14, 2003, all smaller controlled affiliates shall comply with the terms of the Business Associate Agreement
for Blue Cross and Blue Shield Licensees to the extent they perform the functions of a business associate or
subcontractor to a business associate, as defined by the Business Associate Agreement.
Amended as of September 19, 2014
-36-

-- 239 of 533 --

EXHIBIT B-1
ADDENDUM TO CONTROLLED AFFILIATE LICENSE TO BE EXECUTED BY CONTROLLED AFFILIATES
LICENSED UNDER CONTROLLED AFFILIATE LICENSE STANDARD 1C.
ADDENDUM TO CONTROLLED AFFILIATE LICENSE
This Addendum is made to that certain Blue Cross Controlled Affiliate License Agreement executed by and
among Blue Cross and Blue Shield Association (“Licensor”), __________________________(“Controlled Affiliate
Licensee”) and
__________________________________________(“Sponsoring Plan”) dated the_____day
of_____________________(“Agreement”). The parties to this Addendum are Licensor, Controlled Affiliate Licensee,
Sponsoring Plan, and the undersigned other Plans (‘Other Plans”). This Addendum is made and shall be deemed
effective as of the date of the Agreement.
WHEREAS, the Sponsoring Plan asserts that it can serve the Medicaid, Medicare Advantage PPO, Medicare
Advantage HMO and/or Special Need Plans market in its Service Area more efficiently and with less risk through an
enterprise jointly owned and controlled with other Plans than through a wholly owned and Controlled Affiliate Licensee.
WHEREAS, in such circumstance Controlled Affiliate License Standard 1C permits the licensing of a Controlled
Affiliate that is less than 50% owned and controlled by the Sponsoring Plan but which is 100% owned and controlled by
Plans including the Sponsoring Plan, subject to certain conditions;
WHEREAS, one such condition is that the Sponsoring Plan and all such other owning and controlling Plans enter
into this Addendum;
NOW THEREFORE, for good and valuable consideration, including the promises and covenants set forth herein,
the parties agree as follows:
1. 	This Addendum is limited to [identify product name].
2. 	The Sponsoring Plan shall participate operationally in Controlled Affiliate’s business that is conducted under the
Licensed Marks. The parties understand that participation may take many forms, one of which should be providing a
network of providers in the Service Area of the Controlled Affiliate for the Medicaid, Medicare Advantage PPO,
Medicare Advantage HMO and/or Special Need Plans services being offered under the Agreement and being
involved in network development and provider engagement functions.
3. 	Each of the Other Plans agrees that (i) it will cooperate fully with the Sponsoring Plan and BCBSA as needed to
enable Sponsoring Plan and Controlled Affiliate Licensee to meet their obligations to Licensor under the Agreement
and all associated rules and regulations of Licensor, including the Brand Regulations, (ii) it
-37-

-- 240 of 533 --

will not take any action, either individually or jointly with any of the Other Plans, that would cause Sponsoring Plan or
Controlled Affiliate Licensee to violate the Agreement, and (iii) it will not fail to take any action, either individually or
jointly with any of the Other Plans, where such failure would cause Sponsoring Plan or Controlled Affiliate Licensee
to violate the Agreement.
4. 	Each of the Other Plans acknowledges that it has reviewed the Agreement and understands that Sponsoring Plan
has the right to terminate the Agreement without cause upon notice as provided in Paragraph 8 of the Agreement,
and that such right is unfettered and may be exercised by Sponsoring Plan in its sole discretion.
WHEREFORE, by signing below the parties agree to be bound to the terms stated herein.
BLUE CROSS BLUE SHIELD ASSOCIATION
By: ___________________________________________________
[Controlled Affiliate Licensee]
By: ___________________________________________________
[Sponsoring Plan]
By: ___________________________________________________
[Other Plan 1 ]
By: ___________________________________________________
[Other Plan 2 ]
By: ___________________________________________________
Amended September 27, 2018
-38-

-- 241 of 533 --

EXHIBIT B-2
ADDENDUM TO CONTROLLED AFFILIATE LICENSE TO BE EXECUTED BY CONTROLLED AFFILIATES
LICENSED UNDER CONTROLLED AFFILIATE LICENSE STANDARD 1D.
ADDENDUM TO CONTROLLED AFFILIATE LICENSE
This Addendum is made to that certain Blue Cross Controlled Affiliate License Agreement executed by and
among Blue Cross and Blue Shield Association (“Licensor”), ___________________________________(“Controlled
Affiliate Licensee”), _______________________________________________(“Sponsoring Plan”) and
______________________________________________ (“Participating Plan”) dated the _____day of
__________________(“Agreement”).
WHEREAS, the Participating Plan is defined as the Plan that holds the Primary License with BCBSA to use the
Service Marks in the Service Area where the Controlled Affiliate will use the Service Marks;
WHEREAS, the Participating Plan asserts that it can offer a lower cost Basic Medicare Part D Prescription Drug
Plan product more efficiently in the Participating Plan’s Service Area through the Controlled Affiliate Licensee;
WHEREAS, the Controlled Affiliate shall only use the Service Marks inside of the Participating Plan(s) Service
Area subject to each Participating Plan signing a separate Addendum;
WHEREAS, in such circumstance Controlled Affiliate License Standard 1D permits the licensing of a Controlled
Affiliate that is 100% owned and controlled by a Sponsoring Plan, subject to certain conditions;
WHEREAS, one such condition is that the Sponsoring Plan, Controlled Affiliate and the Participating Plan enter into this
Addendum;
NOW THEREFORE, for good and valuable consideration, including the promises and covenants set forth herein,
the parties agree as follows:
1. 	The Participating Plan shall participate in Controlled Affiliate’s business that is conducted under the
Licensed Marks. The parties understand that the Participating Plan shall conduct sales support and
marketing of the Controlled Affiliate’s Basic Medicare Part D Prescription Drug Plan product offered in
the Participating Plan’s Service Area. Any other form of participation shall require BCBSA’s written
approval.
2. 	Participating Plan agrees that (i) it will cooperate fully with the Sponsoring Plan and BCBSA as
needed to enable Sponsoring Plan and
-39-

-- 242 of 533 --

Controlled Affiliate Licensee to meet their obligations to Licensor under the Agreement and all associated rules and
regulations of Licensor, including the Brand Regulations, (ii) it will not take any action that would cause Sponsoring
Plan or Controlled Affiliate Licensee to violate the Agreement, and (iii) it will not fail to take any action, either
individually or jointly with the Sponsoring Plan or Controlled Affiliate Licensee, where such failure would cause
Sponsoring Plan or Controlled Affiliate Licensee to violate the Agreement.
3. 	The Controlled Affiliate Licensee shall only use the Licensed Marks authorized by the Participating Plan in
connection with the Basic Medicare Part D Prescription Drug Plan product offered in the Participating Plan’s
Service Area.
4. 	The Sponsoring Plan and Controlled Affiliate acknowledge that it has reviewed the Agreement and understands that
Participating Plan has the right to terminate this Agreement: (i) immediately upon the expiration or termination of the
Plan Participation Agreement by and between Participating Plan and Controlled Affiliate upon written notice to the
Sponsoring Plan, Controlled Affiliate Licensee and Licensor, or (ii) without cause upon 18 months written notice to
the Sponsoring Plan, Controlled Affiliate Licensee and Licensor, and that such right is unfettered and may be
exercised by Participating Plan in its sole discretion. In the event that Participating Plan and Controlled Affiliate fail
to execute the Plan Participation Agreement by_______(Date), Participating Plan may terminate this Agreement
immediately upon notice to Sponsoring Plan, Controlled Affiliate Licensee and Licensor.
5. 	This Agreement and all of Controlled Affiliate Licensee's rights hereunder shall immediately terminate without any
further action by any party or entity in the event that the Sponsoring Plan or Participating Plan ceases to be
authorized to use the Licensed Marks and Name.
WHEREFORE, by signing below the parties agree to be bound to the terms stated herein. BLUE CROSS BLUE
SHIELD ASSOCIATION
By: ____________________________________________________
[Controlled Affiliate Licensee]
By: ____________________________________________________
[Sponsoring Plan]
By: ____________________________________________________
[Participating Plan]
By: ____________________________________________________
Amended March 17, 2016
-40-

-- 243 of 533 --

EXHIBIT C
ROYALTY FORMULA FOR SECTION 9 OF THE CONTROLLED
AFFILIATE LICENSE AGREEMENT
Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following formula:
FOR RISK PRODUCTS:
For Controlled Affiliates not underwriting the indemnity portion of workers’ compensation insurance:
An amount equal to its pro rata share of Sponsoring Plan's dues payable to BCBSA computed with the addition of the
Controlled Affiliate's members using the Marks on health care plans and related services as reported on the Quarterly
Enrollment Report with BCBSA. The payment by Sponsoring Plan of its dues to BCBSA, including that portion described
in this paragraph, will satisfy the requirement of this paragraph, and no separate payment will be necessary.
For Controlled Affiliates underwriting the indemnity portion of workers’ compensation insurance:
An amount equal to 0.35 percent of the gross revenue per annum of Controlled Affiliate arising from products using the
marks; plus, an annual fee of $5,000 per license for a Controlled Affiliate subject to Standard 7.
Amended as of September 19, 2014
-41-

-- 244 of 533 --

EXHIBIT C (Continued)
FOR NONRISK PRODUCTS:
For third-party administrative business, an amount equal to its pro rata share of Sponsoring Plan’s dues payable to
BCBSA computed with the addition of the Controlled Affiliate’s members using the Marks on health care plans and related
services as reported on the Quarterly Enrollment Report with BCBSA. The payment by Sponsoring Plan of its dues to
BCBSA, including that portion described in this paragraph, will satisfy the requirement of this paragraph, and no separate
payment will be necessary.
For non-third party administrative business (e.g., case management, provider networks, etc.), an amount equal to 0.24
percent of the gross revenue per annum of Controlled Affiliate arising from products using the marks; plus:
1) An annual fee of $5,000 per license for a Controlled Affiliate subject to Standard 6 D.
2) An annual fee of $2,000 per license for all other Controlled Affiliates.
The foregoing shall be reduced by one-half where both a BLUE CROSS® and BLUE SHIELD® License are issued to the
same Controlled Affiliate. In the event that any license period is greater or less than one (1) year, any amounts due shall
be prorated. Royalties under this formula will be calculated, billed and paid in arrears.
Amended as of September 19, 2014
-42-

-- 245 of 533 --

EXHIBIT 1A
CONTROLLED AFFILIATE LICENSE AGREEMENT APPLICABLE TO LIFE
INSURANCE COMPANIES
(Includes revisions adopted by Member Plans through their November 16, 2023 meeting)
This agreement by and among Blue Cross and Blue Shield Association ("BCBSA")
___________________________("Controlled Affiliate"), a Controlled Affiliate of the Blue Cross Plan(s), known
as_______________________________________("Plan").
WHEREAS, BCBSA is the owner of the BLUE CROSS and BLUE CROSS Design service marks;
WHEREAS, the Plan and the Controlled Affiliate desire that the latter be entitled to use the BLUE
CROSS and BLUE CROSS Design service marks (collectively the "Licensed Marks") as service marks and be
entitled to use the term BLUE CROSS in a trade name ("Licensed Name");
NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby
agree as follows:
1. GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to the Controlled Affiliate the exclusive
right to use the licensed Marks and Names in connection with and only in connection with those life insurance and
related services authorized by applicable state law, other than health care plans and related services (as defined in
the Plan's License Agreements with BCBSA) which services are not separately licensed to Controlled Affiliate by
BCBSA, in the Service Area served by the Plan, except that BCBSA reserves the right to use the Licensed Marks
and Name in said Service Area, and except to the extent that said Service Area may overlap the area or areas
served by one or more other licensed Blue Cross Plans as of the date of this License as to which overlapping areas
the rights hereby granted are non-exclusive as to such other Plan or Plans and their respective Licensed Controlled
Affiliates only. Controlled Affiliate cannot use the Licensed Marks or Name outside the Service Area or in its legal or
trade name; provided, however, that if and only for so long as Controlled Affiliate also holds a Blue Cross Controlled
Affiliate License Agreement applicable to health care plans and related services, Controlled Affiliate may use the
Licensed Marks and Name in its legal and trade name according to the terms of such license agreement.
Amended as of June 12, 2003
-1-

-- 246 of 533 --

2. QUALITY CONTROL
A. 	Controlled Affiliate agrees to use the Licensed Marks and Name only in relation to the sale, marketing and
rendering of authorized products and further agrees to be bound by the conditions regarding quality control
shown in Exhibit A as it may be amended by BCBSA from time-to-time.
B. 	Controlled Affiliate agrees that Plan and/or BCBSA may, from time-to-time, upon reasonable notice, review and
inspect the manner and method of ControlledAffiliate's rendering of service and use of the Licensed Marks and
Name.
C. 	Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by
Plan or by BCBSA) a report to Plan and BCBSA demonstrating Controlled Affiliate's compliance with the
requirements of this Agreement including but not limited to the quality control provisions of Exhibit A.
D. 	As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner that it is
subject to the bona fide control of a Plan or Plans. Absent written approval by BCBSA of an alternative method
of control, bona fide control shall mean the legal authority, directly or indirectly through wholly-owned
subsidiaries: (a) to select members of the Controlled Affiliate's governing body having not less than 51% voting
control thereof; (b) to exercise operational control with respect to the governance thereof; and (c) to prevent
any change in its articles of incorporation, bylaws or other governing documents deemed inappropriate. In
addition, a Plan or Plans shall own at least 51% of any for-profit Controlled Affiliate. If the Controlled Affiliate is
a mutual company, the Plan or its designee(s) shall have and maintain, in lieu of the requirements of items (a)
and (c) above, proxies representing 51% of the votes at any meeting of the policyholders and shall
demonstrate that there is no reason to believe this such proxies shall be revoked by sufficient policyholders to
reduce such percentage below 51%.
3. SERVICE MARK USE
Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks, including but not limited
to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks, and shall comply with such
rules (applicable to all Controlled Affiliates licensed to use the Marks) relative to service mark use, as are issued
from
time-to-time by BCBSA. If there is any public reference to the affiliation between the Plan and the Controlled
Affiliate, all of the Controlled Affiliate's licensed services in the Service Area of the Plan shall be rendered under the
Licensed Marks. Controlled Affiliate recognizes and agrees that all use of the Licensed Marks by Controlled Affiliate
shall inure to the benefit of BCBSA.
-2-

-- 247 of 533 --

4. SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not sublicense, transfer, hypothecate, sell, encumber or mortgage, by operation of law or
otherwise, the rights granted hereunder and any such act shall be voidable at the option of Plan or BCBSA. This
Agreement and all rights and duties hereunder are personal to Controlled Affiliate.
5. INFRINGEMENTS
Controlled Affiliate shall promptly notify Plan and BCBSA of any suspected acts of infringement, unfair competition
or passing off which may occur in relation to the Licensed Marks. Controlled Affiliate shall not be entitled to require
Plan or BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or
passing off by third parties. Controlled Affiliate agrees to render to Plan and BCBSA, free of charge, all reasonable
assistance in connection with any matter pertaining to the protection of the Licensed Marks by BCBSA.
6. LIABILITY INDEMNIFICATION
Controlled Affiliate hereby agrees to save, defend, indemnify and hold Plan and BCBSA harmless from and against
all claims, damages, liabilities and costs of every kind, nature and description which may arise as a result of
Controlled Affiliate's rendering of health care services under the Licensed Marks.
7. LICENSE TERM
The license granted by this Agreement shall remain in effect for a period of one (1) year and shall be automatically
extended for additional one (1) year periods upon evidence satisfactory to the Plan and BCBSA that Controlled
Affiliate meets the then applicable quality control standards, unless one of the parties hereto notifies the other party
of the termination hereof at least sixty (60) days prior to expiration of any license period.
This Agreement may be terminated by the Plan or by BCBSA for cause at any time provided that Controlled Affiliate
has been given a reasonable opportunity to cure and shall not effect such a cure within thirty (30) days of receiving
written notice of the intent to terminate (or commence a cure within such thirty day period and continue diligent
efforts to complete the cure if such curing cannot reasonably be completed within such thirty day period). By way of
example and not for purposes of limitation, Controlled Affiliate's failure to abide by the quality control provisions of
Paragraph 2, above, shall be considered a proper ground for cancellation of this Agreement.
-3-

-- 248 of 533 --

This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further
action by any party or entity in the event that:
A. 	Controlled Affiliate shall no longer comply with Standard No. 1 (Organization and Governance) of Exhibit A
or, following an opportunity to cure, with the remaining quality control provisions of Exhibit A, as it may be
amended from time-to-time; or
B. 	Plan ceases to be authorized to use the Licensed Marks; or
C. 	Appropriate dues for Controlled Affiliate pursuant to item 8 hereof, which are the royalties for this License
Agreement are more than sixty (60) days in arrears to BCBSA.
Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately
discontinue all use of the Licensed Marks including any use in its trade name.
In the event of any disagreement between Plan and BCBSA as to whether grounds exist for termination or as
to any other term or condition hereof, the decision of BCBSA shall control, subject to provisions for mediation
or mandatory dispute resolution in effect between the parties.
Upon termination of this Agreement, Licensed Controlled Affiliate shall immediately notify all of its customers
that it is no longer a licensee of the Blue Cross and Blue Shield Association and provide instruction on how the
customer can contact the Blue Cross and Blue Shield Association or a designated licensee to obtain further
information on securing coverage. The written notification required by this paragraph shall be in writing and in a
form approved by the Association. The Association shall have the right to audit the terminated entity's books
and records to verify compliance with this paragraph.
8. DUES
Controlled Affiliate will pay to BCBSA a fee for this license in accordance with the following formula:
• 	An annual fee of five thousand dollars ($5,000) per license, plus
• 	.05% of gross revenue per year from branded group products, plus
• 	.5% of gross revenue per year from branded individual products plus
• 	.14% of gross revenue per year from branded individual annuity products.
-4-

-- 249 of 533 --

The foregoing percentages shall be reduced by one-half where both a BLUE CROSS® and BLUE SHIELD® license
are issued to the same entity. In the event that any License period is greater or less than one (1) year, any amounts
due shall be prorated. Royalties under this formula will be calculated, billed and paid in arrears.
Plan will promptly and timely transmit to BCBSA all dues owed by Controlled Affiliate as determined by the above
formula and if Plan shall fail to do so, Controlled Affiliate shall pay such dues directly.
9. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or
employment relationship between Plan and Controlled Affiliate or between either and BCBSA.
9A. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the
Blue Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes
equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes
(if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all
questions requiring an affirmative three-fourths weighted vote of the Plans, voting shall occur pursuant to BCBA’s
Bylaws.
10. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall
be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its
President and, if any, its General Counsel.
Amended as of June 15, 2023
-5-

-- 250 of 533 --

11. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This
Agreement may only be amended by a writing executed by all parties.
12. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such finding shall in no way
effect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for
any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of
this Agreement.
13. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of the Controlled Affiliate or any other licensee
of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or
default in performance of said terms, covenants or conditions.
14. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of
Illinois.
Amended as of June 16, 2005
-6-

-- 251 of 533 --

IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed, effective as of the date of last
signature written below.
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:_____________________________________________
Date:____________________________________________
Controlled Affiliate:
By:______________________________________________
Date:____________________________________________
Plan:
By:_______________________________________________
Date:_____________________________________________
-7-

-- 252 of 533 --

EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
LIFE INSURANCE COMPANIES
Page 1 of 2
PREAMBLE
The standards for licensing Life Insurance Companies (Life and Health Insurance companies, as defined by state statute)
are established by BCBSA and are subject to change from time-to- time upon the affirmative vote of three- fourths (3/4) of
the Plans and three-fourths (3/4) of the total weighted vote of all Plans. Each Licensed Plan is required to use a standard
controlled affiliate license form provided by BCBSA and to cooperate fully in assuring that the licensed Life Insurance
Company maintains compliance with the license standards.
An organization meeting the following standards shall be eligible for a license to use the Licensed Marks within the
service area of its sponsoring Licensed Plan to the extent and the manner authorized under the Controlled Affiliate
License applicable to Life Insurance Companies and the principal license to the Plan.
Standard 1 - Organization and Governance
The LIC shall be organized and operated in such a manner that it is controlled by a licensed Plan or Plans which have,
directly or indirectly: 1) not less than 51% of the voting control of the LIC; and 2) the legal ability to prevent any change in
the articles of incorporation, bylaws or other establishing or governing documents of the LIC with which it does not
concur; and 3) operational control of the LIC.
If the LIC is a mutual company, the Plan or its designee(s) shall have and maintain, in lieu of the requirements of items 1
and 2 above, proxies representing at least 51% of the votes at any policyholder meeting and shall demonstrate that there
is no reason to believe such proxies shall be revoked by sufficient policyholders to reduce such percentage below 51%.
Standard 2 - State Licensure
The LIC must maintain unimpaired licensure or certificate of authority to operate under applicable state laws as a life
and health insurance company in each state in which the LIC does business.
-1-

-- 253 of 533 --

EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
LIFE INSURANCE COMPANIES
Page 2 of 2
Standard 3 - Records and Examination
The LIC and its sponsoring licensed Plan(s) shall maintain and furnish, on a timely and accurate basis, such records and
reports regarding the LIC as may be required in order to establish compliance with the license agreement. The LIC and
its sponsoring licensed Plan(s) shall permit BCBSA to examine the affairs of the LIC and shall agree that BCBSA's board
may submit a written report to the chief executive officer(s) and the board(s) of directors of the sponsoring Plan(s).
Standard 4 - Mediation
The LIC and its sponsoring Plan(s) shall agree to use the then-current BCBSA mediation and mandatory dispute
resolution processes, in lieu of a legal action between or among another licensed controlled affiliate, a licensed Plan or
BCBSA.
Standard 5 - Financial Responsibility
The LIC shall maintain adequate financial resources to protect its customers and meet its business obligations.
Standard 6 - Cooperation with Affiliate License Performance Response Process Protocol
The LIC and its Sponsoring Plan(s) shall cooperate with BCBSA’s Board of Directors and its Organization and
Governance Committee in the administration of the Affiliate License Performance Response Process Protocol (ALPRPP)
and in addressing LIC compliance problems identified thereunder.
-2-

-- 254 of 533 --

Exhibit 1A1
CONTROLLED AFFILIATE
TRADEMARK LICENSE AGREEMENT
FOR LIFE AND DISABILTY INSURANCE PRODUCTS
This Agreement by and among Blue Cross and Blue Shield Association ("BCBSA") and ________________, (“Life and
Disability Controlled Affiliate”) which is a company offering life and disability insurance products owned and controlled
by___________________, ___________________, ___________________(individually, “Sponsoring Plan” and when referred
to collectively, “Sponsoring Plans”).
Whereas, BCBSA is the owner of the BLUE CROSS and BLUE SHIELD word and design service marks and any
derivatives thereof (“Licensed Marks”);
Whereas, each Sponsoring Plan is licensed separately by BCBSA to use one or more of the Licensed Marks in a
particular Service Area;
Whereas, the Sponsoring Plans and the Life and Disability Controlled Affiliate desire that the latter be entitled to
use the appropriate Licensed Marks in connection with life and disability insurance products in some or all of such
Sponsoring Plans’ Service Areas and in the Service Areas of other Regular Member Plans, as defined in the BCBSA By-
laws, (“Blue Plans”) consistent with the terms of this Agreement.
NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby
agree as follows:
1. GRANT OF LICENSE

-- 255 of 533 --

A. Subject to the terms and conditions of this Agreement, BCBSA hereby grants to the Life and Disability
Controlled Affiliate the limited right to use the Licensed Marks in connection with and only in connection with
the following life and disability insurance products authorized by state law: (1) Group: Term Life, Long Term
Disability, Whole Life, Benefit Life, Universal Life; (2)Individual: Term Life, Whole Life, Dependent Life,
Spouse Life; (3) Other: Disability Income, Short Term Disability, Long Term Disability, Income Replacement;
and (4) such other life and disability products approved by BCBSA in writing (“Licensed Products”) in the
Service Areas served by the Sponsoring Plans or in the Service Area or Areas of one or more other licensed
Blue Plans, provided that such Blue Plans have consented to such use as authorized by this Agreement. Life
and Disability Controlled Affiliate may not use the Licensed Marks in its legal or trade name.
-1-

-- 256 of 533 --

B. 	Notwithstanding that the license granted to Life and Disability Controlled Affiliate is a license to use all of the
Licensed Marks, Life and Disability Controlled Affiliate may only use those of the Licensed Marks in the
Service Area of a Sponsoring Plan or other consenting Blue Plan as described below that such Plan is
authorized to use as a Blue Plan pursuant to its separate license agreements with BCBSA.
C. 	Life and Disability Controlled Affiliate may use the Licensed Marks in the Service Areas of Sponsoring Plans or
in the Service Area of a Blue Plan that is not a signatory to this Agreement only after such Sponsoring Plan(s)
or non-signatory Blue Plan consents to such use by executing a written consent in substantially the same form
as the Consent Agreement attached as Exhibit B.
D. The following provisions apply with respect to Consent Agreements once such agreements have been
fully and properly executed:
(1) All sales, marketing and advertising materials developed by and proposed for use by Life and Disability
Controlled Affiliate in the Service Area of Sponsoring Plan or consenting Blue Plan (hereinafter, such
consenting Sponsoring Plan or consenting Blue Plan collectively referred to “Consenting Plan(s)”) must
clearly identify the Consenting Plan (for example, a statement on such materials that reads “This product
is offered with the cooperation of Blue Cross and/or Blue Shield of [Geography]”);
(2) To the extent the Consenting Plan has separate divisions or other Affiliates that use the Licensed Marks
in distinct geographic areas within its Service Area, consent obtained under this Agreement may be
limited to one or more of such specific geographic areas as specified by the Consenting Plan in its
signed Consent Agreement. For purposes of this entire Agreement, all references to the Service Area of
a Sponsoring Plan, Blue Plan or Consenting Plan may include the entire Service Area or a distinct
geographic area within such Service Area as specified in this Section 1 D (2);
(3) Where BCBSA has licensed two or more Blue Plans to use the same Licensed Marks in the same
Service Area, in addition to the requirements set forth in Section D (1) above, the sales, marketing and
advertising materials referenced in such section above must be communicated to the Consenting Plan’s
existing and prospective accounts through or with the approval of such Consenting Plan, and the
personnel of such Consenting Plan must actively participate in all sales and marketing activities
conducted by Life and Disability Controlled Affiliate in the same Service Area, including participating in
meetings (whether in- person or via telephone, video or internet conference) with both existing and
prospective accounts of the Consenting Plan;
-2-

-- 257 of 533 --

(4) Life and Disability Controlled Affiliate shall be entitled to use in a Service Area only those Licensed
Marks that the Consenting Plan has been granted by BCBSA the license to use under its Blue Plan
license
(5) agreements (for example, if a Consenting Plan is licensed to use only the Blue Cross Marks in its
Service Area, the materials used by Life and Disability Controlled Affiliate in that Service Area may only
contain or reference the Blue Cross Marks and not the Blue Shield Marks).
(6) If a Consent Agreement is terminated, Life and Disability Controlled Affiliate shall, unless BCBSA and the
Consenting Plan agree in their sole discretion to a phase out in writing, immediately (i) cease all use of
the Licensed Marks, including in connection with any and all sales and marketing of the Licensed
Products in the Service Area where consent has been terminated, and (ii) notify its customers that it is no
longer a licensee and provide instruction on how the customer can contact BCBSA or a designated
licensee to obtain further information on securing coverage. The notification required by this paragraph
shall be in writing and in form approved by BCBSA.
2. QUALITY CONTROL
A. 	Life and Disability Controlled Affiliate agrees to use the Licensed Marks only in relation to the sale,
marketing and administration of the Licensed Products and further agrees to be bound by the conditions
regarding quality control shown in Exhibit A and the Guidelines to Administer the Standards for Trademark
License Agreement for Life and Disability Insurance Products attached thereto.
B. 	Life and Disability Controlled Affiliate agrees that BCBSA may, from time-to-time, upon reasonable notice,
review and inspect the manner and method of Life and Disability Controlled Affiliate's rendering of service
and use of the Licensed Marks.
C. 	Life and Disability Controlled Affiliate agrees that it will provide on an annual basis (or more often if
reasonably required by BCBSA) a report to BCBSA demonstrating Life and Disability Controlled Affiliate's
compliance with the requirements of this Agreement including but not limited to the quality control provisions
of Exhibit A.
D. 	As used herein, a Life and Disability Controlled Affiliate is defined as: An entity organized and operated in
such a manner that it is 100% owned and controlled by Sponsoring Plans. Absent written approval by
BCBSA of an alternative method of control, control shall mean the legal authority, directly or indirectly
through wholly- owned subsidiaries: (a) to select members of the Life and Disability Controlled Affiliate's
governing body having not less than 100% voting control thereof; (b) to exercise operational control with
respect to the governance
-3-

-- 258 of 533 --

thereof; and (c) to prevent any change in its articles of incorporation, bylaws or other governing documents
deemed inappropriate. In addition, a Sponsoring Plan or Plans shall own at least 100% of any for profit Life
and Disability Controlled Affiliate.
3. SERVICE MARK USE
Life and Disability Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and
shall ensure all uses of the Licensed Marks comply with the BCBSA Brand Regulations, as amended by BCBSA
from time to time. Life and Disability Controlled Affiliate recognizes and agrees that all use of the Licensed Marks
by Life and Disability Controlled Affiliate shall inure to the benefit of BCBSA.
4. SUBLICENSING AND ASSIGNMENT
The license hereby granted to Life and Disability Controlled Affiliate to use the Licensed Marks is and shall be
personal to Life and Disability Controlled Affiliate and shall not be assignable by any act of the Life and Disability
Controlled Affiliate, directly or indirectly, without the written consent of BCBSA. Said license shall not be
assignable by operation of law, nor shall Life and Disability Controlled Affiliate mortgage or part with possession or
control of this license or any right hereunder, and the Life and Disability Controlled Affiliate shall have no right to
grant any sublicense to use the Licensed Marks.
5. INFRINGEMENTS
Life and Disability Controlled Affiliate shall promptly notify BCBSA of any suspected acts of infringement, unfair
competition or passing off which may occur in relation to the Licensed Marks. Life and Disability Controlled Affiliate
shall not be entitled to require BCBSA to take any actions or institute any proceedings to prevent infringement,
unfair competition or passing off by third parties. Life and Disability Controlled Affiliate agrees to render to BCBSA,
free of charge, all reasonable assistance in connection with any matter pertaining to the protection of the Licensed
Marks by BCBSA. BCBSA shall have sole control of the defense and resolution of any claim of infringement
brought or threatened by others.
6. LIABILITY INDEMNIFICATION
Life and Disability Controlled Affiliate hereby agrees to save, defend, indemnify and hold BCBSA harmless from
and against all claims, damages, liabilities and costs of every kind, nature and description which may arise as a
result of Life and Disability Controlled Affiliate's conduct.
-4-

-- 259 of 533 --

7. LICENSE TERM
A. The license granted by this Agreement shall remain in effect for a period of one (1) year and shall be
automatically extended for additional one (1) year periods, unless either BCBSA or Life and Disability
Controlled Affiliate notifies the other party in writing of the termination hereof at least sixty (60) days prior to
expiration of any license period.
B. This Agreement may be terminated by BCBSA for cause at any time provided that Life and Disability Controlled
Affiliate has been given a reasonable opportunity to cure and shall not effect such a cure within thirty (30) days
of receiving written notice of the intent to terminate (or commence a cure within such thirty day period and
continue diligent efforts to complete the cure if such curing cannot reasonably be completed within such thirty
day period). By way of example and not for purposes of limitation, Life and Disability Controlled Affiliate's failure
to abide by the conditions regarding use of the Licensed Marks set forth in Section 1 of this Agreement or the
quality control provisions of Section 2 (other than with respect to Section 2 D which is subject to immediate
termination as stated in Section 7 C (1) below) shall be considered proper grounds for termination of this
Agreement.
C. This Agreement and all of Life and Disability Controlled Affiliate's rights hereunder shall immediately
terminate without any further action by any party or entity in the event that:
(1) Life and Disability Controlled Affiliate shall no longer comply with Section 2 D (or Standard No. 1
(Organization and Governance) of Exhibit A); or
(2) Any Sponsoring Plan ceases to be authorized to use the Licensed Marks; or
(3) Appropriate fees for Life and Disability Controlled Affiliate pursuant to Section 8 of this Agreement are
more than sixty (60) days in arrears to BCBSA.
Upon termination of this Agreement for cause or otherwise, Life and Disability Controlled Affiliate agrees that it shall
immediately discontinue all use of the Licensed Marks.
In the event of any disagreement between Life and Disability Controlled Affiliate and BCBSA as to whether grounds
exist for termination or as to any other term or condition hereof, the decision of BCBSA shall control, subject to
provisions for mediation or mandatory dispute resolution in effect between the parties.
-5-

-- 260 of 533 --

Upon termination of this Agreement, Licensed Life and Disability Controlled Affiliate shall immediately notify all of its
customers that it is no longer a licensee of BCBSA and provide instruction on how the customer can contact BCBSA
or a designated licensee to obtain further information on securing coverage. The notification required by this
paragraph shall be in writing and in a form approved by BCBSA. BCBSA shall have the right to audit the terminated
entity's books and records to verify compliance with this paragraph.
8. ROYALTIES
Life and Disability Controlled Affiliate will pay to BCBSA a fee for this license in accordance with the following
formula:
• An annual fee of five thousand dollars ($5,000) per license, plus
• .05% of gross revenue per year from group products sold under the Licensed Marks, plus
• .5% of gross revenue per year from individual products sold under the Licensed Marks
In the event that any license period is greater or less than one (1) year, any amounts due shall be prorated.
Royalties under this formula will be calculated, billed and paid in arrears.
Life and Disability Controlled Affiliate will promptly and timely transmit to BCBSA all fees owed by Life and Disability
Controlled Affiliate as determined by the above formula.
9. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or
employment relationship between any Sponsoring Plan and Life and Disability Controlled Affiliate or between
among them and/or BCBSA.
10. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the
Blue Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes
equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes
(if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all
questions requiring an affirmative three-fourths weighted vote of the Plans, voting shall occur pursuant to BCBSA’s
Bylaws.
Amended as of June 15, 2023
-6-

-- 261 of 533 --

11. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall
be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its
President and, if any, its General Counsel.
12. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This
Agreement may only be amended by: (a) a writing signed by all parties; or (b) a writing approved by the affirmative
vote of three-fourths of the Blue Plans and three-fourths of the total then current weighted vote of all the Blue Plans
as officially recorded by the BCBSA Corporate Secretary. Upon such adoption by the Blue Plans, this Agreement and
all other Trademark License Agreements for Life and Disability Insurance Products then in effect shall simultaneously
be amended.
13. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such finding shall in no way
affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for
any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of
this Agreement.
14. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of the Life and Disability Controlled Affiliate
or any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any
subsequent breach or default in performance of said terms, covenants or conditions.
15. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of
Illinois.
-7-

-- 262 of 533 --

IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed, effective as of the date of last
signature written below.
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:_________________________________________________________
Date:_______________________________________________________
Life and Disability Controlled Affiliate:
By:_________________________________________________________
Date:_______________________________________________________
Sponsoring Plan:
By:_________________________________________________________
Date:_______________________________________________________
Name:_______________________________________________________
Sponsoring Plan:
By:_________________________________________________________
Date:_______________________________________________________
Name:_______________________________________________________
[Add other Sponsoring Plans as necessary]
-8-

-- 263 of 533 --

EXHIBIT A
LICENSE STANDARDS APPLICABLE TO TRADEMARK LICENSE AGREEMENT FOR LIFE AND
DISABILITY INSURANCE PRODUCTS
Page 1 of 2
Standard 1 - Organization and Governance
Any Life and Disability Controlled Affiliate licensed under the Trademark License Agreement for Life and Disability
Insurance Products (“licensee”) shall be organized and operated in such a manner that it is an entity organized and
operated in such a manner that it is 100% owned and controlled by Sponsoring Plans. Absent written approval by BCBSA
of an alternative method of control, control shall mean the legal authority, directly or indirectly through wholly-owned
subsidiaries: (a) to select members of the Life and Disability Controlled Affiliate's governing body having not less than
100% voting control thereof; (b) to exercise operational control with respect to the governance thereof; and (c) to prevent
any change in its articles of incorporation, bylaws or other governing documents deemed inappropriate. In addition, a
Sponsoring Plan or Plans shall own at least 100% of any for profit Life and Disability Controlled Affiliate.
Standard 2 - State Licensure
The licensee must maintain unimpaired licensure or certificate of authority to operate under applicable state laws as a life
company in each state in which the licensee does business.
Standard 3 - Records and Examination
The licensee shall maintain and furnish, on a timely and accurate basis, such records and reports regarding the licensee
as may be required in order to establish compliance with the Agreement. The licensee shall permit BCBSA to examine the
affairs of the licensee and shall agree that BCBSA's board may submit a written report to the chief executive officer(s) and
the board(s) of directors of the Sponsoring Plan(s).
Standard 4 - Mediation
The licensee, its Sponsoring Plan(s) and all consenting Blue Plans shall agree to use the then- current BCBSA mediation
and mandatory dispute resolution processes, in lieu of a legal action between or among another licensed Life and
Disability Controlled Affiliate, a Sponsoring Plan and or consenting Blue Plan or BCBSA.
-1-

-- 264 of 533 --

EXHIBIT A
LICENSE STANDARDS APPLICABLE TO TRADEMARK LICENSE AGREEMENT FOR LIFE AND
DISABILITY INSURANCE PRODUCTS
Page 2 of 2
Standard 5 - Financial Responsibility
The licensee shall maintain adequate financial resources to protect its customers and meet its business obligations.
Standard 6 - Cooperation with BCBSA Governance
The licensee shall cooperate with BCBSA’s Board of Directors and its Organization and Governance Committee
in the administration of and in addressing licensee compliance problems that may be identified in connection with
the operation or administration of the Trademark License Agreement for Life and Disability Insurance Products.
-2-

-- 265 of 533 --

EXHIBIT B
CONSENT AGREEMENT
This Consent Agreement is made and entered into by and among the undersigned Blue Plan,
and________________________________(“Life and Disability Controlled Affiliate”), and the Blue Cross and Blue Shield
Association (“BCBSA”) and shall be deemed effective on___________________________________________(“Effective
Date”).
Whereas, BCBSA owns the Blue Cross and Blue Shield word and design service marks and any derivative
mark thereof (the “Brands”);
Whereas, the undersigned Blue Plan is licensed to use one or more of the Brands within a specific geographic
area (“Service Area”);
Whereas Life and Disability Controlled Affiliate is licensed by BCBSA to use one or more of the Brands to offer
life and disability insurance products (“Products”) as defined and authorized in the Trademark License Agreement for Life
and Disability Insurance Products (“Life and Disability License Agreement”);
Whereas neither the Blue Plan nor its affiliates offer the Products under any of the Brands in such Blue Plan’s
Service Area or portion thereof where Blue Plan has consented to sale of the Products by Life and Disability Controlled
Affiliate; and
Whereas BCBSA and the undersigned Blue Plan desire to consent to Life and Disability Controlled Affiliate’s
use of the Brands in Blue Plan’s Service Area consistent with the terms of the Life and Disability License Agreement and
this Consent Agreement.
Now, therefore, in consideration of the obligations and conditions stated in this Agreement, Blue Plan, Life and
Disability Controlled Affiliate and BCBSA agree as follows:
1. Life and Disability Controlled Affiliate may market, sell, administer and underwrite the Products in Blue Plan’s
Service Area under the Brands licensed to Blue Plan in such Service Area subject to the terms of this Consent
Agreement, the Life and Disability License Agreement and Blue Plan’s license agreement(s) with BCBSA. Life
and Disability Controlled Affiliate’s rights under the Brands to offer the Products under the Brands are limited to
offering the Products only under the Brand(s) licensed to the consenting Blue Plan.
2. Life and Disability Controlled Affiliate shall work with the undersigned Blue Plan to develop a written sales and
marketing agreement that identifies the relationship between it and Blue Plan for the sales, marketing and
customer service for the Products. The term of the sales and marketing agreement shall be the same as the term
of this Consent Agreement.
1

-- 266 of 533 --

3. 	All sales, marketing and advertising materials developed by and proposed for use by Life and
Disability Controlled Affiliate in a consenting Blue Plan’s Service Area must clearly identify the
consenting Blue Plan (for example, a statement on such materials that reads “This product is
offered with the cooperation of Blue Cross and/or Blue Shield of [Geography]”);
4. 	Life and Disability Controlled Affiliate may use the Brands to sell the Products in the following
Service Area or portion thereof as designated by Blue Plan:
________________________________________________________
5. 	If two or more Blue Plans to use the same Licensed Marks in the same Service Area, Life and
Disability Controlled Affiliate shall work with the consenting Blue Plan in the following manner: (a)
the sales, marketing and advertising materials must be communicated to the consenting Blue
Plan’s existing and prospective accounts through or with the approval of such Blue Plan, and (b)
the personnel of such Blue Plan must actively participate in all sales and marketing activities
conducted by Life and Disability Controlled Affiliate in the same Service Area, including
participating in meetings (whether in-person or via telephone, video or internet conference) with
both existing and prospective accounts of the consenting Blue Plan;
6. 	Life and Disability Controlled Affiliate shall be entitled to use in a Service Area only those
Licensed Marks that the consenting Blue Plan has been granted by BCBSA the license to use
under its license agreement (for example, if a consenting Blue Plan is licensed to use only the
Blue Cross Marks in its Service Area, the materials used by Life and Disability Controlled
Affiliate in that Service Area may only contain or reference the Blue Cross Marks and not the
Blue Shield Marks).
7. 	If this Consent Agreement is terminated, Life and Disability Controlled Affiliate shall, unless each
BCBSA and the Blue Plan agree in their sole discretion to a phase out in writing, immediately (i)
cease all use of the Licensed Marks, including in connection with any and all sales and marketing
of the Licensed Products in the Service Area where consent has been terminated, and (ii) notify its
customers that it is no longer a licensee of BCBSA and provide instruction on how the customer
can contact BCBSA or a designated licensee to obtain further information on securing coverage.
The notification required by this paragraph shall be in writing and in form approved by BCBSA.
2

-- 267 of 533 --

8. 	The term of this Consent Agreement shall be one year from the Effective Date. Unless either Blue Plan or Life and
Disability Controlled Affiliate provides the other party with written notice of its desire not to renew this Consent
Agreement at least 60 days prior to expiration of the term or any extended term or unless terminated as provided in
Paragraph 9 below, this Consent Agreement shall automatically renew for subsequent one year periods.
9. 	This Consent Agreement may be terminated as follows:
A. Upon mutual written consent of Life and Disability Controlled Affiliate and Blue Plan;
B. By Blue Plan or Life and Disability Controlled Affiliate upon 60 days advance written notice to the non-terminating
party and BCBSA; or
C. By Blue Plan immediately if Life and Disability Controlled Affiliate does not comply with this Consent
Agreement or the sales protocol agreement.
10. This Consent Agreement shall automatically terminate if Blue Plan’s primary licensee agreement terminates for
any reason or if the Life and Disability License Agreement terminates for any reason.
Agreed and Accepted by:
[Blue Plan]:
By:________________________________
Title:_______________________________
BLUE CROSS AND BLUE SHIELD ASSOCIATION:
By:__________________________________
Title:__________________________________
LIFE AND DISABILITY CONTROLLED AFFILIATE:
By:__________________________________
Title:_________________________________
3

-- 268 of 533 --

Exhibit 1B
BLUE CROSS
CONTROLLED AFFILIATE LICENSE AGREEMENT
APPLICABLE TO REGIONAL MEDICARE ADVANTAGE PPO PRODUCTS
(Adopted by Member Plans at their November 16, 2023 meeting)
This Agreement by and among Blue Cross and Blue Shield Association (“BCBSA”) and _____________(“Controlled
Affiliate”), a Controlled Affiliate of the Blue Cross Plan(s), known as ______________ (“Controlling Plans”), each of which is also
a Party signatory hereto.
WHEREAS, BCBSA is the owner of the BLUE CROSS and BLUE CROSS Design service marks;
WHEREAS, under the Medicare Modernization Act, companies may apply to and be awarded a contract by the
Centers for Medicare and Medicaid Services (“CMS”) to offer Medicare Advantage PPO products in geographic regions
designated by CMS (hereafter “regional MAPPO products”).
WHEREAS, some of the CMS-designated regions include the Service Areas, or portions thereof, of more than one Plan.
WHEREAS, the Controlling Plans and Controlled Affiliate desire that the latter be entitled to use the BLUE CROSS
and BLUE CROSS Design service marks (collectively the "Licensed Marks") as service marks and be entitled to use the
term BLUE CROSS in a trade name ("Licensed Name") to offer regional MAPPO products in a region that includes the
Service Areas, or portions thereof, of more than one Controlling Plan;
NOW THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby
agree as follows:
1. GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled Affiliate the right to
use the Licensed Marks and Name in connection with, and only in connection with the sale, marketing and
administration of regional MAPPO products and related services.
This grant of rights is non-exclusive and is limited to the following states:
_______(the “Region”). Controlled Affiliate may use the Licensed
-1-

-- 269 of 533 --

Marks and Name in its legal name on the following conditions: (i) the legal name must be approved in advance,
in writing, by BCBSA; (ii) Controlled Affiliate shall not do business outside the Region under any name or mark
except business conducted in the Service Area of a Controlling Plan provided that Controlled Affiliate is
separately licensed by BCBSA to use the Licensed Marks and Name in connection with health care plans and
related services in the Service Area of such Controlling Plan; and (iii) Controlled Affiliate shall not use the
Licensed Marks and Name, or any derivative thereof, as part of any name or symbol used to identify itself in
any securities market. Controlled Affiliate may use the Licensed Marks and Name in its Trade Name only with
the prior, written, consent of BCBSA.
2. QUALITY CONTROL
A. 	Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services
and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they
may be amended by BCBSA from time-to-time.
B. 	Controlled Affiliate agrees to comply with all applicable federal, state and local laws.
C. Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by the
Controlling Plans or by BCBSA) a report or reports to the Controlling Plans and BCBSA demonstrating
Controlled Affiliate's compliance with the requirements of this Agreement including but not limited to the
quality control provisions of this paragraph and the attached Exhibit A.
D. Controlled Affiliate agrees that the Controlling Plans and/or BCBSA may, from time-to-time, upon
reasonable notice, review and inspect the manner and method of Controlled Affiliate's rendering of service
and use of the Licensed Marks and Name.
E. 	As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a
manner, that it meets the following requirements:
(1) Controlled Affiliate is owned or controlled by two or more Controlling Plans;
(2) Each Controlling Plan is authorized pursuant to a separate Blue Cross License Agreement to use the
Licensed Marks in a geographic area in the
Region and every geographic area in the Region is so licensed to at least one of the Controlling Plans;
and
-2-

-- 270 of 533 --

(3) The Controlling Plans must have the legal authority directly or indirectly through wholly-owned
subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having not less than 100% voting
control thereof;
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing
documents of the Controlled Affiliate with which the Controlling Plans do not concur;
(c) to exercise control over the policy and operations of the Controlled Affiliate; and
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s establishing
or governing documents must also require written approval by each of the Controlling Plans before the
Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates (except such approval shall not be required
with respect to business of the Controlled Affiliate conducted under the Licensed Marks
within the Service Area of one of the Controlling Plans pursuant to a separate controlled
affiliate license agreement with BCBSA sponsored by such Controlling Plan);
(iii) change any of the type(s) of businesses in which it engages (except such approval shall
not be required with respect to business of the Controlled Affiliate conducted under the
Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a
separate controlled affiliate license agreement with BCBSA sponsored by such Controlling
Plan);
(iv) take any action that any Controlling Plan or BCBSA reasonably believes will adversely
affect the Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly owned subsidiaries shall own 100% of any
for-profit Controlled Affiliate.
-3-

-- 271 of 533 --

3. SERVICE MARK USE
A. 	Controlled Affiliate recognizes the importance of a comprehensive national network of independent BCBSA
licensees which are committed to strengthening the Licensed Marks and Name. The Controlled Affiliate further
recognizes that its actions within the Region may affect the value of the Licensed Marks and Name nationwide.
B. 	Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and Name, including but
not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks and Name and
shall comply with such rules (generally applicable to Controlled Affiliates licensed to use the Licensed Marks and
Name) relative to service mark use, as are issued from time-to-time by BCBSA. Controlled Affiliate recognizes and
agrees that all use of the Licensed Marks and Name by Controlled Affiliate shall inure to the benefit of BCBSA.
C. 	Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in a manner that transfers or is
intended to transfer in the Region the goodwill associated therewith to another mark or name, nor may Controlled
Affiliate engage in activity that may dilute or tarnish the unique value of the Licensed Marks and Name.
D. 	Controlled Affiliate shall use its best efforts to promote and build the value of the Licensed Marks and Name in
connection with the sale, marketing and administration of regional MAPPO products and related services.
4. SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell, encumber or mortgage, by
operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the sole option of
any Controlling Plan or BCBSA. This Agreement and all rights and duties hereunder are personal to Controlled
Affiliate.
-4-

-- 272 of 533 --

5. INFRINGEMENT
Controlled Affiliate shall promptly notify the Controlling Plans and the Controlling Plans shall promptly notify BCBSA
of any suspected acts of infringement, unfair competition or passing off that may occur in relation to the Licensed
Marks and Name. Controlled Affiliate shall not be entitled to require the Controlling Plans or BCBSA to take any
actions or institute any proceedings to prevent infringement, unfair competition or passing off by third parties.
Controlled Affiliate agrees to render to the Controlling Plans and BCBSA, without charge, all reasonable assistance
in connection with any matter pertaining to the protection of the Licensed Marks and Name by BCBSA.
6. LIABILITY INDEMNIFICATION
Controlled Affiliate and the Controlling Plans hereby agree to save, defend, indemnify and hold BCBSA harmless
from and against all claims, damages, liabilities and costs of every kind, nature and description (except those
arising solely as a result of BCBSA's negligence) that may arise as a result of or related to Controlled Affiliate's
rendering of services under the Licensed Marks and Name.
7. LICENSE TERM
A. 	Except as otherwise provided herein, the license granted by this Agreement shall remain in effect for a period
of one (1) year and shall be automatically extended for additional one (1) year periods unless terminated
pursuant to the provisions herein.
B. 	This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further
action by any party or entity in the event that: (i) any one of the Controlling Plans ceases to be authorized to
use the Licensed Marks and Name; or (ii) pursuant to Paragraph 15(a)(x) of the Blue Cross License
Agreement any one of the Controlling Plans ceases to be authorized to use the Licensed Names and Marks in
the Region.
C. 	Notwithstanding any other provision of this Agreement, this license to use the Licensed Marks and Name
may be forthwith terminated by the Controlling Plans or the affirmative vote of the majority of the Board of
Directors of BCBSA present and voting at a special meeting expressly called by BCBSA for the purpose on
ten (10) days written notice to the Controlling Plans advising of the specific matters at issue and granting the
Controlling Plans an opportunity to be heard and to present their response to the Board for: (1) failure to
comply with any applicable minimum capital or liquidity requirement under the quality control standards of
this
-5-

-- 273 of 533 --

Agreement; or (2) failure to comply with the "Organization and Governance" quality control standard of this
Agreement; or (3) impending financial insolvency; or (4)failure to comply with any of the applicable
requirements of Standards 2, 3, 4, or 5 of attached Exhibit A; or (5) the pendency of any action instituted
against the Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking appointment of a
trustee, interim trustee, receiver or other custodian for any of its property or business or seeking the
declaration or establishment of a trust for any of its property or business, unless this Controlled Affiliate
License Agreement has been earlier terminated under paragraph 7(E); or (6) such other reason as is
determined in good faith immediately and irreparably to threaten the integrity and reputation of BCBSA, the
Plans (including the Controlling Plans), any other licensee including Controlled Affiliate and/or the Licensed
Marks and Name.
D. 	Except as otherwise provided in Paragraphs 7(B), 7(C) or 7(E) herein, should Controlled Affiliate fail to comply
with the provisions of this Agreement and not cure such failure within thirty (30) days of receiving written notice
thereof (or commence a cure within such thirty day period and continue diligent efforts to complete the cure if
such curing cannot reasonably be completed within such thirty day period) BCBSA or the Controlling Plans
shall have the right to issue a notice that the Controlled Affiliate is in a state of noncompliance. If a state of
noncompliance as aforesaid is
undisputed by the Controlled Affiliate or is found to exist by a mandatory dispute resolution panel and is
uncured as provided above, BCBSA shall have the right to seek judicial enforcement of the Agreement or to
issue a notice of termination thereof. Notwithstanding any other provisions of this Agreement, any disputes as
to the termination of this License pursuant to Paragraphs 7(B), 7(C) or 7(E) of this Agreement shall not be
subject to mediation and mandatory dispute resolution. All other disputes between or among BCBSA, any of the
Controlling Plans and/or Controlled Affiliate shall be submitted promptly to mediation and mandatory dispute
resolution. The mandatory dispute resolution panel shall have authority to issue orders for specific performance
and assess monetary penalties. Except, however, as provided in Paragraphs 7(B) and 7(E) of this Agreement,
this license to use the Licensed Marks and Name may not be finally terminated for any reason without the
affirmative vote of a majority of the present and voting members of the Board of Directors of BCBSA.
E. 	This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further
action by any party or entity in the event that:
(1) Controlled Affiliate shall no longer comply with item 2(E) above;
(2) Appropriate dues, royalties and other payments for Controlled Affiliate pursuant to paragraph 9 hereof,
which are the royalties for this License Agreement, are more than sixty (60) days in arrears to BCBSA; or
-6-

-- 274 of 533 --

(3) Any of the following events occur: (i) a voluntary petition shall be filed by Controlled Affiliate seeking
bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the
United States or any other law governing insolvency or debtor relief, or (ii) an involuntary petition or
proceeding shall be filed against Controlled Affiliate seeking bankruptcy, reorganization, arrangement
with creditors or other relief under the bankruptcy laws of the United States or any other law governing
insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by Controlled
Affiliate or is not dismissed within sixty (60) days of the date upon which the petition or other document
commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order for relief is entered
against Controlled Affiliate in any case under the bankruptcy laws of the United States, or Controlled
Affiliate is adjudged bankrupt or insolvent as those terms are defined in the Uniform Commercial Code as
enacted in the State of Illinois by any court of competent jurisdiction, or (iv) Controlled Affiliate makes a
general assignment of its assets for the benefit of creditors, or (v) any government or any government
official, office, agency, branch, or unit assumes control of Controlled Affiliate or delinquency proceedings
(voluntary or involuntary) are instituted, or (vi) an action is brought by Controlled Affiliate seeking its
dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or
other custodian for any of its property or business, or (vii) an action is instituted by any governmental
entity or officer against Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the
appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business
and such action is consented to or acquiesced in by Controlled Affiliate or is not dismissed within one
hundred thirty (130) days of the date upon which the pleading or other document commencing the action
is served upon the Controlled Affiliate, provided that if the action is stayed or its prosecution is enjoined,
the one hundred thirty (130) day period is tolled for the duration of the stay or injunction, and provided
further, that the Association’s Board of Directors may toll or extend the 130 day period at any time prior to
its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any of Controlled Affiliate's
property or business is appointed or the Controlled Affiliate is ordered dissolved or liquidated.
Notwithstanding any other provision of this Agreement, a declaration or a request for declaration of the
existence of a trust over any of the Controlled Affiliate’s property or business shall not in itself be deemed
to constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of
subparagraphs 7(E)(3)(vii) and (viii) of this Agreement.
F. 	Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately
discontinue all use of the Licensed Marks and Name, including any use in its trade name, except to the extent
that it continues to be authorized to use the Licensed Marks within the Service Area of one of the Controlling
Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling
Plan.
7

-- 275 of 533 --

G. Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its customers to whom it
provides products or services under the Licensed Marks pursuant to this Agreement that it is no longer a
licensee of BCBSA and, if directed by the Association’s Board of Directors, shall provide instruction on how the
customer can contact BCBSA or a designated licensee to obtain further information on securing coverage. The
notification required by this paragraph shall be in writing and in a form approved by BCBSA. The BCBSA shall
have the right to audit the terminated entity's books and records to verify compliance with this paragraph.
H. 	In the event this Agreement terminates pursuant to 7(B) hereof, upon termination of this Agreement the
provisions of Paragraph 7(G) shall not apply and the following provisions shall apply, except that, in the event
that Controlled Affiliate is separately licensed by BCBSA to use the Licensed Marks in the Service Area of a
Controlling Plan and termination of this Agreement is due to a partial termination of such Controlling Plan’s
license pursuant to Paragraph 15(a)(x)(ii) of the Blue Cross License Agreement, the notices, national account
listing, payment, and audit right listed below shall be applicable solely with respect to the Region and the
geographic area for which the Controlling Plan’s license to use the Licensed Names and Marks is terminated:
(1) The Controlled Affiliate shall send a notice through the U.S. mails, with first class postage affixed, to
all individual and group customers, providers, brokers and agents of products or services sold,
marketed, underwritten or administered by the Controlled Affiliate under the Licensed Marks and
Name.
The form and content of the notice shall be specified by BCBSA and shall, at a minimum, notify the recipient of
the termination of the license, the consequences thereof, and instructions for obtaining alternate products or
services licensed by BCBSA. This notice shall be mailed within 15 days after termination.
(2) The Controlled Affiliate shall deliver to BCBSA within five days of a request by BCBSA a listing of national
accounts in which the Controlled Affiliate is involved (in a control, participating or servicing capacity), identifying
the national account and the Controlled Affiliate’s role therein.
(3) Unless the cause of termination is an event respecting BCBSA stated in paragraph 15(a) or (b) of the Plan’s
license agreement with BCBSA to use the Licensed Marks and Name, the Controlled Affiliate, the Controlling
Plans, and any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for payment to
BCBSA of an amount equal to $25 multiplied by the number of Licensed Enrollees of the Controlled Affiliate;
provided that if any Plan other than a Controlling Plan is permitted by BCBSA to use marks or names licensed
by BCBSA in a geographic area in the Region, the payment for Licensed Enrollees in such geographic area
shall be multiplied by a fraction, the numerator of which is the number of Licensed Enrollees of the Controlled
Affiliate, the Controlling Plans, and
8

-- 276 of 533 --

any other Licensed Controlled Affiliates of the Controlling Plans in such geographic area and the
denominator of which is the total number of Licensed Enrollees in such geographic area. Licensed
Enrollee means each and every person and covered dependent who is enrolled as an individual or
member of a group receiving products or services sold, marketed or administered under marks or names
licensed by BCBSA as determined at the earlier of (i) the end of the last fiscal year of the terminated
entity which ended prior to termination or (ii) the fiscal year which ended before any transactions causing
the termination began. Notwithstanding the foregoing, the amount payable pursuant to this subparagraph
H. (3) shall be due only to the extent that, in BCBSA’s opinion, it does not cause the net worth of the
Controlled Affiliate, the Controlling Plans or any other Licensed Controlled Affiliates of the Controlling
Plans to fall below 100% of the Health Risk-Based Capital formula, or its equivalent under any successor
formula, as set forth in the applicable financial responsibility standards established by BCBSA (provided
such equivalent is approved for purposes of this subparagraph by the affirmative vote of three- fourths of
the Plans and three-fourths of the total then current weighted vote of all the Plans); measured as of the
date of termination, and adjusted for the value of any transactions not made in the ordinary course of
business. This payment shall not be due in connection with transactions exclusively by or among Plans
(including the Controlling Plans) or their affiliates, including reorganizations, combinations or mergers,
where the BCBSA Board of Directors determines that the license termination does not result in a material
diminution in the number of Licensed Enrollees or the extent of their coverage. In the event that the
Controlled Affiliate’s license is reinstated by BCBSA or is deemed to have remained in effect without
interruption by a court of competent jurisdiction, BCBSA shall reimburse the Controlled Affiliate (and/or
the Controlling Plans or their other Licensed Controlled Affiliates, as the case may be) for payments
made under this subparagraph 7.H.(3) only to the extent that such payments exceed the amounts due to
BCBSA pursuant to paragraph 7.K. and any costs associated with reestablishing the terminated
Controlling Plan’s Service Area or the Region, including any payments made by BCBSA to a Plan or
Plans (including the other Controlling Plans), or their Licensed Controlled Affiliates, for purposes of
replacing the Controlled Affiliate.
(4) BCBSA shall have the right to audit the books and records of the Controlled Affiliate, the Controlling Plans, and
any other Licensed Controlled Affiliates of the Controlling Plans to verify compliance with this paragraph 7.H.
(5) 	As to a breach of 7.H.(1), (2), (3) or (4), the parties agree that the obligations are immediately enforceable in a
court of competent jurisdiction. As to a breach of 7.H.(1), (2) or (4) by the Controlled Affiliate, the parties agree
there is no adequate remedy at law and BCBSA is entitled to obtain specific performance.
-9-

-- 277 of 533 --

I. 	BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of competent jurisdiction
from entry into any transaction which would result in a termination of this Agreement unless a Controlling
Plan’s license from BCBSA to use the Licensed Marks and Names has been terminated pursuant to 10(d) of
such Controlling Plan’s license agreement upon the required 6 month written notice.
J. 	BCBSA acknowledges that it is not the owner of assets of the Controlled Affiliate.
K. 	In the event this Agreement terminates and is subsequently reinstated by BCBSA or is deemed to have
remained in effect without interruption by a court of competent jurisdiction, the Controlled Affiliate, the
Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for
reimbursing BCBSA the reasonable costs incurred by BCBSA in connection with the termination and the
reinstatement or court action, and any associated legal proceedings, including but not limited to: outside legal
fees, consulting fees, public relations fees, advertising costs, and costs incurred to develop, lease or establish
an interim provider network. Any amount due to BCBSA under this subparagraph may be waived in whole or
in part by the BCBSA Board of Directors in its sole discretion.
8. DISPUTE RESOLUTION
The parties agree that any disputes between or among them or between or among any of them and one or more
Plans or Controlled Affiliates of Plans that use in any manner the Blue Cross and Blue Cross Marks and Name are
subject to the Mediation and Mandatory Dispute Resolution process attached to and made a part of each
Controlling Plan’s License from BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-
to-time, which documents are incorporated herein by reference as though fully set forth herein.
9. LICENSE FEE
Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth in Exhibit
B.
10. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or
employment relationship between the Controlling Plans and Controlled Affiliate or between either and BCBSA.
11. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall
be addressed in duplicate to the last
-10-

-- 278 of 533 --

known address of each other party, marked respectively to the attention of its President and, if any, its General
Counsel.
12. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This
Agreement may only be amended by the affirmative vote of three-fourths of the Plans and three-fourths of the
total then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.
13. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such findings shall in no way
affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for
any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of
this Agreement.
14. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or any other licensee
of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or
default in performance of said terms, covenants or conditions.
14A. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the
Blue Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes
equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes
(if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all
questions requiring an affirmative three-fourths weighted vote of the Plans, voting shall occur pursuant to BCBSA
Bylaws.
-11-

-- 279 of 533 --

15. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with, the
laws of the State of Illinois.
16. HEADINGS
The headings inserted in this agreement are for convenience only and shall have no bearing on the
interpretation hereof.
-12-

-- 280 of 533 --

IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed and effective as of the date of
last signature written below.
Controlled Affiliate:
By:_____________________________________________________
Date:___________________________________________________
Controlling Plan:
By: ____________________________________________________
Date:___________________________________________________
Controlling Plan:
By: ____________________________________________________
Date:___________________________________________________
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:_____________________________________________________
Date:___________________________________________________
-13-

-- 281 of 533 --

EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS APPLICABLE TO
REGIONAL MEDICARE ADVANTAGE PPO PRODUCTS
November 2023 PREAMBLE
The standards for licensing Controlled Affiliates for Medicare Advantage PPO Products are established by BCBSA and
are subject to change from time-to-time upon the affirmative vote of three-fourths (3/4) of the Plans and three-fourths
(3/4) of the total weighted vote. Each Controlling Plan is required to use a standard Controlled Affiliate license form
provided by BCBSA and to cooperate fully in assuring that the licensed Controlled Affiliate maintains compliance with the
license standards.
Standard 1 - Organization and Governance
A Controlled Affiliate is defined as an entity organized and operated in such a manner, that it meets the following
requirements:
(1) Controlled Affiliate is owned or controlled by two or more Controlling Plans;
(2) Each Controlling Plan is authorized pursuant to a separate Blue Cross License Agreement to use the Licensed
Marks in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of
the Controlling Plans; and
(3) The Controlling Plans must have the legal authority directly or indirectly through wholly- owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having not less than 100% voting control
thereof;
(b) prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of
the Controlled Affiliate with which the Controlling Plans do not concur;
(c) exercise control over the policy and operations of the Controlled Affiliate; and
-1-

-- 282 of 533 --

EXHIBIT A (continued)
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s establishing or governing
documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates (except such approval shall not be required with respect to
business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the
Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such
Controlling Plan);
(iii) change any of the type(s) of businesses in which it engages (except such approval shall not be required with
respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of
one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA
sponsored by such Controlling Plan);
(iv) take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the
Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly owned subsidiaries shall own 100% of any for-
profit Controlled Affiliate.
Standard 2 - Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its
contractual obligations to its customers.
Standard 3 - State Licensure/Certification
A Controlled Affiliate shall maintain appropriate and unimpaired licensure and certifications.
-2-

-- 283 of 533 --

EXHIBIT A (continued)
Standard 4 - Certain Disclosures
A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public statements of:
a. the structure of the Blue Cross and Blue Shield System; and
b. the independent nature of every licensee.
Standard 5 - Reports and Records for Controlled Affiliates
A Controlled Affiliate and/or its Controlling Plans shall furnish, on a timely and accurate basis, reports and records relating
to these Standards and the License Agreements between BCBSA and Controlled Affiliate.
Standard 6 - Best Efforts
During each year, a Controlled Affiliate shall use its best efforts to promote and build the value of the Blue Cross Marks.
Standard 7 - Participation in Certain National Programs
A Controlled Affiliate shall effectively and efficiently participate in certain national programs from time to time as may be
adopted by Member Plans for the purposes of providing ease of claims processing for customers receiving benefits
outside of the Controlled Affiliate’s service area.
National program requirements include:
a. Inter-Plan Teleprocessing System (ITS); and
b. Inter-Plan Medicare Advantage Program.
Standard 8 - Participation in Master Business Associate Agreement
Controlled Affiliates shall comply with the terms of the Business Associate Agreement for Blue Cross and Blue Shield
Licensees to the extent they perform the functions of a business associate or subcontractor to a business associate, as
defined by the Business Associate Agreement.
Amended as of November 15, 2007
-3-

-- 284 of 533 --

EXHIBIT B
ROYALTY FORMULA FOR SECTION 9 OF THE CONTROLLED AFFILIATE LICENSE
AGREEMENTS
APPLICABLE TO REGIONAL MEDICARE ADVANTAGE PPO PRODUCTS
Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following formula:
An amount equal to its pro rata share of each Controlling Plan dues payable to BCBSA computed
with the addition of the Controlled Affiliate's members using the Marks on regional MAPPO
products and related services as reported on the Quarterly Enrollment Report with BCBSA. The
payment by each Controlling Plan of its dues to BCBSA, including that portion described in this
paragraph, will satisfy the requirement of this paragraph, and no separate payment will be
necessary.
Amended as of June 14, 2007
-4-

-- 285 of 533 --

Exhibit 1C
BLUE CROSS
CONTROLLED AFFILIATE LICENSE AGREEMENT APPLICABLE TO REGIONAL MEDICARE PART D
PRESCRIPTION
DRUG PLAN PRODUCTS
(Adopted by Member Plans at their November 16, 2023 meeting)
This Agreement by and among Blue Cross and Blue Shield Association ("BCBSA") and
______________(“Controlled Affiliate"), a Controlled Affiliate of the Blue Cross Plan(s), known as
_________________________(“Controlling Plans”), each of which is also a Party hereto.
WHEREAS, BCBSA is the owner of the BLUE CROSS and BLUE CROSS Design service marks;
WHEREAS, under the Medicare Modernization Act, companies may apply to and be awarded a contract by the
Centers for Medicare and Medicaid Services (“CMS”) to offer Medicare Part D Prescription Drug Plan products in
geographic regions designated by CMS (hereafter “regional PDP products).”
WHEREAS, some of the CMS-designated regions include the Service Areas, or portions thereof, of more than one Plan.
WHEREAS, the Controlling Plans and Controlled Affiliate desire that the latter be entitled to use the BLUE CROSS
and BLUE CROSS Design service marks (collectively the "Licensed Marks") as service marks and be entitled to use the
term BLUE CROSS in a trade name ("Licensed Name") to offer regional PDP products in a region that includes the
Service Areas, or portions thereof, of more than one Controlling Plan;
NOW THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby
agree as follows:
1. 	GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled Affiliate the right to use
the Licensed Marks and Name in connection with, and only in connection with the sale, marketing and administration
of regional PDP products and related services.
This grant of rights is non-exclusive and is limited to the following states:
__(the “Region”). Controlled Affiliate may use the Licensed
-1-

-- 286 of 533 --

Marks and Name in its legal name on the following conditions: (i) the legal name must be approved in advance, in
writing, by BCBSA; (ii) Controlled Affiliate shall not do business outside the Region under any name or mark except
business conducted in the Service Area of a Controlling Plan provided that Controlled Affiliate is separately licensed
by BCBSA to use the Licensed Marks and Name in connection with health care plans and related services in the
Service Area of such Controlling Plan; and (iii) Controlled Affiliate shall not use the Licensed Marks and Name, or
any derivative thereof, as part of any name or symbol used to identify itself in any securities market. Controlled
Affiliate may use the Licensed Marks and Name in its Trade Name only with the prior, written, consent of BCBSA.
2. 	QUALITY CONTROL
A. 	Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services
and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they
may be amended by BCBSA from time-to-time.
B. 	Controlled Affiliate agrees to comply with all applicable federal, state and local laws.
C. 	Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by the
Controlling Plans or by BCBSA) a report or reports to the Controlling Plans and BCBSA demonstrating
Controlled Affiliate's compliance with the requirements of this Agreement including but not limited to the quality
control provisions of this paragraph and the attached Exhibit A.
D. 	Controlled Affiliate agrees that the Controlling Plans and/or BCBSA may, from time- to-time, upon reasonable
notice, review and inspect the manner and method of Controlled Affiliate's rendering of service and use of the
Licensed Marks and Name.
E. 	As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner, that it
meets the following requirements:
A. Controlled Affiliate is owned or controlled by two or more Controlling Plans;
B. Each Controlling Plan is authorized pursuant to a separate Blue Cross License Agreement to use the
Licensed Marks in a geographic area in the
Region and every geographic area in the Region is so licensed to at least one of the Controlling Plans;
and
-2-

-- 287 of 533 --

C. The Controlling Plans must have the legal authority directly or indirectly through wholly-owned
subsidiaries:
(a) to select members of the Controlled Affiliate’s governing Body having not less than 100% voting
control thereof;
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing
documents of the Controlled Affiliate with which the Controlling Plans do not concur;
(c) to exercise control over the policy and operations of the Controlled Affiliate; and
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s establishing
or governing documents must also require written approval by each of the Controlling Plans before the
Controlled Affiliate can:
i. change its legal and/or trade names;
ii. change the geographic area in which it operates (except such approval shall not be required with
respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service
Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement
with BCBSA sponsored by such Controlling Plan);
(iii) change any of the type(s) of businesses in which it engages (except such approval shall not
be required with respect to business of the Controlled Affiliate conducted under the Licensed
Marks within the Service Area of one of the Controlling Plans pursuant to a separate
controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan);
(iv) take any action that any Controlling Plan or BCBSA reasonably believes will adversely
affect the Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly-owned subsidiaries shall own 100% of any
for-profit Controlled Affiliate.
-3-

-- 288 of 533 --

3. 	SERVICE MARK USE
A. Controlled Affiliate recognizes the importance of a comprehensive national network of independent BCBSA
licensees which are committed to strengthening the Licensed Marks and Name. The Controlled Affiliate further
recognizes that its actions within the Region may affect the value of the Licensed Marks and Name nationwide.
B. Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and Name, including
but not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks and
Name and shall comply with such rules (generally applicable to Controlled Affiliates licensed to use the
Licensed Marks and Name) relative to service mark use, as are issued from time-to-time by BCBSA. Controlled
Affiliate recognizes and agrees that all use of the Licensed Marks and Name by Controlled Affiliate shall inure
to the benefit of BCBSA.
C. Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in a manner that transfers
or is intended to transfer in the Region the goodwill associated therewith to another mark or name, nor may
Controlled Affiliate engage in activity that may dilute or tarnish the unique value of the Licensed Marks and
Name.
D. Controlled Affiliate shall use its best efforts to promote and build the value of the Licensed Marks and Name in
connection with the sale, marketing and administration of regional PDP products and related services.
4. 	SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell, encumber or mortgage, by
operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the sole option of
any Controlling Plan or BCBSA. This Agreement and all rights and duties hereunder are personal to Controlled
Affiliate.
5. 	INFRINGEMENT
Controlled Affiliate shall promptly notify the Controlling Plans and the Controlling Plans shall promptly notify BCBSA
of any suspected acts of infringement, unfair competition or passing off that may occur in relation to the Licensed
Marks and Name. Controlled Affiliate shall not be entitled to require the Controlling Plans or BCBSA to take any
actions or institute any proceedings to prevent infringement, unfair competition or passing off by third parties.
Controlled Affiliate agrees to render to the Controlling Plans and BCBSA, without charge, all reasonable assistance
in connection with any matter pertaining to the protection of the Licensed Marks and Name by BCBSA.
-4-

-- 289 of 533 --

6. LIABILITY INDEMNIFICATION
Controlled Affiliate and the Controlling Plans hereby agree to save, defend, indemnify and hold
BCBSA harmless from and against all claims, damages, liabilities and costs of every kind, nature
and description (except those arising solely as a result of BCBSA's negligence) that may arise as
a result of or related to Controlled Affiliate's rendering of services under the Licensed Marks and
Name.
7. LICENSE TERM
A. Except as otherwise provided herein, the license granted by this Agreement shall remain in effect for a period
of one (1) year and shall be automatically extended for additional one (1) year periods unless terminated
pursuant to the provisions herein.
B. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further
action by any party or entity in the event that: (i) any one of the Controlling Plans ceases to be authorized to
use the Licensed Marks and Name; or (ii) pursuant to Paragraph 15(a)(x) of the Blue Cross License
Agreement any one of the Controlling Plans ceases to be authorized to use the Licensed Names and Marks in
the Region.
C. Notwithstanding any other provision of this Agreement, this license to use the Licensed Marks and Name may
be forthwith terminated by the Controlling Plans or the affirmative vote of the majority of the Board of Directors
of BCBSA present and voting at a special meeting expressly called by BCBSA for the purpose on ten (10)
days written notice to the Controlling Plans advising of the specific matters at issue and granting the
Controlling Plans an opportunity to be heard and to present their response to the Board for: (1) failure to
comply with any applicable minimum capital or liquidity requirement under the quality control standards of this
Agreement; or (2) failure to comply with the "Organization and Governance" quality control standard of this
Agreement; or (3) impending financial insolvency; or (4) failure to comply with any of the applicable
requirements of Standards 2, 3, 4, or 5 of attached Exhibit A; or
(5) the pendency of any action instituted against the Controlled Affiliate seeking its dissolution or liquidation of
its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for any of its property
or business or seeking the declaration or establishment of a trust for any of its property or business, unless this
Controlled Affiliate License Agreement has been earlier terminated under paragraph 7(E); or (6) such other
reason as is determined in good faith immediately and irreparably to threaten the integrity and reputation of
BCBSA, the Plans (including the Controlling Plans), any other licensee including Controlled Affiliate and/or the
Licensed Marks and Name.
D. Except as otherwise provided in Paragraphs 7(B), 7(C) or 7(E) herein, should Controlled Affiliate fail to comply
with the provisions of this Agreement and not cure such failure within thirty (30) days of receiving written notice
thereof (or commence a cure within such thirty day period and continue diligent efforts to
-5-

-- 290 of 533 --

complete the cure if such curing cannot reasonably be completed within such thirty day period) BCBSA or the
Controlling Plans shall have the right to issue a notice that the Controlled Affiliate is in a state of
noncompliance. If a state of noncompliance as aforesaid is undisputed by the Controlled Affiliate or is found to
exist by a mandatory dispute resolution panel and is uncured as provided above, BCBSA shall have the right to
seek judicial enforcement of the Agreement or to issue a notice of termination thereof. Notwithstanding any
other provisions of this Agreement, any disputes as to the termination of this License pursuant to Paragraphs
7(B), 7(C) or 7(E) of this Agreement shall not be subject to mediation and mandatory dispute resolution. All
other disputes between or among BCBSA, any of the Controlling Plans and/or Controlled Affiliate shall be
submitted promptly to mediation and mandatory dispute resolution. The mandatory dispute resolution panel
shall have authority to issue orders for specific performance and assess monetary penalties. Except, however,
as provided in Paragraphs 7(B) and 7(E) of this Agreement, this license to use the Licensed Marks and Name
may not be finally terminated for any reason without the affirmative vote of a majority of the present and voting
members of the Board of Directors of BCBSA.
E. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further
action by any party or entity in the event that:
(1) Controlled Affiliate shall no longer comply with item 2(E) above;
(2) Appropriate dues, royalties and other payments for Controlled Affiliate pursuant to paragraph 9 hereof,
which are the royalties for this License Agreement, are more than sixty (60) days in arrears to BCBSA; or
(3) Any of the following events occur: (i) a voluntary petition shall be filed by Controlled Affiliate seeking
bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the
United States or any other law governing insolvency or debtor relief, or (ii) an involuntary petition or
proceeding shall be filed against Controlled Affiliate seeking bankruptcy, reorganization, arrangement
with creditors or other relief under the bankruptcy laws of the United States or any other law governing
insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by
Controlled Affiliate or is not dismissed within sixty (60) days of the date upon which the petition or other
document commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order for relief is
entered against Controlled Affiliate in any case under the bankruptcy laws of the United States, or
Controlled Affiliate is adjudged bankrupt or insolvent as those terms are defined in the Uniform
Commercial Code as enacted in the State of Illinois by any court of competent jurisdiction, or (iv)
Controlled Affiliate makes a general assignment of its assets for the benefit of creditors, or (v) any
government or any government official, office, agency, branch, or unit assumes control of Controlled
Affiliate or delinquency proceedings (voluntary or involuntary) are instituted, or (vi) an action is brought
by Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a
trustee, interim
-6-

-- 291 of 533 --

trustee, receiver or other custodian for any of its property or business, or (vii) an action is instituted by
any governmental entity or officer against Controlled Affiliate seeking its dissolution or liquidation of its
assets or seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its
property or business and such action is consented to or acquiesced in by Controlled Affiliate or is not
dismissed within one hundred thirty (130) days of the date upon which the pleading or other document
commencing the action is served upon the Controlled Affiliate, provided that if the action is stayed or its
prosecution is enjoined, the one hundred thirty (130) day period is tolled for the duration of the stay or
injunction, and provided further, that the Association’s Board of Directors may toll or extend the 130 day
period at any time prior to its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for
any of Controlled Affiliate's property or business is appointed or the Controlled Affiliate is ordered
dissolved or liquidated. Notwithstanding any other provision of this Agreement, a declaration or a request
for declaration of the existence of a trust over any of the Controlled Affiliate’s property or business shall
not in itself be deemed to constitute or seek appointment of a trustee, interim trustee, receiver or other
custodian for purposes of subparagraphs 7(E)(3)(vii) and
(viii) of this Agreement.
F. Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately
discontinue all use of the Licensed Marks and Name, including any use in its trade name, except to the extent
that it continues to be authorized to use the Licensed Marks within the Service Area of one of the Controlling
Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling
Plan.
G. Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its customers to whom it
provides products or services under the Licensed Marks pursuant to this Agreement that it is no longer a
licensee of BCBSA and, if directed by the Association’s Board of Directors, shall provide instruction on how the
customer can contact BCBSA or a designated licensee to obtain further information on securing coverage. The
notification required by this paragraph shall be in writing and in a form approved by BCBSA. The BCBSA shall
have the right to audit the terminated entity's books and records to verify compliance with this paragraph.
H. In the event this Agreement terminates pursuant to 7(B) hereof, upon termination of this Agreement the
provisions of Paragraph 7(G) shall not apply and the following provisions shall apply, except that, in the event
that Controlled Affiliate is separately licensed by BCBSA to use the Licensed Marks in the Service Area of a
Controlling Plan and termination of this Agreement is due to a partial termination of such Controlling Plan’s
license pursuant to Paragraph 15(a)(x)(ii) of the Blue Cross License Agreement, the notices, national account
listing, payment, and audit right listed below shall be applicable solely with respect to the Region and the
geographic area for which the Controlling Plan’s license to use the Licensed Names and Marks is terminated:
-7-

-- 292 of 533 --

(1) The Controlled Affiliate shall send a notice through the U.S. mails, with first class postage affixed, to
all individual and group customers,
providers, brokers and agents of products or services sold, marketed, underwritten or administered by the
Controlled Affiliate under the Licensed Marks and Name. The form and content of the notice shall be
specified by BCBSA and shall, at a minimum, notify the recipient of the termination of the license, the
consequences thereof, and instructions for obtaining alternate products or services licensed by BCBSA.
This notice shall be mailed within 15 days after termination.
(2) The Controlled Affiliate shall deliver to BCBSA within five days of a request by BCBSA a listing of national
accounts in which the Controlled Affiliate is involved (in a control, participating or servicing capacity),
identifying the national account and the Controlled Affiliate’s role therein.
(3) Unless the cause of termination is an event respecting BCBSA stated in paragraph 15(a) or (b) of the
Plan’s license agreement with BCBSA to use the Licensed Marks and Name, the Controlled Affiliate, the
Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly
liable for payment to BCBSA of an amount equal to $25 multiplied by the number of Licensed Enrollees of
the Controlled Affiliate; provided that if any Plan other than a Controlling Plan is permitted by BCBSA to
use marks or names licensed by BCBSA in a geographic area in the Region, the payment for Licensed
Enrollees in such geographic area shall be multiplied by a fraction, the numerator of which is the number
of Licensed Enrollees of the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled
Affiliates of the Controlling Plans in such geographic area and the denominator of which is the total
number of Licensed Enrollees in such geographic area. Licensed Enrollee means each and every person
and covered dependent who is enrolled as an individual or member of a group receiving products or
services sold, marketed or administered under marks or names licensed by BCBSA as determined at the
earlier of (i) the end of the last fiscal year of the terminated entity which ended prior to termination or (ii)
the fiscal year which ended before any transactions causing the termination began. Notwithstanding the
foregoing, the amount payable pursuant to this subparagraph H. (3) shall be due only to the extent that,
in BCBSA’s opinion, it does not cause the net worth of the Controlled Affiliate, the Controlling Plans or
any other Licensed Controlled Affiliates of the Controlling Plans to fall below 100% of the Health Risk-
Based Capital formula, or its equivalent under any successor formula, as set forth in the applicable
financial responsibility standards established by BCBSA (provided such equivalent is approved for
purposes of this subparagraph by the affirmative vote of three-fourths of the Plans and three-fourths of
the total then current weighted vote of all the Plans); measured as of the date of termination and adjusted
for the value of any transactions not made in the ordinary course of business. This payment shall not be
due in connection with transactions exclusively by or among Plans (including the Controlling Plans) or
their affiliates, including reorganizations, combinations or mergers, where the BCBSA Board of Directors
determines that the license
-8-

-- 293 of 533 --

termination does not result in a material diminution in the number of Licensed Enrollees or the extent of
their coverage. In the event that the Controlled Affiliate’s license is reinstated by BCBSA or is deemed to
have remained in effect without interruption by a court of competent jurisdiction, BCBSA shall reimburse
the Controlled Affiliate (and/or the Controlling Plans or their other Licensed Controlled Affiliates, as the
case may be) for payments made under this subparagraph 7.H.(3) only to the extent that such payments
exceed the amounts due to BCBSA pursuant to paragraph 7.K. and any costs associated with
reestablishing the terminated Controlling Plan’s Service Area or the Region, including any payments
made by BCBSA to a Plan or Plans (including the other Controlling Plans), or their Licensed Controlled
Affiliates, for purposes of replacing the Controlled Affiliate.
(4) BCBSA shall have the right to audit the books and records of the Controlled Affiliate, the Controlling
Plans, and any other Licensed Controlled Affiliates of the Controlling Plans to verify compliance with
this paragraph 7.H.
(5) As to a breach of 7.H.(1), (2), (3) or (4), the parties agree that
the obligations are immediately enforceable in a court of competent jurisdiction. As to a breach of 7.H.(1),
(2) or (4) by the Controlled Affiliate, the parties agree there is no adequate remedy at law and BCBSA is
entitled to obtain specific performance.
I. BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of competent jurisdiction
from entry into any transaction which would result in a termination of this Agreement unless a Controlling
Plan’s license from BCBSA to use the Licensed Marks and Names has been terminated pursuant to 10(d) of
such Controlling Plan’s license agreement upon the required 6 month written notice.
J. BCBSA acknowledges that it is not the owner of assets of the Controlled Affiliate.
K. In the event this Agreement terminates and is subsequently reinstated by BCBSA or is deemed to have
remained in effect without interruption by a court of competent jurisdiction, the Controlled Affiliate, the
Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for
reimbursing BCBSA the reasonable costs incurred by BCBSA in connection with the
termination and the reinstatement or court action, and any associated legal proceedings, including but not
limited to: outside legal fees, consulting fees, public relations fees, advertising costs, and costs incurred to
develop, lease or establish an interim provider network. Any amount due to BCBSA under this subparagraph
may be waived in whole or in part by the BCBSA Board of Directors in its sole discretion.
-9-

-- 294 of 533 --

8. DISPUTE RESOLUTION
The parties agree that any disputes between or among them or between or among any of them and one or more
Plans or Controlled Affiliates of Plans that use in any manner the Blue Cross and Blue Cross Marks and Name are
subject to the Mediation and Mandatory Dispute Resolution process attached to and made a part of each
Controlling Plan’s License from BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-
to-time, which documents are incorporated herein by reference as though fully set forth herein.
9. LICENSE FEE
Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth in Exhibit
B.
10. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or
employment relationship between the Controlling Plans and Controlled Affiliate or between either and BCBSA.
11. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall
be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its
President and, if any, its General Counsel.
12. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This
Agreement may only be amended by the affirmative vote of three-fourths of the Plans and three-fourths of the
total then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.
-10-

-- 295 of 533 --

13. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such findings shall in no way
affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for
any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of
this Agreement.
14. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or any other licensee
of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or
default in performance of said terms, covenants or conditions.
14A. 	VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the
Blue Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes
equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes
(if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all
questions requiring an affirmative three-fourths weighted vote of the Plans, shall occur pursuant to BCBSA’s Bylaws.
15. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of
Illinois.
16. HEADINGS
The headings inserted in this agreement are for convenience only and shall have no bearing on the interpretation
hereof.
-11-

-- 296 of 533 --

IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed and
effective as of the date of last signature written below.
Controlled Affiliate:
By:____________________________________________________
Date:__________________________________________________
Controlling Plan:
By: ____________________________________________________
Date:___________________________________________________
Controlling Plan:
By:_____________________________________________________
Date:___________________________________________________
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:_____________________________________________________
Date:___________________________________________________
-12-

-- 297 of 533 --

EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS APPLICABLE TO REGIONAL
MEDICARE
PART D PRESCRIPTION DRUG PLAN PRODUCTS
November 2023 PREAMBLE
The standards for licensing Controlled Affiliates for Medicare Part D Prescription Drug Plan Products are established by
BCBSA and are subject to change from time- to-time upon the affirmative vote of three-fourths (3/4) of the Plans and
three-fourths (3/4) of the total weighted vote. Each Controlling Plan is required to use a standard Controlled Affiliate
license form provided by BCBSA and to cooperate fully in assuring that the licensed Controlled Affiliate maintains
compliance with the license standards.
Standard 1 - Organization and Governance
A Controlled Affiliate is defined as an entity organized and operated in such a manner, that it meets the following
requirements:
(1) 	Controlled Affiliate is owned or controlled by two or more Controlling Plans;
(2) 	Each Controlling Plan is authorized pursuant to a separate Blue Cross License Agreement to use the Licensed
Marks in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of
the Controlling Plans; and
(3) 	The Controlling Plans must have the legal authority directly or indirectly through wholly- owned subsidiaries:
(a) 	to select members of the Controlled Affiliate’s governing body having not less than 100% voting control
thereof;
(b) 	prevent any change in the articles of incorporation, bylaws or other establishing or governing documents
of the Controlled Affiliate with which the Controlling Plans do not concur;
(c) 	exercise control over the policy and operations of the Controlled Affiliate; and
-13-

-- 298 of 533 --

EXHIBIT A (continued)
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s establishing or governing
documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates (except such approval shall not be required with respect
to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one
of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA
sponsored by such Controlling Plan);
(iii) change any of the type(s) of businesses in which it engages (except such approval shall not be required
with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the
Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license agreement
with BCBSA sponsored by such Controlling Plan);
(iv) take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the
Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly-owned subsidiaries shall own 100% of any for-
profit Controlled Affiliate.
Standard 2 - Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its
contractual obligations to its customers.
Standard 3 - State Licensure/Certification
A Controlled Affiliate shall maintain appropriate and unimpaired licensure and certifications.
-14-

-- 299 of 533 --

EXHIBIT A (continued)
Standard 4 - Certain Disclosures
A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public statements of:
a. the structure of the Blue Cross and Blue Shield System; and
b. the independent nature of every licensee.
Standard 5 - Reports and Records for Controlled Affiliates
A Controlled Affiliate and/or its Controlling Plans shall furnish, on a timely and accurate basis, reports and records relating
to these Standards and the License Agreements between BCBSA and Controlled Affiliate.
Standard 6 - Best Efforts
During each year, a Controlled Affiliate shall use its best efforts to promote and build the value of the Blue Cross Marks.
Standard 7 - Participation in Master Business Associate Agreement
Controlled Affiliates shall comply with the terms of the Business Associate Agreement for Blue Cross and Blue Shield
Licensees to the extent they perform the functions of a business associate or subcontractor to a business associate, as
defined by the Business Associate Agreement.
-15-

-- 300 of 533 --

EXHIBIT B
ROYALTY FORMULA FOR SECTION 9 OF THE CONTROLLED AFFILIATE LICENSE
AGREEMENTS
APPLICABLE TO REGIONAL MEDICARE PART D PRESCRIPTION DRUG PLAN PRODUCTS
Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following formula:
An amount equal to its pro rata share of each Controlling Plan dues payable to BCBSA computed with the addition of the
Controlled Affiliate's members using the Marks on regional PDP products and related services as reported on the
Quarterly Enrollment Report with BCBSA. The payment by each Controlling Plan of its dues to BCBSA, including that
portion described in this paragraph, will satisfy the requirement of this paragraph, and no separate payment will be
necessary.
Amended as of June 14, 2007
-16-

-- 301 of 533 --

EXHIBIT 2
Membership Standards
Page 1 of 5
Preamble
The Membership Standards apply to all organizations seeking to become or to continue as Regular Members of the Blue
Cross and Blue Shield Association. Any organization seeking to become a Regular Member must be found to be in
substantial compliance with all Membership Standards at the time membership is granted and the organization must be
found to be in substantial compliance with all Membership Standards for a period of two (2) years preceding the date of its
application. If Membership is sought by an entity which controls or is controlled by one or more Plans, such compliance
shall be determined on the basis of compliance by such Plan or Plans.
The Regular Member Plans shall have authority to interpret these Standards.
A Regular Member Plan that operates as a “Shell Holding Company” is defined as an entity that assumes no underwriting
risk and has less than 1% of the consolidated enterprise assets (excludes investments in subsidiaries) and less than 5%
of the consolidated enterprise net general and administrative expenses.
A Regular Member Plan that operates as a “Hybrid Holding Company” is defined as an entity that assumes no
underwriting risk and has either more than 1% of the consolidated enterprise assets (excludes investments in
subsidiaries) or more than 5% of the consolidated enterprise net general and administrative expenses.
Standard 1: A Plan shall maintain a governing Board, which shall control the Plan and ensure that the Plan follows
appropriate practices of corporate governance. A Plan's Board shall not be controlled by any special
interest group, shall make an annual determination that a majority of its directors are independent, and
shall act in the best interest of its Corporation and its customers. The Board shall be composed of a
majority of persons other than providers of health care services, who shall be known as public members. A
public member shall not be an employee of or have a financial interest in a health care provider, nor be a
member of a profession which provides health care services.
Amended as of March 15, 2007

-- 302 of 533 --

EXHIBIT 2
Membership Standards
Page 2 of 5
Standard 2: A Plan shall furnish to the Association on a timely and accurate basis reports and records relating to
compliance with these Standards and the License Agreements between the Association and the Plans.
Such reports and records are the following:
A. 	BCBSA Membership Information Request;
B. 	Triennial trade name and service mark usage material, including disclosure material under Standard
7;
C. Changes in the governance of the Plan, including changes in a Plan's Charter, Articles of
Incorporation, or Bylaws, changes in a Plan's Board composition, or changes in the identity of the
Plan's Principal Officers;
D. 	Written notice to BCBSA as soon as practicable but no later than 30 days after receipt of notice of
any litigation filed against the Plan or any of its licensed controlled affiliates that includes allegations
or claims that directly reference and seeks to enjoin or otherwise challenge the License
Agreements, the structure of the Blue system, exclusive service areas, BCBSA, or any BCBSA rule,
regulation, policy or Standard (Qualifying Litigation).
• Notice of Qualifying Litigation to BCBSA must include (1) Name of the Case; (2) Case Number;
(3) Location/Where Case Pending; and (4) Date Plan Received, and be provided to BCBSA
Senior Vice President, General Counsel and Corporate Secretary.
E. 	Quarterly Financial Report, Semi-annual “Health Risk- Based Capital (HRBC) Report” as defined by
the NAIC, Annual Budget, Annual Certified Audit Report, Insurance Department Examination
Report, Annual Statement filed with State Insurance Department (with all attachments), Plan,
Subsidiary and Affiliate Report; (new version starting for period ended 12/31/20 and thereafter); and
• Plans that are a Shell Holding Company as defined in the Preamble hereto are required to
furnish only a calendar year-end “Health Risk- Based Capital (HRBC) Report” as defined by the
NAIC.
Amended as of March 17, 2022

-- 303 of 533 --

EXHIBIT 2
Membership Standards
Page 3 of 5
F. Quarterly Enrollment Report, Quarterly Member Touchpoint Measures Index (MTM) through
12/31/2011, and Semi-annual MTM Index starting 1/1/2012 and thereafter.
• For purposes of MTM reporting only, a Plan shall file a separate MTM report for each Geographic
Market.
Standard 3: A Plan shall be operated in a manner that provides reasonable financial assurance that it can fulfill
its contractual obligations to its customers.
Standard 4: A Plan shall be operated in a manner responsive to customer needs and requirements.
Standard 5: A Plan shall effectively and efficiently participate in each national program as from time to time may be
adopted by the Member Plans for the purposes of providing portability of membership between the Plans
and ease of claims processing for customers receiving benefits outside of the Plan's Service Area.
Such programs are applicable to Blue Cross and Blue Shield Plans, and include:
A. 	Inter-Plan Teleprocessing System (ITS);
B. 	BlueCard Program;
C. 	National Account Programs;
D. 	Business Associate Agreement for Blue Cross and Blue Shield Licensees,
effective April 14, 2003; and
E. 	Inter-Plan Medicare Advantage Program.
Amended as of March 17, 2022

-- 304 of 533 --

EXHIBIT 2
Membership Standards
Page 4 of 5
Standard 6: 	In addition to requirements under the national programs listed in Standard 5: Participation in National
Programs, a Plan shall take such action as required to ensure its financial performance in programs and
contracts of an inter-Plan nature or where the Association is a party.
Standard 7: 	A Plan shall make adequate disclosure in contracting with third parties and in disseminating public
statements of (i) the structure of the Blue Cross and Blue Shield System, (ii) the independent nature of
every Plan, and (iii) the Plan's financial condition.
Standard 8: 	A Plan shall cooperate with the Association's Board of Directors and its Organization and Governance
Committee in the administration of the Plan Performance Response Process and in addressing Plan
performance problems identified thereunder.
Standard 9: 	A Plan shall obtain a rating of its financial strength from an independent rating agency approved by the
Association's Board of Directors for such purpose.
Standard 10: Notwithstanding any other provision in this License Agreement, during each year, a Plan and its Controlled
Affiliate(s) engaged in providing licensable services (excluding Life Insurance and Charitable Foundation
Services) shall use their best efforts to promote and build the value of the Blue Cross Marks.
Standard 11: Neither a Plan nor any Larger Controlled Affiliate shall cause or permit an entity other than a Plan or a
Licensed Controlled Affiliate thereof to obtain control of the Plan or Larger Controlled Affiliate or to acquire
a substantial portion of its assets related to licensable services.
Amended as of June 16, 2005

-- 305 of 533 --

EXHIBIT 2
Membership Standards
Page 5 of 5
Standard 12: No provider network, or portion thereof, shall be rented or otherwise made available to a National
Competitor if the Licensed Marks or Names are used in any way with such network.
A provider network may be rented or otherwise made available, provided there is no use of the Licensed
Marks or Names with respect to the network being rented.
Standard 13: Each Plan shall operate in a manner to reasonably: 1) protect the security and confidentiality of Personally
Identifiable Information (PII) and Protected Health Information (PHI); 2) protect the Brands from
reputational damage; and 3) cooperate with BCBSA and other Plans if a data security incident or data
breach occurs.
Amended as of June 18, 2015

-- 306 of 533 --

EXHIBIT 3
GUIDELINES WITH RESPECT TO USE OF
LICENSED NAME AND MARKS IN CONNECTION WITH NATIONAL
ACCOUNTS
Page 1 of 3
1. 	The strength of the Blue Cross/Blue Cross National Accounts mechanism, and the continued provision of cost
effective, quality health care benefits to National Accounts, are predicated on locally managed provider networks
coordinated on a national scale in a manner consistent with effective service to National Account customers and
consistent with the preservation of the integrity of the Blue Cross/Blue Shield system and the Licensed Marks.
These guidelines shall be interpreted in keeping with such ends.
2. 	A National Account is an entity with employee and/or retiree locations in more than one Plan's Service Area. Unless
otherwise agreed, a National Account is deemed located in the Service Area in which the corporate headquarters of
the National Account is located. A local plant, office or division headquarters of an entity may be deemed a separate
National Account when that local plant, office or division headquarters 1) has employee locations in more than one
Service Area, and 2) has independent health benefit decision- making authority for the employees working at such
local plant, office or division headquarters and for employees working at other locations outside the Service Area. In
such a case, the local plant, office or division headquarters is a National Account that is deemed located in the
Service Area in which such local plant, office or division headquarters is located. The Control Plan of a National
Account is the Plan in whose Service Area the National Account is located. A participating ("Par") Plan is a Plan in
whose Service Area the National Account has employee and/or retiree locations, but in which the National Account
is not located. In the event that a National Account parent company consolidates health benefit- decision making for
itself and its wholly-owned subsidiary companies, the parent company and the subsidiary companies shall be
considered one National Account. The Control Plan for such a National Account shall be the Plan in whose Service
Area the parent company headquarters is located.
3. 	The National Account Guidelines enunciated herein below shall be applicable only with respect to the business of
new National Accounts acquired after January 1, 1991.
4. 	Control Plans shall utilize National Account identification cards complying with then currently effective BCBSA
graphic standards in connection with all National Accounts business to facilitate administration thereof, to minimize
subscriber and provider confusion, and to reflect a commitment to cooperation among Plans.
Amended as of June 12, 2003

-- 307 of 533 --

EXHIBIT 3
Page 2 of 3
5. 	Disputes among Plans and/or BCBSA as to the interpretation or implementation of these Guidelines or as to other
National Accounts issues shall be submitted to mediation and mandatory dispute resolution as provided in the
License Agreement. For two years from the effective date of the License Agreement, however, such disputes shall
be subject to mediation only, with the results of such mediation to be collected and reported in order to establish
more definitive operating parameters for National Accounts business and to serve as ground rules for future
binding dispute resolution.
6. 	The Control Plan may use the BlueCard Program (as defined by IPPC) to deliver benefits to employees and non-
Medicare eligible retirees in a Participating Plan’s service area if an alternative arrangement with the Participating
Plan cannot be negotiated. The Participating Plan’s minimum servicing requirement for those employees and non-
Medicare retirees in its service area is to deliver benefits using the BlueCard Program. Account delivery is subject to
the policies, provisions and procedures of the BlueCard Program.
7. 	For provider payments in a Participating Plan’s area (on non-BlueCard claims), payment to the provider may be
made by the Participating Plan or the Control Plan at the Participating Plan's option. If the Participating Plan elects to
pay the provider, it may not withhold payment of a claim verified by the Control Plan or its designated processor, and
payment must be in conformity with service criteria established by the Board of Directors of BCBSA (or an
authorized committee thereof) to assure prompt payment, good service and minimum confusion with providers and
subscribers. The Control Plan, at the Participating Plan's request, will also assure that measures are taken to protect
the confidentiality of the data pertaining to provider reimbursement levels and profiles.
Amended as of June 14, 1996

-- 308 of 533 --

EXHIBIT 3
Page 3 of 3
8. 	The Control Plan, in its financial agreements with a National Account, is expected to reasonably reflect the
aggregate amount of differentials passed along to the Control Plan by all Participating Plans in a National Account.
9. 	Other than in contracting with health care providers or soliciting such contracts in areas contiguous to a Plan's
Service Area in order to serve its subscribers or those of its licensed Controlled Affiliate residing or working in its
Service Area, a Control Plan may not use the Licensed Marks and/or Name, as a tag line or otherwise, to negotiate
directly with providers outside its Service Area.
Amended as of March 13, 2003

-- 309 of 533 --

EXHIBIT 4
GOVERNMENT PROGRAMS AND CERTAIN OTHER USES
Page 1 of 14
1. 	A Plan and its licensed Controlled Affiliate(s) “Licensees” may use the Licensed Marks and Name in bidding on and
executing a contract to serve a Government Program, and in thereafter communicating with the Government
concerning the Program. Licensees may NOT use the Brands in communications or transactions with beneficiaries
or providers in a Government program located outside its Service Area. For purposes of this Paragraph 1, the term
“Government Programs” shall mean any non-risk Medicare, Medicaid, and other non-risk program administered by a
government authority, and any successor program. Contracts with the United States Government or the Government
of a State or Municipality to provide health care coverage to its employees are not considered Government
programs.
2. 	In connection with activity otherwise in furtherance of the License Agreement, Licensees, except for Regional MA
PPO and PD Controlled Affiliates (see paragraph 3 below), may use the Licensed Marks and Name (also referred
to as “Brands”) outside the Licensee’s Service Area in the following circumstances which are deemed legitimate
and necessary and not likely to cause consumer confusion:
2.1 	Common Business Communications
a. sending letterhead, envelopes, and similar items solely for administrative purposes (e.g., not for purposes of
marketing, advertising, promoting, selling or soliciting the sale of health care plans and related services);
b. distributing business cards other than in marketing and selling;
c. advertising in publications or electronic media solely to persons for employment;
Amended as of June 15, 2023

-- 310 of 533 --

EXHIBIT 4
Page 2 of 14
2.2 Marketing Spillover
a. 	advertising in print, electronic or other media which serve, as a substantial market, the Service Area of the
Licensee, provided that no Licensee may advertise outside its Service Area on the national broadcast or cable
networks and that advertisements in national print media are limited to the smallest regional edition
encompassing the Service Area;
b. 	advertising by direct mail where the addressee's zip code plus 4 includes, at least in part, the Licensee’s
Service Area;
2.3 Provider Contracting
a. 	contracting with health care providers or soliciting such contracts in a Contiguous Area in order to serve its
subscribers residing or working in its service area;
b. 	issuing a small sign containing the legal name or trade name of the Licensee for display by a provider in a
Contiguous Area to identify the provider as a participating provider of the Licensee;
c. 	negotiating case-specific reimbursement rates with a provider that does not have a contract applicable to a
specific member’s services rendered or to be rendered with the Licensee (or any of the Licensees in the case
of overlapping Service Areas) in whose Service Area the health care provider is located, so long as
(1) the Licensee engaging in the negotiations complies with all applicable Inter- Plan Programs Policies and
Provisions and Brand Regulations related to case- specific rate negotiations, and
(2) the Licensee (or all Licensees in the case of overlapping Service Areas) in whose Service Area the health
care provider is located provides consent before negotiations commence.
d. 	contracting with a pharmacy management organization (“Pharmacy Intermediary”) to gain access to a national
or regional pharmacy network to provide self-administered prescription drugs to deliver a pharmacy benefit for
all of the Licensee’s members nationwide, provided, however, that the Pharmacy Intermediary may not use the
Licensed Marks or Name in contracting with the pharmacy providers in such network.
Amended as of June 15, 2023

-- 311 of 533 --

EXHIBIT 4
Page 3 of 14
e. 	contracting with the corporate owner of a national or regional retail pharmacy chain to gain access to the
pharmacies in the chain to provide self-administered prescription drugs to deliver a pharmacy benefit for all of
the Licensee’s members nationwide, provided that (1) the Plan and the Controlled Affiliate may not contract
directly with pharmacists or pharmacy stores outside the Plan’s Service Area, and (2) neither the Plan’s or the
Controlled Affiliate’s name nor the Licensed Marks or Name may be posted or otherwise displayed at or by any
pharmacy store outside the Plan’s Service Area;
f. 	contracting with a dental management organization (“Dental Intermediary”) to gain access to a national or
regional dental network to deliver a routine dental benefit for all of the Licensee’s members nationwide,
provided, however, that the Dental Intermediary may not use the Licensed Marks or Name in contracting with
the dental providers in such network;
(i) For purposes of this Exhibit, “routine dental benefit” covers four classes of dental services: (1)
preventative services (e.g., teeth cleaning, oral exams, x-ray and lab exams); (2) restorative
services (e.g. fillings, crowns, inlays/onlays, root canal, periodontal treatments, extractions,
repairs to partials); (3) construction of dentures and bridges; and (4) orthodontic tooth guidance
appliances (e.g., braces, habit-breaking appliances).
(ii) Examples of services that are not within the scope of “routine dental” include any medical
oral or maxillofacial procedures, including maxillofacial surgery, and diagnosis or treatment of
the oral or maxillofacial region as a result of disease, chronic illness, or injury.
g. contracting with a vision management organization (“Vision Intermediary”) to gain access to a national or
regional vision network to deliver a routine vision benefit for all of the Licensee’s members nationwide,
provided, however, that the Vision Intermediary may not use the Licensed Marks or Name in contracting with
the vision providers in such network;
(i) For purposes of this Exhibit, “routine vision benefit” covers routine eye exams, glasses (frames
and lenses), contact lenses, and Lasik surgery.
(ii) Examples of services that are not within the scope of “routine vision” include any medical vision
procedures, including eye surgery, and the diagnosis or treatment of the eye as a result of
disease, chronic illness, or injury.
h. 	contracting with an independent clinical laboratory for analysis and clinical assessment of specimens that
are collected within the Licensee’s Service Area;
i. 	contracting with a durable medical equipment or home medical equipment company for durable medical
equipment and supplies and home medical equipment and supplies that are shipped to a location within the
Licensee’s Service Area;
Amended as of June 15, 2023

-- 312 of 533 --

EXHIBIT 4
Page 4 of 14
j. 	contracting with a specialty pharmaceutical company for non-routine biological therapeutics that are
ordered by a health care professional located within the Licensee’s Service Area;
k. 	contracting with a company that operates provider sites in the Licensee’s Service Area, provided that the
contract is solely for services rendered at a site (e.g., hospital, mobile van) that is within the Licensee’s
Service Area;
l. 	contracting with a company that makes health care professionals available in the Licensee’s Service Area (e.g.,
traveling home health nurse), provided that the contract is solely for services rendered by health care
professionals who are located within the Licensee’s Service Area.
m. 	Permitting Control/Home Plans’ ability to resolve members’ service issues requiring outreach to out-of-area
providers as set forth in the Inter-Plan Programs and Inter- Plan Medicare Advantage Program Policies.
n. 	contracting with national telemedicine and virtual healthcare (i.e., telehealth providers) companies nationally for
all virtual-only health care services in accordance with Inter-Plan Programs and Inter-Plan Medicare Advantage
Policies and Provisions.
2.4 Services to National Accounts
a. 	in conjunction with contracting with a National Account as Control Licensee or Alternate Control Licensee (as
those terms are defined in the Inter-Plan Programs Policies and Provisions (“IP Policies”) to offer Blue-
branded Health Coverage to the National Account, offering Blue-branded Health and Wellness Programs to
all members of the National Account, including members who have not enrolled in the Blue-branded Health
Coverage (“non-Blue Health Coverage members”), provided that:
(i) the Licensee has no contact or interaction with providers outside of the Licensee’s Service
Area, except as specifically provided in the IP Policies and in 2.4(b); and
(ii) if in accordance with IP Policies another Licensee is soliciting or servicing under the Licensed
Marks and Name a local plant, office or division of the account that is outside of the
Control/Alternate Licensee’s Service Area, the Control/Alternate Licensee may not offer Blue-
branded Health and Wellness Programs to any employees working at such local plant, office or
division without the consent of such other Licensee; and
(iii) if the Licensee provides an information card to the non-Blue Health Coverage members, the
card may not display the Licensed Marks in the masthead, must contain a prominent disclosure
conveying that it is not a health insurance card, and otherwise must be designed so that it is
dissimilar to a Blue member identification card.
Amended as of June 15, 2023

-- 313 of 533 --

EXHIBIT 4
Page 5 of 14
2.4 Services to National Accounts (continued)
For purposes of this subparagraph a, and below subparagraph b,the following definitions apply:
“Health and Wellness Program” shall mean a program that includes at least one of the following elements or a
related element:
• 	Health Risk Assessment and/or Preventive Screenings
• 	Exercise and Fitness Programs
• 	Health and Wellness Events (e.g., attendance at a health fair, a 5K walk)
• 	Nutrition and Weight Management
• 	Health Education (e.g., smoking cessation classes)
• 	Prenatal and Parenting Education
• 	Disease or Chronic Condition Management
The above listing is intended to represent examples of the types of programs that may be offered, and other
programs, including those offered through different media such as the internet or telephonically, may also be
deemed Health and Wellness programs.
“Health Coverage” shall mean providing or administering medical, surgical, hospital, major medical, or catastrophic
coverage, or any HMO, PPO, POS or other managed care plan for the foregoing services.
b. 	as part of a Health and Wellness Program that is otherwise compliant with subparagraph a above, contracting
with a health and wellness organization to gain access to providers to deliver a discrete health and wellness
event (“Event”) held at a National Account’s worksite outside of the Licensee’s Service Area, provided that:
(i) 	the services delivered at the Event are limited to fingerstick screenings for cholesterol and glucose,
seasonal flu immunizations, blood pressure measurements, body mass index measurements, and other
routine screenings, immunizations and measurements; and
(ii) 	neither such services nor their costs are applied as claims against any benefit plan; and
(iii) the Event is presented during one or more limited periods during a benefit year and is available to all
employees at the worksite.
Amended as of June 15, 2023

-- 314 of 533 --

EXHIBIT 4
Page 6 of 14
c. 	in conjunction with contracting with a National Account as Control/Alternate Licensee to offer Blue-branded
Health Coverage to the National Account, performing the Eligibility and Enrollment functions of HR
administration for all benefit plans offered by the National Account to its members, including benefit plans that
are not underwritten or administered by the Control/Alternate Licensee, provided that:
(i) 	in performing such functions, Licensee does not use the Licensed Marks and Name in any
communications with health care providers outside of the Licensee’s Service Area, and otherwise limits
its use of the Licensed Marks and Name outside of the Service Area to communications with the
account’s members, the other benefit plan providers with which the account has contracted and other
reasonably necessary communications to perform such functions; and
(ii) 	if in accordance with IP Policies another Licensee is soliciting or servicing under the Licensed Marks
and Name a local plant, office or division of the account that is outside of the Plan’s Service Area,
Licensee may not perform Eligibility and Enrollment functions for employees working at such local
plant, office or division without the consent of such other Licensee;
d. 	in conjunction with contracting with a National Account as Control/Alternate Licensee to perform or investigate
fraud, waste and abuse investigation activities for a non- participating provider in a Par/Host Plan’s service
area, as long as the Control/Home Plan is given permission to do so by the Par/Host Plan and specific
conditions are met in accordance with Inter-Plan Programs and Inter-Plan Medicare Advantage Program
policies.
Amended as of June 15, 2023

-- 315 of 533 --

EXHIBIT 4
Page 7 of 14
For purposes of this Exhibit, the following definitions apply:
“Eligibility” means services that manage the account’s eligibility data and determine or process determinations
relating to eligibility for benefit plans offered by the account to its employees, including such services as:
• 	monitoring and auditing data to ensure that only entitled individuals are enrolled in each such benefit plan;
• 	review of eligibility documentation (e.g. marriage licenses, birth certificates, student status verification
letters, employment records);
• 	identification of key member segments such as over-age dependents, part-time employees, employees
reaching certain milestones (e.g. Medicare-eligible, retirees);
• 	termination of coverage for those individuals found to be ineligible for coverage under a benefit plan, and,
if applicable, generation of a COBRA event; and
• 	management of “hour-banking” for union environments in which union members can bank hours to remain
eligible for benefits.
“Enrollment” means services that enroll eligible individuals and their spouses/dependents or terminate or change
their enrollment in the account’s benefit plans on an ongoing basis and during open enrollment periods, including
such services as:
• 	the coordination of each step in open enrollment process from project planning and system set-up to the
generation of confirmation statements;
• 	ongoing enrollment support for new hires and changes due to life events and work status adjustments;
• 	evidence of insurability (EOI) administration for life and disability coverage;
• 	transmission of eligibility/enrollment information to the account’s benefit plan providers;
• 	review and reconciliation of error reports received from the account’s benefit plan providers; and
• 	transmission of information to the account’s payroll system (e.g., benefit deductions, employee
demographic data).
Amended as of March 26, 2015

-- 316 of 533 --

EXHIBIT 4
Page 8 of 14
2.5 Conferences and Symposiums
a. 	submitting scholarly articles authored or co-authored by the Licensee or its respective employees for
publication in peer-reviewed journals (see BCBSA’s Brand Use Center);
b. 	permitting an internal representative of the Licensee to participate at a conference or symposium outside of the
Licensee’s Service Area regarding either (i) healthcare financing, administration, delivery or policy, or (ii) topics
within the representative’s functional discipline or expertise at the Licensee, for which the event sponsor will
issue communications to promote, administer, and/or recap the event that will identify the Licensee and/or the
Licensee’s representative as a participant. The communications outside of the Licensee’s Service Area that
mention the Licensee and/or the Licensee’s representative shall be limited to materials and digital media
provided to attendees, on-site signage, advertising in relevant trade publications, direct mail and email to
attendees and prospective attendees, and the sponsor’s website. A participating Licensee will also be
permitted to display/share communications at the conference or symposium subject to the requirements set
forth in (c) below.
c. 	Participating in any conference or symposium outside of the Licensee’s Service Area may not be for the
purpose of marketing or selling products or services unless there is a clear connection between the Licensee
and the reasoning for attending such conference or symposium (e.g., healthcare decision makers within the
Licensee’s service area will also be at the conference, the conference has a nexus to the Licensee’s service
area even though the conference is taking place elsewhere) and the Licensee has provided BCBSA with
advanced written notice prior to participating.
(i) 	Licensees may establish a booth to support at Conferences or Symposiums consistent with the above.
Any materials containing the Brands must include a disclosure clearly indicating the Licensee’s name or
trade name as well as an indication of where the Licensee provides products and services (i.e. BCBS of
Geography).
(ii) 	Licensees may not co-exhibit or promote the products and/or services of an unlicensed affiliate.
Amended as of November 16, 2023

-- 317 of 533 --

EXHIBIT 4
Page 9 of 14
2.6 Other Uses*
a. 	entering into a license agreement between and among BCBSA, the Licensee and a debit card issuer located
outside the Licensee’s Service Area, and entering into a corresponding operating agreement or agreements,
in order to offer a debit card bearing the Licensed Marks and Name to eligible persons as defined by the
aforementioned license agreement;
b. 	appearing in communications issued by an independent third party to recognize outstanding performance of
the Licensee or a member of the Licensee’s senior management as part of an established program of the
third party for which the Licensee has provided information to be considered for the recognition The areas of
recognition must relate to a Licensee’s performance as an employer or corporate citizen, or for a corporate
business function other than sales or marketing (e.g. human resources, underwriting). The third party’s
communication of the recognition must appear only in its customary media and form used with the established
program.
c. 	to identify itself as being a joint sponsor of an event, program or activity (e.g, a 5k run, a public event, a
wellness education seminar) along with other Licensees provided that the following conditions are met:
(i) Written notification is provided to BCBSA staff at least 30 days before the event or when the Licensee
executes a sponsorship agreement, whichever is earlier, identifying the joint sponsorship opportunity and
the participating licensees, and including a sample of the proposed branding consistent with the template
that is required under 2.6(c)(v).
(ii) Communications and materials relating to such joint sponsorship may appear solely within the Service
Areas of Licensees who have provided prior consent, are participating in such joint sponsorship program
and whose names appear in such communications and materials. In each participating Licensee’s
Service Area, such participating Licensee’s name must appear in all such communications and materials
with at least equal prominence as the names of other listed participating Licensees;
(iii) The joint sponsorship program may not involve the marketing, promotions, or sale of products or
services;
Amended as of June 15, 2023

-- 318 of 533 --

EXHIBIT 4
Page 10 of 14
(i) 	If in any Service area or portion thereof covered by the joint sponsorship program, a Licensee that has
exclusive rights to one of the Brands (e.g. Blue Shield marks) is not participating, the participating
Licensees may not use that Brand in that Service Area or portion thereof. For example, if BCBS of
Geography A and Blue Cross of Geography B enter into a joint sponsorship program to be displayed in
Blue Cross of Geography B’s Service Area, but Blue Shield of Geography B has exclusive rights to use
the Blue Shield marks in Geography B and does not participate, then the Blue Shield marks may not be
used in Geography B in any manner in connections with the joint sponsorship program, not even in BCBS
of Geography A’s name. BCBS of Geography A may apply for approval under the BlueCross BlueShield
Brand Book to adopt a shortened trade name (e.g., Blue Cross of Geography A) for use in connection
with the program in Geography B, and
(v.) Subject to the limitations set forth above, the participating Licensees shall use one of the designated
templates shown in Appendix C of the BlueCross BlueShield Brand Book for branding of the joint
sponsorship. For clarification,
the templates identified herein shall apply only to the manner in which the participating Licensees’ Blue
logos appear in one visual representation to identify the sponsors and does not apply to any other aspect
of the sponsorship branding.
d. 	hosting meetings or events (collectively, “events”) in Washington, D.C. or a Plan’s State Capitol related to policy
and business issues in the Licensee’s Service Area, or hosting events in conjunction with the assemblies or
conventions of national political parties. Such events may not involve marketing or selling products or services.
Use of the Licensed Marks and Name outside the Licensee’s Service Area in connection with such events
shall be limited to materials and digital media provided to attendees and prospective attendees and onsite
signage. For any such events in Washington,
D.C. that are open to attendees other than government officials or their staffs, or are briefings open to all
Congressional staff, or are otherwise likely to receive media coverage, the Licensee is required to provide
advance notice to BCBSA. For events hosted outside of Washington, D.C. in conjunction with the assemblies
or conventions of national political parties, the Licensee is required to provide advance notice to BCGSA and
to the local Plan(s);
e. 	permitting an affiliate that is not licensed to use the Licensed Names and Marks to identify its corporate
relationship with the Plan pursuant to the BlueCross BlueShield Brand Book as amended by BCBSA from time
to time;
*(Illustrative examples of Other Uses provisions are found on BCBSA’s Brand Use Center).
Amended as of June 15, 2023

-- 319 of 533 --

EXHIBIT 4
Page 11 of 14
2.7. Definition of Contiguous Area
For the purposes of this Exhibit, Contiguous Area means the greater of;
• 	One county into an adjoining Service Area; or
• 	An entire Metropolitan Statistical Area (“MSA”) as defined by the most recent publication of the United States
Department of Commerce, partly in a Licensee’s Service Area and partly in portions of other Licensee(s) Service
Area; or
• 	A larger area in an adjoining Service Area approved in advance by the Organization and Governance Committee
because of unique geographical or demographic circumstance.
3. In connection with activity otherwise in furtherance of the License Agreement, a Controlled Affiliate that is licensed to
use the Licensed Marks and Name pursuant to a Controlled Affiliate License Agreement authorized in clauses d) or
e) of Paragraph 2 of the Plan’s License Agreement with BCBSA may use the Licensed Marks and Name outside the
Region (as that term is defined in such respective Controlled Affiliate License Agreements) in the following
circumstances which are deemed legitimate and necessary and not likely to cause consumer confusion:
a. sending letterhead, envelopes, and similar items solely for administrative purposes (e.g., not for purposes of
marketing, advertising, promoting, selling or soliciting the sale of health care plans and related services).
b. distributing business cards other than in marketing and selling;
c. contracting with health care providers or soliciting such contracts in areas contiguous to the Region in order to
serve its subscribers residing in the Region, provided that the Controlled Affiliate may not use the names of
any of its Controlling Plans in connection with such contracting unless the provider is located in a geographic
area that is also contiguous to such Controlling Plan’s Service Area;
d. issuing a small sign containing the legal name or trade name of the Controlled Affiliate for display by a provider
to identify the latter as a participating provider of the Controlled Affiliate, provided that the Controlled Affiliate
may not use the names of any of its Controlling Plans on such signs unless the provider is located in a
geographic area that is also contiguous to such Controlling Plan’s Service Area;
e. advertising in publications or electronic media solely to persons for employment;
Amended as of June 15, 2023

-- 320 of 533 --

EXHIBIT 4
Page 12 of 14
f. 	advertising in print, electronic or other media which serve, as a substantial market, the Region, provided that the
Controlled Affiliate may not advertise outside its Region on the national broadcast and cable networks and that
advertisements in national print media are limited to the smallest regional edition encompassing the Region,
and provided further that any such advertising by the Controlled Affiliate may not reference the name of any of
its Controlling Plans unless the respective Controlling Plan is authorized under paragraph 2 of this Exhibit 4 to
advertise in such media;
g. 	advertising by direct mail where the addressee's zip code plus 4 includes, at least in part, the Region,
provided that such advertising by the Controlled Affiliate may not reference the name of any of its Controlling
Plans unless the respective Controlling Plan is authorized under paragraph 2 of this Exhibit 4 to send direct
mail to such zip code plus 4.
h. 	[Intentionally left blank, pending review by the Inter-Plan Programs Committee of the applicability of the case
management rule to such Controlled Affiliates.]
i. 	contracting with a pharmacy management organization (“Pharmacy Intermediary”) to gain access to a national
or regional pharmacy network to provide self-administered prescription drugs to deliver a pharmacy benefit for
the Controlled Affiliate’s regional Medicare Advantage PPO or regional Medicare Part D Prescription Drug
members enrolled under the Licensed Marks pursuant to such respective Controlled Affiliate License
Agreements, provided, however, that the Pharmacy Intermediary may not use the Licensed Marks or Name in
contracting with the pharmacy providers in such network;
j. 	contracting with the corporate owner of a national or regional retail pharmacy chain to gain access to the
pharmacies in the chain to provide self-administered prescription drugs to deliver a pharmacy benefit to the
Controlled Affiliate’s regional Medicare Advantage PPO or regional Medicare Part D Prescription Drug
members enrolled under the Licensed Marks pursuant to such respective Controlled Affiliate License
Agreements, provided that (1) the Controlled Affiliate may not contract directly with pharmacists or pharmacy
stores outside the Region, and (2) neither the Controlled Affiliate’s name nor the Licensed Marks or Name
may be posted or otherwise displayed at or by any pharmacy store outside the Region;
k. 	contracting with a dental management organization (“Dental Intermediary”) to gain access to a national or
regional dental network to deliver a routine dental benefit for the Controlled Affiliate’s regional Medicare
Advantage PPO members enrolled under the Licensed Marks pursuant to such Controlled Affiliate License
Agreement, provided, however, that the Dental Intermediary may not use the Licensed Marks or Name in
contracting with the dental providers in such network;
Amended as of June 15, 2023

-- 321 of 533 --

EXHIBIT 4
Page 13 of 14
l. 	contracting with a vision management organization (“Vision Intermediary”) to gain access to a national or
regional vision network to deliver a routine vision benefit for the Controlled Affiliate’s regional Medicare
Advantage members enrolled under the Licensed Marks pursuant to such Controlled Affiliate License
Agreement, provided, however, that the Vision Intermediary may not use the Licensed Marks or Name in
contracting with the vision providers in such network;
m. 	contracting with an independent clinical laboratory for analysis and clinical assessment of specimens that are
collected within the Controlled Affiliate’s Region;
n. 	contracting with a durable medical equipment or home medical equipment company for durable medical
equipment and supplies and home medical equipment and supplies that are shipped to a location within the
Controlled Affiliate’s Region;
o. 	contracting with a specialty pharmaceutical company for non-routine biological therapeutics that are ordered by
a health care professional located within the Region;
p. 	contracting with a company that operates provider sites in the Region, provided that the contract is solely for
services rendered at a site (e.g., hospital, mobile van) that is within the Region;
q. 	contracting with a company that makes health care professionals available in the Region (e.g., traveling
home health nurse), provided that the contract is solely for services rendered by health care professionals
who are located within the Region.
Amended as of June 15, 2023

-- 322 of 533 --

EXHIBIT 4
Page 14 of 14
4. BCBSA shall retain the right to use the Licensed Marks in conjunction with the Federal Employee Program and with
any other national offering made to federal employees pursuant to the Federal Employees Health Benefits
Program (FEHBP), including the right to license such use to its vendors, but only in the following manner.
a. 	the Licensed Marks may only be used by BCBSA with the term “Federal Employee Program”, “Federal”,
“FEP”, or similar language identifying the program as a benefit program for federal employees;
b. 	the Licensed Marks may not be used by BCBSA with the name(s) of a specific Plan or Plans and;
c. 	any use by BCBSA in conjunction with a new national FEHBP program proposed after the enactment of this
amendment will require the approval of the BCBSA Board of Directors.
5. 	Where required by applicable state or local law or regulation, a Plan or its licensed Controlled Affiliate may submit
documents that contain the Brands to, and file forms that contain the Brands with, state or local regulators in a state
not included in its Service Area, provided that it gives reasonable advance notice to the local Plan of its intent to
submit such documents or file such forms. Notwithstanding, in no event may a Plan or its licensed Controlled Affiliate
use the Brands to register, or to obtain or maintain a license, a certificate of authority, or an equivalent document
authorizing it to act as a risk-bearing entity or third-party administrator in a state not included in its Service Area. If the
local Plan advises BCBSA that it believes its License Agreement has been or would be violated by any submission or
filing, BCBSA shall determine whether such submission or filing is required by state or local law or regulation and
violates the License Agreement, subject to the Plan’s or licensed Controlled Affiliate’s rights to obtain an independent
review of such determination under Paragraph 9(a) and Exhibit 5 of its License Agreement or Paragraph 8 of the
Controlled Affiliate License. For purposes of this paragraph, “local Plan” is defined as each Plan whose Service Area
includes all or part of the state in which the foregoing applicable state or local law or regulation has been enacted.
Amended as of June 15, 2023

-- 323 of 533 --

EXHIBIT 5
Page 1 of 23
MEDIATION AND MANDATORY DISPUTE RESOLUTION (MMDR) RULES
The Blue Cross and Blue Shield Plans ("Plans") and the Blue Cross Blue Shield Association ("BCBSA") recognize and
acknowledge that the Blue Cross and Blue Shield system is a unique nonprofit and for-profit system offering cost effective
health care financing and services. The Plans and BCBSA desire to utilize Mediation and Mandatory Dispute Resolution
(“MMDR”) to avoid expensive and time-consuming litigation that may otherwise occur in the federal and state judicial
systems. Even MMDR should be viewed, however, as methods of last resort, all other procedures for dispute resolution
having failed. Except as otherwise provided in the License Agreements, the Plans, their Controlled Affiliates and BCBSA
agree to submit all disputes to MMDR pursuant to these Rules and in lieu of litigation.
1. Initiation of Proceedings
A. 	Pre-MMDR Efforts
Before filing a Complaint to invoke the MMDR process, the CEO of a complaining party, or his/her designated
representative, shall undertake good faith efforts with the other side(s) to try to resolve any dispute.
B. 	Complaint
To commence a proceeding, the complaining party (or parties) shall provide by certified mail, return receipt
requested, a written Complaint to the BCBSA Corporate Secretary (which shall also constitute service on
BCBSA if it is a respondent) and to any Plan(s) and/or Controlled Affiliate(s) named therein. The Complaint
shall contain:
i. identification of the complaining party (or parties) requesting the proceeding;
ii. identification of the respondent(s);
iii. identification of any other persons or entities who are interested in a resolution of the dispute;
iv. a full statement describing the nature of the dispute;
v. identification of all of the issues that are being submitted for resolution;
Amended as of November 21, 1996

-- 324 of 533 --

EXHIBIT 5
Page 2 of 23
vi. the remedy sought;
vii. a statement as to whether the complaining party (or parties) elect(s) first to pursue Mediation;
viii. any request, if applicable, that the matter be handled on an expedited basis and the reasons
therefor; and
ix. a statement signed by the CEO of the complaining party affirming that the CEO has undertaken efforts, or
has directed efforts to be undertaken, to resolve the dispute before resorting to the MMDR process.
The complaining party (or parties) shall file and serve with the Complaint copies of all documents which the
party (or parties) intend(s) to offer at the Arbitration Hearing and a statement identifying the witnesses the party
(or parties) intend(s) to present at the Hearing, along with a summary of each witness' expected testimony.
C. 	Answer
Within twenty (20) days after receipt of the Complaint, each respondent shall serve on BCBSA and on the
complaining party (or parties):
i. a full Answer to the aforesaid Complaint;
ii. a statement of any Counterclaims against the complaining party (or parties), providing with respect
thereto the information specified in Paragraph 1.B., above;
iii. a statement as to whether the respondent elects to first pursue Mediation; and
iv. any request, if applicable, that the matter be handled on an expedited basis and the reasons therefor.
The respondent(s) shall file and serve with the Answer or by the date of the Initial Conference set forth in
Paragraph 3.C., below, copies of all documents which the respondent(s) intend(s) to offer at the Arbitration
Hearing and a statement identifying the witnesses the party (or parties) intend(s) to present at the Hearing,
along with a summary of each witness' expected testimony.
Amended as of September 20, 2007

-- 325 of 533 --

EXHIBIT 5
Page 3 of 23
D. 	Reply To Counterclaim
Within ten (10) days after receipt of any Counterclaim, the complaining party (or parties) shall serve on
BCBSA and on the responding party (or parties), a Reply to the Counterclaim. Such Reply must provide the
same information required by Paragraph 1.C., above.
1. Mediation
To facilitate the mediation of disputes between or among BCBSA, the Plans and/or their Controlled Affiliates, the
BCBSA Board has provided for Mediation under these Rules. Mediation may be pursued in lieu of or in an effort to
obviate the Mandatory Dispute Resolution process, and all parties are strongly urged, but not required, to exhaust
the mediation procedure provided for herein. In the event any party refuses to proceed with Mediation, the parties
shall proceed immediately to Mandatory Dispute Resolution, as provided in Section 3.
A. 	Selection of Mediators
If all parties agree to pursue Mediation, they shall promptly attempt to agree upon: (i) the number of mediators
desired, not to exceed three mediators; and (ii) the selection of experienced mediator(s) from an independent
entity to mediate all disputes set forth in the Complaint and Answer (and Counterclaim and Reply, if any). In
the event the parties are unable to agree upon the selection or number of mediators, both within five (5) days
of the service of the Answer or Reply to Counterclaim, whichever is later, the BCBSA Corporate Secretary
shall immediately refer the matter to a nationally recognized professional ADR organization (such as CPR or
JAMS) for mediation by a single mediator to be selected by the ADR organization.
B. 	Binding Decision
Before the Mediation Hearing described below, the BCBSA Corporate Secretary shall contact the parties to
determine whether they wish to be bound by any recommendation of the selected mediator(s) for resolution of
the disputes. If all wish to be bound, the Corporate Secretary will send appropriate documentation to them for
their signatures before the Mediation Hearing begins.
Amended as of September 20, 2007

-- 326 of 533 --

EXHIBIT 5
Page 4 of 23
C. 	Mediation Procedure
The Mediator(s) shall apply the mediation procedures and processes provided for herein (not the rules of the
ADR organization with which they are affiliated) and shall promptly advise the parties of a scheduled
Mediation Hearing date. Unless a party requests an expedited procedure, or unless all parties to the
proceeding agree to one or more extensions of time, the Mediation Hearing set forth below shall be completed
within forty (40) days of BCBSA's receipt of the Complaint. The selected mediator(s), unless the parties
otherwise agree, shall adhere to the following procedure:
i. 	Each party must be represented by its CEO or other representative who has been delegated full authority
to resolve the dispute. However, parties may send additional representatives as they see fit.
ii. 	Each party will be given one-half hour to present its case, beginning with the complaining party (or
parties), followed by the other party or parties. The parties are free to structure their presentations as
they see fit, using oral statements or direct examination of witnesses. However, neither cross-
examination nor questioning of opposing representatives will be permitted. At the close of each
presentation, the selected mediator(s) will be given an opportunity to ask questions of the presenters
and witnesses. All parties must be present throughout the Mediation Hearing. The selected mediator(s)
may extend the time allowed for each party's presentation at the Mediation Hearing. The selected
mediator(s) may meet in executive session, outside the presence of the parties, or may meet with the
parties separately, to discuss the controversy.
iii. 	After the close of the presentations, the parties will attempt to negotiate a settlement of the dispute. If
the parties desire, the selected mediator(s), or any one or more of the selected mediators, will sit in on
the negotiations.
Amended as of September 20, 2007

-- 327 of 533 --

EXHIBIT 5
Page 5 of 23
iv. 	After the close of the presentations, the selected mediator(s) may meet privately to agree upon a
recommendation for resolution of the dispute which would be submitted to the parties for their
consideration and approval. If the parties have previously agreed to be bound by the results of this
procedure, this recommendation shall be binding upon the parties.
v. 	The purpose of the Mediation Hearing is to assist the parties to settle their grievances short of
mandatory dispute resolution. As a result, the Mediation Hearing has been designed to be as informal
as possible. Rules of evidence shall not apply. There will be no transcript of the proceedings, and no
party may make a tape recording of the Mediation Hearing.
vi. 	In order to facilitate a free and open discussion, the Mediation proceeding shall remain confidential. A
"Stipulation to Confidentiality" which prohibits future use of settlement offers, all position papers or other
statements furnished to the selected mediator(s), and decisions or recommendations in any Mediation
proceeding shall be executed by each party.
vii. Upon request of the selected mediator(s), or one of the parties, BCBSA staff may also submit documentation
at any time during the proceedings.
D. Notice of Termination of Mediation
If the Mediation cannot be completed within the prescribed or agreed time period due to the lack of cooperation
of any party, as determined by the selected mediator(s), or if the Mediation does not result in a final resolution
of all disputes at the Mediation Hearing or within ten (10) days after the Mediation Hearing, any party or any
one of the selected mediators shall so notify the BCBSA Corporate Secretary, who shall promptly issue a
Notice of Termination of Mediation to all parties, to the selected mediator(s), and to the MDR Administrator.
Such notice shall serve to bring the Mediation to an end and to initiate Mandatory Dispute Resolution. Upon
agreement of all parties and the mediator(s), the Mediation process may continue at the same time the MDR
process is invoked. In such case, the Notice of Termination of Mediation described above serves to initiate the
MDR proceeding, but does not terminate mediation proceedings, which may proceed simultaneous with the
MDR proceeding.
Amended as of September 20, 2007

-- 328 of 533 --

EXHIBIT 5
Page 6 of 23
2. Mandatory Dispute Resolution (MDR)
If any party elects not to first pursue Mediation, or if a Notice of Termination of Mediation is issued as set forth in
Paragraph 2.D., above, then the unresolved disputes set forth in any Complaint and Answer (and Counterclaim and Reply,
if any) shall be subject to mandatory binding arbitration (herein referred to as “MDR”).
A. 	MDR Administrator
The Administrator for purposes of Mandatory Arbitration shall be an independent nationally recognized entity
such as CPR or JAMS, specializing in alternative dispute resolution. In the event the parties pursued Mediation
with CPR, JAMS or a similar organization, that organization also shall serve as the MDR Administrator, unless
all parties notify the BCBSA Corporate Secretary in writing within two (2) days of receiving the Notice of
Termination of Mediation that they wish to pursue MDR with another nationally recognized organization serving
as MDR Administrator.
In the event the parties (i) did not pursue Mediation, (ii) pursued mediation with a Mediator not affiliated with
an ADR organization that offers a panel of arbitrators, or
(iii) all parties that pursued Mediation notified the BCBSA Corporate Secretary that they wish to have an MDR
Administrator that is different from the organization with which their mediator was affiliated, they shall promptly
attempt to agree on a nationally recognized ADR entity that supplies a panel of arbitrators. If they reach such
agreement within five (5) days of the Notice of Termination of Mediation or receipt of the Answer or Reply to
Counterclaim (whichever is later), the parties shall promptly inform the BCBSA Corporate Secretary of their
agreed upon ADR organization. In the event the parties are unable to reach agreement on an MDR
Administrator within that timeframe, the BCBSA Corporate Secretary shall immediately refer the matter to
CPR, JAMS or a similar organization for MDR.
Any person who served as a Mediator shall not serve as an arbitrator for the same or similar dispute for purposes of
MDR.
B. 	Rules for MDR
The rules controlling all aspects of MDR shall be exclusively those provided for herein. The rules promulgated
or otherwise used by the MDR Administrator organization shall not apply.
Amended as of September 20, 2007

-- 329 of 533 --

EXHIBIT 5
Page 7 of 23
C. 	Initial Conference
Within seven (7) days after a Notice of Termination has issued or the matter has otherwise been referred to an
MDR Administrator, or within five (5) days after the time for filing and serving the Answer or Reply to any
Counterclaim (whichever is later) if the parties elect first not to mediate, the parties shall confer with the
Administrator to discuss selecting a dispute resolution panel ("the Panel"). This conference (the “Initial
Conference”) may be by telephone. The parties are encouraged to agree to the composition of the Panel and
to present that agreement to the Administrator at the Initial Conference. If the parties do not agree on the
composition of the Panel by the time of the Initial Conference, or by any extension thereof agreed to by all
parties and the Administrator, then the Panel Selection Process set forth in subparagraph D, below, shall be
followed.
D. 	Panel Selection Process
The Administrator shall designate, prior to the Initial Conference, at least seven potential arbitrators. Each
party shall be permitted to strike any designee for cause and the Administrator shall determine the sufficiency
thereof in its sole discretion. The Administrator will designate a replacement for any designee so stricken.
Each party shall then be permitted one peremptory strike from the list of designees. The Administrator shall
set the dates for exercising all strikes, which shall be set to encourage the prompt selection of arbitrators.
After the parties exercise any designee strikes for cause and their peremptory strike against any designee of
their choice, the parties shall each rank the remaining panel members in order of preference and provide the
Administrator, without serving on any other party, their ranked list. The Administrator shall not disclose any
party’s ranked list to members of the panel or to other parties.
From the remaining designees, and after considering opportunities to maximize, so far as possible, the
collectively stated arbitrator preferences provided by the parties on their ranked lists, the Administrator shall
select athree member Panel. The Panel Selection Process shall be completed no later than ten (10) days
after the Initial Conference.
Each Arbitrator shall be compensated at his or her normal hourly rate or, in the absence of an established
rate, at a reasonable hourly rate to be promptly fixed by the Administrator for all time spent in connection with
the proceedings and shall be reimbursed for any travel and other reasonable expenses.
Amended as of September 20, 2007

-- 330 of 533 --

EXHIBIT 5
Page 8 of 23
E. 	Duties Of The Arbitrators
The Panel shall promptly designate a Presiding Arbitrator for the purposes reflected below but shall retain the
power to review and modify any ruling or other action of said Presiding Arbitrator. Each Arbitrator shall be an
independent Arbitrator, shall be governed by the Code of Ethics for Arbitrators in Commercial Disputes and
shall at or prior to the commencement of any Arbitration Hearing take an oath to that effect. Each Arbitrator
shall promptly disclose in writing to the Panel and to the parties any circumstances, whenever arising, that
might cause doubt as to such Arbitrator's compliance, or ability to comply, with said Code of Ethics, and,
absent resignation by such Arbitrator, the remaining Arbitrators shall determine in their sole discretion whether
the circumstances so disclosed constitute grounds for disqualification and for replacement. With respect to
such circumstances arising or coming to the attention of a party after an Arbitrator's selection, a party may
likewise request the Arbitrator's resignation or a determination as to disqualification by the remaining
Arbitrators. With respect to a sole Arbitrator, the determination as to disqualification shall be made by the
Administrator.
There shall be no ex parte communication between the parties or their counsel and any member of the Panel.
F. 	Panel's Jurisdiction And Authority
The Panel's jurisdiction and authority shall extend to all disputes between or among the Plans, their Controlled
Affiliates, and/or BCBSA, except for those disputes excepted from these MMDR procedures as set forth in the
License Agreements.
With the exception of punitive or treble damages, the Panel shall have full authority to award the relief it
deems appropriate to resolve the parties' disputes, including monetary awards and injunctions, mandatory or
prohibitory. The Panel has no authority to award punitive or treble damages except that the Panel may
allocate or assess responsibility for punitive or treble damages assessed by another tribunal. Subject to the
above limitations, the Panel may, by way of example, but not of limitation:
Amended as of September 20, 2007

-- 331 of 533 --

EXHIBIT 5
Page 9 of 23
i. 	interpret or construe the meaning of any terms, phrase or provision in any license between BCBSA and a
Plan or a Controlled Affiliate relating to the use of the BLUE CROSS® or BLUE SHIELD® service
marks.
ii. 	determine whether BCBSA, a Plan or a Controlled Affiliate has violated the terms or conditions of
any license between the BCBSA and a Plan or a Controlled Affiliate relating to the use of the BLUE
CROSS® or BLUE SHIELD® service marks.
iii. 	decide challenges as to its own jurisdiction.
iv. 	issue such orders for interim relief as it deems appropriate pending Hearing and Award in any
Arbitration.
It is understood that the Panel is expected to resolve issues based on governing principles of law,
preserving to the maximum extent legally possible the continued integrity of the Licensed Marks and the
BLUE CROSS/BLUE SHIELD system. The Panel shall apply federal law to all issues which, if asserted in
the United States District Court, would give rise to federal question jurisdiction, 28 U.S.C. § 1331. The
Panel shall apply Illinois law to all issues involving interpretation, performance or construction of any
License Agreement or Controlled Affiliate License Agreement unless the agreement otherwise provides.
As to other issues, the Panel shall choose the applicable law based on conflicts of law principles of the
State of Illinois.
G. 	Administrative Conference
Within five (5) days of the Panel being selected, the Presiding Arbitrator shall confer with the parties and
the other members of the Panel and shall schedule, in writing, a conference in which the parties and the
Panel shall participate (the “Administrative Conference”). The Administrative Conference shall take place
no later than fifteen (15) days after the Panel is selected. At the Administrative Conference the parties
and the Panel shall discuss the scheduling of the Arbitration Hearing and any other matter appropriate to
be considered, including but not limited to: any written discovery in the form of requests for production of
documents or requests to admit facts; the identity of any witness whose deposition a party may desire
and a showing of exceptional good cause for the taking of any such deposition; the desirability of
bifurcation or other separation of the issues; the need for and the type of record of conferences and
hearings, including the need for transcripts; the need for expert witnesses and
Amended as of September 20, 2007

-- 332 of 533 --

EXHIBIT 5
Page 10 of 23
how expert testimony should be presented; the appropriateness of motions to dismiss and/or for full or partial
summary judgment; consideration of stipulations; the desirability of presenting any direct testimony in writing;
and the necessity for any on- site inspection by the Panel. If the parties agree, the Administrative Conference
may be by telephone.
H. 	Discovery
i. 	Requests for Production of Documents: All requests for the production of documents must be served
no later than five (5) days after the date of the Initial Conference. Within twenty (20) days after receipt of
a request for production of documents, a party shall (a) serve responses and objections to the request,
(b) produce all responsive, non-privileged documents to the requesting party, and (c) to the extent any
responsive documents are withheld on the grounds of attorney-client privilege or work product, produce a
log identifying such documents in the manner specified in Fed. R. Civ. P. 26(b)(5). If, after reviewing a
privilege log, the requesting party believes attorney-client privilege or work product protection was
improperly claimed by the producing party with respect to any document, the requesting party may ask
the Presiding Arbitrator to conduct an in-camera inspection of the same. With respect to documentary
and other discovery produced in any MDR proceeding by BCBSA, the fact that a party’s CEO or other
senior officers may serve on the BCBSA Board of Directors, BCBSA Board Committees or other BCBSA
work groups, task forces and the like, shall not be a basis for defeating an otherwise valid claim of
attorney-client privilege or work product protection over such documentary or other discovery materials
by BCBSA.
ii. 	Requests for Admissions: Requests for Admissions may be served up to twenty-one (21) days prior to
the discovery cut-off set by the Presiding Arbitrator. A party served with Requests For Admissions must
respond within twenty (20) days of receipt of said request. The good faith use of and response to
Requests for Admissions is encouraged, and the Panel shall have full discretion, with reference to the
Federal Rules of Civil Procedure, in awarding appropriate sanctions with respect to abuse of the
procedure.
Amended as of September 20, 2007

-- 333 of 533 --

EXHIBIT 5
Page 11 of 23
iii. 	Depositions: As a general rule, the parties will not be permitted to take party or non-party deposition
testimony for discovery purposes. The Presiding Arbitrator, in his or her sole discretion, shall have the
authority to permit a party to take such deposition testimony upon a showing of exceptional good cause.
The parties will be permitted to take de bene esse deposition1 testimony to the fullest extent permitted by
law of any witness who cannot be compelled to testify at the Arbitration Hearing. No deposition, for
discovery purposes or otherwise, shall exceed three (3) hours, excluding objections and colloquy of
counsel. Depositions may be recorded in any manner recognized by the Federal Rules of Civil Procedure
and the parties shall specify in each notice of deposition or request for permission to take deposition
testimony the manner in which such deposition shall be recorded.
iv. 	Expert witness(es): If a party intends to present the testimony of an expert witness during the oral
hearing, it shall provide all other parties with a written statement setting forth the information required to
be provided by Fed. R. Civ.
P. 26(a)(2) (B) ten (10) days prior to the discovery cut-off set by the Presiding Arbitrator. If a party
intends to present the testimony of a rebuttal expert witness during the Arbitration Hearing, it shall
provide all other parties with a written statement setting forth the information required to be provided by
Fed.
R. Civ. P. 26(a)(2)(B) within twenty (20) days after the date on which the written statement of the expert
witness whose testimony is to be rebutted was produced.
v. 	Discovery cut-off: The Presiding Arbitrator shall determine the date on which the discovery period will
end, but the discovery period shall not exceed thirty (30) days from the date of the Administrative
Conference without the agreement of all parties.
Amended as of September 20, 2007
_____________________________________
1 As used in these Rules, "de bene esse deposition" means a deposition that is not taken for discovery purposes, but is taken for the purpose of reading part or all of
the deposition transcript into the record at the Arbitration Hearing, to the extent permitted by the Panel, because the witness cannot be compelled to testify at the
Arbitration Hearing or has exercised a right provided under these Rules to provide deposition testimony in lieu of testimony at the Arbitration Hearing.

-- 334 of 533 --

EXHIBIT 5
Page 12 of 23
vi. 	Additional discovery: Any additional discovery will be at the discretion of the Presiding Arbitrator.
vii. Discovery Disputes: Any discovery disputes shall be raised by motion to the Presiding Arbitrator, who
is authorized to resolve all such disputes, and whose resolution will be binding on the parties unless
modified by the Arbitration Panel. Prior to raising any discovery dispute with the Presiding Arbitrator, the
parties shall meet and confer, telephonically or in person, in an attempt to resolve or narrow the dispute.
If a party refuses to comply with a decision resolving a discovery dispute, the Panel, in keeping with Fed.
R. Civ. P. 37, may refuse to allow that party to support or oppose designated claims or defenses, prohibit
that party from introducing designated matters into evidence or, in extreme cases, decide an issue
submitted for resolution adversely to that party.
viii. Extensions: The time for responding to discovery requests may be extended by the Presiding Arbitrator
for good and sufficient cause shown. Any request for such an extension shall be made in writing.
I. 	Panel Suggested Settlement/Mediation
At any point during the proceedings, the Panel at the request of any party or on its own initiative, may suggest
that the parties explore settlement and that they do so at or before the conclusion of the Arbitration Hearing,
and the Panel shall give such assistance in settlement negotiations as the parties may request and the Panel
may deem appropriate. Alternatively, the Panel may direct the parties to endeavor to mediate their disputes as
provided above, or to explore a mini-trial proceeding, or to have an independent party render a neutral
evaluation of the parties’ respective positions. The Panel shall enter such sanctions as it deems appropriate
with respect to any party failing to pursue in good faith such Mediation or other alternate dispute resolution
methods.
Amended as of September 20, 2007

-- 335 of 533 --

EXHIBIT 5
Page 13 of 23
J. 	Subpoenas on Third Parties
Pursuant to, and consistent with, the Federal Arbitration Act, 9 U.S.C. § 9 et seq., and subject to Paragraph
3.G(iii) above, a party may request the issuance of a subpoena on any third party, including but not limited to
any third party Blue Plan or any officer, employee or director of a third party Blue Plan, to compel deposition
testimony or the production of documents, and, if good and sufficient cause is shown, the Panel shall issue
such a subpoena.
K. 	Arbitration Hearing
An Arbitration Hearing will be held within thirty (30) days after the Administrative Conference if no discovery is
taken, or within thirty (30) days after the close of discovery, unless all parties and the Panel agree to extend
the Arbitration Hearing date, or unless the parties agree in writing to waive the Arbitration Hearing. The parties
may mutually agree on the location of the Arbitration Hearing. If the parties fail to agree, the Arbitration Hearing
shall be held in Chicago, Illinois, or at such other location determined by the Presiding Arbitrator to be most
convenient to the participants. The Panel will determine the date(s) and time(s) of the Arbitration Hearing(s)
after consultation with all parties and shall provide reasonable notice thereof to all parties or their
representatives.
L. 	Arbitration Hearing Memoranda
Twenty (20) days prior to the Arbitration Hearing, each party shall submit to the other party (or parties) and to
the Panel an Arbitration Hearing Memorandum which sets forth the applicable law and any argument as to any
relevant issue. The Arbitration Hearing Memorandum will supplement, and not repeat, the allegations,
information and documents contained in or with the Complaint, Answer, Counterclaim and Reply, if any. Ten
(10) days prior to the Arbitration Hearing, each party shall submit to each other party a list of all expert and fact
witnesses (but not including rebuttal fact witness) that such party intends to have testify at the Arbitration
Hearing and a brief summary of the testimony each such witness is expected to give. In addition, no later than
five (5) days prior to the Arbitration, each party may submit to each other party and to the Panel a Response
Arbitration Hearing Memorandum which sets forth any response to another party's Arbitration Hearing
Memorandum.
Amended as of September 20, 2007

-- 336 of 533 --

EXHIBIT 5
Page 14 of 23
M. 	Notice For Testimony
Ten (10) days prior to the Arbitration Hearing, any party may serve a Notice on any other party (or parties)
requesting the attendance at the Arbitration Hearing of any officer, employee or director of the other party (or
parties) for the purpose of providing noncumulative testimony. If a party fails to produce one of its officers,
employees or directors whose noncumulative testimony during the Arbitration Hearing is reasonably requested
by an adverse party, the Panel may refuse to allow that party to support or oppose designated claims or
defenses, prohibit that party from introducing designated matters into evidence or, in extreme cases, decide an
issue submitted for mandatory dispute resolution adversely to that party; provided, however, that a party may
refuse to produce a director to testify if, within two (2) days of receiving a notice requesting the attendance of
such director at the Arbitration Hearing, the party agrees to make the director available for a de bene esse
deposition at a mutually convenient time at any location within fifty (50) miles of the director’s primary
residence chosen by the party requesting the director’s testimony. This Rule may not be used for the purpose
of burdening or harassing any party, and the Presiding Arbitrator may impose such orders as are appropriate
so as to prevent or remedy any such burden or harassment.
Pursuant to, and consistent with, the Federal Arbitration Act, 9 U.S.C. § 9 et seq., twenty (20) days or more
prior to the Arbitration Hearing, a party may request the issuance of a subpoena on any third party, including
but not limited to any third party Blue Plan, BCBSA or any officer, employee or director of a third party Blue
Plan or BCBSA for the purpose of providing noncummulative testimony at the Arbitration Hearing, and, if good
and sufficient cause is shown, the Panel shall issue such a subpoena; provided however, that a director of a
third party Blue Plan or BCBSA may refuse to testify if, within two (2) days of receiving a subpoena requesting
the attendance of such director at the Arbitration Hearing, the director agrees to make him/herself available
for a de bene esse deposition at a mutually convenient time at any location within fifty (50) miles of the
director’s primary residence chosen by the party requesting the director’s testimony. Each Blue Plan agrees to
waive, on its own behalf and on behalf of its directors and officers, any objection it otherwise might have to
any such subpoena based on service, venue or extraterritoriality.
Amended as of September 20, 2007

-- 337 of 533 --

EXHIBIT 5
Page 15 of 23
N. 	Arbitration Hearing Procedures
i. 	Attendance at Arbitration Hearing: Any person having a direct interest in the proceeding is entitled to
attend the Arbitration Hearing. The Presiding Arbitrator shall otherwise have the power to require the
exclusion of any witness, other than a party or other essential person, during the testimony of any other
witness. It shall be discretionary with the Presiding Arbitrator to determine the propriety of the attendance
of any other person.
ii. 	Confidentiality: The Panel and all parties shall maintain the privacy of the Arbitration Proceeding. The
parties and the Panel shall treat the Arbitration Hearing and any discovery or other proceedings or events
related thereto, including any award resulting therefrom, as confidential except as otherwise necessary in
connection with a judicial challenge to or enforcement of an award or unless otherwise required by law.
iii. 	Stenographic Record: Any party, or if the parties do not object, the Panel, may request that a
stenographic or other record be made of any Arbitration Hearing or portion thereof. The costs of the
recording and/or of preparing the transcript shall be borne by the requesting party and by any party who
receives a copy thereof. If the Panel requests a recording and/or a transcript, the costs thereof shall be
borne equally by the parties.
iv. 	Oaths: The Panel may require witnesses to testify under oath or affirmation administered by any duly
qualified person and, if requested by any party, shall do so.
v. 	Order of Arbitration Hearing: An Arbitration Hearing shall be opened by the recording of the date, time,
and place of the Arbitration Hearing, and the presence of the Panel, the parties, and their
representatives, if any. The Panel may, at the beginning of the Arbitration Hearing, ask for statements
clarifying the issues involved.
Amended as of September 20, 2007

-- 338 of 533 --

EXHIBIT 5
Page 16 of 23
Unless otherwise agreed, the complaining party (or parties) shall then present evidence to support their
claim(s). The respondent(s) shall then present evidence supporting their defenses and Counterclaims, if
any. The complaining party (or parties) shall then present evidence supporting defenses to the
Counterclaims, if any, and rebuttal.
Witnesses for each party shall submit to questions by adverse parties and/or the Panel.
The Panel has the discretion to vary these procedures but shall afford a full and equal opportunity to all
parties for the presentation of any material and relevant evidence.
vi. Evidence: The parties may offer such evidence as is relevant and material to the dispute and shall
produce such evidence as the Panel may deem necessary to an understanding and resolution of the
dispute. Unless good cause is shown, as determined by the Panel or agreed to by all other parties, no
party shall be permitted to offer evidence at the Arbitration Hearing which was not disclosed prior to the
Arbitration Hearing by that party. The Panel may receive and consider the evidence of witnesses by
affidavit upon such terms as the Panel deems appropriate.
The Panel shall be the judge of the relevance and materiality of the evidence offered, and conformity to
legal rules of evidence, other than enforcement of the attorney-client privilege and the work product
protection, shall not be necessary. The Federal Rules of Evidence shall be considered by the Panel in
conducting the Arbitration Hearing but those rules shall not be controlling. All evidence shall be taken in
the presence of the Panel and all of the parties, except where any party is in default or has waived the
right to be present.
Settlement offers by any party in connection with Mediation or MDR proceedings, decisions or
recommendations of the selected mediators, and a party's position papers or statements furnished to the
selected mediators shall not be admissible evidence or considered by the Panel without the consent of
all parties.

-- 339 of 533 --

EXHIBIT 5
Page 17 of 23
vii. Closing of Arbitration Hearing: The Presiding Arbitrator shall specifically inquire of all parties whether
they have any further proofs to offer or witnesses to be heard. Upon receiving negative replies or if he or
she is satisfied that the record is complete, the Presiding Arbitrator shall declare the Arbitration Hearing
closed with an appropriate notation made on the record. Subject to being reopened as provided below,
the time within which the Panel is required to make the award shall commence to run, in the absence of
contrary agreement by the parties, upon the closing of the Arbitration Hearing.
With respect to complex disputes, the Panel may, in its sole discretion, defer the closing of the
Arbitration Hearing for a period of up to thirty (30) days after the presentation of proofs in order to permit
the parties to submit post-hearing briefs and argument, as the Panel deems appropriate, prior to making
an award.
For good cause, the Arbitration Hearing may be reopened for up to thirty (30) days on the Panel's
initiative, or upon application of a party, at any time before the award is made
O. Awards
An Award must be in writing and shall be made promptly by the Panel and, unless otherwise agreed by the
parties or specified by law, no later than thirty (30) days from the date of closing the Arbitration Hearing. If all
parties so request, the Award shall contain findings of fact and conclusions of law. The Award, and all other
rulings and determinations by the Panel, may be by a majority vote.
Parties shall accept as legal delivery of the Award the placing of the Award or a true copy thereof in the mail
addressed to a party or its representative at its last known address or personal service of the Award on a party
or its representative.
Awards are binding only on the parties to the Arbitration and are not binding on any non-parties to the
Arbitration and may not be used or cited as precedent in any other proceeding.
Amended as of September 20, 2007

-- 340 of 533 --

EXHIBIT 5
Page 18 of 23
After the expiration of twenty (20) days from initial delivery, the Award (with corrections, if any) shall be final
and binding on the parties, and the parties shall undertake to carry out the Award without delay.
Proceedings to confirm, modify or vacate an Award shall be conducted in conformity with and controlled by
the Federal Arbitration Act. 9 U.S.C. § 1, et seq.
P. Return of Documents
Within sixty (60) days after the Award and the conclusion of any judicial proceedings with respect thereto, each
party and the Panel shall return any documents produced by any other party, including all copies thereof. If a
party receives a discovery request in any other proceeding which would require it to produce any documents
produced to it by any other party in a proceeding hereunder, it shall not produce such documents without first
notifying the producing party and giving said party reasonable time to respond, if appropriate, to the discovery
request.
3. Miscellaneous
A. Expedited Procedures
Any party to a Mediation may direct a request for an expedited Mediation Hearing to the Chairman of the
Mediation Committee, to the selected Mediators, and to all other parties at any time. The Chairman of the
Mediation Committee, or at his or her direction, the then selected Mediators, shall grant any request which is
supported by good and sufficient reasons. If such a request is granted, the Mediation shall be completed within
as short a period as practicable, as determined by the Chairman of the Mediation Committee or, at his or her
direction, the then selected Mediators.
Any party to an Arbitration may direct a request for expedited proceedings to the Administrator, to the Panel,
and to all other parties at any time. The Administrator, or the Presiding Arbitrator if the Panel has been
selected, shall grant any such request which is supported by good and sufficient reasons. If such a request is
granted, the Arbitration shall be completed within as short a time as practicable, as determined by the
Administrator and/or the Presiding Arbitrator.
Amended as of September 20, 2007

-- 341 of 533 --

EXHIBIT 5
Page 19 of 23
B. Temporary or Preliminary Injunctive Relief
Any party may seek temporary or preliminary injunctive relief with the filing of a Complaint or at any time
thereafter. If such relief is sought prior to the time that an Arbitration Panel has been selected, then the
Administrator shall select a single Arbitrator who is a lawyer who has no interest in the subject matter of the
dispute, and no connection to any of the parties, to hear and determine the request for temporary or
preliminary injunction. If such relief is sought after the time that an Arbitration Panel has been selected, then
the Arbitration Panel will hear and determine the request. The request for temporary or preliminary injunctive
relief will be determined with reference to the temporary or preliminary injunction standards set forth in Fed. R.
Civ. P. 65.
C. Defaults and Proceedings in the Absence of a Party
Whenever a party fails to comply with the MDR Rules in a manner deemed material by the Panel, the Panel
shall fix a reasonable time for compliance and, if the party does not comply within said period, the Panel may
enter an Order of default or afford such other relief as it deems appropriate. Arbitration may proceed in the
event of a default or in the absence of any party who, after due notice, fails to be present or fails to obtain an
extension. An Award shall not be made solely on the default or absence of a party, but the Panel shall require
the party who is present to submit such evidence as the Panel may require for the making of findings,
determinations, conclusions, and Awards.
D. Notice
Each party shall be deemed to have consented that any papers, notices, or process necessary or proper for
the initiation or continuation of a proceeding under these rules or for any court action in connection therewith
may be served on a party by mail addressed to the party or its representative at its last known address or by
personal service, in or outside the state where the MDR proceeding is to be held.
The Corporate Secretary and the parties may also use facsimile transmission, telex, telegram, or other written
forms of electronic communication to give the notices required by these rules.

-- 342 of 533 --

EXHIBIT 5
Page 20 of 23
E. Expenses
The expenses of witnesses shall be paid by the party causing or requesting the appearance of such witnesses.
All expenses of the MDR proceeding, including compensation, required travel and other reasonable expenses
of the Panel, and the cost of any proof produced at the direct request of the Panel, shall be borne equally by
the parties and shall be paid periodically on a timely basis, unless they agree otherwise or unless the Panel in
the Award assesses such expenses, or any part thereof against any party (or parties). In exceptional cases, the
Panel may award reasonable attorneys' fees as an item of expense, and the Panel shall promptly determine
the amount of such fees based on affidavits or such other proofs as the Panel deems sufficient.
F. Disqualification or Disability of A Panel Member
In the event that any Arbitrator of a Panel with more than one Arbitrator should become disqualified, resign,
die, or refuse or be unable to perform or discharge his or her duties after the commencement of MDR but prior
to the rendition of an Award, and the parties are unable to agree upon a replacement, the remaining Panel
member(s):
i. 	shall designate a replacement, subject to the right of any party to challenge such replacement for
cause.
ii. shall decide the extent to which previously held hearings shall be repeated.
If the remaining Panel members consider the proceedings to have progressed to a stage as to make
replacement impracticable, the parties may agree, as an alternative to the recommencement of the Mandatory
Dispute Resolution process, to resolution of the dispute by the remaining Panel members.
In the event that a single Arbitrator should become disqualified, resign, die, or refuse or be unable to perform
or discharge his or her duties after the commencement of MDR but prior to the rendition of an Award, and the
parties are unable to agree upon a replacement, the Administrator shall appoint a successor, subject to the
right of any party to challenge such successor for cause, and the successor shall decide the extent to which
previously held proceedings shall be repeated.

-- 343 of 533 --

EXHIBIT 5
Page 21 of 23
G. 	Extensions of Time
Subject to the provisions of Paragraph 3.H.(viii.), any time limit set forth in these Rules may be extended upon
agreement of the parties and approval of: (1) the Mediator if the proceeding is then in Mediation; (2) the
Administrator if the proceeding is in Arbitration, but no Arbitration Panel has been selected; or (3) the
Arbitration Panel, if the proceeding is in Arbitration and the Arbitration Panel has been selected.
H. 	Intervention
The Plans, their Controlled Affiliates, and BCBSA, to the extent subject to MMDR pursuant to their License
Agreements, shall have the right to move to intervene in any pending Arbitration. A written motion for
intervention shall be made to: (1) the Administrator, if the proceeding is in Arbitration, but no Arbitration Panel
has been selected; or (2) the Arbitration Panel, if the proceeding is in Arbitration and the Arbitration Panel has
been selected. The written motion for intervention shall be delivered to the BCBSA Corporate Secretary
(which shall also constitute service on the BCBSA if it is a respondent) and to any Plan(s) and/or Controlled
Affiliate(s) which are parties to the proceeding. Any party to the proceeding can submit written objections to
the motion to intervene. The motion for intervention shall be granted upon good cause shown. Intervention
also may be allowed by stipulation of the parties to the Arbitration proceeding. Intervention shall be allowed
upon such terms as the Arbitration Panel decides.
I. 	BCBSA Assistance in Resolution of Disputes
The resources and personnel of the BCBSA may be requested by any member Plan at any time to try to
resolve disputes with another Plan.
J. 	Neutral Evaluation
The parties can voluntarily agree at any time to have an independent party render a neutral evaluation of the
parties’ respective positions.
Amended as of September 20, 2007

-- 344 of 533 --

EXHIBIT 5
Page 22 of 23
K. 	Recovery of Attorney Fees and Expenses
i. 	Motions to Compel
Nothwithstanding any other provisions of these Rules, any Party subject to the License Agreements (for
purposes of this Section K and all of its sub- sections only hereinafter referred to collectively and
individually as a “Party”) that initiates a court action or administrative proceeding solely to compel
adherence to these Rules shall not be determined to have violated these Rules by initiating such action
or proceeding.
ii 	Recovery of Fees, Expenses and Costs
The Arbitration Panel may, in its sole discretion, award a Party its reasonable attorneys’ fees, expenses
and costs associated with a filing to compel adherence to these Rules and/or reasonable attorneys’ fees,
expenses and costs incurred in responding to an action filed in violation of these Rules; provided,
however, that neither fees, expenses, nor costs shall be awarded by the Arbitration Panel if the Party
from which the award is sought can demonstrate to the Arbitration panel, in its sole discretion, that it did
not violate these Rules or that it had reasonable grounds for believing that its action did not violate these
Rules.
iii 	Requests for Reimbursement
For purposes of this Section K, any Party may request reimbursement of fees, expenses and/or costs by
submitting said request in writing to the Arbitration Panel at any time before an award is delivered
pursuant Paragraph to 3.O above with a copy to the Party from which reimbursement is sought,
explaining why it is entitled to such reimbursement. The Party from which reimbursement is sought shall
have twenty (20) days to submit a response to such request to the Arbitration Panel with a copy to the
Party seeking reimbursement.
Amended as of September 20, 2007

-- 345 of 533 --

EXHIBIT 5
Page 23 of 23
L. Calculation of Time and Deadlines
In computing any period of time prescribed or allowed under these rules, the day of the act or event from
which the designated period of time begins to run shall not be included. The last day of the period so
computed shall be included, unless it is a Saturday, a Sunday, or a legal holiday, in which event the period
runs until the end of the next day which is not one of the aforementioned days. When the period of time
prescribed is less than six (6) days, intermediate Saturdays, Sundays and legal holidays shall be excluded in
the computation. As used in this rule, “legal holiday” includes New Year’s Day, Martin Luther King, Jr. Day,
Washington’s Birthday, Memorial Day, Independence Day, Labor Day, Columbus Day, Veterans Day,
Thanksgiving Day, Christmas Day and any other day appointed as a holiday by the President or the Congress
of the United States.
Amended as of September 20, 2007

-- 346 of 533 --

Exhibit 10.13
BLUE SHIELD LICENSE AGREEMENT
(Includes revisions, if any, adopted by Member Plans through their November 16, 2023 meeting)
This agreement by and between Blue Cross and Blue Shield Association ("BCBSA") and The Blue Shield Plan, known as
_______________(the "Plan").
Preamble
WHEREAS, the Plan and/or its predecessor(s) in interest (collectively the "Plan") had the right to use the BLUE SHIELD and
BLUE SHIELD Design service marks (collectively the "Licensed Marks") for health care plans in its service area, which was essentially
local in nature;
WHEREAS, the Plan was desirous of assuring nationwide protection of the Licensed Marks, maintaining uniform quality controls
among Plans (unless otherwise defined in this Agreement, Plans shall mean Member Plans as that term is defined in BCBSA’s Bylaws)
(“Member Plans”), facilitating the provision of cost effective health care services to the public and otherwise benefiting the public;
WHEREAS, to better attain such ends, the Plan and the predecessor of BCBSA executed the Agreement(s) Relating to the
Collective Service Mark "Blue Shield"; and
WHEREAS, BCBSA and the Plan desire to supercede said Agreement(s) to reflect their current practices and to assure the
continued integrity of the Licensed Marks and of the BLUE SHIELD system;
NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:
Amended as of June 15, 2023

-- 347 of 533 --

Agreement
1. BCBSA hereby grants to the Plan, upon the terms and conditions of this License Agreement (“Agreement” or “Primary
License Agreement”), the right to use BLUE SHIELD in its trade and/or corporate name (the "Licensed Name"), and
the right to use the Licensed Marks, in the sale, marketing and administration of health care plans and related
services in the Service Area set forth and defined in paragraph 5 below. As used herein, health care plans and
related services shall include acting as a nonprofit health care plan, a for-profit health care plan, or mutual health
insurer operating on a not-for-profit or for- profit basis, under state law; financing access to health care services;
when working with a bank that holds the relevant license to use the Licensed Name and Marks, offering: (i) tax-
favored savings accounts for medical expenses and means for accessing such accounts, such as debit cards or
checks, that are provided solely to support access to such tax- favored savings accounts, all pursuant to such
license, or (ii) prepaid rewards cards that are provided for completion of a wellness program, all pursuant to such
license; providing health care management and administration; administering, but not underwriting, non- health
portions of Workers’ Compensation Insurance; delivering health care services, except hospital services (as defined
in the Guidelines to Membership Standards Applicable to Regular Members); and performing the Eligibility and
Enrollment functions of HR administration for all benefit plans offered by a group account to its members, including
benefit plans not provided by the Plan, provided that the Plan has contracted to provide Health Coverage under the
Licensed Marks to the account (as the terms “Health Coverage”, “Eligibility” and “Enrollment” are defined in Exhibit
4, Paragraph 2.t.).
2. The Plan may use the Licensed Marks and Name in connection with the offering of: i) health care plans and related
services in the Service Area through Controlled Affiliates, provided that each such Controlled Affiliate is separately
licensed to use the Licensed Marks and Name under the terms and conditions contained in the agreement attached
as Exhibit 1 hereto (the "Controlled Affiliate License Agreement"); and ii) insurance coverages offered by life insurers
under the applicable law in the Service Area, other than those which the Plan may offer in its own name, provided
through Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed to use the Licensed
Marks and Name under the terms and conditions contained in the agreement attached as Exhibit 1A hereto (the
"Controlled Affiliate License Agreement Applicable to Life Insurance Companies") or the agreement attached as
Exhibit 1A1 hereto (the “Controlled Affiliate Trademark License Agreement for Life and Disability Insurance
Products”) and further provided that the offering of such services does not and will not dilute or tarnish the unique
value of the Licensed Marks and Name; and iii) administration and underwriting of Workers’ Compensation
Insurance Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed to use the
Licensed Marks and Name under the terms and conditions contained in the agreement attached as Exhibit 1 hereto
(the “Controlled Affiliate License”); and iv) regional Medicare Advantage PPO Products in cooperation with one or
more other Plans through jointly-held Controlled Affiliates, provided that each such Controlled Affiliate is separately
licensed to use the Licensed Marks and Name under the terms and conditions contained in the agreement attached
as Exhibit 1B hereto (the “Controlled Affiliate License Agreement Applicable to Regional Medicare Advantage PPO
Products”); and v) regional Medicare Part D Prescription Drug Plan products in cooperation with one or more other
Plans through jointly-held Controlled Affiliates, provided that each such Controlled Affiliate is separately licensed to
use the Licensed Marks and Name under the terms and conditions contained in the agreement attached as Exhibit
1C hereto (the “Controlled Affiliate License Agreement Applicable to Regional Medicare Part D Prescription Drug
Plan Products”). A “Controlled Affiliate” is defined as an entity that meets the requirements of bona fide control stated
herein and has executed a Controlled Affiliate License Agreement. Unless otherwise approved in writing by BCBSA,
bona fide control shall have the meaning set forth in Paragraphs 2a and 2b. If the entity meets the standards of
Paragraph 2a.B but not Paragraph 2a.A, the entity, its owners, and persons with authority to select or appoint
members or board members, other than a Plan or Plans, have received written approval of BCBSA.
Amended as of June 15, 2023

-- 348 of 533 --

2a. With respect to the Controlled Affiliate Licenses authorized in clauses i) through iii) of Paragraph 2, bona fide control
shall mean that the Plan (the “Sponsoring Plan”) must have:
A. The legal authority, directly or indirectly through wholly-owned subsidiaries: (a) to select members of the
Controlled Affiliate's governing body having more than 50% voting control thereof; (b) to exercise control over
the policy and operations of the Controlled Affiliate; (c) to prevent any change in the articles of incorporation,
bylaws or other establishing or governing documents of the Controlled Affiliate with which
the Sponsoring Plan do not concur. In addition, the Sponsoring Plan directly or indirectly through wholly-owned
subsidiaries shall own more than 50% of any for-profit Controlled Affiliate, provided that in instances where the
Sponsoring Plan formed a publicly traded Controlled Affiliate Licensee and such publicly traded Controlled
Affiliate Licensee owns and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or
indirectly shall own and control more than 50% of any Controlled Affiliate that is indirectly owned and controlled
by the publicly traded Controlled Affiliate Licensee; or
B. The legal authority directly or indirectly through wholly-owned subsidiaries (a) to select members of the
Controlled Affiliate's governing body having not less than 50% voting control thereof; (b) to prevent any change
in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled Affiliate
with which the Sponsoring Plan do not concur; (c) to exercise control over the policy and operations of the
Controlled Affiliate at least equal to that exercised by persons or entities (jointly or individually) other than the
Sponsoring Plan. Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s
establishing or governing documents must also require written approval by the Sponsoring Plan before the
Controlled Affiliate can:
1. Change its legal and/or trade name;
2. Change the geographic area in which it operates;
3. Change any of the types of businesses in which it engages;
4. Create, or become liable for by way of guarantee, any indebtedness, other than indebtedness arising in the
ordinary course of business;
5. Sell any assets, except for sales in the ordinary course of business or sales of equipment no longer useful or
being replaced;
6. Make any loans or advances except in the ordinary course of business;
7. Enter into any arrangement or agreement with any party directly or indirectly affiliated with any of the owners
of the Controlled Affiliate or persons or entities with the authority to select or appoint members or board
members of the Controlled Affiliate, other than the Sponsoring Plan or other Plans (excluding owners of
stock holdings of under 5% in a publicly traded Controlled Affiliate);
8. Conduct any business other than under the Licensed Marks and Name;
9. Take any action that the Sponsoring Plan or BCBSA reasonably believes will adversely affect the Licensed Marks
or Names.
Amended as of June 15, 2023
-2-

-- 349 of 533 --

In addition, the Sponsoring Plan directly or indirectly through wholly owned subsidiaries shall own at least 50%
of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan formed a publicly
traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate Licensee owns and controls
other Controlled Affiliate Licensees, the Sponsoring Plan directly or indirectly shall own and control at least 50%
of any Controlled Affiliate that is indirectly owned and controlled by the publicly traded Controlled Affiliate
Licensee; or
C. With respect to a Controlled Affiliate that is 100% controlled by Member Plans including the Sponsoring Plan and
which offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and/or Special Need Plans
products and services, the legal authority by the Sponsoring Plan together with such other Member Plan (a) to
select all members of the Controlled Affiliate’s governing body; (b) to prevent any change in the articles of
incorporation, bylaws, or other establishing or governing documents of the Controlled Affiliate; (c) to exercise
control over the policy and operations of the Controlled Affiliate. In addition, the Sponsoring Plan and such other
Member Plans shall own 100% of any for-profit Controlled Affiliate, with the Sponsoring Plan and such other
Member Plans each having an ownership interest. Such 100% control and ownership by Member Plans shall be
direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA. Further, the
Sponsoring Plan and such other Member Plans shall execute the “Addendum to Controlled Affiliate License”
attached as Exhibit B-1 to Exhibit 1 attached hereto; or
Amended as of June 20, 2019
-2a-

-- 350 of 533 --

D. With respect to a Controlled Affiliate that is 100% controlled by another Member Plan which on a Blue-branded
basis within the Plan’s Service Area, offers solely a Basic Medicare Part D Prescription Drug product, the legal
authority by the other Member Plan (a) to select all members of the Controlled Affiliate’s governing body; (b) to
prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the
Controlled Affiliate; (c) to exercise control over the policy and operations of the Controlled Affiliate. In addition,
the Member Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control and ownership by the
Member Plan shall be direct or, if indirect, solely through affiliates that are licensed to use marks owned by
BCBSA. Further, the Sponsoring Plan and Participating Plan as defined on the Controlled Affiliate License
Agreement shall execute the “Addendum to Controlled Affiliate License” attached as Exhibit B-2 to Exhibit 1
attached hereto.
E. With respect to a Controlled Affiliate that operates as a clinic, the legal authority by the Sponsoring Plan to
exercise control over the policy and operations of the Controlled Affiliate as defined in Exhibit 1, Standard
1(E) and the Guidelines to Administer Standard 1 (E). In addition, if the clinic is for-profit, the Sponsoring Plan
shall own at least 50% of the Controlled Affiliate and prevent any change in the articles of incorporation,
bylaws or other establishing documents of the Controlled Affiliate with which the Sponsoring Plan does not
concur.
F. With respect to any Plan affiliation(s) entered into after June 15, 2023, the Plan has entered into a contractual
agreement that meets the criteria set forth in Exhibit 1, Standard 1(F) and the Guidelines to Administer
Standard 1(F) and Protocol for Determining Automatic Transfer of Primary License Agreement Pursuant to
Contractual Control.
2b. With respect to the Controlled Affiliate License Agreements authorized in clauses iv) and v) of Paragraph 2, bona fide
control shall mean that the Controlled Affiliate is organized and operated in such a manner that it meets the following
requirements:
A. The Controlled Affiliate is owned or controlled by two or more Plans authorized to use the Licensed Marks
pursuant to this License Agreement with BCBSA (for purposes of this subparagraph A. through subparagraph
C., the “Controlling Plans”); and
Amended as of June 15, 2023
-2b-

-- 351 of 533 --

B. Each Controlling Plan is authorized pursuant to this Agreement to use the Licensed Marks in a geographic area
in the Region (as that term is defined in such Controlled Affiliate License Agreements) and every geographic
area in the Region is so licensed to at least one of the Controlling Plans; and
C. The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries (a)
to select members of the Controlled Affiliate’s governing body having not less than 100% voting control
thereof; (b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing
documents of the Controlled Affiliate with which the Controlling Plans do not concur; and (c) to exercise
control over the policy and operations of the Controlled Affiliate. Notwithstanding anything to the contrary in
(a) through (c) of this subparagraph E., the Controlled Affiliate’s establishing or governing documents must
also require written approval by each of the Controlling Plans before the Controlled Affiliate can:
1. Change its legal and/or trade names;
2. Change the geographic area in which it operates (except such approval shall not be required with respect
to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one
of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA
sponsored by such Controlling Plan);
3. Change any of the type(s) of businesses in which it engages (except such approval shall not be required with
respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of
one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA
sponsored by such Controlling Plan);
4. Take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the Licensed Marks
and Name.
In addition, the Controlling Plans directly or indirectly through wholly-owned subsidiaries shall own 100% of any for-
profit Controlled Affiliate.
Amended as of June 20, 2019
(the next page is 3)
-2c-

-- 352 of 533 --

3. With respect to an affiliate that is not licensed to use the Licensed Marks and Name, the Plan may, in
communications that contain the Licensed Marks or Name, indicate its corporate relationship to the affiliate and
permit such affiliate to indicate its corporate relationship to the Plan, solely in the circumstances, style and manner
specified in the BlueCross BlueShield Brand Book consistent with the avoidance of confusion or mistake or the
dilution or tarnishment of the Licensed Marks and Name. No rights are hereby created in any unlicensed affiliate to
use the Licensed Marks or Name.
4. The Plan recognizes the importance of a comprehensive national network of independent BCBSA licensees which
are committed to strengthening the Licensed Marks and Name. The Plan further recognizes that its actions within its
Service Area may affect the value of the Licensed Marks and Name nationwide. The Plan agrees (a) to maintain in
good standing its membership in BCBSA; (b) promptly to pay its dues to BCBSA, said dues to represent the
royalties for this License Agreement; (c) materially to comply with all applicable laws; (d) to comply with the
Membership Standards Applicable to Regular Members of BCBSA, a current copy of which is attached as Exhibit 2
hereto; and (e) reasonably to permit BCBSA, upon a written, good faith request and during reasonable business
hours, to inspect the Plan's books and records necessary to ascertain compliance herewith. As to other Plans and
third parties, BCBSA shall maintain the confidentiality of all documents and information furnished by the Plan
pursuant hereto, or pursuant to the Membership Standards, and clearly designated by the Plan as containing
proprietary information of the Plan.
5. The rights hereby granted are exclusive to the Plan within the geographical area(s) served by the Plan on June 30,
1972, and/or as to which the Plan has been granted a subsequent license, which is hereby defined as the "Service
Area, except that BCBSA reserves the right to use the Licensed Marks in said Service Area, and except to the extent
that said Service Area may overlap areas served by one or more other licensed Blue Shield Plans as of said date or
subsequent license, as to which overlapping areas the rights hereby granted are nonexclusive as to such other Plan
or Plans only.
Amended as of June 15, 2023
-3-

-- 353 of 533 --

6. Except as expressly provided by BCBSA with respect to National Accounts, Government Programs and certain other
necessary and collateral uses, the current rules and regulations governing which are attached as Exhibit 3 and
Exhibit 4 hereto, and are contained in other documents referenced herein, or as expressly provided herein, the Plan
may not use the Licensed Marks and Name outside the Service Area or in connection with other goods and
services, nor may the Plan use the Licensed Marks or Name in a manner which is intended to transfer in the Service
Area the goodwill associated therewith to another mark or name. Nothing herein shall be construed to prevent the
Plan from engaging in lawful activity anywhere under other marks and names not confusingly similar to the Licensed
Marks and Name, provided that engaging in such activity does and will not dilute or tarnish the unique value of the
Licensed Marks and Name. In addition to any and all remedies available hereunder, BCBSA may impose monetary
fines on the Plan for the Plan’s use of the Licensed Marks and Names outside the Service Area, and provided that
the procedure used in imposing a fine is consistent with procedures specifically prescribed by BCBSA from time to
time in regulations of general application. In the case of regional Medicare Advantage PPO and regional Medicare
Part D Prescription Drug Plan products offered by consenting and participating Plans in a region that includes the
Service Areas, or portions thereof, of more than one Plan, such fine may be imposed jointly on the consenting and
participating Plans for use of the Licensed Marks and Name in any geographic area of the region in which a Plan
having exclusive rights to the Licensed Marks and Name does not consent to and participate in such offering,
provided that the basis for imposition of such fine is consistent with rules specifically prescribed by BCBSA from time
to time in regulations of general application.
7. The Plan agrees that it will display the Licensed Marks and Name only in such form, style and manner as shall be
specifically prescribed by BCBSA from time-to-time in regulations of general application in order to prevent
impairment of the distinctiveness of the Licensed Marks and Name and the goodwill pertaining thereto. The Plan
shall cause to appear on all materials on or in connection with which the Licensed Marks or Name are used such
legends, markings and notices as BCBSA may reasonably request in order to give appropriate notice of service
mark or other proprietary rights therein or pertaining thereto.
8. BCBSA agrees that: (a) it will not grant any other license effective during the term of this License Agreement for the
use of the Licensed Marks or Name which is inconsistent with the rights granted to the Plan hereunder; and (b) it will
not itself use the Licensed Marks in derogation of the rights of the Plan or in a manner to deprive the Plan of the full
benefits of this License Agreement, provided that BCBSA shall have the right to use the Licensed Marks in
conjunction with any national offering under the Federal Employees Health Benefits Program in the manner set forth
in Exhibit 4, Paragraph 4 (including subparagraphs) to this License Agreement. The Plan agrees that it will not attack
the title of BCBSA in and to the Licensed Marks or Name or attack the validity of the Licensed Marks or of this
License Agreement. The Plan further agrees that all use by it of the Licensed Marks and Name or any similar mark
or name shall inure to the benefit of BCBSA, and the Plan shall cooperate with BCBSA in effectuating the
assignment to BCBSA of any service mark or trademark registrations of the Licensed Marks or any similar mark or
name held by the Plan or a Controlled Affiliate of the Plan, all or any portion of which registration consists of the
Licensed Marks.
Amended as of November 16, 2006
-3a-

-- 354 of 533 --

9. (a). Should the Plan fail to comply with the provisions of paragraphs 2-4, 6, 7 and/or 12, and not cure such failure
within thirty (30) days of receiving written notice thereof (or commence curing such failure within such thirty day
period and continue diligent efforts to complete the curing of such failure if such curing cannot reasonably be
completed within such thirty day period), BCBSA shall have the right to issue a
notice that the Plan is in a state of noncompliance. Except as to the termination of a Plan's License Agreement
or the merger of two or more Plans, disputes as to noncompliance, and all other disputes between or among
BCBSA, the Plan, other Plans and/or Controlled Affiliates, shall be submitted promptly to mediation and
mandatory dispute resolution pursuant to the rules and regulations of BCBSA, a current copy of which is
attached as Exhibit 5 hereto, and shall be timely presented and resolved. The mandatory dispute resolution
panel shall have authority to issue orders for specific performance and assess monetary penalties. If a state of
noncompliance as aforesaid is undisputed by the Plan or is found to exist by a mandatory dispute resolution
panel and is uncured as provided above, BCBSA shall have the right to seek judicial enforcement of the License
Agreement.Except, however, as provided in paragraphs 9(d)(iii), 15(a)(i)-(viii), and 15(a)(x) below, no Plan's
license to use the Licensed Marks and Name may be finally terminated for any reason without the affirmative
vote of three-fourths of the Plans and three fourths of the total then current weighted vote of all the Plans.
(b). Notwithstanding any other provision of this License Agreement, a Plan's license to use the Licensed Marks and
Name may be forthwith terminated by the affirmative vote of three-fourths of the Plans and three-fourths of the
total then current weighted vote of all the Plans at a special meeting expressly called by BCBSA for the purpose
on ten (10) days written notice to the Plan advising of the specific matters at issue and granting the Plan an
opportunity to be heard and to present its response to Member Plans for: (i) failure to comply with any minimum
capital or liquidity requirement under the Membership Standard on Financial Responsibility; or (ii) impending
financial insolvency; or (iii) the pendency of any action instituted against the Plan seeking its dissolution or
liquidation or its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for any
of its property or business or seeking the declaration or establishment of a trust for any of its property of
business, unless this License Agreement has been earlier terminated under paragraph 15(a); or (iv) such other
reason as is determined in good faith immediately and irreparably to threaten the integrity and reputation of
BCBSA, the Plans and/or the Licensed Marks.
Amended as of March 16, 2006
-4-

-- 355 of 533 --

(c). To the extent not otherwise provided therein, neither: (i) the Membership Standards Applicable to Regular
Members of BCBSA; nor (ii) the rules and regulations governing Government Programs and certain other uses;
nor (iii) the rules and regulations governing mediation and mandatory dispute resolution, may be amended
unless and until each such amendment is first adopted by the affirmative vote of three-fourths of the Plans and
of three-fourths of the total then current weighted vote of all the Plans. The rules and regulations governing
National Accounts and other national programs required by the Membership Standards Applicable to Regular
Members of BCBSA (Exhibit 2) are contained, in addition to those set forth in Exhibit 3, in the following
documents, as amended from time to time: (1) the Inter-Plan Programs Policies and Provisions; (2) Inter-Plan
Medicare Advantage Program Policies and Provisions. The voting requirements specified in rules and
regulations governing such national programs may not be amended unless and until each such amendment is
first adopted by the affirmative vote of three-fourths of the Plans and of three-fourths of the total then current
weighted vote of all the Plans.
Amended as of November 21, 2014
-4a-

-- 356 of 533 --

(d). The Plan may operate as a for-profit company on the following conditions:
(i) The Plan shall discharge all responsibilities which it has to the Association and
to other Plans by virtue of this Agreement and the Plan's membership in
BCBSA.
(ii) The Plan shall not use the licensed Marks and Name, or any derivative thereof, as part of its legal name or
any symbol used to identify the Plan in any securities market. The Plan shall use the Licensed Marks and
Name as part of its trade name within its service area for the sale, marketing and administration of health
care and related services in the service area.
(iii) The Plan's license to use the Licensed Marks and Name shall automatically terminate effective: (a) thirty
days after the Plan knows, or there is an SEC filing indicating that, any Institutional Investor, has become
the Beneficial Owner of securities representing 10% or more of the voting power of the Plan (“Excess
Institutional Voter”), unless such Excess Institutional Voter shall cease to be an Excess Institutional Voter
prior to such automatic termination becoming effective; (b) thirty days after the Plan knows, or there is an
SEC filing indicating that, any Noninstitutional Investor has become the Beneficial Owner of securities
representing 5% or more of the voting power of the Plan (“Excess Noninstitutional Voter”) unless such
Excess Noninstitutional Voter shall cease to be an Excess Noninstitutional Voter prior to such automatic
termination becoming effective; (c) thirty days after the Plan knows, or there is an SEC filing indicating
that, any Person has become the Beneficial Owner of 20% or more of the Plan’s then outstanding
common stock or other equity securities which (either by themselves or in combination) represent an
ownership interest of 20% or more pursuant to determinations made under paragraph 9(d)(iv) below
(“Excess Owner”), unless such Excess Owner shall cease to be an Excess Owner prior to such automatic
termination becoming effective; (d) ten business days after individuals who at the time the Plan went
public constituted the Board of Directors of the Plan (together with any new directors whose election to
the Board was approved by a vote of 2/3 of the directors then still in office who were directors at the time
the Plan went public or whose election or nomination was previously so approved) (the "Continuing
Directors") cease for any reason to constitute a majority of the Board of Directors; or (e) ten business
days after the Plan consolidates with or merges with or into any person or conveys, assigns, transfers or
sells all or substantially all of its assets to any person other than a merger in which the Plan is the
surviving entity and immediately after which merger, no person is an Excess Institutional Voter, an Excess
Noninstitutional Voter or an Excess Owner: provided that, if requested by the affected Plan in a writing
received by BCBSA prior to such automatic termination
Amended as of September 17, 1997
-5-

-- 357 of 533 --

becoming effective, the provisions of this paragraph 9(d)(iii) may be waived, in whole or in part, upon the
affirmative vote of a majority of the disinterested Plans and a majority of the total then current weighted
vote of the disinterested Plans. Any waiver so granted may be conditioned upon such additional
requirements (including but not limited to imposing new and independent grounds for termination of this
License) as shall be approved by the affirmative vote of a majority of the disinterested Plans and a
majority of the total then current weighted vote of the disinterested Plans. If a timely waiver request is
received, no automatic termination shall become effective until the later of: (1) the conclusion of the
applicable time period specified in paragraphs 9(d)(iii)(a)- (d) above, or (2) the conclusion of the first
Member Plan meeting after receipt of such a waiver request.
In the event that the Plan's license to use the Licensed Marks and Name is terminated pursuant to this
Paragraph 9(d)(iii), the license may be reinstated in BCBSA’s sole discretion if, within 30 days of the date
of such termination, the Plan demonstrates that the Person referred to in clause (a), (b) or (c) of the
preceding paragraph is no longer an Excess Institutional Voter, an Excess Noninstitutional Voter or an
Excess Owner.
(iv) The Plan shall not issue any class or series of security other than (i) shares of common stock having
identical terms or options or derivatives of such common stock, (ii) non-voting, non-convertible debt
securities or (iii) such other securities as the Plan may approve, provided that BCBSA receives notice at
least thirty days prior to the issuance of such securities, including a description of the terms for such
securities, and BCBSA shall have the authority to determine how such other securities will be counted in
determining whether any Person is an Excess Institutional Voter, Excess Noninstitutional Voter or an
Excess Owner.
(v) For purposes of paragraph 9(d)(iii), the following definitions shall apply:
(a) "Affiliate" and "Associate" shall have the respective meanings ascribed to such terms in Rule 12b-2 of the
General Rules and Regulations under the Securities Exchange Act of 1934, as amended and in effect on
November 17, 1993 (the "Exchange Act").
(b) A Person shall be deemed the "Beneficial Owner" of and shall be deemed to "beneficially own" any
securities:
(i) which such Person or any of such Person's Affiliates or Associates
beneficially owns, directly or indirectly;
Amended as of September 17, 1997
-5a-

-- 358 of 533 --

(ii) which such Person or any of such Person's Affiliates or Associates has (A) the right to acquire
(whether such right is exercisable immediately or only after the passage of time) pursuant to
any agreement, arrangement or understanding, or upon the exercise of conversion rights,
exchange rights, warrants or options, or otherwise; or (B) the right to vote pursuant to any
agreement, arrangement or understanding; provided, however, that a Person shall not be
deemed the Beneficial Owner of, or to beneficially own, any security if the agreement,
arrangement or understanding to vote such security (1) arises solely from a revocable proxy or
consent given to such Person in response to a public proxy or consent solicitation made
pursuant to, and in accordance with, the applicable rules and regulations promulgated under the
Exchange Act and (2)
is not also then reportable on Schedule 13D under the Exchange Act (or any comparable or
successor report); or
(iii) which are beneficially owned, directly or indirectly, by any other Person (or any Affiliate or
Associate thereof) with which such Person (or any of such Person's Affiliates or Associates) has
any agreement, arrangement or understanding (other than customary agreements with and
between underwriters and selling group members with respect to a bona fide public offering of
securities) relating to the acquisition, holding, voting (except to the extent contemplated by the
proviso to (b)(ii)(B) above) or disposing of any securities of the Plan.
Notwithstanding anything in this definition of Beneficial Ownership to
the contrary, the phrase "then outstanding," when used with reference to a Person's Beneficial
Ownership of securities of the Plan, shall mean the number of such securities then issued and
outstanding together with the number of such securities not then actually issued and outstanding which
such Person would be deemed to own beneficially hereunder.
(c) A Person shall be deemed an “Institutional Investor” if (but only if) such Person (i) is an entity or group
identified in the SEC’s Rule 13d-1(b)(1)(ii) as constituted on June 1, 1997, and (ii) every filing made by
such Person with the SEC under Regulation 13D-G (or any successor Regulation) with respect to such
Person’s Beneficial Ownership of Plan securities shall have contained a certification identical to the one
required by item 10 of SEC Schedule 13G as constituted on June 1, 1997.
(d) “Noninstitutional Investor” means any Person who is not an Institutional Investor.
(e) Person" shall mean any individual, firm, partnership, corporation, trust, association, joint venture or other
entity, and shall include any successor (by merger or otherwise) of such entity.
Amended as of September 17, 1997
-5b-
(The next page is page 6)

-- 359 of 533 --

10. This License Agreement shall remain in effect: (a) until terminated as provided herein; or (b) until this and all
such other License Agreements are terminated by the affirmative vote of three-fourths of the Plans and three-
fourths of the total then current weighted vote of all the Plans; (c) until terminated by the Plan upon eighteen (18)
months written notice to BCBSA or upon a shorter notice period approved by BCBSA in writing at its sole
discretion.
11. Except as otherwise provided in paragraph 15 below or by the affirmative vote of three-fourths of the Plans
and three-fourths of the total then current weighted vote of all the Plans, or unless this and all such other
License Agreements are simultaneously terminated by force of law, the termination of this License Agreement
for any reason whatsoever shall cause the reversion to BCBSA of all rights in and to the Licensed Marks and
Name, and the Plan agrees that it will promptly discontinue all use of the Licensed Marks and Name, will not
use them thereafter, and will promptly, upon written notice from BCBSA, change its corporate name so as to
eliminate the Licensed Name therefrom.
12. The license hereby granted to Plan to use the Licensed Marks and Name is and shall be personal to the Plan
so licensed and shall not be assignable by any act of the Plan, directly or indirectly, without the written
consent of BCBSA. Said license shall not be assignable by operation of law, nor shall Plan mortgage or part
with possession or control of this license or any right hereunder, and the Plan shall have no right to grant any
sublicense to use the Licensed Marks and Name.
13. BCBSA shall maintain appropriate service mark registrations of the Licensed Marks and BCBSA shall take such
lawful steps and proceedings as may be necessary or proper to prevent use of the Licensed Marks by any
person who is not authorized to use the same. Any actions or proceedings undertaken by BCBSA under the
provisions of this paragraph shall be at BCBSA's sole cost and expense. BCBSA shall have the sole right to
determine whether or not any legal action shall be taken on account of unauthorized use of the Licensed Marks,
such right not to be unreasonably exercised. The Plan shall report any unlawful usage of the Licensed Marks to
BCBSA in writing and agrees, free of charge, to cooperate fully with BCBSA's program of enforcing and
protecting the service mark rights, trade name rights and other rights in the Licensed Marks.
14. The Plan hereby agrees to save, defend, indemnify and hold BCBSA And any other Plan(s) harmless from
and against all claims, damages, liabilities and Costs of every kind, nature and description which may arise as
a result of the activities of the Plan or of any hospital, medical group, clinic or other provider of health services
that is owned or controlled directly or indirectly by Plan. BCBSA hereby agrees to save, defend, indemnify and
hold the Plan and any other Plan(s) harmless from and against all claims, damages, liabilities and costs of
every kind, nature and description which may arise exclusively and directly as a result of the activities of
BCBSA.
Amended as of June 21, 2012
-6-

-- 360 of 533 --

15. (a). This Agreement shall automatically terminate upon the occurrence of any of the following events: (i) a
voluntary petition shall be filed by the Plan or by BCBSA seeking bankruptcy, reorganization,
arrangement with creditors or other relief under the bankruptcy laws of the United States or any other law
governing insolvency or debtor relief, or (ii) an involuntary petition or proceeding shall be filed against the
Plan or BCBSA seeking bankruptcy, reorganization, arrangement with creditors or other relief under the
bankruptcy laws of the United States or any other law
governing insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by
the Plan or BCBSA or is not dismissed within sixty (60) days of the date upon which the petition or other
document commencing the proceeding is served upon the Plan or BCBSA respectively, or (iii) an order
for relief is entered against the Plan or BCBSA in any case under the bankruptcy laws of the United
States, or the Plan or BCBSA is adjudged bankrupt or insolvent (as that term is defined in the Uniform
Commercial Code as enacted in the state of Illinois) by any court of competent jurisdiction, or (iv) the
Plan or BCBSA makes a general assignment of its assets for the benefit of creditors, or (v) any
government or any government official, office, agency, branch, or unit assumes control of the Plan or
delinquency proceedings (voluntary or involuntary) are instituted, or (vi) an action is brought by the Plan
or BCBSA seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee,
interim trustee, receiver or other custodian for any of its property or business, or (vii) an action is
instituted by any governmental entity or officer against the Plan or BCBSA seeking its dissolution or
liquidation of its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian
for any of its property or business and such action is consented to or acquiesced in by the Plan or
BCBSA or is not dismissed within one hundred thirty (130) days of the date upon which the pleading or
other document commencing the action is served upon the Plan or BCBSA respectively, provided that if
the action is stayed or its prosecution is enjoined, the one hundred thirty (130) day period is tolled for the
duration of the stay or injunction, and provided further, that the Association’s Board of Directors may toll
or extend the 130 day period at any time prior to its expiration, or (viii) a trustee, interim trustee, receiver
or other custodian for any of the Plan's or BCBSA's property or business is appointed, or the Plan or
BCBSA is ordered dissolved or liquidated, or (ix) the Plan shall fail to pay its dues and shall not cure such
failure within thirty (30) days of receiving written notice thereof, or (x) if, due to regulatory action, the Plan
together with any applicable Controlled Affiliate becomes unable to do business using the Names and
Marks in any State or portion thereof included in its Service Area, provided that: (i) automatic termination
shall not occur prior to the exhaustion by any such Plan of its rights to appeal or challenge such
regulatory action; and (ii) in the event the Plan is licensed to do business using the Names and Marks in
multiple States or portions of States, the termination of its License Agreement shall be solely limited to
the State(s) or portions thereof in which the regulatory action applies. By not appealing or challenging
such regulatory action within the time prescribed by law or regulation, and in any event no later than 120
days after such action is taken, a Plan shall be deemed to have exhausted its rights to appeal or
challenge, and automatic termination shall proceed.
-7-

-- 361 of 533 --

Notwithstanding any other provision of this Agreement, a declaration or a request for declaration of the
existence of a trust over any of the Plan’s or BCBSA’s property or business shall not in itself be deemed to
constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of
subparagraphs 15(a)(vii) and (viii) of this Agreement.
Amended as of March 26, 201
-7a-

-- 362 of 533 --

(b). BCBSA, or the Plans (as provided and in addition to the rights conferred in Paragraph 10(b) above), may
terminate this Agreement immediately upon written notice upon the occurrence of either of the following
events: (a) the Plan or BCBSA becomes insolvent (as that term is defined in the Uniform Commercial Code
enacted in the state of Illinois), or (b) any final judgment against the Plan or BCBSA remains unsatisfied or
unbonded of record for a period of sixty (60) days or longer.
(c). If this License Agreement is terminated as to BCBSA for any reason stated in subparagraphs 15(a) and (b)
above, the ownership of the Licensed Marks shall revert to each of the Plans.
(d). Upon termination of this License Agreement or any Controlled Affiliate License Agreement of a Larger
Controlled Affiliate, as defined in Exhibit 1 to this License Agreement, the following conditions shall apply,
except that, in the event of a partial termination of this Agreement pursuant to Paragraph 15 (a)(x)(ii) of this
Agreement, the notices, national account listing, payment and audit right listed below shall be applicable
solely with respect to the geographic area for which the Plan’s license to use the Licensed Names and Marks
is terminated:
(i) The terminated entity shall send a notice through the U.S. mails, with first class postage affixed, to all
individual and group customers, providers, brokers and agents of products or services sold, marketed,
underwritten or administered by the terminated entity or its Controlled Affiliates under the Licensed Marks
and Name. The form and content of the notice shall be specified by BCBSA and shall, at a minimum,
notify the recipient of the termination of the license, the consequences thereof, and instructions for
obtaining alternate products or services licensed by BCBSA, subject to any conflicting state law and state
regulatory requirements. This notice shall be mailed within 15 days after termination or, if termination is
pursuant to paragraph 10(d) of this Agreement, within 15 days after the written notice to BCBSA described
in paragraph 10(d).
(ii) The terminated entity shall deliver to BCBSA within five days of a request by BCBSA a listing of national
accounts in which the terminated entity is involved (in a Control, Participating or Servicing capacity),
identifying the national account and the terminated entity's role therein. For those accounts where the
terminated entity is the Control Plan, the Plan must also indicate the Participating and Servicing Plans in
the national account syndicate.
Amended as of June 16, 2005
-8-

-- 363 of 533 --

(iii) Unless the cause of termination is an event stated in paragraph 15(a) or (b) above respecting BCBSA, the
Plan and its Licensed Controlled Affiliates shall be jointly liable for payment to BCBSA of an amount equal
to the Re- Establishment Fee (described below) multiplied by the number of Licensed Enrollees of the
terminated entity and its Licensed Controlled Affiliates;
provided that if any other Plan is permitted by BCBSA to use marks or names licensed by BCBSA in the
Service Area established by this Agreement, the Re- Establishment Fee shall be multiplied by a fraction,
the numerator of which is the number of Licensed Enrollees of the terminated entity and its Licensed
Controlled Affiliates and the denominator of which is the total number of Licensed Enrollees in the Service
Area. The Re-Establishment Fee shall be indexed to a base fee of $80. The Re-Establishment Fee
through December
31, 2005 shall be $80. The Re-Establishment Fee for calendar years after December 31, 2005 shall be
adjusted on January 1 of each calendar year up to and including January 1, 2010 and shall be the base
fee multiplied by 100% plus the cumulative percentage increase or decrease in the Plans’ gross
administrative expense (standard BCBSA definition) per Licensed Enrollee since December 31, 2004. The
adjustment shall end on January 1, 2011, at which time the Re-Establishment Fee shall be fixed at the
then-current amount and no longer automatically adjusted. For example, if the Plans’ gross administrative
expense per Licensed Enrollee was $278.60, $285.00 and
$290.00 for calendar year end 2004, 2005 and 2006, respectively, the January 1, 2007 Re-Establishment
Fee would be $83.27 (100% of the base fee plus
$1.84 for calendar year 2005 and $1.43 for calendar year 2006). Licensed Enrollee means each and
every person and covered dependent who is enrolled as an individual or member of a group receiving
products or services sold, marketed or administered under marks or names licensed by BCBSA as
determined at the earlier of (a) the end of the last fiscal year of the terminated entity which ended prior to
termination or (b) the fiscal year which ended before any transactions causing the termination began.
Notwithstanding the
foregoing, the amount payable pursuant to this subparagraph (d)(iii) shall be due only
Amended as of June 16, 2005
-8a-

-- 364 of 533 --

to the extent that, in BCBSA's opinion, it does not cause the net worth of the Plan to fall below 100% of
the Health Risk-Based Capital formula or its equivalent under any successor formula, as set forth in the
applicable financial responsibility standards established by BCBSA (provided such equivalent is approved
for purposes of this sub paragraph by the affirmative vote of three- fourths of the Plans and three-fourths
of the total then current weighted vote of all the Plans), measured as of the date of termination and
adjusted for the value of any transactions not made in the ordinary course of business. This payment shall
not be due in connection with transactions exclusively by or among Plan or their affiliates, including
reorganizations, combinations or mergers, where the BCBSA Board of Directors determines that the
license termination does not result in a material diminution in the number of Licensed Enrollees or the
extent of their coverage. At least 50% of the Re-Establishment Fee shall be awarded to the Plan (or
Plans) that receive the new license(s) for the service area(s) at issue; provided, however, that such award
shall not become due or payable until all disputes, if any, regarding the amount of and BCBSA’s right to
such Re-Establishment Fee have been finally resolved; and provided further that the award shall be
based on the final amount actually received by BCBSA. The Board of Directors shall adopt a resolution
which it may amend from time to time that shall govern BCBSA’s use of its portion of the award. In the
event that the terminated entity’s license is reinstated by BCBSA or is deemed to have remained in effect
without interruption by a court of competent jurisdiction, BCBSA shall reimburse the Plan (and/or its
Licensed Controlled Affiliates, as the case may be) for payments made under this subparagraph only to
the extent that such payments exceed the amounts due to BCBSA pursuant to subparagraph 15(d)(vi)
and any costs associated with reestablishing the Service Area, including any payments made by BCBSA
to a Plan or Plans (or their Licensed Controlled Affiliates) for purposes of replacing the terminated entity.
(iv) The terminated entity shall comply with all financial settlement procedures set forth in BCBSA’s License
Termination Contingency Plan, as amended from time to time and shall work diligently and in good faith
with
Amended as of June 16, 2005
-8b-

-- 365 of 533 --

BCBSA, any Alternative Control Licensee or Replacement Licensee and any existing or potential new account
for Blue-branded products and services to minimize the disruption of termination, and honor, to the fullest
extent possible, the desire of accounts to continue to receive or obtain Blue-branded products and
services through a new Licensee (“Transition”). Such diligence and good faith on the part of the
terminated entity shall include, but not be limited to: (a) working cooperatively with BCBSA to protect the
Names and Marks from potential harm; (b) cooperating with BCBSA’s use of the Names and Marks in the
terminated entity’s former service area during the termination and Transition; (c) transmitting, upon the
request of an existing Blue account or of BCBSA with consent and on behalf of an existing Blue account,
all member and account-data relating to the Federal Employee Program to BCBSA, and all member and
account data relating to other programs to an Alternative Control Licensee or Replacement Licensee; (d)
working with BCBSA and the Alternative Control or Replacement Licensee with respect to potential new
Blue accounts headquartered in the terminated entity’s former service area; (e) continuing to service Blue
accounts during the Transition; (f) continuing to comply with National Programs, Federal Employee
Program and NASCO policies and procedures and all voluntary BCBSA programs, policies and
performance standards, such as Away From Home Care, including being responsible for payment of all
penalties for non-compliance duly levied in conformity with the License Agreements, Membership
Standards, or the Federal Employee Program agreements, that may arise during the Transition;(g)
maintaining and providing access to its provider networks, as defined by Federal Employee Program
agreements and National Account Program Policies and Provisions, and Inter-Plan Programs Policies and
Provisions, and making those networks and discounts available to members and providers who
participate in National Programs and the Federal Employee Program during the Transition; (h) maintaining
its technical connections and processing capabilities during the Transition; and (i) working diligently to
conclude all financial settlements and account reconciliations as negotiated in the termination
transition agreement.
Amended as of November 16, 2006
-8c-

-- 366 of 533 --

(v) Notwithstanding any other provision in this Agreement, BCBSA shall have the right, with the approval of its
Board of Directors, to assess additional fines against the terminated entity during the Transition in the
event it fails to maintain and provide access to provider networks as defined by Federal Employee
Program agreements, National Account Program Policies and Provisions, and Inter-Plans Programs
Policies and Provisions, and/or pass on applicable discounts. Such fines shall be in addition to any other
assessments, fees or liquidated damages payable herein, or under existing policies and programs and
shall be imposed to make whole BCBSA and/or the Plans. Terminated entity shall pay any such fines to
BCBSA no later than 30 days after they are approved by the Board of Directors.
(vi) BCBSA shall have the right to examine and audit and/or hire at terminated entity’s expense a third-party
auditor to examine and audit the books and records of the terminated entity and its Licensed Controlled
Affiliates to verify compliance with the terms and requirements of this paragraph 15(d).
(vii) Subsequent to termination of this Agreement, the terminated entity and its affiliates, agents, and
employees shall have an ongoing and continuing obligation to protect all BCBSA and Blue Licensee data
that was acquired or accessed during the period this Agreement was in force, including but not limited to
all confidential processes, pricing, provider, discount and other strategic and competitively sensitive
information (“Blue Information”) from disclosure, and shall not, either alone or with another entity, disclose
such Blue Information or use it in any manner to compete without the express written permission of
BCBSA.
(viii) As to a breach of 15 (d) (i), (ii), (iii), (iv), (vi), or (vii) the parties agree that the obligations are immediately
enforceable in a court of competent jurisdiction. As to a breach of 15 (d) (i), (ii), (iv), (vi), or (vii) by the
Plan, the parties agree there is no adequate remedy at law and BCBSA is entitled to obtain specific
performance.
Amended as of November 16, 2006
-8d-

-- 367 of 533 --

(ix) In the event that the terminated entity’s license is reinstated by BCBSA or is deemed to have remained in
effect without interruption by a court of competent jurisdiction, the Plan and its Licensed Controlled
Affiliates shall be jointly liable for reimbursing BCBSA the reasonable costs incurred by BCBSA in
connection with the termination and the reinstatement or court action, and any associated legal
proceedings, including but not limited to: outside legal fees, consulting fees, public relations fees,
advertising costs, and costs incurred to develop, lease or establish an interim provider network. Any
amount due to BCBSA under this subparagraph may be waived in whole or in part by the BCBSA Board
of Directors in its sole discretion.
(e). BCBSA shall be entitled to enjoin the Plan or any related party in a court of competent jurisdiction from entry
into any transaction which would result in a termination of this License Agreement unless the License
Agreement has been terminated pursuant to paragraph 10 (d) of this Agreement upon the required six (6)
month written notice.
(f). BCBSA acknowledges that it is not the owner of assets of the Plan.
Amended as of June 16, 2006
-8e-

-- 368 of 533 --

16. This Agreement supersedes any and all other agreements between the parties with respect to the subject matter
herein and contains all of the covenants and agreements of the parties as to the licensing of the Licensed Marks and
Name. This Agreement may be amended only by the affirmative vote of three-fourths of the Plans and three-fourths
of the total then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.
17. If any provision or any part of any provision of this Agreement is judicially declared unlawful, each and every other
provision, or any part of any provision, shall continue in full force and effect notwithstanding such judicial declaration.
18. No waiver by BCBSA or the Plan of any breach or default in performance on the part of BCBSA or the Plan or any
other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any
subsequent breach or default in performance of said terms, covenants or conditions.
19a. All notices provided for hereunder shall be in writing and shall be sent in duplicate by regular mail to BCBSA or the
Plan at the address currently published for each by BCBSA and shall be marked respectively to the attention of the
President and, if any, the General Counsel, of BCBSA or the Plan.
19b. Except as provided in paragraphs 9(b), 9(d)(iii), 15(a), and 15(b) above, this Agreement may be terminated for a
breach only upon at least 30 days’ written notice to the Plan advising of the specific matters at issue and granting
the Plan an opportunity to be heard and to present its response to the Member Plans.
19c. For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the Blue
Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes
equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes
(if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all
questions requiring an affirmative three-fourths weighted vote of the Plans, voting shall occur pursuant to BCBSA’s
Bylaws.
Amended as of June 15, 2023
-8f-
(The next page is page 9)

-- 369 of 533 --

20. Nothing herein contained shall be construed to constitute the parties hereto as partners or joint venturers, or either
as the agent of the other, and Plan shall have no right to bind or obligate BCBSA in any way, nor shall it represent
that it has any right to do so. BCBSA shall have no liability to third parties with respect to any aspect of the business,
activities, operations, products, or services of the Plan.
21. This Agreement shall be governed, construed and interpreted in accordance with the laws of the State of Illinois.
IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed,
effective as of the date of last signature written below.
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By________________________________________
Title_______________________________________
Date_______________________________________
Plan:
By________________________________________
Title_______________________________________
Date_______________________________________
-9-

-- 370 of 533 --

EXHIBIT 1
BLUE SHIELD
CONTROLLED AFFILIATE LICENSE AGREEMENT
(Includes revisions adopted by Member Plans through their November 16 , 2023 meeting)
This Agreement by and among Blue Cross and Blue Shield Association ("BCBSA") and
______________(“Controlled Affiliate"), a Controlled Affiliate of the Blue Shield Plan, known as ______________("Plan" or
“Sponsoring Plan”), which is also a Party signatory hereto.
WHEREAS, BCBSA is the owner of the BLUE SHIELD and BLUE SHIELD Design
service marks;
WHEREAS, Plan and Controlled Affiliate desire that the latter be entitled to use the
BLUE SHIELD and BLUE SHIELD Design service marks (collectively the "Licensed Marks") as
service marks and be entitled to use the term BLUE SHIELD in a trade name ("Licensed
Name");
NOW THEREFORE, in consideration of the foregoing and the mutual agreements
hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties hereby agree as follows:
1. GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled Affiliate the right to use the Licensed
Marks and Name in connection with, and only in connection with: (i) health care plans and related services, as defined in
BCBSA's License Agreement with Plan, and administering the non-health portion of workers’ compensation insurance, and (ii)
underwriting the indemnity portion of workers’ compensation insurance, provided that Controlled Affiliate’s total premium
revenue comprises less than 15 percent of the Sponsoring Plan’s net subscription revenue.
This grant of rights is non-exclusive and is limited to the Service Area served by the Plan. Subject to Paragraph
3A(3) of this Agreement, Controlled Affiliate may use the Licensed Marks and Name in its legal name on the
following conditions: (i) the legal name must be approved in advance, in writing, by BCBSA; (ii) Controlled Affiliate
shall not do business outside the Service Area under any name or mark; and (iii) Controlled Affiliate shall not use
the Licensed Marks and Name, or any derivative thereof, as part of any name or symbol used to identify itself in
any securities market, unless such Controlled Affiliate is
a not-for-profit company which may use the Licensed Marks and Name, or an approved derivative therefor, to
identify itself in debt securities markets. Controlled Affiliate may
use the Licensed Marks and Name in its Trade Name only with the prior, written, consent of BCBSA.
Amended as of March 26, 2015
-1-

-- 371 of 533 --

2. QUALITY CONTROL
A. Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services and
further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they may
be amended by BCBSA from time-to-time.
B. Controlled Affiliate agrees to comply with all applicable federal, state and local laws.
C. Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by Plan or
by BCBSA) a report or reports to Plan and BCBSA demonstrating Controlled Affiliate's compliance with the
requirements of this Agreement including but not limited to the quality control provisions of this paragraph and
the attached Exhibit A.
D. Controlled Affiliate agrees that Plan and/or BCBSA may, from time-to-time, upon reasonable notice, review and
inspect the manner and method of Controlled Affiliate's rendering of service and use of the Licensed Marks and
Name.
E. As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner, that the
Sponsoring Plan has:
(1) The legal authority directly or indirectly through wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having not
less than 50% voting control thereof; and
(b) to prevent any change in the articles of incorporation, bylaws or other
establishing or governing documents of the Controlled Affiliate with which
the Sponsoring Plan does not concur; and
(c) to exercise control over the policy and operations of the Controlled
Affiliate at least equal to that exercised by persons or entities (jointly or individually) other than the
Sponsoring Plan; and
Notwithstanding anything to the contrary in (a) through (c) hereof, the
Controlled Affiliate’s establishing or governing documents must also require
written approval by the Sponsoring Plan before the Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates;
(iii) change any of the type(s) of businesses in which it engages;
Amended as of September 19, 2014
-2-

-- 372 of 533 --

(iv) create, or become liable for by way of guarantee, any indebtedness, other than indebtedness
arising in the ordinary course of business;
(v) sell any assets, except for sales in the ordinary course of business or sales of equipment no longer
useful or being replaced;
(vi) make any loans or advances except in the ordinary course of
business;
(vii) enter into any arrangement or agreement with any party directly or indirectly affiliated with any of
the owners or persons or entities with
the authority to select or appoint members or board members of the Controlled Affiliate, other than
the Sponsoring Plan or other Plans (excluding owners of stock holdings of under 5% in a publicly
traded Controlled Affiliate);
(viii) conduct any business other than under the Licensed Marks
and Name;
(ix) take any action that Sponsoring Plan or BCBSA reasonably
believes will adversely affect the Licensed Marks and Name.
In addition, the Sponsoring Plan directly or indirectly through wholly owned subsidiaries shall own at least
50% of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan formed a
publicly traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate Licensee owns
and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or indirectly shall own and
control at least 50% of any Controlled Affiliate that is indirectly owned and controlled by the publicly
traded Controlled Affiliate Licensee.
Or
(2) The legal authority directly or indirectly through wholly-owned subsidiaries;
(a) to select members of the Controlled Affiliate’s governing body having more than 50% voting control
thereof and to:
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing
documents of the Controlled Affiliate with which the Sponsoring Plan do not concur; and
c) to exercise control over the policy and operations of the Controlled Affiliate.
Amended as of March 26, 2015
-3-

-- 373 of 533 --

In addition, the Sponsoring Plan directly or indirectly through wholly-owned subsidiaries shall own more
than 50% of any for-profit Controlled Affiliate, provided that in instances where the Sponsoring Plan
formed a publicly traded Controlled Affiliate Licensee and such publicly traded Controlled Affiliate
Licensee owns and controls other Controlled Affiliate Licensees, the Sponsoring Plan directly or indirectly
shall own and control more than 50% of any Controlled Affiliate that is indirectly owned and controlled by
the publicly traded Controlled Affiliate Licensee.
Or
(3) With respect to a Controlled Affiliate that is 100% controlled by Plans including the Sponsoring Plan and
which offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage HMO and/or Special Need
Plans products and services, the Sponsoring Plan has the legal authority together with such
other Plans:
(a) to select all members of the Controlled Affiliate’s governing body; and
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing
documents of the Controlled Affiliate; and
(c) to exercise control over the policy and operations of the Controlled Affiliate.
In addition, the Sponsoring Plan and such other Plans shall own 100% of any for-profit Controlled
Affiliate, with the Sponsoring Plan and such other Plans each having an ownership interest. Such control
and ownership by Plans must be direct or, if indirect, solely through affiliates that are licensed to use
marks owned by BCBSA. Further, the Sponsoring Plan and such other Plans shall execute a separate
Addendum to Controlled Affiliate License Agreement attached hereto as Exhibit B-1 for each product
noted in Paragraph 2E(3) that is licensed to use the Marks.
Or
(4) With respect to a Controlled Affiliate that is 100% controlled by a Sponsoring Plan which on a Blue-
branded basis offers solely a Basic Medicare Part D Prescription Drug product, the Sponsoring Plan has
the legal authority:
(a) to select all members of the Controlled Affiliate’s governing body; and
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing
documents of the Controlled Affiliate; and
(c) to exercise control over the policy and operations of the Controlled Affiliate.
Amended June 20, 2019
-4-

-- 374 of 533 --

In addition, the Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control
and ownership by Sponsoring Plan must be direct or, if indirect, solely through affiliates that are licensed
to use marks owned by BCBSA, Further, the Participating Plan as defined in Exhibit B-2 and the
Sponsoring Plan shall execute the Addendum to Controlled Affiliate License Agreement attached hereto
as Exhibit B-2.
Or
(5) With respect to a Controlled Affiliate that is operating as a clinic, absent an alternative method of control
approved in writing by BCBSA, the Sponsoring Plan shall have bonafide operational control over the
Controlled Affiliate as specified in Exhibit A, Standard 1 (E) and the Guidelines to Administer Standard 1
(E). In addition, if the clinic is for-profit, the Sponsoring Plan shall own at least 50% of the Controlled
Affiliate and prevent any change in the articles of incorporation, bylaws or other establishing documents
of the Controlled Affiliate with which it does not concur.
Or
(6) With respect to any Plan affiliation(s) entered into after June 15, 2023, the Controlled Affiliate has entered
into a contractual agreement with the Sponsoring Plan that meets the criteria set forth in Exhibit A,
Standard 1(F) and the Guidelines to Administer Standard 19F) and Protocol for Determining Automatic
Transfer of Primary License Agreement Pursuant to Contractual Control.
Amended as of June 15, 2023
-5-

-- 375 of 533 --

3. FOR-PROFIT, PUBLICLY TRADED LICENSEES
A. The Controlled Affiliate may operate as a for-profit publicly traded company on the following conditions:
(1) The Controlled Affiliate shall discharge all responsibilities which it has to the Association and to other
Plans by virtue of this Agreement.
(2) The Controlled Affiliate shall provide 90 days advance written notice to BCBSA prior to the initial filing
with the SEC.
(3) The Controlled Affiliate shall not use the Licensed Marks and Name, or any derivative thereof, as part of
its legal name or any symbol used to identify the Controlled Affiliate in any securities market. The
Controlled Affiliate shall use the Licensed Marks and Name as part of its trade name within its service
area for the sale, marketing and administration of health care and related services in the service area.
(4) The Controlled Affiliate’s license to use the Licensed Marks and Name shall automatically terminate
effective: (a) thirty days after the Controlled Affiliate knows, or there is an SEC filing indicating that, any
Institutional Investor, has become the Beneficial Owner of securities representing 10% or more of the
voting power of the Controlled Affiliate (“Excess Institutional Voter”), unless
such Excess Institutional Voter shall cease to be an Excess Institutional Voter prior to such automatic
termination becoming effective; (b) thirty days after the Controlled Affiliate knows, or there is an SEC filing
indicating that, any Noninstitutional Investor, other than a Plan or Plans or Controlled Affiliate licensee or
licensees has become the Beneficial Owner of securities representing 5% or more of the voting power of
the Controlled Affiliate (“Excess Noninstitutional Voter”) unless such Excess Noninstitutional Voter shall
cease
to be an Excess Noninstitutional Voter prior to such automatic termination becoming effective; (c) thirty
days after the Controlled Affiliate knows, or there
is an SEC filing indicating that, any Person has become the Beneficial Owner, other than a
Amended as of June 20, 2019
-6-

-- 376 of 533 --

Plan or Plans or Controlled Affiliate licensee or licensees, of 20% or more of the Controlled Affiliate’s then
outstanding common stock or other equity securities which (either by themselves or in combination)
represent an ownership interest of 20% or more pursuant to determinations made under Paragraph 3A(4)
below (“Excess Owner”), unless such Excess Owner shall cease to be an Excess Owner prior to such
automatic termination becoming effective; (d) ten business days after individuals who at the time the
Controlled Affiliate went public constituted the Board of Directors of the Controlled Affiliate (together with
any new directors whose election to the Board was approved by a vote of 2/3 of the directors then still in
office who were directors at the time the Controlled Affiliate went public or whose election or nomination
was previously so approved) (the “Continuing Directors”) cease for any reason to constitute a majority of
the Board of Directors; or (e) ten business days after the Controlled Affiliate consolidates with or merges
with or into any person or conveys, assigns, transfers or sells all or substantially all of its assets to any
person other than a merger in which the Sponsoring Plan is the surviving entity and immediately after
which merger, no person is an Excess Institutional Voter, an Excess Noninstitutional Voter or an Excess
Owner: provided that, if requested by the affected Controlled Affiliate in a writing received by BCBSA prior
to such automatic termination becoming effective, the provision of this paragraph 3A(4) may be waived,
in whole or in part, upon the affirmative vote of a majority of the disinterested Plans and a majority of the
total then current weighted vote of the disinterested Plans. Any waiver so granted may be conditioned
upon such additional requirements (including but not limited to imposing new and independent grounds
for termination of this License) as shall be approved by the affirmative vote of a majority of the
disinterested Plans and a majority of the total then current weighted vote of the disinterested Plans. If a
timely waiver request is received, no automatic termination shall become effective until the later of: (1)
the conclusion of the applicable time period specified in paragraphs 3A(4)(a)-(d) above, or (2) the
conclusion of the first Member Plan meeting after receipt of such a waiver request.
In the event that the Controlled Affiliate’s license, or any other license, to use the Licensed Marks and
Name is terminated pursuant to Paragraph 3A(4), the license may be reinstated in BCBSA’s sole discretion
if, within 30 days of the date of such termination, the Controlled Affiliate demonstrates that the Person
referred to in clause (a), (b) or (c) of the preceding paragraph is no longer an Excess Institutional Voter, an
Excess Noninstitutional Voter or an Excess Owner.
(5) The Controlled Affiliate shall not issue any class or series of security other than (i) shares of common
stock having identical terms or options or derivatives of such common stock, (ii) non-voting, non-
convertible debt securities, or (iii) such other securities as the Controlled Affiliate may approve, provided
that BCBSA receives notice at least thirty days prior to the issuance of such securities, including a
description of the terms for such securities, and BCBSA shall have the authority to determine how such
other securities will be counted in determining whether any Person is an Excess Institutional Voter,
Excess Noninstitutional Voter or an Excess Owner.
(6) For purposes of paragraph 3(A) above, the following definitions shall apply:
(i) “Affiliate” and “Associate” shall have the respective meanings ascribed to such terms in Rule 12b-2 of
the General Rules and Regulations under the Securities Exchange Act of 1934, as amended and in
effect on November 17, 1993 (the “Exchange Act”).
-7-

-- 377 of 533 --

(ii) A Person shall be deemed the “Beneficial Owner” of and shall be deemed to “beneficially own” any securities:
(1) which such Person or any of such Person’s Affiliates or Associates beneficially owns, directly or
indirectly;
(2) which such Person or any of such Person’s Affiliates or Associates has (A) the right to acquire
(whether such right is exercisable immediately or only after the passage of time) pursuant to
any agreement, arrangement or understanding, or upon the exercise of conversion rights,
exchange rights, warrants or options, or
otherwise; or (B) the right to vote pursuant to any agreement, arrangement or understanding;
provided, however, that a Person
shall not be deemed the Beneficial Owner of, or to beneficially own, any security if the
agreement, arrangement or understanding to vote such security (1) arises solely from a
revocable proxy or consent given to such Person in response to a public proxy or consent
solicitation made pursuant to, and in accordance with,the applicable rules and regulations
promulgated under the Exchange Act and (2)
is not also then reportable on Schedule 13D under the Exchange
Act (or any comparable or successor report); or
(3) which are beneficially owned, directly or indirectly, by any other Person (or any Affiliate or
Associate thereof) with which such Person (or any of such Person’s Affiliates or Associates) has
any
agreement, arrangement or understanding (other than customary agreements with and between
underwriters and selling group members with respect to a bona fide public offering of securities)
relating to the acquisition, holding, voting (except to the extent contemplated by the proviso to
(ii)2(B) above) or disposing of any securities of the Controlled Affiliate.
Notwithstanding anything in this definition of Beneficial Ownership to the contrary, the phrase
“then outstanding”, when used with reference to a Person’s Beneficial Ownership of securities
of the Controlled Affiliate, shall mean the number of such securities then issued and outstanding
together with the number of such securities not then actually issued and outstanding which such
Person would
be deemed to own beneficially hereunder.
Amended as of March 26, 2015
-8-

-- 378 of 533 --

(iii) A Person shall be deemed an “Institutional Investor” if (but only if) such Person (i) is an entity or
group identified in the SEC’s Rule 13d-1(b)(1)(ii) as constituted on June 1, 1997, and (ii) every filing
made by such Person with the SEC under Regulation 13D-G (or any successor Regulation) with
respect to such Person’s Beneficial Ownership of Plan securities shall have contained a
certification identical to the one required by item 1 of SEC Schedule 13G as constituted on June 1,
1997.
(iv) “Noninstitutional Investor” means any Person who is not an Institutional Investor.
(v) “Person” shall mean any individual, firm, partnership, corporation, trust, association, joint venture or
other entity, and shall include any successor (by merger or otherwise) of such entity.
4. SERVICE MARK USE
A. Controlled Affiliate recognizes the importance of a comprehensive national network of independent BCBSA
licensees which are committed to strengthening the Licensed Marks and Name. The Controlled Affiliate further
recognizes that its actions within its Service Area may affect the value of the Licensed Marks and Name
nationwide.
B. Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and Name, including
but not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks and
Name and shall comply with such rules (generally applicable to Controlled Affiliates licensed to use the
Licensed Marks and Name) relative to service mark use, as are issued from time-to-time by BCBSA.
Controlled Affiliate recognizes and agrees that all use of the Licensed Marks and Name by Controlled Affiliate
shall inure to the benefit of BCBSA.
C. Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in a manner that transfers or
is intended to transfer in the Service Area the goodwill associated therewith to another mark or name, nor may
Controlled Affiliate engage in activity that may dilute or tarnish the unique value of the Licensed Marks and
Name.
D. If Controlled Affiliate meets the standards of 2E(1) but not 2E(2) above and any of Controlled Affiliate's
advertising or promotional material is reasonably determined by BCBSA and/or the Plan to be in contravention
of rules and regulations governing the use of the Licensed Marks and Name, Controlled Affiliate shall for ninety
(90) days thereafter obtain prior approval from BCBSA of advertising and promotional efforts using the
Licensed Marks and Name, approval or disapproval thereof to be forthcoming within five (5) business days of
receipt of same by BCBSA or its designee. In all advertising and promotional efforts, Controlled Affiliate shall
observe the Service Area limitations applicable to Plan.
Amended as of March 26, 2015
-9-

-- 379 of 533 --

E. Notwithstanding any other provision in the Plan’s License Agreement with BCBSA or in this Agreement,
Controlled Affiliate shall use its best efforts to promote and build the value of the Licensed Marks and Name.
5. SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell, encumber or mortgage, by
operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the sole option of
Plan or BCBSA. This Agreement and all rights and duties hereunder are personal to Controlled Affiliate.
6. INFRINGEMENT
Controlled Affiliate shall promptly notify Plan and Plan shall promptly notify BCBSA of any suspected acts of
infringement, unfair competition or passing off that may occur in relation to the Licensed Marks and Name.
Controlled Affiliate shall not be entitled to require Plan or BCBSA to take any actions or institute any proceedings to
prevent infringement, unfair competition or passing off by third parties. Controlled Affiliate agrees to render to Plan
and BCBSA, without charge, all reasonable assistance in connection with any matter pertaining to the protection of
the Licensed Marks and Name by BCBSA.
7. LIABILITY INDEMNIFICATION
Controlled Affiliate and Plan hereby agree to save, defend, indemnify and hold BCBSA harmless from and against all
claims, damages, liabilities and costs of every kind, nature and description (except those arising solely as a result of
BCBSA's negligence) that may arise as a result of or related to: (i) Controlled Affiliate's rendering of services under
the Licensed Marks and Name; or (ii) the activities of any hospital, medical group, clinic or other provider of health
services that is owned or controlled directly or indirectly by Plan or Controlled Affiliate.
8. LICENSE TERM
A. Except as otherwise provided herein, the license granted by this Agreement shall remain in effect for a period of
one (1) year and shall be automatically extended for additional one (1) year periods unless terminated
pursuant to the provisions herein.
B. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further
action by any party or entity in the event that: (i) the Plan ceases to be authorized to use the Licensed Marks
and Name; or (ii) pursuant to Paragraph 15(a)(x) of the Blue Cross License Agreement the Plan ceases to be
authorized to use the Licensed Names and Marks in the geographic area served by the Controlled Affiliate
provided, however, that if the Controlled Affiliate is serving more than one State or portions thereof, the
termination of this Agreement shall be
Amended as of March 26, 2015
-10-

-- 380 of 533 --

limited to the State(s) or portions thereof in which the Plan’s license to use the Licensed Marks and Names is
terminated. By not appealing or challenging such regulatory action within the time prescribed by law or
regulation, and in any event no later than 120 days after such action is taken, a Plan shall be deemed to have
exhausted its rights to appeal or challenge, and automatic termination shall proceed.
C. Notwithstanding any other provision of this Agreement, this license to use the Licensed Marks and Name may
be forthwith terminated by the Plan or the affirmative vote of the majority of the Board of Directors of BCBSA
present and voting at a special meeting expressly called by BCBSA for the purpose on ten (10) days written
notice to the Plan advising of the specific matters at issue and granting the Plan an opportunity to be heard
and to present its response to the Board for: (1) failure to comply with any applicable minimum capital or
liquidity requirement under the quality control standards of this Agreement; or (2) failure to comply with the
"Organization and Governance" quality control standard of this Agreement; or (3) impending financial
insolvency; or (4) for a Smaller Controlled Affiliate (as defined in Exhibit A), failure to comply with any of the
applicable requirements of Standards 2, 3, 4, 5 or 7 of attached Exhibit A; or (5) the pendency of any action
instituted against the Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking
appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business or
seeking the declaration or establishment of a trust for any of its property or business, unless this Controlled
Affiliate License Agreement has been earlier terminated under paragraph 8(E); or (6) failure by a Controlled
Affiliate that meets the standards of 2E(1) but not 2E(2) above to obtain BCBSA's written consent to a change
in the identity of any owner, in the extent of ownership, or in the identity of any person or entity with the
authority to select or appoint members or board members, provided that as to publicly traded Controlled
Affiliates this provision shall apply only if the change affects a person or entity that owns at least 5% of the
Controlled Affiliate's stock before or after the change; or (7) such other reason as is determined in good faith
immediately and irreparably to threaten the integrity and reputation of BCBSA, the Plans, any other licensee
including Controlled Affiliate and/or the Licensed Marks and Name.
D. Except as otherwise provided in Paragraphs 8(B), 8(C) or 8(E) herein, should Controlled Affiliate fail to comply
with the provisions of this Agreement and not cure such failure within thirty (30) days of receiving written notice
thereof (or commence a cure within such thirty day period and continue diligent efforts to complete the cure if
such curing cannot reasonably be completed within such thirty day period) BCBSA or the Plan shall have the
right to issue a notice that the Controlled Affiliate is in a state of noncompliance. If a state of noncompliance as
aforesaid is undisputed by the Controlled Affiliate or is found to exist by a mandatory dispute resolution panel
and is uncured as provided above, BCBSA shall have the right to seek judicial enforcement of the Agreement or
to issue a notice of termination thereof. Notwithstanding any other provisions of this Agreement, any disputes
as to the termination of this License pursuant to Paragraphs 8(B), 8(C) or 8(E) of this Agreement shall not be
subject to mediation and mandatory dispute resolution. All other disputes between BCBSA, the Plan and/or
Controlled Affiliate shall be submitted promptly to mediation and mandatory dispute
Amended as of March 26, 2015
-11-

-- 381 of 533 --

resolution. The mandatory dispute resolution panel shall have authority to issue
orders for specific performance and assess monetary penalties. Except, however, as provided in Paragraphs 8(B) and 8(E)
of this Agreement, this license to use the Licensed Marks and Name may not be finally terminated for any reason without
the affirmative vote of a majority of the present and voting members of the Board of Directors of BCBSA.
E. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately
terminate without any further action by any party or entity in the event that:
(1) Controlled Affiliate shall no longer comply with item 2(E) above;
(2) Appropriate dues, royalties and other payments for Controlled Affiliate pursuant to paragraph 10 hereof, which are the
royalties for this License Agreement, are more than sixty (60) days in arrears to BCBSA; or
(3) Any of the following events occur: (i) a voluntary petition shall be filed by
Controlled Affiliate seeking bankruptcy, reorganization, arrangement with
creditors or other relief under the bankruptcy laws of the United States or any other law governing insolvency or
debtor relief, or (ii) an involuntary petition or proceeding shall be filed against Controlled Affiliate seeking bankruptcy,
reorganization, arrangement with creditors or other relief under the bankruptcy laws of the United States or any other
law governing insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by
Controlled Affiliate or is not dismissed within sixty (60) days of the date upon which the petition or other document
commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order for relief is entered against
Controlled Affiliate in any case under the bankruptcy laws of the United States, or Controlled Affiliate is adjudged
bankrupt or insolvent as those terms are defined in the Uniform Commercial Code as enacted in the State of Illinois
by any court of competent jurisdiction, or (iv) Controlled Affiliate makes a general assignment of its assets for the
benefit of creditors, or (v) any government or any government official, office, agency, branch, or unit assumes control
of Controlled Affiliate or delinquency proceedings (voluntary or involuntary) are instituted, or (vi) an action is brought
by Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the appointment of a trustee, interim
trustee, receiver or other custodian for any of its property or business, or (vii) an action is instituted by any
governmental entity or officer against Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking
the appointment of a trustee, interim trustee, receiver or other custodian for any
of its property or business and such action is consented to or acquiesced in by Controlled Affiliate or is not
dismissed within one hundred thirty (130) days of the date upon which the pleading or other document
commencing the action is served upon the Controlled Affiliate, provided that if the action is stayed or its
prosecution is enjoined, the one hundred thirty (130) day period is tolled for the duration of the stay or
injunction, and provided further, that the Association’s Board of Directors may toll or extend the 130 day
period at any time prior to its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any
of Controlled Affiliate's property or business is appointed or the Controlled Affiliate is ordered dissolved or
liquidated. Notwithstanding any other provision of this Agreement, a declaration or a request for declaration
of the existence of a trust over any of the Controlled Affiliate’s property or business shall not in itself be
deemed to
Amended as of March 26, 2015
-12-

-- 382 of 533 --

constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of
subparagraphs 8(E)(3)(vii) and (viii) of this
Agreement.
(4) The for-profit, publicly traded Controlled Affiliate is terminated pursuant to Paragraph 3A(4) of this
Agreement. In which case, the licenses of any controlled Affiliates directly or indirectly owned by the
terminated for profit, publicly traded Controlled Affiliate also shall immediately terminate as provided for in
paragraph 3A(4) of this Agreement
F. Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately
discontinue all use of the Licensed Marks and Name, including any use in its trade name.
G. Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its customers that it is no
longer a licensee of BCBSA and, if directed by the Association’s Board of Directors, shall provide instruction on
how the customer can contact BCBSA or a designated licensee to obtain further information on securing
coverage. The notification required by this paragraph shall be in writing and in a form approved by BCBSA. The
BCBSA shall have the right to audit the terminated entity's books and records to verify compliance with this
paragraph.
H. In the event this Agreement terminates pursuant to 8(b) hereof, or in the event the Controlled Affiliate is a Larger
Controlled Affiliate (as defined in Exhibit A), upon termination of this Agreement, the provisions of Paragraph
8.G. shall not apply and the following provisions shall apply, except that, in the event of a partial termination
of this Agreement pursuant to Paragraph 8(B)(ii) of this Agreement, the notices, national account listing,
payment, and audit right listed below shall be applicable solely with respect to the geographic area for which
the Plan’s license to use the Licensed Names and Marks is terminated:
(1) The Controlled Affiliate shall send a notice through the U.S. mails, with first class postage affixed, to all
individual and group customers, providers, brokers and agents of products or services sold, marketed,
underwritten or administered by the Controlled Affiliate under the Licensed Marks and Name. The form
and content of the notice shall be specified by BCBSA and shall, at a minimum, notify the recipient of the
termination of the license, the consequences thereof, and instructions for obtaining alternate products or
services licensed by BCBSA, subject to any conflicting state law and state regulatory requirements. This
notice shall be mailed within 15 days after termination.
(2) The Controlled Affiliate shall deliver to BCBSA within five days of a request by BCBSA a listing of national
accounts in which the Controlled Affiliate is involved (in a control, participating or servicing capacity),
identifying the national account and the Controlled Affiliate’s role therein.
Amended as of March 26, 2015
-13-

-- 383 of 533 --

(3) Unless the cause of termination is an event respecting BCBSA stated in paragraph 15(a) or (b) of the Plan’s
license agreement with BCBSA to use the Licensed Marks and Name, the Controlled Affiliate, the Plan,
and any other Licensed Controlled Affiliates of the Plan shall be jointly liable for payment to BCBSA of an
amount equal to the Re-Establishment Fee (described below) multiplied by the number of Licensed
Enrollees of the Controlled Affiliate; provided that if any other Plan is permitted by BCBSA to use marks or
names licensed by BCBSA in the Service Area established by this Agreement, the Re-Establishment Fee
shall be multiplied by a fraction, the numerator of which is the number of Licensed Enrollees of the
Controlled Affiliate, the Plan, and
any other Licensed Controlled Affiliates and the denominator of which is the total number of Licensed
Enrollees in the Service Area.
The Re-Establishment Fee shall be indexed to a base fee of $80. The Re- Establishment Fee through
December 31, 2005 shall be $80. The Re- Establishment Fee for calendar years after December 31, 2005
shall be adjusted on January 1 of each calendar year up to and including January 1, 2010 and shall be the
base fee multiplied by 100% plus the cumulative percentage increase or decrease in the Plans’ gross
administrative expense (standard BCBSA definition) per Licensed Enrollee since December 31, 2004. The
adjustment shall end on January 1, 2011, at which time the Re- Establishment Fee shall be fixed at the
then-current amount and no longer automatically adjusted. For example, if the Plans’ gross administrative
expense per Licensed Enrollee was $278.60, $285.00 and $290.00 for calendar year end 2004, 2005 and
2006, respectively, the January 1,2007 Re-Establishment Fee would be $83.27 (100% of base fee plus
$1.84 for calendar year 2005 and $1.43 for calendar year 2006. Licensed Enrollee means each and every
person and covered dependent who is enrolled as an individual or member of a group receiving products
or services sold, marketed or administered under marks or names licensed by BCBSA as determined at
the earlier of (i) the end of the last fiscal year of the terminated entity which ended prior to termination or
(ii) the fiscal year which ended before any transactions causing the termination began. Notwithstanding
the foregoing, the amount payable pursuant to this subparagraph H. (3) shall be due only to the extent
that, in BCBSA’s opinion, it does not cause the net worth of the Controlled Affiliate, the Plan or any other
Licensed Controlled Affiliates of the Plan to fall below 100% of the Health Risk-Based Capital formula, or
its equivalent under any successor formula, as set forth in the applicable financial responsibility standards
established by BCBSA (provided such equivalent is approved for purposes of this sub paragraph by the
affirmative vote of three-fourths of the Plans and three-fourths of the total then current weighted vote of all
the Plans); measured as of the date of termination, and adjusted for the value of any transactions not
made in the ordinary course of business. This payment shall not be due in connection with transactions
exclusively by or among Plans or their affiliates, including reorganizations, combinations or mergers,
where the BCBSA Board of Directors determines that the license termination does not result in a material
diminution in the number of Licensed Enrollees or the extent of their coverage. At least 50% of the Re-
Establishment Fee shall be awarded to the Plan (or Plans) that receive the new license(s) for the service
area(s) at issue; provided, however, that such award shall not become due or payable until all disputes, if
any, regarding the amount of and BCBSA’s right to such Re-Establishment Fee have been finally resolved;
and provided
Amended as of March 26, 2015
-14-

-- 384 of 533 --

further that the award shall be based on the final amount actually received by BCBSA. The Board of
Directors shall adopt a resolution which it may amend from time to time that shall govern BCBSA’s use of
its portion of the award. In the event that the Controlled Affiliate’s license is reinstated by BCBSA or is
deemed to have remained in effect without interruption by a court of competent jurisdiction, BCBSA shall
reimburse the Controlled Affiliate (and/or the Plan or its other Licensed Controlled Affiliates, as the case
may be) for payments made under this subparagraph 8.H.(3) only to the extent that such payments
exceed the amounts due to BCBSA pursuant to paragraph 8.M. and any cost associated with
reestablishing the Service Area, including any payments made by BCBSA to a Plan or Plans (or their
Licensed Controlled Affiliates) for purposes of replacing the Controlled Affiliate.
(4) BCBSA shall have the right to examine and audit and/or hire at terminated entity’s expense a third party
auditor to examine and audit the books and records of the Controlled Affiliate, the Plan, and any other
Licensed Controlled Affiliates of the Plan to verify compliance with this paragraph 8.H.
(5) Subsequent to termination of this Agreement, the terminated entity and its affiliates, agents, and
employees shall have an ongoing and continuing obligation to protect all BCBSA and Blue Licensee data
that was acquired or accessed during the period this Agreement was in force, including but not limited to
all confidential processes, pricing, provider, discount and other strategic and competitively sensitive
information (“Blue Information”) from disclosure, and shall not, either alone or with another entity, disclose
such Blue Information or use it in any manner to compete without the express written permission of
BCBSA.
(6) As to a breach of 8.H.(1), (2), (3), (4) or (5) the parties agree that the
obligations are immediately enforceable in a court of competent jurisdiction. As to a breach of 8.H.(1), (2)
or (4) by the Controlled Affiliate, the parties agree there is no adequate remedy at law and BCBSA is
entitled to obtain specific performance.
I. This Agreement shall remain in effect until terminated by the Controlled Affiliate or the Plan upon not less than
eighteen (18) months written notice to the Association or upon a shorter notice period approved by BCBSA in
writing at its sole discretion, or until terminated as otherwise provided herein. The Plan’s right to terminate
without cause upon such notice is unfettered and may be exercised in the Plan’s sole discretion.
J. In the event the Controlled Affiliate is a Smaller Controlled Affiliate (as defined in Exhibit A), the Controlled
Affiliate agrees to be jointly liable for the amount described in H.3.and M. hereof upon termination of the
BCBSA license agreement of any Larger Controlled Affiliate of the Plan.
K. BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of competent jurisdiction
from entry into any transaction which would result in a termination of this Agreement unless the Plan’s license
from BCBSA to use the Licensed Marks and Names has been terminated pursuant to 10(d) of the Plan’s
license agreement upon the required 18 months written notice.
Amended as March 26, 2015
-15-

-- 385 of 533 --

L. BCBSA acknowledges that it is not the owner of assets of the Controlled Affiliate.
M. In the event that the Plan has more than 50 percent voting control of the Controlled Affiliate under Paragraph
2(E)(2) above and is a Larger Controlled Affiliate (as defined in Exhibit A), then the vote called for in
Paragraphs 8(C) and 8(D) above shall require the affirmative vote of three-fourths of the Plans and three-
fourths of the total then current weighted vote of all the Plans.
N. In the event this Agreement terminates and is subsequently reinstated by BCBSA or is deemed to have
remained in effect without interruption by a court of competent jurisdiction, the Controlled Affiliate, the Plan,
and any other Licensed Controlled Affiliates of the Plan shall be jointly liable for reimbursing BCBSA the
reasonable costs incurred by BCBSA in connection with the termination and the reinstatement or court action,
and any associated legal proceedings, including but not limited to: outside legal fees, consulting fees, public
relations fees, advertising costs, and costs incurred to develop, lease or establish an interim provider network.
Any amount due to BCBSA under this subparagraph may be waived in whole or in part by the BCBSA Board of
Directors in its sole discretion.
9. DISPUTE RESOLUTION
The parties agree that any disputes between them or between or among either of them and one or more Plans or
Controlled Affiliates of Plans that use in any manner the Blue Shield and Blue Shield Marks and Name are subject
to the Mediation and Mandatory Dispute Resolution process attached to and made a part of Plan's License from
BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-to-time, which documents are
incorporated herein by reference as though fully set forth herein.
10. LICENSE FEE
Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth in
Exhibit C.
11. JOINT VENTURE
Nothing contained in the Agreement shall be construed as creating a joint venture,
partnership, agency or employment relationship between Plan and Controlled Affiliate or between either and
BCBSA.
12. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and
shall be addressed in duplicate to the last known address of each other party, marked respectively to the attention
of its President and, if any, its General Counsel.
Amended as of March 26, 2015
-16-

-- 386 of 533 --

13. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This
Agreement may only be amended by the affirmative vote of three-fourths of the Plans and three-fourths of the total
then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.
14. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such findings shall in no way
affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for
any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of
this Agreement.
15. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or any other licensee
of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or
default in performance of said terms, covenants or conditions.
15A. 	VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the Blue
Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes
equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes
(if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all
questions requiring an affirmative three-fourths weighted vote of the Plans, voting shall occur pursuant to BCBSA’s
Bylaws.
Amended as of June 15, 2023
-17-

-- 387 of 533 --

THIS PAGE IS INTENTIONALLY BLANK.

-- 388 of 533 --

16. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with,
the laws of the State of Illinois.
17. HEADINGS
The headings inserted in this agreement are for convenience only and shall have no
bearing on the interpretation hereof.
IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed and effective as of the date of last
signature written below.
Controlled Affiliate:
By:______________________________________
Date:____________________________________
Plan:
By:______________________________________
Date:_____________________________________
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:______________________________________
Date:____________________________________
Amended as of March 26, 2015
-18-

-- 389 of 533 --

EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
November 2023
PREAMBLE
For purposes of definition:
• A "smaller Controlled Affiliate:" (1) comprises less than fifteen percent (15%) of Sponsoring Plan's and its licensed
Controlled Affiliates' total member enrollment (as reported on the BCBSA Quarterly Enrollment Report, excluding rider
and freestanding coverage, and
treating an entity seeking licensure as licensed);* or (2) underwrites the indemnity portion of workers’ compensation
insurance and has total premium revenue less than 15 percent of
the Sponsoring Plan’s net subscription revenue.
• A "larger Controlled Affiliate" comprises fifteen percent (15%) or more of Sponsoring Plan's and its licensed Controlled
Affiliates' total member enrollment (as reported on the BCBSA Quarterly Enrollment Report, excluding rider and
freestanding coverage, and treating an entity seeking licensure as licensed.)*
Changes in Controlled Affiliate status:
If any Controlled Affiliate's status changes regarding: its Plan ownership level, its risk acceptance or direct delivery of
medical care, the Controlled Affiliate shall notify BCBSA within thirty (30) days of such occurrence in writing and come into
compliance with the applicable standards within six (6) months.
If a smaller Controlled Affiliate’s health and workers’ compensation administration business reaches or surpasses fifteen
percent (15%) of the total member enrollment of the Sponsoring Plan and licensed Controlled Affiliates, the Controlled
Affiliate shall:
Amended as of September 19, 2014
-19-

-- 390 of 533 --

EXHIBIT A (continued)
1. Within thirty (30) days, notify BCBSA of this fact in writing, including evidence that the Controlled Affiliate meets the
minimum liquidity and capital (BCBSA “Health Risk-Based Capital (HRBC)” as defined by the NAIC and state-
established minimum reserve) requirements of the larger Controlled Affiliate Financial Responsibility standard; and
2. Within six (6) months after reaching or surpassing the fifteen percent (15%) threshold, demonstrate compliance with all
license requirements for a larger Controlled Affiliate.
If a Controlled Affiliate that underwrites the indemnity portion of workers’ compensation
insurance receives a change in rating or proposed change in rating, the Controlled Affiliate shall notify BCBSA within 30
days of notification by the external rating agency.
*For purposes of this calculation,
The numerator equals:
Applicant Controlled Affiliate's member enrollment, as defined in BCBSA's Quarterly Enrollment Report (excluding rider and
freestanding coverage).
The denominator equals:
Numerator PLUS Sponsoring Plan and all other licensed Controlled Affiliates' member
enrollment, as reported in BCBSA's Quarterly Enrollment Report (excluding rider and
freestanding coverage).
Amended as of September 19, 2014
-20-

-- 391 of 533 --

EXHIBIT A (continued)
STANDARDS FOR LICENSED CONTROLLED AFFILIATES
Each licensed controlled affiliate shall be subject to certain standards as determined below:
1. What percent of the licensed controlled affiliate is controlled by the Sponsoring Plan and other Plans?
More than 50% by
Sponsoring Plan
ò
Standard 1A, 4
Or
Contractual Control
ò
Standard 1F, 4
50% by Sponsoring
Plan
ò
Standard 1B, 4
100% Plan Control but
less than 50%
Sponsoring Plan Control
and it offers solely
Medicaid, Medicare
Advantage PPO,
Medicare Advantage
HMO and/or Special
Need Plans products and
services
ò
Standard 1C, 4
100% Sponsoring Plan
control and on a Blue-
branded basis, it only
offers Basic Medicare
Part D Prescription Drug
Plan product
ò
Standard 1D, 4
At least 50% by
Sponsoring Plan or
operational Control by
Sponsoring Plan and it
solely operates as a
Clinic as defined in
Standard 1E.
ò
Standard 1E, 4
IN ADDITION,
2. Is risk being assumed?
Yes 	No
÷ 	ò 	ø 	÷ 	ò
Controlled Affiliate
underwrites any
indemnity portion of
workers’ compensation
insurance
Controlled Affiliate
comprises < 15% of total
member enrollment of
Sponsoring Plan and its
licensed affiliates, and
does not underwrite the
indemnity portion of
workers’ compensation
insurance
Controlled Affiliate
comprises > 15% of total
member enrollment of
Sponsoring Plan and its
licensed affiliates, and
does not underwrite the
indemnity portion of
workers’ compensation
insurance
Controlled Affiliate comprises
< 15% of total member
enrollment of Sponsoring
Plan and its licensed affiliates
Controlled Affiliate
comprises > 15% of total
member enrollment of
Sponsoring Plan and its
licensed affiliates
ò 	ò 	ò 	ò 	ò
Standards 7A-7E, 11 	Standard 2 (Guidelines
1.1, 1.2) and Standard 11
Standard 6H
Standard 2 (Guidelines
1.1,1.3)
and Standard 11
Standard 6H

-- 392 of 533 --

IN ADDITION,
3. Is medical care being directly provided as a staff model HMO?
Yes 	No
ò 	ò
Standard 3A 	Standard 3B
Amended as of June 15, 2023
-21-

-- 393 of 533 --

EXHIBIT A (continued)
STANDARDS FOR LICENSED CONTROLLED AFFILIATES
Each licensed controlled affiliate shall be subject to certain standards as determined below:
IN ADDITION,
4. Is the licensed controlled affiliate operating as a Clinic, as defined in Standard 1(E)?
Yes
ò
Standard 3C and Standard 2, 1.4 (if organized as a health plan that also operates as a Clinic
5. If the controlled affiliate has health or workers’ compensation administration business, does such business comprise 15% or more of the total
member enrollment of Plan and its licensed Controlled Affiliates?
Yes 	No
ò 	÷ 	÷ 	ø
Standards 6A-6J 	Controlled Affiliate is not a
former primary licensee and
is not subject to Standard
1(C)
Controlled Affiliate is a former
primary licensee
Controlled Affiliate is not a
former primary licensee and is
subject to Standard 1(C)
ò 	ò 	ò
Standards 5,8,9B,10,11 	Standards 5,8,9A,10,11
Standards 5,8,9B,11

-- 394 of 533 --

Amended as of June 20, 2019
-22-

-- 395 of 533 --

EXHIBIT A (continued)
Standard 1 - Organization and Governance
1A.) The Standard for more than 50% Plan control is:
A Controlled Affiliate shall be organized and operated in such a manner that a Plan authorized to use the Licensed
Marks in the Service Area of the Controlled Affiliate pursuant to the separate Primary License Agreement with
BCBSA has the legal authority, directly or indirectly through wholly-owned subsidiaries: 1) to select members of the
Controlled Affiliate’s governing body having more than 50% voting control thereof; and 2)
to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the
Controlled Affiliate with which the Sponsoring Plan do not concur; and 3) to exercise control over the policy and
operations of the Controlled Affiliate. In addition, the Sponsoring Plan directly or indirectly through wholly-owned
subsidiaries shall own more than 50% of any for-profit Controlled Affiliate.
1B.) The Standard for 50% Plan control is:
A Controlled Affiliate shall be organized and operated in such a manner that a Plan authorized to use the Licensed
Marks in the Service Area of the Controlled Affiliate pursuant to the separate Primary License Agreement with
BCBSA has the legal authority, directly or indirectly through wholly-owned subsidiaries:
1) to select members of the Controlled Affiliate’s governing body having not less than
50% voting control thereof; and
2) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the
Controlled Affiliate with which the Sponsoring Plan do
not concur; and
3) 	to exercise control over the policy and operations of the Controlled Affiliate at least equal to that exercised by
persons or entities (jointly or individually) other than the Sponsoring Plan.
Amended September 19, 2014
-23-

-- 396 of 533 --

EXHIBIT A (continued)
Notwithstanding anything to the contrary in 1) through 3) hereof, the Controlled Affiliate’s establishing or governing
documents must also require written approval by the Sponsoring
Plan before the Controlled Affiliate can:
• 	change the geographic area in which it operates
• 	change its legal and/or trade names
• 	change any of the types of businesses in which it engages
• 	create, or become liable for by way of guarantee, any indebtedness, other than indebtedness arising in
the ordinary course of business
• 	sell any assets, except for sales in the ordinary course of business or sales of equipment no longer useful
or being replaced
• 	make any loans or advances except in the ordinary course of business
• 	enter into any arrangement or agreement with any party directly or indirectly affiliated with any of the
owners or persons or entities with the authority to select or appoint members or board members of the
Controlled Affiliate, other than the Sponsoring Plan or other Plans (excluding owners of stock holdings of
under 5% in a publicly traded Controlled Affiliate)
• 	conduct any business other than under the Licensed Marks and Name
• 	take any action that the Sponsoring Plan or BCBSA reasonably believes will adversely affect the
Licensed Marks and Name.
In addition, the Sponsoring Plan directly or indirectly through wholly-owned subsidiaries
shall own at least 50% of any for-profit Controlled Affiliate.
1C.) The Standard for a Controlled Affiliate that offers solely Medicaid, Medicare Advantage PPO, Medicare Advantage
HMO and/or Special Need Plans products and service and has100% Plan control but less than 50% Sponsoring
Plan Control:
A Controlled Affiliate shall be organized and operated in such a manner that (i) it offers solely Medicaid, Medicare
Advantage PPO, Medicare Advantage HMO and/or Special Need Plans products and services; and (ii) a Plan
authorized to use the Licensed Marks in the Service Area of the Controlled Affiliate pursuant to the separate Primary
License Agreement with BCBSA (the “Sponsoring Plan,) has the legal authority together with Other Plans:
Amended September 27, 2018
-24-

-- 397 of 533 --

EXHIBIT A (continued)
1) to select all members of the Controlled Affiliate’s governing body; and
2) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of
the Controlled Affiliate; and
3) to exercise control over the policy and operations of the Controlled Affiliate.
In addition, the Sponsoring Plan and such other Plans shall own 100% of any for-profit Controlled Affiliate, with the
Sponsoring Plan and such other Plans each having an ownership interest. Such 100% control and ownership by
Plans shall be direct or, if indirect, solely through affiliates that are licensed to use marks owned by BCBSA.
Further, the Sponsoring Plan and such other Plans shall execute the Addendum to Controlled Affiliate License.
1D). The Standard for a Controlled Affiliate that on a Blue-branded basis, only offers a Basic Medicare Part D Prescription
Drug product and has 100% Plan control is:
A Controlled Affiliate shall be organized and operated in such a manner that (i) on a Blue- branded basis, it only
offers a Basic Medicare Part D Prescription Drug product; and (ii) the Sponsoring Plan has the legal authority:
1) to select all members of the Controlled Affiliate’s governing body; and
2) to prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of
the Controlled Affiliate; and
3) to exercise control over the policy and operations of the Controlled Affiliate.
In addition, the Sponsoring Plan shall own 100% of any for-profit Controlled Affiliate. Such 100% control and
ownership by Sponsoring Plan must be direct or, if indirect, solely through affiliates that are licensed to use marks
owned by BCBSA.
Further, the Sponsoring Plan and Participating Plan shall execute the Addendum to Controlled Affiliate License.
1E). The Standard for a Controlled Affiliate that operates as a Clinic and the Sponsoring Plan has control of the Clinic is:
A Controlled Affiliate shall be organized in such a manner that it operates as a Clinic and Sponsoring Plan exercises
operational control over the Controlled Affiliate.
In addition, if the Clinic is for-profit, the Sponsoring Plan shall own at least 50% of the Controlled Affiliate and prevent
any change in the articles of incorporation, bylaws or other establishing or governing documents of the Controlled
Affiliate.
25-

-- 398 of 533 --

EXHIBIT A (continued)
1F). The Standard for possessing contractual control over a Controlled Affiliate is:
With respect to any Plan affiliations entered into after June 15, 2023, a Primary Licensee has entered into a
contractual agreement where:
(i) It has outsourced 50% or more of the expenditures for overall management and strategic direction to another
Primary Licensee, or
(ii) A regulatory agency has determined that a change of control or a corporate affiliation has occurred, or
(iii) Officers of a Primary Licensee perform roles for another Primary Licensee.
(This excludes Controlled Affiliates pursuant to paragraphs 2(a)(C) and 2(a)(D) of the Primary License Agreement).
The Primary License Agreement will automatically transfer, and the Plan will automatically become a Controlled
Affiliate of the other Primary Licensee unless otherwise approved in writing by BCBSA.
Amended June 15, 2023
-26-

-- 399 of 533 --

EXHIBIT A (continued)
Standard 2 - Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its
contractual obligations to its customers. If a risk-assuming Controlled Affiliate ceases operations for any reason, Blue
Cross and/or Blue Cross Plan coverage will be offered to all Controlled Affiliate subscribers without exclusions, limitations
or conditions based on health status. If a nonrisk-assuming Controlled Affiliate ceases operations for any reason,
Sponsoring Plan will provide for services to its customers. The requirements of the preceding two sentences shall apply
to all lines of business unless a line of business is specially exempted from the requirement(s) by the BCBSA Board of
Directors.
Standard 3 - State Licensure/Certification
3A.) The Standard for a Controlled Affiliate that employs, owns or contracts on a substantially exclusive basis for medical
services is:
A Controlled Affiliate shall maintain unimpaired licensure or certification for its medical care providers to operate
under applicable state laws.
3B.) The Standard for a Controlled Affiliate that does not employ, own or contract on a substantially exclusive basis for
medical services is:
A Controlled Affiliate shall maintain unimpaired licensure or certification to operate under applicable state laws.
3C.) The Standard for a Controlled Affiliate that operates as a Clinic as defined in Standard 1(E) is:
A Controlled Affiliate shall maintain appropriate and unimpaired licensure and certifications.
Standard 4 - Certain Disclosures
A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public statements
of 1) the structure of the Blue Cross and Blue Shield System; and 2) the independent nature of every licensee; and 3) the
Controlled Affiliate's financial condition.
Amended as of June 20, 2019
-27-

-- 400 of 533 --

EXHIBIT A (continued)
Standard 5 - Reports and Records for Certain Smaller Controlled Affiliates
For a smaller Controlled Affiliate that does not underwrite the indemnity portion of workers’ compensation insurance, the
Standard is:
A Controlled Affiliate and/or its Sponsoring licensed Plan shall furnish, on a timely and accurate basis, reports and records
relating to these Standards and the License Agreements between BCBSA and Controlled Affiliate.
Standard 6 - Other Standards for Larger Controlled Affiliates
Standards 6(A) - (I) that follow apply to larger Controlled Affiliates.
Standard 6(A): Board of Directors
A Controlled Affiliate Governing Board shall act in the interest of its Corporation in providing
cost-effective health care services to its customers. A Controlled Affiliate shall maintain a governing Board, which shall
control the Controlled Affiliate, composed of a majority of persons other than providers of health care services, who shall
be known as public members. A public member shall not be an employee of or have a financial interest in a health care
provider, nor be a member of a profession which provides health care services.
Standard 6(B): Responsiveness to Customers
A Controlled Affiliate shall be operated in a manner responsive to customer needs and requirements.
Standard 6(C): Participation in National Programs
A Controlled Affiliate shall effectively and efficiently participate in each national program as from time to time may be adopted
by the Member Plans for the purposes of providing portability of membership between the licensees and ease of claims
processing for customers receiving
benefits outside of the Controlled Affiliate's Service Area.
Amended as of September 19, 2014
-28-

-- 401 of 533 --

EXHIBIT A (continued)
Standard 6(C): Participation in National Programs (continued)
Such programs are applicable to licensees, and include:
1. BlueCard Program;
2. Inter-Plan Teleprocessing System (ITS).
3. National Account Programs;
4. Business Associate Agreement for Blue Cross and Blue Shield Licensees, effective
April 14, 2003; and
5. Inter-Plan Medicare Advantage Program.
Standard 6(D): Financial Performance Requirements
In addition to requirements under the national programs listed in Standard 6C: Participation in National Programs, a
Controlled Affiliate shall take such action as required to ensure its financial performance in programs and contracts of an
inter-licensee nature or where BCBSA is a party.
Standard 6(E): Cooperation with Plan Performance Response Process
A Controlled Affiliate shall cooperate with BCBSA's Board of Directors and its Organization and Governance Committee in
the administration of the Plan Performance Response Process and in addressing Controlled Affiliate performance
problems identified thereunder.
Standard 6(F): Independent Financial Rating
A Controlled Affiliate shall obtain a rating of its financial strength from an independent rating agency approved by
BCBSA's Board of Directors for such purpose.
Standard 6(G): Local Best Efforts
Notwithstanding any other provision in the Plan’s License Agreement with BCBSA or in this License Agreement, during
each year, a Controlled Affiliate shall use its best efforts to promote and build the value of the Blue Shield Mark.
Standard 6(H): Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its
contractual obligations to its customers.
Amended as of April 27, 2021
-29-

-- 402 of 533 --

EXHIBIT A (continued)
Standard 6(I): Reports and Records
A Controlled Affiliate shall furnish to BCBSA on a timely and accurate basis reports and records
relating to compliance with these Standards and the License Agreements between BCBSA and Controlled Affiliate. Such reports
and records are the following:
A) BCBSA Controlled Affiliate Licensure Information Request; and
B) Triennial trade name and service mark usage material, including disclosure material; and
C) Changes in the ownership and governance of the Controlled Affiliate, including changes in
its charter, articles of incorporation, or bylaws, changes in a Controlled Affiliate's Board composition, or changes in the
identity of the Controlled Affiliate's Principal Officers, and changes in risk acceptance, contract growth, or direct
delivery of medical care; and
D) 	Semi-annual “Health Risk-Based Capital (HRBC) Report” as defined by the NAIC, Annual Certified Audit Report,
Insurance Department Examination Report, Annual Statement filed with State Insurance Department (with all
attachments), and
Amended as of November 17, 2011
-30-

-- 403 of 533 --

EXHIBIT A (continued)
Standard 6(J): Control by Unlicensed Entities Prohibited
No Controlled Affiliate shall cause or permit an entity other than a Plan or a Licensed Controlled Affiliate thereof to obtain
control of the Controlled Affiliate or to acquire a substantial portion of
its assets related to licensable services.
Standard 7 - Other Standards for Risk-Assuming Workers’ Compensation Controlled
Affiliates
Standards 7(A) - (E) that follow apply to Controlled Affiliates that underwrite the indemnity portion of workers’
compensation insurance.
Standard 7 (A): Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its
contractual obligations to its customers.
Standard 7(B): Reports and Records
A Controlled Affiliate shall furnish, on a timely and accurate basis, reports and records relating to compliance with these
Standards and the License Agreements between BCBSA and the Controlled Affiliate. Such reports and records are the
following:
A. BCBSA Controlled Affiliate Licensure Information Request; and
B. Triennial trade name and service mark usage materials, including disclosure materials; and
C. Annual Certified Audit Report, Annual Statement as filed with the State Insurance Department (with all
attachments), Annual NAIC’s Risk-Based Capital Worksheets for Property and Casualty Insurers; and
D. Quarterly Estimated Risk-Based Capital for Property and Casualty Insurers, Insurance Department Examination
Report; and
Amended as of November 17, 2011
-31-

-- 404 of 533 --

EXHIBIT A (continued)
E. Notification of all changes and proposed changes to independent ratings within 30 days of receipt and submission of a
copy of all rating reports; and
F. Changes in the ownership and governance of the Controlled Affiliate including changes in its charter, articles of
incorporation, or bylaws, changes in a Controlled Affiliate’s Board composition, Plan control, state license status,
operating area, the Controlled Affiliate’s Principal Officers or direct delivery of medical care.
Standard 7(C): Loss Prevention
A Controlled Affiliate shall apply loss prevention protocol to both new and existing business.
Standard 7(D): Claims Administration
A Controlled Affiliate shall maintain an effective claims administration process that includes all the necessary functions to
assure prompt and proper resolution of medical and indemnity
claims.
Standard 7(E): Disability and Provider Management
A Controlled Affiliate shall arrange for the provision of appropriate and necessary medical and rehabilitative services to
facilitate early intervention by medical professionals and timely and appropriate return to work.
Amended as of November 16, 2000
-32-

-- 405 of 533 --

EXHIBIT A (continued)
Standard 8 - Cooperation with Controlled Affiliate License Performance Response Process Protocol
A Controlled Affiliate and its Sponsoring Plan shall cooperate with BCBSA’s Board of Directors and its Organization and
Governance Committee in the administration of the Controlled Affiliate License Performance Response Process Protocol
(ALPRPP) and in addressing Controlled Affiliate compliance problems identified thereunder.
Standard 9(A) - Participation in National Programs by Smaller Controlled Affiliates that were former Primary
Licensees
A smaller controlled affiliate that formerly was a Primary Licensee shall effectively and efficiently participate in certain
national programs from time to time as may be adopted by Member Plans for the purposes of providing ease of claims
processing for customers receiving benefits outside of the Controlled Affiliate’s service area and be subject to certain
relevant financial and reporting requirements.
A. National program requirements include:
• 	BlueCard Program;
• 	Inter-Plan Teleprocessing System (ITS);
• 	National Account Programs.
B. Financial Requirements include:
• 	Standard 6(D): Financial Performance Requirements and Standard 6(H): Financial Responsibility; or
• 	A financial guarantee covering the Controlled Affiliate’s Inter-Plan Programs obligations in a form, and
from a guarantor, acceptable to BCBSA.
Amended as of November 21, 2014
-33-

-- 406 of 533 --

EXHIBIT A (continued)
Standard 9(A) - Participation in National Programs by Smaller Controlled Affiliates that
were former Primary Licensees
C. Reporting requirements include:
• 	The Semi-annual Health Risk-Based Capital (HRBC) Report.
Amended as of June 13, 2002
-34-

-- 407 of 533 --

Exhibit A (continued)
Standard 9(B) - Participation in National Programs by Smaller Controlled Affiliates
A smaller controlled affiliate shall participate in national programs in accordance with BlueCard and other relevant Policies
and Provisions shall effectively and efficiently participate in national programs from time to time as may be adopted by
Member Plans for the purposes of providing ease of claims processing for customers receiving benefits outside of the
controlled affiliate’s service area and be subject to certain relevant financial and reporting requirements.
A. National program requirements include:
• 	BlueCard Program;
• 	Inter-Plan Teleprocessing System (ITS).
• 	National Account Programs.
B. Financial Requirements include:
• 	Standard 6(D): Financial Performance Requirements and Standard 6(H): Financial Responsibility; or
• 	A financial guarantee covering the Controlled Affiliate’s Inter-Plan Programs obligations in a form, and from a guarantor,
acceptable to BCBSA.
Amended as of June 20, 2013
-35-

-- 408 of 533 --

EXHIBIT A (continued)
Standard 10 - Participation in Inter-Plan Medicare Advantage Program
A smaller controlled affiliate for which this standard applies pursuant to the Preamble section of Exhibit A of the Controlled
Affiliate License Agreement shall effectively and efficiently participate in certain national programs from time to time as may
be adopted by Member Plans for the purposes of providing ease of claims processing for customers receiving benefits
outside of the controlled affiliate’s service area.
National program requirements include:
A. Inter-Plan Medicare Advantage Program.
Standard 11: Participation in Master Business Associate Agreement by Smaller
Controlled Affiliate Licensees
Effective April 14, 2003, all smaller controlled affiliates shall comply with the terms of the Business Associate
Agreement for Blue Cross and Blue Shield Licensees to the extent they perform the functions of a business associate
or subcontractor to a business associate, as defined by the Business Associate Agreement.
Amended as of September 19, 2014
-36-

-- 409 of 533 --

EXHIBIT B-1
ADDENDUM TO CONTROLLED AFFILIATE LICENSE TO BE EXECUTED BY
CONTROLLED AFFILIATES LICENSED UNDER CONTROLLED AFFILIATE LICENSE
STANDARD 1C.
ADDENDUM TO CONTROLLED AFFILIATE LICENSE
This Addendum is made to that certain Blue Shield Controlled Affiliate License Agreement executed by and
among Blue Cross and Blue Shield Association (“Licensor”),
__________________________(“Controlled Affiliate Licensee”) and
__________________________________________(“Sponsoring Plan”) dated the ________day of
___________________, ________(“Agreement”). The parties to this Addendum are Licensor, Controlled Affiliate
Licensee, Sponsoring Plan, and the undersigned other Plans (‘Other Plans”). This Addendum is made and shall be
deemed effective as of the date of the Agreement.
WHEREAS, the Sponsoring Plan asserts that it can serve the Medicaid, Medicare Advantage PPO, Medicare
Advantage HMO and/or Special Need Plans market in its Service Area more efficiently and with less risk through an
enterprise jointly owned and controlled with other Plans than through a wholly owned and Controlled Affiliate Licensee;
WHEREAS, in such circumstance Controlled Affiliate License Standard 1C permits the licensing of a Controlled
Affiliate that is less than 50% owned and controlled by the Sponsoring Plan but which is 100% owned and controlled by
Plans including the Sponsoring Plan, subject to certain conditions;
WHEREAS, one such condition is that the Sponsoring Plan and all such other owning and controlling Plans
enter into this Addendum;
NOW THEREFORE, for good and valuable consideration, including the promises and covenants set forth
herein, the parties agree as follows:
1. This Addendum is limited to [identify product name].
2. The Sponsoring Plan shall participate operationally in Controlled Affiliate’s business that is conducted under the
Licensed Marks. The parties understand that participation may take many forms, one of which should be providing a
network of providers in the Service Area
of the Controlled Affiliate for the Medicaid, Medicare Advantage PPO, Medicare
Advantage HMO and/or Special Need Plans services being offered under the Agreement and being involved in
network development and provider engagement functions.
3. Each of the Other Plans agrees that (i) it will cooperate fully with the Sponsoring Plan and BCBSA as needed to
enable Sponsoring Plan and Controlled Affiliate Licensee to meet their obligations to Licensor under the Agreement
and all associated rules and regulations of Licensor, including the Brand Regulations, (ii) it
-37-

-- 410 of 533 --

will not take any action, either individually or jointly with any of the Other Plans, that would cause Sponsoring Plan or
Controlled Affiliate Licensee to violate the Agreement, and (iii) it will not fail to take any action, either individually or
jointly with any of the Other Plans, where such failure would cause Sponsoring Plan or Controlled Affiliate Licensee to
violate the Agreement.
4. Each of the Other Plans acknowledges that it has reviewed the Agreement and understands that Sponsoring Plan has
the right to terminate the Agreement without cause upon notice as provided in Paragraph 8 of the Agreement, and
that such right is unfettered and may be exercised by Sponsoring Plan in its sole discretion.
WHEREFORE, by signing below the parties agree to be bound to the terms stated herein.
BLUE CROSS BLUE SHIELD ASSOCIATION
By:_______________________________________
[Controlled Affiliate Licensee]
By:_______________________________________
[Sponsoring Plan]
By:_______________________________________
[Other Plan 1]
By:_______________________________________
[Other Plan 2]
By:_______________________________________
Amended as of September 27, 2018
-38-

-- 411 of 533 --

EXHIBIT B-2
ADDENDUM TO CONTROLLED AFFILIATE LICENSE TO BE EXECUTED BY
CONTROLLED AFFILIATES LICENSED UNDER CONTROLLED AFFILIATE LICENSE
STANDARD 1D.
ADDENDUM TO CONTROLLED AFFILIATE LICENSE
This Addendum is made to that certain Blue Shield Controlled Affiliate License Agreement executed by and among
Blue Cross and Blue Shield Association (“Licensor”), ___________________________(“Controlled Affiliate Licensee”),
______________________________________(“Sponsoring Plan”) and _____________________________________
(“Participating Plan”) dated the ________day of
_____________, ________(“Agreement”).
WHEREAS, the Participating Plan is defined as the Plan that holds the Primary License with BCBSA to use the
Service Marks in the Service Area where the Controlled Affiliate will use the Service Marks;
WHEREAS, the Participating Plan asserts that it can offer a lower cost Basic Medicare Part D Prescription Drug
Plan product more efficiently in the Participating Plan’s Service Area through the Controlled Affiliate Licensee;
WHEREAS, the Controlled Affiliate shall only use the Service Marks inside of the Participating Plan(s) Service Area
subject to each Participating Plan signing a separate Addendum;
WHEREAS, in such circumstance Controlled Affiliate License Standard 1D permits the licensing of a Controlled
Affiliate that is 100% owned and controlled by a Sponsoring Plan, subject to certain conditions;
WHEREAS, one such condition is that the Sponsoring Plan, Controlled Affiliate and the Participating Plan enter into
this Addendum;
NOW THEREFORE, for good and valuable consideration, including the promises and covenants set forth herein,
the parties agree as follows:
1. The Participating Plan shall participate in Controlled Affiliate’s business that is conducted under the Licensed Marks.
The parties understand that the Participating Plan shall conduct sales support and marketing of the Controlled
Affiliate’s Basic Medicare Part D Prescription Drug Plan product offered in the Participating Plan’s Service Area. Any
other form of participation shall require BCBSA’s written approval.
2. Participating Plan agrees that (i) it will cooperate fully with the Sponsoring Plan and BCBSA as needed to enable
Sponsoring Plan and
-39-

-- 412 of 533 --

Controlled Affiliate Licensee to meet their obligations to Licensor under the Agreement and all associated rules and
regulations of Licensor, including the Brand Regulations, (ii) it will not take any action that would cause Sponsoring
Plan or Controlled Affiliate Licensee to violate the Agreement, and (iii) it will not fail to take any action, either
individually or jointly with the Sponsoring Plan or Controlled Affiliate Licensee, where such failure would cause
Sponsoring Plan or Controlled Affiliate Licensee to violate the Agreement.
3. The Controlled Affiliate Licensee shall only use the Licensed Marks authorized by the Participating Plan in connection
with the Basic Medicare Part D Prescription Drug Plan product offered in the Participating Plan’s Service Area.
4. The Sponsoring Plan and Controlled Affiliate acknowledge that it has reviewed the Agreement and understands that
Participating Plan has the right to terminate this Agreement: (i) immediately upon the expiration or termination of the
Plan Participation Agreement by and between Participating Plan and Controlled Affiliate upon written notice to the
Sponsoring Plan, Controlled Affiliate Licensee and Licensor, or (ii) without cause upon 18 months written notice to
the Sponsoring Plan, Controlled Affiliate Licensee and Licensor, and that such right is unfettered and may be
exercised by Participating Plan in its sole discretion. In the event that Participating Plan and Controlled Affiliate fail
to execute the Plan Participation Agreement by____________(Date),Participating Plan may terminate this
Agreement immediately upon notice to Sponsoring Plan, Controlled Affiliate Licensee and Licensor.
5. This Agreement and all of Controlled Affiliate Licensee's rights hereunder shall immediately terminate without any
further action by any party or entity in the event that the Sponsoring Plan or Participating Plan ceases to be
authorized to use the Licensed Marks and Name.
WHEREFORE, by signing below the parties agree to be bound to the terms stated herein.
BLUE CROSS BLUE SHIELD ASSOCIATION
By: ________________________________________
[Controlled Affiliate Licensee]
By: ________________________________________
[Sponsoring Plan]
By: ________________________________________
[Participating Plan]
By: ________________________________________
Amended March 17, 2016
-40-

-- 413 of 533 --

EXHIBIT C
ROYALTY FORMULA FOR SECTION 9 OF THE
CONTROLLED AFFILIATE LICENSE AGREEMENT
Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following formula:
FOR RISK PRODUCTS:
For Controlled Affiliates not underwriting the indemnity portion of workers’ compensation insurance:
An amount equal to its pro rata share of Sponsoring Plan's dues payable to BCBSA computed with the addition of the
Controlled Affiliate's members using the Marks on health care plans and related services as reported on the Quarterly
Enrollment Report with BCBSA. The payment by Sponsoring Plan of its dues to BCBSA, including that portion described
in this paragraph, will satisfy the requirement of this paragraph, and no separate payment will be necessary.
For Controlled Affiliates underwriting the indemnity portion of workers’ compensation insurance:
An amount equal to 0.35 percent of the gross revenue per annum of Controlled Affiliate arising from products using the
marks; plus, an annual fee of $5,000 per license for a Controlled Affiliate subject to Standard 7.
Amended as of September, 19, 2014
-41-

-- 414 of 533 --

EXHIBIT C (continued)
FOR NONRISK PRODUCTS:
For third-party administrative business, an amount equal to its pro rata share of Sponsoring Plan’s dues payable to
BCBSA computed with the addition of the Controlled Affiliate’s members using the Marks on health care plans and related
services as reported on the Quarterly Enrollment Report with BCBSA. The payment by Sponsoring Plan of its dues to
BCBSA, including that portion described in this paragraph, will satisfy the requirement of this paragraph, and no separate
payment will be necessary.
For non-third-party administrative business (e.g., case management, provider networks, etc.), an amount equal to 0.24
percent of the gross revenue per annum of Controlled Affiliate arising from products using the marks; plus:
1) An annual fee of $5,000 per license for a Controlled Affiliate subject to Standard 6 D.
2) An annual fee of $2,000 per license for all other Controlled Affiliates.
The foregoing shall be reduced by one-half where both a BLUE CROSS® and BLUE SHIELD® License are issued to the
same Controlled Affiliate. In the event that any license period is greater or less than one (1) year, any amounts due shall
be prorated. Royalties under this formula will be calculated, billed and paid in arrears.
Amended as of September 19, 2014
-42-

-- 415 of 533 --

EXHIBIT 1A
CONTROLLED AFFILIATE LICENSE AGREEMENT
APPLICABLE TO LIFE INSURANCE COMPANIES
(Includes revisions adopted by Member Plans through their November 16, 2023 meeting)
This agreement by and among Blue Cross and Blue Shield Association ("BCBSA")
_________________________("Controlled Affiliate"), a Controlled Affiliate of the Blue Shield Plan(s), known as
_______________________________________("Plan").
WHEREAS, BCBSA is the owner of the BLUE SHIELD and BLUE SHIELD Design service marks;
WHEREAS, the Plan and the Controlled Affiliate desire that the latter be entitled to use the BLUE SHIELD and
BLUE SHIELD Design service marks (collectively the "Licensed Marks") as service marks and be entitled to use the term
BLUE SHIELD in a trade name ("Licensed Name");
NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby
agree as follows:
1. GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to the Controlled Affiliate the exclusive
right to use the licensed Marks and Names in connection with and only in connection with those life insurance and
related services authorized by applicable state law, other than health care plans and related services (as defined in
the Plan's License Agreements with BCBSA) which services are not separately licensed to Controlled Affiliate by
BCBSA, in the Service Area served by the Plan, except that BCBSA reserves the right to use the Licensed Marks and
Name in said Service Area, and except
to the extent that said Service Area may overlap the area or areas served by one or more other licensed Blue Shield
Plans as of the date of this License as to which overlapping areas the rights hereby granted are non-exclusive as to
such other Plan or Plans and their respective Licensed Controlled Affiliates only. Controlled Affiliate cannot use the
Licensed Marks or Name outside the Service Area or in its legal or trade name; provided, however, that if and only for
so long as Controlled Affiliate also holds a Blue Shield Affiliate License Agreement applicable to health care plans and
related services, Controlled Affiliate may
use the Licensed Marks and Name in its legal and trade name according to the terms of such license agreement.
Amended as of June 12, 2003
-1-

-- 416 of 533 --

2. QUALITY CONTROL
A. Controlled Affiliate agrees to use the Licensed Marks and Name only in relation to the sale, marketing and
rendering of authorized products and further agrees to be bound by the conditions regarding quality control
shown in Exhibit A as it may be amended by BCBSA from time-to-time.
B. Controlled Affiliate agrees that Plan and/or BCBSA may, from time-to-time, upon reasonable notice, review and
inspect the manner and method of Controlled Affiliate's rendering of service and use of the Licensed Marks
and Name.
C. Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by Plan or
by BCBSA) a report to Plan and BCBSA demonstrating Controlled Affiliate's compliance with the requirements
of this Agreement including but not limited to the quality control provisions of Exhibit A.
D. As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner that it is
subject to the bona fide control of a Plan or Plans. Absent written approval by BCBSA of an alternative method
of control, bona fide control shall mean the legal authority, directly or indirectly through wholly-owned
subsidiaries: (a) to select members of the Controlled Affiliate's governing body having not less than 51% voting
control thereof; (b) to exercise operational control with respect to the governance thereof; and (c) to prevent
any change in its articles of incorporation, bylaws or other governing documents deemed inappropriate. In
addition, a Plan or Plans shall own at least 51% of any for-profit Controlled Affiliate. If the Controlled Affiliate is
a mutual company, the Plan or its designee(s) shall have and maintain, in lieu of the requirements of items (a)
and (c) above, proxies representing 51% of the votes at any meeting of the policyholders and shall
demonstrate that there is no reason to believe this such proxies shall be revoked by sufficient policyholders to
reduce such percentage below 51%.
3. SERVICE MARK USE
Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks, including but not limited to
use of such symbols or words as BCBSA shall specify to
protect the Licensed Marks, and shall comply with such rules (applicable to all Controlled Affiliates licensed to use
the Marks) relative to service mark use, as are issued from
time-to-time by BCBSA. If there is any public reference to the affiliation between the Plan and the Controlled Affiliate,
all of the Controlled Affiliate's licensed services in the Service Area of the Plan shall be rendered under the Licensed
Marks. Controlled Affiliate recognizes and agrees that all use of the Licensed Marks by Controlled Affiliate shall inure
to the benefit of BCBSA
-2-

-- 417 of 533 --

4. SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not sublicense, transfer, hypothecate, sell, encumber or mortgage, by operation of law or
otherwise, the rights granted hereunder and any such act shall be voidable at the option of Plan or BCBSA. This
Agreement and all rights and duties hereunder are personal to Controlled Affiliate.
5. INFRINGEMENTS
Controlled Affiliate shall promptly notify Plan and BCBSA of any suspected acts of infringement, unfair competition or
passing off which may occur in relation to the Licensed Marks. Controlled Affiliate shall not be entitled to require Plan
or BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or passing off
by third parties. Controlled Affiliate agrees to render to Plan and BCBSA, free of
charge, all reasonable assistance in connection with any matter pertaining to the
protection of the Licensed Marks by BCBSA.
6. LIABILITY INDEMNIFICATION
Controlled Affiliate hereby agrees to save, defend, indemnify and hold Plan and BCBSA harmless from and against
all claims, damages, liabilities and costs of every kind, nature and description which may arise as a result of
Controlled Affiliate's rendering of health
care services under the Licensed Marks.
7. LICENSE TERM
The license granted by this Agreement shall remain in effect for a period of one (1) year and shall be automatically
extended for additional one (1) year periods upon evidence satisfactory to the Plan and BCBSA that Controlled
Affiliate meets the then applicable quality control standards, unless one of the parties hereto notifies the other party of
the termination hereof at least sixty (60) days prior to expiration of any license period.
This Agreement may be terminated by the Plan or by BCBSA for cause at any time provided that Controlled Affiliate
has been given a reasonable opportunity to cure and
shall not effect such a cure within thirty (30) days of receiving written notice of the intent to terminate (or commence a
cure within such thirty day period and continue diligent efforts
to complete the cure if such curing cannot reasonably be completed within such thirty day period). By way of example
and not for purposes of limitation, Controlled Affiliate's failure
to abide by the quality control provisions of Paragraph 2, above, shall be considered a proper ground for cancellation
of this Agreement.
-3-

-- 418 of 533 --

This Agreement and all of Controlled Affiliate’s rights hereunder shall immediately terminate without any further
action by any party or entity in the event that:
A. Controlled Affiliate shall no longer comply with Standard No. 1 (Organization and Governance) of Exhibit A or,
following an opportunity to cure, with the remaining quality control provisions of Exhibit A, as it may be
amended from time-to-time; or
B. Plan ceases to be authorized to use the Licensed Marks; or
C. Appropriate dues for Controlled Affiliate pursuant to item 8 hereof, which are the royalties for this License
Agreement are more than sixty (60) days in arrears to BCBSA.
Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately
discontinue all use of the Licensed Marks including any use in its trade name.
In the event of any disagreement between Plan and BCBSA as to whether grounds exist for termination or as to any
other term or condition hereof, the decision of BCBSA shall control, subject to provisions for mediation or mandatory
dispute resolution in effect between the parties.
Upon termination of this Agreement, Licensed Controlled Affiliate shall immediately notify all of its customers that it is
no longer a licensee of the Blue Cross and Blue Shield Association and provide instruction on how the customer can
contact the Blue Cross and Blue Shield Association or a designated licensee to obtain further information on securing
coverage. The written notification required by this paragraph shall be in writing and in a form approved by the
Association. The Association shall have the right to audit the terminated entity's books and records to verify
compliance with this paragraph.
8. DUES
Controlled Affiliate will pay to BCBSA a fee for this license in accordance with the following formula:
An annual fee of five thousand dollars ($5,000) per license, plus
.05% of gross revenue per year from branded group products, plus
.5% of gross revenue per year from branded individual products plus
.14% of gross revenue per year from branded individual annuity products.
4

-- 419 of 533 --

The foregoing percentages shall be reduced by one-half where both a BLUE CROSS® and BLUE SHIELD® license
are issued to the same entity. In the event that any License period is greater or less than one (1) year, any amounts
due shall be prorated. Royalties under this formula will be calculated, billed and paid in arrears.
Plan will promptly and timely transmit to BCBSA all dues owed by Controlled Affiliate as determined by the above
formula and if Plan shall fail to do so, Controlled Affiliate shall pay such dues directly.
9. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or
employment relationship between Plan and Controlled Affiliate or between either and BCBSA.
9A. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the
Blue Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes
equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes
(if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all
questions requiring an affirmative three-fourths weighted vote of the Plans, voting shall occur pursuant to BCBSA’s
Bylaws.
10. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall
be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its
President and, if any, its General Counsel.
Amended as of June 15, 2023
-5-

-- 420 of 533 --

11. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This
Agreement may only be amended by a writing executed by all parties.
12. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such finding shall in no way
effect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for
any unlawful term or condition so
long as the effect of such substitution is to provide the parties with the benefits of this Agreement.
13. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of the Controlled Affiliate or any other
licensee of any of the terms, covenants or conditions of this
Agreement shall constitute a waiver of any subsequent breach or default in performance of said terms, covenants or
conditions.
14. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of
Illinois.
Amended as of June 16, 2005
-6-

-- 421 of 533 --

IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed, effective as of the date of last
signature written below.
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:____________________________________________
Date:__________________________________________
Controlled Affiliate
By:____________________________________________
Date:__________________________________________
Plan
By:____________________________________________
Date:__________________________________________
-7-

-- 422 of 533 --

EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
LIFE INSURANCE COMPANIES
Page 1 of 2
PREAMBLE
The standards for licensing Life Insurance Companies (Life and Health Insurance companies,
as defined by state statute) are established by BCBSA and are subject to change from time-to- time upon the affirmative
vote of three-fourths (3/4) of the Plans and three-fourths (3/4) of the total weighted vote of all Plans. Each Licensed Plan is
required to use a standard controlled
affiliate license form provided by BCBSA and to cooperate fully in assuring that the licensed Life Insurance Company
maintains compliance with the license standards.
An organization meeting the following standards shall be eligible for a license to use the Licensed Marks within the
service area of its sponsoring Licensed Plan to the extent and the manner authorized under the Controlled Affiliate
License applicable to Life Insurance Companies and the principal license to the Plan.
Standard 1 – Organization and Governance
The LIC shall be organized and operated in such a manner that it is controlled by a licensed Plan or Plans which have,
directly or indirectly: 1) not less than 51% of the voting control of the LIC; and 2) the legal ability to prevent any change in
the articles of incorporation, bylaws or other establishing or governing documents of the LIC with which it does not concur;
and 3) operational control of the LIC.
If the LIC is a mutual company, the Plan or its designee(s) shall have and maintain, in lieu of the requirements of items 1
and 2 above, proxies representing at least 51% of the votes at any policyholder meeting and shall demonstrate that there
is no reason to believe such proxies shall be revoked by sufficient policyholders to reduce such percentage below 51%.
Standard 2 – State Licensure
The LIC must maintain unimpaired licensure or certificate of authority to operate under applicable state laws as a life and
health insurance company in each state in which the LIC does business.
-1-

-- 423 of 533 --

EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
LIFE INSURANCE COMPANIES
Page 2 of 2
Standard 3 – Records and Examination
The LIC and its sponsoring licensed Plan(s) shall maintain and furnish, on a timely and accurate basis, such records and
reports regarding the LIC as may be required in order to establish compliance with the license agreement. The LIC and its
sponsoring licensed Plan(s) shall permit BCBSA to examine the affairs of the LIC and shall agree that BCBSA’s board may
submit a written report to the chief executive officer(s) and the board(s) of directors of the sponsoring Plan(s).
Standard 4 – Mediation
The LIC and its sponsoring Plan(s) shall agree to use the then-current BCBSA mediation and mandatory dispute
resolution processes, in lieu of a legal action between or among another licensed controlled affiliate, a licensed Plan or
BCBSA.
Standard 5 – Financial Responsibility
The LIC shall maintain adequate financial resources to protect its customers and meet its business obligations.
Standard 6 – Cooperation with Affiliate License Performance Response Process Protocol
The LIC and its Sponsoring Plan(s) shall cooperate with BCBSA’s Board of Directors and its Organization and
Governance Committee in the administration of the Affiliate License Performance Response Process Protocol (ALPRPP)
and in addressing LIC compliance problems identified thereunder.
-2-

-- 424 of 533 --

Exhibit 1A1
CONTROLLED AFFILIATE
TRADEMARK LICENSE AGREEMENT
FOR LIFE AND DISABILTY INSURANCE PRODUCTS
This Agreement by and among Blue Cross and Blue Shield Association (“BCBSA”) and ___________________,
(“Life and Disability Controlled Affiliate”) which is a company offering life and disability insurance products owned
and controlled by __________________, _____________,_____________( individually, “Sponsoring Plan” and
when referred to collectively, “Sponsoring Plans”).
Whereas, BCBSA is the owner of the BLUE CROSS and BLUE SHIELD word and design service marks and any
derivatives thereof (“Licensed Marks”);
Whereas, each Sponsoring Plan is licensed separately by BCBSA to use one or more of the Licensed Marks in a
particular Service Area;
Whereas, the Sponsoring Plans and the Life and Disability Controlled Affiliate desire that the latter be entitled to
use the appropriate Licensed Marks in connection with life and disability insurance products in some or all of such
Sponsoring Plans’ Service Areas and in the Service Areas of other Regular Member Plans, as defined in the BCBSA By-
laws, (“Blue Plans”) consistent with the terms of this Agreement.
NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby
agree as follows:
1. GRANT OF LICENSE
A. Subject to the terms and conditions of this Agreement, BCBSA hereby grants to the Life and Disability
Controlled Affiliate the limited right to use the Licensed
Marks in connection with and only in connection with the following life and disability insurance products
authorized by state law: (1) Group: Term Life, Long Term Disability, Whole Life, Benefit Life, Universal Life; (2)
Individual: Term Life, Whole Life, Dependent Life, Spouse Life; (3) Other: Disability Income, Short Term
Disability, Long Term Disability, Income Replacement; and (4) such other life and disability products approved
by BCBSA in writing (“Licensed Products”) in the Service Areas served by the Sponsoring Plans or in the
Service Area or Areas of one or more other licensed Blue Plans, provided that such Blue Plans have
consented to such use as authorized by this Agreement. Life and Disability Controlled Affiliate may not use
the Licensed Marks in its legal or trade name.
-1-

-- 425 of 533 --

B. Notwithstanding that the license granted to Life and Disability Controlled Affiliate is a license to use all of the
Licensed Marks, Life and Disability Controlled Affiliate may only use those of the Licensed Marks in the Service
Area of a Sponsoring Plan or other consenting Blue Plan as described below that such Plan is authorized to
use as a Blue Plan pursuant to its separate license agreements with BCBSA.
C. Life and Disability Controlled Affiliate may use the Licensed Marks in the Service Areas of Sponsoring Plans or
in the Service Area of a Blue Plan that is not a signatory to this Agreement only after such Sponsoring Plan(s)
or non-signatory Blue Plan consents to such use by executing a written consent in substantially the same form
as the Consent Agreement attached as Exhibit B.
D. The following provisions apply with respect to Consent Agreements once such agreements have been fully and
properly executed:
(1) All sales, marketing and advertising materials developed by and proposed for use by Life and Disability
Controlled Affiliate in the Service Area of Sponsoring Plan or consenting Blue Plan (hereinafter, such
consenting Sponsoring Plan or consenting Blue Plan collectively referred to “Consenting Plan(s)”) must
clearly identify the Consenting Plan (for example, a statement on such materials that reads “This product
is offered with the cooperation of Blue Cross and/or Blue Shield of [Geography]”);
(2) To the extent the Consenting Plan has separate divisions or other Affiliates that use the Licensed Marks in
distinct geographic areas within its Service Area, consent obtained under this Agreement may be limited to
one or more of such specific geographic areas as specified by the Consenting Plan in its signed Consent
Agreement. For purposes of this entire Agreement, all references to
the Service Area of a Sponsoring Plan, Blue Plan or Consenting Plan may include the entire Service Area
or a distinct geographic area within such
Service Area as specified in this Section 1 D (2);
(3) Where BCBSA has licensed two or more Blue Plans to use the same Licensed Marks in the same Service
Area, in addition to the requirements set forth in Section D (1) above, the sales, marketing and advertising
materials referenced in such section above must be communicated to the Consenting Plan’s existing and
prospective accounts through or with the approval of such Consenting
Plan, and the personnel of such Consenting Plan must actively participate in all sales and marketing
activities conducted by Life and Disability Controlled Affiliate in the same Service Area, including
participating in meetings (whether in-person or via telephone, video or internet conference) with both
existing and prospective accounts of the Consenting Plan;
-2-

-- 426 of 533 --

(4) Life and Disability Controlled Affiliate shall be entitled to use in a Service Area only those Licensed Marks
that the Consenting Plan has been granted by BCBSA the license to use under its Blue Plan license
agreements (for example, if a Consenting Plan is licensed to use only the Blue Cross Marks in its Service
Area, the materials used by Life and Disability Controlled Affiliate in that Service Area may only contain or
reference the Blue Cross Marks and not the Blue Shield Marks).
(5) If a Consent Agreement is terminated, Life and Disability Controlled Affiliate shall, unless BCBSA and the
Consenting Plan agree in their sole discretion to a phase out in writing, immediately (i) cease all use of the
Licensed Marks, including in connection with any and all sales and marketing of the Licensed Products in
the Service Area where consent has been terminated, and (ii) notify its customers that it is no longer a
licensee and provide instruction on how the customer can contact BCBSA or a designated licensee to
obtain further information on securing coverage. The notification required by this paragraph shall be in
writing and in form approved by BCBSA.
15. QUALITY CONTROL
A. Life and Disability Controlled Affiliate agrees to use the Licensed Marks only in relation to the sale, marketing
and administration of the Licensed Products and further agrees to be bound by the conditions regarding
quality control shown in Exhibit A and the Guidelines to Administer the Standards for Trademark License
Agreement for Life and Disability Insurance Products attached thereto.
B. Life and Disability Controlled Affiliate agrees that BCBSA may, from time-to-time, upon reasonable notice,
review and inspect the manner and method of Life and Disability Controlled Affiliate’s rendering of service and
use of the Licensed Marks.
C. Life and Disability Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably
required by BCBSA) a report to BCBSA demonstrating Life and Disability Controlled Affiliate’s compliance with
the requirements of this Agreement including but not limited to the quality control provisions of Exhibit A.
D. As used herein, a Life and Disability Controlled Affiliate is defined as: An entity organized and operated in such
a manner that it is 100% owned and controlled by Sponsoring Plans. Absent written approval by BCBSA of an
alternative method of control, control shall mean the legal authority, directly or indirectly through wholly- owned
subsidiaries: (a) to select members of the Life and Disability Controlled Affiliate’s governing body having not
less than 100% voting control thereof; (b) to exercise operational control with respect to the governance
-3-

-- 427 of 533 --

thereof; and to prevent any change in its articles of incorporation, bylaws or other governing documents
deemed inappropriate. In addition, a Sponsoring Plan or Plans shall own at least 100% of any for profit Life
and Disability Controlled Affiliate
3. SERVICE MARK USE
Life and Disability Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and
shall ensure all uses of the Licensed Marks comply with the BCBSA Brand Regulations, as amended by BCBSA
from time to time. Life and
Disability Controlled Affiliate recognizes and agrees that all use of the Licensed Marks
by Life and Disability Controlled Affiliate shall inure to the benefit of BCBSA.
4. SUBLICENSING AND ASSIGNMENT
The license hereby granted to Life and Disability Controlled Affiliate to use the Licensed Marks is and shall be
personal to Life and Disability Controlled Affiliate and shall not be assignable by any act of the Life and Disability
Controlled Affiliate, directly or indirectly, without the written consent of BCBSA. Said license shall not be assignable
by operation of law, nor shall Life and Disability Controlled Affiliate mortgage or part with possession
or control of this license or any right hereunder, and the Life and Disability Controlled Affiliate shall have no right to
grant any sublicense to use the Licensed Marks.
5. INFRINGEMENTS
Life and Disability Controlled Affiliate shall promptly notify BCBSA of any suspected acts of infringement, unfair
competition or passing off which may occur in relation to the Licensed Marks. Life and Disability Controlled Affiliate
shall not be entitled to require BCBSA to take any actions or institute any proceedings to prevent infringement,
unfair competition or passing off by third parties. Life and Disability Controlled Affiliate agrees
to render to BCBSA, free of charge, all reasonable assistance in connection with any matter pertaining to the
protection of the Licensed Marks by BCBSA. BCBSA shall have sole control of the defense and resolution of any
claim of infringement brought or threatened by others.
6. LIABILITY INDEMNIFICATION
Life and Disability Controlled Affiliate hereby agrees to save, defend, indemnify and hold BCBSA harmless from and
against all claims, damages, liabilities and costs of every
kind, nature and description which may arise as a result of Life and Disability Controlled Affiliate’s conduct.
-4-

-- 428 of 533 --

7. LICENSE TERM
A. The license granted by this Agreement shall remain in effect for a period of one (1) year and shall be
automatically extended for additional one (1) year periods, unless either BCBSA or Life and Disability Controlled
Affiliate notifies the other party in writing of the termination hereof at least sixty (60) days prior to expiration of
any license period.
B. This Agreement may be terminated by BCBSA for cause at any time provided that Life and Disability Controlled
Affiliate has been given a reasonable opportunity to
cure and shall not effect such a cure within thirty (30) days of receiving written notice of the intent to terminate
(or commence a cure within such thirty day period and continue diligent efforts to complete the cure if such
curing cannot reasonably be completed within such thirty day period). By way of example and not for purposes
of limitation, Life and Disability Controlled Affiliate's failure to abide by the conditions regarding use of the
Licensed Marks set forth in Section 1 of this Agreement or the quality control provisions of Section 2 (other than
with respect to Section 2 D which is subject to immediate termination as stated in Section 7 C (1) below) shall
be considered proper grounds for termination of this Agreement.
C. This Agreement and all of Life and Disability Controlled Affiliate's rights hereunder shall immediately terminate
without any further action by any party or entity in the event that:
(1) Life and Disability Controlled Affiliate shall no longer comply with Section 2 D
(or Standard No. 1 (Organization and Governance) of Exhibit A); or
(2) Any Sponsoring Plan ceases to be authorized to use the Licensed Marks; or
(3) Appropriate fees for Life and Disability Controlled Affiliate pursuant to Section 8 of this Agreement are
more than sixty (60) days in arrears to BCBSA.
Upon termination of this Agreement for cause or otherwise, Life and Disability Controlled Affiliate agrees that it shall
immediately discontinue all use of the Licensed Marks.
In the event of any disagreement between Life and Disability Controlled Affiliate and
BCBSA as to whether grounds exist for termination or as to any other term or condition hereof, the decision of BCBSA
shall control, subject to provisions for mediation or mandatory dispute resolution in effect between the parties.
-5-

-- 429 of 533 --

Upon termination of this Agreement, Licensed Life and Disability Controlled Affiliate shall immediately notify all of its
customers that it is no longer a licensee of BCBSA and provide instruction on how the customer can contact BCBSA
or a designated licensee to obtain further information on securing coverage. The notification required by this
paragraph shall be in writing and in a form approved by BCBSA. BCBSA shall have the right to audit the terminated
entity’s books and records to verify compliance with this paragraph.
8. ROYALTIES
Life and Disability Controlled Affiliate will pay to BCBSA a fee for this license in accordance with the following
formula:
• An annual fee of five thousand dollars ($5,000) per license, plus
• .05% of gross revenue per year from group products sold under the Licensed Marks, plus
• .5% of gross revenue per year from individual products sold under the Licensed Marks
In the event that any license period is greater or less than one (1) year, any amounts due shall be prorated. Royalties
under this formula will be calculated, billed and paid in
arrears.
Life and Disability Controlled Affiliate will promptly and timely transmit to BCBSA all fees owed by Life and Disability
Controlled Affiliate as determined by the above formula.
9. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or
employment relationship between any Sponsoring Plan and Life and Disability Controlled Affiliate or between among
them and/or BCBSA.
10. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the
Blue Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote
together. For weighted votes of the Plans, the Plan shall have a number of votes equal to the number of weighted
votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes (if any) that it holds as a Blue
Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all questions requiring an affirmative
three-fourths weighted vote of the Plans, voting shall occur pursuant to BCBSA’s Bylaws.
Amended as of June 15, 2023
-6-

-- 430 of 533 --

11. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall
be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its
President and, if any, its General Counsel.
12. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This
Agreement may only be amended by: (a) a writing signed by all parties; or (b) a writing approved by the affirmative
vote of three-fourths of the Blue Plans and three-fourths of the total then current weighted vote of all the Blue Plans
as officially recorded by the BCBSA Corporate Secretary. Upon such adoption by the Blue Plans, this Agreement
and all other Trademark License Agreements for Life and Disability Insurance Products then in effect shall
simultaneously be amended.
13. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such finding shall in no way
affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for
any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of
this Agreement.
14. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of the Life and Disability Controlled Affiliate
or any other licensee of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any
subsequent breach or default in performance of said terms, covenants or conditions.
15. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of
Illinois.
-7-

-- 431 of 533 --

IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed, effective as of the date of last
signature written below.
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:__________________________________________
Date:_________________________________________
Life and Disability Controlled Affiliate:
By:__________________________________________
Date:_________________________________________
Sponsoring Plan:
By:__________________________________________
Date:_________________________________________
Name:________________________________________
Sponsoring Plan:
By:___________________________________________
Date:_________________________________________
Name:________________________________________
[Add other Sponsoring Plans as necessary]
-8-

-- 432 of 533 --

EXHIBIT A
LICENSE STANDARDS APPLICABLE TO TRADEMARK LICENSE
AGREEMENT FOR LIFE AND DISABILITY INSURANCE PRODUCTS
Page 1 of 2
Standard 1 – Organization and Governance
Any Life and Disability Controlled Affiliate licensed under the Trademark License Agreement for Life and Disability
Insurance Products (“licensee”) shall be organized and operated in such a manner that it is an entity organized and
operated in such a manner that it is 100% owned and controlled by Sponsoring Plans. Absent written approval by BCBSA
of an alternative method of control, control shall mean the legal authority, directly or indirectly through wholly-owned
subsidiaries: (a) to select members of the Life and Disability Controlled Affiliate’s governing body having not less than
100% voting control thereof; (b) to exercise operational control with respect to the governance thereof; and (c) to prevent
any change in its articles of incorporation, bylaws or other governing documents deemed inappropriate. In addition, a
Sponsoring Plan or Plans shall own at least 100% of any for profit Life and Disability Controlled Affiliate.
Standard 2 – State Licensure
The licensee must maintain unimpaired licensure or certificate of authority to operate under applicable state laws as a life
company in each state in which the licensee does business.
Standard 3 – Records and Examination
The licensee shall maintain and furnish, on a timely and accurate basis, such records and reports regarding the licensee
as may be required in order to establish compliance with the Agreement. The licensee shall permit BCBSA to examine the
affairs of the licensee and shall agree that BCBSA’s board may submit a written report to the chief executive officer(s) and
the board(s) of directors of the Sponsoring Plan(s).
Standard 4 – Mediation
The licensee, its Sponsoring Plan(s) and all consenting Blue Plans shall agree to use the then- current BCBSA mediation
and mandatory dispute resolution processes, in lieu of a legal action between or among another licensed Life and
Disability Controlled Affiliate, a Sponsoring Plan and or consenting Blue Plan or BCBSA.
-1-

-- 433 of 533 --

EXHIBIT A
LICENSE STANDARDS APPLICABLE TO TRADEMARK LICENSE
AGREEMENT FOR LIFE AND DISABILITY INSURANCE PRODUCTS
Page 2 of 2
Standard 5 – Financial Responsibility
The licensee shall maintain adequate financial resources to protect its customers and meet its business obligations.
Standard 6 – Cooperation with BCBSA Governance
The licensee shall cooperate with BCBSA’s Board of Directors and its Organization and Governance Committee in the
administration of and in addressing licensee compliance problems that may be identified in connection with the operation
or administration of the Trademark License Agreement for Life and Disability Insurance Products.
-2-

-- 434 of 533 --

EXHIBIT B
CONSENT AGREEMENT
This Consent Agreement is made and entered into by and among the undersigned Blue Plan, and
_____________________(“Life and Disability Controlled Affiliate”), and the Blue Cross and Blue Shield Association (“BCBSA”)
and shall be deemed effective on
__________________(“Effective Date”).
Whereas, BCBSA owns the Blue Cross and Blue Shield word and design service marks and any derivative mark
thereof (the “Brands”);
Whereas, the undersigned Blue Plan is licensed to use one or more of the Brands within a specific geographic area
(“Service Area”);
Whereas Life and Disability Controlled Affiliate is licensed by BCBSA to use one or more of the Brands to offer life
and disability insurance products (“Products”) as defined and authorized in the Trademark License Agreement for Life and
Disability Insurance Products (“Life and Disability License Agreement”);
Whereas neither the Blue Plan nor its affiliates offer the Products under any of the Brands in such Blue Plan’s
Service Area or portion thereof where Blue Plan has consented to sale of the Products by Life and Disability Controlled
Affiliate; and
Whereas BCBSA and the undersigned Blue Plan desire to consent to Life and Disability Controlled Affiliate’s use of the
Brands in Blue Plan’s Service Area consistent with the terms of the Life and Disability License Agreement and this Consent
Agreement.
Now, therefore, in consideration of the obligations and conditions stated in this Agreement, Blue Plan, Life and
Disability Controlled Affiliate and BCBSA agree as follows:
1. Life and Disability Controlled Affiliate may market, sell, administer and underwrite the Products in Blue Plan’s Service
Area under the Brands licensed to Blue Plan in such Service Area subject to the terms of this Consent Agreement, the
Life and Disability License Agreement and Blue Plan’s license agreement(s) with BCBSA. Life and Disability
Controlled Affiliate’s rights under the Brands to offer the Products under the Brands are limited to offering the
Products only under the Brand(s) licensed to the consenting Blue Plan.
2. Life and Disability Controlled Affiliate shall work with the undersigned Blue Plan to develop a written sales and
marketing agreement that identifies the relationship between it and Blue Plan for the sales, marketing and customer
service for the Products. The term of the sales and marketing agreement shall be the same as the term of this
Consent Agreement.
1

-- 435 of 533 --

3. All sales, marketing and advertising materials developed by and proposed for use by Life and Disability Controlled
Affiliate in a consenting Blue Plan’s Service Area must clearly identify the consenting Blue Plan (for example, a
statement on such materials that reads “This product is offered with the cooperation of Blue Cross and/or Blue Shield
of [Geography]”);
4. Life and Disability Controlled Affiliate may use the Brands to sell the Products in the following Service Area or portion
thereof as designated by Blue Plan:
__________________________________________________
5. If two or more Blue Plans to use the same Licensed Marks in the same Service Area, Life and Disability Controlled
Affiliate shall work with the consenting Blue Plan in the following manner: (a) the sales, marketing and advertising
materials must be communicated to the consenting Blue Plan’s existing and prospective accounts through or with the
approval of such Blue Plan, and (b) the personnel of such Blue Plan must actively participate in all sales and
marketing activities conducted by Life and Disability Controlled Affiliate in the same Service Area, including
participating in meetings (whether in-person or via telephone, video or internet conference) with both existing and
prospective accounts of the consenting Blue Plan;
6. Life and Disability Controlled Affiliate shall be entitled to use in a Service Area only those Licensed Marks that the
consenting Blue Plan has been granted by BCBSA the license to use under its license agreement (for example, if a
consenting Blue Plan is licensed to use only the Blue Cross Marks in its Service Area, the materials used by Life and
Disability Controlled Affiliate in that Service Area may only contain or reference the Blue Cross Marks and not the Blue
Shield Marks).
7. If this Consent Agreement is terminated, Life and Disability Controlled Affiliate shall, unless each BCBSA and the Blue
Plan agree in their sole discretion to a phase out in writing, immediately (i) cease all use of the Licensed Marks,
including in connection with any and all sales and marketing of the Licensed Products in the Service Area where
consent has been terminated, and (ii) notify its customers that it is no longer a licensee of BCBSA and provide
instruction on how the customer can contact BCBSA or a designated licensee to obtain further information on
securing coverage. The notification required by this paragraph shall be in writing and in form approved by BCBSA.
2

-- 436 of 533 --

8. The term of this Consent Agreement shall be one year from the Effective Date. Unless either Blue Plan or Life and
Disability Controlled Affiliate provides the other party with written notice of its desire not to renew this Consent
Agreement at least 60 days prior to expiration of the term or any extended term or unless terminated as provided in
Paragraph 9 below, this Consent Agreement shall automatically renew for subsequent one year periods.
9. This Consent Agreement may be terminated as follows:
A. Upon mutual written consent of Life and Disability Controlled Affiliate and Blue Plan;
B. By Blue Plan or Life and Disability Controlled Affiliate upon 60 days advance written notice to the non-terminating party and
BCBSA; or
C. By Blue Plan immediately if Life and Disability Controlled Affiliate does not comply with this Consent Agreement or the sales
protocol agreement.
10. This Consent Agreement shall automatically terminate if Blue Plan’s primary licensee agreement terminates for any reason or if
the Life and Disability License Agreement terminates for any reason.
Agreed and Accepted by:
[Blue Plan]:
By:______________________
Title:_____________________
BLUE CROSS AND BLUE SHIELD ASSOCIATION:
By:_______________________
Title:________________________
LIFE AND DISABILITY CONTROLLED AFFILIATE:
By:________________________
Title:______________________
3

-- 437 of 533 --

Exhibit 1B
BLUE SHIELD
CONTROLLED AFFILIATE LICENSE AGREEMENT
APPLICABLE TO REGIONAL MEDICARE ADVANTAGE PPO PRODUCTS
(Adopted by Member Plans at their November 16, 2023 meeting)
This Agreement by and among Blue Cross and Blue Shield Association (“BCBSA”) and ____________(“Controlled Affiliate”), a
Controlled Affiliate of the Blue Cross Plan(s), known as ____________ (“Controlling Plans”), each of which is also a Party
signatory hereto.
WHEREAS, BCBSA is the owner of the BLUE SHIELD and BLUE SHIELD Design service marks;
WHEREAS, under the Medicare Modernization Act, companies may apply to and be awarded a contract by the Centers for
Medicare and Medicaid Services (“CMS”) to offer Medicare Advantage PPO products in geographic regions designated by CMS
(hereafter “regional MAPPO products”).
WHEREAS, some of the CMS-designated regions include the Service Areas, or portions thereof, of more than one Plan.
WHEREAS, the Controlling Plans and Controlled Affiliate desire that the latter be entitled to use the BLUE SHIELD and BLUE
SHIELD Design service marks (collectively the “Licensed Marks”) as service marks and be entitled to use the term BLUE SHIELD in a
trade name (“Licensed Name”) to offer regional MAPPO products in a region that includes the Service Areas, or portions thereof, of
more than one Controlling Plan;
NOW THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other good and
valuable consideration,the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:
1. GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled Affiliate the right to use the
Licensed Marks and Name in connection with, and only in connection with the sale, marketing and administration of regional
MAPPO products and related services.
This grant of rights is non-exclusive and is limited to the following states:
____________(the “Region”). Controlled Affiliate may use the Licensed
-1-

-- 438 of 533 --

Marks and Name in its legal name on the following conditions: (i) the legal name must be approved in advance, in
writing, by BCBSA; (ii) Controlled Affiliate shall not do business outside the Region under any name or mark except
business conducted in the Service Area of a Controlling Plan provided that Controlled Affiliate is separately licensed
by BCBSA to use the Licensed Marks and Name in connection with health care plans and related services in the
Service Area of such Controlling Plan; and (iii) Controlled Affiliate shall not use the Licensed Marks and Name, or any
derivative thereof, as part of any name or symbol used to identify itself in any securities market. Controlled Affiliate
may use the Licensed Marks and Name in its Trade Name only with the prior, written, consent of BCBSA.
2. QUALITY CONTROL
A. Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services and
further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they may
be amended by BCBSA from time-to-time.
B. Controlled Affiliate agrees to comply with all applicable federal, state and local laws.
C. Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by the
Controlling Plans or by BCBSA) a report or reports to the Controlling Plans and BCBSA demonstrating
Controlled Affiliate’s compliance with the requirements of this Agreement including but not limited to the quality
control provisions of this paragraph and the attached Exhibit A.
D. Controlled Affiliate agrees that the Controlling Plans and/or BCBSA may, from time- to-time, upon reasonable
notice, review and inspect the manner and method of Controlled Affiliate’s rendering of service and use of the
Licensed Marks and Name.
E. As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner, that it
meets the following requirements:
(1) Controlled Affiliate is owned or controlled by two or more Controlling Plans;
(2) Each Controlling Plan is authorized pursuant to a separate Blue Shield License Agreement to use the
Licensed Marks in a geographic area in the Region and every geographic area in the Region is so licensed
to at least one of the Controlling Plans; and
-2-

-- 439 of 533 --

(3) The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having not less than 100% voting
control thereof;
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing
documents of the Controlled Affiliate with which the Controlling Plans do not concur;
(c) to exercise control over the policy and operations of the Controlled Affiliate; and
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s establishing or
governing documents must also require written approval by each of the Controlling Plans before the
Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates (except such approval shall not be required
with respect to business of the Controlled Affiliate conducted under the Licensed Marks within
the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate
license agreement with BCBSA sponsored by such Controlling Plan);
(iii) change any of the type(s) of businesses in which it engages (except such approval shall not be
required with respect to business of the Controlled Affiliate conducted under the Licensed
Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled
affiliate license agreement with BCBSA sponsored by such Controlling Plan);
(iv) take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect
the Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly owned subsidiaries shall own 100% of any
for-profit Controlled Affiliate.
-3-

-- 440 of 533 --

3. SERVICE MARK USE
A. Controlled Affiliate recognizes the importance of a comprehensive national network
of independent BCBSA licensees which are committed to strengthening the Licensed Marks and Name. The
Controlled Affiliate further recognizes that its actions within
the Region may affect the value of the Licensed Marks and Name nationwide.
B. Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and Name, including
but not limited to use of such symbols or words as
BCBSA shall specify to protect the Licensed Marks and Name and shall comply with such rules (generally
applicable to Controlled Affiliates licensed to use the Licensed Marks and Name) relative to service mark use, as
are issued from time-to-time by BCBSA. Controlled Affiliate recognizes and agrees that all use of the Licensed
Marks and Name by Controlled Affiliate shall inure to the benefit of BCBSA.
C. Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in
a manner that transfers or is intended to transfer in the Region the goodwill associated therewith to another mark
or name, nor may Controlled Affiliate engage in activity that may dilute or tarnish the unique value of the
Licensed Marks and Name.
D. Controlled Affiliate shall use its best efforts to promote and build the value of the Licensed Marks and Name in
connection with the sale, marketing and administration of regional MAPPO products and related services.
4. SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell, encumber or mortgage, by
operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the sole option of any
Controlling Plan or BCBSA. This Agreement and all rights and duties hereunder are personal to Controlled Affiliate.
-4-

-- 441 of 533 --

5. INFRINGEMENT
Controlled Affiliate shall promptly notify the Controlling Plans and the Controlling Plans
shall promptly notify BCBSA of any suspected acts of infringement, unfair competition or passing off that may occur in
relation to the Licensed Marks and Name. Controlled Affiliate shall not be entitled to require the Controlling Plans or
BCBSA to take any actions or institute any proceedings to prevent infringement, unfair competition or passing off by
third parties. Controlled Affiliate agrees to render to the Controlling Plans and BCBSA, without charge, all reasonable
assistance in connection with any matter pertaining to the protection of the Licensed Marks and Name by BCBSA
6. LIABILITY INDEMNIFICATION
Controlled Affiliate and the Controlling Plans hereby agree to save, defend, indemnify and hold BCBSA harmless from
and against all claims, damages, liabilities and costs of every kind, nature and description (except those arising solely
as a result of BCBSA's
negligence) that may arise as a result of or related to Controlled Affiliate’s rendering of services under the Licensed
Marks and Name.
7. LICENSE TERM
A. Except as otherwise provided herein, the license granted by this Agreement shall remain in effect for a period of
one (1) year and shall be automatically extended for additional one (1) year periods unless terminated
pursuant to the provisions herein.
B. This Agreement and all of Controlled Affiliate’s rights hereunder shall immediately terminate without any further
action by any party or entity in the event that: (i) any
one of the Controlling Plans ceases to be authorized to use the Licensed Marks and Name; or (ii) pursuant to
Paragraph 15(a)(x) of the Blue Shield License Agreement any one of the Controlling Plans ceases to be
authorized to use the Licensed Names and Marks in the Region.
C. Notwithstanding any other provision of this Agreement, this license to use the Licensed Marks and Name may be
forthwith terminated by the Controlling Plans or
the affirmative vote of the majority of the Board of Directors of BCBSA present and voting at a special meeting
expressly called by BCBSA for the purpose on ten (10) days written notice to the Controlling Plans advising of
the specific matters at issue and granting the Controlling Plans an opportunity to be heard and to present their
response to the Board for: (1) failure to comply with any applicable minimum capital or liquidity requirement
under the quality control standards of this
-5-

-- 442 of 533 --

Agreement; or (2) failure to comply with the "Organization and Governance" quality control standard of this
Agreement; or (3) impending financial insolvency; or (4) failure to comply with any of the applicable
requirements of Standards 2, 3, 4, or 5 of attached Exhibit A; or (5) the pendency of any action instituted against
the Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking appointment of a trustee,
interim trustee, receiver or other custodian for any of its property or business or seeking the declaration or
establishment of a trust for any of its property or business, unless this Controlled Affiliate License Agreement
has been earlier terminated under paragraph (E); or (6) such other reason as is determined in good faith
immediately and irreparably to threaten the integrity and reputation of BCBSA, the Plans (including the
Controlling Plans), any other licensee including Controlled Affiliate and/or the Licensed Marks and Name.
D. Except as otherwise provided in Paragraphs 7(B), 7(C) or 7(E) herein, should Controlled Affiliate fail to comply with
the provisions of this Agreement and not cure such failure within thirty (30) days of receiving written notice thereof
(or commence a cure within such thirty day period and continue diligent efforts to complete the cure if such curing
cannot reasonably be completed within such thirty day period) BCBSA or the Controlling Plans shall have the right
to issue a notice that the Controlled Affiliate is in a state of noncompliance. If a state of noncompliance as aforesaid
is undisputed by the Controlled Affiliate or is found to exist by a mandatory dispute resolution panel and is uncured
as provided above, BCBSA shall have the right to seek judicial enforcement of the Agreement or to issue a notice of
termination thereof. Notwithstanding any other provisions of this Agreement, any disputes as to the termination of
this License pursuant to Paragraphs 7(B), 7(C) or 7(E) of this Agreement shall not be subject to mediation and
mandatory dispute resolution. All other disputes between or among BCBSA, any of the Controlling Plans and/or
Controlled Affiliate shall be submitted promptly to mediation and mandatory dispute resolution. The mandatory
dispute resolution panel shall have authority to issue orders for specific performance and assess monetary
penalties. Except, however, as provided in Paragraphs 7I and 7(E) of this Agreement, this license to use the
Licensed Marks and Name may not be finally terminated for any reason without the affirmative vote of a majority of
the present and voting members of the Board of Directors of BCBSA.
E. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further action by
any party or entity in the event that:
(1) Controlled Affiliate shall no longer comply with item 2(E) above;
(2) Appropriate dues, royalties and other payments for Controlled Affiliate pursuant
to paragraph 9 hereof, which are the royalties for this License Agreement, are more than sixty (60) days in arrears to
BCBSA; or
-6-

-- 443 of 533 --

(3) Any of the following events occur: (i) a voluntary petition shall be filed by Controlled Affiliate seeking
bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the
United States or any other law governing insolvency or debtor relief, or (ii) an involuntary petition or
proceeding shall be filed against Controlled Affiliate seeking bankruptcy, reorganization, arrangement with
creditors or other relief under the bankruptcy laws of the United States or any other law governing
insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by Controlled
Affiliate or is not dismissed within sixty (60) days of the date upon which the petition or other document
commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order for relief is entered
against Controlled Affiliate in any case under the bankruptcy laws of the United States, or Controlled
Affiliate is adjudged bankrupt or insolvent as those terms are defined in the Uniform Commercial Code as
enacted in the State of Illinois by any court of competent jurisdiction, or (iv) Controlled Affiliate makes a
general assignment of its assets for the benefit of creditors, or (v) any government or any government
official, office, agency, branch, or unit assumes control of Controlled Affiliate or delinquency proceedings
(voluntary or involuntary) are instituted, or (vi) an action is brought by Controlled Affiliate seeking its
dissolution or liquidation of its assets or seeking the appointment of a trustee, interim trustee, receiver or
other custodian for any of its property or business, or (vii) an action is instituted by any governmental
entity or officer against Controlled Affiliate seeking its dissolution or liquidation of its assets or seeking the
appointment of a trustee, interim trustee, receiver or other custodian for any of its property or business
and such action is consented to or acquiesced in by Controlled Affiliate or is not dismissed within one
hundred thirty (130) days of the date upon which the pleading or other document commencing the action
is served upon the Controlled Affiliate, provided that if the action is stayed or its prosecution is enjoined,
the one hundred thirty (130) day period is tolled for the duration of the stay or injunction, and provided
further, that the Association’s Board of Directors may toll or extend the 130 day period at any time prior to
its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any of Controlled Affiliate's
property or business is appointed or the Controlled Affiliate is ordered dissolved or liquidated.
Notwithstanding any other provision of this Agreement, a declaration or a request for declaration of the
existence of a trust over any of the Controlled Affiliate’s property or business shall not in itself be deemed
to constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of
paragraphs 7(E)(3)(vii) and (viii) of this Agreement.
F. Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately
discontinue all use of the Licensed Marks and Name, including any use in its trade name, except to the extent
that it continues to be authorized to use the Licensed Marks within the Service Area of one of the Controlling
Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such Controlling
Plan.
-7-

-- 444 of 533 --

G. Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its customers to whom it
provides products or services under the Licensed Marks pursuant to this Agreement that it is no longer a
licensee of BCBSA and, if directed by the Association’s Board of Directors, shall provide instruction on how the
customer can contact BCBSA or a designated licensee to obtain further information on securing coverage. The
notification required by this paragraph shall be in writing and in a form approved by BCBSA. The BCBSA shall
have the right to audit the terminated entity's books and records to verify compliance with this paragraph.
H. In the event this Agreement terminates pursuant to 7(B) hereof, upon termination of this Agreement the
provisions of Paragraph 7(G) shall not apply and the following provisions shall apply, except that, in the event
that Controlled Affiliate is separately licensed by BCBSA to use the Licensed Marks in the Service Area of a
Controlling Plan and termination of this Agreement is due to a partial termination of such Controlling Plan’s
license pursuant to Paragraph 15(a)(x)(ii) of the Blue Shield License Agreement, the notices, national account
listing, payment, and audit right listed below shall be applicable solely with respect to the Region and the
geographic area for which the Controlling Plan’s license to use the Licensed Names and Marks is terminated:
(1) The Controlled Affiliate shall send a notice through the U.S. mails, with first class postage affixed, to all
individual and group customers, providers, brokers and agents of products or services sold, marketed,
underwritten or administered by the Controlled Affiliate under the Licensed Marks and Name. The form
and content of the notice shall be specified by BCBSA and shall, at a minimum, notify the recipient of the
termination of the license, the consequences thereof, and instructions for obtaining alternate products or
services licensed by BCBSA. This notice shall be mailed within 15 days after termination.
(2) The Controlled Affiliate shall deliver to BCBSA within five days of a request by BCBSA a listing of national
accounts in which the Controlled Affiliate is involved (in a control, participating or servicing capacity),
identifying the national account and the Controlled Affiliate’s role therein.
(3) Unless the cause of termination is an event respecting BCBSA stated in paragraph 15(a) or (b) of the
Plan’s license agreement with BCBSA to use the Licensed Marks and Name, the Controlled Affiliate, the
Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly
liable for payment to BCBSA of an amount equal to $25 multiplied by the number of Licensed Enrollees
of the Controlled Affiliate; provided that if any Plan other than a Controlling Plan is permitted by BCBSA to
use marks or names licensed by BCBSA in a geographic area in the Region, the payment for Licensed
Enrollees in such geographic area shall be multiplied by a fraction, the numerator of which is the number
of Licensed Enrollees of the Controlled Affiliate, the Controlling Plans, and
-8-

-- 445 of 533 --

any other Licensed Controlled Affiliates of the Controlling Plans in such geographic area and the denominator
of which is the total number of Licensed Enrollees in such geographic area. Licensed Enrollee means
each and every person and covered dependent who is enrolled as an individual or member of a group
receiving products or services sold, marketed or administered under marks or names licensed by BCBSA
as determined at the earlier of (i) the end of the last fiscal year of the terminated entity which ended prior
to termination or (ii) the fiscal year which ended before any transactions causing the termination began.
Notwithstanding the foregoing, the amount payable pursuant to this subparagraph H. (3) shall be due
only to the extent that, in BCBSA’s opinion, it does not cause the net worth of the Controlled Affiliate, the
Controlling Plans or any other Licensed Controlled Affiliates of the Controlling Plans to fall below 100% of
the Health Risk-Based Capital formula, or its equivalent under any successor formula, as set forth in the
applicable financial responsibility standards established by BCBSA (provided such equivalent is approved
for purposes of this subparagraph by the affirmative vote of three- fourths of the Plans and three-fourths
of the total then current weighted vote of all the Plans); measured as of the date of termination, and
adjusted for the value of any transactions not made in the ordinary course of business. This payment
shall not be due in connection with transactions exclusively by or among Plans (including the Controlling
Plans) or their affiliates, including reorganizations, combinations or mergers, where the BCBSA Board of
Directors determines that the license termination does not result in a material diminution in the number of
Licensed Enrollees or the extent of their coverage. In the event that the Controlled Affiliate’s license is
reinstated by BCBSA or is deemed to have remained in effect without interruption by a court of
competent jurisdiction, BCBSA shall reimburse the Controlled Affiliate (and/or the Controlling Plans or
their other Licensed Controlled Affiliates, as the case may be) for payments made under this
subparagraph 7.H.(3) only to the extent that such payments exceed the amounts due to BCBSA pursuant
to paragraph 7.K. and any costs associated with reestablishing the terminated Controlling Plan’s Service
Area or the Region, including any payments made by BCBSA to a Plan or Plans (including the other
Controlling Plans), or their Licensed Controlled Affiliates, for purposes of replacing the Controlled Affiliate.
(4) BCBSA shall have the right to audit the books and records of the Controlled Affiliate, the Controlling Plans,
and any other Licensed Controlled Affiliates of the Controlling Plans to verify compliance with this
paragraph 7.H.
(5) As to a breach of 7.H.(1), (2), (3) or (4), the parties agree that the obligations are immediately enforceable
in a court of competent jurisdiction. As to a breach of 7.H.(1), (2) or (4) by the Controlled Affiliate, the
parties agree there is no adequate remedy at law and BCBSA is entitled to obtain specific performance.
-9-

-- 446 of 533 --

I. BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of competent jurisdiction
from entry into any transaction which would result in a termination of this Agreement unless a Controlling
Plan’s license from BCBSA to use the Licensed Marks and Names has been terminated pursuant to 10(d) of
such Controlling Plan’s license agreement upon the required 6 month written notice.
J. BCBSA acknowledges that it is not the owner of assets of the Controlled Affiliate.
K. In the event this Agreement terminates and is subsequently reinstated by BCBSA or is deemed to have
remained in effect without interruption by a court of competent jurisdiction, the Controlled Affiliate, the
Controlling Plans, and any other
Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for reimbursing BCBSA the
reasonable costs incurred by BCBSA in connection with the termination and the reinstatement or court action,
and any associated legal proceedings, including but not limited to: outside legal fees, consulting fees, public
relations fees, advertising costs, and costs incurred to develop, lease or establish an interim provider network.
Any amount due to BCBSA under this subparagraph may be waived in whole or in part by the BCBSA Board of
Directors in its sole discretion.
8. DISPUTE RESOLUTION
The parties agree that any disputes between or among them or between or among any of them and one or more
Plans or Controlled Affiliates of Plans that use in any manner the Blue Shield and Blue Shield Marks and Name are
subject to the
Mediation and Mandatory Dispute Resolution process attached to and made a part of each Controlling Plan’s License
from BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-to-time, which documents are
incorporated herein by reference as though fully set forth herein.
9. LICENSE FEE
Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth Exhibit B.
10. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or
employment relationship between the Controlling Plans and Controlled Affiliate or between either and BCBSA.
11. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall
be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its
President and, if any, its General Counsel.
-10-

-- 447 of 533 --

12. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This
Agreement may only be amended by the affirmative vote of three-fourths of the Plans and three-fourths of the total
then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.
13. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such findings shall in no way
affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition for
any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits of
this Agreement.
14. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or any other licensee
of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or
default in performance of said terms, covenants or conditions.
14A. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the Blue
Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes
equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes
(if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all
questions requiring an affirmative three-fourths weighted vote of the Plans, voting shall occur pursuant to BCBSA’s
Bylaws.
Amended as of June 15, 2023
-11-

-- 448 of 533 --

15. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of
Illinois.
16. HEADINGS
The headings inserted in this agreement are for convenience only and shall have no bearing on the interpretation
hereof.
-12-

-- 449 of 533 --

IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed and effective as of the date of last
signature written below.
Controlled Affiliate:
By:_____________________________________
Date:____________________________________
Controlling Plan:
By:_____________________________________
Date:____________________________________
Controlling Plan:
By:_____________________________________
Date:____________________________________
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:______________________________________
Date:_____________________________________
-13-

-- 450 of 533 --

EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
APPLICABLE TO REGIONAL MEDICARE
ADVANTAGE PPO PRODUCTS
November 2023
PREAMBLE
The standards for licensing Controlled Affiliates for Medicare Advantage PPO Products are established by BCBSA and
are subject to change from time-to-time upon the affirmative vote of three-fourths (3/4) of the Plans and three-fourths (3/4)
of the total weighted vote. Each Controlling Plan is required to use a standard Controlled Affiliate license form provided by
BCBSA and to cooperate fully in assuring that the licensed Controlled Affiliate maintains compliance with the license
standards.
Standard 1 - Organization and Governance
A Controlled Affiliate is defined as an entity organized and operated in such a manner, that it meets the following
requirements:
(1) Controlled Affiliate is owned or controlled by two or more Controlling Plans;
(2) Each Controlling Plan is authorized pursuant to a separate Blue Shield License Agreement to use the Licensed Marks
in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of the
Controlling Plans; and
(3) The Controlling Plans must have the legal authority directly or indirectly through wholly- owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having not less than 100% voting control thereof;
(b) prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the
Controlled Affiliate with which the Controlling Plans do not concur;
(c) exercise control over the policy and operations of the Controlled Affiliate; and
-1-

-- 451 of 533 --

EXHIBIT A (continued)
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s establishing or governing
documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates (except such approval shall not be required with respect to
business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one of the
Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored by such
Controlling Plan);
(iii) change any of the type(s) of businesses in which it engages (except such approval shall not be required with
respect to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of
one of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA sponsored
by such Controlling Plan);
(iv) take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the Licensed Marks
and Name.
In addition, the Controlling Plans directly or indirectly through wholly-owned subsidiaries shall own 100% of any for-
profit Controlled Affiliate.
Standard 2 - Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial assurance that it can fulfill all of its
contractual obligations to its customers.
Standard 3 - State Licensure/Certification
A Controlled Affiliate shall maintain appropriate and unimpaired licensure and certifications.
-2-

-- 452 of 533 --

Standard 4 - Certain Disclosures
A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public
statements of:
a. the structure of the Blue Cross and Blue Shield System; and
b. the independent nature of every licensee.
Standard 5 - Reports and Records for Controlled Affiliates
A Controlled Affiliate and/or its Controlling Plans shall furnish, on a timely and accurate basis, reports and records relating
to these Standards and the License Agreements between BCBSA and Controlled Affiliate.
Standard 6 - Best Efforts
During each year, a Controlled Affiliate shall use its best efforts to promote and build the value of the Blue Shield Marks.
Standard 7 - Participation in Certain National Programs
A Controlled Affiliate shall effectively and efficiently participate in certain national programs from time to time as may be
adopted by Member Plans for the purposes of providing ease of claims processing for customers receiving benefits
outside of the Controlled Affiliate’s service area.
National program requirements include:
a. Inter-Plan Teleprocessing System (ITS); and
b. Inter-Plan Medicare Advantage Program.
Standard 8 - Participation in Master Business Associate Agreement
Controlled Affiliates shall comply with the terms of the Business Associate Agreement for Blue Cross and Blue Shield
Licensees to the extent they perform the functions of a business associate or subcontractor to a business associate, as
defined by the Business Associate Agreement.
Amended as of November 15, 2007
-3-

-- 453 of 533 --

EXHIBIT B
ROYALTY FORMULA FOR SECTION 9 OF THE CONTROLLED AFFILIATE LICENSE AGREEMENTS APPLICABLE TO
REGIONAL MEDICARE ADVANTAGE PPO PRODUCTS
Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following formula:
An amount equal to its pro rata share of each Controlling Plan dues payable to BCBSA computed with the addition of the
Controlled Affiliate's members using the Marks on regional MAPPO products and related services as reported on the
Quarterly Enrollment Report with BCBSA. The payment by each Controlling Plan of its dues to BCBSA, including that
portion described in this paragraph, will satisfy the requirement of this paragraph, and no separate payment will be
necessary.
Amended as of June 14, 2007
-4-

-- 454 of 533 --

Exhibit 1C
BLUE SHIELD
CONTROLLED AFFILIATE LICENSE AGREEMENT
APPLICABLE TO REGIONAL MEDICARE PART D PRESCRIPTION
DRUG PLAN PRODUCTS
(Adopted by Member Plans at their November 16, 2023 meeting)
This Agreement by and among Blue Cross and Blue Shield Association ("BCBSA") and ___________(“Controlled
Affiliate"), a Controlled Affiliate of the Blue Cross Plan(s), known as ___________ ("Controlling Plans"), each of which is
also a Party signatory hereto.
WHEREAS, BCBSA is the owner of the BLUE SHIELD and BLUE SHIELD Design service marks;
WHEREAS, under the Medicare Modernization Act, companies may apply to and be awarded a contract by the
Centers for Medicare and Medicaid Services (“CMS”) to offer Medicare Part D Prescription Drug Plan products in
geographic regions designated by CMS (hereafter “regional PDP products”).
WHEREAS, some of the CMS-designated regions include the Service Areas, or portions thereof, of more than one
Plan.
WHEREAS, the Controlling Plans and Controlled Affiliate desire that the latter be entitled to use the BLUE SHIELD
and BLUE SHIELD Design service marks (collectively the "Licensed Marks") as service marks and be entitled to use the
term BLUE SHIELD in a trade name ("Licensed Name") to offer regional PDP products in a region that includes the Service
Areas, or portions thereof, of more than one Controlling Plan;
NOW THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree
as follows:
1. GRANT OF LICENSE
Subject to the terms and conditions of this Agreement, BCBSA hereby grants to Controlled Affiliate the right to use the
Licensed Marks and Name in connection with, and only in connection with the sale, marketing and administration of
regional PDP products and related services.
This grant of rights is non-exclusive and is limited to the following states:
_______________(the “Region”). Controlled Affiliate may use the Licensed
-1-

-- 455 of 533 --

Marks and Name in its legal name on the following conditions: (i) the legal name must be approved in advance, in
writing, by BCBSA; (ii) Controlled Affiliate shall not do business outside the Region under any name or mark except
business conducted in the Service Area of a Controlling Plan provided that Controlled Affiliate is separately licensed
by BCBSA to use the Licensed Marks and Name in connection with health care plans and related services in the
Service Area of such Controlling Plan; and (iii) Controlled Affiliate shall not use the Licensed Marks and Name, or
any derivative thereof, as part of any name or symbol used to identify itself in any securities market. Controlled
Affiliate may use the Licensed Marks and Name in its Trade Name only with the prior, written, consent of BCBSA.
2. QUALITY CONTROL
A. Controlled Affiliate agrees to use the Licensed Marks and Name only in connection with the licensed services
and further agrees to be bound by the conditions regarding quality control shown in attached Exhibit A as they
may be amended by BCBSA from time-to-time.
B. Controlled Affiliate agrees to comply with all applicable federal, state and local laws.
C. Controlled Affiliate agrees that it will provide on an annual basis (or more often if reasonably required by the
Controlling Plans or by BCBSA) a report or reports to the Controlling Plans and BCBSA demonstrating
Controlled Affiliate's compliance with the requirements of this Agreement including but not limited to the quality
control provisions of this paragraph and the attached Exhibit A.
D. Controlled Affiliate agrees that the Controlling Plans and/or BCBSA may, from time- to-time, upon reasonable
notice, review and inspect the manner and method of Controlled Affiliate's rendering of service and use of the
Licensed Marks and Name.
E. As used herein, a Controlled Affiliate is defined as an entity organized and operated in such a manner, that it
meets the following requirements:
(1) Controlled Affiliate is owned or controlled by two or more Controlling Plans;
(2) Each Controlling Plan is authorized pursuant to a separate Blue Shield License Agreement to use the
Licensed Marks in a geographic area in the Region and every geographic area in the Region is so licensed
to at least one of the Controlling Plans; and
-2-

-- 456 of 533 --

(3) The Controlling Plans must have the legal authority directly or indirectly through wholly-owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having not less than 100% voting control
thereof;
(b) to prevent any change in the articles of incorporation, bylaws or other establishing or governing
documents of the Controlled Affiliate with which the Controlling Plans do not concur;
(c) to exercise control over the policy and operations of the Controlled Affiliate; and
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s establishing
or governing documents must also require written approval by each of the Controlling Plans before the
Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates (except such approval shall not be required
with respect to business of the Controlled Affiliate conducted under the Licensed Marks within
the Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate
license agreement with BCBSA sponsored by such Controlling Plan);
(iii) change any of the type(s) of businesses in which it engages (except such approval shall not
be required with respect to business of the Controlled Affiliate conducted under the Licensed
Marks within the Service Area of one of the Controlling Plans pursuant to a separate
controlled affiliate license agreement with BCBSA sponsored by such Controlling Plan);
(iv) take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect
the Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly owned subsidiaries shall own 100%
of any for-profit Controlled Affiliate.
-3-

-- 457 of 533 --

3. SERVICE MARK USE
A. Controlled Affiliate recognizes the importance of a comprehensive national network of independent BCBSA
licensees which are committed to strengthening the Licensed Marks and Name. The Controlled Affiliate further
recognizes that its actions within the Region may affect the value of the Licensed Marks and Name nationwide.
B. Controlled Affiliate shall at all times make proper service mark use of the Licensed Marks and Name, including
but not limited to use of such symbols or words as BCBSA shall specify to protect the Licensed Marks and
Name and shall comply with such rules (generally applicable to Controlled Affiliates licensed to use the
Licensed Marks and Name) relative to service mark use, as are issued from time-to-time by BCBSA.
Controlled Affiliate recognizes and agrees that all use of the Licensed
Marks and Name by Controlled Affiliate shall inure to the benefit of BCBSA.
C. Controlled Affiliate may not directly or indirectly use the Licensed Marks and Name in a manner that transfers or
is intended to transfer in the Region the goodwill associated therewith to another mark or name, nor may
Controlled Affiliate engage in activity that may dilute or tarnish the unique value of the Licensed Marks and
Name.
D. Controlled Affiliate shall use its best efforts to promote and build the value of the Licensed Marks and Name in
connection with the sale, marketing and administration of regional PDP products and related services.
4. SUBLICENSING AND ASSIGNMENT
Controlled Affiliate shall not, directly or indirectly, sublicense, transfer, hypothecate, sell, encumber or mortgage, by
operation of law or otherwise, the rights granted hereunder and any such act shall be voidable at the sole option of
any Controlling Plan or BCBSA. This Agreement and all rights and duties hereunder are personal to Controlled
Affiliate.
5. INFRINGEMENT
Controlled Affiliate shall promptly notify the Controlling Plans and the Controlling Plans shall promptly notify BCBSA of any
suspected acts of infringement, unfair competition or passing off that may occur in relation to the Licensed Marks and Name.
Controlled Affiliate shall not be entitled to require the Controlling Plans or BCBSA to take any actions or institute any
proceedings to prevent infringement, unfair competition or passing off by third parties. Controlled Affiliate agrees to render to
the Controlling Plans and BCBSA, without charge, all reasonable assistance in connection with any matter pertaining to the
protection of the Licensed Marks and Name by BCBSA.
-4-

-- 458 of 533 --

6. LIABILITY INDEMNIFICATION
Controlled Affiliate and the Controlling Plans hereby agree to save, defend, indemnify and hold BCBSA harmless
from and against all claims, damages, liabilities and costs of every kind, nature and description (except those arising
solely as a result of BCBSA's negligence) that may arise as a result of or related to Controlled Affiliate's rendering of
services under the Licensed Marks and Name.
7. LICENSE TERM
A. Except as otherwise provided herein, the license granted by this Agreement shall remain in effect for a period of
one (1) year and shall be automatically extended for additional one (1) year periods unless terminated pursuant
to the provisions herein.
B. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further
action by any party or entity in the event that: (i) any one of the Controlling Plans ceases to be authorized to use
the Licensed Marks and Name; or (ii) pursuant to Paragraph 15(a)(x) of the Blue Shield License Agreement any
one of the Controlling Plans ceases to be authorized to use the Licensed Names and Marks in the Region.
C. Notwithstanding any other provision of this Agreement, this license to use the Licensed Marks and Name may
be forthwith terminated by the Controlling Plans or the affirmative vote of the majority of the Board of Directors
of BCBSA present and voting at a special meeting expressly called by BCBSA for the purpose on ten (10) days
written notice to the Controlling Plans advising of the specific matters at issue and granting the Controlling
Plans an opportunity to be heard and to present their response to the Board for: (1) failure to comply with any
applicable minimum capital or liquidity requirement under the quality control standards of this Agreement; or (2)
failure to comply with the "Organization and Governance" quality control standard of this Agreement; or (3)
impending financial insolvency; or (4) failure to comply with
any of the applicable requirements of Standards 2, 3, 4, or 5 of attached Exhibit A; or
(5) the pendency of any action instituted against the Controlled Affiliate seeking its dissolution or liquidation of
its assets or seeking appointment of a trustee, interim trustee, receiver or other custodian for any of its property
or business or seeking the declaration or establishment of a trust for any of its property or business, unless this
Controlled Affiliate License Agreement has been earlier terminated under paragraph 7(E); or (6) such other
reason as is determined in good faith immediately and irreparably to threaten the integrity and reputation of
BCBSA, the Plans (including the Controlling Plans), any other licensee including Controlled Affiliate and/or the
Licensed Marks and Name.
D. Except as otherwise provided in Paragraphs 7(B), 7(C) or 7(E) herein, should Controlled Affiliate fail to comply
with the provisions of this Agreement and not cure such failure within thirty (30) days of receiving written notice
thereof (or commence a cure within such thirty day period and continue diligent efforts to
-5-

-- 459 of 533 --

complete the cure if such curing cannot reasonably be completed within such thirty day period) BCBSA or the
Controlling Plans shall have the right to issue a notice that the Controlled Affiliate is in a state of noncompliance.
If a state of noncompliance as aforesaid is undisputed by the Controlled Affiliate or is found to exist by a
mandatory dispute resolution panel and is uncured as provided above, BCBSA shall have the right to seek
judicial enforcement of the Agreement or to issue a notice of termination thereof. Notwithstanding any other
provisions of this Agreement, any disputes as to the termination of this License pursuant to Paragraphs 7(B),
7(C) or 7(E) of this Agreement shall not be subject to mediation and mandatory dispute resolution. All other
disputes between or among BCBSA, any of the Controlling Plans and/or Controlled Affiliate shall be submitted
promptly to mediation and mandatory dispute resolution. The mandatory dispute resolution panel shall have
authority to issue orders for specific performance and assess monetary penalties. Except, however, as provided
in Paragraphs 7(B) and 7(E) of this Agreement, this license to use the Licensed Marks and Name may not be
finally terminated for any reason without the affirmative vote of a majority of the present and voting members of
the Board of Directors of BCBSA.
E. This Agreement and all of Controlled Affiliate's rights hereunder shall immediately terminate without any further
action by any party or entity in the event that:
(1) Controlled Affiliate shall no longer comply with item 2(E) above;
(2) 	Appropriate dues, royalties and other payments for Controlled Affiliate pursuant to paragraph 9 hereof,
which are the royalties for this License Agreement, are more than sixty (60) days in arrears to BCBSA; or
(3) 	Any of the following events occur: (i) a voluntary petition shall be filed by Controlled Affiliate seeking
bankruptcy, reorganization, arrangement with creditors or other relief under the bankruptcy laws of the
United States or any other law governing insolvency or debtor relief, or (ii) an involuntary petition or
proceeding shall be filed against Controlled Affiliate seeking bankruptcy, reorganization, arrangement with
creditors or other relief under the bankruptcy laws of the United States or any other law governing
insolvency or debtor relief and such petition or proceeding is consented to or acquiesced in by Controlled
Affiliate or is not dismissed within sixty (60) days of the date upon which the petition or other document
commencing the proceeding is served upon the Controlled Affiliate, or (iii) an order for relief is entered
against Controlled Affiliate in any case under the bankruptcy laws of the United States, or Controlled Affiliate
is adjudged bankrupt or insolvent as those terms are defined in the Uniform Commercial Code as enacted in
the State of Illinois by any court of competent jurisdiction, or (iv) Controlled Affiliate makes a general
assignment of its assets for the benefit of creditors, or (v) any government or any government official, office,
agency, branch, or unit assumes control of Controlled Affiliate or delinquency proceedings (voluntary or
involuntary) are instituted, or (vi) an action is brought by Controlled Affiliate seeking its dissolution or
liquidation of its assets or seeking the appointment of a trustee, interim
-6-

-- 460 of 533 --

trustee, receiver or other custodian for any of its property or business, or (vii) an action is instituted by any
governmental entity or officer against Controlled Affiliate seeking its dissolution or liquidation of its assets or
seeking the appointment of a trustee, interim trustee, receiver or other custodian for any of its property or
business and such action is consented to or acquiesced in by Controlled Affiliate or is not dismissed within
one hundred thirty (130) days of the date upon which the pleading or other document commencing the
action is served upon the Controlled Affiliate, provided that if the action is stayed or its prosecution is
enjoined, the one hundred thirty (130) day period is tolled for the duration of the stay or injunction, and
provided further, that the Association’s Board of Directors may toll or extend the 130 day period at any time
prior to its expiration, or (viii) a trustee, interim trustee, receiver or other custodian for any of Controlled
Affiliate's property or business is appointed or the Controlled Affiliate is ordered dissolved or liquidated.
Notwithstanding any other provision of this Agreement, a declaration or a request for declaration of the
existence of a trust over any of the Controlled Affiliate’s property or business shall not in itself be deemed to
constitute or seek appointment of a trustee, interim trustee, receiver or other custodian for purposes of
subparagraphs 7(E)(3)(vii) and (viii) of this Agreement.
F. Upon termination of this Agreement for cause or otherwise, Controlled Affiliate agrees that it shall immediately discontinue all
use of the Licensed Marks and Name, including any use in its trade name, except to the extent that it continues to be
authorized to use the Licensed Marks within the Service Area of one of the Controlling Plans pursuant to a separate controlled
affiliate license agreement with BCBSA sponsored by such Controlling Plan.
G. Upon termination of this Agreement, Controlled Affiliate shall immediately notify all of its customers to whom it
provides products or services under the Licensed Marks pursuant to this Agreement that it is no longer a
licensee of BCBSA and, if directed by the Association’s Board of Directors, shall provide instruction on how the
customer can contact BCBSA or a designated licensee to obtain further information on securing coverage. The
notification required by this paragraph shall be in writing and in a form approved by BCBSA. The BCBSA shall
have the right to audit the terminated entity's books and records to verify compliance with this paragraph.
H. In the event this Agreement terminates pursuant to 7(B) hereof, upon termination of this Agreement the
provisions of Paragraph 7(G) shall not apply and the following provisions shall apply, except that, in the event
that Controlled Affiliate is separately licensed by BCBSA to use the Licensed Marks in the Service Area of a
Controlling Plan and termination of this Agreement is due to a partial termination of such Controlling Plan’s
license pursuant to Paragraph 15(a)(x)(ii) of the Blue Shield License Agreement, the notices, national account
listing, payment, and audit right listed below shall be applicable solely with respect to the Region and the
geographic area for which the Controlling Plan’s license to use the Licensed Names and Marks is terminated:
-7-

-- 461 of 533 --

(1) The Controlled Affiliate shall send a notice through the U.S. mails, with first class postage affixed, to all
individual and group customers, providers, brokers and agents of products or services sold, marketed,
underwritten or administered by the Controlled Affiliate under the Licensed Marks and Name. The form
and content of the notice shall be specified by BCBSA and shall, at a minimum, notify the recipient of the
termination of the license, the consequences thereof, and instructions for obtaining alternate products or
services licensed by BCBSA. This notice shall be mailed within 15 days after termination.
(2) The Controlled Affiliate shall deliver to BCBSA within five days of a request by BCBSA a listing of national
accounts in which the Controlled Affiliate is involved (in a control, participating or servicing capacity),
identifying the national account and the Controlled Affiliate’s role therein.
(3) Unless the cause of termination is an event respecting BCBSA stated in paragraph 15(a) or (b) of the
Plan’s license agreement with BCBSA to use the Licensed Marks and Name, the Controlled Affiliate, the
Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly
liable for payment to BCBSA of an amount equal to $25 multiplied by the number of Licensed Enrollees
of the Controlled Affiliate; provided that if any Plan other than a Controlling Plan is permitted by BCBSA to
use marks or names licensed by BCBSA in a geographic area in the Region, the payment for Licensed
Enrollees in such geographic area shall be multiplied by a fraction, the numerator of which is the number
of Licensed Enrollees of the Controlled Affiliate, the Controlling Plans, and any other Licensed Controlled
Affiliates of the Controlling Plans in such geographic area and the denominator of which is the total
number of Licensed Enrollees in such geographic area. Licensed Enrollee means each and every person
and covered dependent who is enrolled as an individual or member of a group receiving products or
services sold, marketed or administered under marks or names licensed by BCBSA as determined at the
earlier of (i) the end of the last fiscal year of the terminated entity which ended prior to termination or (ii)
the fiscal year which ended before any transactions causing the termination began. Notwithstanding the
foregoing, the amount payable pursuant to this subparagraph H. (3) shall be due only to the extent that,
in BCBSA’s opinion, it does not cause the net worth of the Controlled Affiliate, the Controlling Plans or
any other Licensed Controlled Affiliates of the Controlling Plans to fall below 100% of the Health Risk-
Based Capital formula, or its equivalent under any successor formula, as set forth in the applicable
financial responsibility standards established by BCBSA (provided such equivalent is approved for
purposes of this subparagraph by the affirmative vote of three-fourths of the Plans and three- fourths of
the total then current weighted vote of all the Plans); measured as of the date of termination, and
adjusted for the value of any transactions not made in the ordinary course of business. This payment
shall not be due in connection with transactions exclusively by or among Plans (including the Controlling
Plans) or their affiliates, including reorganizations, combinations or mergers, where the BCBSA Board of
Directors determines that the license
-8-

-- 462 of 533 --

termination does not result in a material diminution in the number of Licensed Enrollees or the extent of
their coverage. In the event that the Controlled Affiliate’s license is reinstated by BCBSA or is deemed to
have remained in effect without interruption by a court of competent jurisdiction, BCBSA shall reimburse
the Controlled Affiliate (and/or the Controlling Plans or their other Licensed Controlled Affiliates, as the
case may be) for payments made under this subparagraph 7.H.(3) only to the extent that such payments
exceed the amounts due to BCBSA pursuant to paragraph 7.K. and any costs associated with
reestablishing the terminated Controlling Plan’s Service Area or the
Region, including any payments made by BCBSA to a Plan or Plans (including the other Controlling
Plans), or their Licensed Controlled Affiliates, for purposes of replacing the Controlled Affiliate.
(4) BCBSA shall have the right to audit the books and records of the Controlled Affiliate, the Controlling
Plans, and any other Licensed Controlled Affiliates of the Controlling Plans to verify compliance with this
paragraph 7.H.
(5) As to a breach of 7.H.(1), (2), (3) or (4), the parties agree that the obligations are immediately enforceable
in a court of competent jurisdiction. As to a
breach of 7.H.(1), (2) or (4) by the Controlled Affiliate,the parties agree there is no adequate remedy at
law and BCBSA is entitled to obtain specific performance.
I. BCBSA shall be entitled to enjoin the Controlled Affiliate or any related party in a court of competent jurisdiction
from entry into any transaction which would result in a termination of this Agreement unless a Controlling
Plan’s license from BCBSA to use the Licensed Marks and Names has been terminated pursuant to 10(d) of
such Controlling Plan’s license agreement upon the required 6 month written notice.
J. BCBSA acknowledges that it is not the owner of assets of the Controlled Affiliate.
K. In the event this Agreement terminates and is subsequently reinstated by BCBSA or is deemed to have
remained in effect without interruption by a court of competent jurisdiction, the Controlled Affiliate, the
Controlling Plans, and any other Licensed Controlled Affiliates of the Controlling Plans shall be jointly liable for
reimbursing BCBSA the reasonable costs incurred by BCBSA in connection with the termination and the
reinstatement or court action, and any associated legal proceedings, including but not limited to: outside legal
fees, consulting fees, public relations fees, advertising costs, and costs incurred to develop, lease or establish
an interim provider network. Any amount due to BCBSA under this subparagraph may be waived in whole or in
part by the BCBSA Board of Directors in its sole discretion.
-9-

-- 463 of 533 --

8. DISPUTE RESOLUTION
The parties agree that any disputes between or among them or between or among any of them and one or more
Plans or Controlled Affiliates of Plans that use in any manner the Blue Shield and Blue Shield Marks and Name are
subject to the Mediation and Mandatory Dispute Resolution process attached to and made a part of each
Controlling Plan’s License from BCBSA to use the Licensed Marks and Name as Exhibit 5 as amended from time-
to-time, which documents are incorporated herein by reference as though fully set forth herein.
9. LICENSE FEE
Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth in Exhibit
B.
10. JOINT VENTURE
Nothing contained in this Agreement shall be construed as creating a joint venture, partnership, agency or
employment relationship between the Controlling Plans and Controlled Affiliate or between either and BCBSA.
11. NOTICES AND CORRESPONDENCE
Notices regarding the subject matter of this Agreement or breach or termination thereof shall be in writing and shall
be addressed in duplicate to the last known address of each other party, marked respectively to the attention of its
President and, if any, its General Counsel.
12. COMPLETE AGREEMENT
This Agreement contains the complete understandings of the parties in relation to the subject matter hereof. This
Agreement may only be amended by the affirmative vote of three-fourths of the Plans and three-fourths of the total
then current weighted vote of all the Plans as officially recorded by the BCBSA Corporate Secretary.
-10-

-- 464 of 533 --

13. SEVERABILITY
If any term of this Agreement is held to be unlawful by a court of competent jurisdiction, such findings shall in no
way affect the remaining obligations of the parties hereunder and the court may substitute a lawful term or condition
for any unlawful term or condition so long as the effect of such substitution is to provide the parties with the benefits
of this Agreement.
14. NONWAIVER
No waiver by BCBSA of any breach or default in performance on the part of Controlled Affiliate or any other licensee
of any of the terms, covenants or conditions of this Agreement shall constitute a waiver of any subsequent breach or
default in performance of said terms, covenants or conditions.
14A. VOTING
For all provisions of this Agreement referring to voting, the term ‘Plans’ shall mean all entities licensed under the
Blue Cross License Agreement and/or the Blue Shield License Agreement, and in all votes of the Plans under this
Agreement the Plans shall vote together. For weighted votes of the Plans, the Plan shall have a number of votes
equal to the number of weighted votes (if any) that it holds as a Blue Cross Plan plus the number of weighted votes
(if any) that it holds as a Blue Shield Plan. For all other votes of the Plans, the Plan shall have one vote. For all
questions requiring an affirmative three-fourths weighted vote of the Plans, voting shall occur pursuant to BCBSA’s
Bylaws.
15. GOVERNING LAW
This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of
Illinois.
16. HEADINGS
The headings inserted in this agreement are for convenience only and shall have no bearing on the interpretation
hereof.
Amended as of June 15, 2023
-11-

-- 465 of 533 --

IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed
and effective as of the date of last signature written below.
Controlled Affiliate:
By:______________________________________
Date:_____________________________________
Controlling Plan:
By:______________________________________
Date:_____________________________________
Controlling Plan:
By:______________________________________
Date:_____________________________________
BLUE CROSS AND BLUE SHIELD ASSOCIATION
By:______________________________________
Date:_____________________________________
-12-

-- 466 of 533 --

EXHIBIT A
CONTROLLED AFFILIATE LICENSE STANDARDS
APPLICABLE TO REGIONAL MEDICARE
PART D PRESCRIPTION DRUG PLAN PRODUCTS
November 2023
PREAMBLE
The standards for licensing Controlled Affiliates for Medicare Part D Prescription Drug Plan Products are established by
BCBSA and are subject to change from time-to-time upon the affirmative vote of three-fourths (3/4) of the Plans and three-
fourths (3/4) of the total weighted vote. Each Controlling Plan is required to use a standard Controlled Affiliate license form
provided by BCBSA and to cooperate fully in assuring that the licensed Controlled Affiliate maintains compliance with the
license standards.
Standard 1 - Organization and Governance
A Controlled Affiliate is defined as an entity organized and operated in such a manner, that it meets the following
requirements:
(1) Controlled Affiliate is owned or controlled by two or more Controlling Plans;
(2) Each Controlling Plan is authorized pursuant to a separate Blue Shield License Agreement to use the Licensed Marks
in a geographic area in the Region and every geographic area in the Region is so licensed to at least one of the
Controlling Plans; and
(3) The Controlling Plans must have the legal authority directly or indirectly through wholly- owned subsidiaries:
(a) to select members of the Controlled Affiliate’s governing body having not less than 100% voting control thereof;
(b) prevent any change in the articles of incorporation, bylaws or other establishing or governing documents of the
Controlled Affiliate with which the Controlling Plans do not concur;
(c) exercise control over the policy and operations of the Controlled Affiliate; and
-13-

-- 467 of 533 --

EXHIBIT A (continued)
Notwithstanding anything to the contrary in (a) through (c) hereof, the Controlled Affiliate’s establishing or governing
documents must also require written approval by each of the Controlling Plans before the Controlled Affiliate can:
(i) change its legal and/or trade names;
(ii) change the geographic area in which it operates (except such approval shall not be required with respect
to business of the Controlled Affiliate conducted under the Licensed Marks within the Service Area of one
of the Controlling Plans pursuant to a separate controlled affiliate license agreement with BCBSA
sponsored by such Controlling Plan);
(iii) change any of the type(s) of businesses in which it engages (except such approval shall not be required
with respect to business of the Controlled Affiliate conducted under the Licensed Marks within the
Service Area of one of the Controlling Plans pursuant to a separate controlled affiliate license
agreement with BCBSA sponsored by such Controlling Plan);
(iv) take any action that any Controlling Plan or BCBSA reasonably believes will adversely affect the
Licensed Marks and Name.
In addition, the Controlling Plans directly or indirectly through wholly-owned subsidiaries shall own 100% of any for-profit
Controlled Affiliate.
Standard 2 - Financial Responsibility
A Controlled Affiliate shall be operated in a manner that provides reasonable financial
assurance that it can fulfill all of its contractual obligations to its customers.
Standard 3 - State Licensure/Certification
A Controlled Affiliate shall maintain appropriate and unimpaired licensure and certifications.
-14-

-- 468 of 533 --

EXHIBIT A (continued)
Standard 4 - Certain Disclosures
A Controlled Affiliate shall make adequate disclosure in contracting with third parties and in disseminating public statements
of:
a. the structure of the Blue Cross and Blue Shield System; and
b. the independent nature of every licensee.
Standard 5 - Reports and Records for Controlled Affiliates
A Controlled Affiliate and/or its Controlling Plans shall furnish, on a timely and accurate basis, reports and records relating
to these Standards and the License Agreements between BCBSA and Controlled Affiliate.
Standard 6 - Best Efforts
During each year, a Controlled Affiliate shall use its best efforts to promote and build the value of the Blue Shield Marks.
Standard 7 - Participation in Master Business Associate Agreement
Controlled Affiliates shall comply with the terms of the Business Associate Agreement for Blue Cross and Blue Shield
Licensees to the extent they perform the functions of a business associate or subcontractor to a business associate, as
defined by the Business Associate Agreement.
-15-

-- 469 of 533 --

EXHIBIT B
ROYALTY FORMULA FOR SECTION 9 OF THE
CONTROLLED AFFILIATE LICENSE AGREEMENTS
APPLICABLE TO REGIONAL MEDICARE PART D PRESCRIPTION DRUG PLAN PRODUCTS
Controlled Affiliate will pay BCBSA a fee for this license in accordance with the following formula:
An amount equal to its pro rata share of each Controlling Plan dues payable to BCBSA computed with the addition of the
Controlled Affiliate's members using the Marks on regional PDP products and related services as reported on the
Quarterly Enrollment Report with BCBSA. The payment by each Controlling Plan of its dues to BCBSA, including that
portion described in this paragraph, will satisfy the requirement of this paragraph, and no separate payment will be
necessary.
Amended as of June 14, 2007
-16-

-- 470 of 533 --

EXHIBIT 2
Membership Standards
Page 1 of 5
Preamble
The Membership Standards apply to all organizations seeking to become or to continue as Regular Members of the Blue Cross and
Blue Shield Association. Any organization seeking to become a Regular Member must be found to be in substantial compliance with
all Membership Standards at the time membership is granted and the organization must be found to be in substantial compliance with
all Membership Standards for a period of two (2) years preceding the date of its application. If Membership is sought by an entity
which controls or is controlled by one or more Plans, such compliance shall be determined on the basis of compliance by such Plan
or Plans.
The Regular Member Plans shall have authority to interpret these Standards.
A Regular Member Plan that operates as a “Shell Holding Company” is defined as an entity that assumes no underwriting risk and has
less than 1% of the consolidated enterprise assets (excludes investments in subsidiaries) and less than 5% of the consolidated
enterprise net general and administrative expenses.
A Regular Member Plan that operates as a “Hybrid Holding Company” is defined as an entity that assumes no underwriting risk and
has either more than 1% of the consolidated enterprise assets (excludes investments in subsidiaries) or more than 5% of the
consolidated enterprise net general and administrative expenses.
Standard 1: A Plan shall maintain a governing Board, which shall control the Plan and ensure that the Plan follows
appropriate practices of corporate governance. A Plan's Board shall not be controlled by any special interest
group, shall make an annual determination that a majority of its directors are independent, and shall act in
the best interest of its Corporation and its customers. The Board shall be composed
of a majority of persons other than providers of health care services, who shall be known as public members.
A public member shall not be an employee of or
have a financial interest in a health care provider, nor be a member of a
profession which provides health care services.
Amended as of March 15, 2007

-- 471 of 533 --

EXHIBIT 2
Membership Standards
Page 2 of 5
Standard 2: A Plan shall furnish to the Association on a timely and accurate basis reports and records relating to
compliance with these Standards and the License Agreements between the Association and the Plans.
Such reports and records are the following:
A. BCBSA Membership Information Request;
B. Triennial trade name and service mark usage material, including disclosure material under Standard 7;
C. Changes in the governance of the Plan, including changes in a Plan's Charter, Articles of Incorporation,
or Bylaws, changes in a Plan's Board composition, or changes in the identity of the Plan's Principal
Officers;
D. Written notice to BCBSA as soon as practicable but no later than 30 days after receipt of any litigation
filed against the Plan or any of its licensed controlled affiliates that includes allegations or claims that
directly reference and seeks to enjoin or otherwise challenge the License Agreements, the structure of
the Blue system, exclusive service areas, BCBSA, or any BCBSA rule, regulation, policy or Standard
(Qualifying Litigation).
• Notice of Qualifying Litigation to BCBSA must include (1) Name of the Case; (2) Case Number; (3)
Location/Where Case Pending; and (4) Date Plan Received, and be provided to BCBSA Senior
Vice President, General Counsel and Corporate Secretary.
E. Quarterly Financial Report, Semi-annual “Health Risk-Based Capital (HRBC) Report” as defined by
the NAIC, Annual Budget, Annual Certified Audit Report, Insurance Department Examination Report,
Annual Statement filed with State Insurance Department (with all attachments), Plan, Subsidiary and
Affiliate Report (new version starting for period ended 12/31/20 and thereafter); and
• Plans that are a Shell Holding Company as defined in the Preamble hereto are required to furnish
only a calendar year-end “Health Risk-Based Capital (HRBC) Report” as defined by the NAIC.
Amended as of March 17, 2022

-- 472 of 533 --

EXHIBIT 2
Membership Standards
Page 3 of 5
F. Quarterly Enrollment Report, Quarterly Member Touchpoint Measures Index (MTM) through
12/31/2011, and Semi-annual MTM Index starting 1/1/2012 and thereafter.
• 	For purposes of MTM reporting only, a Plan shall file a separate MTM report for each Geographic
Market.
Standard 3: A Plan shall be operated in a manner that provides reasonable financial assurance that it can fulfill its
contractual obligations to its customers.
Standard 4: A Plan shall be operated in a manner responsive to customer needs and requirements.
Standard 5: A Plan shall effectively and efficiently participate in each national program as from time to time may be
adopted by the Member Plans for the purposes of providing portability of membership between the Plans
and ease of claims processing for customers receiving benefits outside of the Plan's Service Area.
Such programs are applicable to Blue Cross and Blue Shield Plans, and include:
A. Inter-Plan Teleprocessing System (ITS);
B. BlueCard Program;
C. National Account Programs;
D. Business Associate Agreement for Blue Cross and Blue Shield Licensees,
effective April 14, 2003; and
E. Inter-Plan Medicare Advantage Program.
Amended as of March 17, 2022

-- 473 of 533 --

EXHIBIT 2
Membership Standards
Page 4 of 5
Standard 6: In addition to requirements under the national programs listed in Standard 5: Participation in National
Programs, a Plan shall take such action as required to ensure its financial performance in programs and
contracts of an inter-Plan nature or where the Association is a party.
Standard 7: A Plan shall make adequate disclosure in contracting with third parties and in disseminating public
statements of (i) the structure of the Blue Cross and Blue Shield System, (ii) the independent nature of
every Plan, and (iii) the Plan's financial condition.
Standard 8: A Plan shall cooperate with the Association's Board of Directors and its Organization and Governance
Committee in the administration of the Plan Performance Response Process and in addressing Plan
performance problems identified thereunder.
Standard 9: A Plan shall obtain a rating of its financial strength from an independent rating agency approved by the
Association's Board of Directors for such purpose.
Standard 10: 	Notwithstanding any other provision in this License Agreement, during each year, a Plan and its
Controlled Affiliate(s) engaged in providing licensable services (excluding Life Insurance and Charitable
Foundation Services) shall use their best efforts to promote and build the value of the Blue Shield Marks.
Standard 11: 	Neither a Plan nor any Larger Controlled Affiliate shall cause or permit an entity other than a Plan or a
Licensed Controlled Affiliate thereof to obtain control of the Plan or Larger Controlled Affiliate or to acquire
a substantial portion of its assets related to licensable services.
Amended as of June 16, 2005

-- 474 of 533 --

EXHIBIT 2
Membership Standards
Page 5 of 5
Standard 12: No provider network, or portion thereof, shall be rented or otherwise made available to a National
Competitor if the Licensed Marks or Names are used in any way with such network.
A provider network may be rented or otherwise made available, provided there is no use of the Licensed
Marks or Names with respect to the network being rented.
Standard 13: Each Plan shall operate in a manner to reasonably: 1) protect the security and confidentiality of Personally
Identifiable Information (PII) and Protected Health Information (PHI); 2) protect the Brands from
reputational damage; and 3) cooperate with BCBSA and other Plans if a data security incident or data
breach occurs.
Amended as of June 18, 2015

-- 475 of 533 --

EXHIBIT 3
GUIDELINES WITH RESPECT TO USE OF
LICENSED NAME AND MARKS IN CONNECTION WITH NATIONAL ACCOUNTS
Page 1 of 3
1. The strength of the Blue Cross/Blue Shield National Accounts mechanism, and the continued provision of cost
effective, quality health care benefits to National Accounts, are predicated on locally managed provider networks
coordinated on a national scale in a manner consistent with effective service to National Account customers and
consistent with the preservation of the integrity of the Blue Cross/Blue Shield system and the Licensed Marks.
These guidelines shall be interpreted in keeping with such ends.
2. A National Account is an entity with employee and/or retiree locations in more than one Plan's Service Area. Unless
otherwise agreed, a National Account is deemed located in the Service Area in which the corporate headquarters of
the National Account is located. A local plant, office or division headquarters of an entity may be deemed a separate
National Account when that local plant, office or division headquarters 1) has employee locations in more than one
Service Area, and 2) has independent health benefit decision-making authority for the employees working at such
local plant, office or division headquarters and for employees working at other locations outside the Service Area. In
such a case, the local plant, office or division headquarters is a National Account that is deemed located in the
Service Area in which such local plant, office or division headquarters is located. The Control Plan of a National
Account is the Plan in whose Service Area the National Account is located. A participating ("Par") Plan is a Plan in
whose Service Area the National Account has employee and/or retiree locations, but in which the National Account
is not located. In the event that a National Account parent company consolidates health benefit- decision making for
itself and its wholly-owned subsidiary companies, the parent company and the subsidiary companies shall be
considered one National Account. The Control
Plan for such a National Account shall be the Plan in whose Service Area the parent company headquarters is
located.
3. The National Account Guidelines enunciated herein below shall be applicable only with respect to the business of
new National Accounts acquired after January 1, 1991.
4. Control Plans shall utilize National Account identification cards complying with then currently effective BCBSA graphic
standards in connection with all National Accounts business to facilitate administration thereof, to minimize subscriber
and provider confusion, and to reflect a commitment to cooperation among Plans.
Amended as of June 12, 2003

-- 476 of 533 --

Exhibit 3
Page 2 of 3
5. Disputes among Plans and/or BCBSA as to the interpretation or implementation of these Guidelines or as to other
National Accounts issues shall be submitted to mediation and mandatory dispute resolution as provided in the
License Agreement. For two years from
the effective date of the License Agreement, however, such disputes shall be subject to mediation only, with the
results of such mediation to be collected and reported in order to establish more definitive operating parameters for
National Accounts business and to
serve as ground rules for future binding dispute resolution.
6. The Control Plan may use the BlueCard Program (as defined by IPPC) to deliver benefits
to employees and non-Medicare eligible retirees in a Participating Plan’s service area if an alternative arrangement
with the Participating Plan cannot be negotiated. The
Participating Plan’s minimum servicing requirement for those employees and non- Medicare retirees in its service
area is to deliver benefits using the BlueCard Program. Account delivery is subject to the policies, provisions and
procedures of the BlueCard Program.
7. For provider payments in a Participating Plan’s area (on non-BlueCard claims), payment to the provider may be made
by the Participating Plan or the Control Plan at the Participating Plan's option. If the Participating Plan elects to pay
the provider, it may not withhold payment of a claim verified by the Control Plan or its designated processor, and
payment must be in conformity with service criteria established by the Board of Directors of BCBSA (or an authorized
committee thereof) to assure prompt payment, good service and minimum confusion with providers and subscribers.
The Control Plan, at the Participating Plan's request, will also assure that measures are taken to protect the
confidentiality of the data pertaining to provider reimbursement levels and profiles.
Amended as of June 14, 1996

-- 477 of 533 --

Exhibit 3
Page 3 of 3
8. The Control Plan, in its financial agreements with a National Account, is expected to reasonably reflect the aggregate
amount of differentials passed along to the Control Plan by all Participating Plans in a National Account.
9. Other than in contracting with health care providers or soliciting such contracts in areas contiguous to a Plan's
Service Area in order to serve its subscribers or those of its licensed Controlled Affiliate residing or working in its
Service Area, a Control Plan may not use the Licensed Marks and/or Name, as a tag line or otherwise, to negotiate
directly with providers outside its Service Area.
Amended as of March 13, 2003

-- 478 of 533 --

EXHIBIT 4
GOVERNMENT PROGRAMS AND CERTAIN OTHER USES
Page 1 of 14
1. A Plan and its licensed Controlled Affiliate(s) “Licensees” may use the Licensed Marks and Name in bidding on and
executing a contract to serve a Government Program, and in thereafter communicating with the Government
concerning the Program. Licensees may NOT use the Brands in communications or transactions with beneficiaries
or providers in a Government program located outside its Service Area. For purposes of this Paragraph 1, the term
“Government Programs” shall mean any non-risk Medicare, Medicaid, and other non-risk program administered by a
government authority, and any successor program. Contracts with the United States Government or the Government
of a State or Municipality to provide health care coverage to its employees are not considered Government
programs.
2. In connection with activity otherwise in furtherance of the License Agreement, Licensees, except for Regional MA
PPO and PD Controlled Affiliates (see paragraph 3 below), may use the Licensed Marks and Name (also referred to
as “Brands”) outside the Licensee’s Service Area in the following circumstances which are deemed legitimate and
necessary and not likely to cause consumer confusion:
2.1 Common Business Communications
a. 	sending letterhead, envelopes, and similar items solely for administrative purposes (e.g., not for purposes of
marketing, advertising, promoting, selling or soliciting the sale of health care plans and related services);
b. distributing business cards other than in marketing and selling;
c. advertising in publications or electronic media solely to persons for employment;
Amended as of June 15, 2023

-- 479 of 533 --

EXHIBIT 4
Page 2 of 14
2.2 Marketing Spillover
a. advertising in print, electronic or other media which serve, as a substantial market, the Service Area of the
Licensee, provided that no Licensee may advertise outside its Service Area on the national broadcast or cable
networks and that advertisements in national print media are limited to the smallest regional edition
encompassing the Service Area;
b. advertising by direct mail where the addressee's zip code plus 4 includes, at least in part, the Licensee’s
Service Area;
2.3 Provider Contracting
a. contracting with health care providers or soliciting such contracts in a Contiguous Area in order to serve its
subscribers residing or working in its service area;
b. issuing a small sign containing the legal name or trade name of the Licensee for display by a provider in a
Contiguous Area to identify the provider as a participating provider of the Licensee;
c. negotiating case-specific reimbursement rates with a provider that does not have a contract applicable to a
specific member’s services rendered or to be rendered with the Licensee (or any of the Licensees in the case
of overlapping Service Areas) in whose Service Area the health care provider is located, so long as
(1) the Licensee engaging in the negotiations complies with all applicable Inter- Plan Programs Policies and
Provisions and Brand Regulations related to case- specific rate negotiations, and
(2) the Licensee (or all Licensees in the case of overlapping Service Areas) in whose Service Area the health
care provider is located provides consent before negotiations commence.
d. contracting with a pharmacy management organization (“Pharmacy Intermediary”) to gain access to a national or
regional pharmacy network to provide self-administered prescription drugs to deliver a pharmacy benefit for all
of the Licensee’s members nationwide, provided, however, that the Pharmacy Intermediary may not use the
Licensed Marks or Name in contracting with the pharmacy providers in such network.
Amended as of June 15, 2023

-- 480 of 533 --

EXHIBIT 4
Page 3 of 14
e. contracting with the corporate owner of a national or regional retail pharmacy chain
to gain access to the pharmacies in the chain to provide self-administered
prescription drugs to deliver a pharmacy benefit for all of the Licensee’s members nationwide, provided that (1)
the Plan and the Controlled Affiliate may not contract directly with pharmacists or pharmacy stores outside the
Plan’s Service Area, and (2) neither the Plan’s or the Controlled Affiliate’s name nor the Licensed Marks or
Name may be posted or otherwise displayed at or by any pharmacy store outside the Plan’s
Service Area;
f. contracting with a dental management organization (“Dental Intermediary”) to gain access to a national or
regional dental network to deliver a routine dental benefit for all of the Licensee’s members nationwide,
provided, however, that the Dental Intermediary may not use the Licensed Marks or Name in contracting with
the dental providers in such network;
(i) For purposes of this Exhibit, “routine dental benefit” covers four classes of dental services: (1)
preventative services (e.g., teeth cleaning, oral exams, x-ray and lab exams); (2) restorative
services (e.g. fillings, crowns, inlays/onlays, root canal, periodontal treatments, extractions,
repairs to partials); (3) construction of dentures and bridges; and (4) orthodontic tooth guidance
appliances (e.g., braces, habit-breaking appliances).
(ii) Examples of services that are not within the scope of “routine dental” include any medical oral or
maxillofacial procedures, including maxillofacial surgery, and diagnosis or treatment of the oral or
maxillofacial region as a result of disease, chronic illness, or injury.
g. contracting with a vision management organization (“Vision Intermediary”) to gain access to a national or
regional vision network to deliver a routine vision benefit for all of the Licensee’s members nationwide,
provided, however, that the Vision Intermediary may not use the Licensed Marks or Name in contracting with
the vision providers in such network;
(i) For purposes of this Exhibit, “routine vision benefit” covers routine eye exams, glasses (frames
and lenses), contact lenses, and Lasik surgery.
(ii) Examples of services that are not within the scope of “routine vision” include any medical vision
procedures, including eye surgery, and the diagnosis or treatment of the eye as a result of
disease, chronic illness, or injury.
h. contracting with an independent clinical laboratory for analysis and clinical assessment of specimens that are
collected within the Licensee’s Service Area;
i. contracting with a durable medical equipment or home medical equipment company for durable medical
equipment and supplies and home medical equipment and supplies that are shipped to a location within the
Licensee’s Service Area;
Amended as of June 15, 2023

-- 481 of 533 --

EXHIBIT 4
Page 4 of 14
j. contracting with a specialty pharmaceutical company for non-routine biological therapeutics that are ordered by a
health care professional located within the Licensee’s Service Area;
k. contracting with a company that operates provider sites in the Licensee’s Service Area, provided that the
contract is solely for services rendered at a site (e.g., hospital, mobile van) that is within the Licensee’s Service
Area;
l. contracting with a company that makes health care professionals available in the Licensee’s Service Area (e.g.,
traveling home health nurse), provided that the contract is solely for services rendered by health care
professionals who are located within the Licensee’s Service Area.
m. Permitting Control/Home Plans’ ability to resolve members’ service issues requiring outreach to out-of-area
providers as set forth in the Inter-Plan Programs and Inter- Plan Medicare Advantage Program Policies.
n. contracting with national telemedicine and virtual healthcare (i.e., telehealth
providers) companies nationally for all virtual-only health care services in accordance with Inter-Plan Programs
and Inter-Plan Medicare Advantage Policies and
Provisions.
2.4 Services to National Accounts
a. in conjunction with contracting with a National Account as Control Licensee or Alternate Control Licensee (as
those terms are defined in the Inter-Plan Programs Policies and Provisions (“IP Policies”) to offer Blue-branded
Health Coverage to the National Account, offering Blue-branded Health and Wellness Programs to all members
of the National Account, including members who have not enrolled in the Blue-branded Health Coverage (“non-
Blue Health Coverage members”), provided that:
(i) the Licensee has no contact or interaction with providers outside of the Licensee’s Service Area,
except as specifically provided in the IP
Policies and in 2.4(b); and
(ii) if in accordance with IP Policies another Licensee is soliciting or servicing under the Licensed Marks
and Name a local plant, office or division of the account that is outside of the Control/Alternate
Licensee’s Service Area,
the Control/Alternate Licensee may not offer Blue-branded Health and Wellness Programs to any
employees working at such local plant, office
or division without the consent of such other Licensee; and
(iii) if the Licensee provides an information card to the non-Blue Health
Coverage members, the card may not display the Licensed Marks in the masthead, must contain a
prominent disclosure conveying that it is not a health insurance card, and otherwise must be designed
so that it is
dissimilar to a Blue member identification card.
Amended as of June 15, 2023

-- 482 of 533 --

EXHIBIT 4
Page 5 of 14
2.4 Services to National Accounts (continued)
For purposes of this subparagraph a, and below subparagraph b,the following definitions apply:
“Health and Wellness Program” shall mean a program that includes at least one of the following elements or a
related element:
• Health Risk Assessment and/or Preventive Screenings
• Exercise and Fitness Programs
• Health and Wellness Events (e.g., attendance at a health fair, a 5K walk)
• Nutrition and Weight Management
• Health Education (e.g., smoking cessation classes)
• Prenatal and Parenting Education
• Disease or Chronic Condition Management
The above listing is intended to represent examples of the types of programs that may be offered, and other programs,
including those offered through different media such as the internet or telephonically, may also be deemed Health and
Wellness programs.
“Health Coverage” shall mean providing or administering medical, surgical, hospital, major medical, or catastrophic
coverage, or any HMO, PPO, POS or other managed care plan for the foregoing services.
b. as part of a Health and Wellness Program that is otherwise compliant with
subparagraph a above, contracting with a health and wellness organization to gain access to providers to deliver a
discrete health and wellness event (“Event”) held at a National Account’s worksite outside of the Licensee’s Service
Area, provided that:
(i) the services delivered at the Event are limited to fingerstick screenings for cholesterol and glucose, seasonal
flu immunizations, blood pressure measurements, body mass index measurements, and other routine
screenings, immunizations and measurements; and
(ii) neither such services nor their costs are applied as claims against any benefit
plan; and
(iii) the Event is presented during one or more limited periods during a benefit year
and is available to all employees at the worksite.
Amended as of June 15, 2023

-- 483 of 533 --

EXHIBIT 4
Page 6 of 14
c. in conjunction with contracting with a National Account as Control/Alternate Licensee to offer Blue-branded
Health Coverage to the National Account, performing the Eligibility and Enrollment functions of HR
administration for all benefit plans offered by the National Account to its members, including benefit plans that
are not underwritten or administered by the Control/Alternate Licensee, provided that:
(i) in performing such functions, Licensee does not use the Licensed Marks and Name in any
communications with health care providers outside of the Licensee’s Service Area, and otherwise limits
its use of the Licensed Marks and Name outside of the Service Area to communications with the
account’s members, the other benefit plan providers with which the account has contracted and other
reasonably necessary communications to perform such functions; and
(ii) if in accordance with IP Policies another Licensee is soliciting or servicing under the Licensed Marks and
Name a local plant, office or division of the account that is outside of the Plan’s Service Area, Licensee
may not perform Eligibility and Enrollment functions for employees working at such local plant, office or
division without the consent of such other Licensee;
d. in conjunction with contracting with a National Account as Control/Alternate Licensee to perform or investigate
fraud, waste and abuse investigation activities for a non- participating provider in a Par/Host Plan’s service
area, as long as the Control/Home Plan is given permission to do so by the Par/Host Plan and specific
conditions are met in accordance with Inter-Plan Programs and Inter-Plan Medicare Advantage Program
policies.
Amended as of June 15, 2023

-- 484 of 533 --

EXHIBIT 4
Page 7 of 14
For purposes of this Exhibit, the following definitions apply:
“Eligibility” means services that manage the account’s eligibility data and determine or process determinations
relating to eligibility for benefit plans offered by the account to its employees, including such services as:
• monitoring and auditing data to ensure that only entitled individuals are enrolled in each such benefit plan;
• review of eligibility documentation (e.g. marriage licenses, birth certificates, student status verification
letters, employment records);
• identification of key member segments such as over-age dependents, part-time employees, employees
reaching certain milestones (e.g. Medicare-eligible, retirees);
• termination of coverage for those individuals found to be ineligible for coverage under a benefit plan, and,
if applicable, generation of a COBRA event; and
•
• management of “hour-banking” for union environments in which union members can bank hours to remain
eligible for benefits.
“Enrollment” means services that enroll eligible individuals and their spouses/dependents or terminate or change
their enrollment in the account’s benefit plans on an ongoing basis and during open enrollment periods, including
such services as:
• the coordination of each step in open enrollment process from project planning and system set-up to the
generation of confirmation statements;
• ongoing enrollment support for new hires and changes due to life events and work status adjustments;
• evidence of insurability (EOI) administration for life and disability coverage;
• transmission of eligibility/enrollment information to the account’s benefit plan providers;
• review and reconciliation of error reports received from the account’s benefit plan providers; and
• transmission of information to the account’s payroll system (e.g., benefit deductions, employee
demographic data).
Amended as of March 26, 2015

-- 485 of 533 --

EXHIBIT 4
Page 8 of 14
2.5 Conferences and Symposiums
a. submitting scholarly articles authored or co-authored by the Licensee or its respective employees for publication
in peer-reviewed journals (see BCBSA’s Brand Use Center);
b. permitting an internal representative of the Licensee to participate at a conference or symposium outside of the
Licensee’s Service Area regarding either (i) healthcare financing, administration, delivery or policy, or (ii) topics
within the representative’s functional discipline or expertise at the Licensee, for which the event sponsor will
issue communications to promote, administer, and/or recap the event that will identify the Licensee and/or the
Licensee’s representative as a participant. The communications outside of the Licensee’s Service Area that
mention the Licensee and/or the Licensee’s representative shall be limited to materials and digital media
provided to attendees, on-site signage, advertising in relevant trade publications, direct mail and email to
attendees and prospective attendees, and the sponsor’s website. A participating Licensee will also be
permitted to display/share communications at the conference or symposium subject to the requirements set
forth in (c) below.
c. Participating in any conference or symposium outside of the Licensee’s Service Area may not be for the purpose
of marketing or selling products or services unless there is a clear connection between the Licensee and the
reasoning for attending such conference or symposium (e.g., health care decision makers within the Licensee’s
service area will also be at the conference, the conference has a nexus to the Licensee’s service area even
though the conference is taking place elsewhere) and the Licensee has provided BCBSA with advanced written
notice prior to participating.
(i) Licensees may establish a booth to support at Conferences or Symposiums consistent with the above.
Any materials containing the Brands must include a disclosure clearly indicating the Licensee’s name or
trade name as well as an indication of where the Licensee provides products and services (i.e. BCBS of
Geography)
(ii) Licensees may not co-exhibit or promote the products and/or services of an unlicensed affiliate.
Amended as of November 16, 2023

-- 486 of 533 --

EXHIBIT 4
Page 9 of 14
2.6 Other Uses*
a. entering into a license agreement between and among BCBSA, the Licensee and a debit card issuer located
outside the Licensee’s Service Area, and entering into a corresponding operating agreement or agreements, in
order to offer a debit card bearing the Licensed Marks and Name to eligible persons as defined by the
aforementioned license agreement;
b. appearing in communications issued by an independent third party to recognize outstanding performance of the
Licensee or a member of the Licensee’s senior management as part of an established program of the third
party for which the Licensee has provided information to be considered for the recognition The areas of
recognition must relate to a Licensee’s performance as an employer or corporate citizen, or for a corporate
business function other than sales or marketing (e.g. human resources, underwriting). The third party’s
communication of the recognition must appear only in its customary media and form used with the established
program.
c. to identify itself as being a joint sponsor of an event, program or activity (e.g, a 5k run, a public event, a
wellness education seminar) along with other Licensees provided that the following conditions are met:
(i) Written notification is provided to BCBSA staff at least 30 days before the event or when the Licensee
executes a sponsorship agreement, whichever is earlier, identifying the joint sponsorship opportunity and
the participating licensees, and including a sample of the proposed branding consistent with the template
that is required under 2.6(c)(v).
(ii) Communications and materials relating to such joint sponsorship may appear solely within the Service
Areas of Licensees who have provided prior consent, are participating in such joint sponsorship program
and whose names appear in such communications and materials. In each participating Licensee’s Service
Area, such participating Licensee’s name must appear in all such communications and materials with at
least equal prominence as the names of other listed participating Licensees;
(iii) The joint sponsorship program may not involve the marketing, promotions, or sale of products or
services;
Amended as of June 15, 2023

-- 487 of 533 --

EXHIBIT 4
Page 10 of 14
(iv) If in any Service area or portion thereof covered by the joint sponsorship program, a Licensee that has
exclusive rights to one of the Brands (e.g. Blue Shield marks) is not participating, the participating
Licensees may not use that Brand in that Service Area or portion thereof. For example, if BCBS of
Geography A and Blue Cross of Geography B enter into a joint sponsorship program to be displayed in
Blue Cross of Geography B’s Service Area, but Blue Shield of Geography B has exclusive rights to use
the Blue Shield marks in Geography B and does not participate, then the Blue Shield marks may not be
used in Geography B in any manner in connections with the joint sponsorship program, not even in BCBS
of Geography A’s name. BCBS of Geography A may apply for approval under the BlueCross BlueShield
Brand Book to adopt a shortened trade name (e.g., Blue Cross of Geography A) for use in connection with
the program in Geography B, and
(v.) Subject to the limitations set forth above, the participating Licensees shall use one of the designated
templates shown in Appendix C of the BlueCross BlueShield Brand Book for branding of the joint
sponsorship. For clarification, the templates identified herein shall apply only to the manner in which the
participating Licensees’ Blue logos appear in one visual representation to identify the sponsors and does
not apply to any other aspect of the sponsorship branding.
d. hosting meetings or events (collectively, “events”) in Washington, D.C. or a Plan’s State Capitol related to policy
and business issues in the Licensee’s Service Area, or hosting events in conjunction with the assemblies or
conventions of national political parties. Such events may not involve marketing or selling products or services.
Use of the Licensed Marks and Name outside the Licensee’s Service Area in connection with such events shall
be limited to materials and digital media provided to attendees and prospective attendees and onsite signage.
For any such events in Washington,
D.C. that are open to attendees other than government officials or their staffs, or are briefings open to all
Congressional staff, or are otherwise likely to receive media coverage, the Licensee is required to provide
advance notice to BCBSA. For events hosted outside of Washington, D.C. in conjunction with the assemblies
or conventions of national political parties, the Licensee is required to provide advance notice to BCGSA and to
the local Plan(s);
e. permitting an affiliate that is not licensed to use the Licensed Names and Marks to identify its corporate
relationship with the Plan pursuant to the BlueCross BlueShield Brand Book as amended by BCBSA from time
to time;
*(Illustrative examples of Other Uses provisions are found on BCBSA’s Brand Use Center).
Amended as of June 15, 2023

-- 488 of 533 --

EXHIBIT 4
Page 11 of 14
2.7. Definition of Contiguous Area
For the purposes of this Exhibit, Contiguous Area means the greater of;
• One county into an adjoining Service Area; or
• An entire Metropolitan Statistical Area (“MSA”) as defined by the most recent publication of the United States Department of
Commerce, partly in a Licensee’s Service Area and partly in portions of other Licensee(s) Service Area; or
• A larger area in an adjoining Service Area approved in advance by the Organization and Governance Committee because of
unique geographical or demographic circumstance.
3. In connection with activity otherwise in furtherance of the License Agreement, a Controlled Affiliate that is licensed to
use the Licensed Marks and Name pursuant to a Controlled Affiliate License Agreement authorized in clauses d) or
e) of Paragraph 2 of the Plan’s License Agreement with BCBSA may use the Licensed Marks and Name outside the
Region (as that term is defined in such respective Controlled Affiliate License Agreements) in the following
circumstances which are deemed legitimate and necessary and not likely to cause consumer confusion:
a. 	sending letterhead, envelopes, and similar items solely for administrative purposes (e.g., not for purposes of
marketing, advertising, promoting, selling or soliciting the sale of health care plans and related services).
b. distributing business cards other than in marketing and selling;
c. contracting with health care providers or soliciting such contracts in areas contiguous to the Region in order to
serve its subscribers residing in the Region, provided that the Controlled Affiliate may not use the names of
any of its Controlling Plans in connection with such contracting unless the provider is located in a geographic
area that is also contiguous to such Controlling Plan’s Service Area;
d. issuing a small sign containing the legal name or trade name of the Controlled Affiliate for display by a provider
to identify the latter as a participating provider of the Controlled Affiliate, provided that the Controlled Affiliate
may not use the names of any of its Controlling Plans on such signs unless the provider is located in a
geographic area that is also contiguous to such Controlling Plan’s Service Area;
e. advertising in publications or electronic media solely to persons for employment;
Amended as of June 15, 2023

-- 489 of 533 --

EXHIBIT 4
Page 12 of 14
f. advertising in print, electronic or other media which serve, as a substantial market, the Region, provided that the
Controlled Affiliate may not advertise outside its Region on the national broadcast and cable networks and that
advertisements in national print media are limited to the smallest regional edition encompassing the Region,
and provided further that any such advertising by the Controlled Affiliate may not reference the name of any of
its Controlling Plans unless the respective Controlling Plan is authorized under paragraph 2 of this Exhibit 4 to
advertise in such media;
g. advertising by direct mail where the addressee's zip code plus 4 includes, at least in part, the Region, provided
that such advertising by the Controlled Affiliate may not reference the name of any of its Controlling Plans
unless the respective Controlling Plan is authorized under paragraph 2 of this Exhibit 4 to send direct mail to
such zip code plus 4.
h. [Intentionally left blank, pending review by the Inter-Plan Programs Committee of the applicability of the case
management rule to such Controlled Affiliates.]
i. contracting with a pharmacy management organization (“Pharmacy Intermediary”) to gain access to a national or
regional pharmacy network to provide self-administered prescription drugs to deliver a pharmacy benefit for the
Controlled Affiliate’s regional Medicare Advantage PPO or regional Medicare Part D Prescription Drug
members enrolled under the Licensed Marks pursuant to such respective Controlled Affiliate License
Agreements, provided, however, that the Pharmacy Intermediary may not use the Licensed Marks or Name in
contracting with the pharmacy providers in such network;
j. contracting with the corporate owner of a national or regional retail pharmacy chain to gain access to the
pharmacies in the chain to provide self-administered prescription drugs to deliver a pharmacy benefit to the
Controlled Affiliate’s regional Medicare Advantage PPO or regional Medicare Part D Prescription Drug
members enrolled under the Licensed Marks pursuant to such respective Controlled Affiliate License
Agreements, provided that (1) the Controlled Affiliate may not contract directly with pharmacists or pharmacy
stores outside the Region, and (2) neither the Controlled Affiliate’s name nor the Licensed Marks or Name may
be posted or otherwise displayed at or by any pharmacy store outside the Region;
k. contracting with a dental management organization (“Dental Intermediary”) to gain access to a national or
regional dental network to deliver a routine dental benefit for the Controlled Affiliate’s regional Medicare
Advantage PPO members enrolled under the Licensed Marks pursuant to such Controlled Affiliate License
Agreement, provided, however, that the Dental Intermediary may not use the Licensed Marks or Name in
contracting with the dental providers in such network;
Amended as of June 15, 2023

-- 490 of 533 --

EXHIBIT 4
Page 13 of 14
l. contracting with a vision management organization (“Vision Intermediary”) to gain access to a national or
regional vision network to deliver a routine vision benefit for the Controlled Affiliate’s regional Medicare
Advantage members enrolled under the Licensed Marks pursuant to such Controlled Affiliate License
Agreement, provided, however, that the Vision Intermediary may not use the Licensed Marks or Name in
contracting with the vision providers in such network;
m. contracting with an independent clinical laboratory for analysis and clinical assessment of specimens that are
collected within the Controlled Affiliate’s Region;
n. contracting with a durable medical equipment or home medical equipment company for durable medical
equipment and supplies and home medical equipment and supplies that are shipped to a location within the
Controlled Affiliate’s Region;
o. contracting with a specialty pharmaceutical company for non-routine biological therapeutics that are ordered by a
health care professional located within the Region;
p. contracting with a company that operates provider sites in the Region, provided that the contract is solely for
services rendered at a site (e.g., hospital, mobile van) that is within the Region;
q. contracting with a company that makes health care professionals available in the Region (e.g., traveling home
health nurse), provided that the contract is solely for services rendered by health care professionals who are
located within the Region.
Amended as of June 15, 2023

-- 491 of 533 --

EXHIBIT 4
Page 14 of 14
4. BCBSA shall retain the right to use the Licensed Marks in conjunction with the Federal Employee Program and with any other
national offering made to federal employees pursuant to the Federal Employees Health Benefits Program (FEHBP), including
the right to license such use to its vendors, but only in the following manner.
a. the Licensed Marks may only be used by BCBSA with the term “Federal Employee Program”, “Federal”, “FEP”,
or similar language identifying the program as a benefit program for federal employees;
b. the Licensed Marks may not be used by BCBSA with the name(s) of a specific Plan
or Plans and;
c. any use by BCBSA in conjunction with a new national FEHBP program proposed after the enactment of this
amendment will require the approval of the BCBSA Board
of Directors.
5. Where required by applicable state or local law or regulation, a Plan or its licensed Controlled Affiliate may submit
documents that contain the Brands to, and file forms that contain the Brands with, state or local regulators in a state
not included in its Service Area, provided that it gives reasonable advance notice to the local Plan of its intent to
submit such documents or file such forms. Notwithstanding, in no event may a Plan or its
licensed Controlled Affiliate use the Brands to register, or to obtain or maintain a license, a certificate of authority, or
an equivalent document authorizing it to act as a risk-bearing entity or third-party administrator in a state not included
in its Service Area. If the local
Plan advises BCBSA that it believes its License Agreement has been or would be violated by any submission or
filing, BCBSA shall determine whether such submission or filing is required by state or local law or regulation and
violates the License Agreement, subject to the Plan’s or licensed Controlled Affiliate’s rights to obtain an independent
review of such determination under Paragraph 9(a) and Exhibit 5 of its License Agreement or Paragraph
8 of the Controlled Affiliate License. For purposes of this paragraph, “local Plan” is defined as each Plan whose
Service Area includes all or part of the state in which the foregoing applicable state or local law or regulation has
been enacted.
Amended as of June 15, 2023

-- 492 of 533 --

EXHIBIT 5
Page 1 of 23
MEDIATION AND MANDATORY DISPUTE RESOLUTION (MMDR) RULES
The Blue Cross and Blue Shield Plans ("Plans") and the Blue Cross Blue Shield Association ("BCBSA") recognize and
acknowledge that the Blue Cross and Blue Shield system is a unique nonprofit and for-profit system offering cost effective
health care financing and services. The Plans and BCBSA desire to utilize Mediation and Mandatory Dispute Resolution
(“MMDR”) to avoid expensive and time-consuming litigation that may otherwise occur in the federal and state judicial
systems. Even MMDR should be viewed, however, as methods of last resort, all other procedures for dispute resolution
having failed. Except as otherwise provided in the License Agreements, the Plans, their Controlled Affiliates and BCBSA
agree to submit all disputes to MMDR pursuant to these Rules and in lieu of litigation.
1. Initiation of Proceedings
A. Pre-MMDR Efforts
Before filing a Complaint to invoke the MMDR process, the CEO of a complaining party, or his/her designated
representative, shall undertake good faith efforts with the other side(s) to try to resolve any dispute.
B. Complaint
To commence a proceeding, the complaining party (or parties) shall provide by certified mail, return receipt
requested, a written Complaint to the BCBSA Corporate Secretary (which shall also constitute service on
BCBSA if it is a respondent) and to any Plan(s) and/or Controlled Affiliate(s) named therein. The Complaint shall
contain:
i. identification of the complaining party (or parties) requesting the proceeding;
ii. identification of the respondent(s);
iii. identification of any other persons or entities who are interested in a resolution
of the dispute;
iv. a full statement describing the nature of the dispute;
v. identification of all of the issues that are being submitted for resolution;
Amended as of November 21, 1996

-- 493 of 533 --

EXHIBIT 5
Page 2 of 23
vi. the remedy sought;
vii. a statement as to whether the complaining party (or parties) elect(s) first to pursue Mediation;
viii. any request, if applicable, that the matter be handled on an expedited basis
and the reasons therefor; and
ix. a statement signed by the CEO of the complaining party affirming that the CEO has undertaken efforts, or
has directed efforts to be undertaken, to resolve the dispute before resorting to the MMDR process.
The complaining party (or parties) shall file and serve with the Complaint copies of all documents which the
party (or parties) intend(s) to offer at the Arbitration Hearing
and a statement identifying the witnesses the party (or parties) intend(s) to present at the Hearing, along with a
summary of each witness' expected testimony.
C. Answer
Within twenty (20) days after receipt of the Complaint, each respondent shall serve on BCBSA and on the
complaining party (or parties):
i. a full Answer to the aforesaid Complaint;
ii. a statement of any Counterclaims against the complaining party (or parties), providing with respect thereto
the information specified in Paragraph 1.B., above;
iii. a statement as to whether the respondent elects to first pursue Mediation; and
iv. any request, if applicable, that the matter be handled on an expedited basis
and the reasons therefor.
The respondent(s) shall file and serve with the Answer or by the date of the Initial Conference set forth in
Paragraph 3.C., below, copies of all documents which the respondent(s) intend(s) to offer at the Arbitration
Hearing and a statement identifying the witnesses the party (or parties) intend(s) to present at the Hearing,
along with a summary of each witness' expected testimony.
Amended as of September 20, 2007

-- 494 of 533 --

EXHIBIT 5
Page 3 of 23
D. Reply To Counterclaim
Within ten (10) days after receipt of any Counterclaim, the complaining party (or parties) shall serve on
BCBSA and on the responding party (or parties) a Reply to the Counterclaim. Such Reply must provide the
same information required by Paragraph 1.C., above.
2. Mediation
To facilitate the mediation of disputes between or among BCBSA, the Plans and/or their Controlled Affiliates, the
BCBSA Board has provided for Mediation under these Rules. Mediation may be pursued in lieu of or in an effort to
obviate the Mandatory Dispute Resolution process, and all parties are strongly urged, but not required, to exhaust
the mediation procedure provided for herein. In the event any party refuses to proceed with Mediation, the parties
shall proceed immediately to Mandatory Dispute Resolution, as provided in Section 3.
A. Selection of Mediators
If all parties agree to pursue Mediation, they shall promptly attempt to agree upon: (i) the number of mediators
desired, not to exceed three mediators; and (ii) the selection of experienced mediator(s) from an independent
entity to mediate all disputes set forth in the Complaint and Answer (and Counterclaim and Reply, if any). In
the event the parties are unable to agree upon the selection or number of mediators, both within five (5) days
of the service of the Answer or Reply to Counterclaim, whichever is later, the BCBSA Corporate Secretary
shall immediately refer the matter to a nationally recognized professional ADR organization (such as CPR or
JAMS) for mediation by a single mediator to be selected by the ADR organization.
B. Binding Decision
Before the Mediation Hearing described below, the BCBSA Corporate Secretary shall contact the parties to
determine whether they wish to be bound by any recommendation of the selected mediator(s) for resolution of
the disputes. If all wish to be bound, the Corporate Secretary will send appropriate documentation to them for
their signatures before the Mediation Hearing begins.
Amended as of September 20, 2007

-- 495 of 533 --

EXHIBIT 5
Page 4 of 23
C. Mediation Procedure
The Mediator(s) shall apply the mediation procedures and processes provided for herein (not the rules of the
ADR organization with which they are affiliated) and shall promptly advise the parties of a scheduled
Mediation Hearing date. Unless a party requests an expedited procedure, or unless all parties to the
proceeding agree to one or more extensions of time, the Mediation Hearing set forth below shall be
completed within forty (40) days of BCBSA's receipt of the Complaint. The selected mediator(s), unless the
parties otherwise agree, shall adhere to the following procedure:
i. Each party must be represented by its CEO or other representative who has been delegated full authority
to resolve the dispute. However, parties may send additional representatives as they see fit.
ii. Each party will be given one-half hour to present its case, beginning with the complaining party (or
parties), followed by the other party or parties. The parties are free to structure their presentations as
they see fit, using oral statements or direct examination of witnesses. However, neither cross-
examination nor questioning of opposing representatives will be permitted. At the close of each
presentation, the selected mediator(s) will be given an opportunity to ask questions of the presenters and
witnesses. All parties must be present throughout the Mediation Hearing. The selected mediator(s) may
extend the time allowed for each party's presentation at the Mediation Hearing. The selected mediator(s)
may meet in executive session, outside the presence of the parties, or may meet with the parties
separately, to discuss the controversy.
iii. After the close of the presentations, the parties will attempt to negotiate a settlement of the dispute. If the
parties desire, the selected mediators, or any one or more of the selected mediator(s), will sit in on the
negotiations.
Amended as of September 20, 2007

-- 496 of 533 --

EXHIBIT 5
Page 5 of 23
iv. After the close of the presentations, the selected mediator(s) may meet privately to agree upon a
recommendation for resolution of the dispute which would be submitted to the parties for their
consideration and approval. If the parties have previously agreed to be bound by the results of this
procedure, this recommendation shall be binding upon the parties.
v. The purpose of the Mediation Hearing is to assist the parties to settle their grievances short of mandatory
dispute resolution. As a result, the Mediation Hearing has been designed to be as informal as possible.
Rules of evidence shall not apply. There will be no transcript of the proceedings, and no party may make
a tape recording of the Mediation Hearing.
vi. In order to facilitate a free and open discussion, the Mediation proceeding shall remain confidential. A
"Stipulation to Confidentiality" which prohibits future use of settlement offers, all position papers or other
statements furnished to the selected mediator(s), and decisions or recommendations in any Mediation
proceeding shall be executed by each party.
vii. Upon request of the selected mediator(s), or one of the parties, BCBSA staff may also submit
documentation at any time during the proceedings.
D. Notice of Termination of Mediation
If the Mediation cannot be completed within the prescribed or agreed time period due to the lack of cooperation
of any party, as determined by the selected mediator(s), or if the Mediation does not result in a final resolution of
all disputes at the Mediation Hearing or within ten (10) days after the Mediation Hearing, any party or any one of
the selected mediator(s) shall so notify the BCBSA Corporate Secretary, who shall promptly issue a Notice of
Termination of Mediation to all parties, to the selected mediator(s), and to the MDR Administrator. Such notice
shall serve to bring the Mediation to an end and to initiate Mandatory Dispute Resolution. Upon agreement
of all parties and the mediator(s), the Mediation process may continue at the same time the MDR process is
invoked. In such case, the Notice of Termination
of Mediation described above serves to initiate the MDR proceeding, but does not terminate mediation
proceedings, which may proceed simultaneous with the MDR proceeding.
Amended as of September 20, 2007

-- 497 of 533 --

EXHIBIT 5
Page 6 of 23
3. Mandatory Dispute Resolution (MDR)
If any party elects not to first pursue Mediation, or if a Notice of Termination of Mediation is issued as set forth in
Paragraph 2.D., above, then the unresolved disputes set forth in any Complaint and Answer (and Counterclaim and
Reply, if any) shall be subject to mandatory binding arbitration (herein referred to as “MDR”).
A. MDR Administrator
The Administrator for purposes of Mandatory Arbitration shall be an independent nationally recognized entity such
as CPR or JAMS, specializing in alternative dispute resolution. In the event the parties pursued Mediation with
CPR, JAMS or a similar organization, that organization also shall serve as the MDR Administrator, unless all
parties notify the BCBSA Corporate Secretary in writing within two (2) days of
receiving the Notice of Termination of Mediation that they wish to pursue MDR with another nationally recognized
organization serving as MDR Administrator.
In the event the parties (i) did not pursue Mediation, (ii) pursued mediation with a Mediator not affiliated with an
ADR organization that offers a panel of arbitrators, or
(iii) all parties that pursued Mediation notified the BCBSA Corporate Secretary that
they wish to have an MDR Administrator that is different from the organization with
which their mediator was affiliated, they shall promptly attempt to agree on a
nationally recognized ADR entity that supplies a panel of arbitrators. If they reach
such agreement within five (5) days of the Notice of Termination of Mediation or
receipt of the Answer or Reply to Counterclaim (whichever is later), the parties shall promptly inform the BCBSA
Corporate Secretary of their agreed upon ADR
organization. In the event the parties are unable to reach agreement on an MDR Administrator within that
timeframe, the BCBSA Corporate Secretary shall
immediately refer the matter to CPR, JAMS or a similar organization for MDR.
Any person who served as a Mediator shall not serve as an arbitrator for the same or similar dispute for purposes
of MDR.
B. Rules for MDR
The rules controlling all aspects of MDR shall be exclusively those provided for
herein. The rules promulgated or otherwise used by the MDR Administrator organization shall not apply.
Amended as of September 20, 2007

-- 498 of 533 --

EXHIBIT 5
Page 7 of 23
C. Initial Conference
Within seven (7) days after a Notice of Termination has issued, or the matter has otherwise been referred to an
MDR Administrator, or within five (5) days after the time for filing and serving the Answer or Reply to any
Counterclaim (whichever is later) if the parties elect first not to mediate, the parties shall confer with the
Administrator to discuss selecting a dispute resolution panel ("the Panel"). This conference (the “Initial
Conference”) may be by telephone. The parties are encouraged to agree to the composition of the Panel and
to present that agreement to the Administrator at the Initial Conference. If the parties do not agree on the
composition of the Panel by the time of the Initial Conference, or by any extension thereof agreed to by all
parties and the Administrator, then the Panel Selection Process set forth in subparagraph D, below, shall be
followed.
D. Panel Selection Process
The Administrator shall designate, prior to the Initial Conference, at least seven potential arbitrators. Each
party shall be permitted to strike any designee for cause and the Administrator shall determine the sufficiency
thereof in its sole discretion. The Administrator will designate a replacement for any designee so stricken.
Each party shall then be permitted one peremptory strike from the list of designees. The Administrator shall set
the dates for exercising all strikes, which shall be set to encourage the prompt selection of arbitrators.
After the parties exercise any designee strikes for cause and their peremptory strike against any designee of
their choice, the parties shall each rank the remaining panel members in order of preference and provide the
Administrator, without serving on
any other party, their ranked list. The Administrator shall not disclose any party’s ranked list to members of the
panel or to other parties.
From the remaining designees, and after considering opportunities to maximize, so far as possible, the
collectively stated arbitrator preferences provided by the parties on their ranked lists, the Administrator shall
select a three member Panel. The Panel Selection Process shall be completed no later than ten (10) days after
the Initial Conference.
Each Arbitrator shall be compensated at his or her normal hourly rate or, in the absence of an established rate,
at a reasonable hourly rate to be promptly fixed by the Administrator for all time spent in connection with the
proceedings and shall be reimbursed for any travel and other reasonable expenses.
Amended as of September 20, 2007

-- 499 of 533 --

EXHIBIT 5
Page 8 of 23
E. Duties Of The Arbitrators
The Panel shall promptly designate a Presiding Arbitrator for the purposes reflected below, but shall retain the
power to review and modify any ruling or other action of said Presiding Arbitrator. Each Arbitrator shall be an
independent Arbitrator, shall be governed by the Code of Ethics for Arbitrators in Commercial Disputes, and
shall at or prior to the commencement of any Arbitration Hearing take an oath to that effect. Each Arbitrator
shall promptly disclose in writing to the Panel and to the parties any circumstances, whenever arising, that
might cause doubt as to such Arbitrator's compliance, or ability to comply, with said Code of Ethics, and,
absent resignation by such Arbitrator, the remaining Arbitrators shall determine in their sole discretion whether
the circumstances so disclosed constitute grounds for disqualification and for replacement. With respect to
such circumstances arising or coming to the attention of a party after an Arbitrator's selection, a party may
likewise request the Arbitrator's resignation or a determination as to disqualification by the remaining
Arbitrators. With respect to a sole Arbitrator, the determination as to disqualification shall be made by the
Administrator.
There shall be no ex parte communication between the parties or their counsel and any member of the Panel.
F. Panel's Jurisdiction And Authority
The Panel's jurisdiction and authority shall extend to all disputes between or among the Plans, their Controlled
Affiliates, and/or BCBSA, except for those disputes excepted from these MMDR procedures as set forth in the
License Agreements.
With the exception of punitive or treble damages, the Panel shall have full authority to award the relief it
deems appropriate to resolve the parties' disputes, including monetary awards and injunctions, mandatory or
prohibitory. The Panel has no authority to award punitive or treble damages except that the Panel may allocate
or assess responsibility for punitive or treble damages assessed by another tribunal. Subject to the above
limitations, the Panel may, by way of example, but not of limitation:
Amended as of September 20, 2007

-- 500 of 533 --

EXHIBIT 5
Page 9 of 23
i. interpret or construe the meaning of any terms, phrase or provision in any license between BCBSA and a
Plan or a Controlled Affiliate relating to the use of the BLUE CROSS® or BLUE SHIELD® service
marks.
ii. determine whether BCBSA, a Plan or a Controlled Affiliate has violated the terms or conditions of any
license between the BCBSA and a Plan or a Controlled Affiliate relating to the use of the BLUE
CROSS® or BLUE SHIELD® service marks.
iii. decide challenges as to its own jurisdiction.
iv. issue such orders for interim relief as it deems appropriate pending Hearing and Award in any Arbitration.
It is understood that the Panel is expected to resolve issues based on governing principles of law, preserving
to the maximum extent legally possible the continued integrity of the Licensed Marks and the BLUE
CROSS/BLUE SHIELD system. The Panel shall apply federal law to all issues which, if asserted in the United
States District Court, would give rise to federal question jurisdiction, 28 U.S.C. § 1331. The Panel shall apply
Illinois law to all issues involving interpretation, performance or construction of any License Agreement or
Controlled Affiliate License Agreement unless the agreement otherwise provides. As to other issues, the Panel
shall choose the applicable law based on conflicts of law principles of the State of Illinois.
G. Administrative Conference
Within five (5) days of the Panel being selected, the Presiding Arbitrator shall confer with the parties and the
other members of the Panel and shall schedule, in writing, a conference in which the parties and the Panel
shall participate (the “Administrative Conference”). The Administrative Conference shall take place no later
than fifteen
(15) days after the Panel is selected. At the Administrative Conference the parties and the Panel shall discuss
the scheduling of the Arbitration Hearing and any other matter appropriate to be considered, including but not
limited to: any written discovery in the form of requests for production of documents or requests to admit facts;
the identity of any witness whose deposition a party may desire and a showing of exceptional good cause for
the taking
Amended as of September 20, 2007

-- 501 of 533 --

EXHIBIT 5
Page 10 of 23
of any such deposition; the desirability of bifurcation or other separation of the issues; the need for and the
type of record of conferences and hearings, including the need for transcripts; the need for expert witnesses
and how expert testimony should be presented; the appropriateness of motions to dismiss and/or for full or
partial summary judgment; consideration of stipulations; the desirability of presenting any direct testimony in
writing; and the necessity for any on-site inspection by the Panel. If the parties agree, the Administrative
Conference may be by telephone.
H. Discovery
i. Requests for Production of Documents: All requests for the production of documents must be served
no later than five (5) days after the date of the Initial Conference. Within twenty (20) days after receipt of
a request for production of documents, a party shall (a) serve responses and objections to the request,
(b) produce all responsive, non-privileged documents to the requesting party, and (c) to the extent any
responsive documents are withheld on the grounds of attorney-client privilege or work product, produce a
log identifying such documents in the manner specified in Fed. R. Civ. P. 26(b)(5). If, after reviewing a
privilege log, the requesting party believes attorney-client privilege or work product protection was
improperly claimed by the producing party with respect to any document, the requesting party may ask
the Presiding Arbitrator to conduct an in-camera inspection of the same. With respect to documentary
and other discovery produced in any MDR proceeding by BCBSA, the fact that a party’s CEO or other
senior officers may serve on the BCBSA Board of Directors, BCBSA Board Committees or other BCBSA
work groups, task forces and the like, shall not be a basis for defeating an otherwise valid claim of
attorney-client privilege or work product protection over such documentary or other discovery materials
by BCBSA.
ii. Requests for Admissions: Requests for Admissions may be served up to twenty-one (21) days prior
to the discovery cut-off set by the Presiding Arbitrator. A party served with Requests For Admissions
must respond within twenty (20) days of receipt of said request. The good faith use of and response to
Requests for Admissions is encouraged, and the Panel shall have full discretion, with reference to the
Federal Rules of Civil Procedure, in awarding appropriate sanctions with respect to abuse of the
procedure.
Amended as of September 20, 2007

-- 502 of 533 --

EXHIBIT 5
Page 11 of 23
iii. Depositions: As a general rule, the parties will not be permitted to take party or non-party deposition
testimony for discovery purposes. The Presiding Arbitrator, in his or her sole discretion, shall have the
authority to permit a party to take such deposition testimony upon a showing of exceptional good cause.
The parties will be permitted to take de bene esse deposition testimony to the fullest extent permitted by
law of any witness who cannot be compelled to testify at the Arbitration Hearing. No deposition, for
discovery purposes or otherwise, shall exceed three (3) hours, excluding objections and colloquy of
counsel. Depositions may be recorded in any manner recognized by the Federal Rules of Civil
Procedure and the parties shall specify in each notice of deposition or request for permission to take
deposition testimony the manner in which such deposition shall be recorded.
iv. Expert witness(es): If a party intends to present the testimony of an expert witness during the oral
hearing, it shall provide all other parties with a written statement setting forth the information required to
be provided by Fed. R. Civ.
P. 26(a)(2)(B) ten (10) days prior to the discovery cut-off set by the Presiding Arbitrator. If a party intends
to present the testimony of a rebuttal expert witness during the Arbitration Hearing, it shall provide all
other parties with a written statement setting forth the information required to be provided by Fed.
R. Civ. P. 26(a)(2)(B) within twenty (20) days after the date on which the written statement of the expert
witness whose testimony is to be rebutted was produced.
v. Discovery cut-off: The Presiding Arbitrator shall determine the date on which the discovery period will
end, but the discovery period shall not exceed thirty
(30) days from the date of the Administrative Conference without the agreement of all parties.
Amended as of September 20, 2007
1 As used in these Rules, "de bene esse deposition" means a deposition that is not taken for discovery purposes, but is taken for the purpose of reading part or all of the
deposition transcript into the record at the Arbitration Hearing, to the extent permitted by the Panel, because the witness cannot be compelled to testify at the Arbitration
Hearing or has exercised a right provided under these Rules to provide deposition testimony in lieu of testimony at the Arbitration Hearing.
1

-- 503 of 533 --

EXHIBIT 5
Page 12 of 23
vi. Additional discovery: Any additional discovery will be at the discretion of the
Presiding Arbitrator.
vii. Discovery Disputes: Any discovery disputes shall be raised by motion to the Presiding Arbitrator, who is
authorized to resolve all such disputes, and whose resolution will be binding on the parties unless
modified by the Arbitration Panel. Prior to raising any discovery dispute with the Presiding Arbitrator, the
parties shall meet and confer, telephonically or in person, in an attempt to resolve or narrow the dispute.
If a party refuses to comply with a decision resolving a discovery dispute, the Panel, in keeping with Fed.
R. Civ. P. 37, may refuse to allow that party to support or oppose designated claims or defenses, prohibit
that party from introducing designated matters into evidence or, in extreme cases, decide an issue
submitted for resolution adversely to that party.
viii. Extensions: The time for responding to discovery requests may be extended by the Presiding
Arbitrator for good and sufficient cause shown. Any request for such an extension shall be made in
writing.
I. Panel Suggested Settlement/Mediation
At any point during the proceedings, the Panel at the request of any party or on its own initiative, may suggest
that the parties explore settlement and that they do so at or before the conclusion of the Arbitration Hearing,
and the Panel shall give such assistance in settlement negotiations as the parties may request and the Panel
may deem appropriate. Alternatively, the Panel may direct the parties to endeavor to mediate their disputes as
provided above, or to explore a mini-trial proceeding, or to have an independent party render a neutral
evaluation of the parties’ respective positions. The Panel shall enter such sanctions as it deems appropriate
with respect to any party failing to pursue in good faith such Mediation or other alternate dispute resolution
methods.
Amended as of September 20, 2007

-- 504 of 533 --

EXHIBIT 5
Page 13 of 23
J. Subpoenas on Third Parties
Pursuant to, and consistent with, the Federal Arbitration Act, 9 U.S.C. § 9 et seq.,
and subject to Paragraph 3.G(iii) above, a party may request the issuance of a subpoena on any third party,
including but not limited to any third party Blue Plan or any officer, employee or director of a third party Blue
Plan, to compel deposition testimony or the production of documents, and, if good and sufficient cause is
shown, the Panel shall issue such a subpoena.
K. Arbitration Hearing
An Arbitration Hearing will be held within thirty (30) days after the Administrative Conference if no discovery is
taken, or within thirty (30) days after the close of discovery, unless all parties and the Panel agree to extend the
Arbitration Hearing date, or unless the parties agree in writing to waive the Arbitration Hearing. The parties may
mutually agree on the location of the Arbitration Hearing. If the parties
fail to agree, the Arbitration Hearing shall be held in Chicago, Illinois, or at such other location determined by
the Presiding Arbitrator to be most convenient to the participants. The Panel will determine the date(s) and
time(s) of the Arbitration Hearing(s) after consultation with all parties and shall provide reasonable notice
thereof to all parties or their representatives.
L. Arbitration Hearing Memoranda
Twenty (20) days prior to the Arbitration Hearing, each party shall submit to the other party (or parties) and to
the Panel an Arbitration Hearing Memorandum which sets forth the applicable law and any argument as to any
relevant issue. The Arbitration Hearing Memorandum will supplement, and not repeat, the allegations,
information and documents contained in or with the Complaint, Answer, Counterclaim and Reply, if any. Ten
(10) days prior to the Arbitration Hearing, each party shall submit to each other party a list of all expert and fact
witnesses (but not including rebuttal fact witness) that such party intends to have testify at the Arbitration
Hearing and a brief summary of the testimony each such witness is expected to give. In addition, no
later than five (5) days prior to the Arbitration, each party may submit to each other party and to the Panel a
Response Arbitration Hearing Memorandum which sets
forth any response to another party's Arbitration Hearing Memorandum.
Amended as of September 20, 2007

-- 505 of 533 --

EXHIBIT 5
Page 14 of 23
M. Notice For Testimony
Ten (10) days prior to the Arbitration Hearing, any party may serve a Notice on any other party (or parties)
requesting the attendance at the Arbitration Hearing of any officer, employee or director of the other party (or
parties) for the purpose of providing noncumulative testimony. If a party fails to produce one of its officers,
employees or directors whose noncumulative testimony during the Arbitration Hearing is reasonably requested
by an adverse party, the Panel may refuse to allow that party to support or oppose designated claims or
defenses, prohibit that party from introducing designated matters into evidence or, in extreme cases, decide an
issue submitted for mandatory dispute resolution adversely to that party; provided, however, that a party may
refuse to produce a director to testify if, within two (2)days of receiving a notice requesting the attendance of
such director at the Arbitration Hearing, the party agrees to make the director available for a de bene esse
deposition at a mutually convenient time at any location within fifty (50) miles of the director’s primary
residence chosen by the party requesting the director’s testimony. This Rule may not be used for the purpose
of burdening or harassing any party, and the Presiding Arbitrator may impose such orders as are appropriate
so as to prevent or remedy any such burden or harassment.
Pursuant to, and consistent with, the Federal Arbitration Act, 9 U.S.C. § 9 et seq., twenty (20) days or more
prior to the Arbitration Hearing, a party may request the issuance of a subpoena on any third party, including
but not limited to any third party Blue Plan, BCBSA or any officer, employee or director of a third party Blue
Plan or BCBSA for the purpose of providing noncumulative testimony at the Arbitration Hearing, and, if good
and sufficient cause is shown, the Panel shall issue such a subpoena; provided however, that a director of a
third party Blue Plan or BCBSA may refuse to testify if, within two (2) days of receiving a subpoena requesting
the attendance of such director at the Arbitration Hearing, the director agrees to make him/herself available for
a de bene esse deposition at a mutually convenient time at any location within fifty (50) miles of the director’s
primary residence chosen by the party requesting the director’s testimony. Each Blue Plan agrees to waive, on
its
own behalf and on behalf of its directors and officers,any objection it otherwise might have to any such
subpoena based on service, venue or extraterritoriality.
Amended as of September 20, 2007

-- 506 of 533 --

EXHIBIT 5
Page 15 of 23
N. Arbitration Hearing Procedures
i. Attendance at Arbitration Hearing: Any person having a direct interest in the proceeding is entitled to
attend the Arbitration Hearing. The Presiding Arbitrator shall otherwise have the power to require the
exclusion of any witness, other than a party or other essential person, during the testimony of any other
witness. It shall be discretionary with the Presiding Arbitrator to determine the propriety of the
attendance of any other person.
ii. Confidentiality: The Panel and all parties shall maintain the privacy of the Arbitration Proceeding. The
parties and the Panel shall treat the Arbitration Hearing and any discovery or other proceedings or events
related thereto, including any award resulting therefrom, as confidential except as otherwise necessary in
connection with a judicial challenge to or enforcement of an award or unless otherwise required by law.
iii. Stenographic Record: Any party, or if the parties do not object, the Panel, may request that a
stenographic or other record be made of any Arbitration Hearing or portion thereof. The costs of the
recording and/or of preparing the transcript shall be borne by the requesting party and by any party who
receives a copy thereof. If the Panel requests a recording and/or a transcript, the costs thereof shall be
borne equally by the parties.
iv. Oaths: The Panel may require witnesses to testify under oath or affirmation administered by any duly
qualified person and, if requested by any party, shall do so.
v. Order of Arbitration Hearing: An Arbitration Hearing shall be opened by the recording of the date, time,
and place of the Arbitration Hearing, and the presence of the Panel, the parties, and their
representatives, if any. The Panel may, at the beginning of the Arbitration Hearing, ask for statements
clarifying the issues involved.
Amended as of September 20, 2007

-- 507 of 533 --

EXHIBIT 5
Page 16 of 23
Unless otherwise agreed, the complaining party (or parties) shall then present evidence to support their
claim(s). The respondent(s) shall then present evidence supporting their defenses and Counterclaims, if
any. The
complaining party (or parties) shall then present evidence supporting defenses to the Counterclaims, if
any, and rebuttal.
Witnesses for each party shall submit to questions by adverse parties and/or the Panel.
The Panel has the discretion to vary these procedures, but shall afford a full and equal opportunity to all
parties for the presentation of any material and relevant evidence.
vi. Evidence: The parties may offer such evidence as is relevant and material to the dispute and shall
produce such evidence as the Panel may deem
necessary to an understanding and resolution of the dispute. Unless good cause is shown, as determined
by the Panel or agreed to by all other parties,
no party shall be permitted to offer evidence at the Arbitration Hearing which was not disclosed prior to the
Arbitration Hearing by that party. The Panel may receive and consider the evidence of witnesses by
affidavit upon such terms as the Panel deems appropriate.
The Panel shall be the judge of the relevance and materiality of the evidence offered, and conformity to
legal rules of evidence, other than enforcement of the attorney-client privilege and the work product
protection, shall not be necessary. The Federal Rules of Evidence shall be considered by the Panel in
conducting the Arbitration Hearing but those rules shall not be controlling. All evidence shall be taken in
the presence of the Panel and all of the parties, except where any party is in default or has waived the
right to be present.
Settlement offers by any party in connection with Mediation or MDR proceedings, decisions or
recommendations of the selected mediators, and a party's position papers or statements furnished to
the selected mediators shall not be admissible evidence or considered by the Panel without the consent
of all parties.

-- 508 of 533 --

EXHIBIT 5
Page 17 of 23
vii. Closing of Arbitration Hearing: The Presiding Arbitrator shall specifically inquire of all parties whether
they have any further proofs to offer or witnesses to be heard. Upon receiving negative replies or if he or
she is satisfied that the record is complete, the Presiding Arbitrator shall declare the Arbitration Hearing
closed with an appropriate notation made on the record. Subject to being reopened as provided below,
the time within which the Panel is required to make the award shall commence to run, in the absence of
contrary agreement by the parties, upon the closing of the Arbitration Hearing.
With respect to complex disputes, the Panel may, in its sole discretion, defer the closing of the
Arbitration Hearing for a period of up to thirty (30) days after the presentation of proofs in order to permit
the parties to submit post-hearing briefs and argument, as the Panel deems appropriate, prior to making
an award.
For good cause, the Arbitration Hearing may be reopened for up to thirty (30) days on the Panel's
initiative, or upon application of a party, at any time before the award is made
O. Awards
An Award must be in writing and shall be made promptly by the Panel and, unless otherwise agreed by the
parties or specified by law, no later than thirty (30) days from the date of closing the Arbitration Hearing. If all
parties so request, the Award shall contain findings of fact and conclusions of law. The Award, and all other
rulings and determinations by the Panel, may be by a majority vote.
Parties shall accept as legal delivery of the Award the placing of the Award or a true copy thereof in the mail
addressed to a party or its representative at its last known address or personal service of the Award on a party
or its representative.
Awards are binding only on the parties to the Arbitration and are not binding on any non-parties to the
Arbitration and may not be used or cited as precedent in any other proceeding.
Amended as of September 20, 2007

-- 509 of 533 --

EXHIBIT 5
Page 18 of 23
After the expiration of twenty (20) days from initial delivery, the Award (with corrections, if any) shall be final
and binding on the parties, and the parties shall undertake to carry out the Award without delay.
Proceedings to confirm, modify or vacate an Award shall be conducted in conformity with and controlled by the
Federal Arbitration Act. 9 U.S.C. § 1, et seq.
P. Return of Documents
Within sixty (60) days after the Award and the conclusion of any judicial proceedings with respect thereto, each
party and the Panel shall return any documents produced by any other party, including all copies thereof. If a
party receives a discovery
request in any other proceeding which would require it to produce any documents produced to it by any other
party in a proceeding hereunder, it shall not produce such documents without first notifying the producing party
and giving said party
reasonable time to respond, if appropriate, to the discovery request.
4. Miscellaneous
A. Expedited Procedures
Any party to a Mediation may direct a request for an expedited Mediation Hearing to the Chairman of the
Mediation Committee, to the selected Mediators, and to all other parties at any time. The Chairman of the
Mediation Committee, or at his or her direction, the then selected Mediators, shall grant any request which is
supported by good and sufficient reasons. If such a request is granted, the Mediation shall be completed within
as short a period as practicable, as determined by the Chairman of the Mediation Committee or, at his or her
direction, the then selected Mediators.
Any party to an Arbitration may direct a request for expedited proceedings to the Administrator, to the Panel,
and to all other parties at any time. The Administrator, or the Presiding Arbitrator if the Panel has been selected,
shall grant any such request which is supported by good and sufficient reasons. If such a request is granted,
the Arbitration shall be completed within as short a time as practicable, as determined by the Administrator
and/or the Presiding Arbitrator.
Amended as of September 20, 2007

-- 510 of 533 --

EXHIBIT 5
Page 19 of 23
B. Temporary or Preliminary Injunctive Relief
Any party may seek temporary or preliminary injunctive relief with the filing of a Complaint or at any time
thereafter. If such relief is sought prior to the time that an Arbitration Panel has been selected, then the
Administrator shall select a single Arbitrator who is a lawyer who has no interest in the subject matter of the
dispute, and no connection to any of the parties, to hear and determine the request for temporary or preliminary
injunction. If such relief is sought after the time that an Arbitration Panel has been selected, then the Arbitration
Panel will hear and determine the request. The request for temporary or preliminary injunctive relief will be
determined with reference to the temporary or preliminary injunction standards set forth in Fed. R. Civ. P. 65.
C. Defaults and Proceedings in the Absence of a Party
Whenever a party fails to comply with the MDR Rules in a manner deemed material by the Panel, the Panel
shall fix a reasonable time for compliance and, if the party does not comply within said period, the Panel may
enter an Order of default or afford such other relief as it deems appropriate. Arbitration may proceed in the
event of a default or in the absence of any party who, after due notice, fails to be present or fails to obtain an
extension. An Award shall not be made solely on the default or absence of a party, but the Panel shall require
the party who is present to submit such evidence as the Panel may require for the making of findings,
determinations, conclusions, and Awards.
D. Notice
Each party shall be deemed to have consented that any papers, notices, or process necessary or proper for the
initiation or continuation of a proceeding under these rules or for any court action in connection therewith may
be served on a party by mail addressed to the party or its representative at its last known address or by
personal service, in or outside the state where the MDR proceeding is to be held.
The Corporate Secretary and the parties may also use facsimile transmission, telex, telegram, or other written
forms of electronic communication to give the notices required by these rules.

-- 511 of 533 --

EXHIBIT 5
Page 20 of 23
E. Expenses
The expenses of witnesses shall be paid by the party causing or requesting the appearance of such
witnesses. All expenses of the MDR proceeding, including compensation, required travel and other reasonable
expenses of the Panel, and the cost of any proof produced at the direct request of the Panel, shall be borne
equally by the parties and shall be paid periodically on a timely basis, unless they agree otherwise or unless
the Panel in the Award assesses such expenses, or any part thereof against any party (or parties). In
exceptional cases, the Panel may award reasonable attorneys' fees as an item of expense, and the Panel
shall promptly determine the amount of such fees based on affidavits or such other proofs as the Panel deems
sufficient.
F. Disqualification or Disability of A Panel Member
In the event that any Arbitrator of a Panel with more than one Arbitrator should become disqualified, resign,
die, or refuse or be unable to perform or discharge his or her duties after the commencement of MDR but prior
to the rendition of an Award, and the parties are unable to agree upon a replacement, the remaining Panel
member(s):
i. shall designate a replacement, subject to the right of any party to challenge
such replacement for cause.
ii. shall decide the extent to which previously held hearings shall be repeated.
If the remaining Panel members consider the proceedings to have progressed to a stage as to make
replacement impracticable, the parties may agree, as an alternative to the recommencement of the Mandatory
Dispute Resolution process, to resolution of the dispute by the remaining Panel members.
In the event that a single Arbitrator should become disqualified, resign, die, or refuse or be unable to perform
or discharge his or her duties after the commencement of MDR but prior to the rendition of an Award, and the
parties are unable to agree upon a replacement, the Administrator shall appoint a successor, subject to the
right of any party to challenge such successor for cause, and the successor shall decide the extent to which
previously held proceedings shall be repeated.

-- 512 of 533 --

EXHIBIT 5
Page 21 of 23
G. Extensions of Time
Subject to the provisions of Paragraph 3.H.(viii), any time limit set forth in these Rules may be extended upon
agreement of the parties and approval of: (1) the Mediator if the proceeding is then in Mediation; (2) the
Administrator if the proceeding is in Arbitration, but no Arbitration Panel has been selected; or (3) the
Arbitration Panel, if the proceeding is in Arbitration and the Arbitration Panel has been selected.
H. Intervention
The Plans, their Controlled Affiliates, and BCBSA, to the extent subject to MMDR pursuant to their License
Agreements, shall have the right to move to intervene in any pending Arbitration. A written motion for
intervention shall be made to: (1) the Administrator, if the proceeding is in Arbitration, but no Arbitration Panel
has been selected; or (2) the Arbitration Panel, if the proceeding is in Arbitration and the Arbitration Panel has
been selected. The written motion for intervention shall be delivered to the BCBSA Corporate Secretary (which
shall also constitute service on the BCBSA if it is a respondent) and to any Plan(s) and/or Controlled Affiliate(s)
which are parties to the proceeding. Any party to the proceeding can submit written objections to the motion to
intervene. The motion for intervention shall be granted upon good cause shown. Intervention also may be
allowed by stipulation of the parties to the Arbitration proceeding. Intervention shall be allowed upon such
terms as the Arbitration Panel decides.
I. BCBSA Assistance In Resolution of Disputes
The resources and personnel of the BCBSA may be requested by any member Plan at any time to try to
resolve disputes with another Plan.
J. Neutral Evaluation
The parties can voluntarily agree at any time to have an independent party render a neutral evaluation of the
parties’ respective positions.
Amended as of September 20, 2007

-- 513 of 533 --

EXHIBIT 5
Page 22 of 23
K. Recovery of Attorney Fees and Expenses
i. Motions to Compel
Notwithstanding any other provisions of these Rules, any Party subject to the License Agreements (for
purposes of this Section K and all of its sub-sections only hereinafter referred to collectively and
individually as a “Party”) that initiates a court action or administrative proceeding solely to compel
adherence to these Rules shall not be determined to have violated these Rules by initiating such action
or proceeding.
ii Recovery of Fees, Expenses and Costs
The Arbitration Panel may, in its sole discretion, award a Party its reasonable attorneys’ fees, expenses
and costs associated with a filing to compel adherence to these Rules and/or reasonable attorneys’ fees,
expenses and costs incurred in responding to an action filed in violation of these Rules; provided,
however, that neither fees, expenses, nor costs shall be awarded by the Arbitration Panel if the Party from
which the award is sought can demonstrate to the Arbitration panel, in its sole discretion, that it did not
violate these Rules or that it had reasonable grounds for believing that its action did not violate these
Rules.
iii Requests for Reimbursement
For purposes of this Section K, any Party may request reimbursement of fees, expenses and/or costs by
submitting said request in writing to the Arbitration Panel at any time before an award is delivered pursuant to
Paragraph 3.O above, with a copy to the Party from which reimbursement is sought, explaining why it is
entitled to such reimbursement. The Party from which reimbursement is sought shall have twenty (20) days to
submit a response to such request to the Arbitration Panel with a copy to the Party seeking reimbursement.
Amended as of September 20, 2007

-- 514 of 533 --

EXHIBIT 5
Page 23 of 23
L. Calculation of Time and Deadlines
In computing any period of time prescribed or allowed under these rules, the day of the act or event from which
the designated period of time begins to run shall not be included. The last day of the period so computed shall
be included, unless it is a Saturday, a Sunday, or a legal holiday, in which event the period runs until the end of
the next day which is not one of the aforementioned days. When the period of time prescribed is less than six (6)
days, intermediate Saturdays, Sundays and legal holidays shall be excluded in the computation. As used in this
rule, “legal holiday” includes New Year’s Day, Martin Luther King, Jr. Day, Washington’s Birthday, Memorial Day,
Independence Day, Labor Day, Columbus Day, Veterans Day, Thanksgiving Day, Christmas Day and any other
day appointed as a holiday by the President or the Congress of the United States.
Amended as of September 20, 2007

-- 515 of 533 --

Exhibit 21
Listed below are subsidiaries of Elevance Health, Inc. as of February 1, 2024 with ownership of 50% and above.
Entity Name 	Domestic Jurisdiction 	Doing Business As
Advantage Medical Group, LLC 	Puerto Rico
Alianza Medicos del SurEste, LLC 	Puerto Rico
Alliance Care Management, LLC 	Delaware
AMERIGROUP Community Care of New Mexico,
Inc.
New Mexico
Amerigroup District of Columbia, Inc. 	District of Columbia
Amerigroup Mississippi, Inc. 	Mississippi
Amerigroup Pennsylvania, Inc. 	Pennsylvania
AMGP Georgia Managed Care Company, Inc. 	Georgia 	AMERIGROUP; AMERIGROUP Community Care;
AMERIGROUP Georgia; AMGP Georgia
AMH Health, LLC 	Maine
AMH Health Plans of Maine, Inc. 	Maine
Anthem Benefits Agency, Inc. f/k/a EHC Benefits
Agency, Inc.
New York
Anthem Blue Cross Life and Health Insurance
Company
California
Anthem Financial, Inc. 	Delaware
Anthem Health Plans, Inc. 	Connecticut 	Anthem Blue Cross and Blue Shield
Anthem Health Plans of Kentucky, Inc. 	Kentucky 	Anthem Blue Cross and Blue Shield
Anthem Health Plans of Maine, Inc. 	Maine 	Anthem Blue Cross and Blue Shield; Associated Hospital
Service
Anthem Health Plans of New Hampshire, Inc. 	New Hampshire 	Anthem Blue Cross and Blue Shield
Anthem Health Plans of Virginia, Inc. 	Virginia 	Anthem Blue Cross and Blue Shield
Anthem HealthChoice Assurance, Inc. f/k/a Empire
HealthChoice Assurance, Inc.
New York 	Anthem Blue Cross, Anthem Blue Cross and Blue Shield
Anthem HealthChoice HMO, Inc. f/k/a Empire
HealthChoice HMO, Inc.
New York 	Anthem Blue Cross, Anthem Blue Cross and Blue Shield
Anthem Holding Corp. 	Indiana 	Anthem Properties, Inc.
Anthem HP, LLC f/k/a HealthPlus HP, LLC 	New York 	Anthem Blue Cross and Blue Shield HP, Anthem Blue
Cross HP
Anthem Insurance Companies, Inc. 	Indiana 	Anthem Blue Cross and Blue Shield Retiree Solutions;
Anthem Blue Cross Retiree Solutions; Blue Cross and
Blue Shield of Indiana; Anthem Blue Cross and Blue
Shield
Anthem Kentucky Managed Care Plan, Inc. 	Kentucky 	Anthem Blue Cross and Blue Shield Medicaid
1

-- 516 of 533 --

Entity Name 	Domestic Jurisdiction 	Doing Business As
Anthem Life & Disability Insurance Company 	New York
Anthem Life Insurance Company 	Indiana
Anthem Partnership Holding Company, LLC 	Indiana
Anthem Southeast, Inc. 	Indiana
APR, LLC 	Indiana
Arcus Enterprises, Inc. 	Delaware
Associated Group, Inc. 	Indiana
ATH Holding Company, LLC 	Indiana
AUMSI UM Services, Inc. 	Indiana
Beacon Health Financing LLC 	Delaware
Beacon Health Holdings LLC 	Delaware
Beacon Health Options Holdco, Inc. 	Delaware
Beacon Health Vista Parent, Inc. 	Delaware
Beacon Plan Funding, LLC 	Delaware
Best Transportation of PR LLC 	Puerto Rico
BioPlus Parent, LLC 	Delaware
BioPlus Specialty Pharmacy Services, LLC 	Florida
Blue Cross Blue Shield Healthcare Plan of Georgia,
Inc.
Georgia 	Anthem Blue Cross and Blue Shield
Blue Cross Blue Shield of Wisconsin 	Wisconsin 	Anthem Blue Cross and Blue Shield
Blue Cross of California 	California 	Anthem Blue Cross
Blue Cross of California Partnership Plan, Inc. 	California 	Anthem Blue Cross Partnership Plan
Carelon Behavioral Care, Inc. 	Delaware
Carelon Behavioral Health Holdings, LLC f/k/a BVO
Holdings, LLC
Delaware
Carelon Behavioral Health, Inc. f/k/a Beacon Health
Options, Inc.
Virginia 	FHC CHOICE
Carelon Behavioral Health IPA, Inc. f/k/a CHCS IPA,
Inc.
New York
Carelon Behavioral Health of California, Inc. f/k/a
Beacon Health Options of California, Inc.
California
Carelon Behavioral Health Strategies IPA, LLC f/k/a
BHS IPA, LLC
New York
Carelon Behavioral Health Strategies, LLC f/k/a
Beacon Health Strategies, LLC
Massachusetts
Carelon Digital Platforms, Inc. 	Indiana
Carelon Digital Platforms Israel Ltd 	Israel
Carelon Employment Company, LLC 	Indiana
2

-- 517 of 533 --

Entity Name 	Domestic Jurisdiction 	Doing Business As
Carelon Global Solutions India LLP 	India
Carelon Global Solutions Ireland Limited 	Ireland
Carelon Global Solutions Philippines, Inc. 	Philippines
Carelon Global Solutions Puerto Rico, L.L.C. 	Puerto Rico
Carelon Global Solutions U.S., Inc. 	Indiana
Carelon Health Federal Services, Inc. f/k/a
ValueOptions Federal Services, Inc.
Virginia
Carelon Health of Arizona, Inc. f/k/a CareMore Heath
Plan of Arizona, Inc.
Arizona
Carelon Health of Nevada, Inc. f/k/a CareMore Health
Plan of Nevada
Nevada
Carelon Health of New Jersey, Inc. f/k/a ValueOptions
of New Jersey, Inc.
New Jersey
Carelon Health of Pennsylvania, Inc. f/k/a Beacon
Health Options of Pennsylvania, Inc.
Pennsylvania
Carelon Health of Texas f/k/a myNEXUS NPHO of
Texas
Texas
Carelon Health of Virginia, LLC f/k/a CareMore, LLC Indiana
Carelon Health Solutions, Inc. f/k/a Health
Management Corporation
Virginia
Carelon Holdings I, Inc. 	Indiana
Carelon Holdings II, LLC. 	Indiana
Carelon Holdings, Inc. 	Indiana
Carelon Insights, Inc. 	Indiana 	DBG, Inc.
Carelon Insights IPA of New York, LLC f/k/a
myNEXUS NY IPA, LLC
New York
Carelon Medical Benefits Management, Inc. f/k/a
American Imaging Management, Inc.
Illinois
Carelon Palliative Care, Inc. f/k/a Aspire Health, Inc. 	Delaware 	Carelon Palliative Care, Inc.
Carelon Post Acute Solutions, Inc. f/k/a MyNexus, Inc. Delaware 	Carelon Post Acute Solutions Administrator Services
Carelon Research, Inc. f/k/a Health Core, Inc. 	Delaware
Carelon Subrogation, LLC f/k/a Meridian Resource
Company, LLC
Wisconsin
CarelonRx, Inc. 	Indiana
CarelonRx Pharmacy, Inc. 	Delaware
CareMore Health IPA of New York, Inc. 	New York
3

-- 518 of 533 --

Entity Name 	Domestic Jurisdiction 	Doing Business As
CareMore Health of Arizona, Inc. 	Arizona
CareMore Health Plan 	California
CareMore Health Plan of Texas, Inc. 	Texas
CareMore Health System 	California
Caribbean Accountable Care, LLC 	Puerto Rico
Castellana Physician Services, LLC 	Puerto Rico
CCHA, LLC 	Colorado 	Colorado Community Health Alliance
Centro Medicina Familiar del Norte, LLC 	Puerto Rico
Centros de Medicina Primaria Advantage del Norte,
LLC
Puerto Rico
Centros Medicos Unidos del Oeste, LLC 	Puerto Rico
Cerulean Companies, Inc. 	Georgia
Claim Management Services, Inc. 	Wisconsin 	Anthem Blue Cross and Blue Shield
Clinica Todo Salud - Aibonito, LLC 	Puerto Rico
Clinica Todo Salud, LLC 	Puerto Rico
Clinical Staff Solutions, LLC 	Puerto Rico
Community Care Health Plan of Kansas, Inc. 	Kansas 	Healthy Blue
Community Care Health Plan of Louisiana, Inc. 	Louisiana 	Healthy Blue
Community Care Health Plan of Nebraska, Inc. 	Nebraska 	WellCare of Nebraska; Healthy Blue
Community Care Health Plan of Nevada, Inc. 	Nevada 	Anthem Blue Cross and Blue Shield Healthcare
Solutions;
Community Insurance Company 	Ohio 	Anthem Blue Cross and Blue Shield
Compcare Health Services Insurance Corporation 	Wisconsin 	Anthem Blue Cross and Blue Shield
Consorcio MultiSalud del Norte, Inc. 	Puerto Rico
Consorcio MultiSalud del Oeste, Inc. 	Puerto Rico
Crossroads Acquisition Corp. 	Delaware
DeCare Analytics, LLC 	Minnesota
DeCare Dental Health International, LLC 	Minnesota
DeCare Dental Insurance Ireland, Ltd. 	Ireland
DeCare Dental Networks, LLC 	Minnesota
DeCare Dental, LLC 	Minnesota
DeCare Operations Ireland, Limited 	Ireland
Delivery Network, LLC 	Florida
Dental Services Organization, LLC 	Puerto Rico
Designated Agent Company, Inc. 	Kentucky
Dogwood Pharmacy, LLC 	Florida 	Medscripts Medical Pharmacy, LLC
EasyScripts Cutler Bay, LLC 	Florida 	EasyScripts, LLC
EasyScripts Hialeah, LLC 	Florida 	EasyScripts, LLC
4

-- 519 of 533 --

Entity Name 	Domestic Jurisdiction 	Doing Business As
EasyScripts Westchester, LLC 	Florida 	EasyScripts, LLC
EasyScripts, LLC 	Florida 	EasyScripts Cutler Bay, LLC, EasyScripts Hialeah, LLC
and EasyScripts Westchester, LLC
Elevance Health Information Technology Services,
Inc. f/k/a WellPoint Information Technology Services,
Inc.
California
ELV Holding Company, LLC 	Indiana
Federal Government Solutions, LLC 	Wisconsin
FHC Health Systems, Inc. 	Virginia 	FHC HEALTH SYSTEMS
Freedom Health, Inc. 	Florida
Freedom SPV, Inc. 	Delaware
Golden West Health Plan, Inc. 	California
Greater Georgia Life Insurance Company 	Georgia 	Anthem Life
GR Health Solutions, LLC 	Pennsylvania
Group Retiree Health Solutions, Inc. 	Pennsylvania 	Blue Medicare Advantage
Grupo Advantage del Oeste, LLC 	Puerto Rico
Grupo Advantage Metro, LLC 	Puerto Rico
Healthcare Subrogation Group, L.L.C. 	Delaware
HealthKeepers, Inc. 	Virginia
HealthLink Administrators, Inc. f/k/a HealthLink
HMO, Inc.
Missouri 	HealthLink HMO
HealthLink, Inc. 	Illinois
Health Ventures Partner, L.L.C. 	Illinois
HealthSun Health Plans, Inc. 	Florida
HealthSun Physicians Network I, LLC 	Florida
HealthSun Physicians Network, LLC 	Florida
Healthy Alliance Life Insurance Company 	Missouri 	Anthem Blue Cross and Blue Shield
Highland Acquisition Holdings, LLC 	Delaware
Highland Intermediate Holdings, LLC 	Delaware
Highland Investor Holdings, LLC 	Delaware
HMO Colorado, Inc. 	Colorado 	HMO Colorado; HMO Nevada
HMO Missouri, Inc. 	Missouri 	Amerigroup Missouri; Anthem Blue Cross and Blue
Shield
IEC Group Holdings, Inc. 	Idaho
IEC Group, Inc. 	Idaho 	AmeriBen
InHealth Management, LLC 	Puerto Rico
IPA Holdings, LLC 	Puerto Rico
Living Complete Technologies, Inc. 	Maryland
MAPR Capital, LLC 	Puerto Rico
MAPR Global, LLC 	Puerto Rico
MAPR Holdings, LLC 	Puerto Rico
5

-- 520 of 533 --

Entity Name 	Domestic Jurisdiction 	Doing Business As
Massachusetts Behavioral Health Partnership, LLP 	Massachusetts
Matthew Thornton Health Plan, Inc. 	New Hampshire
Medical Dental Network Management, LLC 	Puerto Rico
Missouri Care, Incorporated 	Missouri 	Healthy Blue
MMM Healthcare, LLC 	Puerto Rico
MMM Holdings, LLC 	Puerto Rico
MMM Multi Health, LLC 	Puerto Rico
MMM Transportation, LLC 	Puerto Rico
Momentum Health Partners, LLC 	North Carolina
MSO Holdings, LLC 	Puerto Rico
MSO of Puerto Rico, LLC 	Puerto Rico
Nash Holding Company, LLC 	Delaware
National Government Services, Inc. 	Indiana 	NGS of Indiana
New England Research Institutes, Inc. 	Massachusetts
NGS Federal, LLC 	Indiana
Optimum Healthcare, Inc. 	Florida
OPTIONS Health Care, Inc. 	Delaware
Pasteur Medical Bird Road, LLC 	Florida 	Pasteur Medical Center, LLC
Pasteur Medical Center, LLC 	Delaware
Pasteur Medical Cutler Bay, LLC 	Florida 	Pasteur Medical Center, LLC
Pasteur Medical Group, LLC 	Florida 	Pasteur Medical Center, LLC
Pasteur Medical Hialeah Gardens, LLC 	Florida 	Pasteur Medical Center, LLC
Pasteur Medical Kendall, LLC 	Florida 	Pasteur Medical Center, LLC
Pasteur Medical Management, LLC 	Florida 	Pasteur Medical Bird Road, LLC, Pasteur Medical
Center, LLC, Pasteur Medical Cutler Bay, LLC, Pasteur
Medical Group, LLC Pasteur Medical Hialeah Gardens,
LLC, Pasteur Medical Kendall, LLC, Pasteur Medical
Miami Gardens, LLC, Pasteur Medical North Miami
Beach, LLC and Pasteur Medical Partners, LLC
Pasteur Medical Miami Gardens, LLC 	Florida 	Pasteur Medical Center, LLC
Pasteur Medical North Miami Beach, LLC 	Florida 	Pasteur Medical Center, LLC
Pasteur Medical Partners, LLC 	Florida 	Pasteur Medical Center, LLC
PHM Healthcare Solutions, Inc. 	Puerto Rico
PHM IntraHospital Physician Group, LLC 	Puerto Rico
PHM MultiDisciplinary Clinic Aguadilla LLC 	Puerto Rico
PHM MultiDisciplinary Clinic Arecibo LLC 	Puerto Rico
6

-- 521 of 533 --

Entity Name 	Domestic Jurisdiction 	Doing Business As
PHM MultiDisciplinary Clinic Cabo Rojo LLC 	Puerto Rico
PHM MultiDisciplinary Clinic Guayama LLC 	Puerto Rico
PHM MultiDisciplinary Clinic Maunabo LLC 	Puerto Rico
PHM MultiDisciplinary Clinic, LLC 	Puerto Rico
PHM MultiSalud, LLC 	Puerto Rico
PHM Specialty Network, LLC 	Puerto Rico
Physician Group Practices, LLC 	Puerto Rico
PMC Medicare Choice, LLC 	Puerto Rico
Raina RX LLC 	New York 	Route 300 Pharmacy in NY
RightCHOICE Managed Care, Inc. 	Delaware 	RightCHOICE Benefit Administrators; Anthem Blue
Cross and Blue Shield
River Medical Pharmacy, LLC 	Florida
Rocky Mountain Hospital and Medical Service, Inc. 	Colorado 	Anthem Blue Cross and Blue Shield; Anthem Blue Cross
Blue Shield
Santa Barbara Specialty Pharmacy, LLC 	California
SellCore, Inc. 	Delaware 	SellCore Insurance Services, Inc.
Simply Healthcare Plans, Inc. 	Florida 	Clear Health Alliance; Better Health; Amerigroup Florida
Southeast Services, Inc. 	Virginia
State Sponsored Services, Inc. 	Indiana 	Amerigroup GBD Behavioral Health; Anthem GBD
Behavioral Health
The Elevance Health Companies, Inc. 	Indiana 	Anthem Benefit Services; The Anthem Companies
Indiana
The Elevance Health Companies of California, Inc. 	California
The Elevance Health Companies of Puerto Rico, LLC 	Puerto Rico
TrustSolutions, LLC 	Wisconsin
UNICARE Health Plan of West Virginia, Inc. 	West Virginia
UNICARE Illinois Services, Inc. 	Illinois
UNICARE National Services, Inc. 	Delaware
UniCare Specialty Services, Inc. 	Delaware
VITA Care, LLC 	Puerto Rico
Wellmax Health Medical Centers, LLC 	Florida 	Wellmax Medical Center
Wellmax Health Physicians Network, LLC 	Florida
WellPoint Acquisition, LLC 	Indiana
WellPoint California Services, Inc. 	Delaware
7

-- 522 of 533 --

Entity Name 	Domestic Jurisdiction 	Doing Business As
Wellpoint Corporation f/k/a AMERIGROUP
Corporation
Delaware 	Wellpoint Insurance Services; Wellpoint Insurance
Services Corporation
Wellpoint Delaware, Inc. f/k/a Amerigroup Delaware,
Inc.
Delaware
WellPoint Dental Services, Inc. 	Delaware
Wellpoint Federal Corporation 	Indiana
WellPoint Health Solutions, Inc. 	Indiana
WellPoint Holding Corp. 	Delaware
Wellpoint Insurance Company f/k/a Amerigroup
Insurance Company
Texas
Wellpoint Insurance Services, Inc. 	Hawaii
Wellpoint Iowa, Inc. f/k/a Amerigroup Iowa, Inc. 	Iowa
Wellpoint IPA of New York, LLC f/k/a Amerigroup
IPA of New York, LLC
New York
Wellpoint Life and Health Insurance Company f/k/a
UniCare Life & Health Insurance Company
Indiana 	Simply Healthcare
Wellpoint Maryland, Inc. 	Maryland
Wellpoint New Jersey, Inc. f/k/a AMERIGROUP New
Jersey, Inc.
New Jersey
Wellpoint Ohio, Inc. f/k/a AMERIGROUP Ohio, Inc. 	Ohio
Wellpoint Partnership Plan, LLC f/k/a Amerigroup
Partnership Plan, LLC
Illinois
Wellpoint South Carolina, Inc. 	South Carolina
Wellpoint Tennessee, Inc. f/k/a AMERIGROUP
Tennessee, Inc.
Tennessee
Wellpoint Texas, Inc. f/k/a AMERIGROUP Texas, Inc. Texas
Wellpoint Washington, Inc. f/k/a AMERIGROUP
Washington, Inc.
Washington
Wisconsin Collaborative Insurance Company 	Wisconsin
8

-- 523 of 533 --

Exhibit 23
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
• Form S-8 No. 333-84906 and Form S-8 No. 333-129334 pertaining to the Elevance Health 401(k) Plan;
• Form S-8 No. 333-156099 pertaining to the Elevance Health Employee Stock Purchase Plan;
• Form S-8 No. 333-159830 pertaining to the Elevance Health Incentive Compensation Plan;
• Form S-8 No. 333-218190 pertaining to the 2017 Elevance Health Incentive Compensation Plan; and
• Form S-3 No. 333-275251 pertaining to the Elevance Health, Inc. registration of senior debt securities, subordinated debt securities, preferred stock,
common stock, depositary shares, warrants, rights, stock purchase contracts and stock purchase units
of our reports dated February 21, 2024, with respect to the consolidated financial statements and financial statement schedule listed in the Index at Item 15(c) of
Elevance Health, Inc. and the effectiveness of internal control over financial reporting of Elevance Health, Inc., included in this Annual Report (Form 10-K) for the
year ended December 31, 2023.
/S/ Ernst & Young LLP
Indianapolis, Indiana
February 21, 2024
1

-- 524 of 533 --

Exhibit 31.1
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Gail K. Boudreaux, certify that:
1. 	I have reviewed this report on Form 10-K of Elevance Health, Inc.;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. 	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
a) 	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
c) 	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. 	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
a) 	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: February 21, 2024 	/s/ GAIL K. BOUDREAUX
President and Chief Executive Officer

-- 525 of 533 --

Exhibit 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Mark B. Kaye, certify that:
1. 	I have reviewed this report on Form 10-K of Elevance Health, Inc.;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of
the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. 	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) 	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;
b) 	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;
c) 	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) 	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the
registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control
over financial reporting; and
5. 	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the
audit committee of registrant’s board of directors (or persons performing the equivalent function):
a) 	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect
the registrant’s ability to record, process, summarize and report financial information; and
b) 	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 21, 2024 	/s/ MARK B. KAYE
Executive Vice President and
Chief Financial Officer

-- 526 of 533 --

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Elevance Health, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2023 as filed with the Securities
and Exchange Commission on the date hereof (the “Report”), I, Gail K. Boudreaux, President and Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) 	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) 	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ GAIL K. BOUDREAUX
Gail K. Boudreaux
President and Chief Executive Officer
February 21, 2024

-- 527 of 533 --

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Elevance Health, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2023 as filed with the Securities
and Exchange Commission on the date hereof (the “Report”), I, Mark B. Kaye, Executive Vice President and Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) 	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) 	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ MARK B. KAYE
Mark B. Kaye
Executive Vice President and Chief Financial Officer
February 21, 2024

-- 528 of 533 --

Exhibit 97
Elevance Health, Inc.
Incentive Compensation Recoupment Policy
I. Introduction.
The Board of Directors of Elevance Health, Inc. (the “Company”) believes that it is in the best interest of the Company and its
shareholders to create and maintain a culture that emphasizes trustworthiness and accountability, demonstrates good leadership, and
reinforces the Company’s pay-for-performance compensation philosophy. The Board has adopted this policy, which provides for the
recoupment of certain executive compensation in the event of situations that involve certain accounting restatements, violations of
agreed upon covenants or actions that harm the Company’s reputation, all as further described in this policy (the “Policy”).
II. Definitions. For purposes of the Policy, the following terms have the meanings set forth below:
A. 	“Board” means the Company’s Board of Directors or any authorized committee of the Company’s Board of Directors.
B. 	“Exchange” means the New York Stock Exchange, or if the Company’s securities are not listed on the New York Stock
Exchange, the national securities exchange on which the Company’s securities are listed.
C. 	“Equity Compensation” means awards under the Elevance Health, Inc. Incentive Compensation Plan, as amended and restated
effective June 28, 2022, and predecessor or successor equity plans and any other award whose value is based on the
Company’s stock (if granted outside an equity plan) or the stock of any entity acquired by the Company or its affiliates; provided
that, “Equity Compensation” shall not include any awards which constitute Incentive-Based Compensation.
D. 	“Financial Reporting Measures” means measures that are determined and presented in accordance with the accounting
principles used in preparing the Company’s financial statements, and any measures that are derived wholly or in part from such
measures. Stock price and total shareholder return are also “Financial Reporting Measures.” A “Financial Reporting Measure”
need not be presented within the financial statements or included in a filing with the Securities and Exchange Commission
(“SEC”).
E. 	“Incentive-Based Compensation” means any compensation (whether paid in cash, stock, credited to a deferred compensation
program or otherwise) that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting
Measure.
F. 	"Incentive Cash Payments" include, but are not limited to, annual bonuses, long-term bonuses, if any, and any other special
performance-based bonuses (e.g., retention bonuses), whether paid in cash or credited to a deferred compensation program;
provided that, “Incentive Cash Payments” shall not include any compensation which constitutes Incentive-Based
Compensation.
G. 	"Misconduct" means actions involving fraud or such other actions as determined by the Board (or, if authorized by the Board, a
committee of the Board), in its sole discretion, and as further described in this Policy. In making such determination, the Board
will not be bound by determinations by management or by any committee of the Board that an Officer has or has not met any
particular standard of conduct under law or Company policy.

-- 529 of 533 --

Exhibit 97
H. 	"Officer" means the Company’s president, principal financial officer, principal accounting officer (or if there is no such
accounting officer, controller), any vice-president of the Company in charge of a principal business unit, division, or function
(such as sales, administration, or finance), any other officer who performs a policy-making function, and any other person who
performs similar policy-making functions for the Company. For purposes of this Policy, each person who is an “officer” as
defined under Section 16a-1(f) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), shall be an Officer.
I. 	“Received” means, for purposes of determining when Incentive-Based Compensation is received, the Company’s fiscal period
during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the
payment or grant of the Incentive-Based Compensation occurs after the end of that period.
J. 	“Recovery Period” means the three completed fiscal years immediately preceding the Restatement Date.
K. 	“Restatement” means an accounting restatement that the Company is required to prepare due to its material noncompliance
with any financial reporting requirement under the federal securities laws (commonly referred to as a “Big R” restatement),
including any required accounting restatement to correct an error in previously issued financial statements that is material to the
previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current
period or left uncorrected in the current period (commonly referred to as a “Little r” restatement).
L. 	“Restatement Date” means the earlier of (1) the date the Board or the officer or officers of the Company authorized to take such
action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare
a Restatement; or (2) the date that a court, regulator or other legally authorized body directs the Company to prepare a
Restatement.
M. 	“Restrictive Covenants” means any confidentiality, non-competition, non-solicitation and/or non-disparagement obligation to
which an Officer is bound, whether pursuant to any employment agreement, compensation plan, equity compensation
agreement or other agreement with the Company.
III. Events for Recoupment
A. 	Mandatory Recoupment in the Event of Restatements
In the event the Company is required to prepare a Restatement, the Company shall reasonably promptly recover from an Officer, and
such Officer shall forfeit or, if applicable, reimburse the Company for, the amount of any erroneously awarded Incentive-Based
Compensation that is Received by such Officer during the Recovery Period. The amount of erroneously Received Incentive-Based
Compensation will be the excess of the Incentive-Based Compensation Received by the Officer (whether in cash or shares) based on
the erroneous data in the original financial statements over the Incentive-Based Compensation (whether in cash or in shares) that
would have been Received by the Officer had it been based on the restated results, without regard to any tax liabilities incurred or paid
by the Officer.
For Incentive-Based Compensation based on Company stock price or total shareholder return, where the amount of erroneously
awarded compensation is not subject to mathematical recalculation directly from the information in the Restatement, (1) the amount
shall be based on the Company’s reasonable estimate of the effect of the Restatement on the stock price or total shareholder return
upon which the Incentive-Based Compensation was Received and (2) the Company shall maintain documentation of the determination
of that reasonable estimate and provide such estimate to the Exchange.

-- 530 of 533 --

Exhibit 97
This Section III.A. covers all persons who are Officers at any time during the Recovery Period for which Incentive-Based
Compensation is Received. Incentive-Based Compensation shall not be recovered under this Section III.A. to the extent Received by
any person before the date the person was determined to be an Officer.
No recovery shall be required pursuant to this Section III.A. if any of the following conditions are met and the Compensation and Talent
Committee of the Board determines that, on such basis, recovery would be impracticable:
• The direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered, provided
that prior to making a determination that it would be impracticable to recover any Incentive-Based Compensation based on the
expense of enforcement, the Company shall have made a reasonable attempt to recover the Incentive-Based Compensation,
have documented such reasonable attempts(s) to recover the Incentive-Based Compensation, and provided the documentation
to the Exchange.
• Recovery would violate home country law where that law was adopted prior to November 28, 2022, provided that, prior to
making a determination that it would be impracticable to recover any Incentive-Based Compensation based on a violation of
home country law, the Company shall have obtained an opinion of home country counsel acceptable to the Exchange that
recovery would result in such violation, and provided a copy of such opinion to such stock exchange; or
• Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to
employees, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as
amended, and U.S. Treasury regulations promulgated thereunder.
B. Discretionary Recoupment in the Event of Restatements
In the event the Company is required to prepare a Restatement and the provisions of Section III.A. of the Policy do not apply to an
Officer’s Equity Compensation because such Equity Compensation does not constitute Incentive-Based Compensation, then the
Board, in its discretion, may require such Officer to (1) forfeit any such Equity Compensation that has been granted or earned, but is
unpaid, (2) reimburse the Company for any such Equity Compensation previously paid to the Officer during the Recovery Period,
and/or (3) reimburse the Company for any profits realized from the sale of the Company’s stock during the Recovery Period.
In addition, in the event the Company is required to prepare a Restatement and the provisions of Section III.A. and/or the preceding
paragraph of this Section III.B. do not apply because the applicable compensation was Received by (or, in the case of Equity
Compensation, granted to) any person before the date the person was determined to be an Officer, then the Board, in its discretion,
may require such person to (1) forfeit such compensation and/or (2) reimburse the Company for such compensation.
C. Violation of Restrictive Covenants
In the event a current or former Officer violates a Restrictive Covenant, the Board may, in its discretion, require the Officer to forfeit any
earned, but unpaid Incentive-Based Compensation, Incentive Cash Payments, and/or Equity Compensation and/or reimburse the
Company for any Incentive-Based Compensation, Incentive Cash Payments, and/or Equity Compensation paid (1) in the 12 month
period preceding the violation or (2) at any time following the violation before the violation was discovered.

-- 531 of 533 --

Exhibit 97
D. Misconduct
In the event a current or former Officer has engaged in Misconduct, as further defined in this Section, the Board may, in its discretion,
require the Officer to (1) forfeit any earned, but unpaid Incentive-Based Compensation, Incentive Cash Payments, and/or Equity
Compensation, and/or (2) reimburse the Company for any Incentive-Based Compensation, Incentive Cash Payments, and/or Equity
Compensation previously paid to the Officer during the three year period that ends when the Board makes a determination that
Misconduct has occurred. For the avoidance of doubt, the lookback period in the preceding sentence only applies to the scope of
Incentive-Based Compensation, Incentive Cash Payments, and/or Equity Compensation that may be subject to reimbursement, but
such reimbursement may relate to Misconduct that occurred before such lookback period began. The amount of any such forfeiture
and/or reimbursement shall be determined by the Board, in its discretion, taking into account the magnitude and circumstances of the
Misconduct.
For purposes of this Section, Misconduct includes breach of the Company’s code of conduct and intentional actions or a gross
dereliction of the duty to reasonably monitor, supervise and/or manage the applicable conduct and risks that the Board determines has
resulted in significant financial or reputational harm to the Company’s commercial interests and/or its market valuation.
IV. Method of Recoupment
The Board shall determine, in its sole discretion, the method of recovering any compensation pursuant to this Policy, consistent with
applicable law, including withholding any amount due from future compensation.
V. Effect of the Policy
This Policy is not intended to amend or modify any right or obligation to pay or credit any amount due under any incentive
compensation, equity and/or deferred compensation plan, as distinguished from the right to recoup compensation previously paid or
credited.
VI. No Indemnification
The Company shall not indemnify any Officer against the loss of any compensation subject to the Policy (whether in the form of cash or
equity), nor shall the Company pay or reimburse any Officer for premiums incurred or paid for any insurance policy to fund such
Officer’s potential recovery obligations.
VII. Reporting, Disclosure and Monitoring
The Company shall make all required disclosures and filings with the Securities and Exchange Commission (the “SEC”) and the
Exchange with respect to this Policy in accordance with the requirements of the Federal securities laws and applicable listing rules,
including the disclosures required in applicable SEC filings.
VIII. Interpretation
The Board is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for
the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of
Section 10D of the Exchange Act and Rule 10D-1 (or any successor statute or rule) and any other applicable rules or listing standards
adopted by the SEC or the Exchange.
In furtherance of the foregoing, Section III.A. of this Policy is intended to comply with Section 10D of the Exchange Act, Rule 10D-1
promulgated thereunder, and Section 303A.14 of the NYSE Listed Company Manual.

-- 532 of 533 --

Exhibit 97
IX. Amendment; Termination
The Board may amend or terminate this Policy at any time in its discretion, subject to any limitations under applicable law and listing
requirements. Without limiting the foregoing, the Board may amend this Policy as it deems necessary to reflect any regulations
adopted by the SEC and to comply with any rules or standards adopted by the Exchange.
X. Other Recoupment Rights
The Board intends that this Policy will be applied to the fullest extent of the law. The Board may require that any employment
agreement, equity award agreement, or similar agreement entered into on or after the Effective Date shall, as a condition to the grant
of any benefit thereunder, require an Officer to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in
addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms
of any employment agreement, equity award agreement, equity incentive plan, cash incentive plan or similar agreement, plan, or policy
and any other legal remedies available to the Company. In addition to recovery of compensation as provided for in this Policy, the
Board may take any and all other actions as it deems necessary, appropriate and in the Company’s best interest in connection with a
Recoupment Event described in Section III, and nothing in this Policy limits the Company’s rights to take appropriate actions. For the
avoidance of doubt, the provisions of this Policy shall not be amended or superseded by the terms of any other agreement, plan or
policy applicable to an Officer.
XI. Effective Date
This Policy was originally effective as of October 1, 2009 and was amended on July 1, 2018 and March 28, 2019. This Policy is hereby
amended and restated effective as of October 3, 2023 (the “Effective Date”) to comply with Section 10D of the Exchange Act, Rule
10D-1 promulgated thereunder, and Section 303A.14 of the NYSE Listed Company Manual, which require the recovery of certain
Incentive-Based Compensation in the case of a Restatement. For the avoidance of doubt, this Policy shall apply to any Incentive-
Based Compensation that is Received by any Covered Officer on or after the Effective Date that results from attainment of a Financial
Reporting Measure based on or derived from financial information for any fiscal period ending on or after the Effective Date, even if
such Incentive-Based Compensation was approved, awarded, granted, or paid to such Covered Officer prior to the Effective Date.

-- 533 of 533 --